[
  {
    "Code": "U-1",
    "Definition": "PREVENTION OF PREGNANCY"
  },
  {
    "Code": "U-2",
    "Definition": "TREATMENT OR PROPHYLAXIS OF ANGINA PECTORIS AND ARRHYTHMIA"
  },
  {
    "Code": "U-3",
    "Definition": "TREATMENT OF HYPERTENSION"
  },
  {
    "Code": "U-4",
    "Definition": "PROVIDING PREVENTION AND TREATMENT OF EMESIS AND NAUSEA IN MAMMALS"
  },
  {
    "Code": "U-5",
    "Definition": "METHOD OF PRODUCING BRONCHODILATION"
  },
  {
    "Code": "U-6",
    "Definition": "METHOD OF PRODUCING SYMPATHOMIMETIC EFFECTS"
  },
  {
    "Code": "U-7",
    "Definition": "INCREASING CARDIAC CONTRACTILITY"
  },
  {
    "Code": "U-8",
    "Definition": "ACUTE MYOCARDIAL INFARCTION"
  },
  {
    "Code": "U-9",
    "Definition": "CONTROL OF EMESIS ASSOCIATED WITH ANY CANCER CHEMOTHERAPY AGENT"
  },
  {
    "Code": "U-10",
    "Definition": "DIAGNOSTIC METHOD FOR DISTINGUISHING BETWEEN HYPOTHALAMIC MALFUNCTIONS OR LESIONS IN HUMANS"
  },
  {
    "Code": "U-11",
    "Definition": "TREATMENT OR PROPHYLAXIS OF CARDIAC DISORDERS"
  },
  {
    "Code": "U-12",
    "Definition": "METHOD OF TREATING [A] HUMAN SUFFERING FROM DEPRESSION"
  },
  {
    "Code": "U-13",
    "Definition": "A METHOD FOR TREATING ANXIETY IN A HUMAN SUBJECT IN NEED OF SUCH TREATMENT"
  },
  {
    "Code": "U-14",
    "Definition": "ADJUNCTIVE THERAPY FOR THE PREVENTION AND TREATMENT OF HYPERAMMONEMIA IN THE CHRONIC MANAGEMENT OF PATIENTS WITH UREA CYCLE ENZYMOPATHIES"
  },
  {
    "Code": "U-15",
    "Definition": "METHOD OF LOWERING INTRAOCULAR PRESSURE"
  },
  {
    "Code": "U-16",
    "Definition": "USE IN LUNG SCANNING PROCEDURES"
  },
  {
    "Code": "U-17",
    "Definition": "TREATMENT OF VENTRICULAR AND SUPRAVENTRICULAR ARRHYTHMIAS"
  },
  {
    "Code": "U-18",
    "Definition": "METHOD FOR INHIBITING GASTRIC SECRETION IN MAMMALS"
  },
  {
    "Code": "U-19",
    "Definition": "TREATMENT OF INFLAMMATION"
  },
  {
    "Code": "U-20",
    "Definition": "A PROCESS FOR TREATING A PATIENT SUFFERING FROM PARKINSON'S SYNDROME AND IN NEED OF TREATMENT"
  },
  {
    "Code": "U-21",
    "Definition": "TREATMENT OF HUMANS SUFFERING UNDESIRED UROTOXIC SIDE EFFECTS CAUSED BY CYTOSTATICALLY ACTIVE ALKYLATING AGENTS"
  },
  {
    "Code": "U-22",
    "Definition": "METHOD OF COMBATTING PATHOLOGICALLY REDUCED CEREBRAL FUNCTIONS AND PERFORMANCE WEAKNESSES, CEREBRAL INSUFFICIENCY AND DISORDERS IN CEREBRAL CIRCULATION AND METABOLISM IN WARM-BLOODED ANIMALS"
  },
  {
    "Code": "U-23",
    "Definition": "METHOD FOR TREATING PROSTATIC CARCINOMA COMPRISING ADMINISTERING FLUTAMIDE"
  },
  {
    "Code": "U-24",
    "Definition": "METHOD FOR TREATING PROSTATE ADENOCARCINOMA COMPRISING ADMINISTERING AN ANTIANDROGEN INCLUDING FLUTAMIDE AND AN LHRH AGONIST"
  },
  {
    "Code": "U-25",
    "Definition": "REDUCING CHOLESTEROL IN CHOLELITHIASIS PATIENTS"
  },
  {
    "Code": "U-26",
    "Definition": "REDUCING CHOLESTEROL GALLSTONES AND\/OR FRAGMENTS THEREOF"
  },
  {
    "Code": "U-27",
    "Definition": "DISSOLVING CHOLESTEROL GALLSTONES AND\/OR FRAGMENTS THEREOF"
  },
  {
    "Code": "U-28",
    "Definition": "CEREBRAL, CORONARY, PERIPHERAL, VISCERAL AND RENAL ARTERIOGRAPHY, AORTOGRAPHY AND LEFT VENTRICULOGRAPHY"
  },
  {
    "Code": "U-29",
    "Definition": "CT IMAGING OF THE HEAD AND BODY, AND INTRAVENOUS EXCRETORY UROGRAPHY"
  },
  {
    "Code": "U-30",
    "Definition": "CEREBRAL ANGIOGRAPHY, AND VENOGRAPHY"
  },
  {
    "Code": "U-31",
    "Definition": "INTRA-ARTERIAL DIGITAL SUBTRACTION ANGIOGRAPHY"
  },
  {
    "Code": "U-32",
    "Definition": "PALLIATIVE TREATMENT OF PATIENTS WITH OVARIAN CARCINOMA RECURRENT AFTER PRIOR CHEMOTHERAPY, INCLUDING PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH CISPLATIN"
  },
  {
    "Code": "U-33",
    "Definition": "TREATING VIRAL INFECTIONS IN A MAMMAL"
  },
  {
    "Code": "U-34",
    "Definition": "TREATING VIRAL INFECTIONS IN A WARM-BLOODED ANIMAL"
  },
  {
    "Code": "U-35",
    "Definition": "TREATING CYTOMEGALOVIRUS IN A HUMAN WITH AN INJECTABLE COMPOSITION"
  },
  {
    "Code": "U-36",
    "Definition": "METHODS OF TREATING BACTERIAL ILLNESSES"
  },
  {
    "Code": "U-37",
    "Definition": "METHOD OF TREATING GASTROINTESTINAL DISEASE"
  },
  {
    "Code": "U-38",
    "Definition": "TREATMENT OF PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA"
  },
  {
    "Code": "U-39",
    "Definition": "ANGINA PECTORIS"
  },
  {
    "Code": "U-40",
    "Definition": "METHOD OF TREATMENT OF BURNS"
  },
  {
    "Code": "U-41",
    "Definition": "METHOD OF TREATING CARDIAC ARRHYTHMIAS"
  },
  {
    "Code": "U-42",
    "Definition": "ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER"
  },
  {
    "Code": "U-43",
    "Definition": "MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA"
  },
  {
    "Code": "U-44",
    "Definition": "RELIEF OF NAUSEA AND VOMITING"
  },
  {
    "Code": "U-45",
    "Definition": "TREATMENT OF INFLAMMATION AND ANALGESIA"
  },
  {
    "Code": "U-46",
    "Definition": "TREATMENT OF PANIC DISORDER"
  },
  {
    "Code": "U-47",
    "Definition": "STIMULATION OF THE RELEASE OF GROWTH HORMONE"
  },
  {
    "Code": "U-48",
    "Definition": "ANALGESIA"
  },
  {
    "Code": "U-49",
    "Definition": "SYMPTOMATIC CANCER-RELATED HYPERCALCEMIA"
  },
  {
    "Code": "U-50",
    "Definition": "USE IN TREATING INFLAMMATORY DERMATOSES"
  },
  {
    "Code": "U-51",
    "Definition": "BLOOD POOL IMAGING, INCLUDING CARDIAC FIRST PASS AND GATED EQUILIBRIUM IMAGING AND FOR DETECTION OF SITES OF  GASTROINTESTINAL BLEEDING"
  },
  {
    "Code": "U-52",
    "Definition": "TREATMENT OF ADULT AND PEDIATRIC PATIENTS(OVER SIX MONTHS OF AGE) WITH ADVANCED HIV INFECTION"
  },
  {
    "Code": "U-53",
    "Definition": "HYPERCALCEMIA OF MALIGNANCY"
  },
  {
    "Code": "U-54",
    "Definition": "REVERSAL AGENT OR ANTAGONIST OF NONDEPOLARIZING NEUROMUSCULAR BLOCKING AGENTS"
  },
  {
    "Code": "U-55",
    "Definition": "TREATMENT OF PAIN"
  },
  {
    "Code": "U-56",
    "Definition": "AID TO SMOKING CESSATION"
  },
  {
    "Code": "U-57",
    "Definition": "OPHTHALMIC USE OF NORFLOXACIN"
  },
  {
    "Code": "U-58",
    "Definition": "METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES"
  },
  {
    "Code": "U-59",
    "Definition": "METHOD OF TREATING HYPERCHOLESTEROLEMIA"
  },
  {
    "Code": "U-60",
    "Definition": "NASAL ADMINISTRATION OF BUTORPHANOL"
  },
  {
    "Code": "U-61",
    "Definition": "CEREBRAL AND PERIPHERAL ARTERIOGRAPHY AND CT IMAGING OF THE HEAD"
  },
  {
    "Code": "U-62",
    "Definition": "CORONARY ARTERIOGRAPHY, LEFT VENTRICULOGRAPHY, CT IMAGING OF THE BODY, INTRAVENOUS EXCRETORY UROGRAPHY, INTRAVENOUS DIGITAL SUBTRACTION ANGIOGRAPHY AND VENOGRAPHY"
  },
  {
    "Code": "U-63",
    "Definition": "ISOPRENALINE ANTAGONISM ON THE HEART RATE OR BLOOD PRESSURE"
  },
  {
    "Code": "U-64",
    "Definition": "TREATMENT OF VIRAL INFECTIONS"
  },
  {
    "Code": "U-65",
    "Definition": "METHOD OF TREATMENT OF A PATIENT INFECTED WITH HIV"
  },
  {
    "Code": "U-66",
    "Definition": "TRIPHASIC REGIMEN"
  },
  {
    "Code": "U-67",
    "Definition": "METHOD OF INDUCING ANESTHESIA IN A WARM BLOODED ANIMAL"
  },
  {
    "Code": "U-68",
    "Definition": "TREATMENT OF ACTINIC KERATOSIS"
  },
  {
    "Code": "U-69",
    "Definition": "TREATMENT OF PNEUMOCYSTIS CARINII INFECTIONS"
  },
  {
    "Code": "U-70",
    "Definition": "TREATMENT OF TRANSIENT INSOMNIA"
  },
  {
    "Code": "U-71",
    "Definition": "METHOD OF TREATMENT OF HEART FAILURE"
  },
  {
    "Code": "U-72",
    "Definition": "TREATMENT OF MIGRAINE"
  },
  {
    "Code": "U-73",
    "Definition": "METHOD OF TREATING DISEASES OR INFECTIONS CAUSED BY MYCETES"
  },
  {
    "Code": "U-74",
    "Definition": "METHOD OF PROVIDING HYPNOTIC EFFECT"
  },
  {
    "Code": "U-75",
    "Definition": "RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS"
  },
  {
    "Code": "U-76",
    "Definition": "USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM"
  },
  {
    "Code": "U-77",
    "Definition": "TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS"
  },
  {
    "Code": "U-78",
    "Definition": "ULCERATIVE COLITIS"
  },
  {
    "Code": "U-79",
    "Definition": "SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURN DUE TO GERD"
  },
  {
    "Code": "U-80",
    "Definition": "METHOD OF TREATING OCULAR BACTERIAL INFECTIONS"
  },
  {
    "Code": "U-81",
    "Definition": "RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS"
  },
  {
    "Code": "U-82",
    "Definition": "TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE"
  },
  {
    "Code": "U-83",
    "Definition": "TREATMENT OF SEIZURES"
  },
  {
    "Code": "U-84",
    "Definition": "A METHOD OF BLOCKING THE UPTAKE OF MONOAMINES BY BRAIN NEURONS IN ANIMALS"
  },
  {
    "Code": "U-85",
    "Definition": "NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS"
  },
  {
    "Code": "U-86",
    "Definition": "METHOD OF TREATING CERTAIN FORMS OF EPILEPSY"
  },
  {
    "Code": "U-87",
    "Definition": "METHOD FOR NONINVASIVE ADMINISTRATION OF SEDATIVES, ANALGESICS, AND ANESTHETICS"
  },
  {
    "Code": "U-88",
    "Definition": "TREATMENT OF MODERATE PLAQUE PSORIASIS"
  },
  {
    "Code": "U-89",
    "Definition": "TREATMENT OR PROPHYLAXIS OF EMESIS"
  },
  {
    "Code": "U-90",
    "Definition": "TREATMENT OF PSYCHOTIC DISORDERS"
  },
  {
    "Code": "U-91",
    "Definition": "ALTERNATIVE THERAPY TO TRIMETHOPRIM-SULFAMETHOXAZOLE FOR TREATMENT OF MODERATE-TO-SEVERE PNEUMOCYSTIS CARINII PNEUMONIA IN IMMUNOCOMPROMISED AND AIDS PATIENTS"
  },
  {
    "Code": "U-92",
    "Definition": "TREATMENT OF DIABETIC NEPHROPATHY IN PATIENTS WITH TYPE I INSULIN DEPENDENT DIABETES MELLITUS AND RETINOPATHY"
  },
  {
    "Code": "U-93",
    "Definition": "USE AS AN ANTIHISTAMINE\/DECONGESTANT"
  },
  {
    "Code": "U-94",
    "Definition": "TREATMENT-ADULTS W\/ ADVANCED HIV,INTOLERANT OF APPROVED THERAPIES,INTOLERANT OF APPROVED THERAPIES W\/PROVEN BENEFIT OR HAVE EXPERIENCED CLINICAL\/IMMUNOLOGICAL DETERIORATION WHILE RECEIVING..OR FOR WHOM SUCH THERAPIES-CONTRAINDICATED"
  },
  {
    "Code": "U-95",
    "Definition": "SHORT TERM MANAGEMENT OF MODERATE PRURITIS IN ADULTS WITH ATOPIC DERMATITIS AND LICHEN SIMPLEX CHRONICUS"
  },
  {
    "Code": "U-96",
    "Definition": "METHOD OF TREATING VARICELLA ZOSTER (SHINGLES) INFECTIONS"
  },
  {
    "Code": "U-97",
    "Definition": "A METHOD OF TREATING A PATIENT IN NEED OF MEMORY ENHANCEMENT"
  },
  {
    "Code": "U-98",
    "Definition": "A METHOD OF INDUCING REGRESSION OF LEUKEMIA CELL GROWTH IN A MAMMAL"
  },
  {
    "Code": "U-99",
    "Definition": "METHOD OF PROVIDING POTASSIUM TO A SUBJECT IN NEED OF POTASSIUM"
  },
  {
    "Code": "U-100",
    "Definition": "METHOD OF TREATING OCULAR INFLAMMATION"
  },
  {
    "Code": "U-101",
    "Definition": "ADJUNCT TO CONVENTIONAL CT OR MRI IMAGING IN THE LOCALIZATION OF STROKE IN PATIENTS IN WHOM STROKE HAS ALREADY BEEN DIAGNOSED"
  },
  {
    "Code": "U-102",
    "Definition": "METHOD OF HORMONALLY TREATING MENOPAUSAL OR POST-MENOPAUSAL DISORDERS IN WOMEN"
  },
  {
    "Code": "U-103",
    "Definition": "TREATMENT OF OCULAR HYPERTENSION"
  },
  {
    "Code": "U-104",
    "Definition": "TREATMENT OF AQUEOUS HUMOR FORMATION AND INTRAOCULAR PRESSURE"
  },
  {
    "Code": "U-105",
    "Definition": "EMESIS"
  },
  {
    "Code": "U-106",
    "Definition": "TREATMENT OF EPILEPSY"
  },
  {
    "Code": "U-107",
    "Definition": "TREATMENT OF HYPERTENSION AND ANGINA PECTORIS"
  },
  {
    "Code": "U-108",
    "Definition": "SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER, GASTROESOPHAGEAL REFLUX DISEASE (GERD), SEVERE EROSIVE ESOPHAGITIS, POORLY RESPONSIVE SYMPTOMATIC GERD AND PATHOLOGIAL HYPERSECRETORY CONDITIONS AND MAINTENANCE HEALING OF EROSIVE ESOPHAGITIS"
  },
  {
    "Code": "U-109",
    "Definition": "ADJUNCT DIET IN THE TX OF ELEVATED TOTAL CHOLESTEROL AND LDL-C LEVELS IN PTS W\/PRIMARY HYPERCHOLESTEROLEMIA WHOSE RESPONSE TO DIETARY RESTRICTION OF SAT FAT AND CHOLESTEROL AND OTHER NONPHARMACOLOGICAL MEASURES HAS NOT BEEN ADEQUATE"
  },
  {
    "Code": "U-110",
    "Definition": "USE AS A RETRIEVABLE PESSARY"
  },
  {
    "Code": "U-111",
    "Definition": "DIABETES"
  },
  {
    "Code": "U-112",
    "Definition": "CONTRACEPTION"
  },
  {
    "Code": "U-113",
    "Definition": "METHOD OF CONDUCTING RADIOLOGICAL EXAMINATION OF A PATIENT BY ADMINISTERING TO SAID PATIENT A RADIOPAQUE AMOUNT OF IOPROMIDE"
  },
  {
    "Code": "U-114",
    "Definition": "USE FOR INHIBITING BONE RESORPTION"
  },
  {
    "Code": "U-115",
    "Definition": "USE OF VASODILATORS TO EFFECT AND ENHANCE AN ERECTION (AND THUS TREAT ERECTILE DYSFUNCTION), BY INJECTION INTO THE PENIS"
  },
  {
    "Code": "U-116",
    "Definition": "METHOD OF MYOCARDIAL IMAGING"
  },
  {
    "Code": "U-117",
    "Definition": "TREATMENT OF OCULAR ALLERGIC RESPONSE IN HUMAN EYES"
  },
  {
    "Code": "U-118",
    "Definition": "METHOD OF LOWERING BLOOD SUGAR LEVEL"
  },
  {
    "Code": "U-119",
    "Definition": "TREATMENT OF NASAL HYPERSECRETION"
  },
  {
    "Code": "U-120",
    "Definition": "CONTROLLING OR PREVENTING POST-OPERATIVE INTRAOCULAR PRESSURE RISES ASSOCIATED WITH OPHTHALMIC LASER SURGICAL PROCEDURES"
  },
  {
    "Code": "U-121",
    "Definition": "METHOD OF TREATING CONDITIONS MEDIATED THROUGH HISTAMINE H2-RECEPTORS"
  },
  {
    "Code": "U-122",
    "Definition": "A THERAPEUTIC METHOD FOR CONTROLLING THROMBOSIS"
  },
  {
    "Code": "U-123",
    "Definition": "METHOD FOR CONTROLLING THROMBOSIS AND DECREASING BLOOD HYPERCOAGULATION AND HEMORRHAGING RISKS"
  },
  {
    "Code": "U-124",
    "Definition": "TREATMENT OF ACNE"
  },
  {
    "Code": "U-125",
    "Definition": "TREATMENT NEUROGENERATIVE DISEASES"
  },
  {
    "Code": "U-126",
    "Definition": "TREATMENT OF GASTRITIS"
  },
  {
    "Code": "U-127",
    "Definition": "METHOD OF PRODUCING NEUROMUSCULAR BLOCKADE"
  },
  {
    "Code": "U-128",
    "Definition": "METHOD FOR TREATMENT OF TUMORS"
  },
  {
    "Code": "U-129",
    "Definition": "METHOD TO DESTROY OR IMPAIR TARGET CELLS"
  },
  {
    "Code": "U-130",
    "Definition": "MANAGEMENT OF PATIENTS WITH MASTOCYTOSIS"
  },
  {
    "Code": "U-131",
    "Definition": "PHOTODAMAGED SKIN"
  },
  {
    "Code": "U-132",
    "Definition": "INHIBITING HIV PROTEASE"
  },
  {
    "Code": "U-133",
    "Definition": "MANAGEMENT OF OBESITY INCLUDING WEIGHT LOSS AND MAINTENANCE IN PATIENTS ON A REDUCED-CALORIE DIET"
  },
  {
    "Code": "U-134",
    "Definition": "TREATMENT OF ACNE VULGARIS"
  },
  {
    "Code": "U-135",
    "Definition": "ANTITUMOR AGENT"
  },
  {
    "Code": "U-136",
    "Definition": "PROCESS FOR WASTE NITROGEN REMOVAL"
  },
  {
    "Code": "U-137",
    "Definition": "METHOD OF TREATING BACTERIAL VAGINOSIS"
  },
  {
    "Code": "U-138",
    "Definition": "TREATMENT OF ALLERGIC RHINITIS"
  },
  {
    "Code": "U-139",
    "Definition": "TREATMENT OF ALLERGIC REACTIONS"
  },
  {
    "Code": "U-140",
    "Definition": "USE OF NORVIR TO INHIBIT HIV PROTEASE OR TO INHIBIT AN HIV INFECTION"
  },
  {
    "Code": "U-141",
    "Definition": "TREATMENT OF ULCERATIVE COLITIS"
  },
  {
    "Code": "U-142",
    "Definition": "METHOD OF TREATING ALLERGIC REACTIONS IN A MAMMAL BY USING THIS ACTIVE METABOLITE"
  },
  {
    "Code": "U-143",
    "Definition": "BIODEGRADABLE SUPERPARAMAGNETIC METAL OXIDES AS CONTRAST AGENTS FOR MR IMAGING"
  },
  {
    "Code": "U-144",
    "Definition": "BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC MATERIALS FOR USE IN CLINICAL APPLICATIONS"
  },
  {
    "Code": "U-145",
    "Definition": "BIOLOGICALLY DEGRADABLE SUPERPARAMAGNETIC PARTICLES FOR USE AS NUCLEAR MAGNETIC RESONANCE IMAGING AGENTS"
  },
  {
    "Code": "U-146",
    "Definition": "METHOD OF TREATING SUSCEPTIBLE NEOPLASMS IN MAMMALS"
  },
  {
    "Code": "U-147",
    "Definition": "DETECTION OF GASTROINTESTINAL DISORDERS AND THE SUBSEQUENT BREATH COLLECTION AND MEASUREMENT OF 13CO2"
  },
  {
    "Code": "U-148",
    "Definition": "DEVICE FOR COLLECTING A BREATH SAMPLE"
  },
  {
    "Code": "U-149",
    "Definition": "METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS, ACUTE MANIA OR MILD ANXIETY STATES"
  },
  {
    "Code": "U-150",
    "Definition": "METHOD OF USE FOR CONTROLLING HYPERGLYCEMIA BY ADMINISTRATION OF THIS SUSTAINED RELEASE DOSAGE FORM OF GLIPIZIDE"
  },
  {
    "Code": "U-151",
    "Definition": "RELIEF OF SYMPTOMS OF THE COMMON COLD"
  },
  {
    "Code": "U-152",
    "Definition": "METHOD OF TREATING ANXIETY RELATED DISORDERS INCLUDING OBSESSIVE COMPULSIVE DISORDER"
  },
  {
    "Code": "U-153",
    "Definition": "TREATMENT OF INITIAL EPISODE GENITAL HERPES"
  },
  {
    "Code": "U-154",
    "Definition": "METHOD OF TREATING ANIMALS SUFFERING FROM AN APPETITE DISORDER"
  },
  {
    "Code": "U-155",
    "Definition": "TREATMENT OF ERECTILE DYSFUNCTION"
  },
  {
    "Code": "U-156",
    "Definition": "METHOD OF PROVIDING ANESTHESIA"
  },
  {
    "Code": "U-157",
    "Definition": "TREATMENT OF A HUMAN SUFFERING FROM VITAMIN B12 DEFICIENCY"
  },
  {
    "Code": "U-158",
    "Definition": "ANGINA"
  },
  {
    "Code": "U-159",
    "Definition": "TREATMENT OF INTERSTITIAL CYSTITIS"
  },
  {
    "Code": "U-160",
    "Definition": "TREATMENT OF BACTERIAL INFECTIOUS DISEASE"
  },
  {
    "Code": "U-161",
    "Definition": "METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS IN A PATIENT"
  },
  {
    "Code": "U-162",
    "Definition": "METHOD OF USE TO INHIBIT CHOLESTEROL SYNTHESIS IN A HUMAN SUFFERING FROM HYPERCHOLESTEROLEMIA"
  },
  {
    "Code": "U-163",
    "Definition": "METHOD OF USING TROGLITAZONE TO TREAT IMPAIRED GLUCOSE TOLERANCE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS"
  },
  {
    "Code": "U-164",
    "Definition": "METHOD OF USING TROGLITAZONE TO PREVENT OR DELAY THE ONSET OF NONINSULIN-DEPENDENT DIABETES MELLITUS IN A DEFINED POPULATION OF PATIENTS"
  },
  {
    "Code": "U-165",
    "Definition": "TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA"
  },
  {
    "Code": "U-166",
    "Definition": "TREATMENT OF H.PYLORI-ASSOCIATED DUODENAL ULCER"
  },
  {
    "Code": "U-167",
    "Definition": "METHOD FOR TREATING HIV-1 INFECTION"
  },
  {
    "Code": "U-168",
    "Definition": "METHOD OF INHIBITING LIPOXYGENASE ACTIVITY IN A MAMMAL WHICH IS THE MODE OF ACTION IN THE TREATMENT OF ASTHMA"
  },
  {
    "Code": "U-169",
    "Definition": "METHODS OF USING THE COMPOUND\/DRUG PRODUCT AS A CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING"
  },
  {
    "Code": "U-170",
    "Definition": "METHOD OF OBTAINING AN MR IMAGE USING THE COMPOSITION\/DRUG PRODUCT AS A CONTRAST AGENT"
  },
  {
    "Code": "U-171",
    "Definition": "METHODS OF USING THE COMPOUND\/DRUG PRODUCT AS AN ORAL CONTRAST AGENT IN MAGNETIC RESONANCE IMAGING OF THE GASTROINTESTINAL TRACT"
  },
  {
    "Code": "U-172",
    "Definition": "TREATMENT OF GENITAL WARTS"
  },
  {
    "Code": "U-173",
    "Definition": "ADMINISTRATION TO A HOST SUFFERING FROM GESTATIONAL DIABETES"
  },
  {
    "Code": "U-174",
    "Definition": "USE AS AN ANTIHISTAMINE AGENT"
  },
  {
    "Code": "U-175",
    "Definition": "METHOD OF TREATING MALIGNANT TUMORS"
  },
  {
    "Code": "U-176",
    "Definition": "METHOD OF TREATING A PATIENT SUFFERING FROM LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES"
  },
  {
    "Code": "U-177",
    "Definition": "FUNGICIDE"
  },
  {
    "Code": "U-178",
    "Definition": "FACILITATED ADHERENCE OF AGENTS TO SKIN"
  },
  {
    "Code": "U-179",
    "Definition": "ENHANCED CUTANEOUS PENETRATION OF A DERMALLY-APPLIED PHARMACOLOGICALLY ACTIVE AGENT"
  },
  {
    "Code": "U-180",
    "Definition": "TREATMENT OF ADULT AND PEDIATRIC PATIENTS (OVER 6 MONTHS OF AGE) WITH ADVANCED HIV INFECTION"
  },
  {
    "Code": "U-181",
    "Definition": "PRODUCING ALPHA ADRENERGIC ANTAGONISTIC ACTION IN A HOST"
  },
  {
    "Code": "U-182",
    "Definition": "USE OF SALMETEROL IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION"
  },
  {
    "Code": "U-183",
    "Definition": "TREATMENT OF CONDITIONS CAUSED BY DISTURBANCE OF NEURONAL 5HT FUNCTION"
  },
  {
    "Code": "U-184",
    "Definition": "TREATING ALLERGIC EYE DISEASES IN HUMANS"
  },
  {
    "Code": "U-185",
    "Definition": "METHOD OF TREATING HYPERTENSION"
  },
  {
    "Code": "U-186",
    "Definition": "METHOD FOR TREATING GI DISORDERS CAUSED BY H. PYLORI WHICH COMPRISES ADMINISTRATION OF RANITIDINE BISMUTH CITRATE AND CLARITHROMYCIN FOR A GREATER THAN ADDITIVE EFFECT"
  },
  {
    "Code": "U-187",
    "Definition": "THERAPEUTIC TREATMENT OF CALCIFIC TUMORS"
  },
  {
    "Code": "U-188",
    "Definition": "TREATMENT OF H.PYLORI ASSOCIATED DUODENAL ULCER"
  },
  {
    "Code": "U-189",
    "Definition": "ENHANCEMENT OF THE BIOAVAILABILITY OF THE DRUG SUBSTANCE"
  },
  {
    "Code": "U-190",
    "Definition": "USE OF RITONAVIR IN COMBINATION WITH ANY REVERSE TRANSCRIPTASE INHIBITOR"
  },
  {
    "Code": "U-191",
    "Definition": "METHOD OF TREATMENT FOR CONTROLLING AND LOWERING INTRAOCULAR PRESSURE IN A HUMAN"
  },
  {
    "Code": "U-192",
    "Definition": "USE IN TREATING ALLERGIC REACTIONS"
  },
  {
    "Code": "U-193",
    "Definition": "PSORIASIS"
  },
  {
    "Code": "U-194",
    "Definition": "TREATING ANGINA PECTORIS AND HIGH BLOOD PRESSURE"
  },
  {
    "Code": "U-195",
    "Definition": "METHOD FOR THE DIAGNOSIS OF GASTROINTESTINAL DISORDERS BY UREA ISOTOPE OR NITROGEN LABELED CARBON"
  },
  {
    "Code": "U-196",
    "Definition": "TREATMENT OF METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE TUMORS"
  },
  {
    "Code": "U-197",
    "Definition": "USE IN COMBINATION WITH CERTAIN LHRH ANALOGUES FOR THE TREATMENT OF ADVANCED PROSTATE CANCER"
  },
  {
    "Code": "U-198",
    "Definition": "TREATMENT METASTATIC CARCINOMA OF OVARY AFTER 1ST LINE FAILURE OR SUBSEQUENT CHEMOTHERAPY, TREATMENT OF BREAST CANCER AFTER FAILURE OF COMBINATION CHEMOTHERAPY FOR METASTATIC DISEASE AND 2ND LINE TREATMENT OF AIDS RELATED KAPOSI'S SARCOMA"
  },
  {
    "Code": "U-199",
    "Definition": "METHOD OF TREATING INFECTIOUS UPPER GI TRACT DISORDERS CAUSED BY CAMPYLOBACTER PYLORIDIS INFECTION COMPRISING ADMINISTRATION OF A BISMUTH AGENT AND AN ANTIMICROBIAL AGENT"
  },
  {
    "Code": "U-200",
    "Definition": "METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF A BISMUTH-CONTAINING AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT"
  },
  {
    "Code": "U-201",
    "Definition": "METHOD OF TREATING GI DISORDERS COMPRISING ADMINISTRATION OF CAMPYLOBACTER-INHIBITING ANTIMICROBIAL AGENT AND H2 RECEPTOR BLOCKING ANTI-SECRETORY AGENT"
  },
  {
    "Code": "U-202",
    "Definition": "METHOD OF TREATING PEPTIC ULCER DISEASE CAUSED BY CAMPYLOBACTER PYLORIDIS COMPRISING ORAL ADMINISTRATION OF 50 TO 5,000MG BISMUTH DAILY FOR 3-56 DAYS"
  },
  {
    "Code": "U-203",
    "Definition": "TREATMENT OF ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY"
  },
  {
    "Code": "U-204",
    "Definition": "USE OF TAXOL IN COMBINATION WITH G-CSF FOR TREATMENT OF PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA"
  },
  {
    "Code": "U-205",
    "Definition": "METHOD FOR TREATING HEARTBURN"
  },
  {
    "Code": "U-206",
    "Definition": "METHOD OF USING FSH ALONE, WITHOUT THE PRESENCE OF EXOGENEOUS LH, IN IN VITRO FERTILIZATION"
  },
  {
    "Code": "U-207",
    "Definition": "USE AS NASAL SPRAY"
  },
  {
    "Code": "U-208",
    "Definition": "VAGINAL ADMINISTRATION USING SPECIFIED FORMULATION"
  },
  {
    "Code": "U-209",
    "Definition": "VAGINAL ADMINISTRATION OF PROGESTERONE USING SPECIFIED FORMULATION"
  },
  {
    "Code": "U-210",
    "Definition": "METHOD OF TREATING CONGESTIVE HEART FAILURE"
  },
  {
    "Code": "U-211",
    "Definition": "USE IN PATIENTS WITH REVERSIBLE AIRWAY OBSTRUCTION"
  },
  {
    "Code": "U-212",
    "Definition": "METHOD OF TREATMENT OF PARKINSON'S DISEASE"
  },
  {
    "Code": "U-213",
    "Definition": "METHOD OF INHIBITING CHOLESTEROL BIOSYNTHESIS AND TREATING HYPERCHOLESTEROLEMIA AND METHOD FOR TREATING HYPERLIPIDEMIA"
  },
  {
    "Code": "U-214",
    "Definition": "USE AS A BLOOD GLUCOSE-LOWERING AGENT"
  },
  {
    "Code": "U-215",
    "Definition": "TREATMENT OF EPILEPSY TWICE DAILY. TREATING A PATIENT BY ADMINISTERING CARBAMAZEPINE IN A DOSAGE FORM CAPABLE OF MAINTAINING BLOOD CONCENTRATION FROM 4-12MCG\/ML OVER 12 HOURS"
  },
  {
    "Code": "U-216",
    "Definition": "TREATMENT OF ADENOCARCINOMA, INCLUDING STAGE B2-C BY ADMINISTERING AN AGONIST OF LH-RH AND FLUTAMIDE"
  },
  {
    "Code": "U-217",
    "Definition": "METHOD OF PRODUCING ANESTHESIA"
  },
  {
    "Code": "U-218",
    "Definition": "METHOD FOR LIMITING THE POTENTIAL FOR MICROBIAL GROWTH IN THE DRUG PRODUCT"
  },
  {
    "Code": "U-219",
    "Definition": "TREATMENT OF PARKINSON'S DISEASE"
  },
  {
    "Code": "U-220",
    "Definition": "METHOD OF DIAGNOSIS"
  },
  {
    "Code": "U-221",
    "Definition": "SELECTIVE VASODILATION BY CONTINUOUS ADENOSINE INFUSION"
  },
  {
    "Code": "U-222",
    "Definition": "METHOD OF TREATING PAGET'S DISEASE USING ACTONEL"
  },
  {
    "Code": "U-223",
    "Definition": "TREATMENT OF BACTERIAL CONJUNCTIVITIS CAUSED BY SUSCEPTIBLE STRAINS OF MICROORGANISMS"
  },
  {
    "Code": "U-224",
    "Definition": "CONTROLLING INTRAOCULAR PRESSURE"
  },
  {
    "Code": "U-225",
    "Definition": "METHOD FOR DELIVERY"
  },
  {
    "Code": "U-226",
    "Definition": "METHOD OF ENHANCING THE DISSOLUTION PROFILE OF A PHARMACEUTICAL FROM A SOLID DOSAGE FORM CONTAINING THE PHARMACEUTICAL AND SIMETHICONE"
  },
  {
    "Code": "U-227",
    "Definition": "NASAL ADMINISTRATION"
  },
  {
    "Code": "U-228",
    "Definition": "ASTHMA"
  },
  {
    "Code": "U-229",
    "Definition": "CARDIAC INSUFFICIENCY (CONGESTIVE HEART FAILURE)"
  },
  {
    "Code": "U-230",
    "Definition": "PREVENTION OF ACUTE CARDIAC ISCHEMIC EVENTS"
  },
  {
    "Code": "U-231",
    "Definition": "USE IN PARKINSON'S DISEASE"
  },
  {
    "Code": "U-232",
    "Definition": "METHOD OF TREATING MIGRAINE"
  },
  {
    "Code": "U-233",
    "Definition": "DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE"
  },
  {
    "Code": "U-234",
    "Definition": "METHOD OF USING RIBAVIRIN TO TREAT VIRAL INFECTIONS IN MAMMALS"
  },
  {
    "Code": "U-235",
    "Definition": "METHOD OF MODULATING TH1 AND TH2 RESPONSE IN ACTIVATED T CELLS OF A HUMAN COMPRISING ADMINISTERING RIBAVIRIN TO THE T CELLS IN A DOSAGE WHICH PROMOTES THE TH1 RESPONSE AND SUPPRESSES THE TH2 RESPONSE"
  },
  {
    "Code": "U-236",
    "Definition": "TREATING MALE PATTERN BALDNESS WITH 0.05 TO 3.0MG\/DAY"
  },
  {
    "Code": "U-237",
    "Definition": "METHOD OF PERFORMING NMR IMAGING WITH A PATIENT COMPRISING ADMINISTERING TO THE PATIENT AN EFFECTIVE AMOUNT OF CONTRAST AGENT DISCLOSED IN THE CLAIMS"
  },
  {
    "Code": "U-238",
    "Definition": "IMAGING A BODY TISSUE AND SUBJECTING TO NMR TOMOGRAPHY, ADMINISTERING AN AMOUNT OF PHARMACEUTICAL AGENT FOR AFFECTING THE RELAXATION TIMES OF ATOMS IN BODY TISSUES UNDERGOING NMR DIAGNOSIS, WHEREBY THE IMAGE CONTRAST IN ENHANCED...."
  },
  {
    "Code": "U-239",
    "Definition": "TREATING OR CONTROLLING OCULAR INFLAMMATION WHICH COMPRISES TOPICALLY ADMINISTERING TO AFFECTED EYE A COMPOSITION COMPRISING AN NSAID, A POLYMERIC QUATERNARY AMMONIUM COMPOUND AND BORIC ACID"
  },
  {
    "Code": "U-240",
    "Definition": "TREATMENT OF ACUTE MIGRAINE ATTACKS"
  },
  {
    "Code": "U-241",
    "Definition": "FOR SHORT-TERM TREATMENT ACTIVE DUODENAL ULCER, MAINTENANCE THERAPY FOR DUODENAL ULCER PATIENTS AT REDUCED DOSAGE AFTER HEALING OF ACTIVE ULCER, SHORT-TERM TREATMENT ACTIVE BENIGN GASTRIC ULCER & GERD, PATHOLOGICAL HYPERSECRETORY CONDITIONS"
  },
  {
    "Code": "U-242",
    "Definition": "USE OF FOLLITROPIN ALPHA ALONE IN IN-VITRO FERTILIZATION"
  },
  {
    "Code": "U-243",
    "Definition": "TOPICAL ADMINISTRATION"
  },
  {
    "Code": "U-244",
    "Definition": "PLATELET AGGREGATION INHIBITORS"
  },
  {
    "Code": "U-245",
    "Definition": "TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS"
  },
  {
    "Code": "U-246",
    "Definition": "PHOSPHATE BINDING"
  },
  {
    "Code": "U-247",
    "Definition": "TREATMENT OF RHEUMATOID ARTHRITIS"
  },
  {
    "Code": "U-248",
    "Definition": "TREATMENT OF HIV"
  },
  {
    "Code": "U-249",
    "Definition": "METHOD OF TREATING ALLERGIC OR NON-ALLERGIC RHINITIS IN PATIENTS BY ADMINISTERING AEROSOLIZED PARTICLES OF MOMETASONE FUROATE"
  },
  {
    "Code": "U-250",
    "Definition": "TREATMENT OF HEPATITIS B INFECTION"
  },
  {
    "Code": "U-251",
    "Definition": "USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS IN THE TREATMENT OF TYPE II DIABETES"
  },
  {
    "Code": "U-252",
    "Definition": "METHOD OF TREATING A HUMAN SUBJECT HAVING GAUCHER'S DISEASE"
  },
  {
    "Code": "U-253",
    "Definition": "ORAL TRANSMUCOSAL USE"
  },
  {
    "Code": "U-254",
    "Definition": "USE OF AGGRASTAT IN COMBINATION WITH HEPARIN"
  },
  {
    "Code": "U-255",
    "Definition": "IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY"
  },
  {
    "Code": "U-256",
    "Definition": "TREATMENT OF HIV INFECTION IN COMBINATION WITH ONE OR MORE ADDITIONAL HIV ANTIVIRAL AGENTS"
  },
  {
    "Code": "U-257",
    "Definition": "TREATMENT OF HIV INFECTION"
  },
  {
    "Code": "U-258",
    "Definition": "TREATMENT OF NEURODEGENERATIVE DISEASES"
  },
  {
    "Code": "U-259",
    "Definition": "TREATMENT OF ANDROGENIC ALOPECIA BY ORAL ADMINISTRATION DRUG SUBSTANCE"
  },
  {
    "Code": "U-260",
    "Definition": "REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA AND OCULAR HYPERTENSION WHO ARE INTOLERANT OF OTHER IOP LOWERING MEDICATIONS OR INSUFFICIENTLY RESPONSIVE TO ANOTHER IOP LOWERING MEDICATION"
  },
  {
    "Code": "U-261",
    "Definition": "TREATING BENIGN PROSTATIC HYPERPLASIA WITH A GENUS OF COMPOUNDS, INCLUDING FINASTERIDE"
  },
  {
    "Code": "U-262",
    "Definition": "TREATING BENIGN PROSTATIC HYPERTROPHY WITH FINASTERIDE"
  },
  {
    "Code": "U-263",
    "Definition": "METHOD OF TREATING A MALIGNANT CONDITION THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING LEUKEMIA OR LYMPHOMA IN A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVENOUS ADMINISTRATION OF BUSULFAN"
  },
  {
    "Code": "U-264",
    "Definition": "METHOD OF TREATING A MALIGNANT DISEASE THROUGH PARENTERAL ADMINISTRATION OF BUSULFAN. METHOD FOR TREATING A PATIENT UNDERGOING A BONE MARROW TRANSPLANT THROUGH INTRAVASCULAR ADMINISTRATION OF BUSULFAN"
  },
  {
    "Code": "U-265",
    "Definition": "USE AS LAXATIVE"
  },
  {
    "Code": "U-266",
    "Definition": "RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS; RELIEF OF THE SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS IN ADULTS; MANAGEMENT OF ACUTE PAIN IN ADULTS; TREATMENT OF PRIMARY DYSMENORRHEA; ACUTE TREATMENT OF MIGRAINE ATTACKS IN ADULTS"
  },
  {
    "Code": "U-267",
    "Definition": "PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD\/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD\/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE"
  },
  {
    "Code": "U-268",
    "Definition": "ACROMEGALY"
  },
  {
    "Code": "U-269",
    "Definition": "EXCESS GH-SECRETION OR GASTRO-INTESTINAL DISORDERS"
  },
  {
    "Code": "U-270",
    "Definition": "METHOD OF IMPROVING THE TIME FOR ADMINISTRATION OR THE TIME BETWEEN CHANGES OF GIVING SETS FOR THE DRUG PRODUCT"
  },
  {
    "Code": "U-271",
    "Definition": "METHOD OF TREATING TUMORS"
  },
  {
    "Code": "U-272",
    "Definition": "METHOD OF TREATING CARCINOMA"
  },
  {
    "Code": "U-273",
    "Definition": "CUTANEOUS T-CELL LYMPHOMA"
  },
  {
    "Code": "U-274",
    "Definition": "ZANAMIVIR FOR INHALATION"
  },
  {
    "Code": "U-275",
    "Definition": "METHOD OF USE OF THE DRUG SUBSTANCE"
  },
  {
    "Code": "U-276",
    "Definition": "METHOD OF USE OF LEVOBUPIVACAINE"
  },
  {
    "Code": "U-277",
    "Definition": "NEUROLOGICAL AND OTHER DISORDERS (TREATMENT OF EPILEPSY, BID ORAL DOSING)"
  },
  {
    "Code": "U-278",
    "Definition": "METHOD OF USE OF THE INDICATION OF THE DRUG PRODUCT"
  },
  {
    "Code": "U-279",
    "Definition": "METHOD OF USE OF THE APPROVED PRODUCT"
  },
  {
    "Code": "U-280",
    "Definition": "TREATING PRECIPITATED ACUTE URINARY RETENTION WITH FINASTERIDE"
  },
  {
    "Code": "U-281",
    "Definition": "ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS"
  },
  {
    "Code": "U-282",
    "Definition": "METHOD OF TREATING BACTERIAL INFECTIONS"
  },
  {
    "Code": "U-283",
    "Definition": "METHOD FOR TREATING MENOPAUSAL SYMPTOMS IN A POSTMENOPAUSAL FEMALE"
  },
  {
    "Code": "U-284",
    "Definition": "MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE, AND VULVAR AND VAGINAL ATROPHY) AND OSTEOPOROSIS"
  },
  {
    "Code": "U-285",
    "Definition": "DEPRESSION AND SOCIAL ANXIETY DISORDER\/SOCIAL PHOBIA"
  },
  {
    "Code": "U-286",
    "Definition": "DEPRESSION"
  },
  {
    "Code": "U-287",
    "Definition": "TREATMENT OR PREVENTION OF OSTEOPOROSIS"
  },
  {
    "Code": "U-288",
    "Definition": "THERAPY OF INFLUENZA"
  },
  {
    "Code": "U-289",
    "Definition": "TREATMENT OF NON-HYPERKERATOTIC ACTINIC KERATOSES OF FACE AND SCALP"
  },
  {
    "Code": "U-290",
    "Definition": "INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS)"
  },
  {
    "Code": "U-291",
    "Definition": "INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH CYCLOSPORIN"
  },
  {
    "Code": "U-292",
    "Definition": "INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH AZATHIOPRINE"
  },
  {
    "Code": "U-293",
    "Definition": "INHIBITING TRANSPLANT REJECTION USING RAPAMYCIN (SIROLIMUS) IN COMBINATION WITH A CORTICOSTEROID"
  },
  {
    "Code": "U-294",
    "Definition": "TREATMENT OF HYPERPIGMENTARY DISORDERS"
  },
  {
    "Code": "U-295",
    "Definition": "TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS"
  },
  {
    "Code": "U-296",
    "Definition": "TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY"
  },
  {
    "Code": "U-297",
    "Definition": "PREVENTION OR TREATMENT OF REVERSIBLE VASOCONSTRICTION BY THE INHALATION OF NITRIC OXIDE WITH AN OXYGEN CONTAINING GAS"
  },
  {
    "Code": "U-298",
    "Definition": "METHOD OF COMBATING BACTERIA IN A PATIENT"
  },
  {
    "Code": "U-299",
    "Definition": "TREATMENT OF ADENOMATOUS POLYPS"
  },
  {
    "Code": "U-300",
    "Definition": "INDICATED FOR THE REDUCTION OF ELEVATED TOTAL AND LDL CHOLESTEROL LEVELS IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA"
  },
  {
    "Code": "U-301",
    "Definition": "USE OF TROGLITAZONE IN COMBINATION WITH SULFONYLUREAS AND BIGUANIDES IN THE TREATMENT OF TYPE II DIABETES"
  },
  {
    "Code": "U-302",
    "Definition": "TO REDUCE THE RISK OF STROKE IN PATIENTS WHO HAVE HAD TRANSIENT ISCHEMIA OF THE BRAIN OR COMPLETED ISCHEMIC STROKE DUE TO THROMBOSIS"
  },
  {
    "Code": "U-303",
    "Definition": "METHOD OF USE PATENT-PRODUCT APPROVED FOR TREATMENT OF OSTEOPOROSIS, PAGET'S DISEASE, PREVENTION AND TREATMENT OF GLUCOCORTICOID INDUCED OSTEOPOROSIS"
  },
  {
    "Code": "U-304",
    "Definition": "A METHOD OF TREATMENT OF A CONDITION INVOLVING AN ANTIBODY ANTIGEN REACTION"
  },
  {
    "Code": "U-305",
    "Definition": "METHODS FOR USING THE DRUG PRODUCT"
  },
  {
    "Code": "U-306",
    "Definition": "TREATMENT OF POST-MENOPAUSAL UROGENITAL SYMPTOMS ASSOCIATED WITH ESTROGEN DEFICIENCY"
  },
  {
    "Code": "U-307",
    "Definition": "CLAIMS AN OLANZAPINE POLYMORPH USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOSES,EMPLOYING OLANZAPINE AS PER THE INDICATION OF THIS NDA"
  },
  {
    "Code": "U-308",
    "Definition": "CLAIMS A SOLID ORAL FORMULATION INCLUDING TABLETS AND GRANULES OF OLANZAPINE USEFUL FOR TREATING ANY NUMBER OF LISTED CONDITIONS, INCLUDING SPECIFIC PSYCHOLES, EMPLOYING OLANZAPINE AS PER THE INDICATIONS OF THIS NDA"
  },
  {
    "Code": "U-309",
    "Definition": "TREATING SJOEGREN SYNDROME"
  },
  {
    "Code": "U-310",
    "Definition": "TREATMENT OF XEROSTOMIA"
  },
  {
    "Code": "U-311",
    "Definition": "HORMONE REPLACEMENT"
  },
  {
    "Code": "U-312",
    "Definition": "PANIC DISORDER, OBSESSIVE-COMPULSIVE DISORDER, POSTTRAUMATIC STRESS DISORDER"
  },
  {
    "Code": "U-313",
    "Definition": "TREATMENT OF CONGESTIVE HEART FAILURE"
  },
  {
    "Code": "U-314",
    "Definition": "METHOD FOR TREATING HYPERPARATHYROIDISM WHICH COMPRISES SUPPRESSING PARATHYROID ACTIVITY"
  },
  {
    "Code": "U-315",
    "Definition": "METHOD FOR ADMINISTERING DRUG TO GASTROINTESTINAL TRACT"
  },
  {
    "Code": "U-316",
    "Definition": "METHOD OF TREATING A SUBJECT SUFFERING FROM PROSTATE CANCER"
  },
  {
    "Code": "U-317",
    "Definition": "METHOD OF USING TROGLITAZONE TO TREAT PATIENTS HAVING INSULIN RESISTANCE"
  },
  {
    "Code": "U-318",
    "Definition": "TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE"
  },
  {
    "Code": "U-319",
    "Definition": "TREATMENT OF MICROBIAL INFECTIONS"
  },
  {
    "Code": "U-320",
    "Definition": "INHIBITING OR ELIMINATING ACUTE MYELOID LEUKEMIA"
  },
  {
    "Code": "U-321",
    "Definition": "REDUCTION OF ELEVATED IPTH LEVELS IN THE MGT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS UNDERGONG CHRONIC RENAL DIALYSIS"
  },
  {
    "Code": "U-322",
    "Definition": "TREATMENT OF ALZHEIMER'S DEMENTIA"
  },
  {
    "Code": "U-323",
    "Definition": "USE AS A BILE ACID SEQUESTRANT"
  },
  {
    "Code": "U-324",
    "Definition": "METHOD OF TREATING AN ANIMAL, INCLUDING A HUMAN, SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS OR ACUTE MANIA EMPLOYING OLANZAPINE"
  },
  {
    "Code": "U-325",
    "Definition": "METHOD OF TREATING A PATIENT SUFFERING  FROM ANY OF A NUMBER OF LISTED CONDITIONS, INCLUDING 'BIPOLAR DISORDER NOS' EMPLOYING OLANZAPINE"
  },
  {
    "Code": "U-326",
    "Definition": "METHOD OF TREATING SCHIZOPHRENIA AND BIPOLAR DISORDER"
  },
  {
    "Code": "U-327",
    "Definition": "METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED PSYCHOTIC CONDITIONS EMPLOYING OLANZAPINE"
  },
  {
    "Code": "U-328",
    "Definition": "METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF LISTED CONDITIONS INCLUDING 'A PSYCHOTIC CONDITION' EMPLOYING AN OLANZAPINE POLYMORPH"
  },
  {
    "Code": "U-329",
    "Definition": "USE OF AVANDIA AS MONOTHERAPY, IN COMBINATION WITH METFORMIN, AND IN COMBINATION WITH SULFONYLUREAS TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS"
  },
  {
    "Code": "U-330",
    "Definition": "TREATMENT OF NAUSEA AND VOMITING"
  },
  {
    "Code": "U-331",
    "Definition": "METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT"
  },
  {
    "Code": "U-332",
    "Definition": "TREATMENT OR PREVENTION OF BRONCHOSPASM"
  },
  {
    "Code": "U-333",
    "Definition": "METHOD OF TREATING OCULAR HYPERTENSION"
  },
  {
    "Code": "U-334",
    "Definition": "TREATMENT OF EXCESSIVE FEMALE FACIAL HAIR"
  },
  {
    "Code": "U-335",
    "Definition": "USE OF PRAVASTATIN SODIUM FOR SECONDARY PREVENTION OF CORONARY EVENTS IN MEN AND WOMEN WHO HAVE HAD A MYOCARDIAL INFARCTION AND HAVE NORMAL CHOLESTEROL LEVELS"
  },
  {
    "Code": "U-336",
    "Definition": "DIAGNOSTIC RADIOIMAGING"
  },
  {
    "Code": "U-337",
    "Definition": "USE OF CARDIOLITE\/MIRALUMA KIT FOR THE PREPARATION OF TC99M SESTAMIBI"
  },
  {
    "Code": "U-338",
    "Definition": "METHODS FOR TREATING DISTURBANCES OF MOOD, DISTURBANCES OF APPETITE, DEPRESSED MOOD, OR CARBOHYDRATE CRAVING ALL ASSOCIATED WITH PREMENSTRUAL SYNDROME"
  },
  {
    "Code": "U-339",
    "Definition": "PREVENTION OF CARDIO-TOXICITY CAUSED BY THE ADMINISTRATION OF DOXORUBICIN"
  },
  {
    "Code": "U-340",
    "Definition": "THE LONG TERM TREATMENT OF GROWTH FAILURE DUE TO LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION IN CHILDREN"
  },
  {
    "Code": "U-341",
    "Definition": "METHOD FOR ENHANCING THE TREATMENT OF ... LATE LUTEAL PHASE DYSPHORIC DISORDER"
  },
  {
    "Code": "U-342",
    "Definition": "METHOD FOR TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER"
  },
  {
    "Code": "U-343",
    "Definition": "REDUCTION OF INTESTINAL GAS, CRAMPING AND ANORECTAL IRRITATION"
  },
  {
    "Code": "U-344",
    "Definition": "METHOD FOR INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH ANOTHER HIV PROTEASE INHIBITOR"
  },
  {
    "Code": "U-345",
    "Definition": "RITONAVIR AND ANOTHER HIV PROTEASE INHIBITOR FOR CONCOMITANT ADMINISTRATION FOR THE TREATMENT OF AN HIV INFECTION"
  },
  {
    "Code": "U-346",
    "Definition": "METHOD FOR INHIBITING CYTOCHROME P450 MONOOXYGENASE WITH RITONAVIR AND A METHOD FOR IMPROVING THE PHARMACOKINETICS OF A DRUG THAT IS METABOLIZED BY CYTOCHROME P450 MONOOXYGENASE BY ADMIN THE DRUG AND RITONAVIR"
  },
  {
    "Code": "U-347",
    "Definition": "METHOD OF USE IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS"
  },
  {
    "Code": "U-348",
    "Definition": "METHOD OF USE FOR INHIBITING HIV INFECTION"
  },
  {
    "Code": "U-349",
    "Definition": "METHOD OF USE WHICH IS SUBJECT OF THE APPLICATION"
  },
  {
    "Code": "U-350",
    "Definition": "PREPARATION OF A PHARMACEUTICAL COMPOSITION FOR CONCOMITANT ADMIN WITH A REVERSE TRANSCRIPTASE INHIBITOR"
  },
  {
    "Code": "U-351",
    "Definition": "INHIBITING PROTEASE WITH LOPINAVIR AND INHIBITING AN HIV INFECTION WITH LOPINAVIR"
  },
  {
    "Code": "U-352",
    "Definition": "INHIBITING HIV INFECTION BY ADMINISTERING RITONAVIR IN COMBINATION WITH A REVERSE TRANSCRIPTASE INHIBITOR"
  },
  {
    "Code": "U-353",
    "Definition": "PREVENTION AND TREATMENT OF OSTEOPOROSIS"
  },
  {
    "Code": "U-354",
    "Definition": "METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT"
  },
  {
    "Code": "U-355",
    "Definition": "METHOD OF ASSISTING PERSON TO QUIT SMOKING...TRANSDERMALLY ADMIN NICOTINE VIA..PATCH ADHERED TO SKIN AT DOSING RATE APPROX SAME AS ABSORBED FROM SMOKING"
  },
  {
    "Code": "U-356",
    "Definition": "DELIVERING A MEDICINAL AEROSOL FORMULATION USING CFC-FREE PROPELLANT 134A."
  },
  {
    "Code": "U-357",
    "Definition": "USE OF THE DRUG PRODUCT IN PHOTODYNAMIC THERAPEUTIC PROTOCOLS FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND RELATED CONDITIONS INVOLVING UNWANTED NEOVASCULATURE IN THE EYE"
  },
  {
    "Code": "U-358",
    "Definition": "DEPRESSION, OBSESSIVE COMPULSIVE DISORDER, PANIC DISORDER AND SOCIAL ANXIETY DISORDER"
  },
  {
    "Code": "U-359",
    "Definition": "METHOD OF USE OF VISICOL"
  },
  {
    "Code": "U-360",
    "Definition": "METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS INCLUDING MENTAL DISORDERS EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011"
  },
  {
    "Code": "U-361",
    "Definition": "MANAGEMENT OF ANXIETY DISORDERS AND THE SHORT-TERM RELIEF OF THE SYMPTOMS OF ANXIETY"
  },
  {
    "Code": "U-362",
    "Definition": "USE OF APPROVED FORMULATIONS TO TREAT ALL APPROVED DISEASE INDICATIONS"
  },
  {
    "Code": "U-363",
    "Definition": "METHOD OF TREATING A PATIENT SUFFERING FROM ANY OF A NUMBER OF PATHOLOGICAL PSYCHOLOGICAL CONDITIONS THAT RELATE TO THE USE OF A PSYCHOACTIVE SUBSTANCE EMPLOYING OLANZAPINE AS PER THE INDICATION THE SUBJECT MATTER OF SUPPLEMENT 011"
  },
  {
    "Code": "U-364",
    "Definition": "TREATING A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ANY NUMBER OF LISTED CONDITIONS INCLUDING PSYCHOSIS, EMPLOYING OLANZAPINE AS PER THE INDICATION WHICH IS THE SUBJECT MATTER OF THIS SNDA-011"
  },
  {
    "Code": "U-365",
    "Definition": "METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN OUR EXTENDED, CONTROLLED RELEASE FORMULATION"
  },
  {
    "Code": "U-366",
    "Definition": "METHOD FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THROUGH THE ADMINISTRATION OF A CALCIUM BLOCKING VASODILATOR IN A DELAYED RELEASE FORMULATION"
  },
  {
    "Code": "U-367",
    "Definition": "TREATMENT OF CARDIOVASCULAR DISORDERS"
  },
  {
    "Code": "U-368",
    "Definition": "HEARTBURN"
  },
  {
    "Code": "U-369",
    "Definition": "METHOD OF CONTROLLING AND LOWERING INTRAOCULAR PRESSURE"
  },
  {
    "Code": "U-370",
    "Definition": "INTRAVAGINAL TREATMENT OF VAGINAL INFECTIONS WITH BUFFERED METRONIDAZOLE COMPOSITIONS"
  },
  {
    "Code": "U-371",
    "Definition": "APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED 'SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY' (S.T.E.P.S.)"
  },
  {
    "Code": "U-372",
    "Definition": "METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL..."
  },
  {
    "Code": "U-373",
    "Definition": "GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING 'PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OF GERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE"
  },
  {
    "Code": "U-374",
    "Definition": "KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX"
  },
  {
    "Code": "U-375",
    "Definition": "METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C"
  },
  {
    "Code": "U-376",
    "Definition": "TREATMENT OF INFLUENZA"
  },
  {
    "Code": "U-377",
    "Definition": "METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES\/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS"
  },
  {
    "Code": "U-378",
    "Definition": "METHOD FOR TREATING INCONTINENCE"
  },
  {
    "Code": "U-379",
    "Definition": "METHOD OF TREATING ONYCHOMYCOSIS"
  },
  {
    "Code": "U-380",
    "Definition": "COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS"
  },
  {
    "Code": "U-381",
    "Definition": "TREATMENT OF HYPERPHOSPHATEMIA"
  },
  {
    "Code": "U-382",
    "Definition": "METHOD OF STABILIZING PROSTAGLANDIN"
  },
  {
    "Code": "U-383",
    "Definition": "METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION"
  },
  {
    "Code": "U-384",
    "Definition": "TREATMENT OF CMV RETINITIS"
  },
  {
    "Code": "U-385",
    "Definition": "TREATMENT OF PEPTIC ULCERS"
  },
  {
    "Code": "U-386",
    "Definition": "TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA"
  },
  {
    "Code": "U-387",
    "Definition": "TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS"
  },
  {
    "Code": "U-388",
    "Definition": "SMOKING CESSATION AID APPLIED TO THE SKIN"
  },
  {
    "Code": "U-389",
    "Definition": "SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS"
  },
  {
    "Code": "U-390",
    "Definition": "METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS)"
  },
  {
    "Code": "U-391",
    "Definition": "USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER"
  },
  {
    "Code": "U-392",
    "Definition": "TREATMENT OF PATIENTS FOR INFLAMMATION"
  },
  {
    "Code": "U-393",
    "Definition": "MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT"
  },
  {
    "Code": "U-394",
    "Definition": "METHOD OF USE OF ALPHAGAN"
  },
  {
    "Code": "U-395",
    "Definition": "METHOD OF USE OF ALPHAGAN P"
  },
  {
    "Code": "U-396",
    "Definition": "METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION"
  },
  {
    "Code": "U-397",
    "Definition": "METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA"
  },
  {
    "Code": "U-398",
    "Definition": "TREATMENT OF GENERALIZED ANXIETY DISORDER"
  },
  {
    "Code": "U-399",
    "Definition": "IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS"
  },
  {
    "Code": "U-400",
    "Definition": "USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESP0NSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS"
  },
  {
    "Code": "U-401",
    "Definition": "USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS"
  },
  {
    "Code": "U-402",
    "Definition": "TREATMENT OF ACTINIC KERATOSES"
  },
  {
    "Code": "U-403",
    "Definition": "ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES"
  },
  {
    "Code": "U-404",
    "Definition": "TREATMENT OF ALLERGIC CONJUNCTIVITIS"
  },
  {
    "Code": "U-405",
    "Definition": "FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS)"
  },
  {
    "Code": "U-406",
    "Definition": "METHOD OF USE OF ATOVAQUONE AND PROGUANIL"
  },
  {
    "Code": "U-407",
    "Definition": "METHOD OF TREATING OTOPATHY"
  },
  {
    "Code": "U-408",
    "Definition": "FOR INDUCING OVULATION IN CONJUNCTION WITH A GONADOTROPIN RELEASING FACTOR ANTAGONIST AND RECRUITING OOCYTES FOR IN-VITRO FERTILIZATION"
  },
  {
    "Code": "U-409",
    "Definition": "METHOD OF TREATING INFLAMMATION USING DRUG SUBSTANCE"
  },
  {
    "Code": "U-410",
    "Definition": "METHOD OF REDUCING AMOUNT OF RESPECTIVE ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (INCLUDING PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER"
  },
  {
    "Code": "U-411",
    "Definition": "METHOD OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN PREPARATION"
  },
  {
    "Code": "U-412",
    "Definition": "TREATMENT OF TYPE 2 DIABETES"
  },
  {
    "Code": "U-413",
    "Definition": "USE OF THE ACTIVE INGREDIENT FOR INHIBITING THE BIOSYNTHESIS OF CHOLESTEROL AND TREATMENT OF ATHEROSCLEROSIS"
  },
  {
    "Code": "U-414",
    "Definition": "A METHOD OF TREATING GLYCOMETABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE"
  },
  {
    "Code": "U-415",
    "Definition": "A METHOD FOR REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS"
  },
  {
    "Code": "U-416",
    "Definition": "A METHOD FOR REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE AS SAID ACTIVE COMPONENTS"
  },
  {
    "Code": "U-417",
    "Definition": "COMBINATION USE OF AD-4833 WITH A BIGUANIDE"
  },
  {
    "Code": "U-418",
    "Definition": "A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING A CHEMICAL COMPOUND HAVING A PARTICULAR FORMULA (WHICH INCLUDES PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER"
  },
  {
    "Code": "U-419",
    "Definition": "A METHOD OF TREATING LIPID METABOLISM DISORDERS BY ADMINISTERING AN INSULIN SENSITIVITY ENHANCER (INCLUDING PIOGLITAZONE) IN COMBINATION WITH A BIGUANIDE"
  },
  {
    "Code": "U-420",
    "Definition": "METHOD OF TREATMENT OF TYPE II DIABETES"
  },
  {
    "Code": "U-421",
    "Definition": "USE FOR SEDATION"
  },
  {
    "Code": "U-422",
    "Definition": "METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER AND ATTENTION DEFICIT HYPERACTIVITY DISORDER"
  },
  {
    "Code": "U-423",
    "Definition": "METHOD OF TREATING AT LEAST ONE OF ATTENTION DEFICIT DISORDER, ATTENTION DEFICIT HYPERACTIVITY DISORDER, OR AIDS RELATED DEMENTIA"
  },
  {
    "Code": "U-424",
    "Definition": "FOR ONCE DAILY, BOLUS ADMINISTRATION TO A PATIENT IN ORDER TO ENGENDER TREATMENT FOR A NERVOUS DISORDER FOR SUBSTANTIALLY AN ENTIRE DAY ON A CHRONIC BASIS"
  },
  {
    "Code": "U-425",
    "Definition": "METHOD OF REDUCING SIDE EFFECTS OF ACTIVE COMPONENTS ADMIN TO A DIABETIC BY ADMIN A CHEMICAL COMPOUND HAVING FORMULA (INCL PIOGLITAZONE) IN COMBINATION WITH AN INSULIN SECRETION ENHANCER"
  },
  {
    "Code": "U-426",
    "Definition": "PREVENTION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN STIMULATION"
  },
  {
    "Code": "U-427",
    "Definition": "METHOD OF TREATING ALLERGIC REACTIONS IN MAMMALS"
  },
  {
    "Code": "U-428",
    "Definition": "METHOD OF TREATING ALLERGY IN A MAMMAL USING THIS ACTIVE METABOLITE"
  },
  {
    "Code": "U-429",
    "Definition": "METHOD OF USING DESLORATADINE TO TREAT ALLERGIC RHINITIS"
  },
  {
    "Code": "U-430",
    "Definition": "METHOD OF TREATING A DIABETIC BY ADMINISTERING AN INSULIN SENSITIZER IN COMBINATION WITH AN INSULIN SECRETION ENHANCER, AND A DRUG PRODUCT COMPRISING AN INSULIN SENSITIZER AND AN INSULIN SECRETION ENHANCER"
  },
  {
    "Code": "U-431",
    "Definition": "POSTTRAUMATIC STRESS DISORDER"
  },
  {
    "Code": "U-432",
    "Definition": "REDUCTION OF ATHEROSCLEROTIC EVENTS (MYOCARDIAL INFARCTION, STROKE, AND VASCULAR DEATH) IN PATIENTS WITH ATHEROSCLEROSIS DOCUMENTED BY RECENT STROKE, RECENT MYOCARDIAL INFARCTION OR ESTABLISHED PERIPHERAL ARTERIAL DISEASE"
  },
  {
    "Code": "U-433",
    "Definition": "USE OF LEVOCARNITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS"
  },
  {
    "Code": "U-434",
    "Definition": "CONTROLLED SYMPTOMS OF DIARRHEA, BLOATING PRESSURE AND CRAMPS, COMMONLY REFERRED TO AS GAS"
  },
  {
    "Code": "U-435",
    "Definition": "A TITRATION DOSING REGIMEN FOR THE TREATMENT OF PAIN USING AN INITIAL DOSE OF ABOUT 25MG"
  },
  {
    "Code": "U-436",
    "Definition": "ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS"
  },
  {
    "Code": "U-437",
    "Definition": "METHOD OF USE EQUAL TO PROCESS OF PREPARATION"
  },
  {
    "Code": "U-438",
    "Definition": "TREATMENT\/PREVENTION OF NEURODEGENERATIVE DISEASE"
  },
  {
    "Code": "U-439",
    "Definition": "TREATMENT OF OBESITY"
  },
  {
    "Code": "U-440",
    "Definition": "METHOD FOR TRANSDERMAL ADMINISTRATION OF A DRUG THROUGH NON-SCROTAL SKIN USING A TRANSDERMAL DRUG DELIVERY DEVICE CONTAINING THE DRUG AND HAVING AN ADHESIVE SURFACE"
  },
  {
    "Code": "U-441",
    "Definition": "METHOD OF TREATING MS BY ADMINISTERING COPAXONE"
  },
  {
    "Code": "U-442",
    "Definition": "METHOD FOR DELIVERING A DRUG TO A PATIENT IN NEED OF THE DRUG, WHILE AVOIDING THE OCCURRENCE OF AN ADVERSE SIDE EFFECT KNOWN OR SUSPECTED OF BEING CAUSED BY SAID DRUG"
  },
  {
    "Code": "U-443",
    "Definition": "MANAGEMENT OF MODERATE TO SEVERE PAIN WHEN A CONTINUOUS, AROUND-THE-CLOCK ANALGESIC IS NEEDED FOR AN EXTENDED PERIOD OF TIME"
  },
  {
    "Code": "U-444",
    "Definition": "TREATMENT OF MIGRAINE"
  },
  {
    "Code": "U-445",
    "Definition": "USE AS AN ANTIMYCOTIC AGENT"
  },
  {
    "Code": "U-446",
    "Definition": "TOPICAL TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA"
  },
  {
    "Code": "U-447",
    "Definition": "METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT"
  },
  {
    "Code": "U-448",
    "Definition": "METHOD OF TREATING HYPERLIPIDEMIA WITH NICOTINIC ACID WITHOUT CAUSING TREATMENT-LIMITING ELEVATIONS IN URIC ACID OR GLUCOSE LEVELS OR CAUSING LIVER DAMAGE, BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT"
  },
  {
    "Code": "U-449",
    "Definition": "USE IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER WHERE THE DOSE OF LEUCOVORIN IS AT LEAST 200MG PER SQUARE METER"
  },
  {
    "Code": "U-450",
    "Definition": "INTERMEDIATE REL NICOTINIC ACID FORMULATIONS HAVING UNIQUE URINARY METAB PROFILES RESULTING FROM ABSORPTION PROFILES OF NICOTINIC ACID FROM THE INTERMEDIATE NICOTINIC ACID FORMULATIONS,SUITABLE FOR TX HYPERLIPIDEMIA FOLLOWING QD DOSING"
  },
  {
    "Code": "U-451",
    "Definition": "TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER"
  },
  {
    "Code": "U-452",
    "Definition": "USE OF LANSOPRAZOLE FOR COMBATTING DISEASES CAUSED BY THE GENUS CAMPYLOBACTER (C.PYLORI=H.PYLORI)"
  },
  {
    "Code": "U-453",
    "Definition": "TREATMENT OF PLATELET ASSOCIATED ISCHEMIC DISORDERS"
  },
  {
    "Code": "U-454",
    "Definition": "METHOD OF TX A PT SUSPECTED OF HAVING HEPATITIS C BY ADMIN, IN COMBINATION, A CONJUGATE COMPRISING PEG 12000 & INTERFERON ALFA-2B IN AN AMT OF FROM 0.5MCG\/KG TO 2MCG\/KG, ONCE WEEKLY, AND RIBAVIRIN"
  },
  {
    "Code": "U-455",
    "Definition": "TREATMENT OF PULMONARY HYPERTENSION WITH UT-15"
  },
  {
    "Code": "U-456",
    "Definition": "METHOD OF DECREASING THE PRODUCTION OF A-BETA USING A COMPOSITION WHICH DECREASES BLOOD CHOLESTEROL IN PATIENTS AT RISK OF OR EXHIBITING SYMPTOMS OF ALZHEIMER'S DISEASE"
  },
  {
    "Code": "U-457",
    "Definition": "METHOD OF TREATING A VAGINAL FUNGAL INFECTION IN A FEMALE HUMAN"
  },
  {
    "Code": "U-458",
    "Definition": "METHOD OF USE OF IMAGENT"
  },
  {
    "Code": "U-459",
    "Definition": "TREATMENT OF DEPRESSION AND GENERALIZED ANXIETY DISORDER"
  },
  {
    "Code": "U-460",
    "Definition": "METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING SERTRALINE"
  },
  {
    "Code": "U-461",
    "Definition": "METHOD OF TREATMENT OF LATE LUTEAL PHASE DYSPHORIC DISORDER (PMDD) USING SERTRALINE"
  },
  {
    "Code": "U-462",
    "Definition": "SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND ADULT RHEUMATOID ARTHRITIS AND TREATMENT OF PRIMARY DYSMENORRHEA"
  },
  {
    "Code": "U-463",
    "Definition": "VENOGRAPHY"
  },
  {
    "Code": "U-464",
    "Definition": "PERIPHERAL ARTERIOGRAPHY"
  },
  {
    "Code": "U-465",
    "Definition": "CT IMAGING OF THE HEAD"
  },
  {
    "Code": "U-466",
    "Definition": "TREATMENT OF IRRITABLE BOWEL SYNDROME"
  },
  {
    "Code": "U-467",
    "Definition": "USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR FOR TREATING HYPERTENSION"
  },
  {
    "Code": "U-468",
    "Definition": "METHOD OF USING FEXOFENADINE HCL IN TREATING ALLERGIC RHINITIS"
  },
  {
    "Code": "U-469",
    "Definition": "TREATMENT OF GASTROESOPHAGEAL REFLEX DISEASE (GERD) AND ERADICATION OF H.PYLORI TO REDUCE RISK OF DUODENAL ULCER RECURRENCE"
  },
  {
    "Code": "U-470",
    "Definition": "THERAPY IN CHRONIC HEPATITIS B VIRUS INFECTION"
  },
  {
    "Code": "U-471",
    "Definition": "METHOD OF TREATING A PATIENT SUFFERING FROM DIABETES MELLITUS"
  },
  {
    "Code": "U-472",
    "Definition": "TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING METHYLPHENIDATE BI-MODAL RELEASE PROFILE EXTENDED-RELEASE CAPSULES"
  },
  {
    "Code": "U-473",
    "Definition": "TO REDUCE PLASMA CHOLESTEROL LEVELS IN A MAMMAL"
  },
  {
    "Code": "U-474",
    "Definition": "TO REDUCE PLASMA CHOLESTEROL LEVELS BY ADMIN EZETIMIBE IN COMBO WITH CHOLESTEROL BIOSYNTHESIS INHIB SELECTED FROM GROUP CONSISTING OF HMG COA REDUCTASE INHIBITORS INCL SIMVASTATIN"
  },
  {
    "Code": "U-475",
    "Definition": "TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY"
  },
  {
    "Code": "U-476",
    "Definition": "METHOD OF TREATING ANDROGEN RESPONSIVE\/MEDIATED CONDITION IN MAMMAL BY ADMIN A SAFE, EFFECTIVE AMOUNT OF DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE DERIVATIVE THEREOF..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY"
  },
  {
    "Code": "U-477",
    "Definition": "METHOD OF INHIBITING 5 ALPHA TESTOSTERONE REDUCTASE ENZYME WITH DUTASTERIDE OR ITS DERIVATIVE AND TREATING ANDROGEN RESPONSIVE\/MEDIATED DISEASE INCLUDING BENIGN PROSTATIC HYPERPLASIA"
  },
  {
    "Code": "U-478",
    "Definition": "METHOD OF TREATING HEPATITIS C VIRAL INFECTION BY CONTINUOUS PARENTERAL ADMIN INTERFERON ALPHA 2-10 MILLION IU WEEKLY, SUBCUTANEOUSLY, INJECTION OF POLYMER-INTERFERON ALPHA CONJUGATE-POLYMER IS PEG-INTERFERON IS ALPHA 2B"
  },
  {
    "Code": "U-479",
    "Definition": "METHOD OF USING PEG-INTRON\/REBETOL COMBINATION THERAPY AND INTRON\/REBETOL COMBINATION THERAPY"
  },
  {
    "Code": "U-480",
    "Definition": "CONTRAST AGENT FOR MRI"
  },
  {
    "Code": "U-481",
    "Definition": "DISUBSTITUTED ACETYLENES BEARING HETEROAROMATIC AND HETEROBICYCLIC GROUPS HAVING RETINOID-LIKE ACTIVITY"
  },
  {
    "Code": "U-482",
    "Definition": "METHOD OF IN VITRO FERTILIZATION THERAPY INCLUDING MEANS FOR INDUCING OVULATION...."
  },
  {
    "Code": "U-483",
    "Definition": "METHOD FOR THE ADMINISTRATION OF DRUGS USING THAT COMPOUND"
  },
  {
    "Code": "U-484",
    "Definition": "METHOD OF TREATING A SKIN DISEASE WITH A CORTICOSTEROID-CONTAINING PHARMACEUTICAL COMPOSITION"
  },
  {
    "Code": "U-485",
    "Definition": "METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)"
  },
  {
    "Code": "U-486",
    "Definition": "EXTERNAL PREPARATION FOR APPLICATION TO THE SKIN CONTAINING LIDOCAINE-DRUG RETAINING LAYER PLACED ON SUPPORT AND COMPRISES ADHESIVE GEL BASE 1-10% BY WEIGHT OF LIDOCAINE"
  },
  {
    "Code": "U-487",
    "Definition": "METHOD AND COMPOSITION FOR REDUCING NERVE INJURY PAIN ASSOCIATED WITH SHINGLES (HERPES ZOSTER AND POST-HERPETIC NEURALGIA)"
  },
  {
    "Code": "U-488",
    "Definition": "METHOD FOR REDUCING THE PAIN ASSOCIATED WITH HERPES-ZOSTER AND POST-HERPETIC NEURALGIA"
  },
  {
    "Code": "U-489",
    "Definition": "EXPECTORANT"
  },
  {
    "Code": "U-490",
    "Definition": "TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE"
  },
  {
    "Code": "U-491",
    "Definition": "METHOD OF DELIVERING A DRUG TO THE LUNG"
  },
  {
    "Code": "U-492",
    "Definition": "METHOD FOR THE TREATMENT OF SKIN, SUFFERING FROM A CONDITION SELECTED FROM A GROUP CONSISTING OF NONACNE INFLAMMATORY DERMATOSES... COMPRISING APPLYING TO AFFECTED AREA. A THERAPEUTICALLY EFFECTIVE AMT AZELAIC ACID"
  },
  {
    "Code": "U-493",
    "Definition": "TREATMENT OF TYPE 2 DIABETES MELLITUS"
  },
  {
    "Code": "U-494",
    "Definition": "TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER"
  },
  {
    "Code": "U-495",
    "Definition": "PERITONEAL DIALYSIS SOLUTION"
  },
  {
    "Code": "U-496",
    "Definition": "METHOD FOR TREATING CHRONIC RENAL FAILURE"
  },
  {
    "Code": "U-497",
    "Definition": "RELIEF OF THE SIGNS AND SYMPTOMS OF OSTEOARTHRITIS AND RHEUMATOID ARTHRITIS"
  },
  {
    "Code": "U-498",
    "Definition": "INTRA-ARTERIAL AND INTRAVENOUS USES OF ULTRAVIST"
  },
  {
    "Code": "U-499",
    "Definition": "METHOD OF USING REBETOL CAPSULES IN COMBINATION WITH A CONJUGATE COMPRISING POLYETHYLENE GLYCOL(PEG) AND AN ALPHA INTERFERON, INCLUDING, FOR EXAMPLE, PEG-INTRON POWDER FOR INJECTION"
  },
  {
    "Code": "U-500",
    "Definition": "USE AS AN ANTIHYPERTENSIVE AGENT"
  },
  {
    "Code": "U-501",
    "Definition": "TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) IN ADULTS"
  },
  {
    "Code": "U-502",
    "Definition": "PITYRIASIS VERSICOLOR"
  },
  {
    "Code": "U-503",
    "Definition": "GENERATOR MUST BE USED WITH INFUSION SYSTEM SPECIFICALLY LABELED FOR USE WITH GENERATOR"
  },
  {
    "Code": "U-504",
    "Definition": "TINEA PEDIS, TINEA CRURIS, TINEA CORPORIS"
  },
  {
    "Code": "U-505",
    "Definition": "ULTRASOUND CONTRAST AGENT"
  },
  {
    "Code": "U-506",
    "Definition": "PHARM PRODUCT CONTAINER 1ST CHAMBER IS DISPOSED AQUEOUS DILUENT SOL 2ND CHAMBER PHARM ACTIVE AGENT COMPRISING ACETYLCHOLINE,BUFFER IN 1ST CHAM IS SUFFICIENT TO BUFFER PH OF MIXED SOL RESULTING MIXTURE OF AQUEOUS DILUENT SOL & PHARM ACTIVE.."
  },
  {
    "Code": "U-507",
    "Definition": "ACROMEGALY IN PATIENTS W\/INADEQUATE RESPONSE TO SURGERY AND\/OR RADIATION THERAPY AND\/OR MEDICAL THERAPIES, OR FOR WHOM THESE THERAPIES ARE NOT APPROPRIATE"
  },
  {
    "Code": "U-508",
    "Definition": "METHOD OF RELEASING 17-BETA OESTRADIOL PRECURSOR IN A SUBSTANTIALLY ZERO ORDER PATTERN FOR AT LEAST THREE WEEKS"
  },
  {
    "Code": "U-509",
    "Definition": "TREATMENT OF CUTANEOUS MANIFESTATIONS OF CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO ARE REFRACTORY TO AT LEAST ONE PRIOR SYSTEMIC THERAPY"
  },
  {
    "Code": "U-510",
    "Definition": "TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (STAGE IA AND IB) WHO HAVE REFRACTORY OR PERSISTENT DISEASE AFTER OTHER THERAPIES OR WHO HAVE NOT TOLERATED OTHER THERAPIES"
  },
  {
    "Code": "U-511",
    "Definition": "USE OF QUINOLONE COMPOUNDS AGAINST ANAEROBIC PATHOGENIC BACTERIA"
  },
  {
    "Code": "U-512",
    "Definition": "USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA"
  },
  {
    "Code": "U-513",
    "Definition": "METHODS OF USE OF ANTIMICROBIAL COMPOUNDS AGAINST PATHOGENIC AMYCOPLASMA BACTERIA"
  },
  {
    "Code": "U-514",
    "Definition": "PREVENTION OF OVULATION IN A WOMAN"
  },
  {
    "Code": "U-515",
    "Definition": "TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES AND HAVE DEMONSTRATED DISEASE PROGRESSION ON THE LAST THERAPY"
  },
  {
    "Code": "U-516",
    "Definition": "METHOD OF TREATING A PSYCHOTIC DISEASE"
  },
  {
    "Code": "U-517",
    "Definition": "STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS"
  },
  {
    "Code": "U-518",
    "Definition": "OBSESSIVE COMPULSIVE DISORDER"
  },
  {
    "Code": "U-519",
    "Definition": "POST OPERATIVE NAUSEA AND VOMITING"
  },
  {
    "Code": "U-520",
    "Definition": "PREMENOPAUSAL OSTEOPOROSIS"
  },
  {
    "Code": "U-521",
    "Definition": "METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTRON A (INTERFERON ALPHA-2 B RECOMBINANT) INJECTION TO TREAT PATIENTS WITH CHRONIC HEPATITIS C"
  },
  {
    "Code": "U-522",
    "Definition": "TREATMENT OF CMV RETINITIS BY INTRAVITREAL ADMIN OF A PHOSPHOROTHIOATE OLIGONUCLEOTIDE CAPABLE OF HYBRIDIZING WITH CMV MRNA"
  },
  {
    "Code": "U-523",
    "Definition": "METHOD OF TREATING INFECTION BY CRYPTOSPORIDIUM PARVUM IN AN IMMUNOCOMPROMISED MAMMAL"
  },
  {
    "Code": "U-524",
    "Definition": "METHOD OF TREATING DIARRHEA"
  },
  {
    "Code": "U-525",
    "Definition": "METHOD OF TREATING PARASITIC INFECTIONS"
  },
  {
    "Code": "U-526",
    "Definition": "METHOD OF PROVIDING CONTROLLED RELEASE OF A TREATING AGENT USING A CONTROLLED RELEASE COMPOSITION"
  },
  {
    "Code": "U-527",
    "Definition": "METHOD OF DELIVERING AN ACTIVE INGREDIENT USING A PROGRESSIVE HYDRATION BIOADHESIVE"
  },
  {
    "Code": "U-528",
    "Definition": "PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING"
  },
  {
    "Code": "U-529",
    "Definition": "ONCE DAILY TREATMENT OF ASTHMA WITH NEBULIZED BUDESONIDE"
  },
  {
    "Code": "U-530",
    "Definition": "TREATMENT OF HERPES ZOSTER, TREATMENT OF GENITAL HERPES, TREATMENT OF COLD SORES, SUPPRESSION OF GENITAL HERPES IN IMMUNOCOMPETENT AND HIV-INFECTED INDIVIDUALS, REDUCTION OF RISK OF HETEROSEXUAL TRANSMISSION OF GENITAL HERPES"
  },
  {
    "Code": "U-531",
    "Definition": "TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION.  MAY BE USED ALONE OR GIVEN WITH OTHER CLASSES OF ANTIHYPERTENSIVES, ESPECIALLY THIAZIDE DERIVATIVES"
  },
  {
    "Code": "U-532",
    "Definition": "TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD IN PATIENTS REQUIRING MORE THAN ONE BRONCHO DILATOR"
  },
  {
    "Code": "U-533",
    "Definition": "ERECTILE DYSFUNCTION"
  },
  {
    "Code": "U-534",
    "Definition": "HUMALOG IS AN INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS FOR THE CONTROL OF HYPERGLYCEMIA"
  },
  {
    "Code": "U-535",
    "Definition": "TREATMENT OF SOCIAL ANXIETY DISORDER"
  },
  {
    "Code": "U-536",
    "Definition": "CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING"
  },
  {
    "Code": "U-537",
    "Definition": "TREATMENT OF CONDITIONS RELATED TO HYPERALDOSTERONISM SUCH AS HYPERTENSION AND CARDIAC INSUFFICIENCY, WITH EPLERENONE"
  },
  {
    "Code": "U-538",
    "Definition": "FIRST LINE TREATMENT OF SEVERE HYPERTENSION, IN PATIENTS WITH HYPERTENSION SEVERE ENOUGH THAT THE VALUE OF ACHIEVING PROMPT BLOOD PRESSURE CONTROL EXCEEDS THE RISK OF INITIATING COMBINATION THERAPY IN THESE PATIENTS"
  },
  {
    "Code": "U-539",
    "Definition": "TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE"
  },
  {
    "Code": "U-540",
    "Definition": "TREATMENT OF FUNGAL INFECTIONS"
  },
  {
    "Code": "U-541",
    "Definition": "METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1"
  },
  {
    "Code": "U-542",
    "Definition": "METHOD OF TREATING PATIENT WITH TYPE 2 DIABETES BY ONCE DAILY ADMINISTRATION"
  },
  {
    "Code": "U-543",
    "Definition": "TREATMENT OF SCHIZOPHRENIA"
  },
  {
    "Code": "U-544",
    "Definition": "TREATMENT OF OVERACTIVE BLADDER. TREATMENT OF URINARY INCONTINENCE."
  },
  {
    "Code": "U-545",
    "Definition": "METHOD FOR THE PREVENTION AND\/OR TREATMENT OF THROMBOTIC EPISODES, SUCH AS MYOCARDIAL INFARCTION, IN A HUMAN PATIENT AND METHOD FOR THE PREVENTION OF VENOUS THROMBOSIS IN A POSTOPERATIVE HUMAN PATIENT"
  },
  {
    "Code": "U-546",
    "Definition": "USE OF REPAGLINIDE IN COMBINATION WITH METFORMIN TO LOWER BLOOD GLUCOSE"
  },
  {
    "Code": "U-547",
    "Definition": "MAINTENANCE MONOTHERAPY FOR BIPOLAR DISORDER"
  },
  {
    "Code": "U-548",
    "Definition": "A METHOD OF REDUCING FLUSH IN AN INDIVIDUAL BEING TREATED FOR A LIPIDEMIC DISORDER AND EFFECTIVELY TREATING THE LIPIDEMIC DISORDER"
  },
  {
    "Code": "U-549",
    "Definition": "USE IN THE TREATMENT OF MEN WITH ADVANCED SYMPTOMATIC PROSTATE CANCER"
  },
  {
    "Code": "U-550",
    "Definition": "TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA"
  },
  {
    "Code": "U-551",
    "Definition": "METHOD FOR REDUCING TOXICITY OF ALIMTA TREATED PATIENTS BY ADMINISTERING FOLIC ACID"
  },
  {
    "Code": "U-552",
    "Definition": "TREATMENT OF HYPERTENSION AND HYPERLIPIDEMIA WITH A SINGLE COMPOSITION"
  },
  {
    "Code": "U-553",
    "Definition": "MANAGEMENT OF PAIN AND DISCOMFORT ASSOCIATED WITH PERIDONTAL SCALING AND ROOT PLANNING PROCEDURES BY APPLICATION OF AN EUTECTIC MIXTURE OF LOCAL ANESTHETICS TO PERIDONTAL POCKETS"
  },
  {
    "Code": "U-554",
    "Definition": "TREATING HIV INFECTION WITH INDINAVIR SULFATE IN COMBINATION WITH ANTIRETROVIRAL AGENTS"
  },
  {
    "Code": "U-555",
    "Definition": "TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS AND ACUTE UNCOMPLICATED PYELONEPHRITIS"
  },
  {
    "Code": "U-556",
    "Definition": "USE AS ADJUNCT DIAGNOSTIC FOR SERUM THYROGLOBULIN (TG) TESTING"
  },
  {
    "Code": "U-557",
    "Definition": "NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS"
  },
  {
    "Code": "U-558",
    "Definition": "INDICATED FOR THE RELIEF OF BRONCHOSPASM IN PATIENTS 2-12 YEARS OF AGE WITH ASTHMA (REVERSIBLE OBSTRUCTIVE AIRWAY DISEASE)"
  },
  {
    "Code": "U-559",
    "Definition": "METHOD OF DECREASING OR REDUCING PARATHYROID HORMONE LEVEL; METHOD OF MODULATING PARATHYROID HORMONE SECRETION;METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF REDUCING SERUM IONIZED CALCIUM LEVEL"
  },
  {
    "Code": "U-560",
    "Definition": "METHOD OF DECREASING PARATHYROID HORMONE LEVEL;METHOD OF TREATING HYPERPARATHYROIDISM"
  },
  {
    "Code": "U-561",
    "Definition": "COSOPT IS INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION WHO ARE INSUFFICIENTLY RESPONSIVE TO BETA BLOCKERS"
  },
  {
    "Code": "U-562",
    "Definition": "TOPICAL TREATMENT OF CUTANEOUS LESIONS IN PATIENTS WITH AIDS-RELATED KAPOSI'S SARCOMA"
  },
  {
    "Code": "U-563",
    "Definition": "MARINOL IS INDICATED FOR, INTER ALIA, ANOREXIA ASSOCIATED WITH WEIGHT LOSS IN PATIENTS WITH AIDS"
  },
  {
    "Code": "U-564",
    "Definition": "TREATMENT OF HIV IN CONCOMITANT THERAPY"
  },
  {
    "Code": "U-565",
    "Definition": "TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS, AND CHRONIC URTICARIA"
  },
  {
    "Code": "U-566",
    "Definition": "FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA"
  },
  {
    "Code": "U-567",
    "Definition": "METHOD OF TREATING INFERTILITY"
  },
  {
    "Code": "U-568",
    "Definition": "METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION"
  },
  {
    "Code": "U-569",
    "Definition": "METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THEREAFTER AN OVULATORY INDUCING AMOUNT OF HCG IS ADMINISTERED"
  },
  {
    "Code": "U-570",
    "Definition": "METHOD OF USING FSH ALONE (WITHOUT EXOGENOUS LH) IN IN VITRO FERTILIZATION AND WHEREIN THE DAILY AMOUNT OF FSH IS ABOUT 5-10 IU\/KG"
  },
  {
    "Code": "U-571",
    "Definition": "TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA AND BIPOLAR I MANIA"
  },
  {
    "Code": "U-572",
    "Definition": "INTENSIVE CARE UNIT SEDATION"
  },
  {
    "Code": "U-573",
    "Definition": "TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)"
  },
  {
    "Code": "U-574",
    "Definition": "PROPHYLAXIS AND TREATMENT OF THE NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND TREATMENT OF THE NASAL SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-575",
    "Definition": "LOTEMAX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TREATMENT OF STEROID RESPONSIVE CONDITIONS OF THE PALPEBRAL BULBAR CONJUNCTIVA, CORNEA AND ANTERIOR SEGMENT OF THE GLOBE."
  },
  {
    "Code": "U-576",
    "Definition": "ALREX OPHTHALMIC SUSPENSION IS INDICATED FOR THE TEMPORARY RELIEF OF THE SIGNS AND SYMPTOMS OF SEASONAL ALLERGIC CONJUNCTIVITIS."
  },
  {
    "Code": "U-577",
    "Definition": "TREATMENT OF BENIGN PROSTATIC HYPERPLASIA WITH FINASTERIDE IN COMBINATION WITH DOXAZOSIN"
  },
  {
    "Code": "U-578",
    "Definition": "TREATMENT OF COMMUNITY ACQUIRED PNEUMONIA, ACUTE EXACERBATION OF CHRONIC BRONCHITIS, AND ACUTE BACTERIAL SINUSITIS CAUSED BY SUSCEPTIBLE STRAINS OF DESIGNATED MICROORGANISMS IN PATIENTS 18 YEARS AND OLDER."
  },
  {
    "Code": "U-579",
    "Definition": "TREATMENT OF EPILEPSY AND\/OR MIGRAINE."
  },
  {
    "Code": "U-580",
    "Definition": "TREATMENT OF DISORDERS OF THE SEROTONERGIC SYSTEM SUCH AS DEPRESSION AND ANXIETY-RELATED DISORDERS"
  },
  {
    "Code": "U-581",
    "Definition": "METHOD OF TREATING A CONDITION CAPABLE OF TREATMENT BY INHALATION, E.G. ASTHMA, COMPRISING ADMINISTRATION OF A FORMULATION CLAIMED IN US PATENT NO. 6743413"
  },
  {
    "Code": "U-582",
    "Definition": "METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO. 6253762"
  },
  {
    "Code": "U-583",
    "Definition": "METHOD FOR THE TREATMENT OF A RESPIRATORY DISORDER, E.G. ASTHMA, COMPRISING ADMINISTERING TO A PATIENT BY INHALATION, A METERED AEROSOL DOSE OF A DRUG FORMULATION FROM THE METERED DOSE INHALER SYSTEM CLAIMED IN US 6546928"
  },
  {
    "Code": "U-584",
    "Definition": "SINGLE-DOSE ADMINISTRATION BY THE EPIDURAL ROUTE, AT THE LUMBAR LEVEL, FOR THE TREATMENT OF PAIN FOLLOWING MAJOR SURGERY"
  },
  {
    "Code": "U-585",
    "Definition": "TO PROMOTE WEIGHT GAIN AFTER WEIGHT LOSS IN CERTAIN TYPES OF PATIENTS"
  },
  {
    "Code": "U-586",
    "Definition": "AN INTERMEDIATE RELEASE NICOTINIC ACID FORMULATION SUITABLE FOR ORAL ADMINISTRATION ONCE-A-DAY AS A SINGLE DOSE FOR TREATING HYPERLIPIDEMIA WITHOUT CAUSING DRUG-INDUCED HEPATOTOXICITY OR ELEVATIONS IN URIC ACID OR GLUCOSE OR BOTH"
  },
  {
    "Code": "U-587",
    "Definition": "USE OF EPLERENONE IN COMBINATION WITH AN ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITOR (AND OPTIONALLY A DIURETIC) FOR TREATING CONGESTIVE HEART FAILURE AND HYPERTENSION"
  },
  {
    "Code": "U-588",
    "Definition": "SHORT-TERM TREATMENT OF ACTIVE DUODENAL ULCER; TREATMENT OF HEARTBURN AND OTHER SYMPTOMS ASSOCIATED WITH GERD; SHORT-TERM TREATMENT OF EROSIVE ESOPHAGITIS; MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS"
  },
  {
    "Code": "U-589",
    "Definition": "METHOD FOR TREATMENT OF A RESPIRATORY DISORDER, E.G., BRONCHOSPASM, COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AN AEROSOL COMPOSITION TO A PATIENT FROM A METERED DOSE INHALER SYSTEM AS CLAIMED IN U.S. PATENT NO. 6131966"
  },
  {
    "Code": "U-590",
    "Definition": "METHOD FOR TREATMENT OF A RESPIRATORY DISORDER,E.G.,BRONCHOSPASM,COMPRISING ADMINISTERING TO A PATIENT BY ORAL OR NASAL INHALATION A DRUG FORMULATION BY USING THE METERED DOSE INHALER SYSTEM AS CLAIMED IN US PATENT NO.6532955"
  },
  {
    "Code": "U-591",
    "Definition": "TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER USING A DOSAGE FORM WHICH PROVIDES ONCE-DAILY ORAL ADMINISTRATION OF A PHENIDATE DRUG"
  },
  {
    "Code": "U-592",
    "Definition": "TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND\/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)"
  },
  {
    "Code": "U-593",
    "Definition": "TREATMENT OF PRIMARY HYPERCHOLESTEROLEMIA, MIXED HYPERLIPIDEMIA AND\/OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)"
  },
  {
    "Code": "U-594",
    "Definition": "PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS"
  },
  {
    "Code": "U-595",
    "Definition": "35 MG ORALLY ONCE A WEEK FOR PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN; 35 MG ORALLY ONCE A WEEK FOR TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN"
  },
  {
    "Code": "U-596",
    "Definition": "TREATMENT OF HORMONE RECEPTOR POSITIVE METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN WITH DISEASE PROGRESSION FOLLOWING ANTIESTROGEN THERAPY"
  },
  {
    "Code": "U-597",
    "Definition": "FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT HIGH RISK FOR FRACTURE"
  },
  {
    "Code": "U-598",
    "Definition": "PROPHYLACTIC TREATMENT OF MIGRAINE"
  },
  {
    "Code": "U-599",
    "Definition": "METHOD FOR TREATING ALLERGIC CONJUNCTIVITIS"
  },
  {
    "Code": "U-600",
    "Definition": "A METHOD OF TREATING A PATIENT IN NEED OF OPHTHALMIC ANTIMICROBIAL THERAPY WITH LEVOFLOXACIN"
  },
  {
    "Code": "U-601",
    "Definition": "TREATMENT OF BIPOLAR DISORDER"
  },
  {
    "Code": "U-602",
    "Definition": "SIGNS AND SYMPTOMS OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS IN ADULTS, AND\/OR PAUCIARTICULAR OR POLYARTICULAR COURSE JUVENILE RHEUMATOID ARTHRITIS, ACUTE PAIN IN ADULTS; PRIMARY DYSMENORRHEA; AND\/OR ACUTE MIGRAINE ATTACKS IN ADULTS"
  },
  {
    "Code": "U-603",
    "Definition": "METHOD OF TREATING INFECTIONS COMPRISING ORALLY ADMINISTERING AN EFFECTIVE AMOUNT OF THE FDA APPROVED ORAL SUSPENSION"
  },
  {
    "Code": "U-604",
    "Definition": "METHOD OF LOWERING BLOOD GLUCOSE BY ONCE DAILY ADMINISTRATION"
  },
  {
    "Code": "U-605",
    "Definition": "TREATMENT OF MAJOR DEPRESSIVE DISORDER(MDD);ALTHOUGH THE MECHANISM OF THE ANTIDEPRESSANT ACTION OF DULOXETINE IN HUMANS IS UNKNOWN, IT IS BELIEVED TO BE RELATED TO ITS POTENTIATION OF SERATONERGIC AND NORADRENERGIC ACTIVITY IN THE CNS"
  },
  {
    "Code": "U-606",
    "Definition": "USE OF IRINOTECAN IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER"
  },
  {
    "Code": "U-607",
    "Definition": "CANCIDAS IS INDICATED FOR EMPIRICAL THERAPY FOR PRESUMED FUNGAL INFECTIONS IN FEBRILE, NEUTROPENIC PATIENTS."
  },
  {
    "Code": "U-608",
    "Definition": "USE OF QUINOLONE COMPOUNDS AGAINST PNEUMOCOCCAL PATHOGENIC BACTERIA"
  },
  {
    "Code": "U-609",
    "Definition": "USE OF QUINOLONE COMPOUNDS AGAINST QUINOLONE-RESISTANT PNEUMOCOCCAL PATHOGENIC BACTERIA"
  },
  {
    "Code": "U-610",
    "Definition": "ATROVENT HFA (IPRATROPIUM BROMIDE HFA) INHALATION AEROSOL IS INDICATED AS A BRONCHODILATOR FOR MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA."
  },
  {
    "Code": "U-611",
    "Definition": "METHOD OF USING DESLORATADINE TO TREAT SEASONAL AND PERENNIAL ALLERGIC RHINITIS, PRURITIS, AND CHRONIC IDIOPATHIC URTICARIA IN PATIENTS 2 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-612",
    "Definition": "TREATMENT OF SEASONAL ALLERGY SYMPTOMS WITH NASAL CONGESTION IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-613",
    "Definition": "REDUCTION OF SERUM PHOSPHATE"
  },
  {
    "Code": "U-614",
    "Definition": "TREATMENT OF SEXUAL DYSFUNCTION"
  },
  {
    "Code": "U-615",
    "Definition": "ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TOTAL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)"
  },
  {
    "Code": "U-616",
    "Definition": "MANAGEMENT OF PERSISTENT, MODERATE TO SEVERE PAIN IN PATIENTS REQUIRING CONTINUOUS, AROUND-THE-CLOCK ANALGESIA WITH A HIGH POTENCY OPIOID FOR AN EXTENDED PERIOD OF TIME GENERALLY WEEKS TO MONTHS OR LONGER"
  },
  {
    "Code": "U-617",
    "Definition": "TREATMENT OF ACUTE PROMYELOGENOUS LEUKEMIA (APL)"
  },
  {
    "Code": "U-618",
    "Definition": "USE OF ROSUVASTATIN CALCIUM TO REDUCE ELEVATED TOTAL-C, LDL-C, APOB, NONHDL-C OR TG LEVELS; TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA; AND TO SLOW THE PROGRESSION OF ATHEROSCLEROSIS."
  },
  {
    "Code": "U-619",
    "Definition": "TREATMENT OF MALIGNANT NEOPLASM"
  },
  {
    "Code": "U-620",
    "Definition": "TREATMENT OF INSOMNIA"
  },
  {
    "Code": "U-621",
    "Definition": "METHOD OF TREATING CANCER"
  },
  {
    "Code": "U-622",
    "Definition": "TREATMENT OF VEGF MEDIATED OCULAR DISEASE."
  },
  {
    "Code": "U-623",
    "Definition": "SHORT TERM TREATMENT OF ACTIVE BENIGN GASTRIC ULCER"
  },
  {
    "Code": "U-624",
    "Definition": "REDUCTION OF RISK OF UPPER GASTROINTESTINAL BLEEDING IN CRITICALLY ILL PATIENTS"
  },
  {
    "Code": "U-625",
    "Definition": "ALLERGIC RHINITIS OR NASAL POLYPS"
  },
  {
    "Code": "U-626",
    "Definition": "CLOLAR IS INDICATED FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 TO 21 YEARS OLD WITH RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AFTER AT LEAST TWO PRIOR REGIMENS"
  },
  {
    "Code": "U-627",
    "Definition": "TREATMENT OF PATIENTS USING EXTENDED-RELEASE CARBAMAZEPINE"
  },
  {
    "Code": "U-628",
    "Definition": "USE OF AVANDIA IN COMBINATION WITH A SULFONYLUREA, AND IN COMBINATION WITH METFORMIN AND A SULFONYLUREA TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS"
  },
  {
    "Code": "U-629",
    "Definition": "METHOD OF INDUCING A HYPNOTIC OR SEDATIVE EFFECT IN A HUMAN BY ADMINISTERING ESZOPICLONE"
  },
  {
    "Code": "U-630",
    "Definition": "TREATING URINARY INCONTINENCE BY ADMINISTERING AN EXTENDED-RELEASE FORM OF DARIFENACIN"
  },
  {
    "Code": "U-631",
    "Definition": "TREATING A DISEASE OF ALTERED MOTILITY OR TONE OF SMOOTH MUSCLE BY ADMINISTERING A MUSCARINIC RECEPTOR ANTAGONIZING AMOUNT OF DARIFENACIN"
  },
  {
    "Code": "U-632",
    "Definition": "METHOD OF TREATMENT OF CANCER BY ADMINISTERING PARTICLES OF PACLITAXEL THAT HAVE A PROTEIN COATING"
  },
  {
    "Code": "U-633",
    "Definition": "METHOD FOR TREATMENT OF TUMORS BY ADMINISTERING PACLITAXEL AT A DOSE IN THE RANGE OF ABOUT 30MG\/METER SQUARE TO ABOUT 100MG\/METER SQUARE IN A PHARMACEUTICALLY ACCEPTABLE FORMULATION THAT DOES NOT CONTAIN CREMOPHOR"
  },
  {
    "Code": "U-634",
    "Definition": "METHOD FOR DELIVERY OF A BIOLOGIC (INCLUDING ANTINEOPLASTIC AGENTS) BY ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF A BIOLOGIC AS A SOLID OR LIQUID WITH A POLYMERIC BIOCOMPATIBLE MATERIAL"
  },
  {
    "Code": "U-635",
    "Definition": "TREATMENT OF GERD, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND RISK REDUCTION OF NSAID ASSOCIATED GASTRIC ULCERS"
  },
  {
    "Code": "U-636",
    "Definition": "TREATMENT OR PREVENTION OF BRONCHOSPASM OR ASTHMATIC SYMPTOMS"
  },
  {
    "Code": "U-637",
    "Definition": "TREATMENT OF DIABETES WITH AN AMYLIN AGONIST"
  },
  {
    "Code": "U-638",
    "Definition": "TREATMENT OF DIABETES WITH AN AMYLIN AGONIST, INCLUDING WITH INSULIN"
  },
  {
    "Code": "U-639",
    "Definition": "TREATMENT OF A MAMMAL HAVING A NEED OF OR REDUCED ABILITY TO PRODUCE INSULIN WITH AN INSULIN AND AN AMYLIN SUCH AS PRAMLINTIDE"
  },
  {
    "Code": "U-640",
    "Definition": "USE OF AN AMYLIN AGONIST TO REDUCE GASTRIC MOTILITY AND TREAT POST PRANDIAL HYPERGLYCEMIA"
  },
  {
    "Code": "U-641",
    "Definition": "USE OF AN AMYLIN AGONIST HAVING SPECIFIED BINDING ACTIVITY TO REDUCE GASTRIC MOTILITY, INCLUDING USE THROUGH PARENTERAL ADMINISTRATION"
  },
  {
    "Code": "U-642",
    "Definition": "TREATMENT AND PREVENTION OF OSTEOPOROSIS"
  },
  {
    "Code": "U-643",
    "Definition": "THE SHORT TERM TREATMENT (UP TO 10 DAYS) IN PTS HAVING GASTROESOPHAGEAL REFLUX DISEASE (GERD) AS AN ALTERNATIVE TO ORAL THERAPY IN PTS WHEN THERAPY WITH NEXIUM CAPSULES IS NOT POSSIBLE OR APPROPRIATE"
  },
  {
    "Code": "U-644",
    "Definition": "TREATMENT OF SEASONAL ALLERGIC RHINITIS"
  },
  {
    "Code": "U-645",
    "Definition": "TREATMENT OF ASTHMA"
  },
  {
    "Code": "U-646",
    "Definition": "METHOD OF TREATING OTITIS"
  },
  {
    "Code": "U-647",
    "Definition": "TREATMENT OF OSTEOPOROSIS IN POST MENOPAUSAL WOMEN AND\/OR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS"
  },
  {
    "Code": "U-648",
    "Definition": "THE TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AND\/OR THE TREATMENT TO INCREASE BONE MASS IN MEN"
  },
  {
    "Code": "U-649",
    "Definition": "A METHOD FOR TREATING A TUMOR DISEASE"
  },
  {
    "Code": "U-650",
    "Definition": "TREATMENT OF ESOPHAGEAL CANDIDIASIS AND PROPHYLAXIS OF CANDIDA INFECTIONS IN HSCT PATIENTS"
  },
  {
    "Code": "U-651",
    "Definition": "TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL)"
  },
  {
    "Code": "U-652",
    "Definition": "TREATMENT OF CARDIAC ARRHYTHMIA"
  },
  {
    "Code": "U-653",
    "Definition": "STIMULATING INSULIN RELEASE BY ADMINISTERING EXENATIDE"
  },
  {
    "Code": "U-654",
    "Definition": "LOWERING PLASMA GLUCAGON IN A SUBJECT IN NEED THEREOF, INCLUDING ONE WITH TYPE 2 DIABETES, BY ADMINISTERING AN EXENDIN OR ANALOG, SUCH AS EXENDIN-4"
  },
  {
    "Code": "U-655",
    "Definition": "TREATMENT OF MILD TO MODERATE ACTIVE CHROHN'S DISEASE INVOLVING THE ILEUM AND\/OR THE ASCENDING COLON AND THE MAINTENANCE OF CLINICAL REMISSION OF MILD TO MODERATE CROHN'S DISEASE INVOLVING THE ILEUM AND\/OR ASCENDING COLON FOR UP TO 3 MONTHS"
  },
  {
    "Code": "U-656",
    "Definition": "REDUCING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY ADMINISTERING AN EXENDIN, SUCH AS EXENDIN-4"
  },
  {
    "Code": "U-657",
    "Definition": "PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN"
  },
  {
    "Code": "U-658",
    "Definition": "TREATMENT OF ADVANCED HORMONE-DEPENDENT BREAST CANCER"
  },
  {
    "Code": "U-659",
    "Definition": "TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN"
  },
  {
    "Code": "U-660",
    "Definition": "TREATMENT OF HYPERTENSION AND TREATMENT OF HEART FAILURE"
  },
  {
    "Code": "U-661",
    "Definition": "TREATMENT OF SEIZURE DISORDER"
  },
  {
    "Code": "U-662",
    "Definition": "TREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN"
  },
  {
    "Code": "U-663",
    "Definition": "THE TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTIONS"
  },
  {
    "Code": "U-664",
    "Definition": "TREATMENT OF CONDITIONS FOR WHICH AN ALDOSTERONE RECEPTOR BLOCKER IS INDICATED, SUCH AS HYPERTENSION, HEART FAILURE, AND POST-MYOCARDIAL INFARCTION"
  },
  {
    "Code": "U-665",
    "Definition": "METHOD OF USING THE DRUG SUBSTANCE\/DRUG PRODUCT FOR ULTRASOUND IMAGING"
  },
  {
    "Code": "U-666",
    "Definition": "METHOD OF TREATING ADHD"
  },
  {
    "Code": "U-667",
    "Definition": "MANAGEMENT OF INCONTINENCE; METHOD FOR TREATING INCONTINENCE"
  },
  {
    "Code": "U-668",
    "Definition": "LEVEMIR IS A LONG-ACTING BASAL INSULIN ANALOG THAT IS INDICATED IN THE TREATMENT OF PATIENTS WITH DIABETES MELLITUS"
  },
  {
    "Code": "U-669",
    "Definition": "INDICATION OF TYPE II DIABETES"
  },
  {
    "Code": "U-670",
    "Definition": "TREATMENT OF HIV-1 INFECTION BY THE CO-ADMINISTRATION OF TIPRANAVIR AND RITONAVIR."
  },
  {
    "Code": "U-671",
    "Definition": "PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 3 AND 4"
  },
  {
    "Code": "U-672",
    "Definition": "TREATMENT OF INFLAMMATION OR AN INFLAMMATION-ASSOCIATED DISORDER"
  },
  {
    "Code": "U-673",
    "Definition": "METHOD OF TREATMENT WITH ONCE-DAILY DOSES OF 625MG\/5ML"
  },
  {
    "Code": "U-674",
    "Definition": "METHOD OF TREATING INSOMNIA CHARACTERIZED BY DIFFICULTY WITH SLEEP ONSET"
  },
  {
    "Code": "U-675",
    "Definition": "PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA; RELIEF OF SYMPTOMS OF ALLERGIC RHINITIS"
  },
  {
    "Code": "U-676",
    "Definition": "METHOD OF TREATING ATTENTION DEFICIT DISORDER USING ORAL ADMINISTRATION OF A BI-MODAL OR PULSATILE RELEASE COMPOSITION"
  },
  {
    "Code": "U-677",
    "Definition": "A METHOD OF TREATING DISEASE AMENABLE TO TREATMENT WITH A PHENIDATE DRUG BY ONCE DAILY ORAL ADMINISTRATION OF AN EXTENDED RELEASE DOSAGE FORM"
  },
  {
    "Code": "U-678",
    "Definition": "METHOD OF TREATING ATTENTION DEFICIT DISORDER AND\/OR ATTENTION DEFICIT HYPERACTIVITY DISORDER"
  },
  {
    "Code": "U-679",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN"
  },
  {
    "Code": "U-680",
    "Definition": "A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM"
  },
  {
    "Code": "U-681",
    "Definition": "TREATMENT OF PRIMARY IGF-1 DEFICIENCY"
  },
  {
    "Code": "U-682",
    "Definition": "NON-BENZODIAZEPINE HYPNOTIC AGENT INDICATED FOR TREATMENT OF INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND\/OR SLEEP MAINTENANCE"
  },
  {
    "Code": "U-683",
    "Definition": "PREVENTION OR TREATMENT OF ISCHEMIC HEART DISEASE"
  },
  {
    "Code": "U-684",
    "Definition": "TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-685",
    "Definition": "EXPECTORANT AND COUGH SUPPRESSANT"
  },
  {
    "Code": "U-686",
    "Definition": "EXPECTORANT AND NASAL DECONGESTANT"
  },
  {
    "Code": "U-687",
    "Definition": "REDUCING FOOD INTAKE IN A SUBJECT WITH TYPE 2 DIABETES BY ADMINISTERING AN EXENDIN, SUCH AS  EXENDIN-4"
  },
  {
    "Code": "U-688",
    "Definition": "TREATMENT OF HIV-INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS"
  },
  {
    "Code": "U-689",
    "Definition": "TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS"
  },
  {
    "Code": "U-690",
    "Definition": "TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS"
  },
  {
    "Code": "U-691",
    "Definition": "USE AS A MONOTHERAPY, IN COMBINATION WITH A SULFONYLUREA, METFORMIN OR INSULIN OR IN COMBINATION WITH A SULFONYLUREA PLUS METFORMIN TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS"
  },
  {
    "Code": "U-692",
    "Definition": "USE OF VALSARTAN TO REDUCE CARDIOVASCULAR MORTALITY IN CLINICALLY STABLE PATIENTS WITH LEFT VENTRICULAR FAILURE OR LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION"
  },
  {
    "Code": "U-693",
    "Definition": "THE RECOMMENDED INITIAL DOSE OF EQUETRO IS 400MG\/DAY GIVEN IN DIVIDED DOSES, TWICE DAILY. THE DOSE SHOULD BE ADJUSTED IN 200MG DAILY INCREMENTS TO ACHIEVE OPTIMAL CLINICAL RESPONSE."
  },
  {
    "Code": "U-694",
    "Definition": "LENALIDOMIDE IS AN ANALOGUE OF THALIDOMIDE. THALIDOMIDE IS A KNOWN HUMAN TERATOGEN THAT CAUSES SEVERE LIFE-THREATENING HUMAN BIRTH DEFECTS.  IF LENALIDOMIDE IS TAKEN DURING PREGNANCY, IT MAY CAUSE BIRTH DEFECTS OR DEATH TO AN UNBORN BABY."
  },
  {
    "Code": "U-695",
    "Definition": "TREATMENT OF PATIENTS WITH T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA AND T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS"
  },
  {
    "Code": "U-696",
    "Definition": "TREATMENT OF PATIENTS WITH T-CELL LYMPHOBLASTIC LYMPHOMA WHOSE DISEASE HAS NOT RESPONDED TO OR HAS RELAPSED FOLLOWING TREATMENT WITH AT LEAST TWO CHEMOTHERAPY REGIMENS"
  },
  {
    "Code": "U-697",
    "Definition": "A METHOD OF USING RINFABATE RECOMBINANT (RHIGFBP-3) WITH MECASERMIN RECOMBINANT (RHIGF-1) TO PROMOTE LINEAR GROWTH IN THE TREATMENT OF PRIMARY IGF-1 DEFICIENCY"
  },
  {
    "Code": "U-698",
    "Definition": "METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH EUVOLEMIC HYPONATREMIA"
  },
  {
    "Code": "U-699",
    "Definition": "NASAL TREATMENT OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS SYMPTOMS"
  },
  {
    "Code": "U-700",
    "Definition": "TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN"
  },
  {
    "Code": "U-701",
    "Definition": "TREATMENT OF HYPERCHOLESTEROLEMIA AND\/OR HYPERTRIGLYCERIDEMIA"
  },
  {
    "Code": "U-702",
    "Definition": "TOPICAL AEROSOL HAIR REGROWTH TREATMENT"
  },
  {
    "Code": "U-703",
    "Definition": "TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMOR AND RENAL CELL CARCINOMA WITH SUNITINIB"
  },
  {
    "Code": "U-704",
    "Definition": "METHOD OF ADMINISTERING INSULIN VIA INHALATION"
  },
  {
    "Code": "U-705",
    "Definition": "TREATING CHRONIC ANGINA BY ADMINISTERING AN EXTENDED RELEASE FORM OF RANOLAZINE"
  },
  {
    "Code": "U-706",
    "Definition": "TREATMENT OF BENIGN PROSTATIC HYPERPLASIA"
  },
  {
    "Code": "U-707",
    "Definition": "ALLERGIC RHINITIS"
  },
  {
    "Code": "U-708",
    "Definition": "TREATMENT OF CHRONIC NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE"
  },
  {
    "Code": "U-709",
    "Definition": "METHOD OF COMBATING BACTERIA IN A PATIENT"
  },
  {
    "Code": "U-710",
    "Definition": "A METHOD OF TREATING RESPIRATORY DISORDERS, E.G., ASTHMA, WHICH COMPRISES ADMINISTRATION BY INHALATION OF AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT NO. 5658549"
  },
  {
    "Code": "U-711",
    "Definition": "ACUTE AND LONGER-TERM TREATMENT OF MAJOR DEPRESSIVE DISORDER"
  },
  {
    "Code": "U-712",
    "Definition": "A METHOD OF USING A NICOTINIC ACID FORMULATION TO REDUCE ELEVATED TC, LDL-C AND TG LEVELS, AND RAISE HDL-C LEVELS IN PATIENTS WITH HYPERLIPIDEMIA"
  },
  {
    "Code": "U-713",
    "Definition": "TREATMENT OF MILD TO MODERATE DEMENTIA OF THE ALZHEIMER'S TYPE"
  },
  {
    "Code": "U-714",
    "Definition": "TOPICAL TREATMENT OF INTERDIGITAL TINEA PEDIS AND TINEA CORPORIS DUE TO TRICHOPHYTON RUBRUM, TRICHOPHYTON MENTAGROPHYTES OR EPIDERMOPHYTON FLOCCOSUM"
  },
  {
    "Code": "U-715",
    "Definition": "FOR CLEANSING THE BOWEL IN PREPARATION FOR COLONOSCOPY, IN ADULTS 18 YEARS OF AGE OR OLDER"
  },
  {
    "Code": "U-716",
    "Definition": "THE TREATMENT OR PREVENTION OF BRONCHOSPASM IN ADULTS AND CHILDREN 4 YEARS OF AGE AND OLDER WITH REVERSIBLE OBSTRUCTIVE AIRWAYS DISEASE AND THE PREVENTION OF EXERCISED-INDUCED BRONCHOSPASM IN PATIENTS 4 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-717",
    "Definition": "METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT"
  },
  {
    "Code": "U-718",
    "Definition": "TREATMENT OF FUNGAL INFECTIONS"
  },
  {
    "Code": "U-719",
    "Definition": "TREATMENT OF PSYCHOSIS"
  },
  {
    "Code": "U-720",
    "Definition": "TREATMENT OF NEUROLEPTIC DISEASES"
  },
  {
    "Code": "U-721",
    "Definition": "TREATMENT OF INFLUENZA"
  },
  {
    "Code": "U-722",
    "Definition": "PROPHYLAXIS OF INFLUENZA"
  },
  {
    "Code": "U-723",
    "Definition": "PROPHYLACTIC TREATMENT OF MIGRAINE"
  },
  {
    "Code": "U-724",
    "Definition": "METHOD OF TREATING SEIZURES"
  },
  {
    "Code": "U-725",
    "Definition": "ALLERGIC RHINITIS AND URTICARIA"
  },
  {
    "Code": "U-726",
    "Definition": "ALLERGIC RHINITIS"
  },
  {
    "Code": "U-727",
    "Definition": "FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)"
  },
  {
    "Code": "U-728",
    "Definition": "METHOD FOR TREATING BACTERIAL INFECTION"
  },
  {
    "Code": "U-729",
    "Definition": "TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD), RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER, H. PYLORI ERADICATION TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE"
  },
  {
    "Code": "U-730",
    "Definition": "USE AS A NASAL SPRAY FOR TREATMENT OF THE SYMPTOMS OF SEASONAL ALLERGIC RHINITIS AND VASOMOTOR RHINITIS"
  },
  {
    "Code": "U-731",
    "Definition": "USE IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA"
  },
  {
    "Code": "U-732",
    "Definition": "ACUTE TREATMENT OF THE CUTANEOUS MANIFESTATIONS OF MODERATE TO SEVERE ERYTHEMA NODOSUM LEPROSUM (ENL)"
  },
  {
    "Code": "U-733",
    "Definition": "MAINTENANCE THERAPY FOR PREVENTION AND SUPPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE"
  },
  {
    "Code": "U-734",
    "Definition": "FIRST LINE THERAPY FOR TYPE 2 DIABETES MELLITUS"
  },
  {
    "Code": "U-735",
    "Definition": "METHOD OF TREATING CHRONIC IRON OVERLOAD"
  },
  {
    "Code": "U-736",
    "Definition": "METHOD FOR IONTOPHORETIC TRANSDERMAL DELIVERY OF FENTANYL HYDROCHLORIDE"
  },
  {
    "Code": "U-737",
    "Definition": "DISINFECTION OF PATIENT SKIN PRIOR TO AN INVASIVE PROCEDURE"
  },
  {
    "Code": "U-738",
    "Definition": "INDICATED FOR THE LONG-TERM, TWICE-DAILY MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE OR OLDER"
  },
  {
    "Code": "U-739",
    "Definition": "METHOD FOR TREATING CONSTIPATION BY OPENING CIC CHANNELS IN A MAMMALIAN SUBJECT"
  },
  {
    "Code": "U-740",
    "Definition": "FOR THE TREATMENT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS"
  },
  {
    "Code": "U-741",
    "Definition": "COMBINATION THERAPY WITH CISPLATIN FOR THE TREATMENT OF LATE STAGE CERVICAL CANCER"
  },
  {
    "Code": "U-742",
    "Definition": "TWICE DAILY TOPICAL TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS."
  },
  {
    "Code": "U-743",
    "Definition": "ONCE A DAY TOPICAL TREATMENT OF THE INFLAMMATORY LESIONS OF ROSACEA"
  },
  {
    "Code": "U-744",
    "Definition": "TREATMENT OF HIV INFECTION IN ANTIRETROVIRAL TREATMENT-EXPERIENCED ADULT PATIENTS"
  },
  {
    "Code": "U-745",
    "Definition": "TREATMENT OR PREVENTION OF EMESIS"
  },
  {
    "Code": "U-746",
    "Definition": "PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT"
  },
  {
    "Code": "U-747",
    "Definition": "PREVENTION OR TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING"
  },
  {
    "Code": "U-748",
    "Definition": "A METHOD FOR THE TREATMENT OF A PROTEIN TYROSINE KINASE-ASSOCIATED DISORDER"
  },
  {
    "Code": "U-749",
    "Definition": "METHOD OF CONTRACEPTION"
  },
  {
    "Code": "U-750",
    "Definition": "TREATMENT OF HIV-1 INFECTION IN ADULTS"
  },
  {
    "Code": "U-751",
    "Definition": "ONCE DAILY DOSING OF BUDESONIDE VIA NEBULIZER FOR THE TREATMENT OF ASTHMA"
  },
  {
    "Code": "U-752",
    "Definition": "SUNSCREEN"
  },
  {
    "Code": "U-753",
    "Definition": "AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES"
  },
  {
    "Code": "U-754",
    "Definition": "USE FOR THE LONG-TERM MAINTENANCE TREATMENT OF ASTHMA"
  },
  {
    "Code": "U-755",
    "Definition": "TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)"
  },
  {
    "Code": "U-756",
    "Definition": "ADDITION OF ONCE-WEEKLY DOSING FOR THE TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS"
  },
  {
    "Code": "U-757",
    "Definition": "USE AS A BILE ACID SEQUESTRANT FOR LOWERING CHOLESTEROL"
  },
  {
    "Code": "U-758",
    "Definition": "TREATMENT OF SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER"
  },
  {
    "Code": "U-759",
    "Definition": "METHOD OF USE OF ADMINISTERING LEVOTHYROXINE"
  },
  {
    "Code": "U-760",
    "Definition": "PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS AND TREATMENT OF OROPHARYNGEAL CANDIDIASIS"
  },
  {
    "Code": "U-761",
    "Definition": "TREATMENT OF SCHIZOPHRENIA INCLUDING MAINTAINING STABILITY IN PATIENTS WITH SCHIZOPHRENIA"
  },
  {
    "Code": "U-762",
    "Definition": "TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE"
  },
  {
    "Code": "U-763",
    "Definition": "ADMINISTRATION OF ARIPIPRAZOLE BY INJECTION"
  },
  {
    "Code": "U-764",
    "Definition": "TREATMENT OF SCHIZOPHRENIA"
  },
  {
    "Code": "U-765",
    "Definition": "METHOD OF TREATING ALLERGIC CONJUNCTIVITIS"
  },
  {
    "Code": "U-766",
    "Definition": "TREATMENT OF SEIZURES"
  },
  {
    "Code": "U-767",
    "Definition": "MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER"
  },
  {
    "Code": "U-768",
    "Definition": "A METHOD OF REDUCING THE CAPACITY OF EXTENDED RELEASE NICOTINIC ACID TO PROVOKE A FLUSHING REACTION BY PRETREATING AN INDIVIDUAL WITH A FLUSH INHIBITING AGENT PRIOR TO THE ADMINISTRATION OF THE EXTENDED RELEASE NICOTINIC ACID"
  },
  {
    "Code": "U-769",
    "Definition": "REVLIMID (LENALIDOMIDE) IN COMBINATION WITH DEXAMETHASONE IS INDICATED FOR THE TREATMENT OF MULTIPLE MYELOMA PATIENTS WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY"
  },
  {
    "Code": "U-770",
    "Definition": "LONG-TERM TREATMENT OF PATHOLOGICAL HYPERSECRETORY CONDITIONS"
  },
  {
    "Code": "U-771",
    "Definition": "METHOD FOR THE TREATMENT OF DIABETES MELLITUS, SUCH AS TYPE 1 DIABETES MELLITUS OR TYPE 2 DIABETES MELLITUS, IN A HUMAN PATIENT"
  },
  {
    "Code": "U-772",
    "Definition": "RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN CHILDREN 2 TO 11 YEARS AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 MONTHS TO 11 YEARS"
  },
  {
    "Code": "U-773",
    "Definition": "PATHOLOGICAL HYPERSECRETORY CONDITIONS"
  },
  {
    "Code": "U-774",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR"
  },
  {
    "Code": "U-775",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND\/OR A SULFONYLUREA"
  },
  {
    "Code": "U-776",
    "Definition": "TREATMENT OF CUTANEOUS MANIFESTATION IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) WHO HAVE PROGRESSIVE, PERSISTENT OR RECURRENT DISEASE ON OR FOLLOWING TWO SYSTEMIC THERAPIES."
  },
  {
    "Code": "U-777",
    "Definition": "DECREASING MORTALITY CAUSED BY CONGESTIVE HEART FAILURE"
  },
  {
    "Code": "U-778",
    "Definition": "REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION"
  },
  {
    "Code": "U-779",
    "Definition": "A METHOD FOR TREATMENT OF A CANCER, WHEREIN THE CANCER IS CHRONIC MYELOGENOUS LEUKEMIA"
  },
  {
    "Code": "U-780",
    "Definition": "A METHOD FOR THE TREATMENT OF CANCER"
  },
  {
    "Code": "U-781",
    "Definition": "FOR TREATMENT OF ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS WHO ARE NAIVE TO PHARMACOLOGIC THERAPY"
  },
  {
    "Code": "U-782",
    "Definition": "TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS WITH EVIDENCE OF VIRAL REPLICATION AND EITHER EVIDENCE OF PERSISTENT ELEVATIONS IN SERUM AMINOTRANSFERASES (ALT OR AST) OR HISTOLOGICALLY ACTIVE DISEASE"
  },
  {
    "Code": "U-783",
    "Definition": "DESONATE GEL IS INDICATED FOR THE TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN PATIENTS 3 MONTHS OF AGE AND OLDER"
  },
  {
    "Code": "U-784",
    "Definition": "TREATMENT OF MODERATE TO SEVERE PRIMARY RESTLESS LEGS SYNDROME (RLS)"
  },
  {
    "Code": "U-785",
    "Definition": "USE AS REPLACEMENT SOLUTION, HEMOFILTRATION SOLUTION OR HEMODIAFILTRATION SOLUTION IN CONTINUOUS RENAL REPLACEMENT THERAPY"
  },
  {
    "Code": "U-786",
    "Definition": "PRODUCT IS APPROVED FOR THE TOPICAL TREATMENT OF TINEA PEDIS"
  },
  {
    "Code": "U-787",
    "Definition": "MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND PEDIATRIC PATIENTS SIX YEARS OF AGE OR OLDER, INCLUDING PATIENTS REQUIRING ORAL CORTICOSTEROID THERAPY FOR ASTHMA"
  },
  {
    "Code": "U-788",
    "Definition": "METHOD OF TREATING PSYCHIATRIC SYMPTOMS ASSOCIATED WITH PREMENSTRUAL DISORDERS USING PAROXETINE"
  },
  {
    "Code": "U-789",
    "Definition": "TREATMENT OF KNOWN OR SUSPECTED CYANIDE POISONING"
  },
  {
    "Code": "U-790",
    "Definition": "FORTEO IS INDICATED FOR THE TREATMENT OF POST MENOPAUSAL WOMEN WITH OSTEOPOROSIS WHO ARE AT RISK FOR FRACTURE. FORTEO CAN BE USED BY PEOPLE WHO HAVE HAD A FRACTURE RELATED TO OSTEOPOROSIS"
  },
  {
    "Code": "U-791",
    "Definition": "GLEEVEC IS ALSO INDICATED FOR THE TREATMENT OF PATIENTS WITH KIT (CD117) POSITIVE UNRESECTABLE AND\/OR METASTATIC MALIGNANT GASTROINTESTINAL STROMAL TUMORS (GIST)"
  },
  {
    "Code": "U-792",
    "Definition": "TREATMENT OF SEBORRHEA DERMATITIS IN HUMANS"
  },
  {
    "Code": "U-793",
    "Definition": "FOR THE LONG TERM TREATMENT, TWICE DAILY (MORNING AND EVENING) MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA"
  },
  {
    "Code": "U-794",
    "Definition": "CLOSURE OF A CLINICALLY SIGNIFICANT PATENT DUCTUS ARTERIOSUS IN PREMATURE INFANTS WEIGHING BETWEEN 500 AND 1500G, WHO ARE NO MORE THAN 32 WEEKS GESTATIONAL AGE WHEN USUAL MEDICAL MANAGEMENT IS INEFFECTIVE"
  },
  {
    "Code": "U-795",
    "Definition": "METHOD FOR INHIBITING NOREPINEPHRINE UPTAKE"
  },
  {
    "Code": "U-796",
    "Definition": "METHOD OF TREATING DEPRESSION"
  },
  {
    "Code": "U-797",
    "Definition": "METHOD OF TREATING ANXIETY"
  },
  {
    "Code": "U-798",
    "Definition": "TREATMENT AND PREVENTION OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN BY ONCE-MONTHLY ORAL ADMINISTRATION OF IBANDRONATE SODIUM MONOHYDRATE EQUIVALENT TO 150MG OF IBANDRONIC ACID"
  },
  {
    "Code": "U-799",
    "Definition": "METHOD FOR INHIBITING SEROTONIN UPTAKE"
  },
  {
    "Code": "U-800",
    "Definition": "TREATMENT OF PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER WHOSE TUMORS OVEREXPRESS HER2 AND WHO HAVE RECEIVED PRIOR THERAPY INCLUDING ANTHRACYCLINE, A TAXANE AND TRASTUZUMAB"
  },
  {
    "Code": "U-801",
    "Definition": "METHOD OF TREATING CANCER"
  },
  {
    "Code": "U-802",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR"
  },
  {
    "Code": "U-803",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN"
  },
  {
    "Code": "U-804",
    "Definition": "TREATMENT OF ACTINIC KERATOSES BY PHOTODYNAMIC THERAPY"
  },
  {
    "Code": "U-805",
    "Definition": "TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES"
  },
  {
    "Code": "U-806",
    "Definition": "INTRATHECAL TREATMENT OF LYMPHOMATOUS MENINGITIS"
  },
  {
    "Code": "U-807",
    "Definition": "PREVENTION OF EXERCISE-INDUCED BRONCHOCONSTRICTION"
  },
  {
    "Code": "U-808",
    "Definition": "THE TREATMENT OF THE SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN PATIENTS 2 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-809",
    "Definition": "TREATMENT OF CHRONIC IDIOPATHIC URTICARIA"
  },
  {
    "Code": "U-810",
    "Definition": "METHOD OF TREATMENT TO ALLEVIATE INFLAMMATION OF THE EYE"
  },
  {
    "Code": "U-811",
    "Definition": "RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS AND TREATMENT OF THE UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA"
  },
  {
    "Code": "U-812",
    "Definition": "RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS"
  },
  {
    "Code": "U-813",
    "Definition": "MAINTENANCE TREATMENT OF BRONCHOCONSTRICTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"
  },
  {
    "Code": "U-814",
    "Definition": "TREATMENT OF SCHIZOPHRENIA"
  },
  {
    "Code": "U-815",
    "Definition": "TREATS COLD SORES\/FEVER BLISTERS ON THE FACE OR LIPS. SHORTENS HEALING TIME AND DURATION OF SYMPTOMS: TINGLING, PAIN, BURNING AND\/OR ITCHING"
  },
  {
    "Code": "U-816",
    "Definition": "DEPRESSION, PANIC DISORDER, PREMENSTRUAL DISORDERS AND SOCIAL ANXIETY DISORDER"
  },
  {
    "Code": "U-817",
    "Definition": "NASAL ADMINISTRATION OF CYANOCOBALAMIN"
  },
  {
    "Code": "U-818",
    "Definition": "TOPICAL TREATMENT OF ACNE VULGARIS"
  },
  {
    "Code": "U-819",
    "Definition": "MANAGEMENT OF FIBROMYALGIA"
  },
  {
    "Code": "U-820",
    "Definition": "IMPROVED WAKEFULNESS IN PATIENTS WITH EXCESSIVE SLEEPINESS ASSOCIATED WITH NARCOLEPSY, OBSTRUCTIVE SLEEP APNEA\/HYPOPNEA SYNDROME, AND SHIFT WORK SLEEP DISORDER"
  },
  {
    "Code": "U-821",
    "Definition": "METHOD OF INHIBITING ENTHOTHELIN RECEPTORS BY ADMINISTERING AMBRISENTAN TO A PATIENT TO TREAT PULMONARY ARTERIAL HYPERTENSION."
  },
  {
    "Code": "U-822",
    "Definition": "USE IN LIPID MANAGEMENT"
  },
  {
    "Code": "U-823",
    "Definition": "RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS AND FOR THE TREATMENT OF UNCOMPLICATED SKIN MANIFESTATIONS OF CHRONIC IDIOPATHIC URTICARIA IN CHILDREN 6 TO 11 YEARS OF AGE"
  },
  {
    "Code": "U-824",
    "Definition": "METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1"
  },
  {
    "Code": "U-825",
    "Definition": "USE FOR PREVENTION OF BREAST CANCER"
  },
  {
    "Code": "U-826",
    "Definition": "RELIEF OF MODERATE TO SEVERE PAIN"
  },
  {
    "Code": "U-827",
    "Definition": "USE FOR TREATMENT OF DIABETES, PARTICULARLY TYPE 2 DIABETES"
  },
  {
    "Code": "U-828",
    "Definition": "PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION"
  },
  {
    "Code": "U-829",
    "Definition": "TREATMENT OF EXTRAVASATION RESULTING FROM IV ANTHRACYCLINE CHEMOTHERAPY"
  },
  {
    "Code": "U-830",
    "Definition": "TREATMENT OF RELAPSED SMALL CELL LUNG CANCER"
  },
  {
    "Code": "U-831",
    "Definition": "METHOD OF ADMINISTERING LANREOTIDE ACETATE"
  },
  {
    "Code": "U-832",
    "Definition": "ZINGO IS INDICATED FOR THE USE ON INTACT SKIN TO PROVIDE LOCAL ANALGESIA PRIOR TO VENIPUNCTURE OR INTRAVENOUS CANNULATION."
  },
  {
    "Code": "U-833",
    "Definition": "METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.25% BY WEIGHT OF ROPIVACAINE"
  },
  {
    "Code": "U-834",
    "Definition": "INVIRASE IN COMBINATION WITH RITONAVIR AND OTHER ANTIRETROVIRAL AGENTS IS INDICATED FOR THE TREATMENT OF HIV INFECTION"
  },
  {
    "Code": "U-835",
    "Definition": "RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF ATOPIC DERMATITIS IN PATIENTS ONE YEAR OF AGE OR OLDER"
  },
  {
    "Code": "U-836",
    "Definition": "A METHOD FOR THE TREATMENT OF LEUKEMIAS"
  },
  {
    "Code": "U-837",
    "Definition": "GASTROINTESTINAL LAVAGE INDICATED FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY IN ADULTS"
  },
  {
    "Code": "U-838",
    "Definition": "METHOD OF TREATING PAIN USING A PHARMACEUTICALLY ACCEPTABLE SALT OF ROPIVACAINE AND ADMINISTERING A COMPOSITION CONTAINING LESS THAN 0.5% BY WEIGHT OF ROPIVACAINE"
  },
  {
    "Code": "U-839",
    "Definition": "TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)"
  },
  {
    "Code": "U-840",
    "Definition": "TREATMENT FOR TYPE 2 DIABETES MELLITUS"
  },
  {
    "Code": "U-841",
    "Definition": "INDICATED FOR THE LONG-TERM, MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 12 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-842",
    "Definition": "INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT\/HYPERACTIVITY DISORDER (ADHD)"
  },
  {
    "Code": "U-843",
    "Definition": "METHOD FOR ADMINISTRATION OF TESTOSTERONE"
  },
  {
    "Code": "U-844",
    "Definition": "PREFEST IS INDICATED IN WOMEN WHO HAVE A UTERUS FOR THE TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE; TREATMENT OF VULVAR AND VAGINAL ATROPHY; PREVENTION OF OSTEOPOROSIS"
  },
  {
    "Code": "U-845",
    "Definition": "TREATMENT OF PATIENTS WITH CANDIDEMIA, ACUTE DISSEMINATED CANDIDIASIS, CANDIDA PERITONITIS AND ABSCESSES"
  },
  {
    "Code": "U-846",
    "Definition": "USE FOR DELINEATION (VISUALIZATION) DURING A VITRECTOMY SURGICAL PROCEDURE"
  },
  {
    "Code": "U-847",
    "Definition": "ADJUNCTIVE THERAPY TO DIET IN ADULTS TO REDUCE LDL-C, TRIGLYCERIDES AND APO B, AND INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR MIXED DYSLIPIDEMIA (TYPES IIA, IIB) AND TO TREAT HYPERTRIGLYCERIDEMIA (TYPES IV, V)"
  },
  {
    "Code": "U-848",
    "Definition": "ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA"
  },
  {
    "Code": "U-849",
    "Definition": "REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP. DOSE IS ONE DROP OF COMBIGAN IN THE AFFECTED EYE TWICE DAILY"
  },
  {
    "Code": "U-850",
    "Definition": "PREVENTION OR TREATMENT OF NAUSEA OR EMESIS INDUCED BY A CANCER CHEMOTHERAPEUTIC AGENT"
  },
  {
    "Code": "U-851",
    "Definition": "TREATMENT OF TYPE 2 DIABETES MELLITUS"
  },
  {
    "Code": "U-852",
    "Definition": "RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS"
  },
  {
    "Code": "U-853",
    "Definition": "TREATMENT OR PREVENTION OF EMESIS"
  },
  {
    "Code": "U-854",
    "Definition": "PREVENTION OF CMV DISEASE IN KIDNEY, HEART, AND KIDNEY-PANCREAS TRANSPLANT PATIENTS AT HIGH RISK (DONOR CMV SEROPOSITIVE\/RECIPIENT CMV SERONEGATIVE)"
  },
  {
    "Code": "U-855",
    "Definition": "METHOD TO INDUCE NATRIURESIS, DIURESIS AND\/OR VASODILATION"
  },
  {
    "Code": "U-856",
    "Definition": "SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN"
  },
  {
    "Code": "U-857",
    "Definition": "INHIBITION OF TRANSPLANT REJECTION"
  },
  {
    "Code": "U-858",
    "Definition": "PEDIATRIC USE AGED 1-11 YEARS, GERD AND EROSIVE ESOPHAGITIS"
  },
  {
    "Code": "U-859",
    "Definition": "EROSIVE ESOPHAGITIS, HYPERSECRETORY CONDITIONS INCLUDING ZOLLINGER-ELLISON SYNDROME, MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND REDUCTION OF SYMPTOMS IN PATIENTS WITH GERD"
  },
  {
    "Code": "U-860",
    "Definition": "FOR THE APPROVED USES AND CONDITIONS OF USE, INCLUDING DEPRESSION"
  },
  {
    "Code": "U-861",
    "Definition": "RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER"
  },
  {
    "Code": "U-862",
    "Definition": "ADJUNCT TO DIET TO REDUCE ELEVATED TOTAL-C, LDL-C, NON-HDL-C, APO B, TG, AND LP(A) LEVELS AND TO INCREASE HDL-C IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA, MIXED DYSLIPIDEMIA, AND HYPERTRIGLYCERIDEMIA"
  },
  {
    "Code": "U-863",
    "Definition": "TAKING ASPIRIN OR NON-STEROIDAL ANTI-INFLAMMATORY MEDICATIONS APPROXIMATELY 30 MINUTES BEFORE DOSING CAN MINIMIZE FLUSHING, A COMMON SIDE EFFECT OF NIACIN THERAPY"
  },
  {
    "Code": "U-864",
    "Definition": "PEDIATRIC USE AGES 1-2 YEARS, GERD AND EROSIVE ESOPHAGITIS"
  },
  {
    "Code": "U-865",
    "Definition": "TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND A HIGH RISK FOR BONE FRACTURE BY REDUCING THE RISK OF VERTEBRAL AND NONVERTEBRAL BONE FRACTURE"
  },
  {
    "Code": "U-866",
    "Definition": "THE LABEL REFERENCES THE EFFECTS OF THE ACTIVE INGREDIENT OF REVLIMID UPON CYTOKINES"
  },
  {
    "Code": "U-867",
    "Definition": "TREATMENT OF MIGRAINE"
  },
  {
    "Code": "U-868",
    "Definition": "METHOD OF USING ANTAGONIST OF ARGININE VASOPRESSIN (AVA) V1A AND V2 RECEPTORS FOR INTRAVENOUS TREATMENT OF PATIENTS WITH HYPERVOLEMIC HYPONATREMIA"
  },
  {
    "Code": "U-869",
    "Definition": "METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART"
  },
  {
    "Code": "U-870",
    "Definition": "METHOD OF PRODUCING CORONARY VASODILATION WITHOUT PERIPHERAL VASODILATION"
  },
  {
    "Code": "U-871",
    "Definition": "METHOD OF REDUCING RISK OF MYOCARDIAL INFARCTION, STROKE AND DEATH"
  },
  {
    "Code": "U-872",
    "Definition": "TWICE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA. TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS"
  },
  {
    "Code": "U-873",
    "Definition": "METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME BY OPENING CHLORIDE CHANNELS (CIC)"
  },
  {
    "Code": "U-874",
    "Definition": "METHOD OF TREATING CONSTIPATION IN A PATIENT WITH IRRITABLE BOWEL SYNDROME"
  },
  {
    "Code": "U-875",
    "Definition": "FIRST-LINE TREATMENT OF LOCALLY ADVANCED UNRESECTABLE OR METASTATIC PANCREATIC CANCER, IN COMBINATION WITH GEMCITABINE"
  },
  {
    "Code": "U-876",
    "Definition": "TREATMENT OF MIGRAINE WITH OR WITHOUT AURA"
  },
  {
    "Code": "U-877",
    "Definition": "FOR USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PEPTIC ULCER"
  },
  {
    "Code": "U-878",
    "Definition": "A METHOD FOR BINDING A PERIPHERAL OPIOID RECEPTOR"
  },
  {
    "Code": "U-879",
    "Definition": "A METHOD OF TREATING OR PREVENTING ILEUS"
  },
  {
    "Code": "U-880",
    "Definition": "ENDOMETRIN IS A PROGESTERONE INDICATED TO SUPPORT EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN"
  },
  {
    "Code": "U-881",
    "Definition": "TREATMENT OF NON-SMALL CELL LUNG CANCER"
  },
  {
    "Code": "U-882",
    "Definition": "MANAGEMENT OF FIBROMYALGIA (FM)"
  },
  {
    "Code": "U-883",
    "Definition": "TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH SUNITINIB"
  },
  {
    "Code": "U-884",
    "Definition": "TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA"
  },
  {
    "Code": "U-885",
    "Definition": "TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR THERAPY"
  },
  {
    "Code": "U-886",
    "Definition": "ADMINISTERING DESLORATADINE TO TREAT THE SYMPTOMS OF PERENNIAL ALLERGIC RHINITIS, SEASONAL ALLERGIC RHINITIS, OR CHRONIC IDIOPATHIC URTICARIA"
  },
  {
    "Code": "U-887",
    "Definition": "TREATMENT AND PREVENTION OF OSTEOPOROSIS"
  },
  {
    "Code": "U-888",
    "Definition": "FEMALE HORMONE REPLACEMENT THERAPY FOR POSTMENOPAUSAL WOMEN"
  },
  {
    "Code": "U-889",
    "Definition": "MENOPAUSAL AND POSTMENOPAUSAL DISORDERS (INCLUDING VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE)"
  },
  {
    "Code": "U-890",
    "Definition": "REDUCTION OF SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE"
  },
  {
    "Code": "U-891",
    "Definition": "USE AS AN INTRAOCULAR IRRIGATING SOLUTION DURING SURGICAL PROCEDURES INVOLVING PERFUSION OF THE EYE"
  },
  {
    "Code": "U-892",
    "Definition": "TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL)"
  },
  {
    "Code": "U-893",
    "Definition": "CLEVIPREX IS A DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER INDICATED FOR THE REDUCTION OF BLOOD PRESSURE WHEN ORAL THERAPY IS NOT FEASIBLE OR NOT DESIRABLE"
  },
  {
    "Code": "U-894",
    "Definition": "TREATMENT OF COLD SORES IN PEDIATRIC PATIENTS TWELVE YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-895",
    "Definition": "TREATMENT OF HIV INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS"
  },
  {
    "Code": "U-896",
    "Definition": "TREATMENT OF NASAL SYMPTOMS OF SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN TWO YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-897",
    "Definition": "METHOD OF TREATING TONSILLITIS AND\/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT"
  },
  {
    "Code": "U-898",
    "Definition": "USE OF GLUTAMINE TOGETHER WITH GROWTH HORMONE FOR THE TREATMENT OF PATIENTS WITH SHORT BOWEL SYNDROME"
  },
  {
    "Code": "U-899",
    "Definition": "USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA"
  },
  {
    "Code": "U-900",
    "Definition": "INTEGRASE INHIBITION FOR THE TREATMENT OF HIV INFECTION"
  },
  {
    "Code": "U-901",
    "Definition": "PREVENTION OF POSTOPERATIVE NAUSEA AND VOMITING"
  },
  {
    "Code": "U-902",
    "Definition": "USE IN THE TREATMENT OF THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA (BPH)"
  },
  {
    "Code": "U-903",
    "Definition": "TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN ADULT PATIENTS"
  },
  {
    "Code": "U-904",
    "Definition": "TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS ASSOCIATED WITH MENOPAUSE"
  },
  {
    "Code": "U-905",
    "Definition": "TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE"
  },
  {
    "Code": "U-906",
    "Definition": "PROPHYLAXIS OF ORGAN REJECTION IN KIDNEY, LIVER AND HEART ALLOGENIC TRANSPLANTS; TREATMENT OF PATIENTS WITH SEVERE ACTIVE, RHEUMATOID ARTHRITIS; TREATMENT OF ADULT, NONIMMUNOCOMPROMISED PATIENTS WITH SEVERE, RECALCITRANT, PLAQUE PSORIASIS"
  },
  {
    "Code": "U-907",
    "Definition": "FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS IN SUBJECTS 18 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-908",
    "Definition": "PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS RECEIVING ALLOGENEIC RENAL TRANSPLANTS"
  },
  {
    "Code": "U-909",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS PATIENTS WITH PSEUDOMONAS AERUGINOSA"
  },
  {
    "Code": "U-910",
    "Definition": "TREATMENT OF METASTATIC CARCINOMA OF THE OVARY AFTER FAILURE OF INITIAL OR SUBSEQUENT CHEMOTHERAPY"
  },
  {
    "Code": "U-911",
    "Definition": "METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL TREATMENT IS TEMPORARILY NOT FEASIBLE"
  },
  {
    "Code": "U-912",
    "Definition": "SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND\/OR DURING SURGICAL AND OTHER PROCEDURES"
  },
  {
    "Code": "U-913",
    "Definition": "TREATMENT OF OVERACTIVE BLADDER WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND FREQUENCY"
  },
  {
    "Code": "U-914",
    "Definition": "METHOD OF TREATING, AS ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER"
  },
  {
    "Code": "U-915",
    "Definition": "TREATMENT OF MUSCULOSKELETAL CONDITIONS"
  },
  {
    "Code": "U-916",
    "Definition": "TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OR OLDER"
  },
  {
    "Code": "U-917",
    "Definition": "TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS"
  },
  {
    "Code": "U-918",
    "Definition": "TO TREAT OR PREVENT INFECTIONS CAUSED BY SUSCEPTIBLE BACTERIA USING DELAYED-RELEASE TABLETS CONSISTING OF DOXYCYCLINE HYCLATE COATED PELLETS IN A TABLET"
  },
  {
    "Code": "U-919",
    "Definition": "FOR THE TREATMENT OF DERMATITIS"
  },
  {
    "Code": "U-920",
    "Definition": "STEROID-RESPONSIVE INFLAMMATORY OCULAR CONDITIONS FOR WHICH A CORTICOSTEROID IS INDICATED AND WHERE SUPERFICIAL BACTERIAL OCULAR INFECTION OR A RISK OF BACTERIAL OCULAR INFECTION EXISTS"
  },
  {
    "Code": "U-921",
    "Definition": "TREATMENT OF ACNE VULGARIS"
  },
  {
    "Code": "U-922",
    "Definition": "FOR THE TREATMENT OF FUNGAL INFECTIONS"
  },
  {
    "Code": "U-923",
    "Definition": "METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION"
  },
  {
    "Code": "U-924",
    "Definition": "TREATMENT OF MILD TO MODERATE INFECTION CAUSED BY SUSCEPTIBLE STRAINS"
  },
  {
    "Code": "U-925",
    "Definition": "TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA"
  },
  {
    "Code": "U-926",
    "Definition": "MGT SPECIFIC BACTERIAL INFECTIONS. TREATMENT PTS W\/ COMMUNITY ACQUIRED PNEUMONIA OR BACTERIAL SINUSITIS DUE TO CONFIRMED, OR SUSPECTED B-LACTAMASE PRODUCING PATHOGENS & S. PNEUMONIAE WITH REDUCED SUSCEPTIBILITY TO PENICILLIN (MIC=2MC\/ML)"
  },
  {
    "Code": "U-927",
    "Definition": "METHOD FOR INCREASING TEAR PRODUCTION"
  },
  {
    "Code": "U-928",
    "Definition": "TREATMENT OF BACTERIAL INFECTIOUS DISEASE"
  },
  {
    "Code": "U-929",
    "Definition": "TREATMENT OF OBSESSIVE COMPULSIVE DISORDER TREATABLE WITH AN SSRI"
  },
  {
    "Code": "U-930",
    "Definition": "TREATMENT OF IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)"
  },
  {
    "Code": "U-931",
    "Definition": "RELIEF OF MODERATE TO SEVERE ACUTE PAIN"
  },
  {
    "Code": "U-932",
    "Definition": "PYLERA CAPSULES, IN COMBINATION WITH OMEPRAZOLE ARE INDICATED FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI"
  },
  {
    "Code": "U-933",
    "Definition": "FOR THE TREATMENT OF PATIENTS WITH HELICOBACTER PYLORI INFECTION AND DUODENAL ULCER DISEASE TO ERADICATE H. PYLORI. THE ERADICATION OF HELICOBACTER PYLORI HAS BEEN SHOWN TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE"
  },
  {
    "Code": "U-934",
    "Definition": "IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELL TO THE PERIPHERAL BLOOD FOR COLLECTION AND SUBSEQUENT AUTOLOGOUS TRANSPLANTATION WITH  NON-HODGKINS LYMPHOMA AND MULTIPLE MYELOMA"
  },
  {
    "Code": "U-935",
    "Definition": "TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) IN PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-936",
    "Definition": "USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE MYELOMA"
  },
  {
    "Code": "U-937",
    "Definition": "TREATMENT OF PROSTATE CANCER"
  },
  {
    "Code": "U-938",
    "Definition": "TREATMENT OF HAIR LOSS AND HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS"
  },
  {
    "Code": "U-939",
    "Definition": "TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING AND STIMULATING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS"
  },
  {
    "Code": "U-940",
    "Definition": "METHOD TO TREAT AIDS-RELATED KAPOSI'S SARCOMA"
  },
  {
    "Code": "U-941",
    "Definition": "METHOD TO TREAT OVARIAN CANCER"
  },
  {
    "Code": "U-942",
    "Definition": "METHOD TO TREAT MULTIPLE MYELOMA"
  },
  {
    "Code": "U-943",
    "Definition": "GNRH ANTAGONIST INDICATED FOR TREATMENT OF PATIENTS WITH ADVANCED PROSTATE CANCER"
  },
  {
    "Code": "U-944",
    "Definition": "TREATMENT OF PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)"
  },
  {
    "Code": "U-945",
    "Definition": "SEDATIVE-HYPNOTIC AGENT INDICATED FOR MONITORED ANESTHESIA CARE (MAC) SEDATION"
  },
  {
    "Code": "U-946",
    "Definition": "TREATMENT OF BREAST CANCER"
  },
  {
    "Code": "U-947",
    "Definition": "WHEN PATIENTS ARE UNABLE TO TAKE THE ORAL FORMULATIONS, PREVACID IV, FOR INJECTION IS INDICATED AS AN ALTERNATIVE FOR THE SHORT-TERM TREATMENT (UP TO 7 DAYS) OF ALL GRADES OF EROSIVE ESOPHAGITIS"
  },
  {
    "Code": "U-948",
    "Definition": "TREATMENT OF DIABETES MELLITUS"
  },
  {
    "Code": "U-949",
    "Definition": "HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 8 WEEKS"
  },
  {
    "Code": "U-950",
    "Definition": "MAINTAIN HEALING OF EROSIVE ESOPHAGITIS (EE) FOR UP TO 6 MONTHS"
  },
  {
    "Code": "U-951",
    "Definition": "TREATMENT OF HEARTBURN ASSOCIATED WITH NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (GERD) FOR 4 WEEKS"
  },
  {
    "Code": "U-952",
    "Definition": "USE AS AN ANALGESIC"
  },
  {
    "Code": "U-953",
    "Definition": "METHOD OF TREATING OPHTHALMIC INFLAMMATION AND INFECTION"
  },
  {
    "Code": "U-954",
    "Definition": "CHRONIC MANAGEMENT OF HYPERURICEMIA IN PATIENTS WITH GOUT. NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA"
  },
  {
    "Code": "U-955",
    "Definition": "PROPHYLACTIC TREATMENT OF MIGRAINE"
  },
  {
    "Code": "U-956",
    "Definition": "TREATMENT OF PATIENTS WITH H. PYLORI INFECTION AND DUODENAL ULCER DISEASE"
  },
  {
    "Code": "U-957",
    "Definition": "A METHOD OF TREATING CANCER IN A PATIENT COMPRISING ADMINISTERING IXABEPILONE OR PHARMACEUTICAL COMPOSITIONS COMPRISING IXABEPILONE"
  },
  {
    "Code": "U-958",
    "Definition": "METHOD OF TREATING PATIENT COMPRISING MIXING FIRST AND SECOND VIALS OF PRODUCT COMPRISING LYOPHILIZED IXABEPILONE TO PROVIDE AN EPOTHILONE ANALOG SOLUTION, DILUTING SOLUTION WITH A SUITABLE DILUENT TO PREPARE INTRAVENOUS FORMULATION FOR PT"
  },
  {
    "Code": "U-959",
    "Definition": "METHOD OF TREATING CANCER, IV ADMIN, LYOPHILIZED IXABEPILONE DILUTED, EVERY WEEK OR 3 WEEKS; LYOPHILIZED IXABEPILONE  WITH SOLVENT(DEHYDRATED ETHANOL)  DILUTED TO CONCENTRATION OF 0.1MG\/ML TO 0.9MG\/ML"
  },
  {
    "Code": "U-960",
    "Definition": "METHOD OF TREATING CANCER IN A PATIENT COMPRISING INTRAVENOUSLY ADMINISTERING TO THE PATIENT IXABEPILONE DILUTED IN A PARENTERAL DILUENT"
  },
  {
    "Code": "U-961",
    "Definition": "METHOD OF TREATING BREAST CANCER BY ADMINISTERING IXABEPILONE; A METHOD OF TREATING A CANCER RESPONSIBLE TO MICROTUBULE STABILIZATION BY ADMINISTERING IXABEPILONE"
  },
  {
    "Code": "U-962",
    "Definition": "SYMBYAX IS INDICATED FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS"
  },
  {
    "Code": "U-963",
    "Definition": "PROZAC AND OLANZAPINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS"
  },
  {
    "Code": "U-964",
    "Definition": "ZYPREXA ZYDIS AND FLUOXETINE IN COMBINATION FOR THE ACUTE TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS"
  },
  {
    "Code": "U-965",
    "Definition": "USE OF IXABEPILONE IN COMBINATION WITH CAPECITABINE IN TREATMENT OF METASTASIS BREAST CANCER"
  },
  {
    "Code": "U-966",
    "Definition": "TREATMENT OF ASTHMA (MAINTENANCE AND PROPHYLACTIC THERAPY)"
  },
  {
    "Code": "U-967",
    "Definition": "A METHOD OF REVERSING SOFT-TISSUE ANESTHESIA I.E. ANESTHESIA OF THE LIP AND TONGUE, AND THE ASSOCIATED FUNCTIONAL DEFICITS RESULTING FROM AN INTRAORAL SUBMUCOSAL INJECTION OF A LOCAL ANESTHETIC"
  },
  {
    "Code": "U-968",
    "Definition": "A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS"
  },
  {
    "Code": "U-969",
    "Definition": "TREATMENT OF MIGRAINE"
  },
  {
    "Code": "U-970",
    "Definition": "TOPICAL TREATMENT OF LICE INFESTATIONS"
  },
  {
    "Code": "U-971",
    "Definition": "INDICATED FOR THE ACUTE TREATMENT OF ADULTS WITH SCHIZOPHRENIA"
  },
  {
    "Code": "U-972",
    "Definition": "MONOTHERAPY OR AS ADJUNCTIVE THERAPY TO LITHIUM OR VALPROATE FOR THE MAINTENANCE TREATMENT OF BIPOLAR I DISORDER"
  },
  {
    "Code": "U-973",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH PIOGLITAZONE AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON PIOGLITAZONE OR METFORMIN ALONE"
  },
  {
    "Code": "U-974",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN"
  },
  {
    "Code": "U-975",
    "Definition": "TREATMENT OF PULMONARY HYPERTENSION"
  },
  {
    "Code": "U-976",
    "Definition": "IMPROVEMENT OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES"
  },
  {
    "Code": "U-977",
    "Definition": "TREATMENT OF ACUTE, UNCOMPLICATED MALARIA INFECTION DUE TO PLASMODIUM FALCIPARUM IN PATIENTS OF 5KG BODYWEIGHT AND ABOVE"
  },
  {
    "Code": "U-978",
    "Definition": "METHOD OF TREATING HYPONATREMIA"
  },
  {
    "Code": "U-979",
    "Definition": "RELIEF OF MUSCLE SPASM"
  },
  {
    "Code": "U-980",
    "Definition": "NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN"
  },
  {
    "Code": "U-981",
    "Definition": "MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY"
  },
  {
    "Code": "U-982",
    "Definition": "A METHOD OF TREATING OSTEOPOROSIS"
  },
  {
    "Code": "U-983",
    "Definition": "METHOD OF TREATING OSTEOPOROSIS IN A POST-MENOPAUSAL WOMAN AT RISK FOR FRACTURE"
  },
  {
    "Code": "U-984",
    "Definition": "METHOD FOR THE TREATMENT OF A WOMAN WITH OSTEOPOROSIS AND AT RISK FOR BONE FRACTURE"
  },
  {
    "Code": "U-985",
    "Definition": "TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO)"
  },
  {
    "Code": "U-986",
    "Definition": "TREATMENT OF PATIENTS INFECTED WITH PEDICULUS HUMANUS CAPITIS (HEAD LICE AND THEIR OVA) OF THE SCALP HAIR"
  },
  {
    "Code": "U-987",
    "Definition": "TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS"
  },
  {
    "Code": "U-988",
    "Definition": "TREATMENT OF RHINITIS COMPRISING THE NASAL APPLICATION OF A PHARMACEUTICAL FORMULATION AS CLAIMED IN US PATENT 7541350"
  },
  {
    "Code": "U-989",
    "Definition": "FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA"
  },
  {
    "Code": "U-990",
    "Definition": "TREATMENT OF PROTOZOAL INFECTION"
  },
  {
    "Code": "U-991",
    "Definition": "TREATMENT OR PROPHYLAXIS OF THROMBOSIS OR EMBOLISMS"
  },
  {
    "Code": "U-992",
    "Definition": "REDUCTION OF THE RISK OF CARDIOVASCULAR HOSPITALIZATION"
  },
  {
    "Code": "U-993",
    "Definition": "METHOD OF TREATING INFERTILITY"
  },
  {
    "Code": "U-994",
    "Definition": "METHOD OF TREATMENT OF OSTEOPOROSIS WHEREIN THE OSTEOPOROSIS IS STEROID-INDUCED"
  },
  {
    "Code": "U-995",
    "Definition": "METHOD FOR TREATING TYPE II DIABETES BY ADMINISTERING SAXAGLIPTIN"
  },
  {
    "Code": "U-996",
    "Definition": "AN ADJUNCTIVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL (TC), LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES, AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIX DYSLIPIDEMIA"
  },
  {
    "Code": "U-997",
    "Definition": "TREATMENT OF MAJOR DEPRESSIVE DISORDER BY DOSING AT INTERVALS OF 24 HOURS"
  },
  {
    "Code": "U-998",
    "Definition": "ADJUNCTIVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA"
  },
  {
    "Code": "U-999",
    "Definition": "TREATMENT OF CHRONIC HEPATITIS B IN ADULT PATIENTS"
  },
  {
    "Code": "U-1000",
    "Definition": "ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH HYPERLIPIDEMIAS"
  },
  {
    "Code": "U-1001",
    "Definition": "METHOD FOR DELIVERING DRUG TO LUNG OF MAMMAL, COMPRISING ADMINISTERING DRUG PRODUCT BY INHALATION. TREATING A MAMMAL HAVING A CONDITION CAPABLE OF TREATMENT BY INHALATION, COMPRISING ADMINISTERING TO THE LUNG THE DRUG PRODUCT BY INHALATION"
  },
  {
    "Code": "U-1002",
    "Definition": "METHOD OF TREATING INFLAMMATORY CONDITIONS"
  },
  {
    "Code": "U-1003",
    "Definition": "A METHOD OF MYOCARDIAL PERFUSION IMAGING AND INCREASING CORONARY BLOOD FLOW"
  },
  {
    "Code": "U-1004",
    "Definition": "TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA"
  },
  {
    "Code": "U-1005",
    "Definition": "METHOD OF TREATING A STAPHYLOCOCCAL INFECTION"
  },
  {
    "Code": "U-1006",
    "Definition": "NEW COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND ADOLESCENTS (12 YEARS OF AGE AND OLDER)"
  },
  {
    "Code": "U-1007",
    "Definition": "METHOD OF TREATING GOUT FLARES"
  },
  {
    "Code": "U-1008",
    "Definition": "APPLICATION OF ANTISEPTIC WITH MOISTURIZERS FOR SURGICAL AND HEALTHCARE PERSONNEL SKIN DISINFECTION"
  },
  {
    "Code": "U-1009",
    "Definition": "METHOD FOR ADMINISTRATION OF TESTOSTERONE"
  },
  {
    "Code": "U-1010",
    "Definition": "TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA DUE TO TETRA HYDROBIOPTERIN RESPONSIVE PHENYLKETONURIA. KUVAN SHOULD BE TAKEN ORALLY WITH FOOD TO INCREASE ABSORPTION"
  },
  {
    "Code": "U-1011",
    "Definition": "USE OF GRANISETRON TRANSDERMAL SYSTEM TO TREAT\/PREVENT CHEMOTHERAPY INDUCED NAUSEA AND VOMITING"
  },
  {
    "Code": "U-1012",
    "Definition": "METHOD FOR TREATING INSOMNIA WHILE REDUCING THE RISK OF AN ADVERSE DRUG INTERACTION"
  },
  {
    "Code": "U-1013",
    "Definition": "METHOD OF USING RIBAVIRIN IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2B TO TREAT PATIENTS WITH CHRONIC HEPATITIS C"
  },
  {
    "Code": "U-1014",
    "Definition": "METHOD OF USING RIBAVIRIN IN COMBINATION WITH INTERFERON ALPHA-2B(PEGYLATED AND NONPEGYLATED) TO TREAT PATIENTS WITH CHRONIC HEPATITIS C"
  },
  {
    "Code": "U-1015",
    "Definition": "TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA"
  },
  {
    "Code": "U-1016",
    "Definition": "IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-EXPERIENCED ADULT PATIENTS, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO AN NNRTI AND OTHER ANTIRETROVIRAL AGENTS"
  },
  {
    "Code": "U-1017",
    "Definition": "A METHOD OF TREATING NASAL AND NON-NASAL SYMPTOMS OF SEASONAL ALLERGIC RHINITIS"
  },
  {
    "Code": "U-1018",
    "Definition": "TREATMENT OF PULMONARY HYPERTENSION BY INHALATION"
  },
  {
    "Code": "U-1019",
    "Definition": "TREATMENT OF PULMONARY HYPERTENSION"
  },
  {
    "Code": "U-1020",
    "Definition": "METHOD OF USING COLCHICINE FOR THE PROPHYLAXIS OF GOUT FLARES"
  },
  {
    "Code": "U-1021",
    "Definition": "SHORT-TERM TREATMENT (4-8 WEEKS) OF ACTIVE BENIGN GASTRIC ULCER"
  },
  {
    "Code": "U-1022",
    "Definition": "FOR THE PREPARATION OF SKIN PRIOR TO SURGERY; HELPS REDUCE BACTERIA THAT CAN POTENTIALLY CAUSE SKIN INFECTION"
  },
  {
    "Code": "U-1023",
    "Definition": "TREATMENT OF ATROPHIC VAGINITIS DUE TO MENOPAUSE"
  },
  {
    "Code": "U-1024",
    "Definition": "REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION WHO REQUIRE ADJUNCTIVE OR REPLACEMENT THERAPY DUE TO INADEQUATELY CONTROLLED IOP"
  },
  {
    "Code": "U-1025",
    "Definition": "TREATING FREQUENT HEARTBURN"
  },
  {
    "Code": "U-1026",
    "Definition": "A METHOD OF TREATING HUMAN SUFFERING FROM OR SUSCEPTIBLE TO PSYCHOSIS."
  },
  {
    "Code": "U-1027",
    "Definition": "REDUCTION OF ELEVATED PLASMA STEROL AND\/OR STANOL LEVELS IN A MAMMAL"
  },
  {
    "Code": "U-1028",
    "Definition": "A METHOD OF DISTRIBUTING SODIUM OXYBATE UNDER CONTROL OF A CENTRAL PHARMACY"
  },
  {
    "Code": "U-1029",
    "Definition": "METHOD FOR TREATING ACUTE ELEVATIONS OF BLOOD PRESSURE IN HUMAN SUBJECT IN NEED THEREOF"
  },
  {
    "Code": "U-1030",
    "Definition": "IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)"
  },
  {
    "Code": "U-1031",
    "Definition": "IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA"
  },
  {
    "Code": "U-1032",
    "Definition": "USE OF ROSUVASTATIN CALCIUM FOR THE PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE IN INDIVIDUALS WITHOUT CLINICALLY EVIDENT CORONARY HEART DISEASE BUT WITH INCREASED RISK FACTORS"
  },
  {
    "Code": "U-1033",
    "Definition": "TOPICAL TREATMENT OF ACNE VULGARIS"
  },
  {
    "Code": "U-1034",
    "Definition": "TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN ADULTS"
  },
  {
    "Code": "U-1035",
    "Definition": "NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN"
  },
  {
    "Code": "U-1036",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH INSULIN"
  },
  {
    "Code": "U-1037",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH A PPAR-GAMMA AGONIST"
  },
  {
    "Code": "U-1038",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN AND A PPAR-GAMMA AGONIST"
  },
  {
    "Code": "U-1039",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH METFORMIN"
  },
  {
    "Code": "U-1040",
    "Definition": "INHIBITION OF THROMBIN IN A PATIENT"
  },
  {
    "Code": "U-1041",
    "Definition": "TREATMENT OF DISORDERS RESPONSIVE TO GROWTH HORMONE"
  },
  {
    "Code": "U-1042",
    "Definition": "METHOD FOR STIMULATING CORONARY VASODILATION FOR PURPOSES OF IMAGING THE HEART"
  },
  {
    "Code": "U-1043",
    "Definition": "MANAGEMENT OF MODERATE TO SEVERE PAIN"
  },
  {
    "Code": "U-1044",
    "Definition": "TOPICAL TREATMENT OF SCALP PSORIASIS"
  },
  {
    "Code": "U-1045",
    "Definition": "MAINTENANCE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHO HAVE NOT PROGRESSED ON 1ST-LINE TREATMENT WITH PLATINUM-BASED CHEMOTHERAPY"
  },
  {
    "Code": "U-1046",
    "Definition": "MAINTENANCE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NSCLC WHOSE DISEASE HAS NOT PROGRESSED AFTER FOUR CYCLES PLATINUM-BASED CHEMOTHERAPY"
  },
  {
    "Code": "U-1047",
    "Definition": "TREATMENT OF BIOPSY-CONFIRMED, PRIMARY SUPERFICIAL BASAL CELL CARCINOMA (SBCC)"
  },
  {
    "Code": "U-1048",
    "Definition": "WORKS THROUGH THE INDUCTION OF INTERFERON AND OTHER CYTOKINES"
  },
  {
    "Code": "U-1049",
    "Definition": "PROPHYLAXIS OF ORGAN REJECTION IN ADULT PATIENTS AT LOW-MODERATE IMMUNOLOGIC RISK RECEIVING A RENAL TRANSPLANT"
  },
  {
    "Code": "U-1050",
    "Definition": "USE OF METAXALONE FOR TREATMENT OF MUSCULOSKELETAL CONDITIONS"
  },
  {
    "Code": "U-1051",
    "Definition": "TREATMENT OF OROPHARYNGEAL CANDIDIASIS"
  },
  {
    "Code": "U-1052",
    "Definition": "RELIEF OF SIGNS AND SYMPTOMS OF ARTHRITIS AND RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER"
  },
  {
    "Code": "U-1053",
    "Definition": "RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER"
  },
  {
    "Code": "U-1054",
    "Definition": "ONYCHOMYCOSIS OF THE TOENAIL CAUSED BY TRICOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES, ONCE DAILY USE FOR 12 CONSECUTIVE WEEKS"
  },
  {
    "Code": "U-1055",
    "Definition": "AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH A THIAZOLIDINEDIONE (TZD) AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A TZD OR METFORMIN ALONE"
  },
  {
    "Code": "U-1056",
    "Definition": "TREATMENT OF PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE"
  },
  {
    "Code": "U-1057",
    "Definition": "TREATMENT OF INFLAMMATION AND PAIN USING A NASAL SPRAY OF KETOROLAC TROMETHAMINE"
  },
  {
    "Code": "U-1058",
    "Definition": "USE OF THALIDOMIDE IN COMBINATION WITH DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA"
  },
  {
    "Code": "U-1059",
    "Definition": "ADJUNCTIVE THERAPY TO DIET TO PATIENTS WITH HYPERTRIGLYCERIDEMIA"
  },
  {
    "Code": "U-1060",
    "Definition": "ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH ELEVATED CHOLESTEROL AND\/OR LIPID LEVELS"
  },
  {
    "Code": "U-1061",
    "Definition": "ADJUNCTIVE THERAPY TO DIET IN PATIENTS WITH MIXED DYSLIPIDEMIA"
  },
  {
    "Code": "U-1062",
    "Definition": "ADMINISTRATION OF APPROVED PRODUCT FOR TREATMENT OF ALZHEIMER'S DISEASE"
  },
  {
    "Code": "U-1063",
    "Definition": "TREATMENT OF ONLY INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA"
  },
  {
    "Code": "U-1064",
    "Definition": "TREATMENT OF BIPOLAR DISORDER AND SCHIZOPHRENIA"
  },
  {
    "Code": "U-1065",
    "Definition": "METHOD OF TREATING ANDROGEN RESPONSIVE OR MEDICATED CONDITION IN A MAMMAL BY ADMINISTERING A SAFE & EFFECTIVE AMOUNT OF DUTASTERIDE OR A PHARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF.. CONDITIONS INCLUDE BENIGN PROSTATIC HYPERTROPHY"
  },
  {
    "Code": "U-1066",
    "Definition": "METHOD OF TREATING AN ANDROGEN RESPONSE OR MEDIATED DISEASE IN A MAMMAL BY ADMINISTERING AN EFFECTIVE ANDROGEN RESPONSIVE OR MEDICATED DISEASE AMOUNT OF DUTASTERIDE..CONDITIONS INCLUDE BENIGN PROSTATIC HYPERPLASIA"
  },
  {
    "Code": "U-1067",
    "Definition": "TREATMENT OF CANCER"
  },
  {
    "Code": "U-1068",
    "Definition": "TREATMENT OF ASTHMA"
  },
  {
    "Code": "U-1069",
    "Definition": "A METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING AN EXCLUSIVE COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION"
  },
  {
    "Code": "U-1070",
    "Definition": "A METHOD TO CONTROL ABUSE OF A SENSITIVE DRUG BY CONTROLLING WITH A COMPUTER PROCESSOR THE DISTRIBUTION OF THE SENSITIVE DRUG VIA AN EXCLUSIVITY CENTRAL PHARMACY THAT MAINTAINS A CENTRAL DATABASE"
  },
  {
    "Code": "U-1071",
    "Definition": "METHOD OF TREATING BLADDER DYSFUNCTION WITH ONCE A DAY TROSPIUM SALT FORMULATION"
  },
  {
    "Code": "U-1072",
    "Definition": "THE MANAGEMENT OF MODERATE TO SEVERE CHRONIC PAIN IN PATIENTS REQUIRING A CONTINUOUS, AROUND-THE-CLOCK OPIOID ANALGESIC FOR AN EXTENDED PERIOD OF TIME"
  },
  {
    "Code": "U-1073",
    "Definition": "USE FOR THE TREATMENT OF ASTHMA AND COPD"
  },
  {
    "Code": "U-1074",
    "Definition": "USE OF EXENATIDE MAY RESULT IN REDUCTION IN BODY WEIGHT"
  },
  {
    "Code": "U-1075",
    "Definition": "USE FOR THE TREATMENT OF ASTHMA"
  },
  {
    "Code": "U-1076",
    "Definition": "REDUCE CHRONIC SEVERE DROOLING (I.E., SIALORRHEA)  IN PATIENTS WITH NEUROLOGIC CONDITIONS ASSOCIATED WITH PROBLEM DROOLING"
  },
  {
    "Code": "U-1077",
    "Definition": "PRETREATMENT OF PATIENTS WITH VITAMIN B12 AND FOLIC ACID PRIOR TO PEMETREXED DISODIUM ADMINISTRATION"
  },
  {
    "Code": "U-1078",
    "Definition": "TREATMENT OF ACNE"
  },
  {
    "Code": "U-1079",
    "Definition": "REVLIMID (LENALIDOMIDE) IS INDICATED FOR THE TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)"
  },
  {
    "Code": "U-1080",
    "Definition": "METHOD TO TREAT PULMONARY HYPERTENSION BY ADMINISTERING AMBRISENTAN TO A PATIENT"
  },
  {
    "Code": "U-1081",
    "Definition": "LUMIGAN IS A PROSTAGLANDIN ANALOG INDICATED FOR THE REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION"
  },
  {
    "Code": "U-1082",
    "Definition": "USE OF A COMBINATION OF TOBRAMYCIN AND DEXAMETHASONE TO TREAT OCULAR INFLAMMATION WHERE AN INFECTION OR RISK OF INFECTION EXISTS"
  },
  {
    "Code": "U-1083",
    "Definition": "ACUTE TREATMENT OF MIGRAINE ATTACKS, WITH OR WITHOUT AURA, AND THE TREATMENT OF CLUSTER HEADACHE EPISODES"
  },
  {
    "Code": "U-1084",
    "Definition": "RELIEF OF THE INFLAMMATORY AND PRURITIC MANIFESTATIONS OF CORTICOSTEROID RESPONSIVE DERMATOSES IN PATIENTS 12 YEARS OF AGE OR OLDER"
  },
  {
    "Code": "U-1085",
    "Definition": "METHOD FOR TREATING IRRITABLE BOWEL SYNDROME AND METHOD FOR TREATING ABDOMINAL DISCOMFORT ASSOCIATED WITH IRRITABLE BOWEL SYNDROME"
  },
  {
    "Code": "U-1086",
    "Definition": "TREATMENT OF AUTOIMMUNE DISEASE"
  },
  {
    "Code": "U-1087",
    "Definition": "DETECTION OF NON-MUSCLE INVASIVE PAPILLARY CANCER OF THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY"
  },
  {
    "Code": "U-1088",
    "Definition": "RELIEF OF MUSCLE SPASM"
  },
  {
    "Code": "U-1089",
    "Definition": "INHIBITION OF THROMBIN"
  },
  {
    "Code": "U-1090",
    "Definition": "LO LOESTRIN FE IS INDICATED FOR THE PREVENTION OF PREGNANCY IN WOMEN WHO ELECT TO USE ORAL CONTRACEPTIVES AS A METHOD OF CONTRACEPTION"
  },
  {
    "Code": "U-1091",
    "Definition": "ASSESSMENT OF BRONCHIAL HYPERRESPONSIVENESS IN PATIENTS 6 YEARS OF AGE OR OLDER WHO DO NOT HAVE CLINICALLY APPARENT ASTHMA"
  },
  {
    "Code": "U-1092",
    "Definition": "TREATMENT OF BREAST CANCER"
  },
  {
    "Code": "U-1093",
    "Definition": "TREATMENT OF PSEUDOBULBAR AFFECT"
  },
  {
    "Code": "U-1094",
    "Definition": "MANAGEMENT OF CHRONIC MUSCULOSKELETAL PAIN"
  },
  {
    "Code": "U-1095",
    "Definition": "METHOD OF TREATING OCULAR INFLAMMATION"
  },
  {
    "Code": "U-1096",
    "Definition": "TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER"
  },
  {
    "Code": "U-1097",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHEN TREATMENT  WITH BOTH SAXAGLIPTIN AND METFORMIN IS APPROPRIATE"
  },
  {
    "Code": "U-1098",
    "Definition": "METHOD OF TREATING HYPERPARATHYROIDISM; METHOD OF TREATING HYPERCALCEMIA"
  },
  {
    "Code": "U-1099",
    "Definition": "TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA"
  },
  {
    "Code": "U-1100",
    "Definition": "REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY"
  },
  {
    "Code": "U-1101",
    "Definition": "METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY"
  },
  {
    "Code": "U-1102",
    "Definition": "METHOD OF TREATING CATAPLEXY IN PATIENTS WITH NARCOLEPSY"
  },
  {
    "Code": "U-1103",
    "Definition": "TESTOSTERONE REPLACEMENT THERAPY IN MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE"
  },
  {
    "Code": "U-1104",
    "Definition": "USE OF TRAMADOL FOR THE MANAGEMENT OF MODERATE TO MODERATELY SEVERE CHRONIC PAIN"
  },
  {
    "Code": "U-1105",
    "Definition": "TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS FOUR (4) YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-1106",
    "Definition": "TREATING HYPERTRIGLYCERIDEMIAS WITH REDUCTION OF FOOD EFFECT"
  },
  {
    "Code": "U-1107",
    "Definition": "TREATING HYPERCHOLESTEROLEMIAS WITH REDUCTION OF FOOD EFFECT"
  },
  {
    "Code": "U-1108",
    "Definition": "TREATING TYPE 2 DIABETES MELLITUS WITH EXENATIDE BY STIMULATING INSULIN RELEASE"
  },
  {
    "Code": "U-1109",
    "Definition": "TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL) IN CONNECTION WITH A SPECIAL PROGRAM APPROVED BY FDA CALLED 'SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY' (S.T.E.P.S.)"
  },
  {
    "Code": "U-1110",
    "Definition": "METHOD OF TREATING A PATIENT WITH A PRESCRIPTION DRUG USING A COMPUTER DATABASE IN A COMPUTER SYSTEM FOR DISTRIBUTION"
  },
  {
    "Code": "U-1111",
    "Definition": "NONSTEROIDAL ANTI-INFLAMMATORY DRUG INDICATED FOR RELIEF OF MILD TO MODERATE ACUTE PAIN"
  },
  {
    "Code": "U-1112",
    "Definition": "METHOD OF MR IMAGING OF A MAMMAL"
  },
  {
    "Code": "U-1113",
    "Definition": "TREATMENT AND PROPHYLAXIS OF INFLUENZA"
  },
  {
    "Code": "U-1114",
    "Definition": "TREATMENT WITH GABAPENTIN, INCLUDING TREATMENT OF NEUROPATHIC PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH POSTHERPETIC NEURALGIA"
  },
  {
    "Code": "U-1115",
    "Definition": "TREATMENT TO REDUCE THE RISK OF COPD EXACERBATIONS IN PATIENTS WITH SEVERE COPD ASSOCIATED WITH CHRONIC BRONCHITIS AND A HISTORY OF EXACERBATIONS"
  },
  {
    "Code": "U-1116",
    "Definition": "METHOD OF ADMINISTERING COLCHICINE TO FAMILIAL MEDITERRANEAN FEVER PATIENTS"
  },
  {
    "Code": "U-1117",
    "Definition": "TREATMENT OF BREAST CANCER"
  },
  {
    "Code": "U-1118",
    "Definition": "USE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA"
  },
  {
    "Code": "U-1119",
    "Definition": "CONTRAST AGENT FOR MAGNETIC RESONANCE IMAGING"
  },
  {
    "Code": "U-1120",
    "Definition": "TO REDUCE GASTROINTESTINAL SIDE EFFECTS ADMINISTER WITH A MEAL; AS STARTING DOSE ADMINISTER ONCE DAILY WITH EVENING MEAL"
  },
  {
    "Code": "U-1121",
    "Definition": "METHOD OF TREATING TRAVELERS' DIARRHEA"
  },
  {
    "Code": "U-1122",
    "Definition": "TREATMENT OF SECONDARILY INFECTED TRAUMATIC SKIN LESIONS DUE TO S. AUREUS AND S. PYOGENES"
  },
  {
    "Code": "U-1123",
    "Definition": "TREATMENT OF ALCOHOL DEPENDENCE"
  },
  {
    "Code": "U-1124",
    "Definition": "PREVENTION OF RELAPSE TO OPIOID DEPENDENCE, FOLLOWING OPIOID DETOXIFICATION"
  },
  {
    "Code": "U-1125",
    "Definition": "METHOD FOR THE DETECTION OF NEUROENDOCRINE TUMORS"
  },
  {
    "Code": "U-1126",
    "Definition": "USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE RECEIVED PRIOR CHEMOTHERAPY CONTAINING DOCETAXEL"
  },
  {
    "Code": "U-1127",
    "Definition": "TREATMENT OF PATENT DUCTUS ARTERIOSUS"
  },
  {
    "Code": "U-1128",
    "Definition": "TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION IN COMBINATION WITH PEGINTERFERON ALFA AND RIBAVIRIN IN ADULT PATIENTS (>=18 YEARS OF AGE) WITH COMPENSATED LIVER DISEASE"
  },
  {
    "Code": "U-1129",
    "Definition": "TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN"
  },
  {
    "Code": "U-1130",
    "Definition": "SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR A NIGHT WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN"
  },
  {
    "Code": "U-1131",
    "Definition": "TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN"
  },
  {
    "Code": "U-1132",
    "Definition": "TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT"
  },
  {
    "Code": "U-1133",
    "Definition": "SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT"
  },
  {
    "Code": "U-1134",
    "Definition": "TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT"
  },
  {
    "Code": "U-1135",
    "Definition": "TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A) AND INCREASE OF HDL-C"
  },
  {
    "Code": "U-1136",
    "Definition": "SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C"
  },
  {
    "Code": "U-1137",
    "Definition": "TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C"
  },
  {
    "Code": "U-1138",
    "Definition": "TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT"
  },
  {
    "Code": "U-1139",
    "Definition": "REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT"
  },
  {
    "Code": "U-1140",
    "Definition": "REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT"
  },
  {
    "Code": "U-1141",
    "Definition": "REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT"
  },
  {
    "Code": "U-1142",
    "Definition": "TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN"
  },
  {
    "Code": "U-1143",
    "Definition": "REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR A T NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN"
  },
  {
    "Code": "U-1144",
    "Definition": "REDUCTION IN ELEVATED TC AND LDL-C BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN"
  },
  {
    "Code": "U-1145",
    "Definition": "REDUCTION IN TG BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN"
  },
  {
    "Code": "U-1146",
    "Definition": "REDUCTION IN TG WITH REDUCED FLUSHING BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT"
  },
  {
    "Code": "U-1147",
    "Definition": "TREATMENT OF PRIMARY AND MIXED DYSLIPIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C"
  },
  {
    "Code": "U-1148",
    "Definition": "REDUCTION IN RISK OF RECURRENT NONFATAL MYOCARDIAL INFARCTION BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION OF LDL-C, TC, TG, LP(A), AND INCREASE OF HDL-C"
  },
  {
    "Code": "U-1149",
    "Definition": "TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, WITH PRETREATMENT WITH A FLUSH INHIBITING AGENT SUCH AS ASPIRIN"
  },
  {
    "Code": "U-1150",
    "Definition": "TREATMENT OF HYPERCHOLESTEROLEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, TG, LP(A), AND INCREASE OF HDL-C"
  },
  {
    "Code": "U-1151",
    "Definition": "TREATMENT OF HYPERTRIGLYCERIDEMIA BY DOSING ONCE PER DAY IN THE EVENING OR AT NIGHT, THROUGH REDUCTION IN TOTAL-C, LDL-C, LP(A), AND INCREASE OF HDL-C"
  },
  {
    "Code": "U-1152",
    "Definition": "CYANOCOBALAMIN ADMINISTRATION THROUGH NASAL INFUSION"
  },
  {
    "Code": "U-1153",
    "Definition": "IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, IS INDICATED FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN ANTIRETROVIRAL TREATMENT-NAIVE ADULT PATIENTS, AS SET FORTH IN THE LABELING, INCLUDING I&U SECTION"
  },
  {
    "Code": "U-1154",
    "Definition": "TREATMENT OF PROTEIN KINASE RELATED DISORDERS, SUCH AS GASTROINTESTINAL STROMAL TUMORS, RENAL CELL CARCINOMA AND ADVANCED PANCREATIC NEUROENDOCRINE TUMORS, WITH SUNITINIB"
  },
  {
    "Code": "U-1155",
    "Definition": "USE OF THALIDOMIDE IN TREATMENT OF CUTANEOUS MANIFESTATIONS OF ERYTHEMA NODOSUM LEPROSUM (ENL)"
  },
  {
    "Code": "U-1156",
    "Definition": "TO REDUCE BLOOD PHENYLALANINE (PHE) LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA (HPA)"
  },
  {
    "Code": "U-1157",
    "Definition": "RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES IN ADULTS AND CHILDREN 2 YEARS OF AGE AND OLDER AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS  AND CHILDREN 6 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-1158",
    "Definition": "RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-1159",
    "Definition": "RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES, SWELLING OF THE NASAL PASSAGES AND SINUS CONGESTION AND PRESSURE IN ADULTS AND CHILDREN 12 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-1160",
    "Definition": "RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES AND FOR THE RELIEF OF SYMPTOMS ASSOCIATED WITH HIVES (URTICARIA) IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER AND 12 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-1161",
    "Definition": "FOR THE TREATMENT AND PROPHYLAXIS OF GOUT FLARES & THE TREATMENT OF FAMILIAL MEDITERRANEAN FEVER"
  },
  {
    "Code": "U-1162",
    "Definition": "TREATMENT OF SEBORRHEIC DERMATITIS OF THE SCALP"
  },
  {
    "Code": "U-1163",
    "Definition": "METHOD OF TREATING THROMBOSIS"
  },
  {
    "Code": "U-1164",
    "Definition": "METHOD OF TREATING AN ARGATROBAN TREATABLE CONDITION"
  },
  {
    "Code": "U-1165",
    "Definition": "USE FOR THE TREATMENT OF MULTIPLE MYELOMA"
  },
  {
    "Code": "U-1166",
    "Definition": "A METHOD FOR TREATMENT OF GOUT FLARES DURING PROPHYLAXIS"
  },
  {
    "Code": "U-1167",
    "Definition": "PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)"
  },
  {
    "Code": "U-1168",
    "Definition": "THE LONG TERM, ONCE-DAILY MAINTENANCE BRONCHODILATOR TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND\/OR EMPHYSEMA"
  },
  {
    "Code": "U-1169",
    "Definition": "MANAGEMENT OF BREAKTHROUGH PAIN IN CANCER PATIENTS 18 YEARS OF AGE AND OLDER WHO ARE RECEIVING AND TOLERANT TO OPIOID THERAPY FOR THEIR UNDERLYING PERSISTENT CANCER PAIN"
  },
  {
    "Code": "U-1170",
    "Definition": "TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-1171",
    "Definition": "REDUCTION OF THE RATE OF THROMBOTIC EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME"
  },
  {
    "Code": "U-1172",
    "Definition": "TO REDUCE ELEVATED TOTAL-C, APO B, AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE IN COMBINATION WITH A STATIN"
  },
  {
    "Code": "U-1173",
    "Definition": "TO REDUCE ELEVATED TOTAL-C, LDL-C, APO B AND NON-HDL-C IN PATIENTS WITH PRIMARY HYPERLIPIDEMIA BY ADMINISTRATION OF EZETIMIBE ALONE OR IN COMBINATION WITH A STATIN OR WITH FENOFIBRATE"
  },
  {
    "Code": "U-1174",
    "Definition": "ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION, 0.9% SODIUM CHLORIDE INJECTION, OR FLOLAN STERILE DILUENT FOR INJECTION PRIOR TO ADMINISTRATION"
  },
  {
    "Code": "U-1175",
    "Definition": "REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION"
  },
  {
    "Code": "U-1176",
    "Definition": "TREATMENT OR PREVENTION OF STROKE"
  },
  {
    "Code": "U-1177",
    "Definition": "REDUCTION OF CARDIAC TISSUE DAMAGE ASSOCIATED WITH MYOCARDIAL INFARCTION"
  },
  {
    "Code": "U-1178",
    "Definition": "RELIEF OF MODERATE TO SEVERE CHRONIC PAIN"
  },
  {
    "Code": "U-1179",
    "Definition": "TREATMENT OF A CANCER MEDIATED BY AN ANAPLASTIC LYMPHOMA KINASE (ALK)"
  },
  {
    "Code": "U-1180",
    "Definition": "TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS"
  },
  {
    "Code": "U-1181",
    "Definition": "A METHOD OF TREATING OR PREVENTING OCULAR PAIN IN A PATIENT"
  },
  {
    "Code": "U-1182",
    "Definition": "TREATMENT OF CYCLIC HEAVY MENSTRUAL BLEEDING"
  },
  {
    "Code": "U-1183",
    "Definition": "A METHOD FOR ADMINISTERING FOLLICLE STIMULATING HORMONE (FSH) FOR OVARIAN FOLLICLE OR TESTICULAR STIMULATION IN THE HUMAN"
  },
  {
    "Code": "U-1184",
    "Definition": "TREATMENT OF ERECTILE DYSFUNCTION AND THE SIGNS AND SYMPTOMS OF BENIGN PROSTATIC HYPERPLASIA"
  },
  {
    "Code": "U-1185",
    "Definition": "TREATMENT OF OPIOID-INDUCED CONSTIPATION"
  },
  {
    "Code": "U-1186",
    "Definition": "ADMINISTRATION OF AN INHALABLE POWDER COMPRISING TIOTROPIUM VIA DEVICE"
  },
  {
    "Code": "U-1187",
    "Definition": "TREATMENT OF PATHOLOGICAL STATE BY ANTAGONIZING BRADYKININ RECEPTOR INCLUDING TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA (HAE)"
  },
  {
    "Code": "U-1188",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE"
  },
  {
    "Code": "U-1189",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH METFORMIN"
  },
  {
    "Code": "U-1190",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH INSULIN"
  },
  {
    "Code": "U-1191",
    "Definition": "METHOD OF TX TYPE 2 DM IN PTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBO WITH AN AGENT ACTING ON AN ATP-DEPENDENT CHANNEL IN BETA CELLS SUCH AS A SULFONYLUREA(INCL GLIPIZIDE, GLIMEPIRIDE & GLYBURIDE)"
  },
  {
    "Code": "U-1192",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A SULFONYLUREA (SUCH AS GLIPIZIDE, GLIMEPIRIDE AND GLYBURIDE)"
  },
  {
    "Code": "U-1193",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND SIMVASTATIN IS APPROPRIATE, IN COMBINATION WITH A PPAR-GAMMA AGONIST (SUCH AS PIOGLITAZONE AND ROSIGLITAZONE)"
  },
  {
    "Code": "U-1194",
    "Definition": "METHOD FOR TREATING INSOMNIA"
  },
  {
    "Code": "U-1195",
    "Definition": "PREVENTION AND TREATMENT OF SECONDARY HYPERPARATHYROIDISM ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD) STAGE 5, WHICH MAY RESULT IN RENAL OSTEODYSTROPHY, WHILE AVOIDING HYPERPHOSPHATEMIA"
  },
  {
    "Code": "U-1196",
    "Definition": "RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS"
  },
  {
    "Code": "U-1197",
    "Definition": "METHOD OF TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY"
  },
  {
    "Code": "U-1198",
    "Definition": "RECTIV IS A NITRATE VASODILATOR INDICATED FOR THE TREATMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH CHRONIC ANAL FISSURE"
  },
  {
    "Code": "U-1199",
    "Definition": "TREATMENT AND PREVENTION OF POSTMENOPAUSAL OR GLUCOCORTICOID-INDUCED OSTEOPOROSIS AND TREATMENT TO INCREASE BONE MASS IN MEN WITH OSTEOPOROSIS"
  },
  {
    "Code": "U-1200",
    "Definition": "REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM"
  },
  {
    "Code": "U-1201",
    "Definition": "FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS"
  },
  {
    "Code": "U-1202",
    "Definition": "METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT  WITH IRRITABLE BOWEL SYNDROME"
  },
  {
    "Code": "U-1203",
    "Definition": "METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A HUMAN CONSTIPATED PATIENT"
  },
  {
    "Code": "U-1204",
    "Definition": "TREATMENT OF UVEITIS"
  },
  {
    "Code": "U-1205",
    "Definition": "TREATMENT OF MACULAR EDEMA"
  },
  {
    "Code": "U-1206",
    "Definition": "DELIVERING AN OCULAR IMPLANT AS DESCRIBED IN THE DOSAGE AND ADMINISTRATION SECTION OF THE APPROVED LABELING OF OZURDEX"
  },
  {
    "Code": "U-1207",
    "Definition": "INFANT USE AGED 1 MONTH TO LESS THAN ONE YEAR,  GERD AND EROSIVE ESOPHAGITIS"
  },
  {
    "Code": "U-1208",
    "Definition": "TREATMENT OF HYPOTRICHOSIS OF THE EYELASHES BY INCREASING THEIR GROWTH INCLUDING LENGTH, THICKNESS AND DARKNESS"
  },
  {
    "Code": "U-1209",
    "Definition": "TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN ADULT PATIENTS, AND TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-1210",
    "Definition": "USE OF REVLIMID (LENALIDOMIDE) WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO REVLIMID (LENALIDOMIDE)"
  },
  {
    "Code": "U-1211",
    "Definition": "USE OF REVLIMID (LENALIDOMIDE) TO INHIBIT THE SECRETION OF PRO-INFLAMMATORY CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA"
  },
  {
    "Code": "U-1212",
    "Definition": "USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA AND TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)"
  },
  {
    "Code": "U-1213",
    "Definition": "TOPICAL TREATMENT OF SEBORRHEIC DERMATITIS IN IMMUNOCOMPETENT PATIENTS 12 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-1214",
    "Definition": "METHOD FOR RELIEVING CONSTIPATION IN A HUMAN PATIENT THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING (I) 24MCG+\/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT"
  },
  {
    "Code": "U-1215",
    "Definition": "USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF TRANSFUSION-DEPENDENT ANEMIA IN MYELODYSPLASTIC SYNDROMES (MDS)"
  },
  {
    "Code": "U-1216",
    "Definition": "USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA"
  },
  {
    "Code": "U-1217",
    "Definition": "METHOD OF INCREASING HAIR GROWTH"
  },
  {
    "Code": "U-1218",
    "Definition": "METHOD OF STIMULATING HAIR GROWTH"
  },
  {
    "Code": "U-1219",
    "Definition": "METHOD OF INCREASING THE NUMBER OF HAIRS"
  },
  {
    "Code": "U-1220",
    "Definition": "TREATMENT OF RENAL CELL CARCINOMA"
  },
  {
    "Code": "U-1221",
    "Definition": "TO STIMULATE THE IMMUNE SYSTEM TO INDUCE T CELL PROLIFERATION"
  },
  {
    "Code": "U-1222",
    "Definition": "TO INHIBIT THE PROLIFERATIVE ACTIVITY OF NEOPLASTIC CELLS"
  },
  {
    "Code": "U-1223",
    "Definition": "METHOD FOR TREATING TYPE 2 DIABETES USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENATIDE"
  },
  {
    "Code": "U-1224",
    "Definition": "REDUCTIONS IN BODY WEIGHT ARE OBSERVED WITH EXENATIDE"
  },
  {
    "Code": "U-1225",
    "Definition": "ACCELERATING THE  TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING PARTIAL LARGE OR SMALL BOWEL RESECTION SURGERY WITH PRIMARY ANASTOMOSIS"
  },
  {
    "Code": "U-1226",
    "Definition": "A METHOD OF PROVIDING A PREDETERMINED CONCENTRATION OF NITRIC OXIDE TO A PATIENT"
  },
  {
    "Code": "U-1227",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE"
  },
  {
    "Code": "U-1228",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS FOR WHOM TREATMENT WITH BOTH SITAGLIPTIN AND METFORMIN HCL EXTENDED RELEASE IS APPROPRIATE ALONE OR IN COMBINATION WITH INSULIN"
  },
  {
    "Code": "U-1229",
    "Definition": "TREATMENT OF MILDLY TO MODERATELY ACTIVE ULCERATIVE COLITIS IN MALE PATIENTS"
  },
  {
    "Code": "U-1230",
    "Definition": "A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT"
  },
  {
    "Code": "U-1231",
    "Definition": "TREATMENT OF MODERATE-TO-SEVERE PRIMARY RESTLESS LEG SYNDROME IN ADULTS"
  },
  {
    "Code": "U-1232",
    "Definition": "USE AS ANTICOAGULANT IN PTS W\/ UNSTABLE ANGINA UNDERGOING PTCA; W\/ PROVISIONAL USE OF GLYCOPROTEIN IIB\/IIIA INHIBITOR, AS ANTICOAGULANT IN PTS UNDERGOING PCI AND FOR PTS W\/, OR AT RISK OF, HIT\/HITTS UNDERGOING PCI.INTENDED FOR USE W\/ASPIRIN"
  },
  {
    "Code": "U-1233",
    "Definition": "TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION, ADMINISTERED WITH FOOD"
  },
  {
    "Code": "U-1234",
    "Definition": "FOR REDUCING TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES, AND TREATING HYPERTRIGLYCERIDEMIA"
  },
  {
    "Code": "U-1235",
    "Definition": "REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION"
  },
  {
    "Code": "U-1236",
    "Definition": "USE OF THALOMID (THALIDOMIDE) FOR THE TREATMENT OF MULTIPLE MYELOMA"
  },
  {
    "Code": "U-1237",
    "Definition": "COMBO W\/ OTHER ANTIRETROVIRALS FOR TX OF HIV-1 IN ANTIRETROVIRAL TX-EXPERIENCED PT 6 YEARS UP, WHO HAVE EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHER  ANTIRETROVIRALS"
  },
  {
    "Code": "U-1238",
    "Definition": "TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE"
  },
  {
    "Code": "U-1239",
    "Definition": "MAGNETIC RESONANCE IMAGING OF THE LIVER"
  },
  {
    "Code": "U-1240",
    "Definition": "TREATMENT OF HEAVY MENSTRUAL BLEEDING IN WOMEN WITHOUT ORGANIC PATHOLOGY WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION"
  },
  {
    "Code": "U-1241",
    "Definition": "MANAGEMENT OF MODERATE TO SEVERE PAIN BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED"
  },
  {
    "Code": "U-1242",
    "Definition": "PREVENTION OF RESPIRATORY DISTRESS (RDS) IN PREMATURE INFANTS"
  },
  {
    "Code": "U-1243",
    "Definition": "WITH DRY HANDS, GENTLY REMOVE THE SUPRENZA (PHENTERMINE HYDROCHLORIDE ODT) TABLET FROM THE BOTTLE. IMMEDIATELY PLACE THE SUPRENZA TABLET ON TOP OF THE TONGUE WHERE IT WILL DISSOLVE, THEN SWALLOW WITH OR WITHOUT WATER"
  },
  {
    "Code": "U-1244",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH SULFONYLUREA"
  },
  {
    "Code": "U-1245",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-4 INHIBITOR IN COMBINATION WITH PIOGLITAZONE"
  },
  {
    "Code": "U-1246",
    "Definition": "SINGLE DOSE ADMINISTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA"
  },
  {
    "Code": "U-1247",
    "Definition": "MANAGEMENT OF POSTHERPETIC NEURALGIA (PHN) IN ADULTS"
  },
  {
    "Code": "U-1248",
    "Definition": "USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL MEDICATION ON THE SAME KNEE"
  },
  {
    "Code": "U-1249",
    "Definition": "TREATMENT OF MALE PATIENT HAVING A DISEASE OR CONDITION RESPONSIVE TO A TERATOGENIC DRUG"
  },
  {
    "Code": "U-1250",
    "Definition": "TREATMENT OF PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY OR SPINAL CORD INJURY, POSTHERPETIC NEURALGIA, AND FIBROMYALGIA"
  },
  {
    "Code": "U-1251",
    "Definition": "A METHOD OF CONTROLLING POSTOPERATIVE OCULAR PAIN AND BURNING\/STINGING IN A PATIENT"
  },
  {
    "Code": "U-1252",
    "Definition": "METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE"
  },
  {
    "Code": "U-1253",
    "Definition": "METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY"
  },
  {
    "Code": "U-1254",
    "Definition": "METHOD FOR CHRONIC WEIGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN"
  },
  {
    "Code": "U-1255",
    "Definition": "METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY"
  },
  {
    "Code": "U-1256",
    "Definition": "TREATMENT OF SEBORRHEIC DERMATITIS"
  },
  {
    "Code": "U-1257",
    "Definition": "TREATMENT OF OPHTHALMIC DISORDERS"
  },
  {
    "Code": "U-1258",
    "Definition": "VISUALIZATION DURING VITRECTOMY PROCEDURES"
  },
  {
    "Code": "U-1259",
    "Definition": "PROPHYLAXIS OF HIV-1 INFECTION"
  },
  {
    "Code": "U-1260",
    "Definition": "TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR THERAPIES INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT AND HAVE DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETION OF THE LAST THERAPY"
  },
  {
    "Code": "U-1261",
    "Definition": "REDUCTION OF THE RISK OF HOSPITALIZATION FOR ATRIAL FIBRILLATION"
  },
  {
    "Code": "U-1262",
    "Definition": "USE OF QSYMIA (PHENTERMINE AND TOPIRAMATE) FOR WEIGHT MANAGEMENT, INCLUDING, BUT NOT LIMITED TO EFFECTING WEIGHT LOSS, TREATING OBESITY, AND\/OR TREATING OVERWEIGHT"
  },
  {
    "Code": "U-1263",
    "Definition": "TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) OR CHRONIC BRONCHITIS"
  },
  {
    "Code": "U-1264",
    "Definition": "TREATMENT OF A RESPIRATORY DISEASE"
  },
  {
    "Code": "U-1265",
    "Definition": "PATENTED METHOD OF USING REPAGLINIDE IN COMBINATION WITH METFORMIN AS INDICATED FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS"
  },
  {
    "Code": "U-1266",
    "Definition": "METHOD OF TREATING MIDDLE-OF-THE-NIGHT INSOMNIA"
  },
  {
    "Code": "U-1267",
    "Definition": "TREATMENT OF RHEUMATOID ARTHRITIS BY DELAYED RELEASE FORMULATION OF 1MG OR 2MG OF PREDNISONE"
  },
  {
    "Code": "U-1268",
    "Definition": "TREATMENT OF PULMONARY, GASTROINTESTINAL AND\/OR RHEUMATOLOGICAL DISEASES OR CONDITIONS BY USE OF DELAYED RELEASE FORMULATIONS OF 1MG OR 2MG PREDNISONE"
  },
  {
    "Code": "U-1269",
    "Definition": "TREATMENT OF RHEUMATOLOGIC, ALLERGIC, PULMONARY,  GASTROINTESTINAL,  DERMATOLOGIC DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 5MG PREDNISONE TABLET"
  },
  {
    "Code": "U-1270",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH INSULIN (WITH OR WITHOUT METFORMIN AND\/OR PIOGLITAZONE)"
  },
  {
    "Code": "U-1271",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH PHILADELPHIA CHROMOSOME-NEGATIVE(PH-) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN SECOND OR GREATER RELAPSE OR WHOSE DISEASE HAS PROGRESSED FOLLOWING TWO OR MORE ANTI-LEUKEMIA THERAPIES"
  },
  {
    "Code": "U-1272",
    "Definition": "TREATMENT OF SIGNS AND SYMPTOMS OF PARKINSON'S DISEASE BY APPLICATION OF CLAIMED TRANSDERMAL SYSTEM"
  },
  {
    "Code": "U-1273",
    "Definition": "TREATMENT OF RESTLESS LEGS SYNDROME BY APPLICATION OF CLAIMED TRANSDERMAL DELIVERY SYSTEM"
  },
  {
    "Code": "U-1274",
    "Definition": "TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY DUE TO CYSTIC FIBROSIS OR OTHER CONDITIONS"
  },
  {
    "Code": "U-1275",
    "Definition": "TREATMENT OF CHRONIC HEPATITIS B IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-1276",
    "Definition": "MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY"
  },
  {
    "Code": "U-1277",
    "Definition": "METHOD OF INCREASING EYELASH GROWTH INCLUDING LENGTH, THICKNESS, DARKNESS AND\/OR NUMBER OF EYELASHES BY ADMINISTERING BIMATOPROST TO AN EYELID MARGIN"
  },
  {
    "Code": "U-1278",
    "Definition": "METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULTS"
  },
  {
    "Code": "U-1279",
    "Definition": "TREATMENT OF HIV INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE"
  },
  {
    "Code": "U-1280",
    "Definition": "USE OF A CALCIPOTRIENE CONTAINING FOAM FOR THE TREATMENT OF PSORIASIS"
  },
  {
    "Code": "U-1281",
    "Definition": "THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAVE PREVIOUSLY RECEIVED DOCETAXEL"
  },
  {
    "Code": "U-1282",
    "Definition": "PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING"
  },
  {
    "Code": "U-1283",
    "Definition": "A METHOD OF TREATING CHRONIC MYELOGENOUS LEUKEMIA"
  },
  {
    "Code": "U-1284",
    "Definition": "A METHOD OF TREATING A NEOPLASM"
  },
  {
    "Code": "U-1285",
    "Definition": "TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS"
  },
  {
    "Code": "U-1286",
    "Definition": "A METHOD OF REDUCING THE RISK OF PULMONARY EDEMA IN PATIENTS IN NEED OF TREATMENT WITH INHALED NITRIC OXIDE"
  },
  {
    "Code": "U-1287",
    "Definition": "METHOD OF REDUCING TG LEVELS IN PATIENT SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA"
  },
  {
    "Code": "U-1288",
    "Definition": "TREATMENT OF ERECTILE DYSFUNCTION BY ADMINISTERING A FILM-COATED TABLET"
  },
  {
    "Code": "U-1289",
    "Definition": "MANAGEMENT OF MODERATE TO SEVERE ACUTE PAIN"
  },
  {
    "Code": "U-1290",
    "Definition": "TREATMENT OF LUNG CANCER"
  },
  {
    "Code": "U-1291",
    "Definition": "TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA (APL) IN PATIENTS WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE (15;17) TRANSLOCATION OR PML\/RAR-ALPHA GENE EXPRESSION"
  },
  {
    "Code": "U-1292",
    "Definition": "TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED RELEASE 1, 2, OR 5 MG PREDNISONE TABLET"
  },
  {
    "Code": "U-1293",
    "Definition": "A METHOD OF LOWERING INTRAOCULAR PRESSURE IN A PATIENT WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION"
  },
  {
    "Code": "U-1294",
    "Definition": "METHOD OF TREATING GLAUCOMA IN A PATIENT"
  },
  {
    "Code": "U-1295",
    "Definition": "A METHOD OF TREATING A PATIENT WITH GLAUCOMA OR OCULAR HYPERTENSION"
  },
  {
    "Code": "U-1296",
    "Definition": "USE OF PEMETREXED WITH PRIOR AND\/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION"
  },
  {
    "Code": "U-1297",
    "Definition": "TREATMENT OF PULMONARY ARTERIAL HYPERTENSION BY INHIBITING ENDOTHELIN RECEPTORS"
  },
  {
    "Code": "U-1298",
    "Definition": "ADJUNCTIVE THERAPY IN THE TREATMENT OF PARTIAL SEIZURES"
  },
  {
    "Code": "U-1299",
    "Definition": "TREATMENT OF PATIENTS WITH LEUKEMIA INCLUDING CHRONIC MYELOID\/MYELOGENOUS LEUKEMIA (CML)"
  },
  {
    "Code": "U-1300",
    "Definition": "TREATMENT OF PATIENTS WITH TYROSINE KINASE INHIBITOR (TKI) RESISTANT OR INTOLERANT CHRONIC MYELOID\/MYELOGENOUS LEUKEMIA (CML)"
  },
  {
    "Code": "U-1301",
    "Definition": "TREATMENT OF DEEP VEIN THROMBOSIS (DVT)"
  },
  {
    "Code": "U-1302",
    "Definition": "TREATMENT OF PULMONARY EMBOLISM (PE)"
  },
  {
    "Code": "U-1303",
    "Definition": "REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM"
  },
  {
    "Code": "U-1304",
    "Definition": "USE OF ONCE-A-DAY AMOXICILLIN PRODUCT TO TREAT TONSILLITIS AND\/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES"
  },
  {
    "Code": "U-1305",
    "Definition": "TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS, AND TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS 3 YEARS OF AGE AND OLDER, CO-ADMINISTERED WITH RITONAVIR (PREZISTA\/RITONAVIR) AND WITH OTHER ANTIRETROVIRAL AGENTS"
  },
  {
    "Code": "U-1306",
    "Definition": "TREATMENT OF THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY"
  },
  {
    "Code": "U-1307",
    "Definition": "IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE ADULT PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THERAPY"
  },
  {
    "Code": "U-1308",
    "Definition": "MULTIPLE MYELOMA"
  },
  {
    "Code": "U-1309",
    "Definition": "BONE METASTASES"
  },
  {
    "Code": "U-1310",
    "Definition": "FOR THE MAINTENANCE OF REMISSION OF ULCERATIVE COLITIS"
  },
  {
    "Code": "U-1311",
    "Definition": "METHOD OF TREATING CYSTIC FIBROSIS"
  },
  {
    "Code": "U-1312",
    "Definition": "USE FOR THE TREATMENT OF HYPERGLYCEMIA"
  },
  {
    "Code": "U-1313",
    "Definition": "AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS"
  },
  {
    "Code": "U-1314",
    "Definition": "USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER"
  },
  {
    "Code": "U-1315",
    "Definition": "THE LONG TERM TREATMENT OF PROPHYLACTIC MANAGEMENT OF OCULAR HYPERTENSION AND GLAUCOMA"
  },
  {
    "Code": "U-1316",
    "Definition": "A DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES"
  },
  {
    "Code": "U-1317",
    "Definition": "TREATMENT OF HYPERCHOLESTEROLEMIA, HYPERLIPIDEMIA AND HYPERLIPOPROTEINEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA"
  },
  {
    "Code": "U-1318",
    "Definition": "TREATMENT OF HYPERCHOLESTEROLEMIA BY DECREASING THE AMOUNT OR ACTIVITY OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA"
  },
  {
    "Code": "U-1319",
    "Definition": "SYMPTOMATIC RELIEF OF NON-INFECTIOUS DIARRHEA"
  },
  {
    "Code": "U-1320",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT"
  },
  {
    "Code": "U-1321",
    "Definition": "TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS"
  },
  {
    "Code": "U-1322",
    "Definition": "METHOD OF REDUCING OCULAR HYPERTENSION"
  },
  {
    "Code": "U-1323",
    "Definition": "REDUCING THE RISK OF STROKE"
  },
  {
    "Code": "U-1324",
    "Definition": "MANAGEMENT OF CYSTIC FIBROSIS PATIENTS"
  },
  {
    "Code": "U-1325",
    "Definition": "INDUCTION OF REMISSION IN PATIENTS WITH ACTIVE, MILD TO MODERATE ULCERATIVE COLITIS"
  },
  {
    "Code": "U-1326",
    "Definition": "METHOD OF INDUCING CONTRACEPTION IN A FEMALE OF REPRODUCTIVE AGE WHO HAS NOT YET REACHED PREMENOPAUSE"
  },
  {
    "Code": "U-1327",
    "Definition": "METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF, USING A FLOWABLE HYDROGEL FORMULATION"
  },
  {
    "Code": "U-1328",
    "Definition": "METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA,  COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF"
  },
  {
    "Code": "U-1329",
    "Definition": "TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER"
  },
  {
    "Code": "U-1330",
    "Definition": "METHODS OF TREATING LIPID METABOLISM AND GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER"
  },
  {
    "Code": "U-1331",
    "Definition": "METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER"
  },
  {
    "Code": "U-1332",
    "Definition": "METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER"
  },
  {
    "Code": "U-1333",
    "Definition": "METHODS OF LOWERING ELEVATED POST PRANDIAL BLOOD GLUCOSE LEVELS COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR"
  },
  {
    "Code": "U-1334",
    "Definition": "METHODS OF TREATING DIABETES  COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN SECRETION ENHANCER"
  },
  {
    "Code": "U-1335",
    "Definition": "METHODS OF MODIFYING GLUCOSE METABOLISM AND TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND ONE OR MORE OTHER THERAPEUTIC AGENTS SUCH AS METFORMIN"
  },
  {
    "Code": "U-1336",
    "Definition": "METHODS OF TREATING DIABETES COMPRISING ADMINISTERING A DIPEPTIDYL PEPTIDASE INHIBITOR AND METFORMIN"
  },
  {
    "Code": "U-1337",
    "Definition": "METHOD OF TREATING DIABETES COMPRISING ADMINISTERING ALOGLIPTIN"
  },
  {
    "Code": "U-1338",
    "Definition": "METHOD OF TREATING DIABETES COMPRISING ADMINISTERING A COMPOUND SUCH AS ALOGLIPTIN"
  },
  {
    "Code": "U-1339",
    "Definition": "METHODS OF TREATING DIABETES COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN"
  },
  {
    "Code": "U-1340",
    "Definition": "METHODS OF TREATING LIPID METABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN"
  },
  {
    "Code": "U-1341",
    "Definition": "METHODS OF TREATING GLYCOMETABOLISM DISORDERS COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN"
  },
  {
    "Code": "U-1342",
    "Definition": "METHODS OF REDUCING THE AMOUNT OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN"
  },
  {
    "Code": "U-1343",
    "Definition": "METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH A BIGUANIDE SUCH AS METFORMIN"
  },
  {
    "Code": "U-1344",
    "Definition": "METHODS OF REDUCING THE SIDE EFFECTS OF ACTIVE COMPONENTS ADMINISTERED TO A DIABETIC PATIENT COMPRISING ADMINISTERING AN INSULIN SENSITIVITY ENHANCER SUCH AS PIOGLITAZONE IN COMBINATION WITH AN INSULIN PREPARATION"
  },
  {
    "Code": "U-1345",
    "Definition": "USE IN RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH A DOSAGE UNIT COMPRISING 24MICROG+\/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT"
  },
  {
    "Code": "U-1346",
    "Definition": "USE OF FEBUXOSTAT FOR THE MANAGEMENT OF HYPERURICEMIA IN PATIENTS SUFFERING FROM GOUT AND, WHEN USED WITH THEOPHYLLINE WITHOUT THE NEED FOR DOSE ADJUSTMENT OF THEOPHYLLINE"
  },
  {
    "Code": "U-1347",
    "Definition": "TREATMENT OF A SKIN DISORDER"
  },
  {
    "Code": "U-1348",
    "Definition": "TREATMENT OF OSTEOARTHRITIS"
  },
  {
    "Code": "U-1349",
    "Definition": "TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS"
  },
  {
    "Code": "U-1350",
    "Definition": "TREATMENT OF ANKYLOSING SPONDYLITIS"
  },
  {
    "Code": "U-1351",
    "Definition": "TREATMENT OF ACUTE PAIN"
  },
  {
    "Code": "U-1352",
    "Definition": "TREATMENT OF PRIMARY DYSMENORRHEA"
  },
  {
    "Code": "U-1353",
    "Definition": "ADJUNCTIVE THERAPY TO LIPID-LOWERING MEDICATIONS AND DIET TO REDUCE LOW DENSITY LIPOPROTEIN-CHOLESTEROL, APOLIPOPROTEIN B, TOTAL CHOLESTEROL, AND NON-HIGH DENSITY LIPOPROTEIN CHOLESTEROL IN PTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA"
  },
  {
    "Code": "U-1354",
    "Definition": "INHIBITION OF PREMATURE LH SURGES IN WOMEN UNDERGOING CONTROLLED OVARIAN HYPERSTIMULATION WITH FSH"
  },
  {
    "Code": "U-1355",
    "Definition": "MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN ADULT AND ADOLESCENT PATIENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHOD FOR TREATING A RESPIRATORY DISEASE IN A CHILD"
  },
  {
    "Code": "U-1356",
    "Definition": "TREATMENT OF NASAL SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER. TREATMENT OF NASAL SYMPTOMS ASSOCIATED W PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-1357",
    "Definition": "TREATMENT OF SYMPTOMS ASSOCIATED WITH SEASONAL AND PERENNIAL ALLERGIC RHINITIS IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER. PATENT CLAIMS METHODS FOR TREATING A RESPIRATORY DISEASE IN A CHILD"
  },
  {
    "Code": "U-1358",
    "Definition": "TREATMENT OF BACTERIAL INFECTIONS IN THE NASAL PASSAGE OF ADULT PATIENTS AND HEALTH CARE WORKERS WITH METHICILLIN RESISTANT S. AUREUS"
  },
  {
    "Code": "U-1359",
    "Definition": "USE OF POMALIDOMIDE TO INHIBIT THE SECRETION OF PRO-INFLAMMATION CYTOKINES, INCLUDING TUMOR NECROSIS FACTOR ALPHA"
  },
  {
    "Code": "U-1360",
    "Definition": "USE OF POMALIDOMIDE FOR THE TREATMENT OF MULTIPLE MYELOMA"
  },
  {
    "Code": "U-1361",
    "Definition": "USE OF POMALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO POMALIDOMIDE"
  },
  {
    "Code": "U-1362",
    "Definition": "TREATMENT OF DISEASES OR CONDITIONS BY THE USE OF A DELAYED-RELEASE 1,2, OR 5MG PREDNISONE TABLET"
  },
  {
    "Code": "U-1363",
    "Definition": "A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING\/STINGING FOLLOWING CORNEAL SURGERY"
  },
  {
    "Code": "U-1364",
    "Definition": "MAINTENANCE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)"
  },
  {
    "Code": "U-1365",
    "Definition": "PROPHYLAXIS OF ALLOGRAFT REJECTION IN ADULT PATIENTS RECEIVING A LIVER TRANSPLANT"
  },
  {
    "Code": "U-1366",
    "Definition": "TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY TO ANOVULATORY INFERTILE WOMEN"
  },
  {
    "Code": "U-1367",
    "Definition": "METHOD OF ADMINISTERING FSH FOR THE TREATMENT OF INFERTILITY THROUGH INDUCTION OF OVULATION AND PREGNANCY IN ANOVULATORY INFERTILE WOMEN"
  },
  {
    "Code": "U-1368",
    "Definition": "TREATMENT OF SOLID EXCRETORY SYSTEM TUMORS; ADVANCED RENAL CELL CARCINOMA (RCC), AFTER FAILURE OF TREATMENT WITH SUNITINIB OR SORAFENIB"
  },
  {
    "Code": "U-1369",
    "Definition": "TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE"
  },
  {
    "Code": "U-1370",
    "Definition": "TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE"
  },
  {
    "Code": "U-1371",
    "Definition": "REDUCTION OF INTRAOCULAR PRESSURE IN PATIENTS WITH ELEVATED INTRAOCULAR PRESSURE OR GLAUCOMA"
  },
  {
    "Code": "U-1372",
    "Definition": "ADMINISTRATION WITHOUT FOOD FOR TREATMENT OF HIV-1 INFECTION"
  },
  {
    "Code": "U-1373",
    "Definition": "METHOD OF TREATING ACETAMINOPHEN OVERDOSE WITH ACETYLCYSTEINE SOLUTIONS"
  },
  {
    "Code": "U-1374",
    "Definition": "TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML)"
  },
  {
    "Code": "U-1375",
    "Definition": "ADASUVE IS A TYPICAL ANTIPSYCHOTIC INDICATED FOR THE ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I DISORDER IN ADULTS"
  },
  {
    "Code": "U-1376",
    "Definition": "TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS"
  },
  {
    "Code": "U-1377",
    "Definition": "IMPROVE RESPIRATORY SYMPTOMS IN CYSTIC FIBROSIS IN PATIENTS WITH PSEUDOMONAS AERUGINOSA"
  },
  {
    "Code": "U-1378",
    "Definition": "TREATMENT OF A NITROGEN METABOLISM DISORDER"
  },
  {
    "Code": "U-1379",
    "Definition": "IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS"
  },
  {
    "Code": "U-1380",
    "Definition": "IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS WHEREIN THE PATIENT HAS CARDIOVASCULAR DISEASE"
  },
  {
    "Code": "U-1381",
    "Definition": "USE OF PRASUGREL AND ASPIRIN IN PATIENTS REQUIRING THE REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS"
  },
  {
    "Code": "U-1382",
    "Definition": "TREATMENT OF NAUSEA AND VOMITING OF PREGNANCY IN WOMEN WHO DO NOT RESPOND TO CONSERVATIVE MANAGEMENT"
  },
  {
    "Code": "U-1383",
    "Definition": "DOSAGE ADJUSTMENT OF A NITROGEN SCAVENGING DRUG IN THE TREATMENT OF A UREA CYCLE DISORDER"
  },
  {
    "Code": "U-1384",
    "Definition": "METHOD OF TREATING MULTIPLE SCLEROSIS"
  },
  {
    "Code": "U-1385",
    "Definition": "METHOD OF TREATING AN AUTOIMMUNE DISEASE SELECTED FROM AUTOIMMUNE POLYARTHRITIS AND MULTIPLE SCLEROSIS BUT NOT TREATING PSORIATIC ARTHRITIS"
  },
  {
    "Code": "U-1386",
    "Definition": "A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF A PERSON IN NEED THEREOF"
  },
  {
    "Code": "U-1387",
    "Definition": "REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS"
  },
  {
    "Code": "U-1388",
    "Definition": "TREATMENT OF PATIENTS WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF WITHOUT SEVERE HEART FAILURE AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS"
  },
  {
    "Code": "U-1389",
    "Definition": "ELLA IS A PROGESTERONE AGONIST\/ANTAGONIST EMERGENCY CONTRACEPTION INDICATED FOR THE PREVENTION OF PREGNANCY FOLLOWING UNPROTECTED INTERCOURSE OR A KNOWN OR SUSPECTED CONTRACEPTIVE FAILURE. ELLA CAN BE TAKEN WITH OR WITHOUT FOOD"
  },
  {
    "Code": "U-1390",
    "Definition": "A METHOD OF INCREASING THE TESTOSTERONE BLOOD LEVEL OF AN ADULT MALE SUBJECT IN NEED THEREOF"
  },
  {
    "Code": "U-1391",
    "Definition": "METHOD FOR TREATING OPIOID-INDUCED CONSTIPATION"
  },
  {
    "Code": "U-1392",
    "Definition": "METHOD OF RELIEVING OR PREVENTING CONSTIPATION IN A HUMAN PATIENT WITH OPIOID-INDUCED CONSTIPATION"
  },
  {
    "Code": "U-1393",
    "Definition": "METHOD FOR RELIEVING OR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION"
  },
  {
    "Code": "U-1394",
    "Definition": "METHOD FOR RELIEVING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION THAT COMPRISES ADMINISTERING TO THE PATIENT A DOSAGE UNIT COMPRISING(I)24MICROG+\/- 10% OF A DRUG SUBSTANCE AND (II) A PHARMACEUTICALLY SUITABLE EXCIPIENT"
  },
  {
    "Code": "U-1395",
    "Definition": "USE IN RELIEVING OR PREVENTING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION WITH A DOSAGE UNIT COMPRISING 24MICROG +\/- 10% OF A DRUG SUBSTANCE AND A PHARMACEUTICALLY SUITABLE EXCIPIENT"
  },
  {
    "Code": "U-1396",
    "Definition": "TREATMENT OF ADVANCED HORMONE RECEPTOR POSITIVE, HER2-NEGATIVE BREAST CANCER IN COMBINATION WITH EXEMESTANE AFTER FAILURE OF TREATMENT WITH LETROZOLE OR ANASTROZOLE"
  },
  {
    "Code": "U-1397",
    "Definition": "USE AS AN ANTISEPTIC FOR THE PREPARATION OF A PATIENT'S SKIN PRIOR TO SURGERY"
  },
  {
    "Code": "U-1398",
    "Definition": "METHOD OF TREATING CHRONIC HEPATITIS C"
  },
  {
    "Code": "U-1399",
    "Definition": "MANAGEMENT OF NEPHROPATHIC CYSTINOSIS BY ADMINISTERING A TOTAL DAILY DOSE IN TWO DIVIDED DOSES"
  },
  {
    "Code": "U-1400",
    "Definition": "FOR THE TREATMENT OF PRIMARY HYPERLIPIDEMIA, MIXED HYPERLIPIDEMIA OR HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA"
  },
  {
    "Code": "U-1401",
    "Definition": "INDICATED FOR LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND\/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PTS WITH A HISTORY OF EXACERBATIONS"
  },
  {
    "Code": "U-1402",
    "Definition": "FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND\/OR INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL)"
  },
  {
    "Code": "U-1403",
    "Definition": "FIRST-LINE TREATMENT OF METASTATIC NON SMALL-CELL LUNG CANCER (NSCLC) WITH EGFR EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST"
  },
  {
    "Code": "U-1404",
    "Definition": "METHOD FOR TREATING CONSTIPATION IN A PATIENT WITH OPIOID-INDUCED CONSTIPATION BY OPENING CIC CHANNELS"
  },
  {
    "Code": "U-1405",
    "Definition": "THERAPEUTIC TREATMENT OF BONE METASTASES"
  },
  {
    "Code": "U-1406",
    "Definition": "TREATMENT OF MELANOMA"
  },
  {
    "Code": "U-1407",
    "Definition": "TREATMENT OF NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH + CML)"
  },
  {
    "Code": "U-1408",
    "Definition": "TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER"
  },
  {
    "Code": "U-1409",
    "Definition": "TREATMENT OF HIV-1 BY ONCE DAILY ADMINISTRATION"
  },
  {
    "Code": "U-1410",
    "Definition": "TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES"
  },
  {
    "Code": "U-1411",
    "Definition": "THIS DRUG IS ADMINISTERED BY SUBLINGUAL ROUTE TO HUMANS FOR MAINTENANCE TREATMENT OF OPIOID DEPENDENCE"
  },
  {
    "Code": "U-1412",
    "Definition": "TREATMENT OF ATOPIC DERMATITIS"
  },
  {
    "Code": "U-1413",
    "Definition": "ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH FLOLAN STERILE DILUENT FOR INJECTION PRIOR TO INFUSION"
  },
  {
    "Code": "U-1414",
    "Definition": "USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF MANTLE CELL LYMPHOMA (MCL)"
  },
  {
    "Code": "U-1415",
    "Definition": "TREATING A PATIENT HAVING A CONDITION SUSCEPTIBLE TO TREATMENT WITH METHYLPHENIDATE, SUCH AS ADHD, BY ADMINISTERING THE FORMULATION RECITED IN CLAIMS 1 OR 2"
  },
  {
    "Code": "U-1416",
    "Definition": "USE OF FENOFIBRATE FOR REDUCING ELEVATED TOTAL CHOLESTEROL (TOTAL-C), LDL-C, APO-LIPOPROTEIN B, OR TOTAL TRIGLYCERIDES"
  },
  {
    "Code": "U-1417",
    "Definition": "USE FOR TREATMENT OF HELICOBACTER INFECTIONS"
  },
  {
    "Code": "U-1418",
    "Definition": "TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAFV600E MUTATION AS DETECTED BY AN FDA APPROVED TEST"
  },
  {
    "Code": "U-1419",
    "Definition": "TREATMENT OF ACUTE CYANIDE POISONING THAT IS JUDGED TO BE LIFE THREATENING"
  },
  {
    "Code": "U-1420",
    "Definition": "METHOD OF ONCE A DAY ADMINISTRATION"
  },
  {
    "Code": "U-1421",
    "Definition": "SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE"
  },
  {
    "Code": "U-1422",
    "Definition": "METHOD OF TREATING PATIENTS NEEDING AN IRON SUPPLEMENT"
  },
  {
    "Code": "U-1423",
    "Definition": "AMYVID IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE BETA-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT"
  },
  {
    "Code": "U-1424",
    "Definition": "LONG-TERM, ONCE DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND\/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS"
  },
  {
    "Code": "U-1425",
    "Definition": "SUBLINGUAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE"
  },
  {
    "Code": "U-1426",
    "Definition": "USE FOR TREATMENT OF DIAPER DERMATITIS COMPLICATED BY CANDIDIASIS"
  },
  {
    "Code": "U-1427",
    "Definition": "ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY"
  },
  {
    "Code": "U-1428",
    "Definition": "TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA"
  },
  {
    "Code": "U-1429",
    "Definition": "TREATMENT OF PATIENTS WITH BREAST CANCER WHOSE TUMORS OVEREXPRESS THE HER2 RECEPTOR"
  },
  {
    "Code": "U-1430",
    "Definition": "TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL AND PERENNIAL ALLERGIC RHINITIS"
  },
  {
    "Code": "U-1431",
    "Definition": "METHOD OF TREATING HYPERGLYCEMIA TO IMPROVE GLYCEMIC CONTROL IN A PATIENT BY ORAL ADMIN OF ONCE A DAY OSMOTIC DOSAGE FORM OF GLIPIZIDE WITH POLYETHYLENE OXIDE, HYDROXYPROPYLMETHYLCELLULOSE, CELLULOSE ACETATE, AND SODIUM CHLORIDE"
  },
  {
    "Code": "U-1432",
    "Definition": "METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX"
  },
  {
    "Code": "U-1433",
    "Definition": "IMPROVEMENTS OF GLYCEMIC CONTROL IN INDIVIDUALS WITH TYPE 2 DIABETES WHO HAVE ONE OR MORE SPECIFIED CARDIOVASCULAR RISK FACTORS"
  },
  {
    "Code": "U-1434",
    "Definition": "TREATMENT OF PANCREATIC CANCER"
  },
  {
    "Code": "U-1435",
    "Definition": "COMBINATION USE OF TOPICAL DICLOFENAC ON THE KNEE AND ADMINISTRATION OF AN ORAL NSAID."
  },
  {
    "Code": "U-1436",
    "Definition": "USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL AGENT SELECTED FROM SUNSCREEN AND INSECT REPELLANT"
  },
  {
    "Code": "U-1437",
    "Definition": "ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE DILUENT FOR FLOLAN OR STERILE DILUENT FOR EPOPROSTENOL SODIUM PRIOR TO ADMINISTRATION"
  },
  {
    "Code": "U-1438",
    "Definition": "ZINGO INTRADERMAL INJECTION SYSTEM IS A DRUG DELIVERY SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION"
  },
  {
    "Code": "U-1439",
    "Definition": "METHOD OF TREATING AN AFFECTIVE DISORDER SUCH AS DEPRESSION"
  },
  {
    "Code": "U-1440",
    "Definition": "USE OF INGENOL MEBUTATE TO TREAT ACTINIC KERATOSIS"
  },
  {
    "Code": "U-1441",
    "Definition": "A METHOD OF TREATING OR REDUCING OCULAR PAIN AND BURNING\/STINGING"
  },
  {
    "Code": "U-1442",
    "Definition": "SUBCUTANEOUS INJECTION OF METHOTREXATE"
  },
  {
    "Code": "U-1443",
    "Definition": "ACCELERATING THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS"
  },
  {
    "Code": "U-1444",
    "Definition": "A DOSING REGIMEN OF AGGRASTAT (TIROFIBAN HYDROCHLORIDE)(25MCG\/KG FOLLOWED BY 0.15MCG\/KG\/MIN INFUSION) TO REDUCE THE RATE OF THROMBOTIC CORONARY EVENTS ASSOCIATED WITH ACUTE CORONARY SYNDROME (ACS) IN PATIENTS WITH NON-ST ELEVATION ACS"
  },
  {
    "Code": "U-1445",
    "Definition": "METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHEREIN THE POLYSORBATE REPRESENTS 0.1 TO 1% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION"
  },
  {
    "Code": "U-1446",
    "Definition": "METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING ADMINISTERING MACITENTAN IN COMBINATION WITH A COMPOUND HAVING PHOSPHODIESTERASE-5 INHIBITORY PROPERTIES"
  },
  {
    "Code": "U-1447",
    "Definition": "TREATING PRIMARY HYPERCHOLESTEROLEMIA AND MIXED DYSLIPIDEMIA"
  },
  {
    "Code": "U-1448",
    "Definition": "TREATING SEVERE HYPERTRIGLYCERIDEMIA"
  },
  {
    "Code": "U-1449",
    "Definition": "METHOD OF ALLEVIATING A SKIN CONDITION"
  },
  {
    "Code": "U-1450",
    "Definition": "TREATMENT OF ALLERGIC RHINITIS SYMPTOMS"
  },
  {
    "Code": "U-1451",
    "Definition": "APPROVED INDICATIONS:  APTIOM (ESLICARBAZEPINE ACETATE) IS INDICATED AS ADJUNCTIVE TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH EPILEPSY.  PATENT CLAIMS:  IN A METHOD OF TREATING A SUBJECT AFFLICTED WITH EPILEPSY"
  },
  {
    "Code": "U-1452",
    "Definition": "METHOD FOR CHRONIC WEIGHT MANAGEMENT"
  },
  {
    "Code": "U-1453",
    "Definition": "A METHOD OF TREATING HYPOXIC RESPIRATORY FAILURE BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT"
  },
  {
    "Code": "U-1454",
    "Definition": "PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS"
  },
  {
    "Code": "U-1455",
    "Definition": "TREATMENT OF PERIANAL WARTS"
  },
  {
    "Code": "U-1456",
    "Definition": "TREATMENT OF MANTLE CELL LYMPHOMA"
  },
  {
    "Code": "U-1457",
    "Definition": "A METHOD OF PURGING A NITRIC OXIDE DELIVERY SYSTEM"
  },
  {
    "Code": "U-1458",
    "Definition": "A METHOD OF REDUCING INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION"
  },
  {
    "Code": "U-1459",
    "Definition": "TREATMENT OF CARCINOMA OF THE THYROID"
  },
  {
    "Code": "U-1460",
    "Definition": "TREATMENT OF HERPES LABIALIS"
  },
  {
    "Code": "U-1461",
    "Definition": "A METHOD OF GENERATING AN INJECTABLE FOAM OF CONTROLLED DENSITY AND BUBBLE SIZE"
  },
  {
    "Code": "U-1462",
    "Definition": "A METHOD OF USING A SCLEROSING AGENT FOR THE TREATMENT OF INCOMPETENT GREAT SAPHENOUS VEINS, ACCESSORY SAPHENOUS VEINS AND VISIBLE VARICOSITIES OF THE GREAT SAPHENOUS (GSV) SYSTEM ABOVE AND BELOW THE KNEE"
  },
  {
    "Code": "U-1463",
    "Definition": "A METHOD OF INTRAVENOUS INJECTION USING ULTRASOUND GUIDANCE, ADMINISTERED VIA A SINGLE CANNULA INTO THE LUMEN OF THE TARGET INCOMPETENT TRUNK VEINS OR BY DIRECT INJECTION INTO VARICOSITIES"
  },
  {
    "Code": "U-1464",
    "Definition": "TREATMENT OF OPIOID DEPENDENCE\/SUBLINGUAL OR BUCCAL APPLICATION"
  },
  {
    "Code": "U-1465",
    "Definition": "USE OF THALIDOMIDE WHILE PREVENTING THE EXPOSURE OF A FETUS OR OTHER CONTRAINDICATED INDIVIDUAL TO THALIDOMIDE"
  },
  {
    "Code": "U-1466",
    "Definition": "RELIEF OF SYMPTOMS ASSOCIATED WITH RESPIRATORY ALLERGIES ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-1467",
    "Definition": "METHOD OF TREATING HEPATITIS C"
  },
  {
    "Code": "U-1468",
    "Definition": "CONTROL OF PHOSPHOROUS LEVELS IN PATIENTS"
  },
  {
    "Code": "U-1469",
    "Definition": "USE OF PHOSLYRA FOR REDUCTION OF SERUM PHOSPHOROUS IN PATIENTS"
  },
  {
    "Code": "U-1470",
    "Definition": "FOR THE TREATMENT OF HEPATITIS C"
  },
  {
    "Code": "U-1471",
    "Definition": "A METHOD FOR TREATING CARDIOVASCULAR DISEASE COMPRISING ADMINISTERING A RECONSTITUTED LYOPHILIZED PHARMACEUTICAL COMPOSITION COMPRISING EPOPROSTENOL, ARGININE AND SODIUM HYDROXIDE."
  },
  {
    "Code": "U-1472",
    "Definition": "INTENSIVE CARE UNIT SEDATION, INCLUDING SEDATION OF NON-INTUBATED PATIENTS PRIOR TO AND\/OR DURING SURGICAL AND OTHER PROCEDURES"
  },
  {
    "Code": "U-1473",
    "Definition": "MANAGEMENT OF RISK OF DRONEDARONE\/BETA-BLOCKER INTERACTION IN PATIENTS IN SINUS RHYTHM WITH A HISTORY OF PAROXYSMAL OR PERSISTENT AF"
  },
  {
    "Code": "U-1474",
    "Definition": "A METHOD FOR THE TREATMENT OF A PATIENT SUFFERING FROM A DISEASE TREATABLE WITH ROTIGOTINE, COMPRISING APPLYING THE CLAIMED TRANSDERMAL DELIVERY SYSTEM (TDS) TO THE SKIN OF THE PATIENT"
  },
  {
    "Code": "U-1475",
    "Definition": "USE OF ORENITRAM FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1)."
  },
  {
    "Code": "U-1476",
    "Definition": "INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND\/OR EMPHYSEMA."
  },
  {
    "Code": "U-1477",
    "Definition": "USE OF TOPICAL DICLOFENAC ON THE KNEE AND A SECOND TOPICAL PRESCRIPTION MEDICATION ON THE SAME KNEE"
  },
  {
    "Code": "U-1478",
    "Definition": "METHOD OF REDUCING TG LEVELS IN PATIENT ON STATIN THERAPY SUFFERING FROM SEVERE HYPERTRIGLYCERIDEMIA"
  },
  {
    "Code": "U-1479",
    "Definition": "INCREASE TEAR PRODUCTION TO TREAT PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE)."
  },
  {
    "Code": "U-1480",
    "Definition": "TREATMENT OF ADVANCED RENAL CELL CARCINOMA"
  },
  {
    "Code": "U-1481",
    "Definition": "REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE"
  },
  {
    "Code": "U-1482",
    "Definition": "DICLOFENAC POTASSIUM FOR RELIEF OF MILD TO MODERATE ACUTE PAIN"
  },
  {
    "Code": "U-1483",
    "Definition": "INCREASE TEAR PRODUCTION IN PATIENTS WITH KERATOCONJUNCTIVITIS SICCA (DRY EYE)."
  },
  {
    "Code": "U-1484",
    "Definition": "COMBINATION PRODUCT FOR THE EARLY TREATMENT OF RECURRENT HERPES LABIALIS (COLD SORES) TO REDUCE THE LIKELIHOOD OF ULCERATIVE COLD SORES AND TO SHORTEN THE LESION HEALING TIME IN ADULTS AND CHILDREN (6 YEARS OF AGE AND OLDER)"
  },
  {
    "Code": "U-1485",
    "Definition": "TREATING A SUBJECT UNDERGOING ABDOMINAL SURGERY BY ADMINISTERING ALVIMOPAN TO ACCELERATE THE TIME TO UPPER AND LOWER GASTROINTESTINAL RECOVERY FOLLOWING SURGERIES THAT INCLUDE PARTIAL BOWEL RESECTION WITH PRIMARY ANASTOMOSIS"
  },
  {
    "Code": "U-1486",
    "Definition": "TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER"
  },
  {
    "Code": "U-1487",
    "Definition": "METHOD OF INCREASING EYELASH GROWTH"
  },
  {
    "Code": "U-1488",
    "Definition": "USE OF TOPICAL DICLOFENAC FOR TREATING PAIN"
  },
  {
    "Code": "U-1489",
    "Definition": "USE OF TOPICAL DICLOFENAC ON A JOINT FOR TREATING OSTEOARTHRITIS"
  },
  {
    "Code": "U-1490",
    "Definition": "FOR USE IN PATIENTS HAVING SYMPTOMATIC OR PROGRESSIVE MEDULLARY THYROID CANCER, WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC DISEASE"
  },
  {
    "Code": "U-1491",
    "Definition": "TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA"
  },
  {
    "Code": "U-1492",
    "Definition": "TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER"
  },
  {
    "Code": "U-1493",
    "Definition": "METHOD FOR PREVENTING ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS"
  },
  {
    "Code": "U-1494",
    "Definition": "SUBLINGUAL OR BUCCAL ADMINISTRATION OF A PHARMACEUTICAL COMPOSITION COMPRISING BUPRENORPHINE AND NALOXONE"
  },
  {
    "Code": "U-1495",
    "Definition": "RISK REDUCTION OF REBLEEDING IN PTS FOLLOWING THERAPEUTIC ENDOSCOPY FOR ACUTE BLEEDING GASTRIC OR DUODENAL ULCERS IN ADULTS."
  },
  {
    "Code": "U-1496",
    "Definition": "METHOD TO TREAT HEMANGIOMA."
  },
  {
    "Code": "U-1497",
    "Definition": "NEURACEQ IS A RADIOACTIVE DIAGNOSTIC AGENT FOR POSITRON EMISSION TOMOGRAPHY (PET) IMAGING OF THE BRAIN TO ESTIMATE P-AMYLOID NEURITIC PLAQUE DENSITY IN ADULT PATIENTS WITH COGNITIVE IMPAIRMENT"
  },
  {
    "Code": "U-1498",
    "Definition": "METHOD OF TREATING PATIENTS WITH GASTRIC RETENTIVE DOSAGE FORM"
  },
  {
    "Code": "U-1499",
    "Definition": "MANAGEMENT OF ACUTE PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA"
  },
  {
    "Code": "U-1500",
    "Definition": "TESTOSTERONE REPLACEMENT THERAPY IN ADULT MALES FOR CONDITIONS ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE; PRIMARY HYPOGONADISM (CONGENITAL OR ACQUIRED); HYPOGONADOTROPIC HYPOGONADISM (CONGENITAL OR ACQUIRED)."
  },
  {
    "Code": "U-1501",
    "Definition": "PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM"
  },
  {
    "Code": "U-1502",
    "Definition": "PROPHYLAXIS OF PULMONARY EMBOLISM"
  },
  {
    "Code": "U-1503",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN"
  },
  {
    "Code": "U-1504",
    "Definition": "USE OF OTEZLA (APREMILAST) FOR INHIBITING PDE4"
  },
  {
    "Code": "U-1505",
    "Definition": "USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS"
  },
  {
    "Code": "U-1506",
    "Definition": "TREATMENT OF PATIENTS WITH GASTROINTESTINAL STROMAL TUMOR (GIST), INCLUDING BUT NOT LIMITED TO PATIENTS PREVIOUSLY TREATED WITH IMATINIB AND PATIENTS WITH GIST HAVING RESISTANCE TO A KIT TYROSINE KINASE INHIBITOR"
  },
  {
    "Code": "U-1507",
    "Definition": "TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN"
  },
  {
    "Code": "U-1508",
    "Definition": "MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING A PLURALITY OF COMPOSITE SUBUNITS AS CLAIMED"
  },
  {
    "Code": "U-1509",
    "Definition": "TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING A GASTRIC ACID REDUCER"
  },
  {
    "Code": "U-1510",
    "Definition": "MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT BY ORALLY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED."
  },
  {
    "Code": "U-1511",
    "Definition": "TREATMENT OF HYPERTRIGLYCERIDEMIA"
  },
  {
    "Code": "U-1512",
    "Definition": "REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS"
  },
  {
    "Code": "U-1513",
    "Definition": "TREATMENT OF HIV-1 INFECTION IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS"
  },
  {
    "Code": "U-1514",
    "Definition": "MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER BY BUCCAL OR SUBLINGUAL ADMINISTRATION OF FENTANYL"
  },
  {
    "Code": "U-1515",
    "Definition": "METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION IN ADULT PATIENTS."
  },
  {
    "Code": "U-1516",
    "Definition": "METHOD OF TREATING CHRONIC IDIOPATHIC CONSTIPATION IN ADULT PATIENTS."
  },
  {
    "Code": "U-1517",
    "Definition": "TREATMENT OF BACTERIAL INFECTIONS USING A TWO-DOSE REGIMEN OF DALBAVANCIN."
  },
  {
    "Code": "U-1518",
    "Definition": "MAINTAINING PUPIL SIZE BY PREVENTING INTRAOPERATIVE MIOSIS AND REDUCING POSTOPERATIVE OCULAR PAIN"
  },
  {
    "Code": "U-1519",
    "Definition": "METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT WITH IRRITABLE BOWEL SYNDROME"
  },
  {
    "Code": "U-1520",
    "Definition": "METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT"
  },
  {
    "Code": "U-1521",
    "Definition": "MAINTENANCE TREATMENT OF OPIOID DEPENDENCE"
  },
  {
    "Code": "U-1522",
    "Definition": "TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT, WHEREIN GLYCEMIC CONTROL (HBA1C < 7.0%) IS NOT ACHIEVABLE USING ONE OR MORE OF INSULIN, METFORMIN, PIOGLITAZONE, OR ROSIGLITAZONE"
  },
  {
    "Code": "U-1523",
    "Definition": "METHOD OF INDUCING TOPICAL ANESTHESIA IN THE EYE"
  },
  {
    "Code": "U-1524",
    "Definition": "REDUCTION OF ELEVATED INTRAOCULAR PRESSURE"
  },
  {
    "Code": "U-1525",
    "Definition": "METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY"
  },
  {
    "Code": "U-1526",
    "Definition": "THE TREATMENT OF PATIENTS WITH TRAVELERS' DIARRHEA (TD) OR THE REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE"
  },
  {
    "Code": "U-1527",
    "Definition": "FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY"
  },
  {
    "Code": "U-1528",
    "Definition": "A METHOD OF LOWERING INTRAOCULAR PRESSURE"
  },
  {
    "Code": "U-1529",
    "Definition": "ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)"
  },
  {
    "Code": "U-1530",
    "Definition": "USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION"
  },
  {
    "Code": "U-1531",
    "Definition": "METHOD FOR TRANSDERMAL DELIVERY OF TESTOSTERONE"
  },
  {
    "Code": "U-1532",
    "Definition": "METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS AND\/OR CATAPLEXY IN NARCOLEPSY PATIENTS WITH SODIUM OXYBATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED."
  },
  {
    "Code": "U-1533",
    "Definition": "PULMONARY ADMINISTRATION OF PARTICLES COMPRISING A DIKETOPIPERAZINE AND INSULIN."
  },
  {
    "Code": "U-1534",
    "Definition": "ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH A DIKETOPIPERAZINE."
  },
  {
    "Code": "U-1535",
    "Definition": "ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN COMPLEXED WITH MICROPARTICLES OF A DIKETOPIPERAZINE."
  },
  {
    "Code": "U-1536",
    "Definition": "ADMINISTRATION OF A COMPOSITION COMPRISING A DIKETOPIPERAZINE AND INSULIN."
  },
  {
    "Code": "U-1537",
    "Definition": "TREATMENT OF A PATIENT HAVING DIABETES MELLITUS WITH A PRANDIAL RAPID ACTING INSULIN."
  },
  {
    "Code": "U-1538",
    "Definition": "ADMINISTRATION OF FDKP MICROPARTICLES COMPRISING INSULIN."
  },
  {
    "Code": "U-1539",
    "Definition": "PULMONARY ADMINISTRATION OF AN INSULIN COMPOSITION COMPRISING FDKP AT THE BEGINNING OF A MEAL TO A PATIENT ALSO BEING TREATED WITH A LONG-ACTING INSULIN."
  },
  {
    "Code": "U-1540",
    "Definition": "BUTRANS IS A PARTIAL OPIOID AGONIST PRODUCT INDICATED FOR THE MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE."
  },
  {
    "Code": "U-1541",
    "Definition": "TREATMENT OF PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX (TSC) WHO HAVE SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) THAT REQUIRES THERAPEUTIC INTERVENTION BUT CANNOT BE CURATIVELY RESECTED."
  },
  {
    "Code": "U-1542",
    "Definition": "FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AND\/OR NON-HODGKINS LYMPHOMA"
  },
  {
    "Code": "U-1543",
    "Definition": "TREATMENT OF A PATIENT BY ADMINISTERING THE FORMULATION RECITED IN CLAIM 1 OR CLAIM 23"
  },
  {
    "Code": "U-1544",
    "Definition": "TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL)."
  },
  {
    "Code": "U-1545",
    "Definition": "A METHOD OF TRANSDERMALLY DELIVERING TESTOSTERONE"
  },
  {
    "Code": "U-1546",
    "Definition": "FOR USE IN THE TREATMENT OF MALIGNANT HYPERTHERMIA IN CONJUNCTION WITH APPROPRIATE SUPPORTIVE MEASURES AND FOR THE PREVENTION OF MALIGNANT HYPERTHERMIA IN PATIENTS AT HIGH RISK."
  },
  {
    "Code": "U-1547",
    "Definition": "TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), CHRONIC BRONCHITIS OR EMPHYSEMA"
  },
  {
    "Code": "U-1548",
    "Definition": "FOR THE LONG-TERM, ONCE-DAILY MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH COPD, INCLUDING CHRONIC BRONCHITIS AND\/OR EMPHYSEMA, ALSO TO REDUCE EXACERBATIONS OF COPD IN PATIENTS WITH A HISTORY OF EXACERBATIONS"
  },
  {
    "Code": "U-1549",
    "Definition": "FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA"
  },
  {
    "Code": "U-1550",
    "Definition": "METHOD OF TREATING METASTATIC PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS."
  },
  {
    "Code": "U-1551",
    "Definition": "METHOD OF TREATING PAPILLARY RENAL CELL CARCINOMA WITH TEMSIROLIMUS, IN THE ABSENCE OF INTERFERON ALPHA."
  },
  {
    "Code": "U-1552",
    "Definition": "FOR HEALING OF ALL GRADES OF EROSIVE ESOPHAGITIS (EE)"
  },
  {
    "Code": "U-1553",
    "Definition": "TO MAINTAIN HEALING OF EE AND RELIEF OF HEARTBURN"
  },
  {
    "Code": "U-1554",
    "Definition": "FOR THE TREATMENT OF HEARTBURN ASSOCIATED WITH SYMPTOMATIC NON-EROSIVE GASTROESOPHAGEAL DISEASE (GERD)"
  },
  {
    "Code": "U-1555",
    "Definition": "MANAGEMENT OF MODERATE TO SEVERE PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE."
  },
  {
    "Code": "U-1556",
    "Definition": "MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE"
  },
  {
    "Code": "U-1557",
    "Definition": "A METHOD OF TESTOSTERONE REPLACEMENT THERAPY COMPRISING THE STEP OF NASALLY ADMINISTERING TO A PATIENT IN NEED OF SUCH TREATMENT AN EFFECTIVE AMOUNT OF TESTOSTERONE GEL FORMULATION."
  },
  {
    "Code": "U-1558",
    "Definition": "FOR THE TREATMENT OF PATIENTS WITH RELAPSED FOLLICULAR B-CELL NON-HODGKIN LYMPHOMA OR [RELAPSED] SMALL LYMPHOCYTIC LYMPHOMA"
  },
  {
    "Code": "U-1559",
    "Definition": "INDICATED FOR THE ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 12 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-1560",
    "Definition": "A METHOD OF DISRUPTING LEUKOCYTE FUNCTION, INCLUDING AS AN INHIBITOR OF PI3KDELTA KINASE"
  },
  {
    "Code": "U-1561",
    "Definition": "USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS"
  },
  {
    "Code": "U-1562",
    "Definition": "TREATMENT OF PATIENTS WITH HEPATIC ENCEPHALOPATHY (HE)"
  },
  {
    "Code": "U-1563",
    "Definition": "A METHOD OF TRANSDERMAL ADMINISTRATION OF A PHYSIOLOGICALLY ACTIVE AGENT TO A SUBJECT."
  },
  {
    "Code": "U-1564",
    "Definition": "A METHOD OF TREATING GAUCHER'S DISEASE"
  },
  {
    "Code": "U-1565",
    "Definition": "METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE"
  },
  {
    "Code": "U-1566",
    "Definition": "METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER"
  },
  {
    "Code": "U-1567",
    "Definition": "METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER"
  },
  {
    "Code": "U-1568",
    "Definition": "METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE"
  },
  {
    "Code": "U-1569",
    "Definition": "TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS"
  },
  {
    "Code": "U-1570",
    "Definition": "TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS USING A SINGLE DOSE"
  },
  {
    "Code": "U-1571",
    "Definition": "TREATMENT OF GAUCHER DISEASE TYPE 1"
  },
  {
    "Code": "U-1572",
    "Definition": "TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION."
  },
  {
    "Code": "U-1573",
    "Definition": "USE OF RUXOLITINIB (JAKAFI) FOR INHIBITING JANUS ASSOCIATED KINASES (JAKS) JAK1 AND\/OR JAK2."
  },
  {
    "Code": "U-1574",
    "Definition": "A METHOD OF CATALYZING THE HYDROLYSIS OF GLUCOCEREBROSIDE TO GLUCOSE AND CERAMIDE."
  },
  {
    "Code": "U-1575",
    "Definition": "PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY"
  },
  {
    "Code": "U-1576",
    "Definition": "TREATMENT OF LEUKEMIA"
  },
  {
    "Code": "U-1577",
    "Definition": "CONTROL OF SERUM PHOSPHOROUS LEVELS"
  },
  {
    "Code": "U-1578",
    "Definition": "TREATMENT OF ACUTE OTITIS MEDIA"
  },
  {
    "Code": "U-1579",
    "Definition": "USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER"
  },
  {
    "Code": "U-1580",
    "Definition": "USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO HAD RECEIVED PRIOR DOCETAXEL CHEMOTHERAPY"
  },
  {
    "Code": "U-1581",
    "Definition": "IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA."
  },
  {
    "Code": "U-1582",
    "Definition": "TREATMENT OF UNRESECTABLE OR METASTATIC MELANOMA"
  },
  {
    "Code": "U-1583",
    "Definition": "FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY"
  },
  {
    "Code": "U-1584",
    "Definition": "USE OF NALTREXONE AND BUPROPION IN A LAYERED FORMULATION FOR CHRONIC WEIGHT MANAGEMENT FOR AFFECTING WEIGHT LOSS"
  },
  {
    "Code": "U-1585",
    "Definition": "USE OF NALTREXONE AND BUPROPION BASED ON AN ESCALATING DOSE SCHEDULE"
  },
  {
    "Code": "U-1586",
    "Definition": "FOR EFFECT ON BLOOD GLUCOSE PARAMETERS IN PATIENTS WITH INSULIN RESISTANCE"
  },
  {
    "Code": "U-1587",
    "Definition": "SINGLE-DOSE INFILTRATION INTO THE SURGICAL SITE TO PRODUCE POSTSURGICAL ANALGESIA."
  },
  {
    "Code": "U-1588",
    "Definition": "THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC)."
  },
  {
    "Code": "U-1589",
    "Definition": "METHOD OF USE FOR REDUCING BLOOD PHENYLALANINE LEVELS IN A HUMAN SUFFERING FROM HYPERPHENYLALANINEMIA"
  },
  {
    "Code": "U-1590",
    "Definition": "KUVAN IS INDICATED TO REDUCE BLOOD PHENYLALANINE LEVELS IN PATIENTS WITH HYPERPHENYLALANINEMIA"
  },
  {
    "Code": "U-1591",
    "Definition": "TREATMENT OF ASTHMA IN PATIENTS AGED 12 YEARS AND OLDER"
  },
  {
    "Code": "U-1592",
    "Definition": "TO REDUCE SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE"
  },
  {
    "Code": "U-1593",
    "Definition": "MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH COPD, INCLUDING CHRONIC BRONCHITIS AND EMPHYSEMA, AND REDUCTION OF EXACERBATIONS IN COPD PATIENTS."
  },
  {
    "Code": "U-1594",
    "Definition": "DILATION OF THE PUPIL"
  },
  {
    "Code": "U-1595",
    "Definition": "USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIASIS"
  },
  {
    "Code": "U-1596",
    "Definition": "LAMICTAL IS AN ANTIEPILEPTIC DRUG (AED) INDICATED FOR: EPILEPSY-ADJUNCTIVE THERAPY IN PATIENTS GREATER THAN OR EQUAL TO 2 YEARS OF AGE: (1.1) PARTIAL SEIZURES PRIMARY GENERALIZED TONIC-CLONIC SEIZURES"
  },
  {
    "Code": "U-1597",
    "Definition": "TREATMENT OF DIABETIC MACULAR EDEMA"
  },
  {
    "Code": "U-1598",
    "Definition": "METHOD OF ADMINISTRATION OF CONTROLLED RELEASE OXYMORPHONE"
  },
  {
    "Code": "U-1599",
    "Definition": "MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANTI-INFLAMMATORY, ANALGESIC, AND ANTIPYRETIC ACTIVITY"
  },
  {
    "Code": "U-1600",
    "Definition": "DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS"
  },
  {
    "Code": "U-1601",
    "Definition": "DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS"
  },
  {
    "Code": "U-1602",
    "Definition": "METHOD OF ADMINISTERING PIRFENIDONE CAPSULES TO TREAT A FIBROTIC CONDITION"
  },
  {
    "Code": "U-1603",
    "Definition": "METHOD FOR ADMINISTERING PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE"
  },
  {
    "Code": "U-1604",
    "Definition": "METHOD FOR ADMINISTERING PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH A STRONG INHIBITOR OF CYP1A2"
  },
  {
    "Code": "U-1605",
    "Definition": "METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING OR AVOIDING ANOTHER STRONG CYP1A2 INDUCER"
  },
  {
    "Code": "U-1606",
    "Definition": "METHOD FOR ADMINISTERING PIRFENIDONE WHILE AVOIDING OR DISCONTINUING CONCOMITANT USE OF A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME INVOLVED IN PIRFENIDONE METABOLISM"
  },
  {
    "Code": "U-1607",
    "Definition": "METHOD OF ADMINISTERING A DOSAGE FORM THAT INCLUDES A GRANULATE FORMULATION OF PIRFENIDONE TO TREAT A  FIBROTIC CONDITION"
  },
  {
    "Code": "U-1608",
    "Definition": "DOSE ESCALATION OVER 14 DAYS FOR TREATMENT OF A FIBROSIS CONDITION"
  },
  {
    "Code": "U-1609",
    "Definition": "CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS"
  },
  {
    "Code": "U-1610",
    "Definition": "CONTINUED DOSING OR DOSAGE MODIFICATION FOLLOWING ELEVATED LIVER ENZYMES IN USE OF PIRFENIDONE"
  },
  {
    "Code": "U-1611",
    "Definition": "METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY DISCONTINUING SMOKING OR BY DISCONTINUING A STRONG CYP1A2 INDUCER"
  },
  {
    "Code": "U-1612",
    "Definition": "METHOD FOR ADMINISTERING PIRFENIDONE TO AVOID REDUCED EFFICACY BY AVOIDING SMOKING OR BY AVOIDING ANOTHER STRONG CYP1A2 INDUCER"
  },
  {
    "Code": "U-1613",
    "Definition": "DOSAGE MODIFICATION IN TREATMENT WITH PIRFENIDONE TO REDUCE DRUG INTERACTIONS WITH CIPROFLOXACIN"
  },
  {
    "Code": "U-1614",
    "Definition": "USE OF TOPICAL DICLOFENAC SODIUM FOR TREATING PAIN"
  },
  {
    "Code": "U-1615",
    "Definition": "FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL"
  },
  {
    "Code": "U-1616",
    "Definition": "NASAL ADMINISTRATION OF A TESTOSTERONE GEL TO A PATIENT TO TREAT THE PATIENT FOR A CONDITION ASSOCIATED WITH A DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE"
  },
  {
    "Code": "U-1617",
    "Definition": "METHOD OF TREATING MEDULLARY THYROID CANCER"
  },
  {
    "Code": "U-1618",
    "Definition": "A METHOD OF TREATING A PATIENT SUFFERING FROM A PAIN ASSOCIATED SLEEP DISTURBANCE COMPRISING ADMINISTERING A LIQUID COMPOSITION FORMULATED INSIDE A SOFT GEL CAPSULE, AS CLAIMED, TO THE PATIENT"
  },
  {
    "Code": "U-1619",
    "Definition": "TREATMENT OF IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)"
  },
  {
    "Code": "U-1620",
    "Definition": "METHOD OF TREATMENT OF IRON-RELATED CONDITIONS WITH AT LEAST 0.6 GRAMS OF ELEMENTAL IRON VIA AN IRON CARBOHYDRATE COMPLEX, WITH A SUBSTANTIALLY NON-IMMUNOGENIC CARBOHYDRATE COMPONENT, IN ABOUT 15 MINUTES OR LESS"
  },
  {
    "Code": "U-1621",
    "Definition": "PULMONARY ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN BOUND TO A COMPLEXING AGENT."
  },
  {
    "Code": "U-1622",
    "Definition": "FOR THE TREATMENT OF POLYCYTHEMIA VERA"
  },
  {
    "Code": "U-1623",
    "Definition": "USE OF EXENATIDE MAY RESULT IN REDUCTION IN APPETITE."
  },
  {
    "Code": "U-1624",
    "Definition": "TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA, ADVANCED RENAL CELL CARCINOMA, OR DIFFERENTIATED THYROID CARCINOMA."
  },
  {
    "Code": "U-1625",
    "Definition": "METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE POOR METABOLIZERS OF CYP2D6"
  },
  {
    "Code": "U-1626",
    "Definition": "A METHOD OF TREATING OR PREVENTING OCULAR PAIN AND BURNING"
  },
  {
    "Code": "U-1627",
    "Definition": "TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN ADULTS"
  },
  {
    "Code": "U-1628",
    "Definition": "METHOD OF TREATING DISORDERS WITH AN ETIOLOGY COMPRISING OR ASSOCIATED WITH EXCESS GH-SECRETION"
  },
  {
    "Code": "U-1629",
    "Definition": "METHOD OF TREATING ACROMEGALY"
  },
  {
    "Code": "U-1630",
    "Definition": "TREATMENT IN COMBINATION WITH A CORTICOID SUCH AS PREDNISONE OF PROSTATE CANCER PREVIOUSLY TREATED WITH DOCETAXEL"
  },
  {
    "Code": "U-1631",
    "Definition": "TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA"
  },
  {
    "Code": "U-1632",
    "Definition": "TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA"
  },
  {
    "Code": "U-1633",
    "Definition": "USE OF ARIPIPRAZOLE IN EXTENDED RELEASE INJECTABLE SUSPENSION IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA"
  },
  {
    "Code": "U-1634",
    "Definition": "TREATMENT OF BRCA MUTATED OVARIAN CANCER USING PARP INHIBITOR"
  },
  {
    "Code": "U-1635",
    "Definition": "USE OF RITONAVIR AS A POTENT CYP3A INHIBITOR TO INCREASE PLASMA DRUG CONCENTRATION OF PARITAPREVIR AND OVERALL DRUG EXPOSURE FOR TREATMENT OF HCV INFECTION"
  },
  {
    "Code": "U-1636",
    "Definition": "USE OF DASABUVIR TO INHIBIT VIRAL REPLICATION FOR THE TREATMENT OF HCV INFECTION."
  },
  {
    "Code": "U-1637",
    "Definition": "TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR WITH RIBAVIRIN."
  },
  {
    "Code": "U-1638",
    "Definition": "TREATMENT OF HCV INFECTION USING PARITAPREVIR"
  },
  {
    "Code": "U-1639",
    "Definition": "USE OF NALTREXONE AND BUPROPION IN EXTENDED-RELEASE FORM FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY"
  },
  {
    "Code": "U-1640",
    "Definition": "TREATMENT OF MODERATE TO SEVERE CHRONIC PAIN BY ADMINISTERING AN INTACT COMPOSITION AS CLAIMED"
  },
  {
    "Code": "U-1641",
    "Definition": "MEMANTINE HCL\/DONEPEZIL HCL COMBINATION FOR THE TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE"
  },
  {
    "Code": "U-1642",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN"
  },
  {
    "Code": "U-1643",
    "Definition": "TREATING CUSHING'S SYNDROME"
  },
  {
    "Code": "U-1644",
    "Definition": "TREATMENT OF OVERACTIVE BLADDER BY APPLICATION OF OXYBUTYNIN CHLORIDE GEL TO SKIN"
  },
  {
    "Code": "U-1645",
    "Definition": "TREATMENT OF PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION"
  },
  {
    "Code": "U-1646",
    "Definition": "TREATMENT OF POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION"
  },
  {
    "Code": "U-1647",
    "Definition": "TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION"
  },
  {
    "Code": "U-1648",
    "Definition": "TREATMENT OF PATIENTS WITH PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION"
  },
  {
    "Code": "U-1649",
    "Definition": "TREATMENT OF POST-ENCEPHALITIC PARKINSONISM"
  },
  {
    "Code": "U-1650",
    "Definition": "TREATMENT OF WALDENSTROM'S MACROGLOBULINEMIA"
  },
  {
    "Code": "U-1651",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN"
  },
  {
    "Code": "U-1652",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN AND METFORMIN"
  },
  {
    "Code": "U-1653",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT METFORMIN)"
  },
  {
    "Code": "U-1654",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN (WITH OR WITHOUT INSULIN OR A SULFONYLUREA)"
  },
  {
    "Code": "U-1655",
    "Definition": "A METHOD TO ACCELERATE THE TIME TO GASTROINTESTINAL RECOVERY BY ADMINISTERING ABOUT 12 MG OF ALVIMOPAN TO THE PATIENT FROM ABOUT 30 TO 60 MINUTES PRIOR TO SURGERY"
  },
  {
    "Code": "U-1656",
    "Definition": "METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT"
  },
  {
    "Code": "U-1657",
    "Definition": "METHOD FOR PROVIDING POST COITAL CONTRACEPTION TO A WOMAN BY ADMINISTERING ABOUT 30 MG OF ULIPRISTAL ACETATE WITHIN ABOUT 120 HOURS AFTER INTERCOURSE, WHEREIN THE WOMAN IS OVERWEIGHT  HAVING A BMI OF 25 TO 29.99"
  },
  {
    "Code": "U-1658",
    "Definition": "TREATMENT OF ER-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER IN COMBINATION WITH LETROZOLE AS INITIAL ENDOCRINE-BASED THERAPY FOR METASTATIC DISEASE IN POSTMENOPAUSAL WOMEN"
  },
  {
    "Code": "U-1659",
    "Definition": "MANAGEMENT OF PAIN"
  },
  {
    "Code": "U-1660",
    "Definition": "TREATMENT OF HIV-1 INFECTION IN ADULTS WITH NO DARUNAVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS"
  },
  {
    "Code": "U-1661",
    "Definition": "RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCERS IN PATIENTS ALSO TAKING LOW DOSE ASPIRIN"
  },
  {
    "Code": "U-1662",
    "Definition": "A METHOD OF TREATING OCULAR PAIN"
  },
  {
    "Code": "U-1663",
    "Definition": "TREATMENT OF HIV-1 INFECTION"
  },
  {
    "Code": "U-1664",
    "Definition": "TREATMENT OF BACTERIAL VAGINOSIS WITH METRONIDAZOLE GEL"
  },
  {
    "Code": "U-1665",
    "Definition": "METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING THE COMPOSITION OF CLAIM 1"
  },
  {
    "Code": "U-1666",
    "Definition": "PALLIATIVE TREATMENT OF PROSTATE CANCER"
  },
  {
    "Code": "U-1667",
    "Definition": "TREATMENT OF ALLERGIC RHINITIS, INCLUDING SEASONAL ALLERGIC RHINITIS"
  },
  {
    "Code": "U-1668",
    "Definition": "METHOD OF TREATING DEPRESSION OR MAJOR DEPRESSIVE DISORDER"
  },
  {
    "Code": "U-1669",
    "Definition": "TREATMENT OF MULTIPLE MYELOMA, IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE"
  },
  {
    "Code": "U-1670",
    "Definition": "NATROBA TOPICAL SUSPENSION IS A PEDICULICIDE INDICATED FOR THE TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS SIX (6) MONTHS OF AGE AND OLDER."
  },
  {
    "Code": "U-1671",
    "Definition": "TREATMENT OF OCULAR ITCHING ASSOCIATED WITH CONJUNCTIVITIS"
  },
  {
    "Code": "U-1672",
    "Definition": "TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION"
  },
  {
    "Code": "U-1673",
    "Definition": "TREATMENT OF COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS"
  },
  {
    "Code": "U-1674",
    "Definition": "DOSAGE MODIFICATION TO REDUCE RISKS ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE"
  },
  {
    "Code": "U-1675",
    "Definition": "USE OF TROKENDI XR FOR THE TREATMENT OF EPILEPSY"
  },
  {
    "Code": "U-1676",
    "Definition": "METHODS FOR TREATING BACTERIAL INFECTIONS"
  },
  {
    "Code": "U-1677",
    "Definition": "TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS (IPF)"
  },
  {
    "Code": "U-1678",
    "Definition": "FOR THE TREATMENT OF PATIENTS WITH CLL, FL, OR SLL"
  },
  {
    "Code": "U-1679",
    "Definition": "TREATMENT OF ACUTE OTITIS EXTERNA"
  },
  {
    "Code": "U-1680",
    "Definition": "TREATMENT OF OCULAR ITCHING ASSOCIATED WITH ALLERGIC CONJUNCTIVITIS"
  },
  {
    "Code": "U-1681",
    "Definition": "TREATMENT OF PATIENTS WITH PROGRESSIVE NEUROENDOCRINE TUMORS OF PANCREATIC ORIGIN (PNET) THAT ARE UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC"
  },
  {
    "Code": "U-1682",
    "Definition": "TREATMENT OF BACTERIAL VAGINOSIS"
  },
  {
    "Code": "U-1683",
    "Definition": "TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION"
  },
  {
    "Code": "U-1684",
    "Definition": "TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA"
  },
  {
    "Code": "U-1685",
    "Definition": "DOSAGE MODIFICATION TO REDUCE THE RISK ASSOCIATED WITH QT PROLONGATION NOT INDUCED BY OTHER DRUGS DURING TREATMENT WITH ILOPERIDONE"
  },
  {
    "Code": "U-1686",
    "Definition": "A METHOD TO REDUCE WITHDRAWAL SYMPTOMS, INCLUDING NICOTINE CRAVING, ASSOCIATED WITH SMOKING CESSATION"
  },
  {
    "Code": "U-1687",
    "Definition": "TREATMENT OF HCV INFECTION USING OMBITASVIR"
  },
  {
    "Code": "U-1688",
    "Definition": "METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD"
  },
  {
    "Code": "U-1689",
    "Definition": "METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD"
  },
  {
    "Code": "U-1690",
    "Definition": "METHOD FOR REDUCTION OF SUBMENTAL FAT"
  },
  {
    "Code": "U-1691",
    "Definition": "INDICATED FOR THE ONCE-DAILY INHALED TREATMENT FOR ASTHMA IN ADULTS AGED 18 YEARS AND OLDER"
  },
  {
    "Code": "U-1692",
    "Definition": "METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN AN INDIVIDUAL WHO DOES NOT HAVE SEVERE RENAL IMPAIRMENT OR ESRD"
  },
  {
    "Code": "U-1693",
    "Definition": "METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS"
  },
  {
    "Code": "U-1694",
    "Definition": "A METHOD FOR TREATING HEART FAILURE IN A HUMAN USING A CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE"
  },
  {
    "Code": "U-1695",
    "Definition": "METHOD FOR TREATING THYROID CARCINOMA INCLUDING DIFFERENTIATED THYROID CANCER"
  },
  {
    "Code": "U-1696",
    "Definition": "TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA"
  },
  {
    "Code": "U-1697",
    "Definition": "PULMONARY ADMINISTRATION OF A COMPOSITION COMPRISING INSULIN BOUND TO A DIKETOPIPERAZINE."
  },
  {
    "Code": "U-1698",
    "Definition": "PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS"
  },
  {
    "Code": "U-1699",
    "Definition": "A METHOD FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA"
  },
  {
    "Code": "U-1700",
    "Definition": "A METHOD FOR TREATING PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA"
  },
  {
    "Code": "U-1701",
    "Definition": "A METHOD FOR TREATING LEUKEMIA RESULTING FROM A MUTATION IN THE BCR-ABL KINASE DOMAIN"
  },
  {
    "Code": "U-1702",
    "Definition": "TREATMENT OF COPD"
  },
  {
    "Code": "U-1703",
    "Definition": "TREATMENT OF RESPIRATORY COMPLAINTS"
  },
  {
    "Code": "U-1704",
    "Definition": "USE FOR TREATMENT IN PATIENTS WITH DIABETES"
  },
  {
    "Code": "U-1705",
    "Definition": "USE FOR TREATMENT IN PATIENTS WITH HYPERGLYCEMIA"
  },
  {
    "Code": "U-1706",
    "Definition": "TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE WHEREIN THE COMBINED THERAPEUTIC EFFECT IS GREATER THAN THE ADDITIVE EFFECT OF ADMINISTERING EACH AGENT ALONE"
  },
  {
    "Code": "U-1707",
    "Definition": "TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS AND SYMPTOMS THEREOF"
  },
  {
    "Code": "U-1708",
    "Definition": "TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS"
  },
  {
    "Code": "U-1709",
    "Definition": "TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE)."
  },
  {
    "Code": "U-1710",
    "Definition": "TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH FLUVOXAMINE"
  },
  {
    "Code": "U-1711",
    "Definition": "FOR THE TREATMENT OF PATIENTS WITH CLL, FL OR SLL"
  },
  {
    "Code": "U-1712",
    "Definition": "MEKINIST IN COMBINATION WITH DABRAFENIB FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA"
  },
  {
    "Code": "U-1713",
    "Definition": "TAFINLAR IN COMBINATION WITH TRAMETINIB FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA"
  },
  {
    "Code": "U-1714",
    "Definition": "TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)"
  },
  {
    "Code": "U-1715",
    "Definition": "P2Y12 PLATELET INHIBITOR FOR USE AS ADJUNCT TO PERCUTANEOUS CORONARY INTERVENTION TO REDUCE RISK OF VARIOUS DISEASES\/CONDITIONS IN PATIENTS NOT TREATED WITH A P2Y12 PLATELET INHIBITOR AND NOT GIVEN A GLYCOPROTEIN IIB\/IIIA INHIBITOR"
  },
  {
    "Code": "U-1716",
    "Definition": "TREATMENT OF COUGH AND SYMPTOMS ASSOCIATED WITH UPPER RESPIRATORY ALLERGIES OR A COMMON COLD WITH CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE ORALLY ADMINISTERED EXTENDED RELEASE TABLETS"
  },
  {
    "Code": "U-1717",
    "Definition": "METHOD OF TREATING CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE"
  },
  {
    "Code": "U-1718",
    "Definition": "METHOD OF TREATING CYSTIC FIBROSIS IN PATIENTS WHO HAVE THE F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE."
  },
  {
    "Code": "U-1719",
    "Definition": "ACUTE TREATMENT OF MIGRAINE"
  },
  {
    "Code": "U-1720",
    "Definition": "METHOD OF PROVIDING A THERAPEUTICALLY EFFECTIVE AND STABLE MEDIAN BLOOD PLASMA LEVEL OF LEVODOPA"
  },
  {
    "Code": "U-1721",
    "Definition": "USE OF RUXOLITINIB (JAKAFI) FOR BLOCKING SIGNAL TRANSDUCTION OF JANUS ASSOCIATED KINASES (JAKS) JAK1 AND\/OR JAK2"
  },
  {
    "Code": "U-1722",
    "Definition": "TREATMENT OF BASAL CELL CARCINOMA"
  },
  {
    "Code": "U-1723",
    "Definition": "TREATMENT OF HEART FAILURE"
  },
  {
    "Code": "U-1724",
    "Definition": "METHOD OF INHIBITING HEPATITIS C VIRUS"
  },
  {
    "Code": "U-1725",
    "Definition": "METHOD OF INHIBITING HEPATITIS C VIRUS WITH DAKLINZA AND AT LEAST ONE ADDITIONAL COMPOUND HAVING ANTI-HCV ACTIVITY"
  },
  {
    "Code": "U-1726",
    "Definition": "REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH CORONARY HEART DISEASE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS"
  },
  {
    "Code": "U-1727",
    "Definition": "TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA"
  },
  {
    "Code": "U-1728",
    "Definition": "REDUCTION IN RISK OF HOSPITALIZATION IN PATIENTS WITH STABLE NYHA CLASS III HEART FAILURE AND A HISTORY OF PAROXYSMAL OR PERSISTENT AF AND WITH ONE OR MORE RISK FACTORS BY ADMINISTRATION TWICE A DAY WITH MORNING AND EVENING MEALS"
  },
  {
    "Code": "U-1729",
    "Definition": "REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT)"
  },
  {
    "Code": "U-1730",
    "Definition": "REDUCE THE RISK OF RECURRENT PULMONARY EMBOLISM"
  },
  {
    "Code": "U-1731",
    "Definition": "TEMPORARY RELIEF OF MINOR ACHES AND PAINS"
  },
  {
    "Code": "U-1732",
    "Definition": "TEMPORARY REDUCTION OF FEVER"
  },
  {
    "Code": "U-1733",
    "Definition": "TREATMENT\/PREVENTION OF CARDIOVASCULAR DISEASE"
  },
  {
    "Code": "U-1734",
    "Definition": "USE OF FLIBANSERIN OR A PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALT THEREOF TO TREAT HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)"
  },
  {
    "Code": "U-1735",
    "Definition": "METHODS OF TREATING PAIN, INFLAMMATION AND\/OR FEVER WITH INTRAVENOUS IBUPROFEN SUCH THAT MEAN ARTERIAL BLOOD PRESSURE DOES NOT INCREASE THE DOSAGE INTERVAL"
  },
  {
    "Code": "U-1736",
    "Definition": "TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)"
  },
  {
    "Code": "U-1737",
    "Definition": "METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING ILOPERIDONE TO A PATIENT BY REDUCING THE DOSE IN PATIENTS WHO ARE BEING TREATED WITH FLUOXETINE"
  },
  {
    "Code": "U-1738",
    "Definition": "TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE)"
  },
  {
    "Code": "U-1739",
    "Definition": "MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND -THE-CLOCK, LONG-TERM OPIOID TREATMENT, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY"
  },
  {
    "Code": "U-1740",
    "Definition": "IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN TREATMENT-NAIVE PATIENTS WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THERAPY"
  },
  {
    "Code": "U-1741",
    "Definition": "PREVENTION OF DELAYED NAUSEA AND VOMITING ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY"
  },
  {
    "Code": "U-1742",
    "Definition": "ROLAPITANT IS APPROVED FOR THE PREVENTION OF DELAYED NAUSEA AND VOMITING (I.E., EMESIS) ASSOCIATED WITH EMETOGENIC CANCER CHEMOTHERAPY"
  },
  {
    "Code": "U-1743",
    "Definition": "FOR THE PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY"
  },
  {
    "Code": "U-1744",
    "Definition": "PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING"
  },
  {
    "Code": "U-1745",
    "Definition": "FOR THE TREATMENT OF PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA"
  },
  {
    "Code": "U-1746",
    "Definition": "MONOTHERAPY OR ADJUNCTIVE THERAPY FOR TREATMENT OF PARTIAL-ONSET SEIZURES AND APPROVED IN PATIENTS WITH EPILEPSY"
  },
  {
    "Code": "U-1747",
    "Definition": "FOR CLAIMS 1-3,6-13,16-24  AND 26-32: METHOD OF TREATING ADHD"
  },
  {
    "Code": "U-1748",
    "Definition": "FOR CLAIMS 1-4,6-14,16-24 AND 26-32: METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS"
  },
  {
    "Code": "U-1749",
    "Definition": "ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER"
  },
  {
    "Code": "U-1750",
    "Definition": "TREATMENT OF SCHIZOPHRENIA AND\/OR ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE"
  },
  {
    "Code": "U-1751",
    "Definition": "TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER WHO HAVE BEEN PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN-BASED CHEMOTHERAPY, AN ANTI-VEGF BIOLOGICAL THERAPY, AND IF RAS WILD-TYPE, AN ANTI-EGFR THERAPY"
  },
  {
    "Code": "U-1752",
    "Definition": "PROPHYLAXIS OF ORGAN REJECTION"
  },
  {
    "Code": "U-1753",
    "Definition": "TREATMENT OF HCV INFECTION USING DASABUVIR"
  },
  {
    "Code": "U-1754",
    "Definition": "FOR THE TREATMENT OF PULMONARY HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL"
  },
  {
    "Code": "U-1755",
    "Definition": "FIRST-LINE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21 (L858R) SUBSTITUTION MUTATIONS"
  },
  {
    "Code": "U-1756",
    "Definition": "METHODS OF TREATING PAIN, INFLAMMATION AND\/OR FEVER IN A CRITICALLY ILL PATIENT WITH INTRAVENOUS IBUPROFEN IN NEED THEREOF"
  },
  {
    "Code": "U-1757",
    "Definition": "INHIBITION ON PI3K KINASE"
  },
  {
    "Code": "U-1758",
    "Definition": "METHOD OF TREATING ALLERGIC REACTION VIA INJECTION"
  },
  {
    "Code": "U-1759",
    "Definition": "METHOD OF REVERSING THE ANTICOAGULANT EFFECT OF DABIGATRAN USING IDARUCIZUMAB"
  },
  {
    "Code": "U-1760",
    "Definition": "RISK-REDUCTION OF NSAID GASTRIC ULCER IN PATIENTS REQUIRING CHRONIC NSAID TREATMENT"
  },
  {
    "Code": "U-1761",
    "Definition": "PLAQUE PSORIASIS"
  },
  {
    "Code": "U-1762",
    "Definition": "USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT"
  },
  {
    "Code": "U-1763",
    "Definition": "USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT"
  },
  {
    "Code": "U-1764",
    "Definition": "USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT"
  },
  {
    "Code": "U-1765",
    "Definition": "USE OF BELVIQ (LORCASERIN HYDROCHLORIDE) FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT"
  },
  {
    "Code": "U-1766",
    "Definition": "TREATMENT OF HYPERKALEMIA"
  },
  {
    "Code": "U-1767",
    "Definition": "USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 18 YEARS AND OLDER"
  },
  {
    "Code": "U-1768",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN"
  },
  {
    "Code": "U-1769",
    "Definition": "TREATMENT OF PAIN BY TRANSMUCOSAL DELIVERY OF BUPRENORPHINE"
  },
  {
    "Code": "U-1770",
    "Definition": "TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN NEGATIVE SYMPTOMS AND\/OR COGNITIVE DYSFUNCTION OF SCHIZOPHRENIA"
  },
  {
    "Code": "U-1771",
    "Definition": "ADMINISTRATION OF REMODULIN DILUTED FOR INTRAVENOUS INFUSION WITH STERILE WATER FOR INJECTION OR 0.9% SODIUM CHLORIDE  INJECTION PRIOR TO ADMINISTRATION"
  },
  {
    "Code": "U-1772",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH EMPAGLIFLOZIN"
  },
  {
    "Code": "U-1773",
    "Definition": "LONG-TERM MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"
  },
  {
    "Code": "U-1774",
    "Definition": "USE OF A LOTION CONTAINING HALOBETASOL PROPIONATE FOR THE TREATMENT OF CORTICOSTEROID-RESPONSIVE"
  },
  {
    "Code": "U-1775",
    "Definition": "USE OF A LOTION CONTAINING HALOBETASOL PROPIONATE FOR THE TREATMENT OF CORTICOSTEROID-RESPONSIVE DERMATOSES INCLUDING PSORIASIS"
  },
  {
    "Code": "U-1776",
    "Definition": "METHOD OF USING COBIMETINIB FOR THE TREATMENT OF MELANOMA"
  },
  {
    "Code": "U-1777",
    "Definition": "TREATMENT OF PATIENTS WITH METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) T790M MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC), WHO HAVE PROGRESSED ON OR AFTER EGFR TKI THERAPY"
  },
  {
    "Code": "U-1778",
    "Definition": "METHOD FOR TREATING MULTIPLE MYELOMA"
  },
  {
    "Code": "U-1779",
    "Definition": "METHOD FOR TREATING MULTIPLE MYELOMA WITH ONE OR MORE OTHER THERAPEUTIC AGENTS"
  },
  {
    "Code": "U-1780",
    "Definition": "METHOD FOR TREATING CANCER, INCLUDING MULTIPLE MYELOMA"
  },
  {
    "Code": "U-1781",
    "Definition": "RISK-REDUCTION OF NSAID-ASSOCIATED GASTRIC ULCER IN PATIENTS REQUIRING NSAID TREATMENT"
  },
  {
    "Code": "U-1782",
    "Definition": "FOR HEAD LICE INFESTATIONS"
  },
  {
    "Code": "U-1783",
    "Definition": "METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM AS CLAIMED"
  },
  {
    "Code": "U-1784",
    "Definition": "METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM TRIHYDRATE AS CLAIMED"
  },
  {
    "Code": "U-1785",
    "Definition": "METHOD OF TREATING FREQUENT HEARTBURN BY ADMINISTERING AN ESOMEPRAZOLE MAGNESIUM FORMULATION AS CLAIMED"
  },
  {
    "Code": "U-1786",
    "Definition": "TREATMENT OF PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS WHILE MANAGING THE RISK OF TERIFLUNOMIDE AND ROSUVASTATIN INTERACTION BY LIMITING THE ROSUVASTATIN DOSE TO NO MORE THAN 10MG AND\/OR ADMINISTERING ABOUT HALF THE NORMAL DOSE"
  },
  {
    "Code": "U-1787",
    "Definition": "TREATMENT OF EXOCRINE PANCREATIC INSUFFICIENCY"
  },
  {
    "Code": "U-1788",
    "Definition": "TREATMENT OF PATIENT HAVING DIABETES MELLITUS VIA ORAL INHALATION OF FDKP MICROPARTICLES COMPRISING INSULIN"
  },
  {
    "Code": "U-1789",
    "Definition": "METHOD OF ADMINISTERING AN ETHANOL-FREE TAXANE LIQUID NANODISPERSION FORMULATION TO A SUBJECT COMBINING THE FORMULATION WITH AN AQUEOUS MEDIUM TO PROVIDE AN ETHANOL-FREE TAXANE DILUTED SOLUTION"
  },
  {
    "Code": "U-1790",
    "Definition": "FOR USE IN TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND\/OR NON-HODGKIN'S LYMPHOMA"
  },
  {
    "Code": "U-1791",
    "Definition": "EMERGENCY TREATMENT OF ADULT & PEDIATRIC PATIENTS FOLLOWING FLUOROURACIL OR CAPECITABINE OVERDOSE,OR WHO EXHIBIT EARLY-ONSET,SEVERE OR LIFE-THREATENING CARDIAC OR CNS TOXICITY OR UNUSUALLY SEVERE ADVERSE REACTIONS WITHIN 96 HOURS"
  },
  {
    "Code": "U-1792",
    "Definition": "TREATMENT OF OTIC INFECTION OR INFLAMMATION"
  },
  {
    "Code": "U-1793",
    "Definition": "TREATMENT OF PEDIATRIC PATIENTS WITH OTITIS MEDIA WITH EFFUSION UNDERGOING TYMPANOSTOMY TUBE PLACEMENT"
  },
  {
    "Code": "U-1794",
    "Definition": "REVERSAL OF DRUG-INDUCED NEUROMUSCULAR BLOCK"
  },
  {
    "Code": "U-1795",
    "Definition": "REVERSAL OF NEUROMUSCULAR BLOCKAGE INDUCED BY ROCURONIUM BROMIDE OR VECURONIUM BROMIDE"
  },
  {
    "Code": "U-1796",
    "Definition": "TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA"
  },
  {
    "Code": "U-1797",
    "Definition": "METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING SELEXIPAG"
  },
  {
    "Code": "U-1798",
    "Definition": "METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING SELEXIPAG IN COMBINATION WITH THE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN"
  },
  {
    "Code": "U-1799",
    "Definition": "METHOD OF INCREASING GROWTH OF HAIR INCLUDING EYELASHES"
  },
  {
    "Code": "U-1800",
    "Definition": "A METHOD OF TREATING OCULAR PAIN AND\/OR ENHANCING OCULAR COMFORT"
  },
  {
    "Code": "U-1801",
    "Definition": "REDUCTION OF SERUM URIC ACID LEVELS"
  },
  {
    "Code": "U-1802",
    "Definition": "TREATMENT OF GOUT"
  },
  {
    "Code": "U-1803",
    "Definition": "TREATMENT OF HYPERURICEMIA"
  },
  {
    "Code": "U-1804",
    "Definition": "ACHIEVING A THERAPEUTIC BENEFIT IN A SUBJECT WITH GOUT"
  },
  {
    "Code": "U-1805",
    "Definition": "USE OF DEXLANSOPRAZOLE IN PATIENTS TAKING CLOPIDOGREL WITHOUT MEANINGFUL CYP2C19 INTERACTIONS"
  },
  {
    "Code": "U-1806",
    "Definition": "COADMINISTERING WITH ALLOPURINOL TO REDUCE SERUM URIC ACID (SUA) BELOW 4 MG\/DL; BELOW 6MG\/DL IN PATIENTS HAVING URIC ACID DEPOSITS; AND\/OR BELOW 6MG\/DL WITH SUA INTRADAY CHANGE MORE THAN 50% AND\/OR ADVERSE EVENT RATE LESS THAN 15%"
  },
  {
    "Code": "U-1807",
    "Definition": "TREATMENT OF PEDIATRIC PATIENTS 8 TO 17 YEARS OF AGE WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)"
  },
  {
    "Code": "U-1808",
    "Definition": "USE OF NALTREXONE AND BUPROPION FOR CHRONIC WEIGHT MANAGEMENT FOR TREATING OVERWEIGHT OR OBESITY IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER"
  },
  {
    "Code": "U-1809",
    "Definition": "METHOD OF DRUG DELIVERY VIA THE NASAL CAVITY"
  },
  {
    "Code": "U-1810",
    "Definition": "TREATMENT OF PAIN IN PATIENTS WITH HEPATIC IMPAIRMENT"
  },
  {
    "Code": "U-1811",
    "Definition": "TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATIONS AFTER CONFIRMING THE PRESENCE OF BRAF V600E MUTATION"
  },
  {
    "Code": "U-1812",
    "Definition": "TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA"
  },
  {
    "Code": "U-1813",
    "Definition": "TREATMENT OF PATIENTS INFECTED WITH HEPATITIS C VIRUS"
  },
  {
    "Code": "U-1814",
    "Definition": "METHOD OF TREATING GLAUCOMA OR ELEVATED INTRAOCULAR PRESSURE"
  },
  {
    "Code": "U-1815",
    "Definition": "TREATMENT OF PARTIAL-ONSET SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY"
  },
  {
    "Code": "U-1816",
    "Definition": "TREATMENT OF A UREA CYCLE DISORDER"
  },
  {
    "Code": "U-1817",
    "Definition": "PEDIATRIC USE AGES 1 MONTH TO 2 YEARS, GERD AND EROSIVE ESOPHAGITIS"
  },
  {
    "Code": "U-1818",
    "Definition": "TREATING HR-POS., HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER WITH PALBOCICLIB IN COMBO WITH LETROZOLE AS INITIAL ENDOCRINE BASED THERAPY IN POSTMENOPAUSAL WOMEN, OR FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY"
  },
  {
    "Code": "U-1819",
    "Definition": "MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE"
  },
  {
    "Code": "U-1820",
    "Definition": "METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING MACITENTAN AND A POLYSORBATE, WHEREIN THE POLYSORBATE REPRESENTS 0.1 TO 3% OF THE WEIGHT OF SAID PHARMACEUTICAL COMPOSITION"
  },
  {
    "Code": "U-1821",
    "Definition": "METHOD FOR CONTRACEPTION TO A WOMAN COMPRISING ADMINISTERING TO THE WOMAN 30MG OF ULIPRISTAL ACETATE MORE THAN 72 HOURS AND UP TO 120 HOURS AFTER AN UNPROTECTED INTERCOURSE"
  },
  {
    "Code": "U-1822",
    "Definition": "TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA AND\/OR BIPOLAR DISORDER"
  },
  {
    "Code": "U-1823",
    "Definition": "A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY COMPENSATING LONG-TERM SENSITIVITY DRIFT OF ELECTROCHEMICAL GAS SENSORS USED IN SYSTEMS FOR DELIVERING THERAPEUTIC NITRIC OXIDE TO A PATIENT"
  },
  {
    "Code": "U-1824",
    "Definition": "A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY VERIFYING GAS INFORMATION OF NITRIC OXIDE PRIOR TO DELIVERY TO PATIENT"
  },
  {
    "Code": "U-1825",
    "Definition": "METHOD OF USING VISMODEGIB TO TREAT CANCER IN A MAMMAL"
  },
  {
    "Code": "U-1826",
    "Definition": "TREATMENT OF HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION WITH PALBOCICLIB IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY"
  },
  {
    "Code": "U-1827",
    "Definition": "A METHOD OF PROVIDING A SUBJECT WITH THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET ACCORDING TO CLAIM 1"
  },
  {
    "Code": "U-1828",
    "Definition": "INCREASING MEAN ARTERIAL BLOOD PRESSURE IN ADULT PATIENTS WITH HYPOTENSION ASSOCIATED WITH SEPTIC SHOCK"
  },
  {
    "Code": "U-1829",
    "Definition": "EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE I), INCLUDING ANAPHYLAXIS"
  },
  {
    "Code": "U-1830",
    "Definition": "INDUCTION AND MAINTENANCE OF MYDRIASIS DURING INTRAOCULAR SURGERY"
  },
  {
    "Code": "U-1831",
    "Definition": "METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A CRYSTALLINE FORM OF SELEXIPAG"
  },
  {
    "Code": "U-1832",
    "Definition": "IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE"
  },
  {
    "Code": "U-1833",
    "Definition": "REDUCTION OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION"
  },
  {
    "Code": "U-1834",
    "Definition": "TREATMENT OF POSTOPERATIVE INFLAMMATION AND PREVENTION OF OCULAR PAIN IN PATIENTS UNDERGOING CATARACT SURGERY"
  },
  {
    "Code": "U-1835",
    "Definition": "TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION, AS DETECTED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY"
  },
  {
    "Code": "U-1836",
    "Definition": "TREATMENT OF HEREDITARY TYROSINEMIA TYPE 1 (HT-1) IN COMBINATION WITH DIETARY RESTRICTION OF TYROSINE AND PHENYLALANINE"
  },
  {
    "Code": "U-1837",
    "Definition": "METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN ALONE OR IN COMBINATION WITH INSULIN, METFORMIN, A THIAZOLIDINEDIONE, GLYBURIDE OR METFORMIN PLUS A SULFONYLUREA"
  },
  {
    "Code": "U-1838",
    "Definition": "METHOD FOR TREATING TYPE II DIABETES MELLITUS BY ADMINISTERING SAXAGLIPTIN IN COMBINATION WITH METFORMIN"
  },
  {
    "Code": "U-1839",
    "Definition": "COMPOSITION AND METHOD FOR PROVIDING A REDUCTION IN SIDE EFFECTS FOR HUMAN PATIENTS IN NEED OF ACETYLCYSTEINE THERAPY"
  },
  {
    "Code": "U-1840",
    "Definition": "TREATMENT OF HCV INFECTION USING PARITAPREVIR, OMBITASVIR, RITONAVIR, AND DASABUVIR, WITHOUT RIBAVIRIN"
  },
  {
    "Code": "U-1841",
    "Definition": "USE IN THE LONG-TERM, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"
  },
  {
    "Code": "U-1842",
    "Definition": "METHOD OF TREATING EPILEPSY"
  },
  {
    "Code": "U-1843",
    "Definition": "TREATMENT OF PSYCHOSIS"
  },
  {
    "Code": "U-1844",
    "Definition": "TREATMENT OF PARKINSON'S DISEASE PSYCHOSIS"
  },
  {
    "Code": "U-1845",
    "Definition": "TREATMENT OF PSYCHOSIS OR A SYMPTOM THEREOF"
  },
  {
    "Code": "U-1846",
    "Definition": "TREATMENT OF A NEURODEGENERATIVE DISEASE OR A SYMPTOM THEREOF"
  },
  {
    "Code": "U-1847",
    "Definition": "METHOD OF TREATING A BACTERIAL INFECTION"
  },
  {
    "Code": "U-1848",
    "Definition": "TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN"
  },
  {
    "Code": "U-1849",
    "Definition": "METHOD OF TREATING PULMONARY HYPERTENSION BY ADMINISTERING TREPROSTINIL OR A SALT THEREOF BY INHALATION USING A DEVICE"
  },
  {
    "Code": "U-1850",
    "Definition": "METHOD OF ADMINISTERING LEVETIRACETAM"
  },
  {
    "Code": "U-1851",
    "Definition": "A DOSING REGIMEN FOR THE TREATMENT OF  HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES"
  },
  {
    "Code": "U-1852",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES"
  },
  {
    "Code": "U-1853",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS BY ADMINISTERING A DIPEPTIDYL PEPTIDASE-IV INHIBITOR IN COMBINATION WITH METFORMIN AND, OPTIONALLY, A SULFONYLUREA"
  },
  {
    "Code": "U-1854",
    "Definition": "TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)"
  },
  {
    "Code": "U-1855",
    "Definition": "IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS"
  },
  {
    "Code": "U-1856",
    "Definition": "TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, IN A PATIENT HOMOZYGOUS FOR THE UGT1A1*28 ALLELE"
  },
  {
    "Code": "U-1857",
    "Definition": "TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES"
  },
  {
    "Code": "U-1858",
    "Definition": "TREATMENT OF PLAQUE PSORIASIS"
  },
  {
    "Code": "U-1859",
    "Definition": "TREATMENT OF SCHIZOPHRENIA, ACUTE TREATMENT OF MANIC AND MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER, ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER, AND TREATMENT OF IRRITABILITY ASSOCIATED WITH AUTISTIC DISORDER"
  },
  {
    "Code": "U-1860",
    "Definition": "REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION"
  },
  {
    "Code": "U-1861",
    "Definition": "USE OF AN INHALER TO ADMINISTER DRY POWDER MEDICAMENT"
  },
  {
    "Code": "U-1862",
    "Definition": "TREATMENT OF POST-MYOCARDIAL INFARCTION"
  },
  {
    "Code": "U-1863",
    "Definition": "TREATMENT OF STROKE"
  },
  {
    "Code": "U-1864",
    "Definition": "TREATMENT OF MYOCARDIAL INFARCTION"
  },
  {
    "Code": "U-1865",
    "Definition": "TREATMENT OF THROMBOTIC STROKE"
  },
  {
    "Code": "U-1866",
    "Definition": "TREATMENT OF STABLE AND UNSTABLE ANGINA"
  },
  {
    "Code": "U-1867",
    "Definition": "METHOD OF INHIBITING PLATELET AGGREGATION"
  },
  {
    "Code": "U-1868",
    "Definition": "TREATMENT OF ARTERIAL THROMBOTIC COMPLICATIONS SELECTED FROM THE GROUP CONSISTING OF UNSTABLE ANGINA, THROMBOTIC OR EMBOLIC STROKE, TRANSIENT ISCHAEMIC ATTACKS, PERIPHERAL VASCULAR DISEASE AND MYOCARDIAL INFARCTION"
  },
  {
    "Code": "U-1869",
    "Definition": "TREATMENT OF AN ARTERIAL THROMBOTIC COMPLICATION IN A PATIENT WITH CORONARY ARTERY, CEREBROVASCULAR OR PERIPHERAL VASCULAR DISEASE"
  },
  {
    "Code": "U-1870",
    "Definition": "ZINGO IS A POWDER INTRADERMAL SYSTEM THAT IS CAPABLE OF DELIVERING FINE DRY POWDERED LIDOCAINE HYDROCHLORIDE MONOHYDRATE FOR LOCAL ANESTHETIC ACTION"
  },
  {
    "Code": "U-1871",
    "Definition": "TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH STAGE 3 OR 4 CHRONIC KIDNEY DISEASE USING CONTROLLED RELEASE, ORAL 25-HYDROXYVITAMIN D"
  },
  {
    "Code": "U-1872",
    "Definition": "USE OF SUSTAINED RELEASE 25-HYDROXYVITAMIN D IN TREATING PATIENTS HAVING 25-HYDROXYVITAMIN D INSUFFICIENCY OR DEFICIENCY"
  },
  {
    "Code": "U-1873",
    "Definition": "ADMINISTRATION OF 25-HYDROXYVITAMIN D3 BY CONTROLLED RELEASE"
  },
  {
    "Code": "U-1874",
    "Definition": "TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING OMEPRAZOLE ACCORDING TO CLAIMS 1-8"
  },
  {
    "Code": "U-1875",
    "Definition": "TREATMENT OF FREQUENT HEARTBURN BY ADMINISTERING S-OMEPRAZOLE TRIHYDRATE ACCORDING TO CLAIMS 1-3"
  },
  {
    "Code": "U-1876",
    "Definition": "METHOD OF ANESTHETIZING AT LEAST A PORTION OF THE MAXILLARY DENTAL ARCH"
  },
  {
    "Code": "U-1877",
    "Definition": "METHOD OF TREATING PULMONARY HYPERTENSION BY ORALLY ADMINISTERING A FORMULATION OF A PHARMACEUTICALLY ACCEPTABLE SALT OF TREPROSTINIL"
  },
  {
    "Code": "U-1878",
    "Definition": "FOR OPIOID DEPENDENCE"
  },
  {
    "Code": "U-1879",
    "Definition": "METHOD OF DIAGNOSING TUMORS USING POSITRON EMISSION TOMOGRAPHY"
  },
  {
    "Code": "U-1880",
    "Definition": "TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)"
  },
  {
    "Code": "U-1881",
    "Definition": "IMPROVEMENT IN GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR"
  },
  {
    "Code": "U-1882",
    "Definition": "MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS, REDUCTION IN FEVER THROUGH ANALGESIC AND ANTIPYRETIC ACTIVITY"
  },
  {
    "Code": "U-1883",
    "Definition": "TREATMENT OF GASTROINTESTINAL STROMAL TUMORS (GIST)"
  },
  {
    "Code": "U-1884",
    "Definition": "USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT"
  },
  {
    "Code": "U-1885",
    "Definition": "USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT"
  },
  {
    "Code": "U-1886",
    "Definition": "USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT"
  },
  {
    "Code": "U-1887",
    "Definition": "USE OF LORCASERIN HYDROCHLORIDE FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY IN PATIENTS ON A REDUCED-CALORIE DIET AND WHO HAVE ACHIEVED A GREATER THAN OR EQUAL TO 5% WEIGHT LOSS BY WEEK 12 OF TREATMENT"
  },
  {
    "Code": "U-1888",
    "Definition": "USE OF CONTROLLED RELEASE 25-HYDROXYVITAMIN D IN TREATING SECONDARY HYPERPARATHYROIDISM IN PATIENTS HAVING CHRONIC KIDNEY DISEASE"
  },
  {
    "Code": "U-1889",
    "Definition": "TREATMENT OF HCV INFECTION USING DASABUVIR\/OMBITASVIR\/PARITAPREVIR\/RITONAVIR FIXED DOSE COMBINATION"
  },
  {
    "Code": "U-1890",
    "Definition": "OTC USE: ALLERGY SYMPTOM RELIEVER; TEMPORARILY RELIEVES THESE SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES; NASAL CONGESTION, RUNNY NOSE, SNEEZING, ITCHY NOSE, AND (ITCHY WATER EYES (AGES 12 AND UP))"
  },
  {
    "Code": "U-1891",
    "Definition": "TREATMENT OR PREVENTION OF NAUSEA AND VOMITING"
  },
  {
    "Code": "U-1892",
    "Definition": "METHOD OF TREATING LEFT VENTRICULAR DYSFUNCTION"
  },
  {
    "Code": "U-1893",
    "Definition": "METHOD OF TREATING MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR DISORDER IN PEDIATRIC PATIENTS"
  },
  {
    "Code": "U-1894",
    "Definition": "COMBINATION TREATMENT WITH A GLITAZONE FOR IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS"
  },
  {
    "Code": "U-1895",
    "Definition": "METHOD OF TREATING PROSTATE CANCER"
  },
  {
    "Code": "U-1896",
    "Definition": "SUPPLEMENT FOR VITAMIN B12 DEFICIENCIES"
  },
  {
    "Code": "U-1897",
    "Definition": "METHOD OF TREATING ACS USING ANGIOPLASTY WITH AGGRASTAT (TIROFIBAN HYDROCHLORIDE)"
  },
  {
    "Code": "U-1898",
    "Definition": "METHOD OF INHIBITING PLATELET AGGREGATION WITH AGGRASTAT (TIROFIBAN HYDROCHLORIDE)"
  },
  {
    "Code": "U-1899",
    "Definition": "TREATMENT OF PANCREATIC CANCER THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN"
  },
  {
    "Code": "U-1900",
    "Definition": "TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)"
  },
  {
    "Code": "U-1901",
    "Definition": "TREATMENT OF SCHIZOAFFECTIVE DISORDER AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS"
  },
  {
    "Code": "U-1902",
    "Definition": "TREATMENT OR SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE, CARDIOVASCULAR EVENTS, OR CEREBROVASCULAR EVENTS AND RISK-REDUCTION OF ASPIRIN-ASSOCIATED GASTRIC ULCERS"
  },
  {
    "Code": "U-1903",
    "Definition": "USE OF NALOXONE HYDROCHLORIDE FOR EMERGENCY TREATMENT OF KNOWN OR SUSPECTED OPIOID OVERDOSE, AS MANIFESTED BY RESPIRATORY AND\/OR CENTRAL NERVOUS SYSTEM DEPRESSION."
  },
  {
    "Code": "U-1904",
    "Definition": "(I)TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY; (II)RESTORING\/INCREASING FUNCTIONAL DYSTROPHIN PROTEIN; OR (III) INDUCING SKIPPING; EACH OF (I)-(III) IN PATIENTS HAVING A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING"
  },
  {
    "Code": "U-1905",
    "Definition": "METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS, THE PATIENT HAVING A R117H MUTATION IN CFTR, USING N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE"
  },
  {
    "Code": "U-1906",
    "Definition": "METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS, SUCH AS A PATIENT HAVING A G551D MUTATION IN CFTR, USING N-(5-HYDROXY-2,4-DI-TERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE"
  },
  {
    "Code": "U-1907",
    "Definition": "USE OF A DELIVERY DEVICE TO ADMINISTER A DOSE OF NALOXONE"
  },
  {
    "Code": "U-1908",
    "Definition": "METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING IVACAFTOR AND FORM I LUMACAFTOR"
  },
  {
    "Code": "U-1909",
    "Definition": "METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING IVACAFTOR AND LUMACAFTOR"
  },
  {
    "Code": "U-1910",
    "Definition": "METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING THE DOSAGE UNIT OF CLAIM 1 OF U.S. PATENT NO. 8,716,338"
  },
  {
    "Code": "U-1911",
    "Definition": "METHOD OF TREATING A PATIENT HAVING CYSTIC FIBROSIS USING IVACAFTOR AND LUMACAFTOR"
  },
  {
    "Code": "U-1912",
    "Definition": "METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT, THE PATIENT HAVING THE F508DEL MUTATION IN CFTR, USING A DOSAGE UNIT AS DEFINED IN CLAIM 1 OF U.S. PATENT NO. 9,192,606"
  },
  {
    "Code": "U-1913",
    "Definition": "TREATMENT OF PEDIATRIC PATIENTS WITH BILATERAL OTITIS MEDIA WITH EFFUSION UNDERGOING TYMPANOSTOMY TUBE PLACEMENT"
  },
  {
    "Code": "U-1914",
    "Definition": "IN COMBINATION WITH RITUXIMAB, FOR THE TREATMENT OF PATIENTS WITH RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)"
  },
  {
    "Code": "U-1915",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN PATIENTS WITH SEVERE CHRONIC RENAL IMPAIRMENT AND WHO ARE INELIGIBLE FOR METFORMIN THERAPY BY ADMINISTERING LINAGLIPTIN"
  },
  {
    "Code": "U-1916",
    "Definition": "PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH CHEMOTHERAPY (CINV)"
  },
  {
    "Code": "U-1917",
    "Definition": "TREATMENT OF EXOCRINE PANCREATIC CANCER THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN"
  },
  {
    "Code": "U-1918",
    "Definition": "TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING"
  },
  {
    "Code": "U-1919",
    "Definition": "RESTORING AN MRNA READING FRAME TO INDUCE DYSTROPHIN PROTEIN PRODUCTION IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING"
  },
  {
    "Code": "U-1920",
    "Definition": "USE OF EXTENDED RELEASE ORAL 25-HYDROXYVITAMIN D3 IN TREATING SECONDARY HYPERPARATHYROIDISM IN ADULT PATIENTS HAVING CHRONIC KIDNEY DISEASE STAGE 3 OR STAGE 4"
  },
  {
    "Code": "U-1921",
    "Definition": "MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE BY PROVIDING AN ABUSE-DETERRENT ORAL CONTROLLED RELEASE COMBINATION DRUG PRODUCT"
  },
  {
    "Code": "U-1922",
    "Definition": "INTRAVAGINAL PRASTERONE (DEHYDROEPIANDROSTERONE) AT A DAILY DOSE OF 6.5MG FOR THE TREATMENT OF DYSPAREUNIA, A SYMPTOM OF VULVAR AND VAGINAL ATROPHY, DUE TO MENOPAUSE"
  },
  {
    "Code": "U-1923",
    "Definition": "IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY BASAL INSULIN OR LIXISENATIDE BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE"
  },
  {
    "Code": "U-1924",
    "Definition": "KYPROLIS IS INDICATED IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY"
  },
  {
    "Code": "U-1925",
    "Definition": "USE OF AN AUTO INJECTOR TO ADMINISTER NALOXONE HCL"
  },
  {
    "Code": "U-1926",
    "Definition": "METHOD OF TREATING, REDUCING THE INCIDENCE OF, OR PREVENTING AN ISCHEMIC EVENT IN A PATIENT UNDERGOING PCI BY ADMINISTERING INTRAVENOUSLY 30 UG\/KG BOLUS BEFORE PCI AND CONTINUOUS INFUSION OF 4 UG\/KG\/MIN FOR AT LEAST 2 HOURS OR THE DURATION OF THE PCI"
  },
  {
    "Code": "U-1927",
    "Definition": "TREATMENT OF PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE PROGRESSED ON OR ARE INTOLERANT TO CRIZOTINIB"
  },
  {
    "Code": "U-1928",
    "Definition": "RUBRACA IS INDICATED AS MONOTHERAPY FOR THE TREATMENT OF PATIENTS WITH DELETERIOUS BRCA MUTATION (GERMLINE AND\/OR SOMATIC) ASSOCIATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH TWO OR MORE CHEMOTHERAPIES."
  },
  {
    "Code": "U-1929",
    "Definition": "TREATMENT OF DIABETES MELLITUS WITH AN INHALED INSULIN TO IMPROVE GLYCEMIC CONTROL USING A DRY POWDER INHALATION SYSTEM COMPRISING AN INHALER, A CARTRIDGE AND A DRY POWDER MEDICAMENT COMPRISING INSULIN IN A SINGLE INHALATION"
  },
  {
    "Code": "U-1930",
    "Definition": "METHOD OF AEROSOLIZING\/DEAGGLOMERATING AN INSULIN DRY POWDER FOR USE IN TREATING DIABETES MELLITUS VIA ORAL INHALATION USING AN INHALER WITH A CARTRIDGE CONTAINING THE INSULIN DRY POWDER."
  },
  {
    "Code": "U-1931",
    "Definition": "PROPHYLAXIS OR TREATMENT OF VENOUS AND ARTERIAL THROMBOTIC DISEASE"
  },
  {
    "Code": "U-1932",
    "Definition": "METHOD OF TREATING MILD TO MODERATE ATOPIC DERMATITIS."
  },
  {
    "Code": "U-1933",
    "Definition": "TREATMENT OF POSTOPERATIVE INFLAMMATION AND REDUCTION OF OCULAR PAIN IN PATIENTS WHO HAVE UNDERGONE CATARACT SURGERY"
  },
  {
    "Code": "U-1934",
    "Definition": "TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH A STRONG CYP1A2 INHIBITOR"
  },
  {
    "Code": "U-1935",
    "Definition": "REDUCTION OF THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION"
  },
  {
    "Code": "U-1936",
    "Definition": "TREATMENT OF MYOCARDIAL INFARCTION AND STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION"
  },
  {
    "Code": "U-1937",
    "Definition": "TREATMENT OF MYOCARDIAL INFARCTION IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION"
  },
  {
    "Code": "U-1938",
    "Definition": "TREATMENT OF STROKE IN PATIENTS WITH ACUTE CORONARY SYNDROME OR A HISTORY OF MYOCARDIAL INFARCTION"
  },
  {
    "Code": "U-1939",
    "Definition": "ADMINISTRATION ONCE DAILY WITHIN TWO HOURS AFTER WAKING IN THE MORNING FOR IMPROVEMENT OF GLYCEMIC CONTROL IN A TYPE 2 DIABETES PATIENT"
  },
  {
    "Code": "U-1940",
    "Definition": "IMPROVEMENT IN THE APPEARANCE OF MODERATE TO SEVERE CONVEXITY OR FULLNESS ASSOCIATED WITH SUBMENTAL FAT IN ADULTS BY MEANS OF REDUCING SUBMENTAL FAT VOLUME AS DESCRIBED IN THE APPROVED LABELING"
  },
  {
    "Code": "U-1941",
    "Definition": "TREATMENT OF INFANTILE-ONSET SPINAL MUSCULAR ATROPHY"
  },
  {
    "Code": "U-1942",
    "Definition": "TREATMENT OF SPINAL MUSCULAR ATROPHY BY INCREASING EXON-7 INCLUSION IN SMN2 MRNA"
  },
  {
    "Code": "U-1943",
    "Definition": "TREATMENT OF SPINAL MUSCULAR ATROPHY"
  },
  {
    "Code": "U-1944",
    "Definition": "TREATMENT OF SPINAL MUSCULAR ATROPHY BY INHIBITING AN SMN2 PRE-MRNA INTRONIC SPLICING SILENCER SITE"
  },
  {
    "Code": "U-1945",
    "Definition": "IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN."
  },
  {
    "Code": "U-1946",
    "Definition": "TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA"
  },
  {
    "Code": "U-1947",
    "Definition": "TREATMENT OF MARGINAL ZONE LYMPHOMA"
  },
  {
    "Code": "U-1948",
    "Definition": "A METHOD FOR TREATING CHRONIC MYELOID LEUKEMIA"
  },
  {
    "Code": "U-1949",
    "Definition": "FOR USE IN THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)"
  },
  {
    "Code": "U-1950",
    "Definition": "TREATMENT OF PATIENTS WITH ADVANCED (METASTATIC) NON-SMALL CELL LUNG CANCER WHOSE DISEASE PROGRESSED DURING OR AFTER PLATINUM-BASED CHEMOTHERAPY"
  },
  {
    "Code": "U-1951",
    "Definition": "TREATMENT OF ONYCHOMYCOSIS OF A TOENAIL"
  },
  {
    "Code": "U-1952",
    "Definition": "FOR USE IN THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA"
  },
  {
    "Code": "U-1953",
    "Definition": "REDUCE THE RISK OF STROKE IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS"
  },
  {
    "Code": "U-1954",
    "Definition": "TREATMENT OF DEEP VEIN THROMBOSIS WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS"
  },
  {
    "Code": "U-1955",
    "Definition": "TREATMENT OF PULMONARY EMBOLISM WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS"
  },
  {
    "Code": "U-1956",
    "Definition": "FOLLOWING INITIAL 6 MONTHS TREATMENT FOR DEEP VEIN THROMBOSIS (DVT) AND\/OR PULMONARY EMBOLISM (PE), REDUCTION IN THE RISK OF RECURRENCE OF DVT AND OF PE WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS"
  },
  {
    "Code": "U-1957",
    "Definition": "PROPHYLAXIS OF DEEP VEIN THROMBOSIS, WHICH MAY LEAD TO PULMONARY EMBOLISM IN PATIENTS UNDERGOING KNEE OR HIP REPLACEMENT SURGERY, WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST FIVE CONSECUTIVE DAYS"
  },
  {
    "Code": "U-1958",
    "Definition": "FOR THE TREATMENT OF GENOTYPE 1, 2, 3 OR 4 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION AS A COMPONENT OF A COMBINATION ANTIVIRAL TREATMENT REGIMEN WITH RIBAVIRIN"
  },
  {
    "Code": "U-1959",
    "Definition": "TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM"
  },
  {
    "Code": "U-1960",
    "Definition": "USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS"
  },
  {
    "Code": "U-1961",
    "Definition": "USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: ACUTE MONOTHERAPY OF MANIC OR MIXED EPISODES (AGES 10 TO ADULT)"
  },
  {
    "Code": "U-1962",
    "Definition": "USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: MAINTENANCE MONOTHERAPY IN ADULTS"
  },
  {
    "Code": "U-1963",
    "Definition": "USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: AS ADJUNCTIVE TREATMENT TO LITHIUM OR VALPROATE IN ADULTS"
  },
  {
    "Code": "U-1964",
    "Definition": "ELEVATION OF INTRACELLULAR CGMP RESULTING IN INCREASED INTESTINAL FLUID AND ACCELERATED TRANSIT"
  },
  {
    "Code": "U-1965",
    "Definition": "FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) IN COMBINATION WITH TADALAFIL, WHEREIN THE WEIGHT RATIO OF AMBRISENTAN TO TADALAFIL IS ABOUT 1:2 TO ABOUT 1:3"
  },
  {
    "Code": "U-1966",
    "Definition": "USE OF THE ATYPICAL ANTIPSYCHOTIC ASENAPINE FOR TREATMENT OF MANIC OR MIXED EPISODES OF BIPOLAR I DISORDER: ACUTE MONOTHERAPY OF MANIC OR MIXED EPISODES IN PEDIATRIC PATIENTS AGE 10-17"
  },
  {
    "Code": "U-1967",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH ONE OR MORE CONVENTIONAL ANTIHYPERGLYCEMIC AGENTS BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN"
  },
  {
    "Code": "U-1968",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES IN PATIENTS WHO HAVE NOT BEEN PREVIOUSLY TREATED WITH AN ANTIHYPERGLYCEMIC AGENT BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN"
  },
  {
    "Code": "U-1969",
    "Definition": "TOPICAL TREATMENT OF ONYCHOMYCOSIS OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES"
  },
  {
    "Code": "U-1970",
    "Definition": "TREATMENT OF ONYCHOMYCHOSIS OF A TOENAIL CAUSED BY TRICHOPHYTON RUBRUM OR TRICHOPHYTON MENTAGROPHYTES"
  },
  {
    "Code": "U-1971",
    "Definition": "FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA"
  },
  {
    "Code": "U-1972",
    "Definition": "FOR THE TREATMENT OF PATIENTS WITH INDOLENT B-CELL NON-HODGKIN LYMPHOMA"
  },
  {
    "Code": "U-1973",
    "Definition": "METHOD OF TREATING CYSTIC FIBROSIS USING N-(5-HYDROXY-2,4-DITERT-BUTYL-PHENYL)-4-OXO-1H-QUINOLINE-3-CARBOXAMIDE AND 3-(6-(1-2,2-DIFLUOROBENZO[D][1,3]DIOXOL-5-YL) CYCLOPROPANECARBOXAMIDO)-3-METHYLPYRIDIN-2-YL)BENZOIC ACID"
  },
  {
    "Code": "U-1974",
    "Definition": "TREATMENT OF HALLUCINATIONS AND DELUSIONS ASSOCIATED WITH PARKINSON'S DISEASE PSYCHOSIS"
  },
  {
    "Code": "U-1975",
    "Definition": "METHOD OF INCREASING EYELASH GROWTH WITH BIMATOPROST"
  },
  {
    "Code": "U-1976",
    "Definition": "METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO HAVE INADEQUATE CONTROL WITH DAPAGLIFLOZIN"
  },
  {
    "Code": "U-1977",
    "Definition": "METHOD FOR TREATING TYPE 2 DIABETES MELLITUS (T2DM) IN PATIENTS WHO ARE ALREADY TREATED WITH DAPAGLIFLOZIN AND SAXAGLIPTIN"
  },
  {
    "Code": "U-1978",
    "Definition": "TREATMENT OF ADVANCED PROSTATE CANCER WITH A REDUCED LIKELIHOOD OF CAUSING A GONADOTROPHIN RELEASING HORMONE AGONIST SIDE-EFFECT"
  },
  {
    "Code": "U-1979",
    "Definition": "THE TREATMENT OF CARCINOID SYNDROME DIARRHEA IN COMBINATION WITH SOMATOSTATIN ANALOG (SSA) THERAPY IN ADULTS INADEQUATELY CONTROLLED BY SSA THERAPY"
  },
  {
    "Code": "U-1980",
    "Definition": "A METHOD OF TREATING NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS"
  },
  {
    "Code": "U-1981",
    "Definition": "IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER-2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER"
  },
  {
    "Code": "U-1982",
    "Definition": "USE OF REVLIMID (LENALIDOMIDE) FOR TREATMENT OF PATIENTS WITH TRANSFUSION-DEPENDENT ANEMIA DUE TO LOW-OR INTERMEDIATE-1-RISK MYELODYSPLASTIC SYNDROMES ASSOCIATED WITH A DELETION 5Q ABNORMALITY WITH OR WITHOUT ADDITIONAL CYTOGENETIC ABNORMALITIES"
  },
  {
    "Code": "U-1983",
    "Definition": "USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MANTLE CELL LYMPHOMA WHOSE DISEASE HAS RELAPSED OR PROGRESSED AFTER TWO PRIOR THERAPIES, ONE OF WHICH INCLUDED BORTEZOMIB"
  },
  {
    "Code": "U-1984",
    "Definition": "USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE"
  },
  {
    "Code": "U-1985",
    "Definition": "USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, AS MAINTENANCE FOLLOWING AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTO-HSCT)"
  },
  {
    "Code": "U-1986",
    "Definition": "USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA, IN COMBINATION WITH DEXAMETHASONE, WHEREIN THOSE PATIENTS HAVE NOT RECEIVED PREVIOUS TREATMENT FOR MULTIPLE MYELOMA"
  },
  {
    "Code": "U-1987",
    "Definition": "METHOD OF CONTROLLING GLYCEMIA IN DIABETICS BY ADMINISTERING AN INITIAL DOSE OF INSULIN-FDKP WITH A MEAL; DETERMINING BLOOD GLUCOSE LEVEL 1-2 HRS AFTER AND ADMINISTERING A SUPPLEMENTAL DOSE OF INSULIN-FDKP IF POSTPRANDIAL GLUCOSE LEVEL IS >140 MG\/DL"
  },
  {
    "Code": "U-1988",
    "Definition": "METHOD TO TREAT INFANTILE HEMANGIOMA"
  },
  {
    "Code": "U-1989",
    "Definition": "INTRAVITREAL TREATMENT OF MACULAR EDEMA FOLLOWING BRANCH RETINAL VEIN OCCLUSION (BRVO) OR CENTRAL RETINAL VEIN OCCLUSION (CRVO)"
  },
  {
    "Code": "U-1990",
    "Definition": "INTRAVITREAL TREATMENT OF DIABETIC MACULAR EDEMA"
  },
  {
    "Code": "U-1991",
    "Definition": "REDUCTION OF MORTALITY IN ACUTE MYOCARDIAL INFARCTION"
  },
  {
    "Code": "U-1992",
    "Definition": "USE OF TROKENDI XR FOR PROPHYLACTIC TREATMENT OF MIGRAINE"
  },
  {
    "Code": "U-1993",
    "Definition": "ADJUNCTIVE TREATMENT TO LEVODOPA\/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE EXPERIENCING 'OFF' EPISODES"
  },
  {
    "Code": "U-1994",
    "Definition": "REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) IN ADULTS"
  },
  {
    "Code": "U-1995",
    "Definition": "TREATMENT OF TARDIVE DYSKINESIA"
  },
  {
    "Code": "U-1996",
    "Definition": "IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS"
  },
  {
    "Code": "U-1997",
    "Definition": "IMPROVEMENT OF GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND\/OR A PPAR-GAMMA AGONIST AND\/OR SULFONYLUREA AND\/OR INSULIN"
  },
  {
    "Code": "U-1998",
    "Definition": "TREATING HR-POS., HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER WITH PALBOCICLIB IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE BASED THERAPY IN POSTMENOPAUSAL WOMEN OR FULVESTRANT IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY"
  },
  {
    "Code": "U-1999",
    "Definition": "CHRONIC IDIOPATHIC CONSTIPATION"
  },
  {
    "Code": "U-2000",
    "Definition": "MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS"
  },
  {
    "Code": "U-2001",
    "Definition": "USE FOR THE TREATMENT OF ASTHMA IN PATIENTS 6 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-2002",
    "Definition": "USE FOR MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE"
  },
  {
    "Code": "U-2003",
    "Definition": "A METHOD OF POSITIONING AN INTRAUTERINE SYSTEM BY HOLDING AN INSERTER HANDLE WITH ONE HAND, ADVANCING THE INSERTER THROUGH THE CERVIX AND INTO THE UTERUS, AND RETRACTING A SLIDER ON THE HANDLE TO RELEASE THE INTRAUTERINE SYSTEM"
  },
  {
    "Code": "U-2004",
    "Definition": "REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH PARTIAL SEIZURES WITH COMPLEX SYMPTOMATOLOGY"
  },
  {
    "Code": "U-2005",
    "Definition": "REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH GENERALIZED TONIC-CLONIC SEIZURES"
  },
  {
    "Code": "U-2006",
    "Definition": "REPLACEMENT THERAPY FOR ORAL CARBAMAZEPINE IN ADULTS WITH MIXED SEIZURE PATTERNS THAT INCLUDE PARTIAL SEIZURES WITH COMPLEX SYMPTOMATOLOGY, GENERALIZED TONIC-CLONIC SEIZURES, OR OTHER PARTIAL OR GENERALIZED SEIZURES"
  },
  {
    "Code": "U-2007",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) WHO ARE FLT3 MUTATION-POSITIVE, IN COMBINATION WITH STANDARD CYTARABINE AND DAUNORUBICIN INDUCTION AND CYTARABINE CONSOLIDATION CHEMOTHERAPY"
  },
  {
    "Code": "U-2008",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), OR MAST CELL LEUKEMIA (MCL)"
  },
  {
    "Code": "U-2009",
    "Definition": "METHOD OF TREATING POSTMENOPAUSAL WOMEN WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE."
  },
  {
    "Code": "U-2010",
    "Definition": "ACUTE TREATMENT OF MIGRAINE BY DELIVERING A POWDERED SUBSTANCE COMPRISING SUMATRIPTAN VIA A BREATH-POWERED DELIVERY DEVICE"
  },
  {
    "Code": "U-2011",
    "Definition": "TREATMENT OF MIGRAINE VIA DELIVERY OF SUMATRIPTAN VIA THE NASAL CAVITY"
  },
  {
    "Code": "U-2012",
    "Definition": "A METHOD FOR TREATING OVARIAN CANCER BY ADMINISTERING RUCAPARIB, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION"
  },
  {
    "Code": "U-2013",
    "Definition": "TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)"
  },
  {
    "Code": "U-2014",
    "Definition": "A METHOD OF TREATING SECONDARY HYPERPARATHYROIDISM (SHPT)"
  },
  {
    "Code": "U-2015",
    "Definition": "SODIUM THIOSULFATE INJECTION IS INDICATED FOR SEQUENTIAL USE WITH SODIUM NITRITE FOR THE TREATMENT OF ACUTE CYANIDE POISONING"
  },
  {
    "Code": "U-2016",
    "Definition": "TREATMENT FOR ONYCHOMYCOSIS THAT IS TINEA UNGUIUM"
  },
  {
    "Code": "U-2017",
    "Definition": "TREATMENT OF OPIOID DEPENDENCE"
  },
  {
    "Code": "U-2018",
    "Definition": "MANAGEMENT OF MILD TO MODERATE PAIN, MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS IN A CRITICALLY ILL PATIENT WITH INTRAVENOUS IBUPROFEN IN NEED THEREOF"
  },
  {
    "Code": "U-2019",
    "Definition": "METHOD OF DELIVERING TO A PATIENT WITH DIABETES MELLITUS IN A SINGLE INHALATION, GREATER THAN 75% OF A DRY POWDER DOSE COMPRISING INSULIN AND FUMARYL DIKETOPIPERAZINE USING A HIGH RESISTANCE TO FLOW DRY POWDER INHALER."
  },
  {
    "Code": "U-2020",
    "Definition": "MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST"
  },
  {
    "Code": "U-2021",
    "Definition": "METHOD OF ADMINISTERING LEVETIRACETAM UNDER FASTED CONDITIONS"
  },
  {
    "Code": "U-2022",
    "Definition": "METHOD OF ADMINISTERING LEVETIRACETAM UNDER FED CONDITIONS"
  },
  {
    "Code": "U-2023",
    "Definition": "A METHOD OF INCREASING THE BIOAVAILABILITY OF GUAIFENESIN IN A SOLUTION CONTAINING 54% TO 66% BY WEIGHT OF PROPYLENE GLYCOL AND GLYCEROL, WHEREIN THE METHOD INCREASES THE CMAX BY AT LEAST 1.5 AND\/OR INCREASES THE AUC (0-INF) BY AT LEAST 1.4"
  },
  {
    "Code": "U-2024",
    "Definition": "METHOD FOR TRANSDERMALLY DELIVERING A DRUG TO A USER IN NEED THEREOF"
  },
  {
    "Code": "U-2025",
    "Definition": "TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER"
  },
  {
    "Code": "U-2026",
    "Definition": "TAFINLAR(R) IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST."
  },
  {
    "Code": "U-2027",
    "Definition": "TAFINLAR(R) IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST."
  },
  {
    "Code": "U-2028",
    "Definition": "TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY DESIGNATED SUSCEPTIBLE BACTERIA IN ADULTS"
  },
  {
    "Code": "U-2029",
    "Definition": "PREVENTING CONDITION CHARACTERIZED BY UNDESIRED THROMBOSIS"
  },
  {
    "Code": "U-2030",
    "Definition": "PROPHYLAXIS OF VENOUS THROMBOSIS"
  },
  {
    "Code": "U-2031",
    "Definition": "TAFINLAR IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST"
  },
  {
    "Code": "U-2032",
    "Definition": "TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST."
  },
  {
    "Code": "U-2033",
    "Definition": "MEKINIST IS INDICATED, AS A SINGLE AGENT OR IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS"
  },
  {
    "Code": "U-2034",
    "Definition": "INHIBITING COAGULATION"
  },
  {
    "Code": "U-2035",
    "Definition": "PROPHYLAXIS OF VENOUS THROMBOEMBOLISM"
  },
  {
    "Code": "U-2036",
    "Definition": "A METHOD OF TREATING PULMONARY HYPERTENSION COMPRISING PARENTERALLY ADMINISTERING A FORMULATION COMPRISING A) 0.1 TO 5% W\/V OF TREPROSTINIL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND B) A CITRATE BUFFER"
  },
  {
    "Code": "U-2037",
    "Definition": "MEKINIST IS INDICATED, AS A SINGLE AGENT OR IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST"
  },
  {
    "Code": "U-2038",
    "Definition": "MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION AS DETECTED BY AN FDA-APPROVED TEST"
  },
  {
    "Code": "U-2039",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1, 2, 3, 4, 5, OR 6 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING AN NS5A INHIBITOR"
  },
  {
    "Code": "U-2040",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH CHRONIC HCV INFECTION WHO HAVE GENOTYPE 1A OR 3 INFECTION AND HAVE PREVIOUSLY BEEN TREATED WITH AN HCV REGIMEN CONTAINING SOFOSBUVIR WITHOUT AN NS5A INHIBITOR"
  },
  {
    "Code": "U-2041",
    "Definition": "TREATMENT OF PARTIAL-ONSET SEIZURES"
  },
  {
    "Code": "U-2042",
    "Definition": "DISCONTINUING ADMINISTRATION OF FLUVOXAMINE TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE AND THEN ADMINISTERING PIRFENIDONE"
  },
  {
    "Code": "U-2043",
    "Definition": "EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY STAGE HER2-OVEREXPRESSED\/AMPLIFIED BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASE THERAPY"
  },
  {
    "Code": "U-2044",
    "Definition": "DOSE REDUCTION OF PIRFENIDONE BY ABOUT ONE HALF DURING CONCURRENT ADMINISTRATION OF CIPROFLOXACIN AT A DOSE OF 750 MG TWICE DAILY (1500 MG\/DAY) TO REDUCE DRUG INTERACTIONS IN TREATMENT OF A FIBROTIC, INFLAMMATORY, OR AUTOIMMUNE DISORDER"
  },
  {
    "Code": "U-2045",
    "Definition": "ADMINISTRATION OF PIRFENIDONE AND AVOIDING CONCURRENT ADMINISTRATION OF CIPROFLOXACIN AT A DOSE OF 750 MG TO REDUCE DRUG INTERACTIONS IN TREATMENT OF A FIBROTIC, INFLAMMATORY, OR AUTOIMMUNE DISORDER"
  },
  {
    "Code": "U-2046",
    "Definition": "ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT USE OF A CYP1A2 INHIBITOR THAT IS A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME SELECTED FROM CYP2C9, CYP2C19, AND CYP2D6"
  },
  {
    "Code": "U-2047",
    "Definition": "ADMINISTERING PIRFENIDONE CONCURRENTLY WITH FLUVOXAMINE, THE PIRFENIDONE AT A DOSE OF ABOUT 801 MG\/DAY TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE"
  },
  {
    "Code": "U-2048",
    "Definition": "ADMINISTERING PIRFENIDONE WHILE AVOIDING CO-ADMINISTRATION OF A STRONG CYP1A2 INHIBITOR TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE"
  },
  {
    "Code": "U-2049",
    "Definition": "DISCONTINUING ADMINISTRATION OF A STRONG CYP1A2 INHIBITOR TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE AND THEN ADMINISTERING PIRFENIDONE"
  },
  {
    "Code": "U-2050",
    "Definition": "ADMINISTERING PIRFENIDONE WHILE AVOIDING CO-ADMINISTRATION OF FLUVOXAMINE TO AVOID DRUG INTERACTIONS WITH PIRFENIDONE"
  },
  {
    "Code": "U-2051",
    "Definition": "DISCONTINUING SMOKING TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE"
  },
  {
    "Code": "U-2052",
    "Definition": "DISCONTINUING ADMINISTRATION OF A STRONG CYP1A2 INDUCER TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE"
  },
  {
    "Code": "U-2053",
    "Definition": "ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2, INCLUDING CIGARETTE SMOKE, TO AVOID REDUCED PIRFENIDONE EFFICACY"
  },
  {
    "Code": "U-2054",
    "Definition": "ADMINISTERING PIRFENIDONE WHILE AVOIDING CONCOMITANT ADMINISTRATION OF A STRONG INDUCER OF CYP1A2 TO AVOID REDUCED PIRFENIDONE EFFICACY"
  },
  {
    "Code": "U-2055",
    "Definition": "DOSING OF AT LEAST 1600 MG\/DAY FOLLOWING GRADE 2 LIVER ABNORMALITY IN BIOMARKER AST AND\/OR ALT AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF"
  },
  {
    "Code": "U-2056",
    "Definition": "DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND\/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-1600 MG\/DAY, FOLLOWING BY ADMINISTERING AT LEAST 1600 MG\/DAY IN TREATMENT OF IPF"
  },
  {
    "Code": "U-2057",
    "Definition": "DOSING 2403 MG\/DAY PIRFENIDONE FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND\/OR ALT AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF"
  },
  {
    "Code": "U-2058",
    "Definition": "DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND\/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400MG\/DAY DOSE, FOLLOWED BY ADMINISTERING 2403MG\/DAY IN TREATMENT OF IPF"
  },
  {
    "Code": "U-2059",
    "Definition": "DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND\/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, FOLLOWED BY FULL DAILY DOSE IN TREATMENT OF IPF"
  },
  {
    "Code": "U-2060",
    "Definition": "DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER AST AND\/OR ALT AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, THEN AT LEAST 1600MG\/DAY IN TREATMENT OF IPF"
  },
  {
    "Code": "U-2061",
    "Definition": "DOSING OF AT LEAST 1600 MG\/DAY FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF"
  },
  {
    "Code": "U-2062",
    "Definition": "DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-1600 MG\/DAY DOSE, FOLLOWED BY ADMINISTERING AT LEAST 1600 MG\/DAY DOSE IN TREATMENT OF IPF"
  },
  {
    "Code": "U-2063",
    "Definition": "DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY ADMINISTERING AT LEAST 1600 MG\/DAY IN TREATMENT OF IPF"
  },
  {
    "Code": "U-2064",
    "Definition": "DOSING AT LEAST 1602 MG\/DAY FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION"
  },
  {
    "Code": "U-2065",
    "Definition": "FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION"
  },
  {
    "Code": "U-2066",
    "Definition": "DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400 MG\/DAY DOSE, FOLLOWED BY FULL DAILY DOSE"
  },
  {
    "Code": "U-2067",
    "Definition": "DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE, FOLLOWED BY ADMINISTERING AT LEAST 1602 MG\/DAY"
  },
  {
    "Code": "U-2068",
    "Definition": "DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, FOLLOWED BY FULL DAILY DOSE"
  },
  {
    "Code": "U-2069",
    "Definition": "DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING A SUB-1600 MG\/DAY DOSE, FOLLOWED BY ADMINISTERING AT LEAST 1602 MG\/DAY"
  },
  {
    "Code": "U-2070",
    "Definition": "DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN BIOMARKER ALT OR AST AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS OF LIVER FUNCTION ARE WITHIN NORMAL LIMITS, THEN SUB-1600 MG\/DAY, THEN AT LEAST 1602 MG\/DAY"
  },
  {
    "Code": "U-2071",
    "Definition": "FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF"
  },
  {
    "Code": "U-2072",
    "Definition": "FULL DAILY DOSING FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF"
  },
  {
    "Code": "U-2073",
    "Definition": "DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY ADMINISTERING FULL DAILY DOSE IN TREATMENT OF IPF"
  },
  {
    "Code": "U-2074",
    "Definition": "DOSING 1602 MG\/DAY PIRFENIDONE FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION IN TREATMENT OF IPF"
  },
  {
    "Code": "U-2075",
    "Definition": "DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS FOLLOWED BY ADMINISTERING 1602 MG\/DAY IN TREATMENT OF IPF"
  },
  {
    "Code": "U-2076",
    "Definition": "DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING 801 MG\/DAY FOLLOWED BY ADMINISTERING 1602 MG\/DAY IN TREATMENT OF IPF"
  },
  {
    "Code": "U-2077",
    "Definition": "DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400 MG\/DAY DOSE THEN FULL DAY DAILY DOSE IN TREATMENT OF IPF"
  },
  {
    "Code": "U-2078",
    "Definition": "DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN LIMITS, THEN SUB-2400MG\/DAY DOSE, THEN FULL DAILY DOSE IN TREATMENT OF IPF"
  },
  {
    "Code": "U-2079",
    "Definition": "PIRFENIDONE DOSE ESCALATION REGIMEN FOR TREATMENT OF FIBROSIS AS 801 MG\/DAY FOR DAYS 1-7 OF THE REGIMEN, 1602 MG\/DAY FOR DAYS 8-14 OF THE REGIMEN, AND 2403 MG\/DAY FOR AT LEAST DAY 15 OF THE REGIMEN"
  },
  {
    "Code": "U-2080",
    "Definition": "PIRFENIDONE DOSE ESCALATION REGIMEN FOR TREATMENT OF IPF AS 801 MG\/DAY FOR DAYS 1-7 OF THE REGIMEN, 1602 MG\/DAY FOR DAYS 8-14 OF THE REGIMEN, AND 2403 MG\/DAY FOR AT LEAST DAY 15 OF THE REGIMEN"
  },
  {
    "Code": "U-2081",
    "Definition": "DISCONTINUING USE OF A CYP1A2 INHIBITOR THAT IS A MODERATE TO STRONG INHIBITOR OF BOTH CYP1A2 AND ANOTHER CYP ENZYME SELECTED FROM CYP2C9, CYP2C19, AND CYP2D6 AND THEN ADMINISTERING PIRFENIDONE"
  },
  {
    "Code": "U-2082",
    "Definition": "MODIFYING PIRFENIDONE ADMINISTRATION FROM A DOSE OF ABOUT 2400 MG\/DAY DOWNWARD BY ABOUT 1600 MG\/DAY WHILE CO-ADMINISTERING FLUVOXAMINE TO REDUCE DRUG INTERACTIONS WITH FLUVOXAMINE"
  },
  {
    "Code": "U-2083",
    "Definition": "DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, FOLLOWED BY 801 MG\/DAY, DOSE, THEN 1602 MG\/DAY IN TREATMENT OF IPF"
  },
  {
    "Code": "U-2084",
    "Definition": "TREATMENT OF SEVERE CHRONIC PAIN VIA INTRATHECAL INFUSION OF ZICONOTIDE IN PATIENTS ALSO RECEIVING MORPHINE"
  },
  {
    "Code": "U-2085",
    "Definition": "TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH RIFAMPIN"
  },
  {
    "Code": "U-2086",
    "Definition": "A METHOD FOR ADMINISTERING ESTRADIOL COMPRISING A MONOLITHIC TRANSDERMAL DRUG DELIVERY SYSTEM CONSISTING OF (I) A BACKING LAYER AND (II) A SINGLE ADHESIVE POLYMER MATRIX LAYER AS CLAIMED IN US PATENT NO. 9730900"
  },
  {
    "Code": "U-2087",
    "Definition": "TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) WITH AN ISOCITRATE DEHYDROGENASE-2 (IDH2) MUTATION"
  },
  {
    "Code": "U-2088",
    "Definition": "TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY"
  },
  {
    "Code": "U-2089",
    "Definition": "TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY"
  },
  {
    "Code": "U-2090",
    "Definition": "FOR THE TREATMENT OF ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)"
  },
  {
    "Code": "U-2091",
    "Definition": "TREATMENT OF METASTATIC ADENOCARCINOMA OF THE PANCREAS THAT HAS PROGRESSED ON GEMCITABINE-BASED THERAPY, IN COMBINATION WITH 5-FLUOROURACIL AND LEUCOVORIN, IN A PATIENT NOT HOMOZYGOUS FOR THE UGT1A1*28 ALLELE"
  },
  {
    "Code": "U-2092",
    "Definition": "METHOD FOR CONFIRMING DOSE DELIVERY"
  },
  {
    "Code": "U-2093",
    "Definition": "TREATMENT OF TYPE II SPINAL MUSCULAR ATROPHY"
  },
  {
    "Code": "U-2094",
    "Definition": "TREATMENT OF TYPE III SPINAL MUSCULAR ATROPHY"
  },
  {
    "Code": "U-2095",
    "Definition": "MITOSOL IS AN ANTIMETABOLITE INDICATED AS AN ADJUNCT TO AB EXTERNO GLAUCOMA SURGERY. IT IS INTENDED FOR TOPICAL APPLICATION TO THE SITE OF GLAUCOMA FILTRATION SURGERY"
  },
  {
    "Code": "U-2096",
    "Definition": "SOTYLIZE IS INDICATED FOR THE MAINTENANCE OF NORMAL SINUS RHYTHM [DELAY IN TIME TO RECURRENCE OF ATRIAL FIBRILLATION\/ATRIAL FLUTTER (AFIB\/AFL)] IN PATIENTS WITH SYMPTOMATIC AFIB\/AFL WHO ARE CURRENTLY IN SINUS RHYTHM"
  },
  {
    "Code": "U-2097",
    "Definition": "TREATMENT OF DMD IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING"
  },
  {
    "Code": "U-2098",
    "Definition": "INCREASING PRODUCTION OF FUNCTIONAL DYSTROPHIN PROTEIN IN DMD PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING"
  },
  {
    "Code": "U-2099",
    "Definition": "INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF AIRFLOW OBSTRUCTION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING BRONCHITIS AND\/OR EMPHYSEMA"
  },
  {
    "Code": "U-2100",
    "Definition": "INDICATED FOR THE ONCE-DAILY TREATMENT OF ASTHMA IN PATIENTS 18 YEARS AND OLDER"
  },
  {
    "Code": "U-2101",
    "Definition": "MAINTENANCE TREATMENT OF RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY"
  },
  {
    "Code": "U-2102",
    "Definition": "TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY BASED ON AN FDA-APPROVED COMPANION DIAGNOSTIC FOR LYNPARZA"
  },
  {
    "Code": "U-2103",
    "Definition": "MAINTENANCE TREATMENT OF BRCA-MUTATED RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY"
  },
  {
    "Code": "U-2104",
    "Definition": "TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A MEDICALLY APPROPRIATE DAILY DOSE OF ALLOPURINOL ALONE"
  },
  {
    "Code": "U-2105",
    "Definition": "TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING IMMEDIATE RELEASE LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS"
  },
  {
    "Code": "U-2106",
    "Definition": "TREATMENT OF DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS"
  },
  {
    "Code": "U-2107",
    "Definition": "TREATMENT OF LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA REFRACTORY TO RADIOACTIVE IODINE TREATMENT"
  },
  {
    "Code": "U-2108",
    "Definition": "TREATMENT OF HORMONE RECEPTOR POSITIVE HER2-NEGATIVE ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN NOT PREVIOUSLY TREATED WITH ENDOCRINE THERAPY"
  },
  {
    "Code": "U-2109",
    "Definition": "CAROSPIR IS INDICATED FOR TREATMENT OF NYHA CLASS III-IV HEART FAILURE AND REDUCED EJECTION FRACTION TO INCREASE SURVIVAL, MANAGE EDEMA, AND TO REDUCE THE NEED FOR HOSPITALIZATION FOR HEART FAILURE"
  },
  {
    "Code": "U-2110",
    "Definition": "METHOD FOR CHRONIC WEIGHT MANAGEMENT IN PATIENTS WITH MODERATE RENAL IMPAIRMENT WHO ARE OBESE, OR OVERWEIGHT AND HAVE AT LEAST ONE WEIGHT RELATED COMORBID CONDITION"
  },
  {
    "Code": "U-2111",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1-5 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1-5"
  },
  {
    "Code": "U-2112",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 6 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 6"
  },
  {
    "Code": "U-2113",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 7 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 7"
  },
  {
    "Code": "U-2114",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 9 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 9"
  },
  {
    "Code": "U-2115",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 10 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 10"
  },
  {
    "Code": "U-2116",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 12 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 12"
  },
  {
    "Code": "U-2117",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 14-15 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 14-15"
  },
  {
    "Code": "U-2118",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 16-18 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 16-18"
  },
  {
    "Code": "U-2119",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 19"
  },
  {
    "Code": "U-2120",
    "Definition": "TREATMENT OF PATIENTS 18 YEARS OF AGE AND OLDER WITH COMPLICATED URINARY TRACT INFECTIONS CAUSED BY SUSCEPTIBLE MICROORGANISMS"
  },
  {
    "Code": "U-2121",
    "Definition": "TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT SUFFERING FROM OR SUSCEPTIBLE TO ABSENCE SEIZURES"
  },
  {
    "Code": "U-2122",
    "Definition": "USE FOR REDUCING EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE"
  },
  {
    "Code": "U-2123",
    "Definition": "TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY WHO HAVE BEEN PREVIOUSLY TREATED WITH OXCARBAZEPINE"
  },
  {
    "Code": "U-2124",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA WHO HAVE RECEIVED AT LEAST TWO PRIOR SYSTEMIC THERAPIES"
  },
  {
    "Code": "U-2125",
    "Definition": "THE TREATMENT OF AN INFLAMMATORY DISORDER OF THE RESPIRATORY TRACT BY ONCE-PER-DAY ADMINISTRATION OF A PHARMACEUTICAL FORMULATION COMPRISING FLUTICASONE FUROATE AND A LONG-ACTING BETA2 ADRENORECEPTOR AGONIST"
  },
  {
    "Code": "U-2126",
    "Definition": "USE OF FLUTICASONE FUROATE FOR THE TREATMENT OF AN INFLAMMATORY OR ALLERGIC CONDITIONS, INCLUDING CHRONIC OBSTRUCTIVE PULMONARY DISEASE"
  },
  {
    "Code": "U-2127",
    "Definition": "INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND\/OR EMPHYSEMA"
  },
  {
    "Code": "U-2128",
    "Definition": "METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA INHALATION"
  },
  {
    "Code": "U-2129",
    "Definition": "METHOD OF INHIBITING THE BINDING OF ACETYLCHOLINE TO AN ACETYLCHOLINE RECEPTOR IN THE RESPIRATORY TRACT OF A HUMAN, COMPRISING CONTACTING THE RECEPTOR WITH AN EFFECTIVE AMOUNT OF UMECLIDINIUM, VIA TOPICAL APPLICATION"
  },
  {
    "Code": "U-2130",
    "Definition": "TREATMENT OF PARTIAL ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGED 16 YEARS AND OLDER WITH EPILEPSY"
  },
  {
    "Code": "U-2131",
    "Definition": "REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH COMPARABLE EFFICACY, AND A REDUCTION IN SPECIFIED ADVERSE EVENTS, COMPARED TO BRIMONIDINE 0.2% TID"
  },
  {
    "Code": "U-2132",
    "Definition": "IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY"
  },
  {
    "Code": "U-2133",
    "Definition": "METHOD OF DELIVERING FLUTICASONE PROPIONATE TO A NASAL AIRWAY"
  },
  {
    "Code": "U-2134",
    "Definition": "THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY ONCE-PER-DAY ADMINISTRATION OF A PHARMACEUTICAL FORMULATION COMPRISING FLUTICASONE FUROATE AND A LONG-ACTING BETA2 ADRENORECEPTOR"
  },
  {
    "Code": "U-2135",
    "Definition": "AS MONOTHERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY AND PRIOR CHEMOTHERAPY IN THE METASTATIC SETTING"
  },
  {
    "Code": "U-2136",
    "Definition": "TREATMENT OF NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY"
  },
  {
    "Code": "U-2137",
    "Definition": "TREATMENT OF POSTHERPETIC NEURALGIA"
  },
  {
    "Code": "U-2138",
    "Definition": "TOPICAL TREATMENT OF ACTINIC KERATOSIS OF THE FACE OR SCALP USING MORE THAN ONE TREATMENT COURSE OF INGENOL MEBUTATE"
  },
  {
    "Code": "U-2139",
    "Definition": "TREATMENT OF TYPE 2 DIABETES MELLITUS IN COMBINATION WITH EXENATIDE"
  },
  {
    "Code": "U-2140",
    "Definition": "METHOD OF TREATING PARTIAL ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-2141",
    "Definition": "TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6"
  },
  {
    "Code": "U-2142",
    "Definition": "REDUCTION IN THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS (DVT) AND\/OR PULMONARY EMBOLISM (PE) IN PATIENTS AT CONTINUED RISK FOR RECURRENT DVT AND\/OR AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS"
  },
  {
    "Code": "U-2143",
    "Definition": "AFTER COMPLETION OF INITIAL TREATMENT LASTING AT LEAST 6 MONTHS, TO REDUCE THE RISK OF RECURRENCE OF DEEP VEIN THROMBOSIS AND\/OR PULMONARY EMBOLISM IN CERTAIN PATIENTS WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS"
  },
  {
    "Code": "U-2144",
    "Definition": "REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION"
  },
  {
    "Code": "U-2145",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY"
  },
  {
    "Code": "U-2146",
    "Definition": "IMPROVEMENT IN GLYCEMIC CONTROL IN DIABETES MELLITUS PATIENTS BY USE OF A PEN INJECTOR WITH A ROTATING DRIVE SLEEVE"
  },
  {
    "Code": "U-2147",
    "Definition": "TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ORALLY ADMINISTERING 20MG OF TASIMELTEON ONCE DAILY BEFORE BEDTIME"
  },
  {
    "Code": "U-2148",
    "Definition": "A METHOD OF PROVIDING NITRIC OXIDE THERAPY TO A PATIENT BY MEASURING AND DISPLAYING AN INDICATION OF THE CALCULATED DELIVERY CONCENTRATION OF NITRIC OXIDE AS COMPARED TO THE DESIRED DELIVERY CONCENTRATION OF NITRIC OXIDE"
  },
  {
    "Code": "U-2149",
    "Definition": "TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON"
  },
  {
    "Code": "U-2150",
    "Definition": "TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE"
  },
  {
    "Code": "U-2151",
    "Definition": "METHOD OF TREATING PAIN OR INFLAMMATION WITH AN INJECTABLE CONTROLLED OR SUSTAINED RELEASE FORMULATION OF TRIAMCINOLONE ACETONIDE"
  },
  {
    "Code": "U-2152",
    "Definition": "TREATMENT OF PAIN ASSOCIATED WITH IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) WITH VIBERZI (ELUXADOLINE)"
  },
  {
    "Code": "U-2153",
    "Definition": "REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4"
  },
  {
    "Code": "U-2154",
    "Definition": "REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4"
  },
  {
    "Code": "U-2155",
    "Definition": "REDUCING BODY WEIGHT IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4"
  },
  {
    "Code": "U-2156",
    "Definition": "REDUCING HBA1C IN A HUMAN IN NEED THEREOF USING A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4"
  },
  {
    "Code": "U-2157",
    "Definition": "TREATING TYPE 2 DIABETES MELLITUS BY STIMULATING INSULIN RELEASE"
  },
  {
    "Code": "U-2158",
    "Definition": "DECREASING GASTRIC MOTILITY OR DELAYING GASTRIC EMPTYING BY USING A SUSTAINED-RELEASE COMPOSITION"
  },
  {
    "Code": "U-2159",
    "Definition": "TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA\/SMALL LYMPHOCYTIC LYMPHOMA"
  },
  {
    "Code": "U-2160",
    "Definition": "MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 5 MG OF MELOXICAM"
  },
  {
    "Code": "U-2161",
    "Definition": "TREATMENT OF NAUSEA AND VOMITING, INCLUDING THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY OR MODERATELY EMETOGENIC CANCER CHEMOTHERAPY"
  },
  {
    "Code": "U-2162",
    "Definition": "FOR CLEANSING THE LARGE INTESTINE AS A PREPARATION FOR COLONOSCOPY"
  },
  {
    "Code": "U-2163",
    "Definition": "TREATMENT OF HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER-2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN COMBINATION WITH PALBOCICLIB OR ABEMACICLIB IN WOMEN WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY"
  },
  {
    "Code": "U-2164",
    "Definition": "ZELBORAF IS INDICATED FOR THE TREATMENT OF PATIENTS WITH ERDHEIM-CHESTER DISEASE WITH BRAF V600 MUTATION"
  },
  {
    "Code": "U-2165",
    "Definition": "MANAGEMENT OF OSTEOARTHRITIS PAIN BY ADMINISTERING 10 MG OF MELOXICAM"
  },
  {
    "Code": "U-2166",
    "Definition": "TREATMENT OF MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER"
  },
  {
    "Code": "U-2167",
    "Definition": "METHOD OF USING A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER"
  },
  {
    "Code": "U-2168",
    "Definition": "METHOD OF USING A LOGIC CIRCUIT TO STABILIZE BATTERY VOLTAGE SUPPLIED TO A SENSOR EMBEDDED WITH A TABLET AND THAT COMMUNICATES INFORMATION VIA A SIGNAL THROUGH THE BODY OF A PATIENT TO A RECEIVER"
  },
  {
    "Code": "U-2169",
    "Definition": "METHOD OF USING A RECEIVER TO IDENTIFY A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT"
  },
  {
    "Code": "U-2170",
    "Definition": "METHOD OF USING A RECEIVER TO RECEIVE A SIGNAL FROM A TABLET EMBEDDED WITH A SENSOR THAT COMMUNICATES INFORMATION THROUGH THE BODY OF A PATIENT"
  },
  {
    "Code": "U-2171",
    "Definition": "ADJUVANT TREATMENT OF ADULT PATIENTS AT HIGH RISK OF RECURRENT RCC FOLLOWING NEPHRECTOMY"
  },
  {
    "Code": "U-2172",
    "Definition": "METHOD TO TREAT SEVERE ALLERGIC EMERGENCIES IN PATIENTS WEIGHING 7.5 TO 15 KG (16.5 TO 33 LBS)"
  },
  {
    "Code": "U-2173",
    "Definition": "TREATING OPIOID DEPENDENCE BY ADMINISTERING BUPRENORPHINE"
  },
  {
    "Code": "U-2174",
    "Definition": "TREATING OPIOID DEPENDENCY BY ADMINISTERING BUPRENORPHINE ONCE PER MONTH"
  },
  {
    "Code": "U-2175",
    "Definition": "TREATING OPIOID DEPENDENCY BY ADMINISTERING BUPRENORPHINE ONCE MONTHLY"
  },
  {
    "Code": "U-2176",
    "Definition": "TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE"
  },
  {
    "Code": "U-2177",
    "Definition": "TREATING OPIOID ADDICTION BY SUBCUTANEOUS INJECTION OF BUPRENORPHINE"
  },
  {
    "Code": "U-2178",
    "Definition": "TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE COMPOSITION WITH 28 DAY DOSE DURATION"
  },
  {
    "Code": "U-2179",
    "Definition": "IN SITU FORMATION OF SOLID BUPRENORPHINE COMPOSITION"
  },
  {
    "Code": "U-2180",
    "Definition": "TREATING ADDICTION WITH 100 MG OR 300 MG DOSE OF BUPRENORPHINE"
  },
  {
    "Code": "U-2181",
    "Definition": "TREATING OPIOID DEPENDENCY BY SUBCUTANEOUSLY ADMINISTERING BUPRENORPHINE"
  },
  {
    "Code": "U-2182",
    "Definition": "IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS"
  },
  {
    "Code": "U-2183",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 13"
  },
  {
    "Code": "U-2184",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1, 13, AND 14"
  },
  {
    "Code": "U-2185",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 15 AND 27"
  },
  {
    "Code": "U-2186",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 15, 27, AND 28"
  },
  {
    "Code": "U-2187",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 29 AND 39"
  },
  {
    "Code": "U-2188",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 29, 39, AND 40"
  },
  {
    "Code": "U-2189",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 41 AND 52"
  },
  {
    "Code": "U-2190",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 41, 52, AND 53"
  },
  {
    "Code": "U-2191",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 54 AND 64"
  },
  {
    "Code": "U-2192",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 54, 64, AND 65"
  },
  {
    "Code": "U-2193",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 66 AND 75"
  },
  {
    "Code": "U-2194",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 66, 75, AND 76"
  },
  {
    "Code": "U-2195",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 77 AND 87"
  },
  {
    "Code": "U-2196",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 77, 87, AND 88"
  },
  {
    "Code": "U-2197",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 89 AND 99"
  },
  {
    "Code": "U-2198",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 89, 99, AND 100"
  },
  {
    "Code": "U-2199",
    "Definition": "TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN ATTENTION FUNCTION IN SCHIZOPHRENIA"
  },
  {
    "Code": "U-2200",
    "Definition": "COMBINATION TREATMENT WITH INSULIN GLARGINE WITH OR WITHOUT METFORMIN FOR IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES MELLITUS PATIENTS"
  },
  {
    "Code": "U-2201",
    "Definition": "TREATMENT OF BIPOLAR DEPRESSION WITH IMPROVEMENT IN ATTENTION FUNCTION IN BIPOLAR DISORDER"
  },
  {
    "Code": "U-2202",
    "Definition": "OZEMPIC IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS"
  },
  {
    "Code": "U-2203",
    "Definition": "A METHOD OF PROVIDING A SUBJECT WITH A THERAPEUTICALLY EFFECTIVE AMOUNT OF RACEMIC METHYLPHENIDATE BY ORALLY ADMINISTERING TO SAID SUBJECT A SINGLE METHYLPHENIDATE EXTENDED RELEASE CHEWABLE TABLET AS CLAIMED"
  },
  {
    "Code": "U-2204",
    "Definition": "TREATING PATIENTS WITH ACUTE PROMYELOCYTIC LEUKEMIA (APL) WHO ARE REFRACTORY TO, OR HAVE RELAPSED FROM, RETINOID AND ANTHRACYCLINE CHEMOTHERAPY, AND WHOSE APL IS CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML\/RAR-ALPHA GENE EXPRESSION"
  },
  {
    "Code": "U-2205",
    "Definition": "TREATMENT OF SEBORRHEIC KERATOSES THAT ARE RAISED"
  },
  {
    "Code": "U-2206",
    "Definition": "TREATING OPIOID DEPENDENCY BY ADMINISTERING BUPRENORPHINE"
  },
  {
    "Code": "U-2207",
    "Definition": "TREATING ADDICTION BY SUBCUTANEOUS INJECTION OF BUPRENORPHINE"
  },
  {
    "Code": "U-2208",
    "Definition": "TREATING ADDICTION BY ONCE PER MONTH ADMINISTRATION OF BUPRENORPHINE"
  },
  {
    "Code": "U-2209",
    "Definition": "TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE ONCE PER MONTH"
  },
  {
    "Code": "U-2210",
    "Definition": "TREATING OPIOID ADDICTION BY 100 MG OR 300 MG DOSE BUPRENORPHINE"
  },
  {
    "Code": "U-2211",
    "Definition": "TREATING OPIOID ADDICTION BY ADMINISTRATION OF BUPRENORPHINE"
  },
  {
    "Code": "U-2212",
    "Definition": "REDUCING FASTING PLASMA GLUCOSE IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4"
  },
  {
    "Code": "U-2213",
    "Definition": "REDUCING HBA1C IN A HUMAN IN NEED THEREOF IN COMBINATION WITH A SUSTAINED-RELEASE COMPOSITION CONTAINING EXENDIN-4"
  },
  {
    "Code": "U-2214",
    "Definition": "AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES"
  },
  {
    "Code": "U-2215",
    "Definition": "ERTUGLIFLOZIN IN COMBINATION WITH SITAGLIPTIN AND IN FURTHER COMBINATION WITH METFORMIN AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS"
  },
  {
    "Code": "U-2216",
    "Definition": "ERTUGLIFLOZIN AND SITAGLIPTIN IN COMBINATION AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS"
  },
  {
    "Code": "U-2217",
    "Definition": "TREATING HIGH OUTPUT SHOCK WITH ANGIOTENSIN II BY INCREASING MEAN ARTERIAL PRESSURE IN PATIENTS TREATED WITH CATECHOLAMINES AND REDUCING CATECHOLAMINE USE"
  },
  {
    "Code": "U-2218",
    "Definition": "MAINTAINING MEAN ARTERIAL PRESSURE OF ABOUT 65 MMHG OR HIGHER WITH ANGIOTENSIN II IN SHOCK PATIENTS TREATED WITH CATECHOLAMINES AND REDUCING CATECHOLAMINE USE"
  },
  {
    "Code": "U-2219",
    "Definition": "TREATMENT OF CHRONIC SMALL LYMPHOCYTIC LEUKEMIA"
  },
  {
    "Code": "U-2220",
    "Definition": "A METHOD FOR THE DIAGNOSIS OF ADULT GROWTH HORMONE DEFICIENCY BY MEASURING THE LEVEL OF GROWTH HORMONE AFTER ORAL ADMINISTRATION OF MACIMORELIN"
  },
  {
    "Code": "U-2221",
    "Definition": "TREATING REFRACTORY HYPOTENSION WITH ABOUT 20 NG\/KG\/MIN ANGIOTENSIN II IN A PATIENT RECEIVING VASOPRESSOR"
  },
  {
    "Code": "U-2222",
    "Definition": "RELIEVES REDNESS OF THE EYE DUE TO MINOR EYE IRRITATIONS"
  },
  {
    "Code": "U-2223",
    "Definition": "METHOD OF TREATING ANGINA PECTORIS"
  },
  {
    "Code": "U-2224",
    "Definition": "TREATMENT OF DYSKINESIA AND INCREASING ON TIME WITHOUT TROUBLESOME DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS"
  },
  {
    "Code": "U-2225",
    "Definition": "METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN PATIENTS WITH HEPATIC IMPAIRMENT"
  },
  {
    "Code": "U-2226",
    "Definition": "METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN PATIENTS WITH RENAL IMPAIRMENT"
  },
  {
    "Code": "U-2227",
    "Definition": "METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES IN GERIATRIC PATIENTS"
  },
  {
    "Code": "U-2228",
    "Definition": "TREATMENT OF SMALL LYMPHOCYTIC LEUKEMIA"
  },
  {
    "Code": "U-2229",
    "Definition": "IN COMBINATION WITH TRETINOIN, TREATING ADULTS AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH NEWLY-DIAGNOSED LOW-RISK ACUTE PROMYELOCYTIC LEUKEMIA (APL) CHARACTERIZED BY THE PRESENCE OF THE T(15;17) TRANSLOCATION OR PML\/RAR-A GENE EXPRESSION"
  },
  {
    "Code": "U-2230",
    "Definition": "IRRITABLE BOWEL SYNDROME WITH CONSTIPATION"
  },
  {
    "Code": "U-2231",
    "Definition": "TREATING REFRACTORY HYPOTENSION WITH ABOUT 5 NG\/KG\/MIN TO ABOUT 20 NG\/KG\/MIN ANGIOTENSIN II IN A PATIENT RECEIVING VASOPRESSOR"
  },
  {
    "Code": "U-2232",
    "Definition": "TREATMENT OF PSORIATIC ARTHRITIS USING A DOSAGE TITRATION SCHEDULE"
  },
  {
    "Code": "U-2233",
    "Definition": "TREATMENT OF PSORIATIC ARTHRITIS WITH APREMILAST USING A DOSAGE TITRATION SCHEDULE AND A SECOND ACTIVE AGENT"
  },
  {
    "Code": "U-2234",
    "Definition": "USE OF IVACAFTOR FOR TREATING CYSTIC FIBROSIS IN A PATIENT WITH A MILD TO MODERATE CF PHENOTYPE WITH AT LEAST ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND\/OR IN VITRO ASSAY DATA"
  },
  {
    "Code": "U-2235",
    "Definition": "USE IN COMBINATION WITH PREDNISONE FOR THE TREATMENT OF PATIENTS WITH METASTATIC HIGH-RISK CASTRATION-SENSITIVE PROSTATE CANCER"
  },
  {
    "Code": "U-2236",
    "Definition": "REDUCING THE RISK OF PRETERM BIRTH IN WOMEN WITH A SINGLETON PREGNANCY WHO HAVE A HISTORY OF SINGLETON SPONTANEOUS PRETERM BIRTH"
  },
  {
    "Code": "U-2237",
    "Definition": "TREATMENT OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)"
  },
  {
    "Code": "U-2238",
    "Definition": "METHOD OF IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH DIABETES MELLITUS BY ADMINISTERING A MIXTURE OF INSULIN DEGLUDEC AND INSULIN ASPART DURING OR AROUND THE TIME OF THE LARGEST MEAL OF THE DAY"
  },
  {
    "Code": "U-2239",
    "Definition": "REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH A REDUCTION IN SPECIFIED ADVERSE EVENTS, COMPARED TO BRIMONIDINE 0.2% TID"
  },
  {
    "Code": "U-2240",
    "Definition": "REDUCTION OF ELEVATED INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH GLAUCOMA OR OCULAR HYPERTENSION, WITH COMPARABLE EFFICACY TO BRIMONIDINE 0.2% TID"
  },
  {
    "Code": "U-2241",
    "Definition": "TREATMENT OF SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION"
  },
  {
    "Code": "U-2242",
    "Definition": "TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION"
  },
  {
    "Code": "U-2243",
    "Definition": "TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA\/SMALL LYMPHOCYTIC LYMPHOMA WITH 17P DELETION"
  },
  {
    "Code": "U-2244",
    "Definition": "A METHOD OF TREATING BACTERIAL INFECTIONS IN HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP\/VABP) PATIENTS COMPRISING ADMINISTERING A BACTERICIDALLY EFFECTIVE AMOUNT OF AVIBACTAM SODIUM"
  },
  {
    "Code": "U-2245",
    "Definition": "A METHOD OF TREATING A BACTERIAL INFECTION IN HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP\/VABP) PATIENTS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AVIBACTAM SODIUM"
  },
  {
    "Code": "U-2246",
    "Definition": "TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVING AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR\/IVACAFTOR BASED ON IN VITRO DATA AND\/OR CLINICAL EVIDENCE"
  },
  {
    "Code": "U-2247",
    "Definition": "TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF PATIENTS WITH A MILD TO MODERATE CLINICAL PHENOTYPE OF CYSTIC FIBROSIS HAVING AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR\/IVACAFTOR BASED ON IN VITRO DATA AND\/OR CLINICAL EVIDENCE"
  },
  {
    "Code": "U-2248",
    "Definition": "TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HETEROZYGOUS FOR THE F508DEL MUTATION AND A SECOND MUTATION THAT IS RESPONSIVE TO TEZACAFTOR\/IVACAFTOR"
  },
  {
    "Code": "U-2249",
    "Definition": "MANAGEMENT OF ACUTE PAIN SEVERE ENOUGH TO REQUIRE AN OPIOID ANALGESIC AND FOR WHICH ALTERNATIVE TREATMENTS ARE INADEQUATE"
  },
  {
    "Code": "U-2250",
    "Definition": "DETECTION OF CARCINOMA IN THE BLADDER BY PHOTODYNAMIC CYSTOSCOPY"
  },
  {
    "Code": "U-2251",
    "Definition": "IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER"
  },
  {
    "Code": "U-2252",
    "Definition": "THE TREATMENT OF ACUTE OTITIS EXTERNA IN PATIENTS 6 MONTHS OF AGE AND OLDER DUE TO PSEUDOMONAS AERUGINOSA AND STAPHYLOCOCCUS AUREUS"
  },
  {
    "Code": "U-2253",
    "Definition": "PROPHYLACTIC TREATMENT OF NAUSEA AND VOMITING, INCLUDING PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED CHEMOTHERAPY"
  },
  {
    "Code": "U-2254",
    "Definition": "USE OF POMALIDOMIDE WITH DEXAMETHASONE FOR PATIENTS WITH MULTIPLE MYELOMA AFTER AT LEAST TWO PRIOR THERAPIES INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR AND DEMONSTRATED DISEASE PROGRESSION ON OR WITHIN 60 DAYS OF COMPLETING THE LAST THERAPY"
  },
  {
    "Code": "U-2255",
    "Definition": "TREATING SECONDARY HYPERPARATHYROIDISM IN CHRONIC KIDNEY DISEASE WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND THE SUSTAINED RELEASE IS OVER AT LEAST 10 HOURS"
  },
  {
    "Code": "U-2256",
    "Definition": "TREATING SECONDARY HYPERPARATHYROIDISM IN CHRONIC KIDNEY DISEASE WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND CMAX IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING"
  },
  {
    "Code": "U-2257",
    "Definition": "TREATING SHPT IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE SERUM PARATHYROID HORMONE LEVEL AND CHANGE IN SERUM CONCENTRATION OF CALCIFEDIOL IN DOSE INTERVAL IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING"
  },
  {
    "Code": "U-2258",
    "Definition": "TREATING SECONDARY HYPERPARATHYROIDISM IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND CMAX24HR\/C24HR IS REDUCED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING"
  },
  {
    "Code": "U-2259",
    "Definition": "TREATING SECONDARY HYPERPARATHYROIDISM IN CKD WITH SUSTAINED RELEASE CALCIFEDIOL TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL AND TMAX IS INCREASED COMPARED TO BOLUS IV INJECTION AND IMMEDIATE-RELEASE, ORAL DOSING"
  },
  {
    "Code": "U-2260",
    "Definition": "METHOD OF REDUCING THE RISK OF PERIPROCEDURAL MYOCARDIAL INFARCTION, AND STENT THROMBOSIS IN A PATIENT UNDERGOING PCI BY ADMINISTERING INTRAVENOUSLY 30 UG\/KG BOLUS BEFORE PCI AND THEN A CONTINUOUS INFUSION"
  },
  {
    "Code": "U-2261",
    "Definition": "MODIFIED DOSING REGIMEN FOR THE MANAGEMENT OF MILD TO MODERATE PAIN OR MANAGEMENT OF MODERATE TO SEVERE PAIN AS AN ADJUNCT TO OPIOID ANALGESICS"
  },
  {
    "Code": "U-2262",
    "Definition": "MODIFIED DOSING REGIMEN FOR THE REDUCTION OF FEVER"
  },
  {
    "Code": "U-2263",
    "Definition": "MODIFIED DOSING REGIMEN FOR THE MANAGEMENT OF MODERATE TO SEVERE PAIN WITH ADJUNCTIVE OPIOID ANALGESICS"
  },
  {
    "Code": "U-2264",
    "Definition": "METHODS OF TREATING PAIN, INFLAMMATION, FEVER, PATENT DUCTUS ARTERIOSIS WITH AQUEOUS COMPOSITION"
  },
  {
    "Code": "U-2265",
    "Definition": "PREVENTION OF NAUSEA AND VOMITING ASSOCIATED WITH HEC AND MEC IN ADULT AND PEDIATRIC PATIENTS"
  },
  {
    "Code": "U-2266",
    "Definition": "METHODS OF MAKING AQUEOUS COMPOSITION AND TREATING PAIN, INFLAMMATION, FEVER, PATENT DUCTUS ARTERIOSIS WITH AQUEOUS COMPOSITION"
  },
  {
    "Code": "U-2267",
    "Definition": "METHOD FOR RELIEVING THE PAIN ASSOCIATED WITH POST-HERPETIC NEURALGIA"
  },
  {
    "Code": "U-2268",
    "Definition": "DISCONTINUING A STRONG CYP1A2 INDUCER TO AVOID REDUCED PIRFENIDONE EFFICACY AND THEN ADMINISTERING PIRFENIDONE"
  },
  {
    "Code": "U-2269",
    "Definition": "DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY ADMINISTERING SUB-2400MG\/DAY DOSE THEN FULL DAILY DOSE IN TREATMENT OF IPF"
  },
  {
    "Code": "U-2270",
    "Definition": "DOSAGE MODIFICATION FOLLOWING GRADE 2 ABNORMALITY IN LIVER FUNCTION BIOMARKER AFTER PIRFENIDONE ADMINISTRATION, BY DISCONTINUING PIRFENIDONE UNTIL BIOMARKERS ARE WITHIN NORMAL LIMITS, THEN SUB-2400MG\/DAY DOSE, THEN FULL DAILY DOSE IN TREATMENT OF IPF"
  },
  {
    "Code": "U-2271",
    "Definition": "THERAPEUTIC TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER, SYMPTOMATIC BONE METASTASES AND NO KNOWN VISCERAL METASTATIC DISEASE"
  },
  {
    "Code": "U-2272",
    "Definition": "TREATMENT OF NASAL POLYPS IN PATIENTS >=18 YEARS OF AGE WHO HAVE HAD ETHMOID SINUS SURGERY USING A CORTICOSTEROID-ELUTING (MOMETASONE FUROATE) IMPLANT"
  },
  {
    "Code": "U-2273",
    "Definition": "A METHOD FOR TREATING EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION"
  },
  {
    "Code": "U-2274",
    "Definition": "MAINTAINING SERUM 25-HYDROXYVITAMIN D AT A LEVEL OF AT LEAST 30 NG\/ML WITH ORAL, SUSTAINED RELEASE 25-HYDROXYVITAMIN D"
  },
  {
    "Code": "U-2275",
    "Definition": "TREATING CYSTIC FIBROSIS PATIENTS AGES 12 AND OLDER, WHO ARE HOMOZYGOUS FOR F508DEL OR HAVE AT LEAST 1 CFTR GENE MUTATION RESPONSIVE TO TEZACAFTOR\/IVACAFTOR, WITH TEZACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS (<30% CRYSTALLINE) IVACAFTOR"
  },
  {
    "Code": "U-2276",
    "Definition": "METHOD OF TREATING CYSTIC FIBROSIS IN A PATIENT AGE 6 OR OLDER HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS (LESS THAN ABOUT 30% CRYSTALLINE) IVACAFTOR"
  },
  {
    "Code": "U-2277",
    "Definition": "IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY LIXISENATIDE"
  },
  {
    "Code": "U-2278",
    "Definition": "IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY LIXISENATIDE IN COMBINATION WITH METFORMIN"
  },
  {
    "Code": "U-2279",
    "Definition": "IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS INADEQUATELY CONTROLLED BY LIXISENATIDE IN COMBINATION WITH METFORMIN AND A SECOND ORAL ANTIDIABETIC DRUG"
  },
  {
    "Code": "U-2280",
    "Definition": "ADJUNCTIVE TREATMENT OF PATIENTS WITH TSC-ASSOCIATED PARTIAL-ONSET SEIZURES"
  },
  {
    "Code": "U-2281",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1"
  },
  {
    "Code": "U-2282",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 2 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 2"
  },
  {
    "Code": "U-2283",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 3-7 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 3-7"
  },
  {
    "Code": "U-2284",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 8 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 8"
  },
  {
    "Code": "U-2285",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 11 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 11"
  },
  {
    "Code": "U-2286",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 14 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 14"
  },
  {
    "Code": "U-2287",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 16-19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 16-19"
  },
  {
    "Code": "U-2288",
    "Definition": "TREATMENT OF TYPE 2 DIABETES MELLITUS WITH EXENATIDE AS AN ADD-ON TO BASIL INSULIN OR BASAL INSULIN PLUS METFORMIN THERAPY"
  },
  {
    "Code": "U-2289",
    "Definition": "TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19 DELETIONS OR EXON 21L858R MUTATIONS"
  },
  {
    "Code": "U-2290",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML\/MIN\/1.73 M2<=EGFR<60 ML\/MIN\/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN"
  },
  {
    "Code": "U-2291",
    "Definition": "REDUCTION OF THROMBOTIC CARDIOVASCULAR EVENTS IN PATIENTS WITH A HISTORY OF MYOCARDIAL INFARCTION (MI) OR WITH PERIPHERAL ARTERIAL DISEASE (PAD)"
  },
  {
    "Code": "U-2292",
    "Definition": "METHOD OF REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN"
  },
  {
    "Code": "U-2293",
    "Definition": "USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF CANCER CHEMOTHERAPY, INCLUDING, BUT NOT LIMITED TO, HIGHLY EMETOGENIC CHEMOTHERAPY"
  },
  {
    "Code": "U-2294",
    "Definition": "TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT"
  },
  {
    "Code": "U-2295",
    "Definition": "TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-2296",
    "Definition": "TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS, AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION"
  },
  {
    "Code": "U-2297",
    "Definition": "IMPROVEMENT OF GLYCEMIC CONTROL IN TYPE 2 DIABETES PATIENTS BY ADMINISTERING A STARTING DOSE OF 10 MCG FOR 14 DAYS AND INCREASING TO A MAINTENANCE DOSE OF 20 MCG ON DAY 15"
  },
  {
    "Code": "U-2298",
    "Definition": "TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS"
  },
  {
    "Code": "U-2299",
    "Definition": "TAFINLAR IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH BRAF V600E MUTATION"
  },
  {
    "Code": "U-2300",
    "Definition": "USE IN COMBINATION WITH THE MUSCARINIC ANTAGONIST SOLIFENACIN SUCCINATE FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY"
  },
  {
    "Code": "U-2301",
    "Definition": "USE IN COMBINATION WITH DEXAMETHASONE IN ADULTS FOR THE PREVENTION OF ACUTE AND DELAYED NAUSEA AND VOMITING ASSOCIATED WITH INITIAL AND REPEAT COURSES OF HIGHLY EMETOGENIC CANCER CHEMOTHERAPY"
  },
  {
    "Code": "U-2302",
    "Definition": "MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS,  AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION"
  },
  {
    "Code": "U-2303",
    "Definition": "MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION"
  },
  {
    "Code": "U-2304",
    "Definition": "MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION"
  },
  {
    "Code": "U-2305",
    "Definition": "MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC) WITH BRAF V600E MUTATION AND WITH NO SATISFACTORY LOCOREGIONAL TREATMENT OPTIONS"
  },
  {
    "Code": "U-2306",
    "Definition": "ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM"
  },
  {
    "Code": "U-2307",
    "Definition": "TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE"
  },
  {
    "Code": "U-2308",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH SHORT BOWEL SYNDROME WHO ARE DEPENDENT ON PARENTERAL SUPPORT"
  },
  {
    "Code": "U-2309",
    "Definition": "USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE PROCESSING SPEED, AN ASPECT OF COGNITIVE FUNCTION"
  },
  {
    "Code": "U-2310",
    "Definition": "FOR CLEANSING OF THE COLON IN PREPARATION FOR COLONOSCOPY IN ADULTS"
  },
  {
    "Code": "U-2311",
    "Definition": "TREATMENT OF HYPERURICEMIA ASSOCIATED WITH GOUT IN PATIENTS WHO HAVE NOT ACHIEVED TARGET SERUM URIC ACID LEVELS WITH A XANTHINE OXIDASE INHIBITOR ALONE"
  },
  {
    "Code": "U-2312",
    "Definition": "TREATMENT OF HYPERKALEMIA IN ADULTS"
  },
  {
    "Code": "U-2313",
    "Definition": "METHOD OF REDUCING THE RISK OF CARDIOVASCULAR DEATH, NON-FATAL MYOCARDIAL INFARCTION, AND\/OR NON-FATAL STROKE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND ESTABLISHED CARDIOVASCULAR DISEASE BY ADMINISTERING LIRAGLUTIDE"
  },
  {
    "Code": "U-2314",
    "Definition": "TREATMENT OF THROMBOCYTOPENIA IN AN ADULT PATIENT WITH CHRONIC LIVER DISEASE WHO IS SCHEDULED TO UNDERGO A PROCEDURE USING DOPTELET"
  },
  {
    "Code": "U-2315",
    "Definition": "TREATMENT OF MULTIPLE SCLEROSIS IN THE PEDIATRIC PATIENT POPULATION WITH 0.25 MG FINGOLIMOD"
  },
  {
    "Code": "U-2316",
    "Definition": "TREATMENT OF DYSPAREUNIA"
  },
  {
    "Code": "U-2317",
    "Definition": "TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY"
  },
  {
    "Code": "U-2318",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR\/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR"
  },
  {
    "Code": "U-2319",
    "Definition": "KYPROLIS IS INDICATED IN COMBINATION WITH DEXAMETHASONE OR WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY"
  },
  {
    "Code": "U-2320",
    "Definition": "KYPROLIS IS INDICATED AS A SINGLE AGENT FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE OR MORE LINES OF THERAPY"
  },
  {
    "Code": "U-2321",
    "Definition": "A METHOD OF APPLYING TRYPAN BLUE ONTO AN OUTER SURFACE OF THE ANTERIOR LENS CAPSULE TO FACILITATE REMOVAL OF THE LENS SUBSTANCE"
  },
  {
    "Code": "U-2322",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC)"
  },
  {
    "Code": "U-2323",
    "Definition": "TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY"
  },
  {
    "Code": "U-2324",
    "Definition": "FOR SECONDARY PREVENTION OF CARDIOVASCULAR AND CEREBROVASCULAR EVENTS IN PATIENTS AT RISK OF DEVELOPING ASPIRIN-ASSOCIATED GASTRIC ULCERS"
  },
  {
    "Code": "U-2325",
    "Definition": "EMERGENCY TREATMENT OF ALLERGIC REACTIONS (TYPE 1), INCLUDING ANAPHYLAXIS; A METHOD OF TREATING ALLERGIC REACTION, ANAPHYLAXIS, ANAPHYLACTIC SHOCK, OR COMBINATION THEREOF BY AN INJECTION OF AT LEAST ONE DOSAGE OF THE INJECTABLE LIQUID PHARMACEUTICAL"
  },
  {
    "Code": "U-2326",
    "Definition": "TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS"
  },
  {
    "Code": "U-2327",
    "Definition": "TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS, COMPRISING MONITORING A PATIENT'S SERUM SODIUM CONCENTRATION"
  },
  {
    "Code": "U-2328",
    "Definition": "METHOD OF USING PLAZOMICIN TO TREAT BACTERIAL INFECTIONS"
  },
  {
    "Code": "U-2329",
    "Definition": "METHOD OF ADMINISTERING A LOCAL ANESTHETIC PRIOR TO PERFORMING A DIAGNOSTIC OR SURGICAL PROCEDURE ON A SUBJECT WITH HEPATIC OR RENAL IMPAIRMENT"
  },
  {
    "Code": "U-2330",
    "Definition": "METHOD OF TREATING MELANOMA"
  },
  {
    "Code": "U-2331",
    "Definition": "INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA"
  },
  {
    "Code": "U-2332",
    "Definition": "INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA MEDIATED BY A B-RAF PROTEIN KINASE"
  },
  {
    "Code": "U-2333",
    "Definition": "INDICATED IN COMBINATION WITH ENCORAFENIB FOR THE TREATMENT OF MELANOMA WITH A BRAF MUTATION"
  },
  {
    "Code": "U-2334",
    "Definition": "TREATMENT OF MELANOMA WITH A BRAF MUTATION"
  },
  {
    "Code": "U-2335",
    "Definition": "TREATMENT OF MELANOMA"
  },
  {
    "Code": "U-2336",
    "Definition": "TREATMENT OF MELANOMA MEDIATED BY A B-RAF PROTEIN KINASE"
  },
  {
    "Code": "U-2337",
    "Definition": "INDICATED IN COMBINATION WITH BINIMETINIB FOR THE TREATMENT OF MELANOMA WITH A BRAF MUTATION"
  },
  {
    "Code": "U-2338",
    "Definition": "MAINTAINING MEAN ARTERIAL PRESSURE OF ABOUT 65 MMHG OR ABOVE WITH ABOUT 1 NG\/KG\/MIN TO ABOUT 40 NG\/KG\/MIN ANGIOTENSIN II IN HYPOTENSIVE PATIENTS TREATED WITH VASOPRESSIN OR A VASOPRESSIN ANALOGUE AND REDUCING VASOPRESSIN OR VASOPRESSIN ANALOGUE USE"
  },
  {
    "Code": "U-2339",
    "Definition": "USE OF A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN AND A BASIC AMINO ACID TO TREAT TYPE 2 DIABETES MELLITUS"
  },
  {
    "Code": "U-2340",
    "Definition": "TREATMENT OF POSTOPERATIVE INFLAMMATION"
  },
  {
    "Code": "U-2341",
    "Definition": "METHOD OF RECONSTITUTING A LYOPHILIZED LIPOSOMAL COMPOSITION FOR ADMINISTERING CYTARABINE AND DAUNORUBICIN TO TREAT ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)"
  },
  {
    "Code": "U-2342",
    "Definition": "METHOD OF ADMINISTERING A RECONSTITUTED LIPOSOMAL COMPOSITION CONTAINING CYTARABINE AND DAUNORUBICIN TO TREAT ADULTS WITH NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC)"
  },
  {
    "Code": "U-2343",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HETEROZYGOUS FOR F508DEL AND A SECOND CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR\/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR"
  },
  {
    "Code": "U-2344",
    "Definition": "TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC LIVER DISEASE WHO ARE SCHEDULED TO UNDERGO A PROCEDURE"
  },
  {
    "Code": "U-2345",
    "Definition": "TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC)"
  },
  {
    "Code": "U-2346",
    "Definition": "TREATMENT OF HUMAN SMALLPOX DISEASE CAUSED BY VARIOLA VIRUS IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 13 KG"
  },
  {
    "Code": "U-2347",
    "Definition": "TREATMENT OF TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT AND FOR WHOM METFORMIN THERAPY IS INAPPROPRIATE BY ADMINISTERING LINAGLIPTIN WITHOUT DOSE ADJUSTMENT"
  },
  {
    "Code": "U-2348",
    "Definition": "A METHOD FOR PREVENTION OF PREGNANCY"
  },
  {
    "Code": "U-2349",
    "Definition": "FOR ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 5 YEARS AND OLDER"
  },
  {
    "Code": "U-2350",
    "Definition": "A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS ACUTE MYELOGENOUS LEUKEMIA (AML)"
  },
  {
    "Code": "U-2351",
    "Definition": "TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) WITH AN IDH1 MUTATION"
  },
  {
    "Code": "U-2352",
    "Definition": "TREATMENT OF HIV-1 INFECTION IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS"
  },
  {
    "Code": "U-2353",
    "Definition": "TX OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENATES IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TX HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS"
  },
  {
    "Code": "U-2354",
    "Definition": "COMBINATION WITH OTHER ANTIRETROVIRALS (ATV) FOR TREATMENT OF HIV-1 IN ATV TREATMENT-EXPERIENCED PATIENTS 2 YEARS AND OLDER WITH EVIDENCE OF VIRAL REPLICATION AND HIV-1 STRAINS RESISTANT TO NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR AND OTHER ATV"
  },
  {
    "Code": "U-2355",
    "Definition": "IN COMBINATION WITH AN AROMATASE INHIBITOR FOR THE TREATMENT OF PRE\/PERIMENOPAUSAL OR POSTMENOPAUSAL WOMEN WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE-BASED THERAPY"
  },
  {
    "Code": "U-2356",
    "Definition": "IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER, AS INITIAL ENDOCRINE BASED THERAPY OR FOLLOWING DISEASE PROGRESSION ON ENDOCRINE THERAPY"
  },
  {
    "Code": "U-2357",
    "Definition": "METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)"
  },
  {
    "Code": "U-2358",
    "Definition": "TREATMENT OF PATIENTS WITH HORMONE RECEPTOR (HR)-NEGATIVE BREAST CANCER WITH DELETERIOUS OR SUSPECTED DELETERIOUS GBRCAM, HER2-NEGATIVE METASTATIC BREAST CANCER, WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING"
  },
  {
    "Code": "U-2359",
    "Definition": "TREATMENT OF PATIENTS WITH HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER WHO SHOULD HAVE BEEN TREATED WITH PRIOR ENDOCRINE THERAPY OR BE CONSIDERED INAPPROPRIATE FOR ENDOCRINE THERAPY"
  },
  {
    "Code": "U-2360",
    "Definition": "MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS"
  },
  {
    "Code": "U-2361",
    "Definition": "METHOD OF ADMINISTERING A GRANULATE FORMULATION OF 5-METHYL-1-PHENYL-2-(1H)-PYRIDONE AS RECITED IN CLAIM 1, TO TREAT IDIOPATHIC PULMONARY FIBROSIS"
  },
  {
    "Code": "U-2362",
    "Definition": "TREATMENT OF HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6"
  },
  {
    "Code": "U-2363",
    "Definition": "ADMINISTRATION OF RISPERIDONE"
  },
  {
    "Code": "U-2364",
    "Definition": "TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE IN ADULTS WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY"
  },
  {
    "Code": "U-2365",
    "Definition": "TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE IN ADULTS WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS"
  },
  {
    "Code": "U-2366",
    "Definition": "TREATMENT OF LIVER DISEASE THROUGH NUTRITION FOR PATIENTS UNDER THE AGE OF 12"
  },
  {
    "Code": "U-2367",
    "Definition": "USE FOR PATIENTS WITH PARENTERAL NUTRITION ASSOCIATED CHOLESTASIS OR PARENTERAL NUTRITION ASSOCIATED LIVER DISEASE"
  },
  {
    "Code": "U-2368",
    "Definition": "TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 9 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-2369",
    "Definition": "FOR THE TREATMENT OF GENOTYPE 1, 4, 5 OR 6 CHRONIC HEPATITIS C VIRUS (HCV) INFECTION"
  },
  {
    "Code": "U-2370",
    "Definition": "FOR TREATMENT-NAIVE GENOTYPE 1 PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION FOR A DURATION OF 8-WEEKS"
  },
  {
    "Code": "U-2371",
    "Definition": "THE TREATMENT OF FABRY PATIENTS"
  },
  {
    "Code": "U-2372",
    "Definition": "A METHOD OF REDUCING LEFT VENTRICULAR MASS INDEX (LVMI) IN A FABRY PATIENT BY ADMINISTERING MIGALASTAT"
  },
  {
    "Code": "U-2373",
    "Definition": "A METHOD OF REDUCING PODOCYTE GLOBOTRIAOSYLCERAMIDE (GL-3) IN A FABRY PATIENT BY ADMINISTERING MIGALASTAT"
  },
  {
    "Code": "U-2374",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND IVACAFTOR"
  },
  {
    "Code": "U-2375",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR FORM I AND IVACAFTOR"
  },
  {
    "Code": "U-2376",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS AND LESS THAN ABOUT 30% CRYSTALLINE IVACAFTOR"
  },
  {
    "Code": "U-2377",
    "Definition": "USE OF VITAL DYE FOR FACILITATING SURGICAL PROCEDURES FOR VITREO-RETINAL SURGERY"
  },
  {
    "Code": "U-2378",
    "Definition": "TREATMENT OF POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS"
  },
  {
    "Code": "U-2379",
    "Definition": "USE IN IDENTIFICATION OF INTRAOCULAR MEMBRANES TO FACILITATE REMOVAL DURING OPHTHALMIC SURGERY"
  },
  {
    "Code": "U-2380",
    "Definition": "TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS IN PATIENTS 18 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-2381",
    "Definition": "TREATMENT IN COMBINATION WITH A GNRH AGONIST OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)"
  },
  {
    "Code": "U-2382",
    "Definition": "TREATMENT IN COMBINATION WITH A GNRH AGONIST OF HIGH RISK NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)"
  },
  {
    "Code": "U-2383",
    "Definition": "METHOD OF CONTROLLING GLYCEMIA IN A DIABETIC PATIENT WITH DELAYED OR PROLONGED FOOD ABSORPTION BY ADMINISTERING 50 TO 75% OF A PREDETERMINED DOSE OF INSULIN-FDKP AT MEALTIME, AND ADMINISTERING REMAINDER OF DOSE 30-120 MINUTES AFTER BEGINNING OF MEAL"
  },
  {
    "Code": "U-2384",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 10"
  },
  {
    "Code": "U-2385",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1,10 AND 11"
  },
  {
    "Code": "U-2386",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 12 AND 19"
  },
  {
    "Code": "U-2387",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 12, 19 AND 20"
  },
  {
    "Code": "U-2388",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 21 AND 28"
  },
  {
    "Code": "U-2389",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 21, 28, AND 29"
  },
  {
    "Code": "U-2390",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 30 AND 41"
  },
  {
    "Code": "U-2391",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 30, 41, AND 42"
  },
  {
    "Code": "U-2392",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 43 AND 50"
  },
  {
    "Code": "U-2393",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 43, 50 AND 51"
  },
  {
    "Code": "U-2394",
    "Definition": "FOR USE IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS WITH NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY"
  },
  {
    "Code": "U-2395",
    "Definition": "FOR THE TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS WITH NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY"
  },
  {
    "Code": "U-2396",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE DOSAGE UNIT COMPRISING LUMACAFTOR AS RECITED IN CLAIM 1 OF US PATENT 8716338 AND IVACAFTOR"
  },
  {
    "Code": "U-2397",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 2-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE DOSAGE UNIT COMPRISING LUMACAFTOR AND IVACAFTOR AS RECITED IN CLAIM 1 OF US PATENT 9192606"
  },
  {
    "Code": "U-2398",
    "Definition": "TOPICAL TREATMENT OF PRIMARY AXILLARY HYPERHIDROSIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-2399",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 12 YEARS AND OLDER, WITH A F508DEL OR G551D CFTR GENE MUTATION AND A A455E, 2789+5G->A, OR 3849+10KBC->T MUTATION, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF U.S PATENT 10058546"
  },
  {
    "Code": "U-2400",
    "Definition": "REDUCING ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION"
  },
  {
    "Code": "U-2401",
    "Definition": "A METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS IN A PATIENT IN NEED OF SUCH TREATMENT, SAID METHOD COMPRISING ADMINISTERING TO SAID PATIENT AN EFFECTIVE AMOUNT OF A SUSPENSION ACCORDING TO CLAIM 1"
  },
  {
    "Code": "U-2402",
    "Definition": "TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INTRAMUSCULAR INJECTION"
  },
  {
    "Code": "U-2403",
    "Definition": "TREATMENT OF PSORIASIS USING A DOSAGE TITRATION SCHEDULE"
  },
  {
    "Code": "U-2404",
    "Definition": "METHOD OF DELIVERING SUMATRIPTAN TO A NASAL CAVITY"
  },
  {
    "Code": "U-2405",
    "Definition": "A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE"
  },
  {
    "Code": "U-2406",
    "Definition": "A METHOD FOR TREATING A PATIENT 9 YEARS OF AGE AND OLDER SUFFERING FROM AN INFLAMMATORY SKIN DISORDER OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE"
  },
  {
    "Code": "U-2407",
    "Definition": "A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE CRYSTALLINE SALT"
  },
  {
    "Code": "U-2408",
    "Definition": "A METHOD FOR TREATING A BACTERIAL INFECTION IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF SARECYCLINE HYDROCHLORIDE CRYSTALLINE SALT"
  },
  {
    "Code": "U-2409",
    "Definition": "A METHOD FOR TREATING ACNE IN INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS PATIENTS 9 YEARS OF AGE AND OLDER COMPRISING ADMINISTERING SARECYCLINE HYDROCHLORIDE IN 60 MG, 100 MG OR 150 MG EQUIVALENT DOSES"
  },
  {
    "Code": "U-2410",
    "Definition": "TREATMENT OF ADULT PATIENTS FOR WHOM TREATMENT WITH BOTH AMLODIPINE FOR HYPERTENSION AND CELECOXIB FOR OSTEOARTHRITIS ARE APPROPRIATE"
  },
  {
    "Code": "U-2411",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 12 YEARS OR OLDER WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE TABLET COMPRISING LUMACAFTOR AS RECITED IN CLAIM 1, 19, OR 21 OF U.S. PATENT NO. 10,076,513 AND IVACAFTOR"
  },
  {
    "Code": "U-2412",
    "Definition": "FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND\/OR SMALL LYMPHOCYTIC LEUKEMIA (SLL)"
  },
  {
    "Code": "U-2413",
    "Definition": "FOR THE TREATMENT OF PATIENTS WITH FOLLICULAR LYMPHOMA (FL)"
  },
  {
    "Code": "U-2414",
    "Definition": "TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN ADULTS AS PART OF A COMBINATION DRUG REGIMEN"
  },
  {
    "Code": "U-2415",
    "Definition": "TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN ADULTS AS PART OF A COMBINATION ANTIBACTERIAL DRUG REGIMEN"
  },
  {
    "Code": "U-2416",
    "Definition": "TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN ADULTS WITH CYSTIC FIBROSIS AS PART OF A COMBINATION DRUG REGIMEN"
  },
  {
    "Code": "U-2417",
    "Definition": "TREATING MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE IN NON-CYSTIC FIBROSIS ADULTS AS PART OF A COMBINATION ANTIBACTERIAL DRUG REGIMEN"
  },
  {
    "Code": "U-2418",
    "Definition": "METHOD OF ADMINISTERING TESTOSTERONE ENANTHATE SUBCUTANEOUSLY"
  },
  {
    "Code": "U-2419",
    "Definition": "METHOD OF OPERATING AN INJECTION DEVICE"
  },
  {
    "Code": "U-2420",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 12 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR\/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,081,621"
  },
  {
    "Code": "U-2421",
    "Definition": "USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME"
  },
  {
    "Code": "U-2422",
    "Definition": "USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME WHO HAVE BEEN PREVIOUSLY TREATED WITH CLOBAZAM"
  },
  {
    "Code": "U-2423",
    "Definition": "USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME WHO HAVE BEEN PREVIOUSLY TREATED WITH CLOBAZAM"
  },
  {
    "Code": "U-2424",
    "Definition": "USE IN COMBINATION WITH CLOBAZAM FOR TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME"
  },
  {
    "Code": "U-2425",
    "Definition": "USE FOR THE TREATMENT OF CONVULSIVE SEIZURES IN PATIENTS WITH DRAVET SYNDROME"
  },
  {
    "Code": "U-2426",
    "Definition": "USE FOR THE TREATMENT OF CONVULSIVE SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME"
  },
  {
    "Code": "U-2427",
    "Definition": "USE FOR THE TREATMENT OF DROP SEIZURES IN PATIENTS WITH DRAVET SYNDROME"
  },
  {
    "Code": "U-2428",
    "Definition": "TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY 4 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-2429",
    "Definition": "TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-2430",
    "Definition": "TREATMENT OF POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN AMYLOIDOSIS"
  },
  {
    "Code": "U-2431",
    "Definition": "TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS"
  },
  {
    "Code": "U-2432",
    "Definition": "LONG-TERM, MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"
  },
  {
    "Code": "U-2433",
    "Definition": "METHOD OF TREATING A BIOLOGICAL RHYTHM DISORDER, SUCH AS INSOMNIA"
  },
  {
    "Code": "U-2434",
    "Definition": "USE IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY"
  },
  {
    "Code": "U-2435",
    "Definition": "REDUCTION OF RISK OF MAJOR CARDIOVASCULAR EVENTS (CV DEATH, MI, AND STROKE) IN CHRONIC CAD OR PAD"
  },
  {
    "Code": "U-2436",
    "Definition": "USE IN THE TREATMENT OF MAJOR DEPRESSIVE DISORDER TO IMPROVE TREATMENT EMERGENT SEXUAL DYSFUNCTION (TESD) INDUCED BY PRIOR SEROTONIN REUPTAKE INHIBITOR TREATMENT"
  },
  {
    "Code": "U-2437",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BREAST CANCER SUSCEPTIBILITY GENE (BRCA)-MUTATED (GBRCAM) HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER"
  },
  {
    "Code": "U-2438",
    "Definition": "CARDIOVASCULAR OUTCOMES TRIAL OF LIRAGLUTIDE 1.8 MG IN PATIENTS WITH TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE"
  },
  {
    "Code": "U-2439",
    "Definition": "TREATMENT OF MENOPAUSE SYMPTOMS, INCLUDING VASOMOTOR SYMPTOMS"
  },
  {
    "Code": "U-2440",
    "Definition": "FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"
  },
  {
    "Code": "U-2441",
    "Definition": "REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS"
  },
  {
    "Code": "U-2442",
    "Definition": "USE FOR THE TREATMENT OF ATONIC SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME"
  },
  {
    "Code": "U-2443",
    "Definition": "USE FOR THE TREATMENT OF ATONIC SEIZURES IN PATIENTS WITH DRAVET SYNDROME"
  },
  {
    "Code": "U-2444",
    "Definition": "TREATMENT OF SUBJECTS HAVING BACTERIAL SKIN OR SKIN STRUCTURE INFECTION"
  },
  {
    "Code": "U-2445",
    "Definition": "TREATMENT IN COMBINATION WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULTS WHO ARE AGE 75 YEARS OR OLDER, OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY"
  },
  {
    "Code": "U-2446",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL), WITH OR WITHOUT 17P DELETION, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY"
  },
  {
    "Code": "U-2447",
    "Definition": "TREATMENT OF SEVERE HYPERTRIGLYCERIDEMIA (500 MG\/DL) IN ADULT PATIENTS AS AN ADJUNCT TO DIET"
  },
  {
    "Code": "U-2448",
    "Definition": "TREATMENT OF TRAVELERS' DIARRHEA CAUSED BY NON-INVASIVE STRAINS OF ESCHERICHIA COLI IN ADULTS"
  },
  {
    "Code": "U-2449",
    "Definition": "TREATMENT OF BACTERIAL SKIN AND SKIN STRUCTURE INFECTION"
  },
  {
    "Code": "U-2450",
    "Definition": "POSITRON EMISSION TOMOGRAPHY DIAGNOSTIC AGENT IN ADULTS WITH SUSPECTED PROSTATE CANCER RECURRENCE BASED ON ELEVATED BLOOD PROSTATE SPECIFIC ANTIGEN LEVELS FOLLOWING PRIOR TREATMENT"
  },
  {
    "Code": "U-2451",
    "Definition": "TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH CHRONIC IMMUNE (IDIOPATHIC) THROMBOCYTOPENIA (ITP)"
  },
  {
    "Code": "U-2452",
    "Definition": "COMBINATION WITH IMMUNOSUPPRESSIVE THERAPY FOR FIRST-LINE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS AND OLDER WITH SEVERE APLASTIC ANEMIA"
  },
  {
    "Code": "U-2453",
    "Definition": "TREATMENT OF FUNGAL INFECTIONS, INCLUDING BLASTOMYCOSIS, HISTOPLASMOSIS, AND ASPERGILLOSIS"
  },
  {
    "Code": "U-2454",
    "Definition": "USE FOR THE TREATMENT OF DROP SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME"
  },
  {
    "Code": "U-2455",
    "Definition": "USE IN COMBINATION WITH CLOBAZAM FOR TREATMENT OF DROP SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME"
  },
  {
    "Code": "U-2456",
    "Definition": "TREATMENT OF ACUTE MYELOID LEUKEMIA (AML)"
  },
  {
    "Code": "U-2457",
    "Definition": "REINITIATION OF SCHIZOPHRENIA TREATMENT FOLLOWING A MISSED DOSE MORE THAN 9 MONTHS AGO"
  },
  {
    "Code": "U-2458",
    "Definition": "REINITIATION OF SCHIZOPHRENIA TREATMENT FOLLOWING A MISSED DOSE 4-9 MONTHS AGO"
  },
  {
    "Code": "U-2459",
    "Definition": "TREATMENT OF DYSKINESIA AND DECREASING OFF TIME IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS"
  },
  {
    "Code": "U-2460",
    "Definition": "VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF CORONARY ARTERY BYPASS GRAFT IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY"
  },
  {
    "Code": "U-2461",
    "Definition": "VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF CARDIOVASCULAR BYPASS GRAFT AND VASCULATURE IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY"
  },
  {
    "Code": "U-2462",
    "Definition": "VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF VESSEL WITH ARTERIOVENOUS MALFORMATION IN VASCULAR,  GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY"
  },
  {
    "Code": "U-2463",
    "Definition": "VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION IN SURGICAL FLAPS IN VASCULAR,  GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY"
  },
  {
    "Code": "U-2464",
    "Definition": "VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF TRANSPLANTED ORGAN OR ATTACHED VESSEL IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY"
  },
  {
    "Code": "U-2465",
    "Definition": "VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF VESSEL GRAFT IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY"
  },
  {
    "Code": "U-2466",
    "Definition": "VISUALIZATION OF VESSELS, BLOOD FLOW AND TISSUE PERFUSION OF DONOR ORGAN OR ATTACHED VESSEL IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY"
  },
  {
    "Code": "U-2467",
    "Definition": "VISUALIZATION OF EXTRAHEPATIC BILIARY DUCT ATTACHED TO DONOR ORGAN IN PATIENTS 12 YEARS AND OLDER"
  },
  {
    "Code": "U-2468",
    "Definition": "VISUALIZATION OF EXTRAHEPATIC BILIARY DUCT ATTACHED TO TRANSPLANTED ORGAN IN PATIENTS 12 YEARS AND OLDER"
  },
  {
    "Code": "U-2469",
    "Definition": "METHOD OF TREATING CANCEROUS SOLID TUMORS"
  },
  {
    "Code": "U-2470",
    "Definition": "METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION"
  },
  {
    "Code": "U-2471",
    "Definition": "METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK FUSION GENE IN A PEDIATRIC PATIENT"
  },
  {
    "Code": "U-2472",
    "Definition": "METHOD OF TREATING NEUROBLASTOMA, GLIOMA, THYROID, AND BREAST CANCER SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION"
  },
  {
    "Code": "U-2473",
    "Definition": "METHOD OF TREATING CMN, IFS, HGG, DIPGS, PTC, SOFT TISSUE SARCOMA, AND SPINDLE CELL SARCOMA SOLID TUMORS EXHIBITING AN NTRK GENE FUSION IN A PEDIATRIC PATIENT WITH AN ORAL SOLUTION"
  },
  {
    "Code": "U-2474",
    "Definition": "METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION AFTER SURGICAL RESECTION"
  },
  {
    "Code": "U-2475",
    "Definition": "METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION IN A PEDIATRIC PATIENT"
  },
  {
    "Code": "U-2476",
    "Definition": "USE OF A DELIVERY DEVICE TO DELIVER A DOSE OF NALOXONE"
  },
  {
    "Code": "U-2477",
    "Definition": "TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH CYP1A2 STRONG INHIBITORS"
  },
  {
    "Code": "U-2478",
    "Definition": "METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA PRIOR TO PERFORMING A PROCEDURE ON, THROUGH, OR ADJACENT TO THE MUCOUS MEMBRANES"
  },
  {
    "Code": "U-2479",
    "Definition": "METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES"
  },
  {
    "Code": "U-2480",
    "Definition": "MAINTENANCE TREATMENT OF GBRCA- OR SBRCA-MUTATED ADVANCED EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY"
  },
  {
    "Code": "U-2481",
    "Definition": "TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATED ADVANCED OVARIAN CANCER WHO HAVE BEEN TREATED WITH THREE OR MORE PRIOR LINES OF CHEMOTHERAPY"
  },
  {
    "Code": "U-2482",
    "Definition": "TREATMENT OF HR-NEGATIVE, HER-2 NEGATIVE, GBRCA-MUTATED METASTATIC BREAST CANCER, WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING"
  },
  {
    "Code": "U-2483",
    "Definition": "TREATMENT OF HR-POSITIVE, HER-2 NEGATIVE, GBRCA-MUTATED METASTATIC BREAST CANCER, WHO HAVE BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING, AND WITH ENDOCRINE THERAPY OR ARE INAPPROPRIATE FOR ENDOCRINE THERAPY"
  },
  {
    "Code": "U-2484",
    "Definition": "INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH CARBIDOPA\/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES"
  },
  {
    "Code": "U-2485",
    "Definition": "INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE TREATED WITH CARBIDOPA\/LEVODOPA BY INHALATION OF LEVODOPA POWDER PARTICLES THROUGH A SINGLE BREATH ACTIVATED STEP"
  },
  {
    "Code": "U-2486",
    "Definition": "INTERMITTENT TREATMENT OF OFF EPISODES IN PATIENTS WITH PARKINSON'S DISEASE WITH A POWDER INHALER"
  },
  {
    "Code": "U-2487",
    "Definition": "DEXTENZA IS APPROVED FOR THE TREATMENT OF OCULAR PAIN FOLLOWING OPHTHALMIC SURGERY"
  },
  {
    "Code": "U-2488",
    "Definition": "TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC) WHO HAVE BEEN PREVIOUSLY TREATED WITH SORAFENIB"
  },
  {
    "Code": "U-2489",
    "Definition": "TREATMENT OF MODERATE TO SEVERE OPIOID USE DISORDER"
  },
  {
    "Code": "U-2490",
    "Definition": "TREATMENT OF COMPLICATED URINARY TRACT INFECTION (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, AND ENTEROBACTER CLOACAE SPECIES COMPLEX"
  },
  {
    "Code": "U-2491",
    "Definition": "A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE"
  },
  {
    "Code": "U-2492",
    "Definition": "A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER"
  },
  {
    "Code": "U-2493",
    "Definition": "A METHOD FOR TREATING INFLAMMATION AND\/OR OTHER DISORDERS IN AN EYE OF A PATIENT"
  },
  {
    "Code": "U-2494",
    "Definition": "INDICATED FOR THE TREATMENT OF VENTRICULAR ARRHYTHMIAS, SUCH AS SUSTAINED VENTRICULAR TACHYCARDIA, THAT IN THE JUDGEMENT OF THE PHYSICIAN ARE LIFE-THREATENING"
  },
  {
    "Code": "U-2495",
    "Definition": "VENTRICULAR FIBRILLATION"
  },
  {
    "Code": "U-2496",
    "Definition": "IMPROVEMENT IN GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY USE OF A PEN INJECTOR WITH A THREADED DRIVE SLEEVE"
  },
  {
    "Code": "U-2497",
    "Definition": "TREATMENT OF DRUG-INDUCED EXTRAPYRAMIDAL REACTION IN ADULT PATIENTS"
  },
  {
    "Code": "U-2498",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 12 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR\/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,206,877"
  },
  {
    "Code": "U-2499",
    "Definition": "METHOD OF REDUCING ADVERSE EFFECTS IN PATIENTS SUFFERING FROM EXCESSIVE DAYTIME SLEEPINESS AND\/OR CATAPLEXY IN NARCOLEPSY WHO ARE CONCOMITANTLY ADMINISTERED SODIUM OXYBATE AND DIVALPROEX SODIUM"
  },
  {
    "Code": "U-2500",
    "Definition": "USE OF A DELIVERY DEVICE TO DELIVER A BIOEQUIVALENT DOSE OF A NALOXONE COMPOSITION VIA A NEEDLE"
  },
  {
    "Code": "U-2501",
    "Definition": "TREATMENT OF PARTIAL-ONSET SEIZURES"
  },
  {
    "Code": "U-2502",
    "Definition": "TREATMENT OF TREATMENT-RESISTANT DEPRESSION IN ADULT IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT"
  },
  {
    "Code": "U-2503",
    "Definition": "TREATMENT OF ADULTS WITH METASTATIC GASTRIC OR GJA PREVIOUSLY TREATED WITH AT LEAST TWO PRIOR LINES OF CHEMOTHERAPY THAT INCLUDED A FLUOROPYRIMIDINE, A PLATINUM, EITHER A TAXANE OR IRINOTECAN, AND IF APPROPRIATE, HER2\/NEU-TARGETED THERAPY"
  },
  {
    "Code": "U-2504",
    "Definition": "TREATMENT OF HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER IN POSTMENOPAUSAL WOMEN IN COMBINATION WITH RIBOCICLIB AS INITIAL ENDOCRINE BASED THERAPY OR FOLLOWING DISEASE PROGRESSION ON ENDOCRINE THERAPY"
  },
  {
    "Code": "U-2505",
    "Definition": "TREATMENT OF PRE\/PERIMENOPAUSAL WOMEN WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER"
  },
  {
    "Code": "U-2506",
    "Definition": "METHOD OF TREATING TESTOSTERONE DEFICIENCY"
  },
  {
    "Code": "U-2507",
    "Definition": "METHOD OF TREATING ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) CAUSED BY DESIGNATED SUSCEPTIBLE BACTERIA"
  },
  {
    "Code": "U-2508",
    "Definition": "A METHOD OF TREATING BACTERIAL INFECTIONS IN COMPLICATED INTRA-ABDOMINAL INFECTION AND COMPLICATED URINARY TRACT INFECTION, INCLUDING PYELONEPHRITIS, PATIENTS COMPRISING ADMINISTERING A BACTERICIDALLY EFFECTIVE AMOUNT OF AVIBACTAM SODIUM"
  },
  {
    "Code": "U-2509",
    "Definition": "A METHOD OF TREATING A BACTERIAL INFECTION IN COMPLICATED INTRA-ABDOMINAL INFECTION (CIAI) AND COMPLICATED URINARY TRACT INFECTION (CUTI), INCLUDING PYELONEPHRITIS, PATIENTS COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF AVIBACTAM SODIUM"
  },
  {
    "Code": "U-2510",
    "Definition": "A METHOD FOR CONTRACEPTION COMPRISING THE STEP OF ORAL ADMINISTRATION A DOSAGE OF 20 MG TO 30 MG OF ULIPRISTAL ACETATE TO A WOMAN WITHIN 72 HOURS AND UP TO 120 HOURS AFTER AN UNPROTECTED INTERCOURSE"
  },
  {
    "Code": "U-2511",
    "Definition": "A METHOD OF TREATING MULTIPLE SCLEROSIS BY ADMINISTERING SIPONIMOD USING A TITRATION SCHEME TO REACH A MAINTENANCE DOSE"
  },
  {
    "Code": "U-2512",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR\/IVACAFTOR, WITH AN EFFECTIVE AMOUNT OF TEZACAFTOR AND IVACAFTOR"
  },
  {
    "Code": "U-2513",
    "Definition": "MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"
  },
  {
    "Code": "U-2514",
    "Definition": "MAINTENANCE TREATMENT OF BRONCHOSPASM ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"
  },
  {
    "Code": "U-2515",
    "Definition": "PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY IN POSTMENOPAUSAL WOMEN OR MEN, OR WITH FULVESTRANT IN PTS WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY"
  },
  {
    "Code": "U-2516",
    "Definition": "A METHOD FOR REDUCING SERUM GLUCOSE LEVELS IN ADULTS WITH TYPE 2 DIABETES MELLITUS"
  },
  {
    "Code": "U-2517",
    "Definition": "A METHOD FOR REDUCING SERUM GLUCOSE LEVELS IN ADULTS WITH TYPE 2 DIABETES MELLITUS"
  },
  {
    "Code": "U-2518",
    "Definition": "TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT HAS SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY"
  },
  {
    "Code": "U-2519",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY"
  },
  {
    "Code": "U-2520",
    "Definition": "TREATING MS WITH ORAL CLADRIBINE ACC. TO THE STEPS (I) INDUCTION PERIOD WITH ABOUT 1.7 MG\/KG-3.5 MG\/KG CLADRIBINE; (II) CLADRIBINE-FREE PERIOD OF ABOUT 8-10 MONTHS; (III) MAINTENANCE PERIOD WITH ABOUT 1.7 MG\/KG CLADRIBINE; (IV) CLADRIBINE-FREE PERIOD"
  },
  {
    "Code": "U-2521",
    "Definition": "TREATMENT OF MS WITH A TABLET WITH AN ADMIXTURE OF (A) AN AMORPHOUS INCLUSION COMPLEX OF CLADRIBINE AND HYDROXYPROPYL-B-CYCLODEXTRIN AND (B) AMORPHOUS FREE CLADRIBINE AND CYCLODEXTRIN AS A NON-INCLUSION COMPLEX, CLADRIBINE\/CYCLODEXTRIN 1:10-1:16 W\/W"
  },
  {
    "Code": "U-2522",
    "Definition": "TREATING RRMS OR SPMS WITH ORAL CLADRIBINE: (I) 2-4 MONTHS INDUCTION WITH 1.7 MG\/KG - 3.5 MG\/KG CLADRIBINE; (II) CLADRIBINE-FREE PERIOD OF ABOUT 8-10 MONTHS; (III) 2-4 MONTHS MAINTENANCE WITH ABOUT 1.7 MG\/KG CLADRIBINE; (IV) CLADRIBINE-FREE PERIOD"
  },
  {
    "Code": "U-2523",
    "Definition": "TREATMENT OF MS WITH AN ADMIXTURE OF (A) AN AMORPHOUS INCLUSION COMPLEX OF CLADRIBINE (2CDA) AND CYCLODEXTRIN AND (B) AMORPHOUS FREE 2CDA AND CYCLODEXTRIN AS A NON-INCLUSION COMPLEX, FORMULATED AS A SOLID ORAL FORM, W\/O SIGN. AMOUNTS OF CRYST. 2CDA"
  },
  {
    "Code": "U-2524",
    "Definition": "TREATMENT OF THE CARDIOMYOPATHY OF WILD TYPE OR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM)"
  },
  {
    "Code": "U-2525",
    "Definition": "TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY OR URGE INCONTINENCE"
  },
  {
    "Code": "U-2526",
    "Definition": "ACUTE TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E., SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENT'S USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-2527",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND\/OR IN VITRO ASSAY DATA"
  },
  {
    "Code": "U-2528",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS A R117H MUTATION IN THE CFTR GENE"
  },
  {
    "Code": "U-2529",
    "Definition": "TREATMENT OF A MODERATE MILD CLINICAL PHENOTYPE OF CF USING IVACAFTOR IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS ONE CFTR MUTATION RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND\/OR IN VITRO ASSAY DATA"
  },
  {
    "Code": "U-2530",
    "Definition": "TREATMENT OF CF IN A PATIENT AGE 6 MONTHS TO < 6 YEARS WHO HAS ONE CFTR MUTATION RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND\/OR IN VITRO ASSAY DATA USING A SOLID COMPOSITION COMPRISING AMORPHOUS (LESS THAN ABOUT 30% CRYSTALLINE) IVACAFTOR"
  },
  {
    "Code": "U-2531",
    "Definition": "TREATMENT OF CF IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND\/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 10272046"
  },
  {
    "Code": "U-2532",
    "Definition": "TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, OR 6 IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG"
  },
  {
    "Code": "U-2533",
    "Definition": "A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML)"
  },
  {
    "Code": "U-2534",
    "Definition": "A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)"
  },
  {
    "Code": "U-2535",
    "Definition": "USE IN COMBINATION WITH METHYLPREDNISOLONE FOR THE TREATMENT OF PATIENTS WITH PROSTATE CANCER"
  },
  {
    "Code": "U-2536",
    "Definition": "FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE"
  },
  {
    "Code": "U-2537",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)"
  },
  {
    "Code": "U-2538",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LEUKEMIA (SLL) IN COMBINATION WITH A GA101 ANTIBODY SUCH AS OBINUTUZUMAB FOR ONE OR MORE DOSING PERIODS, WHEREIN THE CLL OR SLL IS A CD20-EXPRESSING CANCER"
  },
  {
    "Code": "U-2539",
    "Definition": "IN COMBINATION WITH FULVESTRANT FOR TREATMENT OF POSTMENOPAUSAL WOMEN, AND MEN, WITH HR-POSITIVE, HER-2-NEGATIVE, PIK3CA-MUTATED, ADVANCED OR METASTATIC BREAST CANCER"
  },
  {
    "Code": "U-2540",
    "Definition": "TREATMENT OF HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER IN POSTMENOPAUSAL WOMEN"
  },
  {
    "Code": "U-2541",
    "Definition": "REDUCING THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION (MI), AND STROKE IN A PATIENT RECEIVING 75-100 MG ASPIRIN DAILY WITH A HISTORY OF MI BY ADMINISTERING 60 MG TICAGRELOR TWICE DAILY"
  },
  {
    "Code": "U-2542",
    "Definition": "REDUCING THE RATE OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN A PATIENT RECEIVING 75-100 MG ASPIRIN DAILY AND HAVING OR WHO HAD ACUTE CORONARY SYNDROME BY ADMINISTERING 60 MG TICAGRELOR TWICE DAILY"
  },
  {
    "Code": "U-2543",
    "Definition": "TREATMENT OF SCHIZOPHRENIA WITH CARIPRAZINE"
  },
  {
    "Code": "U-2544",
    "Definition": "TREATMENT OF ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER WITH CARIPRAZINE"
  },
  {
    "Code": "U-2545",
    "Definition": "TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR I DISORDER (BIPOLAR DEPRESSION) WITH CARIPRAZINE"
  },
  {
    "Code": "U-2546",
    "Definition": "USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND\/OR EMPHYSEMA"
  },
  {
    "Code": "U-2547",
    "Definition": "METHOD OF PROVIDING CONTRACEPTION IN A WOMAN HAVING A BMI OF 25 KG\/M2 OR MORE WITH RESULTANT LIMITED BLEEDING EVENTS PER TREATMENT CYCLE"
  },
  {
    "Code": "U-2548",
    "Definition": "TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA (OSA)"
  },
  {
    "Code": "U-2549",
    "Definition": "CONTROL OF SERUM PHOSPHORUS LEVELS"
  },
  {
    "Code": "U-2550",
    "Definition": "USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED FOLLICULAR LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT"
  },
  {
    "Code": "U-2551",
    "Definition": "USE OF REVLIMID (LENALIDOMIDE) FOR THE TREATMENT OF PREVIOUSLY TREATED MARGINAL ZONE LYMPHOMA IN COMBINATION WITH A RITUXIMAB PRODUCT"
  },
  {
    "Code": "U-2552",
    "Definition": "METHOD OF TREATING POSTPARTUM DEPRESSION"
  },
  {
    "Code": "U-2553",
    "Definition": "PREVENTION OF PREGNANCY IN FEMALES OF REPRODUCTIVE AGE"
  },
  {
    "Code": "U-2554",
    "Definition": "TREATMENT OF MILD TO MODERATE ACTIVE CROHN'S DISEASE INVOLVING THE ILEUM AND\/OR THE ASCENDING COLON"
  },
  {
    "Code": "U-2555",
    "Definition": "A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 G OF ELEMENTAL IRON"
  },
  {
    "Code": "U-2556",
    "Definition": "METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULTS WHO HAVE INTOLERANCE TO OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON ASSOCIATED WITH HEAVY UTERINE BLEEDING OR A GASTROINTESTINAL DISORDER BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE"
  },
  {
    "Code": "U-2557",
    "Definition": "A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 GRAMS OF ELEMENTAL IRON"
  },
  {
    "Code": "U-2558",
    "Definition": "TREATMENT OF PATIENTS WITH LOCALLY ADVANCED METASTATIC BREAST CANCER AFTER FAILURE OF PRIOR CHEMOTHERAPY"
  },
  {
    "Code": "U-2559",
    "Definition": "USE IN COMBINATION WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOR ADJUVANT TREATMENT OF PATIENTS WITH OPERABLE NODE-POSITIVE BREAST CANCER"
  },
  {
    "Code": "U-2560",
    "Definition": "TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER AFTER FAILURE OF PRIOR PLATINUM-BASED CHEMOTHERAPY"
  },
  {
    "Code": "U-2561",
    "Definition": "USE IN COMBINATION WITH CISPLATIN FOR TREATMENT OF UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITHOUT PRIOR CHEMOTHERAPY TREATMENT"
  },
  {
    "Code": "U-2562",
    "Definition": "TREATMENT OF PATIENTS WITH ANDROGEN INDEPENDENT (HORMONE REFRACTORY) METASTATIC PROSTATE CANCER IN COMBINATION WITH PREDNISONE"
  },
  {
    "Code": "U-2563",
    "Definition": "TREATMENT OF ADVANCED GASTRIC ADENOCARCINOMA IN COMBINATION WITH CISPLATIN AND FLUOROURACIL IN PATIENTS THAT HAVE NOT RECEIVED PRIOR CHEMOTHERAPY"
  },
  {
    "Code": "U-2564",
    "Definition": "TREATMENT OF PATIENTS WITH LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK IN COMBINATION WITH CISPLATIN AND FLUOROURACIL"
  },
  {
    "Code": "U-2565",
    "Definition": "TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA"
  },
  {
    "Code": "U-2566",
    "Definition": "TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA"
  },
  {
    "Code": "U-2567",
    "Definition": "ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS WITH 1% OXYMETAZOLINE HYDROCHLORIDE CREAM, WHERE THE PATIENT EXPERIENCES NO REBOUND OR WORSENING OF FACIAL ERYTHEMA POST-TREATMENT"
  },
  {
    "Code": "U-2568",
    "Definition": "TREATMENT OF HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)"
  },
  {
    "Code": "U-2569",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR\/IVACAFTOR, WITH AN EFFECTIVE AMOUNT OF TEZACAFTOR AND IVACAFTOR"
  },
  {
    "Code": "U-2570",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 6 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR\/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,206,877"
  },
  {
    "Code": "U-2571",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGES 6 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR ONE F508DEL MUTATION AND A CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR\/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,081,621"
  },
  {
    "Code": "U-2572",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER, WITH A F508DEL OR G551D CFTR GENE MUTATION AND A A455E, 2789+5G->, OR 3849+10KBC->T MUTATION, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF U.S. PATENT 10058546"
  },
  {
    "Code": "U-2573",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HETEROZYGOUS FOR F508DEL AND A SECOND CFTR MUTATION PREDICTED TO BE RESPONSIVE TO TEZACAFTOR\/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR"
  },
  {
    "Code": "U-2574",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 AND OLDER, WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR\/IVACAFTOR, WITH TEZACAFTOR AND IVACAFTOR"
  },
  {
    "Code": "U-2575",
    "Definition": "TREATING CYSTIC FIBROSIS PATIENTS AGES 6 AND OLDER, WHO ARE HOMOZYGOUS FOR F508DEL OR HAVE AT LEAST 1 CFTR GENE MUTATION RESPONSIVE TO TEZACAFTOR\/IVACAFTOR, WITH TEZACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS (<30% CRYSTALLINE) IVACAFTOR"
  },
  {
    "Code": "U-2576",
    "Definition": "TREATMENT OF COMMUNITY ACQUIRED BACTERIAL PNEUMONIA"
  },
  {
    "Code": "U-2577",
    "Definition": "TREATMENT OF THROMBOCYTOPENIA IN AN ADULT PATIENT WITH CHRONIC IMMUNE THROMBOCYTOPENIA WHO HAS HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT"
  },
  {
    "Code": "U-2578",
    "Definition": "TREATMENT OF THROMBOCYTOPENIA IN AN ADULT PATIENT WITH CHRONIC LIVER DISEASE WHO IS SCHEDULED TO UNDERGO A PROCEDURE"
  },
  {
    "Code": "U-2579",
    "Definition": "REDUCTION IN A SUBJECT'S RISK OF EXPERIENCING A BREAKTHROUGH OVERT HEPATIC ENCEPHALOPATHY (HE) EPISODE"
  },
  {
    "Code": "U-2580",
    "Definition": "A METHOD OF TREATING TYPE 2 DIABETES COMPRISING ADMINISTERING SEMAGLUTIDE ONCE WEEKLY IN A AMOUNT OF 1.0 MG TO A SUBJECT IN NEED THEREOF"
  },
  {
    "Code": "U-2581",
    "Definition": "TREATING HYPOTENSION WITH ABOUT 20 NG\/KG\/MIN TO ABOUT 40 NG\/KG\/MIN ANGIOTENSIN II IN A HUMAN SUBJECT HAVING SEPTIC SHOCK"
  },
  {
    "Code": "U-2582",
    "Definition": "FOR THE ORAL PREVENTION\/PROPHYLAXIS OF MALARIA IN ADULTS, COMPRISING A THREE-PHASE DOSING REGIMEN CONSISTING OF A LOADING\/INITIAL DOSE, A MAINTENANCE\/EXPOSURE DOSE, AND A TERMINAL\/POST-EXPOSURE DOSE"
  },
  {
    "Code": "U-2583",
    "Definition": "TREATMENT OF BACTERIAL VAGINOSIS IN ADULT WOMEN"
  },
  {
    "Code": "U-2584",
    "Definition": "XPOVIO IS INDICATED IN COMBINATION WITH DEXAMETHASONE TO TREAT RELAPSED OR REFRACTORY MULTIPLE MYELOMA (REFRACTORY TO AT LEAST AN ANTI-CD38 MAB, 2 PROTEASOME INHIBITORS AND 2 IMMUNOMODULATORY AGENTS) IN ADULTS WHO RECEIVED AT LEAST 4 PRIOR THERAPIES"
  },
  {
    "Code": "U-2585",
    "Definition": "TREATMENT OF PARENTERAL NUTRITION-ASSOCIATED CHOLESTASIS IN PATIENTS UNDER THE AGE OF 12"
  },
  {
    "Code": "U-2586",
    "Definition": "TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS, INCLUDING PYELONEPHRITIS (CUTI)"
  },
  {
    "Code": "U-2587",
    "Definition": "TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI)"
  },
  {
    "Code": "U-2588",
    "Definition": "AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AND METFORMIN"
  },
  {
    "Code": "U-2589",
    "Definition": "AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH BASAL INSULIN OR BASAL INSULIN PLUS METFORMIN"
  },
  {
    "Code": "U-2590",
    "Definition": "AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN, A SULFONYLUREA, A THIAZOLIDINEDIONE, OR COMBINATION OF ANY TWO OF THESE THERAPIES"
  },
  {
    "Code": "U-2591",
    "Definition": "LOWERING PLASMA GLUCAGON IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING EXENATIDE AS AN ADJUNCT TO DIET AND EXERCISE"
  },
  {
    "Code": "U-2592",
    "Definition": "IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE"
  },
  {
    "Code": "U-2593",
    "Definition": "IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG\/ML"
  },
  {
    "Code": "U-2594",
    "Definition": "REDUCING FASTING PLASMA GLUCOSE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG\/ML"
  },
  {
    "Code": "U-2595",
    "Definition": "REDUCING BODY WEIGHT IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG\/ML"
  },
  {
    "Code": "U-2596",
    "Definition": "REDUCING HBA1C IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION ONCE WEEKLY AS AN ADJUNCT TO DIET AND EXERCISE TO ACHIEVE A MEAN STEADY STATE PLASMA CONCENTRATION OF EXENATIDE AT LEAST 170 PG\/ML"
  },
  {
    "Code": "U-2597",
    "Definition": "AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH DAPAGLIFLOZIN AS ADD-ON TO METFORMIN"
  },
  {
    "Code": "U-2598",
    "Definition": "IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN INJECTABLE SUSTAINED RELEASE FORMULATION OF EXENATIDE AS AN ADJUNCT TO DIET AND EXERCISE"
  },
  {
    "Code": "U-2599",
    "Definition": "IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING AN EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE TO PROVIDE A RELEASE PROFILE HAVING A RATIO OF C-MAX TO C-AVG OF ABOUT 3 OR LESS"
  },
  {
    "Code": "U-2600",
    "Definition": "IMPROVING GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A PRE-MIXED EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE"
  },
  {
    "Code": "U-2601",
    "Definition": "STIMULATING INSULIN RELEASE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A PRE-MIXED EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE"
  },
  {
    "Code": "U-2602",
    "Definition": "DELAYING GASTRIC EMPTYING IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A PRE-MIXED EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE"
  },
  {
    "Code": "U-2603",
    "Definition": "METHOD OF TREATING IRON DEFICIENCY"
  },
  {
    "Code": "U-2604",
    "Definition": "TREATMENT OF SEVERE HYPOGLYCEMIA IN PATIENTS WITH DIABETES"
  },
  {
    "Code": "U-2605",
    "Definition": "TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION RESISTANT PROSTATE CANCER"
  },
  {
    "Code": "U-2606",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH SYMPTOMATIC TENOSYNOVIAL GIANT CELL TUMOR (TGCT) ASSOCIATED WITH SEVERE MORBIDITY OR FUNCTIONAL LIMITATIONS AND NOT AMENABLE TO IMPROVEMENT WITH SURGERY"
  },
  {
    "Code": "U-2607",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS"
  },
  {
    "Code": "U-2608",
    "Definition": "METHOD OF TREATING SCHIZOPHRENIA"
  },
  {
    "Code": "U-2609",
    "Definition": "A METHOD FOR INDUCING A REGIONAL ANAESTHESIA VIA INTRATHECAL ADMINISTRATION OF A PATENTED PRESERVATIVE FREE SOLUTION FOR INJECTION (WITH A SPECIFIC COMPOSITION, PH, OSMOLALITY AND DENSITY) CONTAINING 9-11 MG\/ML CHLOROPROCAINE HCL"
  },
  {
    "Code": "U-2610",
    "Definition": "TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS"
  },
  {
    "Code": "U-2611",
    "Definition": "TREATMENT OF COMPLICATED URINARY TRACT INFECTION IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS"
  },
  {
    "Code": "U-2612",
    "Definition": "TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN PATIENTS 10 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-2613",
    "Definition": "TREATMENT OF RELAPSING-REMITTING SCLEROSIS (MS)"
  },
  {
    "Code": "U-2614",
    "Definition": "TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA"
  },
  {
    "Code": "U-2615",
    "Definition": "TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD"
  },
  {
    "Code": "U-2616",
    "Definition": "TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO METHOTREXATE"
  },
  {
    "Code": "U-2617",
    "Definition": "TREATMENT OF ROS1-POSITIVE NON-SMALL CELL LUNG CANCER"
  },
  {
    "Code": "U-2618",
    "Definition": "TREATMENT OF SOLID TUMORS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION"
  },
  {
    "Code": "U-2619",
    "Definition": "TREATMENT OF ADULTS WITH COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA CAUSED BY SUSCEPTIBLE MICROORGANISMS"
  },
  {
    "Code": "U-2620",
    "Definition": "USE OF NINTEDANIB FOR SLOWING THE RATE OF DECLINE IN PULMONARY FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD)"
  },
  {
    "Code": "U-2621",
    "Definition": "MODIFIED DOSING REGIMEN FOR THE MANAGEMENT OF MILD TO MODERATE PAIN"
  },
  {
    "Code": "U-2622",
    "Definition": "TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 2 YEARS AND OLDER"
  },
  {
    "Code": "U-2623",
    "Definition": "A METHOD OF REDUCING OFF TIME FROM L-DOPA THERAPY, COMPRISING ADMINISTERING, TO A HUMAN PATIENT WITH PARKINSON'S DISEASE, AN EFFECTIVE AMOUNT OF ISTRADEFYLLINE, WHEREIN THE PATIENT CURRENTLY RECEIVES SAID L-DOPA THERAPY"
  },
  {
    "Code": "U-2624",
    "Definition": "TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC)"
  },
  {
    "Code": "U-2625",
    "Definition": "TOPICAL TREATMENT OF PLAQUE PSORIASIS IN ADULTS"
  },
  {
    "Code": "U-2626",
    "Definition": "METHOD OF TREATING IRRITABLE BOWEL SYNDROME WITH CONSTIPATION BY ADMINISTERING TENAPANOR"
  },
  {
    "Code": "U-2627",
    "Definition": "TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 12 YEARS AND OLDER"
  },
  {
    "Code": "U-2628",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS"
  },
  {
    "Code": "U-2629",
    "Definition": "TREATMENT OF HIV-1 INFECTION IN ADULT PATIENTS AS A REPLACEMENT THERAPY IN VIROLOGICALLY SUPPRESSED ADULTS WITH NO HISTORY OF TREATMENT FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED WITH RESISTANCE TO THE INDIVIDUAL COMPONENTS OF DELSTRIGO"
  },
  {
    "Code": "U-2630",
    "Definition": "FOR USE IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 AS A REPLACEMENT THERAPY IN VIROLOGICALLY SUPPRESSED ADULTS WITH NO HISTORY OF TREATMENT FAILURE AND NO KNOWN SUBSTITUTIONS ASSOCIATED WITH RESISTANCE TO DORAVIRINE"
  },
  {
    "Code": "U-2631",
    "Definition": "TREATMENT OF COMPLICATED URINARY TRACT INFECTION"
  },
  {
    "Code": "U-2632",
    "Definition": "REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS"
  },
  {
    "Code": "U-2633",
    "Definition": "TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER, PROGRESSED ON: CRIZOTINIB + AT LEAST 1 OTHER ALK INHIBITOR FOR METASTATIC DISEASE; OR ALECTINIB, OR CERITINIB AS FIRST ALK INHIBITOR FOR METASTATIC DISEASE."
  },
  {
    "Code": "U-2634",
    "Definition": "METHOD OF TREATMENT IN PATIENTS WITH CONCOMITANT ANGIOEDEMA"
  },
  {
    "Code": "U-2635",
    "Definition": "TREATMENT OF ACUTE URTICARIA"
  },
  {
    "Code": "U-2636",
    "Definition": "METHOD OF INCREASING PEAK PLASMA OR ONSET OF PLASMA CONCENTRATION BY INTRAVENOUS INJECTION IN INDIVIDUALS IN NEED OF TREATMENT FOR ACUTE URTICARIA"
  },
  {
    "Code": "U-2637",
    "Definition": "TREATMENT OF PATIENTS WITH AN OVERACTIVE BLADDER WITH SYMPTOMS OF URINARY FREQUENCY, URGENCY, OR URGE INCONTINENCE WITH A SINGLE UNIT DOSE OF 10% OXYBUTYNIN CHLORIDE GEL"
  },
  {
    "Code": "U-2638",
    "Definition": "INCREASE PAIN-FREE LIGHT EXPOSURE IN ADULT PATIENTS WITH A HISTORY OF PHOTOTOXIC REACTIONS FROM ERYTHROPOIETIC PROTOPORPHYRIA (EPP)"
  },
  {
    "Code": "U-2639",
    "Definition": "METHOD OF ACTIVATING RARGAMMA RECEPTOR"
  },
  {
    "Code": "U-2640",
    "Definition": "PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS AT RISK FOR THROMBOEMBOLIC COMPLICATIONS NOT AT HIGH RISK OF BLEEDING"
  },
  {
    "Code": "U-2641",
    "Definition": "PROPHYLAXIS OF VENOUS THROMBOEMBOLISM IN ACUTELY ILL MEDICAL PATIENTS AT RISK FOR THROMBOEMBOLIC COMPLICATIONS NOT AT HIGH RISK OF BLEEDING WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS"
  },
  {
    "Code": "U-2642",
    "Definition": "METHOD OF TREATING CANCER BY DETECTING A CREATININE CLEARANCE OF A PATIENT AND ADMINISTERING LONSURF"
  },
  {
    "Code": "U-2643",
    "Definition": "TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS 65 YEARS OF AGE OR OLDER AND SYMPTOMS THEREOF"
  },
  {
    "Code": "U-2644",
    "Definition": "TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULTS 65 YEARS OF AGE OR OLDER"
  },
  {
    "Code": "U-2645",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR"
  },
  {
    "Code": "U-2646",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE ONE F508DEL MUTATION AND ONE R117H MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR"
  },
  {
    "Code": "U-2647",
    "Definition": "TREATMENT OF NON-NODULAR ACNE VULGARIS"
  },
  {
    "Code": "U-2648",
    "Definition": "TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR"
  },
  {
    "Code": "U-2649",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH A COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR; AND ANOTHER COMPOSITION COMPRISING IVACAFTOR"
  },
  {
    "Code": "U-2650",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE USING A SOLID COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AMORPHOUS IVACAFTOR, AND LESS THAN ABOUT 30% CRYSTALLINE IVACAFTOR"
  },
  {
    "Code": "U-2651",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR"
  },
  {
    "Code": "U-2652",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US 10081621"
  },
  {
    "Code": "U-2653",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH AN EFFECTIVE AMOUNT OF ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR"
  },
  {
    "Code": "U-2654",
    "Definition": "TREATMENT OF REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE"
  },
  {
    "Code": "U-2655",
    "Definition": "A METHOD OF TREATMENT OF ADVANCED OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER ASSOCIATED WITH HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD) POSITIVE STATUS"
  },
  {
    "Code": "U-2656",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS"
  },
  {
    "Code": "U-2657",
    "Definition": "TREATMENT OF PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS WHO ARE CANDIDATES FOR PHOTOTHERAPY OR SYSTEMIC THERAPY"
  },
  {
    "Code": "U-2658",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCET'S DISEASE"
  },
  {
    "Code": "U-2659",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCET'S DISEASE USING A DOSAGE TITRATION SCHEDULE"
  },
  {
    "Code": "U-2660",
    "Definition": "TREATMENT OF H. PYLORI INFECTION IN ADULTS"
  },
  {
    "Code": "U-2661",
    "Definition": "CHRONIC WEIGHT MANAGEMENT IN ADULT PATIENTS USING AN EXTENDED RELEASE TABLET CONTAINING LORCARSERIN HYDROCHLORIDE HEMIHYDRATE"
  },
  {
    "Code": "U-2662",
    "Definition": "USE OF CALCIPOTRIENE FOAM FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS AGED 4 YEARS AND OLDER"
  },
  {
    "Code": "U-2663",
    "Definition": "USE IN SONOHYSTEROSALPINOGRAPHY TO ASSESS FALLOPIAN TUBE PATENCY"
  },
  {
    "Code": "U-2664",
    "Definition": "TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING BY INDUCING SKIPPING OF EXON 51"
  },
  {
    "Code": "U-2665",
    "Definition": "TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY"
  },
  {
    "Code": "U-2666",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA"
  },
  {
    "Code": "U-2667",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA"
  },
  {
    "Code": "U-2668",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB"
  },
  {
    "Code": "U-2669",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED SMALL LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB"
  },
  {
    "Code": "U-2670",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA"
  },
  {
    "Code": "U-2671",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB"
  },
  {
    "Code": "U-2672",
    "Definition": "TREATMENT OF ACUTE HEPATIC PORPHYRIA"
  },
  {
    "Code": "U-2673",
    "Definition": "TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING BY CORRECTING A DEFECTIVE GENE FOR DYSTROPHIN"
  },
  {
    "Code": "U-2674",
    "Definition": "TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 51 SKIPPING BY RESTORING OR INCREASING FUNCTIONAL DYSTROPHIN PROTEIN PRODUCTION"
  },
  {
    "Code": "U-2675",
    "Definition": "TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS HAVING A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING"
  },
  {
    "Code": "U-2676",
    "Definition": "TREATMENT OF SICKLE CELL DISEASE BY ADMINISTERING VOXELOTOR, AS RECITED IN CLAIM 1"
  },
  {
    "Code": "U-2677",
    "Definition": "PROPHYLAXIS OF ORGAN REJECTION IN PATIENTS CONVERTED FROM TACROLIMUS IMMEDIATE-RELEASE FORMULATIONS"
  },
  {
    "Code": "U-2678",
    "Definition": "PROPHYLAXIS OF ORGAN REJECTION IN DE NOVO TRANSPLANT PATIENT"
  },
  {
    "Code": "U-2679",
    "Definition": "TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II AT AN INITIAL RATE OF ABOUT 20 NG\/KG\/MIN AND TITRATING DOWN TO ACHIEVE AND\/OR MAINTAIN A MAP OF ABOUT 65 MM HG OR ABOVE"
  },
  {
    "Code": "U-2680",
    "Definition": "TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II WITH AN INITIAL RATE OF ABOUT 5 NG\/KG\/MIN TO ABOUT 20 NG\/KG\/MIN IN A SUBJECT HAVING REFRACTORY HYPOTENSION OR SEVERE HYPOTENSION"
  },
  {
    "Code": "U-2681",
    "Definition": "TREATING LOW BLOOD PRESSURE WITH ANGIOTENSIN II WITH AN INITIAL RATE OF ABOUT 5 NG\/KG\/MIN TO ABOUT 20 NG\/KG\/MIN IN A SUBJECT HAVING REFRACTORY HYPOTENSION OR SEVERE HYPOTENSION, AND TITRATING THE RATE UP"
  },
  {
    "Code": "U-2682",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100MG OF ACALABRUTINIB TWICE DAILY"
  },
  {
    "Code": "U-2683",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100MG OF ACALABRUTINIB TWICE DAILY"
  },
  {
    "Code": "U-2684",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY IN COMBINATION WITH OBINUTUZUMAB"
  },
  {
    "Code": "U-2685",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED SMALL LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY IN COMBINATION WITH OBINUTUZUMAB"
  },
  {
    "Code": "U-2686",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY"
  },
  {
    "Code": "U-2687",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LEUKEMIA IN COMBINATION WITH OBINUTUZUMAB BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY"
  },
  {
    "Code": "U-2688",
    "Definition": "USE OF VASCEPA TO LOWER TRIGLYCERIDES AND LDL-C IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG\/DL TO LESS THAN ABOUT 500 MG\/DL) AND ON STATIN THERAPY"
  },
  {
    "Code": "U-2689",
    "Definition": "USE OF VASCEPA TO TREAT MIXED DYSLIPIDEMIA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (>=150 MG\/DL) AND ON STATIN THERAPY"
  },
  {
    "Code": "U-2690",
    "Definition": "USE OF VASCEPA TO LOWER TRIGLYCERIDES IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG\/DL TO LESS THAN ABOUT 500 MG\/DL) AND ON STATIN THERAPY"
  },
  {
    "Code": "U-2691",
    "Definition": "USE OF VASCEPA TO TREAT HYPERTRIGLYCERIDEMIA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (>= 150 MG\/DL) AND ON STATIN THERAPY"
  },
  {
    "Code": "U-2692",
    "Definition": "USE OF VASCEPA TO REDUCE TRIGLYCERIDES IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (>= 150 MG\/DL) AND ON STATIN THERAPY"
  },
  {
    "Code": "U-2693",
    "Definition": "USE OF VASCEPA TO REDUCE TRIGLYCERIDES IN A MIXED DYSLIPIDEMIA ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (>= 150 MG\/DL) AND ON STATIN THERAPY"
  },
  {
    "Code": "U-2694",
    "Definition": "USE OF VASCEPA TO LOWER TRIGLYCERIDES IN A MIXED DYSLIPIDEMIA ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG\/DL TO LESS THAN ABOUT 500 MG\/DL) AND ON STATIN THERAPY"
  },
  {
    "Code": "U-2695",
    "Definition": "USE OF VASCEPA TO TREAT MIXED HYPERTRIGLYCERIDEMIA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (>= 150 MG\/DL) AND ON STATIN THERAPY"
  },
  {
    "Code": "U-2696",
    "Definition": "USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CARDIOVASCULAR DEATH, CORONARY REVASCULARIZATION, AND UNSTABLE ANGINA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS (TG >= 150 MG\/DL TO ABOUT 500 MG\/DL)"
  },
  {
    "Code": "U-2697",
    "Definition": "USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CARDIOVASCULAR DEATH AND\/OR UNSTABLE ANGINA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS (TG >= 150 MG\/DL TO ABOUT 500 MG\/DL)"
  },
  {
    "Code": "U-2698",
    "Definition": "USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CARDIOVASCULAR DEATH AND\/OR CORONARY REVASCULARIZATION IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS (TG >= 150 MG\/DL TO ABOUT 500 MG\/DL)"
  },
  {
    "Code": "U-2699",
    "Definition": "USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CARDIOVASCULAR EVENT (CORONARY REVASCULARIZATION, UNSTABLE ANGINA, STROKE AND\/OR MYOCARDIAL INFARCTION) IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS"
  },
  {
    "Code": "U-2700",
    "Definition": "USE OF VASCEPA TO REDUCE TRIGLYCERIDES IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG\/DL TO LESS THAN ABOUT 500 MG\/DL) AND ON ROSUVASTATIN THERAPY"
  },
  {
    "Code": "U-2701",
    "Definition": "USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CORONARY REVASCULARIZATION AND\/OR UNSTABLE ANGINA IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS (TG >= 150 MG\/DL TO ABOUT 500 MG\/DL)"
  },
  {
    "Code": "U-2702",
    "Definition": "USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CARDIOVASCULAR EVENT (CARDIOVASCULAR DEATH, CORONARY REVASCULARIZATION AND\/OR UNSTABLE ANGINA) IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS"
  },
  {
    "Code": "U-2703",
    "Definition": "USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CV EVENT (CV DEATH, CORONARY REVASCULARIZATION, UNSTABLE ANGINA, STROKE AND\/OR MYOCARDIAL INFARCTION) IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS AND DIABETES MELLITUS"
  },
  {
    "Code": "U-2704",
    "Definition": "USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS AND AT LEAST ONE RISK FACTOR FOR CARDIOVASCULAR DISEASE"
  },
  {
    "Code": "U-2705",
    "Definition": "METHOD OF USING CAPSAICIN IN COMBINATION WITH A GEL COMPOSITION FOR REMOVAL OF CAPSAICIN FROM A TREATMENT AREA OR UNINTENDED AREA"
  },
  {
    "Code": "U-2706",
    "Definition": "USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF ONSET AND\/OR RECURRENCE OF CARDIOVASCULAR EVENTS IN A PATIENT WHO HAS ESCAPED THE UNSTABLE PERIOD AFTER CARDIOVASCULAR ANGIOPLASTY"
  },
  {
    "Code": "U-2707",
    "Definition": "USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE OCCURRENCE OF A CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH HYPERCHOLESTEROLEMIA"
  },
  {
    "Code": "U-2708",
    "Definition": "THE TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER"
  },
  {
    "Code": "U-2709",
    "Definition": "A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE"
  },
  {
    "Code": "U-2710",
    "Definition": "A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE"
  },
  {
    "Code": "U-2711",
    "Definition": "A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE 750 MG OF ELEMENTAL IRON"
  },
  {
    "Code": "U-2712",
    "Definition": "A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE 750 MG OF ELEMENTAL IRON"
  },
  {
    "Code": "U-2713",
    "Definition": "MODULATION OF 5-HYDROXYTRYPTAMINE 2 RECEPTOR ACTIVITY IN SCHIZOPHRENIA"
  },
  {
    "Code": "U-2714",
    "Definition": "TREATMENT OF SCHIZOPHRENIA WITH IMPROVEMENT IN RESIDUAL SYMPTOMS OF SCHIZOPHRENIA"
  },
  {
    "Code": "U-2715",
    "Definition": "TREATMENT OF SICKLE CELL DISEASE BY ADMINISTERING VOXELOTOR, AS RECITED IN CLAIM 2"
  },
  {
    "Code": "U-2716",
    "Definition": "MAINTENANCE TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GBRCA-MUTATED METASTATIC PANCREATIC ADENOCARCINOMA WHOSE DISEASE HAS NOT PROGRESSED ON AT LEAST 16 WEEKS OF A FIRST-LINE PLATINUM-BASED CHEMOTHERAPY REGIMEN"
  },
  {
    "Code": "U-2717",
    "Definition": "ACUTE TREATMENT OF MIGRAINE WITH HEADACHE, WITH OR WITHOUT AURA IN ADULTS"
  },
  {
    "Code": "U-2718",
    "Definition": "ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN ADULTS"
  },
  {
    "Code": "U-2719",
    "Definition": "TREATMENT OF RELAPSING REMITTING MULTIPLE SCLEROSIS BY DETERMINING VARICELLA ZOSTER VIRUS (VZV) STATUS AND VACCINATING PRIOR TO COMMENCING TREATMENT"
  },
  {
    "Code": "U-2720",
    "Definition": "ANTIMYCOTIC USES, SPECIFICALLY TREATMENT OF ONYCHOMYCOSIS; TOPICAL TREATMENT OF THE TOENAIL(S) DUE TO TRICHOPHYTON RUBRUM AND TRICHOPHYTON MENTAGROPHYTES"
  },
  {
    "Code": "U-2721",
    "Definition": "TOPICAL TREATMENT OF TINEA UNGUIUM BY USING AN APPLICATOR FOR APPLYING A SOLUTION FOR TREATING TINEA UNGUIUM TO AN AFFECTED PART OF A PATIENT"
  },
  {
    "Code": "U-2722",
    "Definition": "METHOD OF INTRAVENOUSLY ADMINISTERING A DILUTED CYSTEINE HYDROCHLORIDE SOLUTION TO A NEONATE IN NEED THEREOF"
  },
  {
    "Code": "U-2723",
    "Definition": "MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR 1 DISORDER"
  },
  {
    "Code": "U-2724",
    "Definition": "A METHOD OF ORAL DELIVERY OF TREPROSTINIL COMPRISING ADMINISTERING AN ORAL OSMOTIC PHARMACEUTICAL DOSAGE FORM"
  },
  {
    "Code": "U-2725",
    "Definition": "A METHOD OF TREATING PULMONARY HYPERTENSION AND PULMONARY ARTERIAL HYPERTENSION BY ADMINISTERING AN ORAL OSMOTIC PHARMACEUTICAL DOSAGE FORM"
  },
  {
    "Code": "U-2726",
    "Definition": "TREATMENT OF UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMOR (GIST) HARBORING A PLATELET-DERIVED GROWTH FACTOR RECEPTOR ALPHA (PDGFRA) EXON 18 MUTATION"
  },
  {
    "Code": "U-2727",
    "Definition": "NASAL ADMINISTRATION OF DIAZEPAM FOR TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY IN PATIENTS 6 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-2728",
    "Definition": "USE OF PEMETREXED WITH PRIOR AND\/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION IN PATIENTS WITH NON-SQUAMOUS NON-SMALL CELL LUNG CANCER"
  },
  {
    "Code": "U-2729",
    "Definition": "USE OF PEMETREXED WITH PRIOR AND\/OR REPEATED VITAMIN B12 AND FOLIC ACID ADMINISTRATION IN PATIENTS WITH MESOTHELIOMA"
  },
  {
    "Code": "U-2730",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN"
  },
  {
    "Code": "U-2731",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (45 ML\/MIN\/1.73 M2<=EGFR<60 ML\/MIN\/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN IN COMBINATION WITH LINAGLIPTIN AND METFORMIN"
  },
  {
    "Code": "U-2732",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES USING A PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN, METFORMIN, EMPAGLIFLOZIN AND A BASIC AMINO ACID"
  },
  {
    "Code": "U-2733",
    "Definition": "METHOD OF TREATING A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH METFORMIN USING A PHARMACEUTICAL COMPOSITION COMPRISING EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN"
  },
  {
    "Code": "U-2734",
    "Definition": "METHOD OF TREATMENT OF IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON, WHO HAVE NON-HEMODIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE, BY ADMINISTERING FERRIC DERISOMALTOSE"
  },
  {
    "Code": "U-2735",
    "Definition": "MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS USING 150MG ELAGOLIX WHILE CO-ADMINISTERING RIFAMPIN"
  },
  {
    "Code": "U-2736",
    "Definition": "METHOD OF TREATING EPITHELIOID SARCOMA"
  },
  {
    "Code": "U-2737",
    "Definition": "METHOD OF TREATING EPITHELIOID SARCOMA BY INHIBITING ENHANCER OF ZESTE HOMOLOG 2 (EZH2)"
  },
  {
    "Code": "U-2738",
    "Definition": "METHOD OF TREATING A LUNG METASTASIS OF EPITHELIOID SARCOMA"
  },
  {
    "Code": "U-2739",
    "Definition": "INCREASING BLOOD PRESSURE WITH AN INITIAL RATE OF ABOUT 20 NG\/KG\/MIN ANGIOTENSIN II IN A HUMAN SUBJECT HAVING SEPTIC SHOCK, AND TITRATING THE RATE UP."
  },
  {
    "Code": "U-2740",
    "Definition": "INCREASING BLOOD PRESSURE WITH A RATE OF ABOUT 20 NG\/KG\/MIN TO ABOUT 40 NG\/KG\/MIN ANGIOTENSIN II IN A HUMAN SUBJECT HAVING SEPTIC SHOCK"
  },
  {
    "Code": "U-2741",
    "Definition": "TREATMENT OF CLOSTRIDIOIDES DIFFICILE-ASSOCIATED DIARRHEA (CDAD) IN PATIENTS FROM 6 MONTHS OF AGE AND OLDER"
  },
  {
    "Code": "U-2742",
    "Definition": "TREATMENT OF SEVERE HYPOGLYCEMIA"
  },
  {
    "Code": "U-2743",
    "Definition": "USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF UNSTABLE ANGINA IN AN ADULT PATIENT WITH ESTABLISHED CARDIOVASCULAR DISEASE"
  },
  {
    "Code": "U-2744",
    "Definition": "USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF STROKE IN AN ADULT PATIENT WITH ESTABLISHED CARDIOVASCULAR DISEASE"
  },
  {
    "Code": "U-2745",
    "Definition": "TREATMENT OF NEUROBLASTOMAS THAT HAVE A NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) GENE FUSION"
  },
  {
    "Code": "U-2746",
    "Definition": "USE OF NEXLIZET AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY TO LOWER LDL-C IN ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE"
  },
  {
    "Code": "U-2747",
    "Definition": "USE OF NEXLETOL AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY TO LOWER LDL-C IN ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE"
  },
  {
    "Code": "U-2748",
    "Definition": "USE OF NEXLETOL AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY FOR INHIBITING CHOLESTEROL SYNTHESIS TO LOWER LDL-C IN ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE"
  },
  {
    "Code": "U-2749",
    "Definition": "USE OF NEXLIZET AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY FOR INHIBITING CHOLESTEROL SYNTHESIS TO LOWER LDL-C IN ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE"
  },
  {
    "Code": "U-2750",
    "Definition": "MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION"
  },
  {
    "Code": "U-2751",
    "Definition": "A TRANSDERMAL METHOD OF CONTRACEPTION"
  },
  {
    "Code": "U-2752",
    "Definition": "METHOD OF USING L-CYSTEINE IN AN ADMIXTURE FOR TREATING PATIENTS NEEDING PARENTERAL NUTRITION"
  },
  {
    "Code": "U-2753",
    "Definition": "INCREASING SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL BY ADMINISTERING AS A 3 WEEK CYCLE CABAZITAXEL AFTER 5 MG DEXCHLORPHENIRAMINE, 8 MG DEXAMETHASONE, AND AN H2-ANTAGONIST"
  },
  {
    "Code": "U-2754",
    "Definition": "TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING"
  },
  {
    "Code": "U-2755",
    "Definition": "OCULAR EXAMINATION, INTRAOCULAR PRESSURE MEASUREMENT, OR REMOVAL OF FOREIGN BODIES OR SUTURES, IN ADULT AND PEDIATRIC PATIENTS REQUIRING A DISCLOSING AGENT IN COMBINATION WITH A TOPICAL OPHTHALMIC ANESTHETIC"
  },
  {
    "Code": "U-2756",
    "Definition": "USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CARDIOVASCULAR DEATH IN AN ADULT PATIENT WITH ESTABLISHED CARDIOVASCULAR DISEASE"
  },
  {
    "Code": "U-2757",
    "Definition": "DOSING REGIMEN FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTERING TWO LOADING DOSES OF PALIPERIDONE PALMITATE FOLLOWED BY MAINTENANCE DOSE(S)"
  },
  {
    "Code": "U-2758",
    "Definition": "DOSING REGIMEN FOR THE TREATMENT OF SCHIZOAFFECTIVE DISORDER IN ADULTS AS A MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS BY ADMINISTERING TWO LOADING DOSES OF PALIPERIDONE PALMITATE FOLLOWED BY MAINTENANCE DOSE(S)"
  },
  {
    "Code": "U-2759",
    "Definition": "REDUCTION OF INTRAOCULAR PRESSURE (IOP) IN PATIENTS WITH OPEN ANGLE GLAUCOMA(OAG) OR OCULAR HYPERTENSION (OHT) WITH A BIODEGRADABLE BIMATOPROST IMPLANT"
  },
  {
    "Code": "U-2760",
    "Definition": "TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 12 YEARS OF AGE OR OLDER"
  },
  {
    "Code": "U-2761",
    "Definition": "INTRAVENOUS SOTALOL DOSING REGIMEN FOR ACHIEVING STEADY STATE CONCENTRATION (EXPOSURE) FASTER COMPARED TO THE CONVENTIONAL ORAL DOSING IN A FACILITY THAT CAN PROVIDE ELECTROCARDIOGRAPHIC MONITORING"
  },
  {
    "Code": "U-2762",
    "Definition": "USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A MAJOR CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH DIABETES MELLITUS AND TWO OR MORE ADDITIONAL RISK FACTORS FOR CARDIOVASCULAR DISEASE"
  },
  {
    "Code": "U-2763",
    "Definition": "METHOD OF TREATING ADULTS WITH SCHIZOPHRENIA COMPRISING ADMINISTERING ASENAPINE VIA A TRANSDERMAL PATCH"
  },
  {
    "Code": "U-2764",
    "Definition": "TREATMENT OF POST-OPERATIVE INFLAMMATION AND PAIN FOLLOWING OCULAR SURGERY"
  },
  {
    "Code": "U-2765",
    "Definition": "TREATMENT OF HIV-1 INFECTION IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40 KG WHO HAVE NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN FOR AT LEAST 6 MONTHS"
  },
  {
    "Code": "U-2766",
    "Definition": "TX OF HIV1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CY P450 MONOXYGENASE IN ADULTS & PEDIATRIC PATIENTS AT LEAST 40KG HAVING NO PRIOR ARV TX HISTORY OR ARE VIROLOGICALLY SUPPRESSED ON A STABLE ARV REGIMEN FOR AT LEAST 6 MO"
  },
  {
    "Code": "U-2767",
    "Definition": "TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CY P450 MONOXYGENASE IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40KG WHO HAVE NO PRIOR ARV TREATMENT HISTORY"
  },
  {
    "Code": "U-2768",
    "Definition": "TREATMENT OF HIV-1 INFECTION USING A COMPOSITION CONTAINING A PK ENHANCER THAT INHIBITS CY P450 MONOXYGENASE IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40KG WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ARV REGIMEN FOR AT LEAST 6 MONTHS"
  },
  {
    "Code": "U-2769",
    "Definition": "DOSING REGIMEN FOR INTRAVENOUS SOTALOL FOR ADMINISTRATION IN A FACILITY THAT CAN PROVIDE CONTINUOUS ELECTROCARDIOGRAPHIC MONITORING AND CARDIAC RESUSCITATION."
  },
  {
    "Code": "U-2770",
    "Definition": "CUSHING'S DISEASE"
  },
  {
    "Code": "U-2771",
    "Definition": "TREATMENT OF MODERATE TO SEVERE PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE OR OLDER"
  },
  {
    "Code": "U-2772",
    "Definition": "MAINTENANCE TREATMENT OF CHRONIC PULMONARY DISEASE (COPD)"
  },
  {
    "Code": "U-2774",
    "Definition": "TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS"
  },
  {
    "Code": "U-2775",
    "Definition": "TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN"
  },
  {
    "Code": "U-2776",
    "Definition": "TREATMENT OF A TYPE 2 DIABETES MELLITUS PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN"
  },
  {
    "Code": "U-2777",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING A PHARMACEUTICAL COMPOSITION ACCORDING TO CLAIM 2 OF U.S. PATENT NO. 10,597,384, FURTHER COMPRISING IVACAFTOR"
  },
  {
    "Code": "U-2778",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 2 TO 5 YEARS OLD WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING A PHARMACEUTICAL COMPOSITION ACCORDING TO CLAIM 2 OF U.S. PATENT NO. 10,597,384, FURTHER COMPRISING IVACAFTOR"
  },
  {
    "Code": "U-2779",
    "Definition": "TREATMENT OF SPASTICITY"
  },
  {
    "Code": "U-2780",
    "Definition": "USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME"
  },
  {
    "Code": "U-2781",
    "Definition": "USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME"
  },
  {
    "Code": "U-2782",
    "Definition": "USE FOR REDUCING CONVULSIVE SEIZURE FREQUENCY IN PATIENTS WITH LENNOX GASTAUT SYNDROME"
  },
  {
    "Code": "U-2783",
    "Definition": "USE FOR REDUCING CONVULSIVE SEIZURE FREQUENCY IN PATIENTS WITH DRAVET SYNDROME"
  },
  {
    "Code": "U-2784",
    "Definition": "A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (AML) AND WHERE THE MUTANT IDH1 HAS THE ABILITY TO CONVERT ALPHA-KETOGLUTARATE INTO 2-HYDROXYGLUTARATE (2-HG)"
  },
  {
    "Code": "U-2785",
    "Definition": "A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) AND WHERE THE MUTANT IDH1 HAS THE ABILITY TO CONVERT ALPHA-KETOGLUTARATE INTO 2-HYDROXYGLUTARATE (2-HG)"
  },
  {
    "Code": "U-2786",
    "Definition": "METHOD OF PREVENTING PREGNANCY BY INSERTING A VAGINAL SYSTEM CONTAINING 103 MG OF SEGESTERONE ACETATE AND 17.4 MG ETHINYL ESTRADIOL INTO A VAGINA FOR UP TO THIRTEEN 21\/7-DAY (IN\/OUT) CYCLES"
  },
  {
    "Code": "U-2787",
    "Definition": "METHOD OF CONTRACEPTION BY INSERTING A VAGINAL SYSTEM FOR UP TO 13 21\/7-DAY (IN\/OUT) CYCLES, WHEREIN EFFICACY REQUIRES THE SYSTEM CANNOT BE OUT OF THE VAGINA FOR MORE THAN 2 CUMULATIVE HOURS IN ANY SUCH CYCLE WITHOUT USING ALTERNATIVE CONTRACEPTION"
  },
  {
    "Code": "U-2788",
    "Definition": "TREATMENT OF BREAST CANCER INCLUDING HER2 (ERBB2)-POSITIVE OR -OVEREXPRESSING BREAST CANCER"
  },
  {
    "Code": "U-2789",
    "Definition": "POTASSIUM PHOSPHATES INJECTION IS INDICATED AS A SOURCE OF PHOSPHORUS IN INTRAVENOUS FLUIDS TO CORRECT HYPOPHOSPHATEMIA IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-2790",
    "Definition": "TREATMENT OF A TREATMENT-NAIVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN"
  },
  {
    "Code": "U-2791",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH INSOMNIA, CHARACTERIZED BY DIFFICULTIES WITH SLEEP ONSET AND\/OR SLEEP MAINTENANCE"
  },
  {
    "Code": "U-2792",
    "Definition": "TREATMENT OF A TREATMENT-NAVE PATIENT WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN"
  },
  {
    "Code": "U-2793",
    "Definition": "A METHOD FOR DELIVERING NITRIC OXIDE TO A PATIENT WITH PULMONARY HYPERTENSION OR HYPOXIA"
  },
  {
    "Code": "U-2794",
    "Definition": "TREATMENT OF TYPE 2 DIABETES MELLITUS WITH 100 MG CANAGLIFLOZIN PER DAY"
  },
  {
    "Code": "U-2795",
    "Definition": "TREATMENT OF TYPE 2 DIABETES MELLITUS WITH 300 MG CANAGLIFLOZIN PER DAY"
  },
  {
    "Code": "U-2796",
    "Definition": "REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 100 MG CANAGLIFLOZIN PER DAY"
  },
  {
    "Code": "U-2797",
    "Definition": "REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 300 MG CANAGLIFLOZIN PER DAY"
  },
  {
    "Code": "U-2798",
    "Definition": "REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 100 MG CANAGLIFLOZIN PER DAY"
  },
  {
    "Code": "U-2799",
    "Definition": "REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 300 MG CANAGLIFLOZIN PER DAY"
  },
  {
    "Code": "U-2800",
    "Definition": "TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC, INOPERABLE PLEXIFORM NEUROFIBROMAS (PN)"
  },
  {
    "Code": "U-2801",
    "Definition": "METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT THERAPY"
  },
  {
    "Code": "U-2802",
    "Definition": "BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH CETUXIMAB, FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC COLORECTAL CANCER (CRC) WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, AFTER PRIOR THERAPY"
  },
  {
    "Code": "U-2803",
    "Definition": "BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH A BRAF V600E OR V600K MUTATION, AS DETECTED BY AN FDA- APPROVED TEST"
  },
  {
    "Code": "U-2804",
    "Definition": "A METHOD FOR THE IMPROVEMENT OF NEUROLOGICAL OUTCOME BY REDUCING THE INCIDENCE AND SEVERITY OF ISCHEMIC DEFICITS IN ADULT PATIENTS WITH SUBARACHNOID HEMORRHAGE (SAH) FROM RUPTURED INTRACRANIAL BERRY ANEURYSMS"
  },
  {
    "Code": "U-2805",
    "Definition": "TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON TO PATIENTS WITH A SMOKING HISTORY"
  },
  {
    "Code": "U-2806",
    "Definition": "TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF FOOD"
  },
  {
    "Code": "U-2807",
    "Definition": "TREATMENT OF MODERATE TO SEVERE MIGRAINE PAIN WITH PAIN FREE AT 2 HOURS POST ADMINISTRATION"
  },
  {
    "Code": "U-2808",
    "Definition": "TREATMENT OF DYSKINESIA, DECREASING OFF TIME, AND INCREASING ON TIME WITHOUT TROUBLESOME DYSKINESIA IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS"
  },
  {
    "Code": "U-2809",
    "Definition": "FOR THE TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FIBROBLAST GROWTH FACTOR RECEPTOR 2 (FGFR2) FUSION OR OTHER REARRANGEMENT"
  },
  {
    "Code": "U-2810",
    "Definition": "METHOD OF SUPPORTING EMBRYO IMPLANTATION AND EARLY PREGNANCY BY SUPPLEMENTATION OF CORPUS LUTEAL FUNCTION AS PART OF AN ASSISTED REPRODUCTIVE TECHNOLOGY (ART) TREATMENT PROGRAM FOR INFERTILE WOMEN"
  },
  {
    "Code": "U-2811",
    "Definition": "METHOD OF TREATING PARKINSON'S DISEASE"
  },
  {
    "Code": "U-2812",
    "Definition": "ADJUNCTIVE TREATMENT TO LEVODOPA\/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE"
  },
  {
    "Code": "U-2813",
    "Definition": "USE FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH A MESENCHYMAL-EPITHELIAL TRANSITION (MET) EXON 14 SKIPPING MUTATION"
  },
  {
    "Code": "U-2814",
    "Definition": "A METHOD OF PROPHYLACTIC TREATMENT OF GOUT FLARES IN ADULTS COMPRISES ADMINISTERING TO A PATIENT A LIQUID COLCHICINE ORAL SOLUTION"
  },
  {
    "Code": "U-2815",
    "Definition": "MEASURING TIME-VARYING CHANGE IN BLOOD IN A TISSUE VOLUME USING MODIFIED BEER-LAMBERT LAW IN VASCULAR, GASTROINTESTINAL, ORGAN TRANSPLANT, AND PLASTIC, MICRO- AND RECONSTRUCTIVE, INCLUDING MINIMALLY INVASIVE, SURGERY"
  },
  {
    "Code": "U-2816",
    "Definition": "METHOD FOR TREATING INFLUENZA"
  },
  {
    "Code": "U-2817",
    "Definition": "METHOD OF INHIBITING COMT IN THE PERIPHERY"
  },
  {
    "Code": "U-2818",
    "Definition": "METHOD OF REDUCING O-METHYLATION OF L-DOPA"
  },
  {
    "Code": "U-2819",
    "Definition": "MAINTENANCE TREATMENT WITH BEVACIZUMAB OF ADV. EPITHELIAL OVARIAN CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION"
  },
  {
    "Code": "U-2820",
    "Definition": "MAINTENANCE TREATMENT WITH BEVACIZUMAB OF ADV. EPITHELIAL OVARIAN CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH GENOMIC INSTABILITY"
  },
  {
    "Code": "U-2821",
    "Definition": "MAINTENANCE TREATMENT WITH BEVACIZUMAB OF FALLOPIAN TUBE CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION"
  },
  {
    "Code": "U-2822",
    "Definition": "MAINTENANCE TREATMENT WITH BEVACIZUMAB OF FALLOPIAN TUBE CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH GENOMIC INSTABILITY"
  },
  {
    "Code": "U-2823",
    "Definition": "MAINTENANCE TREATMENT WITH BEVACIZUMAB OF PRIMARY PERITONEAL CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION"
  },
  {
    "Code": "U-2824",
    "Definition": "MAINTENANCE TREATMENT WITH BEVACIZUMAB OF PRIMARY PERITONEAL CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM CHEMOTHERAPY AND HOMOLOGOUS RECOMBINATION DEFICIENCY-POSITIVE WITH GENOMIC INSTABILITY"
  },
  {
    "Code": "U-2825",
    "Definition": "TREATMENT OF 'OFF' EPISODES IN PATIENTS WITH PARKINSON'S DISEASE"
  },
  {
    "Code": "U-2826",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER"
  },
  {
    "Code": "U-2827",
    "Definition": "TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY"
  },
  {
    "Code": "U-2828",
    "Definition": "TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)"
  },
  {
    "Code": "U-2829",
    "Definition": "TREATMENT OF GASTROINTESTINAL STROMAL TUMORS"
  },
  {
    "Code": "U-2830",
    "Definition": "A METHOD FOR TREATING METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA-MUTATION"
  },
  {
    "Code": "U-2831",
    "Definition": "TREATMENT OF PARTIAL-ONSET SEIZURES IN A PATIENT WITH REFRACTORY PARTIAL-ONSET SEIZURES"
  },
  {
    "Code": "U-2832",
    "Definition": "TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC HOMOLOGOUS RECOMBINATION REPAIR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, WHICH HAS PROGRESSED FOLLOWING PRIOR TREATMENT WITH ENZALUTAMIDE OR ABIRATERONE"
  },
  {
    "Code": "U-2833",
    "Definition": "TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC BRCA-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, WHICH HAS PROGRESSED FOLLOWING PRIOR TREATMENT WITH ENZALUTAMIDE OR ABIRATERONE"
  },
  {
    "Code": "U-2834",
    "Definition": "TREATMENT OF ADULTS WITH PERSISTENT\/RECURRENT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH), (WHO GROUP 4) AFTER SURGICAL TREATMENT, OR INOPERABLE CTEPH, TO IMPROVE EXERCISE CAPACITY AND WHO FUNCTIONAL CLASS"
  },
  {
    "Code": "U-2835",
    "Definition": "TREATMENT OF ADULTS WITH PULMONARY HYPERTENSION (PAH), (WHO GROUP 1), TO IMPROVE EXERCISE CAPACITY, WHO FUNCTIONAL CLASS AND TO DELAY CLINICAL WORSENING"
  },
  {
    "Code": "U-2836",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH SMALL CELL LUNG CANCER (SCLC) WITH DISEASE PROGRESSION ON OR AFTER PLATINUM-BASED CHEMOTHERAPY."
  },
  {
    "Code": "U-2837",
    "Definition": "TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC)"
  },
  {
    "Code": "U-2838",
    "Definition": "REDUCTION OF THE RATE OF A FIRST MYOCARDIAL INFARCTION OR STROKE IN PATIENTS WITH CORONARY ARTERY DISEASE AT HIGH RISK FOR SUCH EVENTS"
  },
  {
    "Code": "U-2839",
    "Definition": "TREATMENT OF MYOCARDIAL INFARCTION OR STROKE IN PATIENTS WITH CORONARY ARTERY DISEASE AT HIGH RISK FOR SUCH EVENTS"
  },
  {
    "Code": "U-2840",
    "Definition": "TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP\/VABP)"
  },
  {
    "Code": "U-2841",
    "Definition": "USE OF VASCEPA WITH HIGH INTENSITY STATIN THERAPY TO REDUCE THE RISK OF A CV EVENT IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS AND (1) ESTABLISHED CV DISEASE, OR (2) DIABETES MELLITUS AND TWO OR MORE ADDITIONAL RISK FACTORS FOR CV DISEASE"
  },
  {
    "Code": "U-2842",
    "Definition": "MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS)"
  },
  {
    "Code": "U-2843",
    "Definition": "NASAL ADMINISTRATION OF METOCLOPRAMIDE FOR TREATMENT OF DIABETIC GASTROPARESIS"
  },
  {
    "Code": "U-2844",
    "Definition": "IN COMBINATION WITH PEMBROLIZUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA"
  },
  {
    "Code": "U-2845",
    "Definition": "A METHOD OF TREATING A HUMAN PATIENT SUFFERING FROM PULMONARY HYPERTENSION"
  },
  {
    "Code": "U-2846",
    "Definition": "TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE REFRACTORY TO SYSTEMIC THERAPY"
  },
  {
    "Code": "U-2847",
    "Definition": "REDUCTION IN RISK OF OVERT HEPATIC ENCEPHALOPATHY (HE) RECURRENCE IN ADULTS"
  },
  {
    "Code": "U-2848",
    "Definition": "TREATMENT OF TRAVELERS' DIARRHEA (TD) CAUSED BY NONINVASIVE STRAINS OF ESCHERIA COLI IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-2849",
    "Definition": "METHOD OF TREATING BLEPHAROPTOSIS"
  },
  {
    "Code": "U-2850",
    "Definition": "MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS USING 150 MG ELAGOLIX WHILE CO-ADMINISTERING KETOCONAZOLE"
  },
  {
    "Code": "U-2851",
    "Definition": "METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION BY INHIBITING EZH2"
  },
  {
    "Code": "U-2852",
    "Definition": "METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION"
  },
  {
    "Code": "U-2853",
    "Definition": "METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA"
  },
  {
    "Code": "U-2854",
    "Definition": "METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA BY INHIBITING EZH2"
  },
  {
    "Code": "U-2855",
    "Definition": "XPOVIO IS INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), NOT OTHERWISE SPECIFIED, INCLUDING DLBCL ARISING FROM FOLLICULAR LYMPHOMA, AFTER AT LEAST 2 LINES OF SYSTEMIC THERAPY"
  },
  {
    "Code": "U-2856",
    "Definition": "INCREASING SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL BY ADMINISTERING 20 TO 25 MG\/M2 CABAZITAXEL AFTER A PREMEDICATION REGIMEN THAT INCLUDES AN H2-ANTAGONIST"
  },
  {
    "Code": "U-2857",
    "Definition": "USE OF ORAL OCTREOTIDE FOR LONG-TERM MAINTENANCE TREATMENT IN ACROMEGALY PATIENTS WHO HAVE RESPONDED TO AND TOLERATED TREATMENT WITH OCTREOTIDE OR LANREOTIDE"
  },
  {
    "Code": "U-2858",
    "Definition": "USE IN COMBINATION WITH STIRIPENTOL, VALPROATE, AND CLOBAZAM FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME"
  },
  {
    "Code": "U-2859",
    "Definition": "USE OF CARDIAC MONITORING AND RESTRICTED DISTRIBUTION OF FENFLURAMINE TO MITIGATE RISK OF CARDIOVASCULAR TOXICITY IN THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME"
  },
  {
    "Code": "U-2860",
    "Definition": "USE IN COMBINATION WITH STIRIPENTOL FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME"
  },
  {
    "Code": "U-2861",
    "Definition": "USE IN COMBINATION WITH CANNABIDIOL FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME"
  },
  {
    "Code": "U-2862",
    "Definition": "USE FOR THE TREATMENT OF FOCAL SEIZURES IN PATIENTS WITH DRAVET SYNDROME"
  },
  {
    "Code": "U-2863",
    "Definition": "TOPICAL TREATMENT OF HEAD LICE INFESTATION IN PATIENTS 6 MONTHS OF AGE AND OLDER"
  },
  {
    "Code": "U-2864",
    "Definition": "METHOD FOR INHIBITING CYTIDINE DEAMINASE BY ADMINISTERING CEDAZURIDINE"
  },
  {
    "Code": "U-2865",
    "Definition": "TREATMENT OF MYELODYSPLASTIC SYNDROME"
  },
  {
    "Code": "U-2866",
    "Definition": "TREATMENT OF CHRONIC MYELOMONOCYTIC LEUKEMIA"
  },
  {
    "Code": "U-2867",
    "Definition": "METHOD FOR INHIBITING DEGRADATION OF A CDA SUBSTRATE BY ADMINISTERING CEDAZURIDINE"
  },
  {
    "Code": "U-2868",
    "Definition": "TREATMENT OF NON-INFECTIOUS UVEITIS AFFECTING THE POSTERIOR SEGMENT OF THE EYE"
  },
  {
    "Code": "U-2869",
    "Definition": "IV ADMINISTRATION OF CANGRELOR BEFORE PCI AND CONTINUOUS INFUSION FOR AT LEAST 2 HOURS OR THE DURATION OF THE PCI AND, DURING OR AFTER THE CONTINUOUS INFUSION, ADMINISTRATION OF A LOADING DOSE OF TICAGRELOR OR AN EQUIVALENT THERAPY (PER LABELING)"
  },
  {
    "Code": "U-2870",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 2"
  },
  {
    "Code": "U-2871",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 2 AND 3"
  },
  {
    "Code": "U-2872",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 4 AND 5"
  },
  {
    "Code": "U-2873",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 4, 5, AND 6"
  },
  {
    "Code": "U-2874",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 7 AND 8"
  },
  {
    "Code": "U-2875",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 7, 8, AND 9"
  },
  {
    "Code": "U-2876",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 10 AND 11"
  },
  {
    "Code": "U-2877",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 10, 11, AND 12"
  },
  {
    "Code": "U-2878",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 13 AND 14"
  },
  {
    "Code": "U-2879",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 13, 14, AND 15"
  },
  {
    "Code": "U-2880",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 16 AND 17"
  },
  {
    "Code": "U-2881",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 16, 17, AND 18"
  },
  {
    "Code": "U-2882",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 19 AND 20"
  },
  {
    "Code": "U-2883",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 19, 20, AND 21"
  },
  {
    "Code": "U-2884",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 22, 23, AND 24"
  },
  {
    "Code": "U-2885",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 25 AND 26"
  },
  {
    "Code": "U-2886",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 25, 26, AND 27"
  },
  {
    "Code": "U-2887",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 28 AND 29"
  },
  {
    "Code": "U-2888",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING MICRONIZED BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 28, 29, AND 30"
  },
  {
    "Code": "U-2889",
    "Definition": "USE FOR THE MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"
  },
  {
    "Code": "U-2890",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 2 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1"
  },
  {
    "Code": "U-2891",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 3 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1"
  },
  {
    "Code": "U-2892",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 4 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1"
  },
  {
    "Code": "U-2893",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 5 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1"
  },
  {
    "Code": "U-2894",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 6 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1"
  },
  {
    "Code": "U-2895",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 7 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1"
  },
  {
    "Code": "U-2896",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 8 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1"
  },
  {
    "Code": "U-2897",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1 AND 9"
  },
  {
    "Code": "U-2898",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1 AND 10"
  },
  {
    "Code": "U-2899",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1 AND 11"
  },
  {
    "Code": "U-2900",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 1 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 1 AND 13"
  },
  {
    "Code": "U-2901",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 15 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1"
  },
  {
    "Code": "U-2902",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 16 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1"
  },
  {
    "Code": "U-2903",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 17 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1"
  },
  {
    "Code": "U-2904",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1, 17 AND 18 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1"
  },
  {
    "Code": "U-2905",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 1 AND 19 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 1"
  },
  {
    "Code": "U-2906",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 22 WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 22"
  },
  {
    "Code": "U-2907",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 22 AND 23 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 22"
  },
  {
    "Code": "U-2908",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 22 AND 24 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 22"
  },
  {
    "Code": "U-2909",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 22 AND 25 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 22"
  },
  {
    "Code": "U-2910",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 26 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26"
  },
  {
    "Code": "U-2911",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 27 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26"
  },
  {
    "Code": "U-2912",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 28 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26"
  },
  {
    "Code": "U-2913",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 29 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26"
  },
  {
    "Code": "U-2914",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 30 WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26"
  },
  {
    "Code": "U-2915",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 31 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26"
  },
  {
    "Code": "U-2916",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 32 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS"
  },
  {
    "Code": "U-2917",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 33 WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS"
  },
  {
    "Code": "U-2918",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 34 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS"
  },
  {
    "Code": "U-2919",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 36 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS"
  },
  {
    "Code": "U-2920",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 38 AND WHEREIN THE EFFECTS ARE AS RECITED  CLAIM 26"
  },
  {
    "Code": "U-2921",
    "Definition": "ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN ADULTS"
  },
  {
    "Code": "U-2922",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 39 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26"
  },
  {
    "Code": "U-2923",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 26 AND 40 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 26"
  },
  {
    "Code": "U-2924",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 42 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 42"
  },
  {
    "Code": "U-2925",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO TREAT GLUCOSE INTOLERANCE IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 42 AND 43 WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 42"
  },
  {
    "Code": "U-2926",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 44 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44"
  },
  {
    "Code": "U-2927",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 45 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44"
  },
  {
    "Code": "U-2928",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 46 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44"
  },
  {
    "Code": "U-2929",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 47 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44"
  },
  {
    "Code": "U-2930",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 48 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44"
  },
  {
    "Code": "U-2931",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 49 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44"
  },
  {
    "Code": "U-2932",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 50 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS"
  },
  {
    "Code": "U-2933",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 51 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS"
  },
  {
    "Code": "U-2934",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 52 WHEREIN THE EFFECTS ARE AS RECITED IN SAID CLAIMS"
  },
  {
    "Code": "U-2935",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIM 44 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIMS 44 AND 54"
  },
  {
    "Code": "U-2936",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 56 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44"
  },
  {
    "Code": "U-2937",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES BY ADMINISTERING BROMOCRIPTINE MESYLATE AND A FIRST-PHASE INSULIN SECRETAGOGUE AS RECITED IN CLAIMS 44 AND 57 AND WHEREIN THE EFFECTS ARE AS RECITED IN CLAIM 44"
  },
  {
    "Code": "U-2938",
    "Definition": "TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS (EDS) IN PATIENTS 7 YEARS OF AGE AND OLDER WITH NARCOLEPSY WITH A MIXTURE OF SODIUM, POTASSIUM, MAGNESIUM, AND CALCIUM SALTS OF GHB"
  },
  {
    "Code": "U-2939",
    "Definition": "TREATMENT OF HIV INFECTION IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 40KG USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE"
  },
  {
    "Code": "U-2940",
    "Definition": "METHOD OF TREATING PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH CENTRAL PRECOCIOUS PUBERTY"
  },
  {
    "Code": "U-2941",
    "Definition": "A METHOD OF USING AN AEROSOL DELIVERY DEVICE TO AEROSOLIZE GLYCOPYRROLATE FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"
  },
  {
    "Code": "U-2942",
    "Definition": "METHOD OF TREATING ACNE VULGARIS WITH TOPICALLY APPLIED CORTEXOLONE 17A-PROPIONATE"
  },
  {
    "Code": "U-2943",
    "Definition": "TREATMENT OF RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA"
  },
  {
    "Code": "U-2944",
    "Definition": "TREATMENT OF RELAPSED OR REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA"
  },
  {
    "Code": "U-2945",
    "Definition": "TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INADEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNABLE TO TOLERATE UDCA"
  },
  {
    "Code": "U-2946",
    "Definition": "TREATMENT OF COLORECTAL CANCER THAT HAS A NEUROTROPHIC TYROSINE RECEPTOR KINASE(NTRK) GENE FUSION"
  },
  {
    "Code": "U-2947",
    "Definition": "KYPROLIS IS INDICATED IN COMBINATION WITH DARATUMUMAB PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY"
  },
  {
    "Code": "U-2948",
    "Definition": "A METHOD OF POSITIONING AN INTRAUTERINE SYSTEM (IUS) BY DETERMINING A DEPTH OF THE UTERUS, HOLDING AN INSERTER HANDLE WITH ONE HAND, INSERTING THE IUS INTO THE UTERUS, AND RETRACTING A SLIDER ON THE HANDLE TO RELEASE THE IUS INTO THE UTERUS"
  },
  {
    "Code": "U-2949",
    "Definition": "A METHOD FOR INDUCING A POST-SURGICAL ANALGESIA SPARING EFFECT BY IMPLANTING AT THE SURGICAL SITE A COLLAGEN SPONGE CONTAINING BUPIVACAINE HCL WHICH PROVIDES LOCAL ANESTHESIA FOR UP TO 24 HOURS FOLLOWING IMPLANTATION"
  },
  {
    "Code": "U-2950",
    "Definition": "CONTINUED TREATMENT OF ADULTS WITH ACUTE MYELOID LEUKEMIA WHO ACHIEVED FIRST COMPLETE REMISSION (CR) OR CR WITH INCOMPLETE BLOOD COUNT RECOVERY FOLLOWING INTENSIVE INDUCTION CHEMOTHERAPY AND ARE NOT ABLE TO COMPLETE INTENSIVE CURATIVE THERAPY"
  },
  {
    "Code": "U-2951",
    "Definition": "USE OF CU-64 DOTATATE WITH POSITRON EMISSION TOMOGRAPHY (PET) FOR LOCALIZATION OF SOMATOSTATIN RECEPTOR POSITIVE NEUROENDOCRINE TUMORS (NETS) IN ADULT PATIENTS"
  },
  {
    "Code": "U-2952",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH METASTATIC REARRANGED DURING TRANSFECTION (RET) FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) AS DETECTED BY AN FDA APPROVED TEST"
  },
  {
    "Code": "U-2953",
    "Definition": "USE OF FLUTICASONE FUROATE FOR THE TREATMENT OF AN INFLAMMATORY OR ALLERGIC CONDITIONS, INCLUDING CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND ASTHMA"
  },
  {
    "Code": "U-2954",
    "Definition": "METHOD OF DISPENSING A COMBINATION MEDICAMENT PRODUCT FROM CLAIMED DELIVERY DEVICE, FOR EXAMPLE FOR THE TREATMENT OF ASTHMA OR COPD"
  },
  {
    "Code": "U-2955",
    "Definition": "INDICATED FOR THE LONG-TERM, ONCE-DAILY, MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), INCLUDING CHRONIC BRONCHITIS AND\/OR EMPHYSEMA; AND ASTHMA"
  },
  {
    "Code": "U-2956",
    "Definition": "METHOD OF TREATING LAMBERT-EATON MYASTHENIC SYNDROME WITH AMIFAMPRIDINE"
  },
  {
    "Code": "U-2957",
    "Definition": "MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS 18 YRS AND OLDER, OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) INCLUDING CHRONIC BRONCHITIS AND\/OR EMPHYSEMA"
  },
  {
    "Code": "U-2958",
    "Definition": "A METHOD FOR CONTRACEPTION, THE METHOD COMPRISING ADMINISTERING A TABLET COMPRISING 20 MG TO 30 MG OF ULIPRISTAL ACETATE TO A WOMAN WITHIN 120 HOURS AFTER AN UNPROTECTED INTERCOURSE"
  },
  {
    "Code": "U-2959",
    "Definition": "USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A THIRD AND FURTHER CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH ELEVATED TG LEVELS (>=150 MG\/DL) AND ESTABLISHED CARDIOVASCULAR DISEASE"
  },
  {
    "Code": "U-2960",
    "Definition": "USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A SECOND OR FURTHER CARDIOVASCULAR (CV) EVENT IN AN ADULT PATIENT WITH ELEVATED TG LEVELS (>= 150 MG\/DL) AND DIABETES MELLITUS AND 2 OR MORE ADDITIONAL RISK FACTORS FOR CV DISEASE"
  },
  {
    "Code": "U-2961",
    "Definition": "USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF MYOCARDIAL INFARCTION, STROKE, BOTH IN AN ADULT PATIENT WITH TYPE 2 DIABETES MELLITUS"
  },
  {
    "Code": "U-2962",
    "Definition": "USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF CORONARY REVASCULARIZATION IN AN ADULT PATIENT WITH ESTABLISHED CARDIOVASCULAR DISEASE"
  },
  {
    "Code": "U-2963",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND\/OR IN VITRO ASSAY DATA"
  },
  {
    "Code": "U-2964",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS A R117H MUTATION IN THE CFTR GENE"
  },
  {
    "Code": "U-2965",
    "Definition": "TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF USING IVACAFTOR IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS ONE CFTR MUTATION RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND\/OR IN VITRO ASSAY DATA"
  },
  {
    "Code": "U-2966",
    "Definition": "TREATMENT OF CF IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS ONE CFTR MUTATION RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND\/OR IN VITRO ASSAY DATA USING A SOLID COMPOSITION COMPRISING AMORPHOUS (LESS THAN ABOUT 30% CRYSTALLINE) IVACAFTOR"
  },
  {
    "Code": "U-2967",
    "Definition": "TREATMENT OF CF IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND\/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 10272046"
  },
  {
    "Code": "U-2968",
    "Definition": "USE OF REMIMAZOLAM FOR INDUCTION AND MAINTENANCE OF PROCEDURAL SEDATION IN ADULTS UNDERGOING PROCEDURES LASTING 30 MINUTES OR LESS"
  },
  {
    "Code": "U-2969",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH CYCLOSPORIN-RESISTANT, STEROID-DEPENDENT\/REFRACTORY, OR STEROID RESISTANT CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY"
  },
  {
    "Code": "U-2970",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY"
  },
  {
    "Code": "U-2971",
    "Definition": "THE TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)"
  },
  {
    "Code": "U-2972",
    "Definition": "THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY"
  },
  {
    "Code": "U-2973",
    "Definition": "TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY, WHEREIN THE CANCER IS PAPILLARY THYROID CANCER"
  },
  {
    "Code": "U-2974",
    "Definition": "TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY, WHEREIN THE CANCER IS MEDULLARY THYROID CANCER"
  },
  {
    "Code": "U-2975",
    "Definition": "TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY, WHEREIN THE CANCER IS DIFFERENTIATED THYROID CANCER"
  },
  {
    "Code": "U-2976",
    "Definition": "TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY, WHEREIN THE CANCER IS RECURRENT THYROID CANCER"
  },
  {
    "Code": "U-2977",
    "Definition": "TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE REFRACTORY DIFFERENTIATED THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND ARE RADIOACTIVE IODINE-REFRACTORY"
  },
  {
    "Code": "U-2978",
    "Definition": "TREATMENT OF HIV-1 INFECTION IN ADULT OR PEDIATRIC PATIENTS (>=40 KG) WITH <50 COPIES\/ML HIV-1 RNA AFTER >= 6 MONTHS ON PRIOR ANTIRETROVIRAL REGIMEN AND NO KNOWN DARUNAVIR OR TENOFOVIR RESISTANCE-ASSOCIATED SUBSTITUTIONS"
  },
  {
    "Code": "U-2979",
    "Definition": "METHOD COMPRISING IV ADMINISTRATION OF CANGRELOR BEFORE PCI THEN CONTINUOUS INFUSION FOR AT LEAST 2 HOURS OR THE DURATION OF PCI AND, DURING OR AFTER CONTINUOUS INFUSION, ADMINISTRATION OF A LOADING DOSE OF TICAGRELOR, OR AN EQUIVALENT METHOD"
  },
  {
    "Code": "U-2980",
    "Definition": "METHOD OF TREATING AN ALLERGIC REACTION USING AN AUTO-INJECTOR"
  },
  {
    "Code": "U-2981",
    "Definition": "A METHOD OF TREATING ACUTE MYELOGENOUS LEUKEMIA (AML) IN A SUBJECT BY ADMINISTERING A PHARMACEUTICAL COMPOSITION WHERE THE AML IS CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 AND THE AML IS NEWLY DIAGNOSED"
  },
  {
    "Code": "U-2982",
    "Definition": "A METHOD OF TREATING ACUTE MYELOGENOUS LEUKEMIA (AML) IN A SUBJECT BY ADMINISTERING A PHARMACEUTICAL COMPOSITION WHERE THE AML IS CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 AND WHERE THE AML IS RELAPSED\/REFRACTORY"
  },
  {
    "Code": "U-2983",
    "Definition": "TREATMENT OF SCHIZOPHRENIA BY RAPID AND CONTINUOUS INJECTION"
  },
  {
    "Code": "U-2984",
    "Definition": "TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG) REQUIRING HOSPITALIZATION"
  },
  {
    "Code": "U-2985",
    "Definition": "A METHOD FOR TREATING DRY EYE IN A PATIENT"
  },
  {
    "Code": "U-2986",
    "Definition": "MANAGEMENT OF ACUTE PAIN BY INTRAVENOUS INJECTION"
  },
  {
    "Code": "U-2987",
    "Definition": "METHOD OF TREATING LUNG CANCER, UNDIFFERENTIATED SARCOMA, OR COLORECTAL CANCER THAT EXHIBITS AN NTRK GENE FUSION"
  },
  {
    "Code": "U-2988",
    "Definition": "REDUCTION OF THE RISK OF STROKE IN PATIENTS WITH ACUTE ISCHEMIC STROKE OR HIGH-RISK TRANSIENT ISCHEMIC ATTACK"
  },
  {
    "Code": "U-2989",
    "Definition": "METHOD OF USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-2990",
    "Definition": "METHOD OF USE FOR TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-2991",
    "Definition": "METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A TABLET CONTAINING SELEXIPAG"
  },
  {
    "Code": "U-2992",
    "Definition": "METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A SOLID PREPARATION CONTAINING SELEXIPAG"
  },
  {
    "Code": "U-2993",
    "Definition": "A METHOD FOR TREATING A SUBJECT HAVING ADHD, SAID METHOD COMPRISING ORALLY ADMINISTERING TO SAID SUBJECT A RACEMIC METHYLPHENIDATE CHEWABLE TABLET AS CLAIMED"
  },
  {
    "Code": "U-2994",
    "Definition": "REDUCTION OF RISK OF MYOCARDIAL INFARCTION, STROKE OR CARDIOVASCULAR DEATH IN A PATIENT WITH CHRONIC CAD OR PAD BY ADMINISTERING CLINICALLY PROVEN EFFECTIVE AMOUNTS THAT ARE 2.5 MG RIVAROXABAN TWICE DAILY AND 75-100 MG ASPIRIN DAILY"
  },
  {
    "Code": "U-2995",
    "Definition": "TREATMENT OF PRIMARY HYPEROXALURIA TYPE 1 (PH1)"
  },
  {
    "Code": "U-2996",
    "Definition": "ADMINISTRATION OF AN EXTENDED RELEASE TABLET FOR THE TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY"
  },
  {
    "Code": "U-2997",
    "Definition": "USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF STROKE IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDES AND ATRIAL FIBRILLATION"
  },
  {
    "Code": "U-2998",
    "Definition": "METHOD OF ADMINISTERING DOCETAXEL TO A SUBJECT COMBINING THE DOCETAXEL PRO-EMULSION FORMULATION WITH AN AQUEOUS MEDIUM TO PRODUCE DOCETAXEL EMULSION"
  },
  {
    "Code": "U-2999",
    "Definition": "METHOD OF USE OF TREATING, AS AN INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY IN PARTIAL ONSET SEIZURE PATIENTS WITH EPILEPSY AGED 17 YEARS OR OLDER"
  },
  {
    "Code": "U-3000",
    "Definition": "METHOD FOR POST-EXPOSURE PROPHYLAXIS OF INFLUENZA"
  },
  {
    "Code": "U-3001",
    "Definition": "PROCEDURES IN ADULT AND PEDIATRIC PATIENTS REQUIRING A DISCLOSING AGENT IN COMBINATION WITH A TOPICAL OPHTHALMIC ANESTHETIC."
  },
  {
    "Code": "U-3002",
    "Definition": "TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)"
  },
  {
    "Code": "U-3003",
    "Definition": "TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON"
  },
  {
    "Code": "U-3004",
    "Definition": "TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH A STRONG CYP1A2 INHIBITOR"
  },
  {
    "Code": "U-3005",
    "Definition": "TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE USE OF TASIMELTEON WITH RIFAMPIN"
  },
  {
    "Code": "U-3006",
    "Definition": "TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE USE OF TASIMELTEON IN COMBINATION WITH CYP1A2 STRONG INHIBITORS"
  },
  {
    "Code": "U-3007",
    "Definition": "TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD"
  },
  {
    "Code": "U-3008",
    "Definition": "TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON TO PATIENTS WITH A SMOKING HISTORY"
  },
  {
    "Code": "U-3009",
    "Definition": "TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY ADMINISTERING TASIMELTEON TO PATIENTS WITH A SMOKING HISTORY"
  },
  {
    "Code": "U-3010",
    "Definition": "PROPHYLAXIS TO PREVENT ATTACKS OF HEREDITARY ANGIOEDEMA (HAE) IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-3011",
    "Definition": "A METHOD FOR TREATING OCULAR INFLAMMATION"
  },
  {
    "Code": "U-3012",
    "Definition": "TREATMENT IN COMBINATION WITH ANDROGEN DEPRIVATION THERAPY OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) THAT IMPROVES METASTASIS FREE SURVIVAL"
  },
  {
    "Code": "U-3013",
    "Definition": "TREATMENT IN COMBINATION WITH ORCHIECTOMY OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC)"
  },
  {
    "Code": "U-3014",
    "Definition": "METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA OF THE MUCOUS MEMBRANES"
  },
  {
    "Code": "U-3015",
    "Definition": "TOPICAL TREATMENT OF ACTINIC KERATOSIS OF THE FACE OR SCALP"
  },
  {
    "Code": "U-3016",
    "Definition": "ADJUVANT THERAPY AFTER TUMOR RESECTION IN PATIENTS WITH NON-SMALL CELL LUNG CANCER(NSCLC) WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 19DELETIONS OR EXON 21 L858R MUTATIONS"
  },
  {
    "Code": "U-3017",
    "Definition": "METHOD OF TREATING EXCESSIVE DAYTIME SLEEPINESS AND\/OR CATAPLEXY IN NARCOLEPSY PATIENTS WITH A SALT OF GAMMA-HYDROXYBUTYRATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED"
  },
  {
    "Code": "U-3018",
    "Definition": "XPOVIO IS INDICATED IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY"
  },
  {
    "Code": "U-3019",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH ADVANCED PROSTATE CANCER THAT IS SEX-HORMONE-DEPENDENT"
  },
  {
    "Code": "U-3020",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH ADVANCED PROSTATE CANCER"
  },
  {
    "Code": "U-3021",
    "Definition": "TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 6 YEARS AND OLDER WHO HAVE A R117H MUTATION IN THE CFTR GENE"
  },
  {
    "Code": "U-3022",
    "Definition": "TREATMENT OF CF IN PATIENTS 12 YEARS AND OLDER WHO HAVE A F508DEL OR G551D CFTR MUTATION AND A 2ND MUTATION SELECTED FROM R117H, A455E, 2789+5G->A, & 3849+10KBC->T, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF US 10058546"
  },
  {
    "Code": "U-3023",
    "Definition": "TREATMENT OF CF IN PATIENTS 6 YEARS AND OLDER WHO HAVE A F508DEL OR G551D CFTR MUTATION AND A 2ND MUTATION SELECTED FROM R117H, A455E, 2789+5G->A, AND 3849+10KBC->T, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF US 10058546"
  },
  {
    "Code": "U-3024",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 12 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR WHO HAVE AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR\/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,081,621"
  },
  {
    "Code": "U-3025",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 6 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR WHO HAVE AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR\/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,081,621"
  },
  {
    "Code": "U-3026",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 12 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR\/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,206,877"
  },
  {
    "Code": "U-3027",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 6 AND OLDER, WHO HAVE TWO COPIES OF THE F508DEL MUTATION OR AT LEAST ONE CFTR MUTATION THAT IS RESPONSIVE TO TEZACAFTOR\/IVACAFTOR, WITH THE COMPOSITION OF CLAIM 1 OF US 10,206,877"
  },
  {
    "Code": "U-3028",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR"
  },
  {
    "Code": "U-3029",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE A R117H MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR"
  },
  {
    "Code": "U-3030",
    "Definition": "TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELX, TEZ, AND IVA"
  },
  {
    "Code": "U-3031",
    "Definition": "TREATMENT OF CF IN PATIENTS 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA USING A SOLID COMPOSITION COMPRISING ELX, TEZ, AMORPHOUS IVA, AND < ~30% CRYSTALLINE IVA"
  },
  {
    "Code": "U-3032",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US 10081621"
  },
  {
    "Code": "U-3033",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH AN EFFECTIVE AMOUNT OF ELX, TEZ, AND IVA"
  },
  {
    "Code": "U-3034",
    "Definition": "TREATMENT OF TRD IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE 2X WEEKLY FOR 4 WEEKS DURING THE INDUCTION PHASE IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT"
  },
  {
    "Code": "U-3035",
    "Definition": "TREATMENT OF DEPRESSIVE SYMPTOMS IN ADULTS WITH MDD WITH ACUTE SUICIDAL IDEATION OR BEHAVIOR BY NASALLY ADMINISTERING 56MG OR 84 MG OF ESKETAMINE 2X WEEKLY FOR 4 WEEKS IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT"
  },
  {
    "Code": "U-3036",
    "Definition": "TREATMENT OF TRD IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE 2X WEEKLY FOR 4 WEEKS DURING THE INDUCTION PHASE FOLLOWED BY A MAINTENANCE PHASE OF 56MG OR 84 MG WEEKLY OR 1X EVERY TWO WEEKS IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT"
  },
  {
    "Code": "U-3037",
    "Definition": "A METHOD OF DELIVERING NITRIC OXIDE TO A PATIENT"
  },
  {
    "Code": "U-3038",
    "Definition": "MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INTRAVENOUS INJECTION IN PATIENTS WITH MILD RENAL IMPAIRMENT"
  },
  {
    "Code": "U-3039",
    "Definition": "TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A CONFIRMED MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 53 SKIPPING"
  },
  {
    "Code": "U-3040",
    "Definition": "LONG-TERM TREATMENT OF ADULTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 EXTENSIVE METABOLIZERS WITH MILD HEPATIC IMPAIRMENT AND ARE CONCURRENTLY TAKING A STRONG OR MODERATE CYP3A INHIBITOR"
  },
  {
    "Code": "U-3041",
    "Definition": "LONG-TERM TREATMENT OF ADULTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 EXTENSIVE METABOLIZERS WITH MODERATE TO SEVERE RENAL IMPAIRMENT"
  },
  {
    "Code": "U-3042",
    "Definition": "LONG-TERM TREATMENT OF ADULTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 POOR METABOLIZERS WITH 84 MG ONCE DAILY OF ELIGLUSTAT (EQUIVALENT TO 100 MG OF ELIGLUSTAT TARTRATE)"
  },
  {
    "Code": "U-3043",
    "Definition": "LONG-TERM TREATMENT OF ADULTS WITH GAUCHER DISEASE TYPE 1 WHO ARE CYP2D6 EXTENSIVE OR INTERMEDIATE METABOLIZERS WITH 84 MG TWICE PER DAY OF ELIGLUSTAT (EQUIVALENT TO 100 MG OF ELIGLUSTAT TARTRATE TWICE PER DAY)"
  },
  {
    "Code": "U-3044",
    "Definition": "AXITINIB IN COMBINATION WITH AVELUMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA"
  },
  {
    "Code": "U-3045",
    "Definition": "TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY"
  },
  {
    "Code": "U-3046",
    "Definition": "METHOD OF ADMINISTERING VALBENAZINE WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER"
  },
  {
    "Code": "U-3047",
    "Definition": "USE IN COMBINATION WITH CAPECITABINE, FOR THE TREATMENT OF ADULT PATIENTS WITH ADVANCED OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR ANTI-HER2 BASED REGIMENS IN THE METASTATIC SETTING"
  },
  {
    "Code": "U-3048",
    "Definition": "A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE 500 TO 750 MG OF ELEMENTAL IRON"
  },
  {
    "Code": "U-3049",
    "Definition": "A METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE 500 TO 750 MG OF ELEMENTAL IRON"
  },
  {
    "Code": "U-3050",
    "Definition": "METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING AT LEAST ABOUT 0.6G OF IRON AS FERRIC CARBOXYMALTOSE IN ABOUT 15 MIN OR LESS"
  },
  {
    "Code": "U-3051",
    "Definition": "METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING AT LEAST ABOUT 0.6G OF IRON AS FERRIC CARBOXYMALTOSE IN ABOUT 15 MIN OR LESS"
  },
  {
    "Code": "U-3052",
    "Definition": "USE OF VASCEPA TO REDUCE TRIGLYCERIDE LEVELS IN AN ADULT PATIENT ON STATIN THERAPY AND HAVING ATRIAL FIBRILLATION AND TRIGLYCERIDE LEVELS OF GREATER THAN 500 MG\/DL"
  },
  {
    "Code": "U-3053",
    "Definition": "USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF MYOCARDIAL INFARCTION IN AN ADULT PATIENT WITH ELEVATED TRIGLYCERIDE LEVELS AND ESTABLISHED CV DISEASE OR DIABETES MELLITUS AND TWO OR MORE ADDITIONAL RISK FACTORS FOR CV DISEASE"
  },
  {
    "Code": "U-3054",
    "Definition": "TREATMENT OF DRUG-INDUCED EXTRAPYRAMIDAL REACTIONS IN ADULT PATIENTS WITH PARKINSON'S DISEASE"
  },
  {
    "Code": "U-3055",
    "Definition": "A METHOD OF TREATING HUNTINGTON'S CHOREA"
  },
  {
    "Code": "U-3056",
    "Definition": "TREATMENT OF PATIENTS WITH ACTIVE LUPUS NEPHRITIS"
  },
  {
    "Code": "U-3057",
    "Definition": "TREATMENT OF PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) THAT IS ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE"
  },
  {
    "Code": "U-3058",
    "Definition": "TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER AND YOUNG ADULTS WITH RELAPSED OR REFRACTORY, SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA (ALCL) THAT IS ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE"
  },
  {
    "Code": "U-3059",
    "Definition": "TREATMENT OF HIV-1 INFECTION IN ADULTS TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN WITH NO HISTORY OF TREATMENT FAILURE"
  },
  {
    "Code": "U-3060",
    "Definition": "TREATMENT OF HIV INFECTION IN ADULTS"
  },
  {
    "Code": "U-3061",
    "Definition": "TREATMENT OF HIV-1 IN AN ADULT IN COMBINATION WITH RILPIVIRINE"
  },
  {
    "Code": "U-3062",
    "Definition": "REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HEART FAILURE (HF) HOSPITALIZATION FOLLOWING A HOSPITALIZATION FOR HF OR NEED FOR OUTPATIENT IV DIURETICS, IN ADULTS WITH SYMPTOMATIC CHRONIC HF AND EJECTION FRACTION LESS THAN 45%"
  },
  {
    "Code": "U-3063",
    "Definition": "RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN"
  },
  {
    "Code": "U-3064",
    "Definition": "RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) WHO HAVE RECEIVED AT LEAST THREE PRIOR LINES OF SYSTEMIC THERAPY"
  },
  {
    "Code": "U-3065",
    "Definition": "TREATMENT OF ADULTS WITH METASTATIC UROTHELIAL CARCINOMA THAT HAS SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY"
  },
  {
    "Code": "U-3066",
    "Definition": "TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC, SURGICALLY UNRESECTABLE UROTHELIAL CARCINOMA THAT HAS SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY"
  },
  {
    "Code": "U-3067",
    "Definition": "TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA THAT HAS SUSCEPTIBLE FGFR3 GENETIC ALTERATIONS AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY"
  },
  {
    "Code": "U-3068",
    "Definition": "TREATMENT IN COMBINATION WITH CABOTEGRAVIR OF HIV-1 INFECTION IN ADULTS TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN WITH NO HISTORY OF TREATMENT FAILURE"
  },
  {
    "Code": "U-3069",
    "Definition": "TREATMENT OF ACUTE UNCOMPLICATED INFLUENZA IN PATIENTS 6 MONTHS AND OLDER"
  },
  {
    "Code": "U-3070",
    "Definition": "REDUCING THE RISK OF MORTALITY IN HUTCHINSON-GILFORD PROGERIA SYNDROME (HGPS)"
  },
  {
    "Code": "U-3071",
    "Definition": "USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX"
  },
  {
    "Code": "U-3072",
    "Definition": "USE FOR THE TREATMENT OF GENERALIZED SEIZURES OR FOCAL SEIZURES WITH IMPAIRMENT IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX"
  },
  {
    "Code": "U-3073",
    "Definition": "USE FOR REDUCING SEIZURE FREQUENCY IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX"
  },
  {
    "Code": "U-3074",
    "Definition": "METHOD FOR PROVIDING SUSTAINED LOCAL ANESTHESIA FOR AT LEAST 24 HOURS"
  },
  {
    "Code": "U-3075",
    "Definition": "TREATMENT OF ADRENAL INSUFFICIENCY"
  },
  {
    "Code": "U-3076",
    "Definition": "METHOD OF TREATING TARDIVE DYSKINESIA WHILE AVOIDING CONCOMITANT USE OF A STRONG CYP3A4 INDUCER"
  },
  {
    "Code": "U-3077",
    "Definition": "TREATING A SOLID TUMOR, INCLUDING LUNG CANCER, WITH A MET ALTERATION(S), OR STABILIZING OR IMPROVING SYMPTOMS ASSOCIATED WITH HAVING A SOLID TUMOR, INCLUDING LUNG CANCER, WITH A MET ALTERATION(S), BY ADMINISTERING AN EFFECTIVE AMOUNT OF TEPOTINIB"
  },
  {
    "Code": "U-3078",
    "Definition": "TREATING A SOLID TUMOR, INCLUDING LUNG CANCER, HAVING A MET KINASE ALTERATION(S) BY ADMINISTERING AN EFFECTIVE AMOUNT OF TEPOTINIB"
  },
  {
    "Code": "U-3079",
    "Definition": "A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A PLATINUM\/ETOPOSIDE-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER"
  },
  {
    "Code": "U-3080",
    "Definition": "A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A TOPOTECAN-CONTAINING REGIMEN FOR EXTENSIVE- STAGE SMALL CELL LUNG CANCER"
  },
  {
    "Code": "U-3081",
    "Definition": "A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A CARBOPLATIN AND ETOPOSIDE-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER"
  },
  {
    "Code": "U-3082",
    "Definition": "TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH OBSTRUCTIVE SLEEP APNEA (OSA) IN AN ADULT THROUGH A DOSING REGIMEN THAT INCLUDES ORAL ADMINISTRATION OF 75 MG ONCE DAILY FOR AT LEAST 3 DAYS FOLLOWED BY 150 MG ONCE DAILY"
  },
  {
    "Code": "U-3083",
    "Definition": "METHOD OF TREATING TRANSFUSIONAL IRON OVERLOAD"
  },
  {
    "Code": "U-3084",
    "Definition": "TREATMENT OF HEART FAILURE WITH PRESERVED EJECTION FRACTION"
  },
  {
    "Code": "U-3085",
    "Definition": "DOSE MODIFICATION FOR RENAL IMPAIRMENT"
  },
  {
    "Code": "U-3086",
    "Definition": "FOR HIGH-DOSE CONDITIONING TREATMENT PRIOR TO HEMATOPOIETIC PROGENITOR (STEM) CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA"
  },
  {
    "Code": "U-3087",
    "Definition": "TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING BY INDUCING EXON-SKIPPING OF EXON 45"
  },
  {
    "Code": "U-3088",
    "Definition": "TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING"
  },
  {
    "Code": "U-3089",
    "Definition": "TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) IN PATIENTS WHO HAVE A MUTATION OF THE DMD GENE THAT IS AMENABLE TO EXON 45 SKIPPING BY RESTORING AN MRNA READING FRAME TO INDUCE DYSTROPHIN PROTEIN PRODUCTION"
  },
  {
    "Code": "U-3090",
    "Definition": "TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS"
  },
  {
    "Code": "U-3091",
    "Definition": "TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA IN PATIENTS WITH END-STAGE RENAL DISEASE ON HEMODIALYSIS"
  },
  {
    "Code": "U-3092",
    "Definition": "METHOD OF TREATING MOLYBDENUM COFACTOR DEFICIENCY TYPE A"
  },
  {
    "Code": "U-3093",
    "Definition": "IN COMBINATION WITH DEXAMETHASONE TO TREAT RELAPSED OR REFRACTORY MULTIPLE MYELOMA (REFACTORY TO AT LEAST 1 PROTEASOME INHIBITOR, 1 IMMUNOMODULATORY AGENT, AND 1 ANTI-CD38 MAB) IN ADULTS WHO RECEIVED AT LEAST 4 PRIOR LINES OF THERAPY"
  },
  {
    "Code": "U-3094",
    "Definition": "TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) WITH SERDEXMETHYLPHENIDATE AND DEXMETHYLPHENIDATE"
  },
  {
    "Code": "U-3095",
    "Definition": "TREATMENT OF HYPERLIPIDEMIA"
  },
  {
    "Code": "U-3096",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHOSE TUMORS ARE ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE AS DETECTED BY AN FDA-APPROVED TEST"
  },
  {
    "Code": "U-3097",
    "Definition": "EXTENDED ADJUVANT TREATMENT OF ADULT PATIENTS WITH EARLY-STAGE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-POSITIVE BREAST CANCER, TO FOLLOW ADJUVANT TRASTUZUMAB BASED THERAPY"
  },
  {
    "Code": "U-3098",
    "Definition": "TREATMENT OF REFRACTORY EPILEPSY PATIENTS WITH FENFLURAMINE THAT REDUCES THE RISK OF CARDIOVASCULAR TOXICITY BY USING CARDIAC MONITORING AND RESTRICTED DISTRIBUTION"
  },
  {
    "Code": "U-3099",
    "Definition": "TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH OBSTRUCTIVE SLEEP APNEA (OSA) IN A PATIENT WITH MODERATE RENAL IMPAIRMENT"
  },
  {
    "Code": "U-3100",
    "Definition": "A METHOD OF TREATING ADULTS WITH RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC THERAPIES BY INHIBITING THE ANGIOGENESIS OF BLOOD VESSELS WITH A VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITOR"
  },
  {
    "Code": "U-3101",
    "Definition": "TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS WITH A SINGLE DOSE OF 1200MG ORITAVANCIN OR ITS SINGLE DOSE EQUIVALENT"
  },
  {
    "Code": "U-3102",
    "Definition": "REDUCTION OF CIRCULATING LYMPHOCYTES IN TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS"
  },
  {
    "Code": "U-3103",
    "Definition": "TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS USING A DOSE TITRATION SCHEDULE FOLLOWED BY A MAINTENANCE DOSE"
  },
  {
    "Code": "U-3104",
    "Definition": "TREATMENT OF C. DIFFICILE-ASSOCIATED DIARRHEA"
  },
  {
    "Code": "U-3105",
    "Definition": "TREATMENT OF STAPHYLOCOCCAL ENTEROCOLITIS"
  },
  {
    "Code": "U-3106",
    "Definition": "TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON TO SMOKERS OR TO PATIENTS BEING TREATED WITH A CYP1A2 INHIBITOR"
  },
  {
    "Code": "U-3107",
    "Definition": "TREATMENT OF NON-24 HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF TASIMELTEON TO SMOKERS OR TO PATIENTS BEING TREATED WITH A CYP1A2 INHIBITOR"
  },
  {
    "Code": "U-3108",
    "Definition": "TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY (NDO) IN PEDIATRIC PATIENTS AGED 3 YEARS AND OLDER BY ADMINISTRATION OF AN EXTENDED-RELEASE SUSPENSION FORMULATION OF MIRABEGRON"
  },
  {
    "Code": "U-3109",
    "Definition": "METHOD OF USING VISMODEGIB TO TREAT BASAL CELL CARCINOMA"
  },
  {
    "Code": "U-3110",
    "Definition": "USE OF NALOXONE FOR THE EMERGENCY TREATMENT OF KNOWN OR SUSPECTED OPIOID OVERDOSE, AS MANIFESTED BY RESPIRATORY AND\/OR CENTRAL NERVOUS SYSTEM DEPRESSION, FOR ADULT AND PEDIATRIC PATIENTS"
  },
  {
    "Code": "U-3111",
    "Definition": "TREATING OPIOID USE DISORDER"
  },
  {
    "Code": "U-3112",
    "Definition": "TREATING NEWLY DIAGNOSED ACUTE MYELOGENOUS LEUKEMIA (AML) CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 BY ADMINISTERING A ONCE DAILY 500 MG ORAL DOSE TO A SUBJECT THAT HAS NOT INGESTED A HIGH-FAT MEAL"
  },
  {
    "Code": "U-3113",
    "Definition": "TREATING RELAPSED\/REFRACTORY ACUTE MYELOGENOUS LEUKEMIA (AML) CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 BY ADMINISTERING A ONCE DAILY 500 MG ORAL DOSE TO A SUBJECT THAT HAS NOT INGESTED A HIGH-FAT MEAL"
  },
  {
    "Code": "U-3114",
    "Definition": "TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) BY ORALLY ADMINISTERING VENETOCLAX TO AN ADULT ACCORDING TO A DOSE RAMP-UP THAT INCLUDES A DOSE OF 50 MG PER DAY FOR 1 WEEK FOLLOWED BY 100 MG PER DAY FOR 1 WEEK"
  },
  {
    "Code": "U-3115",
    "Definition": "METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING ABOUT 1 G OF IRON AS FERRIC CARBOXYMALTOSE IN ABOUT 15 MINUTES OR LESS"
  },
  {
    "Code": "U-3116",
    "Definition": "METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WHO HAVE NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING ABOUT 1 G OF IRON AS FERRIC CARBOXYMALTOSE IN ABOUT 15 MINUTES OR LESS"
  },
  {
    "Code": "U-3117",
    "Definition": "ADMINISTRATION TO THE EYE OF A PATIENT FOR TREATMENT OF DRY EYE CONDITION"
  },
  {
    "Code": "U-3118",
    "Definition": "TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER BUNIONECTOMY, OPEN INGUINAL HERNIORRHAPHY, OR TOTAL KNEE ARTHROPLASTY VIA SOFT TISSUE OR PERIARTICULAR INSTILLATION"
  },
  {
    "Code": "U-3119",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 11"
  },
  {
    "Code": "U-3120",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1, 11, AND 12"
  },
  {
    "Code": "U-3121",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 13 AND 23"
  },
  {
    "Code": "U-3122",
    "Definition": "ADJUNCT TO DIET EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 13, 23, AND 24"
  },
  {
    "Code": "U-3123",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF COMPLEMENT INHIBITOR PEGCETACOPLAN"
  },
  {
    "Code": "U-3124",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF PEGCETACOPLAN"
  },
  {
    "Code": "U-3125",
    "Definition": "USE FOR LOADING DOSE IN PATIENTS WITH SYMPTOMATIC AFIB\/AFL WHO ARE CURRENTLY IN SINUS RHYTHM OR FOR THE TREATMENT OF LIFE-THREATENING VENTRICULAR TACHYCARDIA"
  },
  {
    "Code": "U-3126",
    "Definition": "USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A SECOND AND FURTHER CARDIOVASCULAR EVENT IN AN ADULT PATIENT WITH ESTABLISHED CARDIOVASCULAR DISEASE"
  },
  {
    "Code": "U-3127",
    "Definition": "REDUCTION OF THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION AND WITHOUT TYPE II DIABETES"
  },
  {
    "Code": "U-3128",
    "Definition": "TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI, KLEBSIELLA PNEUMONIA, ENTEROBACTER CLOACAE SPECIES COMPLEX WITH MEROPENEM & VABORBACTAM AS SPECIFIED"
  },
  {
    "Code": "U-3129",
    "Definition": "MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS) IN PREMENOPAUSAL WOMEN"
  },
  {
    "Code": "U-3130",
    "Definition": "METHOD OF POSITRON EMISSION TOMOGRAPHY (PET) IN MEN WITH PROSTATE CANCER"
  },
  {
    "Code": "U-3131",
    "Definition": "USE OF ZUBSOLV FOR TREATMENT OF OPIOID DEPENDENCE"
  },
  {
    "Code": "U-3132",
    "Definition": "INDICATED FOR THE TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS"
  },
  {
    "Code": "U-3133",
    "Definition": "TREATING SICKLE CELL DISEASE BY ADMINISTERING 1500 MG OF VOXELOTOR ORALLY ONCE DAILY"
  },
  {
    "Code": "U-3134",
    "Definition": "INCREASING HEMOGLOBIN TO TREAT SICKLE CELL DISEASE BY ADMINISTERING 1500 MG OF VOXELOTOR ORALLY ONCE DAILY"
  },
  {
    "Code": "U-3135",
    "Definition": "TREATING SCHIZOPHRENIA"
  },
  {
    "Code": "U-3136",
    "Definition": "METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN"
  },
  {
    "Code": "U-3137",
    "Definition": "METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCED ANTIPSYCHOTIC INDUCED WEIGHT GAIN"
  },
  {
    "Code": "U-3138",
    "Definition": "METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCTION OF THE ADVERSE METABOLIC PROFILE"
  },
  {
    "Code": "U-3139",
    "Definition": "METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN, WITH REDUCTION OF THE ADVERSE METABOLIC PROFILE"
  },
  {
    "Code": "U-3140",
    "Definition": "METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN"
  },
  {
    "Code": "U-3141",
    "Definition": "METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING THE ATYPICAL ANTIPSYCHOTIC OLANZAPINE AND SAMIDORPHAN"
  },
  {
    "Code": "U-3142",
    "Definition": "PREVENTIVE TREATMENT OF EPISODIC MIGRAINE IN ADULTS"
  },
  {
    "Code": "U-3143",
    "Definition": "FOR THE TOPICAL TREATMENT OF PLAQUE PSORIASIS IN PATIENTS 18 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-3144",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR"
  },
  {
    "Code": "U-3145",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE A R117H MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR"
  },
  {
    "Code": "U-3146",
    "Definition": "TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELX, TEZ, AND IVA"
  },
  {
    "Code": "U-3147",
    "Definition": "FOR THE TREATMENT OF NEWLY-DIAGNOSED THERAPY-RELATED ACUTE MYELOID LEUKEMIA (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN ADULTS AND PEDIATRIC PATIENTS 1 YEAR AND OLDER"
  },
  {
    "Code": "U-3148",
    "Definition": "METHOD OF TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS BEFORE AND AFTER ADMINISTERING AN INACTIVE VACCINE"
  },
  {
    "Code": "U-3149",
    "Definition": "METHOD OF RECONSTITUTING A LYOPHILIZED LIPOSOMAL COMPOSITION FOR ADMINISTERING CYTARABINE AND DAUNORUBICIN TO TREAT NEWLY-DIAGNOSED THERAPY-RELATED AML (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PATIENTS 1 YEAR AND OLDER"
  },
  {
    "Code": "U-3150",
    "Definition": "METHOD OF ADMINISTERING A RECONSTITUTED LIPOSOMAL COMPOSITION CONTAINING CYTARABINE AND DAUNORUBICIN TO TREAT NEWLY-DIAGNOSED THERAPY-RELATED AML (T-AML) OR AML WITH MYELODYSPLASIA-RELATED CHANGES (AML-MRC) IN PATIENTS 1 YEAR AND OLDER"
  },
  {
    "Code": "U-3151",
    "Definition": "TO IMPROVE WAKEFULNESS IN ADULT PATIENTS WITH EXCESSIVE DAYTIME SLEEPINESS ASSOCIATED WITH NARCOLEPSY OR OBSTRUCTIVE SLEEP APNEA (OSA) WITH A DOSING REGIMEN THAT INCLUDES A DOSE OF 75 MG ONCE DAILY FOR AT LEAST 3 DAYS FOLLOWED BY 150 MG ONCE DAILY"
  },
  {
    "Code": "U-3152",
    "Definition": "USE BY FEMALES OF REPRODUCTIVE POTENTIAL TO PREVENT PREGNANCY"
  },
  {
    "Code": "U-3153",
    "Definition": "TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOR IN PATIENTS HAVING PROGRESSED FROM A FIRST LINE ADMINISTRATION OF IMATINIB, A SECOND LINE ADMINISTRATION OF SUNITINIB, AND A THIRD LINE ADMINISTRATION OF REGORAFENIB"
  },
  {
    "Code": "U-3154",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH A COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR; AND ANOTHER COMPOSITION COMPRISING IVACAFTOR"
  },
  {
    "Code": "U-3155",
    "Definition": "TREATMENT OF CF IN PATIENTS 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA USING A SOLID COMPOSITION COMPRISING ELX, TEZ, AMORPHOUS IVA, AND < ~30% CRYSTALLINE IVA"
  },
  {
    "Code": "U-3156",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR"
  },
  {
    "Code": "U-3157",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US 10081621"
  },
  {
    "Code": "U-3158",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH AN EFFECTIVE AMOUNT OF ELX, TEZ, AND IVA"
  },
  {
    "Code": "U-3159",
    "Definition": "TREATMENT OF ADULT AND POST-MENARCHAL PEDIATRIC FEMALES WITH VULVOVAGINAL CANDIDIASIS (VVC)"
  },
  {
    "Code": "U-3160",
    "Definition": "PROPHYLAXIS OF INVASIVE ASPERGILLUS AND CANDIDA INFECTIONS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WHO ARE SEVERELY IMMUNOCOMPROMISED"
  },
  {
    "Code": "U-3161",
    "Definition": "METHOD FOR WEIGHT MANAGEMENT ACCORDING TO A DOSE ESCALATION SCHEDULE"
  },
  {
    "Code": "U-3162",
    "Definition": "METHOD FOR WEIGHT MANAGEMENT"
  },
  {
    "Code": "U-3163",
    "Definition": "TREATMENT OF ACTINIC KERATOSIS OF UPPER EXTREMITIES BY PHOTODYNAMIC THERAPY"
  },
  {
    "Code": "U-3164",
    "Definition": "GASTROINTESTINAL TABLETS INDICATED FOR CLEANSING THE COLON IN PREPARATION FOR COLONOSCOPY"
  },
  {
    "Code": "U-3165",
    "Definition": "METHOD OF TREATING HUMAN SMALLPOX DISEASE"
  },
  {
    "Code": "U-3166",
    "Definition": "OTC USE: ALLERGY SYMPTOM RELIEVER; TEMPORARY RELIEF OF THESE SYMPTOMS DUE TO HAY FEVER OR OTHER UPPER RESPIRATORY ALLERGIES: NASAL CONGESTION, RUNNY NOSE, SNEEZING AND ITCHY NOSE"
  },
  {
    "Code": "U-3167",
    "Definition": "TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, OR 6 IN PEDIATRIC PATIENTS 3 TO LESS THAN 12 YEARS OF AGE OR WEIGHING LESS THAN 45 KG"
  },
  {
    "Code": "U-3168",
    "Definition": "TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS, INCLUDING PATIENTS WITH AGGRESSIVE SYSTEMIC MASTOCYTOSIS (ASM), SYSTEMIC MASTOCYTOSIS WITH AN ASSOCIATED HEMATOLOGICAL NEOPLASM (SM-AHN), AND MAST CELL LEUKEMIA (MCL)"
  },
  {
    "Code": "U-3169",
    "Definition": "TREATMENT OF TRICHOMONIASIS IN ADULTS"
  },
  {
    "Code": "U-3170",
    "Definition": "TREATING CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION IN PATIENTS NOT TAKING AN ACE INHIBITOR OR AN ARB OR PREVIOUSLY TAKING LOW DOSES OF THESE AGENTS, BY TITRATING UP FROM HALF THE USUALLY RECOMMENDED STARTING DOSE"
  },
  {
    "Code": "U-3171",
    "Definition": "TREATMENT OF INVASIVE ASPERGILLOSIS IN ADULTS AND PEDIATRIC PATIENTS 13 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-3172",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF 1080 MG OF PEGCETACOPLAN"
  },
  {
    "Code": "U-3173",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF 1080 MG OF PEGCETACOPLAN TWICE WEEKLY"
  },
  {
    "Code": "U-3174",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF 1080 MG OF PEGCETACOPLAN EVERY THREE DAYS"
  },
  {
    "Code": "U-3175",
    "Definition": "TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS BY ADMINISTERING THE FORMULATION OF DAPTOMYCIN AS RECITED IN CLAIM 18"
  },
  {
    "Code": "U-3176",
    "Definition": "TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND S. AUREUS BLOODSTREAM INFECTIONS (BACTEREMIA) INCLUDING THOSE WITH RIGHT-SIDED INFECTIVE ENDOCARDITIS BY RECONSTITUTING AND ADMINISTERING THE FORMULATION AS RECITED IN CLAIM 12"
  },
  {
    "Code": "U-3177",
    "Definition": "TREATMENT OF VENOUS THROMBOTIC DISEASE"
  },
  {
    "Code": "U-3178",
    "Definition": "REDUCE THE RISK OF RECURRENCE OF VENOUS THROMBOTIC DISEASE"
  },
  {
    "Code": "U-3179",
    "Definition": "METHOD OF TREATING FOLLICULAR LYMPHOMA"
  },
  {
    "Code": "U-3180",
    "Definition": "DECREASING OFF TIME IN PATIENTS WITH PARKINSON'S DISEASE RECEIVING LEVODOPA-BASED THERAPY, WITH OR WITHOUT CONCOMITANT DOPAMINERGIC MEDICATIONS"
  },
  {
    "Code": "U-3181",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS 6 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE TABLET ACCORDING TO CLAIM 1 OF U.S. PATENT NO. 11,052,075, WHERE THE TABLET FURTHER COMPRISES IVACAFTOR"
  },
  {
    "Code": "U-3182",
    "Definition": "METHOD OF PROVIDING POSTSURGICAL PAIN MANAGEMENT, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA"
  },
  {
    "Code": "U-3183",
    "Definition": "USE OF EPHEDRINE SULFATE FOR TREATING HYPOTENSION"
  },
  {
    "Code": "U-3184",
    "Definition": "MEKINIST(R) IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION"
  },
  {
    "Code": "U-3185",
    "Definition": "TAFINLAR(R) IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE ADJUVANT TREATMENT OF PATIENTS WITH MELANOMA WITH BRAF V600E OR V600K MUTATIONS AS DETECTED BY AN FDA-APPROVED TEST, AND INVOLVEMENT OF LYMPH NODE(S), FOLLOWING COMPLETE RESECTION"
  },
  {
    "Code": "U-3186",
    "Definition": "METHOD OF TREATING PRURITUS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)"
  },
  {
    "Code": "U-3187",
    "Definition": "METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)"
  },
  {
    "Code": "U-3188",
    "Definition": "IMPROVING GLYCEMIC CONTROL IN PATIENTS 10 YEARS OF AGE AND OLDER WITH TYPE 2 DIABETES MELLITUS BY ADMINISTERING A SUSTAINED-RELEASE EXENATIDE FORMULATION AS AN ADJUNCT TO DIET AND EXERCISE"
  },
  {
    "Code": "U-3189",
    "Definition": "AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH INSULIN ALONE OR INSULIN PLUS ONE OTHER ORAL ANTIDIABETIC MEDICATION"
  },
  {
    "Code": "U-3190",
    "Definition": "AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS 10 TO 17 YEARS OF AGE WITH TYPE 2 DIABETES MELLITUS IN COMBINATION WITH METFORMIN AND\/OR SULFONYLUREA"
  },
  {
    "Code": "U-3191",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (30 ML\/MIN\/1.73 M2<=EGFR<60 ML\/MIN\/1.73 M2) BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN"
  },
  {
    "Code": "U-3192",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH RENAL IMPAIRMENT (EGFR<60 ML\/MIN\/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN HCL IF EGFR>=45 ML\/MIN\/1.73 M2 AND DISCONTINUATION IF EGFR <30 ML\/MIN\/1.73 M2"
  },
  {
    "Code": "U-3193",
    "Definition": "METHOD OF TREATING TYPE 2 DIABETES MELLITUS IN A PATENT WITH RENAL IMPAIRMENT (EGFR<60 ML\/MIN\/1.73 M2) BY INITIATION OF EMPAGLIFLOZIN AND METFORMIN HCL IF EGFR>=45 ML\/MIN\/1.73 M2 AND DISCONTINUATION IF EGFR<30 ML\/MIN\/1.73 M2"
  },
  {
    "Code": "U-3194",
    "Definition": "TOPICAL TREATMENT OF ACNE VULGARIS IN ADULTS AND PEDIATRIC PATIENTS 9 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-3195",
    "Definition": "TREATMENT OF ADULTS WITH REFRACTORY, MODERATE-TO-SEVERE ATOPIC DERMATITIS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS OR WHEN USE OF THOSE THERAPIES IS INADVISABLE"
  },
  {
    "Code": "U-3196",
    "Definition": "TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 OR FGFR2 GENETIC ALTERATIONS, AND PROGRESSED DURING OR FOLLOWING PRIOR PLATINUM-CONTAINING CHEMOTHERAPY, WITH DOSING BASED ON SERUM PHOSPHATE LEVELS"
  },
  {
    "Code": "U-3197",
    "Definition": "MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE AN OPIOID ANALGESIC AND FOR WHICH ALTERNATIVE TREATMENTS ARE INADEQUATE"
  },
  {
    "Code": "U-3198",
    "Definition": "METHOD OF TREATING PATIENTS WITH IDIOPATHIC HYPERSOMNIA WITH SODIUM OXYBATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED"
  },
  {
    "Code": "U-3199",
    "Definition": "METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH PLUS HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS, HEART FAILURE AND REDUCED EJECTION FRACTION BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN"
  },
  {
    "Code": "U-3200",
    "Definition": "INCREASING SURVIVAL IN MCRPC PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL BY ADMINISTERING CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE AFTER A PREMEDICATION REGIMEN THAT INCLUDES AN ANTIHISTAMINE, A CORTICOSTEROID, AND AN H2-ANTAGONIST"
  },
  {
    "Code": "U-3201",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH VON HIPPEL-LINDAU DISEASE WHO REQUIRE THERAPY FOR ASSOCIATED RENAL CELL CARCINOMA, CENTRAL NERVOUS SYSTEM HEMANGIOBLASTOMAS, OR PANCREATIC NEUROENDOCRINE TUMORS, NOT REQUIRING IMMEDIATE SURGERY"
  },
  {
    "Code": "U-3202",
    "Definition": "MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) COMPRISING THE ONCE PER DAY ADMINISTRATION OF TRELEGY ELLIPTA, 100 MCG FLUTICASONE FUROATE\/62.5 MCG UMECLIDINIUM\/25 MCG VILANTEROL"
  },
  {
    "Code": "U-3203",
    "Definition": "MAINTENANCE TREATMENT OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)"
  },
  {
    "Code": "U-3204",
    "Definition": "TREATMENT OF MODERATE-TO-SEVERE PRURITUS ASSOCIATED WITH CHRONIC KIDNEY DISEASE (CKD-AP) IN ADULTS UNDERGOING HEMODIALYSIS (HD)"
  },
  {
    "Code": "U-3205",
    "Definition": "REDUCTION OF RISK OF MAJOR CARDIOVASCULAR EVENTS (CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION AND STROKE) IN PATIENTS WITH CAD"
  },
  {
    "Code": "U-3206",
    "Definition": "REDUCTION OF RISK OF MAJOR THROMBOTIC VASCULAR EVENTS (MYOCARDIAL INFARCTION, ISCHEMIC STROKE, ACUTE LIMB ISCHEMIA, AND MAJOR AMPUTATION OF VASCULAR ETIOLOGY) IN PATIENTS WITH PAD"
  },
  {
    "Code": "U-3207",
    "Definition": "REDUCTION OF RISK OF CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE IN PATIENTS WITH CAD BY ADMINISTERING CLINICALLY PROVEN EFFECTIVE AMOUNTS THAT ARE 2.5 MG RIVAROXABAN TWICE DAILY AND 75-100 MG ASPIRIN DAILY"
  },
  {
    "Code": "U-3208",
    "Definition": "REDUCTION OF RISK OF MYOCARDIAL INFARCTION AND ISCHEMIC STROKE IN PATIENTS WITH PAD BY ADMINISTERING CLINICALLY PROVEN EFFECTIVE AMOUNTS THAT ARE 2.5 MG RIVAROXABAN TWICE DAILY AND 75-100 MG ASPIRIN DAILY"
  },
  {
    "Code": "U-3209",
    "Definition": "USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK MYOCARDIAL INFARCTION IN AN ADULT PATIENT HAVING ATRIAL FIBRILLATION OR ATRIAL FLUTTER AND ELEVATED TRIGLYCERIDE LEVELS"
  },
  {
    "Code": "U-3210",
    "Definition": "ONCE DAILY TREATMENT OF ANXIETY DISORDER IN ADULTS"
  },
  {
    "Code": "U-3211",
    "Definition": "TREATING DISTRIBUTIVE SHOCK WITH ANGIOTENSIN II"
  },
  {
    "Code": "U-3212",
    "Definition": "TREATING SEPTIC SHOCK WITH ANGIOTENSIN II"
  },
  {
    "Code": "U-3213",
    "Definition": "A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHEREIN THE CANCER IS PREVIOUSLY TREATED, LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA"
  },
  {
    "Code": "U-3214",
    "Definition": "A METHOD OF TREATING PREVIOUSLY TREATED, LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 BY ADMINISTERING A ONCE DAILY 500 MG ORAL DOSE TO A SUBJECT THAT HAS NOT INGESTED A HIGH-FAT MEAL"
  },
  {
    "Code": "U-3215",
    "Definition": "A METHOD OF TREATING PREVIOUSLY TREATED, LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA CHARACTERIZED BY AN IDH1 MUTATION"
  },
  {
    "Code": "U-3216",
    "Definition": "A METHOD FOR TREATING A BCRABL POSITIVE LEUKEMIA IN A SUBJECT THAT IS RESISTANT TO IMATINIB COMPRISING ADMINISTERING TO THE SUBJECT A THERAPEUTICALLY EFFECTIVE AMOUNT OF BOSUTINIB, WHEREIN THE SUBJECT HAS A MUTATION IN THE BCRABL PROTEIN AT 949T>C"
  },
  {
    "Code": "U-3217",
    "Definition": "A METHOD FOR TREATING A BCRABL POSITIVE LEUKEMIA IN A SUBJECT THAT IS RESISTANT TO IMATINIB COMPRISING ADMINISTERING TO THE SUBJECT A THERAPEUTICALLY EFFECTIVE AMOUNT OF BOSUTINIB, WHEREIN THE SUBJECT HAS A MUTATION IN THE BCRABL PROTEIN AT F317L"
  },
  {
    "Code": "U-3218",
    "Definition": "NASAL ADMINISTRATION OF DIHYDROERGOTAMINE MESYLATE BY METERED SPRAY FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA"
  },
  {
    "Code": "U-3219",
    "Definition": "TREATMENT OF GASTROINTESTINAL STROMAL TUMOR"
  },
  {
    "Code": "U-3220",
    "Definition": "TREATMENT OF PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC) WITH EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) EXON 20 EXON INSERTION MUTATIONS WHOSE DISEASE HAS PROGRESSED ON OR AFTER PLATINUM-BASED CHEMOTHERAPY"
  },
  {
    "Code": "U-3221",
    "Definition": "USE OF VASCEPA AS AN ADJUNCT TO STATIN THERAPY TO REDUCE THE RISK OF A CARDIOVASCULAR EVENT IN A PATIENT WITH PRIOR PERCUTANEOUS CORONARY INTERVENTION"
  },
  {
    "Code": "U-3222",
    "Definition": "TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) BY ORALLY ADMINISTERING VENETOCLAX WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE IN ADULTS 75 YEARS OR OLDER OR HAVING CERTAIN COMORBIDITIES ACCORDING TO A DOSE RAMP-UP INCLUDING A 100 MG PER DAY DOSE"
  },
  {
    "Code": "U-3223",
    "Definition": "TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) BY ORALLY ADMINISTERING VENETOCLAX TO AN ADULT ACCORDING TO A DOSE RAMP-UP INCLUDING A 100 MG PER DAY DOSE"
  },
  {
    "Code": "U-3224",
    "Definition": "A METHOD OF TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE BY DECREASING THE LEVEL OF LDL-C USING A FIXED DOSE COMBINATION OF 180 MG BEMPEDOIC ACID AND 10 MG EZETIMIBE"
  },
  {
    "Code": "U-3225",
    "Definition": "TREATMENT OF DIFFERENTIATED THYROID CANCER THAT HAS PROGRESSED FOLLOWING PRIOR VEGFR-TARGETED THERAPY"
  },
  {
    "Code": "U-3226",
    "Definition": "FOR TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR TWO LINES OF SYSTEMIC THERAPY"
  },
  {
    "Code": "U-3227",
    "Definition": "FOR TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS (MF), INCLUDING PRIMARY MF, POST-POLYCYTHEMIA VERA MF AND POST-ESSENTIAL THROMBOCYTHEMIA MF"
  },
  {
    "Code": "U-3228",
    "Definition": "FOR TREATMENT OF POLYCYTHEMIA VERA (PV) IN PATIENTS WHO HAVE HAD AN INADEQUATE RESPONSE TO OR ARE INTOLERANT OF HYDROXYUREA"
  },
  {
    "Code": "U-3229",
    "Definition": "FOR TOPICAL SHORT-TERM, NON-CONTINUOUS CHRONIC TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN NON-IMMUNOCOMPROMISED PATIENTS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT ADVISABLE"
  },
  {
    "Code": "U-3230",
    "Definition": "FOR TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD)"
  },
  {
    "Code": "U-3231",
    "Definition": "TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA (PH+CML) BY ADMINISTERING NILOTINIB DISPERSED IN A FRUIT PREPARATION"
  },
  {
    "Code": "U-3232",
    "Definition": "USE OF ORAL OCTREOTIDE FOR LONG-TERM MAINTENANCE TREATMENT IN ACROMEGALY PATIENTS WHILE AVOIDING CONCOMITANT ADMINISTRATION OF LEVONORGESTREL"
  },
  {
    "Code": "U-3233",
    "Definition": "USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX IN PATIENTS TAKING EVEROLIMUS"
  },
  {
    "Code": "U-3234",
    "Definition": "TREATMENT OF MACULAR EDEMA ASSOCIATED WITH UVEITIS"
  },
  {
    "Code": "U-3235",
    "Definition": "USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME"
  },
  {
    "Code": "U-3236",
    "Definition": "USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME"
  },
  {
    "Code": "U-3237",
    "Definition": "TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER OR WEIGHING AT LEAST 45 KG"
  },
  {
    "Code": "U-3238",
    "Definition": "TREATMENT OF CHRONIC HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5, OR 6 IN PEDIATRIC PATIENTS 3 TO LESS THAN 12 YEARS OF AGE OR WEIGHING LESS THAN 45 KG"
  },
  {
    "Code": "U-3239",
    "Definition": "TREATMENT OF ADVANCED RENAL CELL CARCINOMA (RCC) IN PATIENTS WHO HAVE RECEIVED PRIOR ANTI-ANGIOGENIC THERAPY"
  },
  {
    "Code": "U-3240",
    "Definition": "USE OF VASCEPA TO REDUCE TRIGLYCERIDE LEVELS IN AN ADULT PATIENT HAVING TRIGLYCERIDE LEVELS OF AT LEAST ABOUT 500 MG\/DL, ON ANTICOAGULANT\/ANTIPLATELET\/THROMBOLYTIC THERAPY, AND HAVING ATRIAL FIBRILLATION AND\/OR ATRIAL FLUTTER"
  },
  {
    "Code": "U-3241",
    "Definition": "IN COMBINATION WITH ENDOCRINE THERAPY (TAMOXIFEN OR AN AROMATASE INHIBITOR) FOR THE ADJUVANT TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE, NODE-POSITIVE, EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE AND A KI-67 SCORE >=20%"
  },
  {
    "Code": "U-3242",
    "Definition": "IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING ENDOCRINE THERAPY"
  },
  {
    "Code": "U-3243",
    "Definition": "IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN, AND MEN WITH HR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER"
  },
  {
    "Code": "U-3244",
    "Definition": "A METHOD FOR TREATMENT OF PAIN IN ADULTS USING TRAMADOL HYDROCHLORIDE AND CELECOXIB"
  },
  {
    "Code": "U-3245",
    "Definition": "MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER"
  },
  {
    "Code": "U-3246",
    "Definition": "FOR THE TREATMENT OF CHRONIC GRAFT VERSUS HOST DISEASE"
  },
  {
    "Code": "U-3247",
    "Definition": "FOR THE TREATMENT OF CHRONIC GRAFT VERSUS HOLD DISEASE"
  },
  {
    "Code": "U-3248",
    "Definition": "TREATING SECONDARY HYPERPARATHYROIDISM IN STAGE 3\/4 CHRONIC KIDNEY DISEASE WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL WHILE AVOIDING PTH OVERSUPPRESSION"
  },
  {
    "Code": "U-3249",
    "Definition": "TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 12 YEARS OF AGE AND 40 KG)"
  },
  {
    "Code": "U-3250",
    "Definition": "METHOD OF TREATING PAIN, FOR EXAMPLE, TREATING POSTSURGICAL PAIN VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA"
  },
  {
    "Code": "U-3251",
    "Definition": "ADMINISTRATION OF FERROUS BISGLYCINATE TABLETS"
  },
  {
    "Code": "U-3252",
    "Definition": "USE OF VUITY FOR THE TREATMENT OF PRESBYOPIA IN ADULTS"
  },
  {
    "Code": "U-3253",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A MUTATION THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOSITION ACCORDING TO AT LEAST ONE OF CLAIMS 1-9 OF US11179367"
  },
  {
    "Code": "U-3254",
    "Definition": "USE, IN COMBINATION WITH LOW-DOSE CYTARABINE, FOR THE TREATMENT OF NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA (AML) IN ADULT PATIENTS WHO ARE >= 75 YEARS OLD OR WHO HAVE COMORBIDITIES THAT PRECLUDE USE OF INTENSIVE INDUCTION CHEMOTHERAPY"
  },
  {
    "Code": "U-3255",
    "Definition": "TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS"
  },
  {
    "Code": "U-3256",
    "Definition": "USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WHO ARE 5 YEARS OF AGE AND OLDER WITH OPEN EPIPHYSES"
  },
  {
    "Code": "U-3257",
    "Definition": "TREATMENT OF TRD IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE IN A MAINTENANCE PHASE WEEKLY OR 1X EVERY TWO WEEKS TO ADULTS WHO HAVE BEEN ADMINISTERED ESKETAMINE IN A INDUCTION PHASE FOR ABOUT 4 WEEKS"
  },
  {
    "Code": "U-3258",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC MALIGNANT PERIVASCULAR EPITHELIOID CELL TUMOR (PECOMA) WITH A DOSE BETWEEN ABOUT 56 MG\/M2 AND ABOUT 100 MG\/M2 ADMINISTERED ON DAYS 1 AND 8 OF A 21-DAY CYCLE"
  },
  {
    "Code": "U-3259",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC MALIGNANT PERIVASCULAR EPITHELIOID CELL TUMOR (PECOMA)"
  },
  {
    "Code": "U-3260",
    "Definition": "METHOD OF TREATING SPASTICITY"
  },
  {
    "Code": "U-3261",
    "Definition": "FOR CLEANSING OF THE COLON AS A PREPARATION FOR COLONOSCOPY"
  },
  {
    "Code": "U-3262",
    "Definition": "TREATING HYPOTENSION WITH ANGIOTENSIN II IN A PATIENT RECEIVING AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR"
  },
  {
    "Code": "U-3263",
    "Definition": "METHOD FOR TREATING SPASTICITY"
  },
  {
    "Code": "U-3264",
    "Definition": "AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER"
  },
  {
    "Code": "U-3265",
    "Definition": "IN COMBINATION WITH AN AROMATASE INHIBITOR AS INITIAL ENDOCRINE-BASED THERAPY FOR THE TREATMENT OF ADULT PATIENTS WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER"
  },
  {
    "Code": "U-3266",
    "Definition": "IN COMBINATION WITH FULVESTRANT AS INITIAL ENDOCRINE-BASED THERAPY OR FOLLOWING DISEASE PROGRESSION ON ENDOCRINE THERAPY IN POSTMENOPAUSAL WOMEN OR IN MEN, FOR THE TREATMENT OF HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER"
  },
  {
    "Code": "U-3267",
    "Definition": "USE OF LASTACAFT TO TEMPORARY RELIEVE ITCHY EYES DUE TO POLLEN, RAGWEED, GRASS, ANIMAL HAIR AND DANDER"
  },
  {
    "Code": "U-3268",
    "Definition": "TREATMENT OF MULTIPLE SCLEROSIS IN PEDIATRIC PATIENTS 10 YEARS OF AGE AND OLDER AND WEIGHING LESS THAN OR EQUAL TO 40 KG"
  },
  {
    "Code": "U-3269",
    "Definition": "TREATMENT OF PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) IN ADULTS AT RISK OF RAPID DISEASE PROGRESSION"
  },
  {
    "Code": "U-3270",
    "Definition": "TREATMENT OF BACTERIAL VAGINOSIS IN FEMALE PATIENTS 12 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-3271",
    "Definition": "TREATMENT OF BIPOLAR DEPRESSION"
  },
  {
    "Code": "U-3272",
    "Definition": "AS AN ADJUNCT TO DIET AND MAXIMALLY TOLERATED STATIN THERAPY FOR THE TREATMENT OF ADULTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH) OR CLINICAL ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD), BY INHIBITING EXPRESSION OF THE PCSK9 GENE"
  },
  {
    "Code": "U-3274",
    "Definition": "TREATMENT OF BIPOLAR I DISORDER, BIPOLAR II DISORDER, OR BIPOLAR DEPRESSION"
  },
  {
    "Code": "U-3275",
    "Definition": "TREATMENT OF ADULTS WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS"
  },
  {
    "Code": "U-3276",
    "Definition": "TREATMENT OF PATIENTS WITH PLAQUE PSORIASIS WHO ARE CANDIDATES FOR PHOTOTHERAPY OR SYSTEMIC THERAPY"
  },
  {
    "Code": "U-3277",
    "Definition": "USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX"
  },
  {
    "Code": "U-3278",
    "Definition": "A METHOD OF REDUCING POST-SURGICAL PAIN FOLLOWING OCULAR SURGERY"
  },
  {
    "Code": "U-3279",
    "Definition": "A METHOD OF TREATING POSTOPERATIVE INFLAMMATION FOLLOWING OCULAR SURGERY"
  },
  {
    "Code": "U-3280",
    "Definition": "METHOD OF TREATING ACNE VULGARIS WITH TOPICALLY APPLIED CORTEXOLONE 17ALPHA-PROPIONATE"
  },
  {
    "Code": "U-3281",
    "Definition": "TREATMENT OF SCHIZOPHRENIA IN ADULTS AND PEDIATRIC PATIENTS AGES 13 YEARS AND OLDER"
  },
  {
    "Code": "U-3282",
    "Definition": "DURING LEVOKETOCONAZOLE DOSAGE TITRATION FOR THE TREATMENT OF CUSHING'S SYNDROME IN PATIENTS WHO CONCOMITANTLY USE METFORMIN, MONITORING GLYCEMIA, KIDNEY FUNCTION AND VITAMIN B-12 AND ADJUSTING DOSAGE OF METFORMIN AS NEEDED"
  },
  {
    "Code": "U-3283",
    "Definition": "TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHINGS SYNDROME FOR WHOM SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE"
  },
  {
    "Code": "U-3284",
    "Definition": "PROPHYLAXIS OF THROMBOEMBOLIC DISEASES IN PEDIATRIC PATIENTS AGED 2 YEARS AND OLDER WITH CONGENITAL HEART DISEASE WHO HAVE UNDERGONE THE FONTAN PROCEDURE AND A BODY WEIGHT OF >=50 KG"
  },
  {
    "Code": "U-3285",
    "Definition": "TREATMENT OF DVT AND\/OR PE AND REDUCTION IN THE RISK OF RECURRENT DVT AND\/OR PE IN PEDIATRIC PATIENTS (>=50 KG) ONCE DAILY WITH RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS AFTER AT LEAST 5 DAYS PARENTERAL ANTICOAGULANT TREATMENT"
  },
  {
    "Code": "U-3286",
    "Definition": "TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) AND THE REDUCTION IN THE RISK OF RECURRENT VTE IN PEDIATRIC PATIENTS FROM BIRTH TO LESS THAN 18 YEARS WITH A BODY WEIGHT OF 30 KG TO 49.9 KG AFTER AT LEAST 5 DAYS OF INITIAL PARENTERAL ANTICOAGULANT TREATMENT"
  },
  {
    "Code": "U-3287",
    "Definition": "TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) AND THE REDUCTION IN THE RISK OF RECURRENT VTE IN PEDIATRIC PATIENTS FROM BIRTH TO LESS THAN 18 YEARS WITH A BODY WEIGHT OF >=50 KG AFTER AT LEAST 5 DAYS OF INITIAL PARENTERAL ANTICOAGULANT TREATMENT"
  },
  {
    "Code": "U-3288",
    "Definition": "PROPHYLAXIS OF PE, DVT AND\/OR STROKE IN PEDIATRIC PATIENTS (>=50 KG) AGED 2 YEARS AND OLDER WITH CONGENITAL HEART DISEASE AFTER FONTAN PROCEDURE WITH ONCE DAILY, RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS"
  },
  {
    "Code": "U-3289",
    "Definition": "TREATMENT OF DVT AND\/OR PE AND REDUCTION IN RISK OF RECURRENT DVT AND\/OR PE IN PEDIATRIC PATIENTS (30-49.9 KG) ONCE DAILY WITH RAPID-RELEASE TABLET ADMINISTERED FOR AT LEAST 5 CONSECUTIVE DAYS AFTER AT LEAST 5 DAYS PARENTERAL ANTICOAGULANT TREATMENT"
  },
  {
    "Code": "U-3290",
    "Definition": "TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS WITH ALAGILLE SYNDROME (ALGS)"
  },
  {
    "Code": "U-3291",
    "Definition": "CYTALUX IS AN OPTICAL IMAGING AGENT INDICATED IN ADULT PATIENTS WITH OVARIAN CANCER AS AN ADJUNCT FOR INTRAOPERATIVE IDENTIFICATION OF MALIGNANT LESIONS"
  },
  {
    "Code": "U-3292",
    "Definition": "USE OF VASCEPA TO REDUCE TRIGLYCERIDE LEVELS IN AN ADULT PATIENT ON STATIN THERAPY AND HAVING ATRIAL FIBRILLATION OR ATRIAL FLUTTER AND TRIGLYCERIDE LEVELS OF ABOUT 500 MG\/DL TO ABOUT 2,000 MG\/DL"
  },
  {
    "Code": "U-3293",
    "Definition": "METHOD OF TREATING BACTERIAL VAGINOSIS BY SINGLE DOSE ADMINISTRATION OF A CLINDAMYCIN PHARMACEUTICAL GEL FORMULATION"
  },
  {
    "Code": "U-3294",
    "Definition": "METHOD OF TREATING A BACTERIAL INFECTION BY ADMINISTERING A RECONSTITUTED SOLID FORMULATION OF DAPTOMYCIN CONTAINING 31.0 TO 59.4% WT TOTAL MANNITOL AND SORBITOL"
  },
  {
    "Code": "U-3295",
    "Definition": "METHOD OFDELIVERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE TO ANASALAIRWAY"
  },
  {
    "Code": "U-3296",
    "Definition": "TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE TO A PEDIATRIC PATIENT"
  },
  {
    "Code": "U-3297",
    "Definition": "TREATMENT OF SEASONAL ALLERGIC RHINITIS BY NASALY ADMINISTERING A COMBINATION OF OLOPATADINE HYDROCHLORIDE AND MOMETASONE FUROATE"
  },
  {
    "Code": "U-3298",
    "Definition": "TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH REFRACTORY, MODERATE TO SEVERE ATOPIC DERMATITIS WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH OTHER SYSTEMIC DRUG PRODUCTS, OR WHEN USE OF THOSE THERAPIES ARE INADVISABLE"
  },
  {
    "Code": "U-3299",
    "Definition": "TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) IN PEDIATRIC PATIENTS"
  },
  {
    "Code": "U-3300",
    "Definition": "PROPHYLAXIS TO PREVENT ATTACKS OF HEREDITARY ANGIOEDEMA (HAE) IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-3301",
    "Definition": "TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH HEPATIC VENO-OCCLUSIVE DISEASE (VOD), ALSO KNOWN AS SINUSOIDAL OBSTRUCTION SYNDROME (SOS), WITH RENAL OR PULMONARY DYSFUNCTION FOLLOWING HEMATOPOIETIC STEM-CELL TRANSPLANTATION (HSCT)"
  },
  {
    "Code": "U-3302",
    "Definition": "TREATMENT OF TRICHOMONIASIS IN PATIENTS 12 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-3303",
    "Definition": "TOPICAL LESION-DIRECTED AND FIELD-DIRECTED TREATMENT OF ACTINIC KERATOSIS OF THE FACE AND SCALP WITH PHOTODYNAMIC THERAPY BY POSITIONING AN ILLUMINATION DEVICE IN AN APPROPRIATE DISTANCE AND ILLUMINATING THE TREATMENT AREA WITH NARROWBAND RED LIGHT"
  },
  {
    "Code": "U-3304",
    "Definition": "METHOD OF TREATING PARKINSON'S DISEASE BY ORALLY ADMINISTERING SEGMENTS OF A FUNCTIONALLY MULTISCORED, BILAYERED TABLET HAVING CARBIDOPA25 MG\/LEVODOPA100 MG, EACH SEGMENT HAVING CARBIDOPA6.25 MG\/LEVODOPA25 MG"
  },
  {
    "Code": "U-3305",
    "Definition": "METHOD OF TREATING PARKINSON'S DISEASE BY ORALLY ADMINISTERING A FUNCTIONALLY MULTISCORED, BILAYERED TABLET HAVING CARBIDOPA25 MG\/LEVODOPA100 MG"
  },
  {
    "Code": "U-3306",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), AS DETERMINED BY AN FDA-APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR SYSTEMIC THERAPY"
  },
  {
    "Code": "U-3307",
    "Definition": "TREATMENT OF HIV-1 INFECTION IN PEDIATRIC PATIENTS WEIGHING AT LEAST 35KG WITH NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPPRESSED"
  },
  {
    "Code": "U-3308",
    "Definition": "FOR USE IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS TO TREAT HIV-1 INFECTION IN PEDIATRIC PATIENTS WEIGHING AT LEAST 35KG WITH NO PRIOR ANTIRETROVIRAL TREATMENT HISTORY OR TO REPLACE THE CURRENT ANTIRETROVIRAL REGIMEN IF VIROLOGICALLY SUPPRESSED"
  },
  {
    "Code": "U-3309",
    "Definition": "NORLIQVA IS INDICATED FOR THE TREATMENT OF HYPERTENSION, TO LOWER BLOOD PRESSURE IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-3310",
    "Definition": "NORLIQVA IS INDICATED FOR THE SYMPTOMATIC TREATMENT OF CHRONIC STABLE ANGINA"
  },
  {
    "Code": "U-3311",
    "Definition": "NORLIQVA IS INDICATED FOR THE TREATMENT OF CONFIRMED OR SUSPECTED VASOSPASTIC ANGINA"
  },
  {
    "Code": "U-3312",
    "Definition": "METHOD TO TREAT IDA IN ADULTS & PEDIATRIC PATIENTS 1 YR & OLDER WITH INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON & WEIGHING AT LEAST 40 KG BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 G OF ELEMENTAL IRON"
  },
  {
    "Code": "U-3313",
    "Definition": "METHOD OF TREATING IDA IN ADULT PATIENTS WITH NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE & WEIGHING AT LEAST 40 KG BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 GRAMS OF ELEMENTAL IRON"
  },
  {
    "Code": "U-3314",
    "Definition": "METHOD OF TREATING IDA IN ADULTS & PEDIATRIC PATIENTS 1 YR & OLDER HAVING INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON ASSOCIATED WITH HEAVY UTERINE BLEEDING OR GASTROINTESTINAL DISORDER BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE"
  },
  {
    "Code": "U-3315",
    "Definition": "METHOD TO TREAT IDA IN ADULTS & PEDIATRIC PATIENTS 1 YR & OLDER WITH INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON & WEIGHING AT LEAST 40 KG BY ADMINISTERING IV AT LEAST ABOUT 0.6 G OF IRON AS FERRIC CARBOXYMALTOSE IN ABOUT 15 MIN OR LESS"
  },
  {
    "Code": "U-3316",
    "Definition": "METHOD OF TREATING IDA IN ADULT PATIENTS WITH NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE & WEIGHING AT LEAST 40 KG BY INTRAVENOUSLY ADMINISTERING AT LEAST ABOUT 0.6 GRAMS OF IRON AS FERRIC CARBOXYMALTOSE IN ABOUT 15 MINUTES OR LESS"
  },
  {
    "Code": "U-3317",
    "Definition": "POSITRON EMISSION TOMOGRAPHY (PET) OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) POSITIVE LESIONS IN MEN WITH PROSTATE CANCER"
  },
  {
    "Code": "U-3318",
    "Definition": "MANAGEMENT OF MODERATE-TO-SEVERE PAIN BY INJECTION"
  },
  {
    "Code": "U-3319",
    "Definition": "METHOD OF USING A PYRUVATE KINASE ACTIVATOR FOR THE TREATMENT OF HEMOLYTIC ANEMIA IN ADULTS WITH PYRUVATE KINASE (PK) DEFICIENCY"
  },
  {
    "Code": "U-3320",
    "Definition": "METHOD FOR INCREASING THE LIFETIME OF RED BLOOD CELLS (RBCS) FOR THE TREATMENT OF HEMOLYTIC ANEMIA IN ADULTS WITH PYRUVATE KINASE (PK) DEFICIENCY"
  },
  {
    "Code": "U-3321",
    "Definition": "METHOD OF USING A PYRUVATE KINASE ACTIVATOR FOR THE TREATMENT OF HEMOLYTIC ANEMIA IN ADULTS WITH PYRUVATE KINASE (PK) DEFICIENCY BY ADMINISTERING A DAILY DOSE OF 10MG TO 100MG"
  },
  {
    "Code": "U-3322",
    "Definition": "USE FOR DETECTING NEUTRALIZING ANTIBODIES"
  },
  {
    "Code": "U-3323",
    "Definition": "METHOD OF REDUCING ADVERSE EFFECTS IN PATIENTS WHO ARE CONCOMITANTLY ADMINISTERED A SALT OF GAMMA-HYDROXYBUTYRATE AND DIVALPROEX SODIUM"
  },
  {
    "Code": "U-3324",
    "Definition": "METHOD OF TREATING PATIENTS WITH A SALT OF GAMMA-HYDROXYBUTYRATE WHEN DIVALPROEX SODIUM IS CONCOMITANTLY ADMINISTERED"
  },
  {
    "Code": "U-3325",
    "Definition": "METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS AND HEART FAILURE BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN"
  },
  {
    "Code": "U-3326",
    "Definition": "A METHOD OF TREATING ANKYLOSING SPONDYLITIS BY ADMINISTERING THE FORMULATION OF TOFACITINIB OF CLAIMS 1, 8, 15-20, 27-31, 34-43, 45, 47, 49, 50, 54, 59, 63, 68-71, 73, 77, 82-84, AND 87-98"
  },
  {
    "Code": "U-3327",
    "Definition": "A METHOD OF TREATING PSORIATIC ARTHRITIS BY ADMINISTERING THE FORMULATION OF TOFACITINIB OF CLAIMS 1, 8, 15-20, 27-31, 34-44, 46, 48, 50, 53, 59, 62, 68-71, 73, 76, 82-84, AND 87-98"
  },
  {
    "Code": "U-3328",
    "Definition": "A METHOD OF TREATING RHEUMATOID ARTHRITIS BY ADMINISTERING THE FORMULATION OF TOFACITINIB OF CLAIMS 1, 2, 8, 9, 15-21, 27-31, 34-43, 50, 51, 59, 60, 68-71, 73, 74, 82-84 AND 87-98"
  },
  {
    "Code": "U-3329",
    "Definition": "A METHOD OF TREATING ULCERATIVE COLITIS, BY ADMINISTERING THE FORMULATION OF TOFACITINIB OF CLAIMS 1, 3, 8, 10, 15-20, 22, 27-31, 34-43, 50, 52, 59, 61, 68-71, 73, 75, 82-84 AND 87-98"
  },
  {
    "Code": "U-3330",
    "Definition": "TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM PALMER-PLANTER ERYTHRODYSESTHESIA SYNDROME"
  },
  {
    "Code": "U-3331",
    "Definition": "TREATMENT OF MYELOFIBROSIS WITH PACRITINIB"
  },
  {
    "Code": "U-3332",
    "Definition": "USE OF PACRITINIB FOR INHIBITING JANUS ASSOCIATED KINASE 2(JAK2)"
  },
  {
    "Code": "U-3333",
    "Definition": "ADJUVANT TREATMENT OF PATIENTS WITH GBRCA-MUTATED HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE HIGH RISK EARLY BREAST CANCER WHO HAVE BEEN TREATED WITH NEOADJUVANT OR ADJUVANT CHEMOTHERAPY"
  },
  {
    "Code": "U-3334",
    "Definition": "A METHOD OF TRANSDERMAL DELIVERY OF DONEPEZIL FOR TREATING MILD, MODERATE AND SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE"
  },
  {
    "Code": "U-3335",
    "Definition": "TREATMENT OF HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA (HABP)"
  },
  {
    "Code": "U-3336",
    "Definition": "TREATMENT OF VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (VABP)"
  },
  {
    "Code": "U-3337",
    "Definition": "ADMINISTERING DAILY A UNIT DOSAGE OF AN IRREVERSIBLE EGFR INHIBITOR COVALENTLY BINDING AS CLAIMED FOR 1ST LINE TREATMENT OF GEFITINIB OF ERLOTINIB RESISTANT METASTATIC NSCLC WITH EGFR EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION"
  },
  {
    "Code": "U-3338",
    "Definition": "ADMINISTERING DAILY A UNIT DOSAGE OF AN IRREVERSIBLE EGFR INHIBITOR COVALENTLY BINDING AS CLAIMED FOR 1ST LINE TREATMENT OF GEFITINIB OR ERLOTINIB RESISTANT METASTATIC NSCLC WITH EGFR EXON 19 DELETION OR EXON 21 L858R SUBSTITUTION WITH T790M MUTATION"
  },
  {
    "Code": "U-3339",
    "Definition": "TREATMENT OF CF IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND\/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 11147770"
  },
  {
    "Code": "U-3340",
    "Definition": "A METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER BY ADMINISTERING A TRANSDERMAL COMPOSITION CONTAINING AMPHETAMINE"
  },
  {
    "Code": "U-3341",
    "Definition": "TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS"
  },
  {
    "Code": "U-3342",
    "Definition": "TREATMENT OF NIGHTTIME SLEEP DISTURBANCES IN SMITH-MAGENIS SYNDROME BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH BETA-ADRENERGIC RECEPTOR ANTAGONISTS"
  },
  {
    "Code": "U-3343",
    "Definition": "TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH BETA-ADRENERGIC RECEPTOR ANTAGONISTS"
  },
  {
    "Code": "U-3344",
    "Definition": "A METHOD OF TREATING ADULTS WITH MULTIPLE MYELOMA USING DEXAMETHASONE IN COMBINATION WITH AN ANTI-MYELOMA PRODUCT"
  },
  {
    "Code": "U-3345",
    "Definition": "FOR TREATMENT OF ADULT PATIENTS WITH PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) WHO HAVE BEEN TREATED WITH ANDROGEN RECEPTOR (AR) PATHWAY INHIBITION AND TAXANE-BASED CHEMOTHERAPY"
  },
  {
    "Code": "U-3346",
    "Definition": "METHOD OF PROVIDING LOCAL OR REGIONAL ANALGESIA VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK OR FEMORAL NERVE BLOCK FOR REGIONAL ANALGESIA"
  },
  {
    "Code": "U-3347",
    "Definition": "USE IN COMBINATION WITH CANNABIDIOL FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME"
  },
  {
    "Code": "U-3348",
    "Definition": "TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG"
  },
  {
    "Code": "U-3349",
    "Definition": "REINITIATION OF SCHIZOPHRENIA TREATMENT WHEREIN MORE THAN 6 MONTHS 3 WEEKS BUT LESS THAN 8 MONTHS HAVE ELAPSED SINCE THE LAST DOSE"
  },
  {
    "Code": "U-3350",
    "Definition": "ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY SUBLINGUAL ADMINISTRATION"
  },
  {
    "Code": "U-3351",
    "Definition": "METHOD OF TREATING IRON DEFICIENCY ANEMIA IN ADULT PATIENTS WITH NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE"
  },
  {
    "Code": "U-3352",
    "Definition": "METHOD TO TREAT IRON DEFICIENCY ANEMIA IN ADULTS & PEDIATRIC PATIENTS 1 YEAR AND OLDER WITH INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE"
  },
  {
    "Code": "U-3353",
    "Definition": "TREATMENT IN COMBINATION WITH CABOTEGRAVIR OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 AND OLDER TO REPLACE CURRENT REGIMEN IN THOSE WHO ARE VIROLOGICALLY SUPPRESSED ON A STABLE ANTIRETROVIRAL REGIMEN WITH NO HISTORY OF TREATMENT FAILURE"
  },
  {
    "Code": "U-3354",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF PEGCETACOPLAN SO AS TO REDUCE THE SENSITIVITY OF CELLS TO COMPLEMENT-DEPENDENT DAMAGE"
  },
  {
    "Code": "U-3355",
    "Definition": "AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS"
  },
  {
    "Code": "U-3356",
    "Definition": "TOPICAL TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA IN ADULTS 18 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-3357",
    "Definition": "TOPICAL TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA IN ADULTS 65 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-3358",
    "Definition": "USE OF VASCEPA TO REDUCE THE INCIDENCE OF MI IN AN ADULT PATIENT ON STATIN THERAPY AND WITH ELEVATED TRIGLYCERIDE LEVELS (>150 MG\/DL), WHEREIN THE PATIENT EXPERIENCES ATRIAL FIBRILLATION AND\/OR FLUTTER INSTEAD OF AN INCIDENCE OF MI"
  },
  {
    "Code": "U-3359",
    "Definition": "TREATMENT OF SCHIZOPHRENIA BY ADMINISTERING A DOSE UP TO TWO WEEKS BEFORE OR THREE WEEKS AFTER THE SCHEDULED SIX-MONTH DOSE"
  },
  {
    "Code": "U-3360",
    "Definition": "COMPLICATED INTRA-ABDOMINAL INFECTIONS (CIAI), USED IN COMBINATION WITH METRONIDAZOLE, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OF AGE)"
  },
  {
    "Code": "U-3361",
    "Definition": "COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, IN ADULT AND PEDIATRIC PATIENTS (BIRTH TO LESS THAN 18 YEARS OLD)"
  },
  {
    "Code": "U-3362",
    "Definition": "TREATMENT OF BIPOLAR DEPRESSION MEDIATED BY THE 5-HT2A RECEPTOR, SEROTONIN TRANSPORTER, AND\/OR DOPAMINE D1\/D2 SIGNALING PATHWAYS"
  },
  {
    "Code": "U-3363",
    "Definition": "TREATMENT OF SCHIZOPHRENIA MEDIATED BY THE 5-HT2A RECEPTOR, SEROTONIN TRANSPORTER, AND\/OR DOPAMINE D1\/D2 SIGNALING PATHWAYS"
  },
  {
    "Code": "U-3364",
    "Definition": "TREATMENT OF BIPOLAR DISORDER I, BIPOLAR DISORDER II, OR BIPOLAR DEPRESSION"
  },
  {
    "Code": "U-3365",
    "Definition": "THE PRODUCT COMPOSITION (NATROBA) IS FOR THE TOPICAL TREATMENT OF HUMAN SCABIES MITE INFESTATIONS BY MELTING AND DELIVERING THE ACTIVE INGREDIENT, SPINOSAD, TO THE STRATUM CORNEUM WHERE SCABIES MITES LIVE AND BREED"
  },
  {
    "Code": "U-3366",
    "Definition": "VIVJOA IS INDICATED TO REDUCE THE INCIDENCE OF RECURRENT VULVOVAGINAL CANDIDIASIS (RVVC) IN FEMALES WITH A HISTORY OF RVVC WHO ARE NOT OF REPRODUCTIVE POTENTIAL"
  },
  {
    "Code": "U-3367",
    "Definition": "TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG) REQUIRING HOSPITALIZATION"
  },
  {
    "Code": "U-3368",
    "Definition": "TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG)"
  },
  {
    "Code": "U-3369",
    "Definition": "TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 AND OLDER WITH SCLERODERMATOUS FORM OF CHRONIC GRAFT-VERSUS-HOST DISEASE ( CGVHD) AFTER FAILURE OF AT LEAST TWO PRIOR LINES OF SYSTEMIC THERAPY"
  },
  {
    "Code": "U-3370",
    "Definition": "A METHOD FOR THE TREATMENT OF ADULT PATIENTS WITH STABLE WILSONS DISEASE WHO ARE DE-COPPERED AND TOLERANT TO PENICILLAMINE"
  },
  {
    "Code": "U-3371",
    "Definition": "TREATMENT OF ADULTS WITH ACTIVE ANKYLOSING SPONDYLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS"
  },
  {
    "Code": "U-3372",
    "Definition": "TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN HOSPITALIZED ADULTS REQUIRING SUPPLEMENTAL OXYGEN, NON-INVASIVE OR INVASIVE MECHANICAL VENTILATION, OR EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)"
  },
  {
    "Code": "U-3373",
    "Definition": "TREATMENT OF ADULTS WITH SYMPTOMATIC NEW YORK HEART ASSOCIATION (NYHA) CLASS II-III OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (HCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS"
  },
  {
    "Code": "U-3374",
    "Definition": "TREATMENT OF SEIZURES ASSOCIATED WITH CYCLIN-DEPENDENT KINASE-LIKE 5 (CDKL5) DEFICIENCY DISORDER (CDD) IN PATIENTS 2 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-3375",
    "Definition": "USE FOR THE TREATMENT OF ABSENCE SEIZURES IN PATIENTS WITH DRAVET SYNDROME"
  },
  {
    "Code": "U-3376",
    "Definition": "USE FOR THE TREATMENT OF ABSENCE SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME"
  },
  {
    "Code": "U-3377",
    "Definition": "TPOXX IS INDICATED FOR THE TREATMENT OF HUMAN SMALLPOX DISEASE IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 3 KG"
  },
  {
    "Code": "U-3378",
    "Definition": "MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS"
  },
  {
    "Code": "U-3379",
    "Definition": "A METHOD FOR ADMINISTERING A THERAPEUTIC DOSE OF EPINEPHRINE"
  },
  {
    "Code": "U-3380",
    "Definition": "METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK FOR REGIONAL ANALGESIA"
  },
  {
    "Code": "U-3381",
    "Definition": "TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM HYPERTENSION"
  },
  {
    "Code": "U-3382",
    "Definition": "TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM A GRADE 3 ADVERSE REACTION WHILE BEING ADMINISTERED RIPRETINIB DAILY"
  },
  {
    "Code": "U-3383",
    "Definition": "TREATING NEWLY DIAGNOSED AML CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 BY ADMINISTERING A ONCE DAILY 500 MG ORAL DOSE OF IVOSIDENIB TO A SUBJECT THAT HAS NOT INGESTED A HIGH-FAT MEAL, IN COMBINATION WITH AZACITIDINE"
  },
  {
    "Code": "U-3384",
    "Definition": "A METHOD FOR TREATING AML BY ADMINISTERING A PHARMACEUTICAL COMPOSITION COMPRISING IVOSIDENIB WHEREIN THE AML IS NEWLY DIAGNOSED AND CHARACTERIZED BY A MUTANT IDH1 AND THE COMPOSITION IS ADMINISTERED IN COMBINATION WITH AZACITIDINE"
  },
  {
    "Code": "U-3385",
    "Definition": "A METHOD FOR TREATING NEWLY DIAGNOSED AML WITH IVOSIDENIB AND AZACITIDINE WHEREIN THE AML HAS AN IDH1 MUTATION CAPABLE OF CONVERTING ALPHA-KETOGLUTARATE TO 2-HYDROXYGLUTARATE (2HG)"
  },
  {
    "Code": "U-3386",
    "Definition": "A METHOD FOR TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WITH IVOSIDENIB IN COMBINATION WITH AZACITIDINE WHEREIN THE CANCER IS NEWLY DIAGNOSED AML"
  },
  {
    "Code": "U-3387",
    "Definition": "A METHOD FOR TREATING NEWLY DIAGNOSED AML CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 SELECTED FROM R132H, R132C, R132L, R132V, R132S AND R132GF BY ADMINISTERING IVOSIDENIB AND AZACITIDINE"
  },
  {
    "Code": "U-3388",
    "Definition": "USE OF ELAGOLIX 200 MG BID FOR 6 MONTHS TO MANAGE MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS IN PREMENOPAUSAL WOMEN TO REDUCE DYSMENORRHEA AND NON-MENSTRUAL PELVIC PAIN"
  },
  {
    "Code": "U-3389",
    "Definition": "USE OF ELAGOLIX 200 MG BID FOR 6 MONTHS TO MANAGE MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS IN PREMENOPAUSAL WOMEN HAVING DYSPAREUNIA ASSOCIATED WITH ENDOMETRIOSIS"
  },
  {
    "Code": "U-3390",
    "Definition": "SODIUM THIOSULFATE INJECTION IS ADMINISTERED BY INTRAVENOUS INJECTION"
  },
  {
    "Code": "U-3391",
    "Definition": "A METHOD OF TITRATING AN OPIOID TO MANAGE PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENTS ARE INADEQUATE"
  },
  {
    "Code": "U-3392",
    "Definition": "A METHOD OF TITRATING AN OPIOID TO MANAGE NEUROPATHIC PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE"
  },
  {
    "Code": "U-3393",
    "Definition": "METHOD OF TREATING ACUTE PAIN DUE TO MINOR STRAINS, SPRAINS, AND CONTUSIONS USING A DICLOFENAC PATCH CONTAINING HEPARIN FOR ONCE DAILY ADMINISTRATION WHERE HEPARIN IS NOT RELEASED"
  },
  {
    "Code": "U-3394",
    "Definition": "SODIUM NITRITE INJECTION IS ADMINISTERED BY INTRAVENOUS INJECTION"
  },
  {
    "Code": "U-3395",
    "Definition": "SODIUM NITRITE INJECTION IS INDICATED FOR SEQUENTIAL USE WITH SODIUM THIOSULFATE FOR THE TREATMENT OF ACUTE CYANIDE POISONING"
  },
  {
    "Code": "U-3396",
    "Definition": "AMVUTTRA IS INDICATED FOR THE TREATMENT OF THE POLYNEUROPATHY OF HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS IN ADULTS"
  },
  {
    "Code": "U-3397",
    "Definition": "TADLIQ IS INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO IMPROVE EXERCISE ABILITY"
  },
  {
    "Code": "U-3398",
    "Definition": "FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG\/M2 OR BMI >=27 KG\/M2 WITH A WEIGHT-RELATED COMORBIDITY, AND PATIENTS AGE 12-17 WITH BMI >=25 KG\/M2 IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX)"
  },
  {
    "Code": "U-3399",
    "Definition": "FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH BMI >=30 KG\/M2, AND PATIENTS AGE 12-17 WITH BMI >=30 KG\/M2 AND IN THE 95TH PERCENTILE OR GREATER (STANDARDIZED FOR AGE AND SEX), EACH HAVING A WEIGHT-RELATED COMORBIDITY"
  },
  {
    "Code": "U-3400",
    "Definition": "FOR USE AFTER RADIOLABELING WITH GALLIUM-68, FOR POSITRON EMISSION TOMOGRAPHY OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-POSITIVE LESIONS IN MEN WITH PROSTATE CANCER"
  },
  {
    "Code": "U-3401",
    "Definition": "CAROSPIR IS INDICATED AS AN ADD-ON THERAPY FOR THE TREATMENT OF HYPERTENSION, TO LOWER BLOOD PRESSURE IN ADULT PATIENTS WHO ARE NOT ADEQUATELY CONTROLLED ON OTHER AGENTS"
  },
  {
    "Code": "U-3402",
    "Definition": "CAROSPIR IS INDICATED FOR THE MANAGEMENT OF EDEMA IN ADULT CIRRHOTIC PATIENTS WHEN EDEMA IS NOT RESPONSIVE TO FLUID AND SODIUM RESTRICTION"
  },
  {
    "Code": "U-3403",
    "Definition": "METHOD OF REVERSING OR INHIBITING THE PROGRESS OF UNRESECTABLE, RECURRENT, OR REFRACTORY INFLAMMATORY MYOFIBROBLASTIC TUMOR (IMT) THAT IS ALK-POSITIVE IN ADULT AND PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER"
  },
  {
    "Code": "U-3404",
    "Definition": "FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-3405",
    "Definition": "TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG BY MONTHLY ADMINISTRATION OF RILPIVIRINE SUSPENSION AS PART OF COMBINATION THERAPY"
  },
  {
    "Code": "U-3406",
    "Definition": "USE OF FENFLURAMINE AT REDUCED AMOUNTS WITH STIRIPENTOL FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME"
  },
  {
    "Code": "U-3407",
    "Definition": "USE OF FENFLURAMINE AT REDUCED AMOUNTS WITH STIRIPENTOL FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX GASTAUT SYNDROME"
  },
  {
    "Code": "U-3408",
    "Definition": "TOPICAL TREATMENT OF PLAQUE PSORIASIS, INCLUDING INTERTRIGINOUS AREAS, IN PATIENTS 12 YEARS OF AGE AND OLDER. (1)"
  },
  {
    "Code": "U-3409",
    "Definition": "TREATING ADULT PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS, MONITORING THIAMINE LEVELS AND ADMINISTERING THIAMINE OR A THIAMINE EQUIVALENT"
  },
  {
    "Code": "U-3410",
    "Definition": "A METHOD OF INJECTING AN IMPLANT"
  },
  {
    "Code": "U-3411",
    "Definition": "TREATING NON-EARLY SPMS BY ADMINISTERING ORAL CLADRIBINE AT A FIXED DOSE PER PATIENT, PER BODY WEIGHT AND PER TREATMENT YEAR, WHICH FIXED DOSE IS 1.75 +\/- 0.2 MG\/KG, TO BE ADMINISTERED WITHIN MONTHS 1 AND 2 IN EACH OF 2 ADJACENT TREATMENT YEARS"
  },
  {
    "Code": "U-3412",
    "Definition": "TREATMENT OF ADULTS WITH RELAPSED, REFRACTORY OR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA INCLUDING A DOSE RAMP-UP AND IN COMBINATION WITH OBINUTUZUMAB IN MULTIPLE 28-DAY DOSING CYCLES FOLLOWED BY ADMINISTRATION IN ABSENCE OF OBINUTUZUMAB"
  },
  {
    "Code": "U-3413",
    "Definition": "INDICATED AS ADJUNCTIVE THERAPY FOR THE TREATMENT OF PARTIAL-ONSET SEIZURES, PRIMARY GENERALIZED TONIC-CLONIC SEIZURES, AND SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME IN PATIENTS 2 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-3414",
    "Definition": "INDICATED AS INITIAL MONOTHERAPY FOR THE TREATMENT OF PARTIAL-ONSET OR PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS 2 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-3415",
    "Definition": "INDICATED FOR THE PREVENTIVE TREATMENT OF MIGRAINE IN PATIENTS 12 YEARS AND OLDER"
  },
  {
    "Code": "U-3416",
    "Definition": "TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS BEING TREATED CONCURRENTLY WITH A CYP3A4 INHIBITOR"
  },
  {
    "Code": "U-3417",
    "Definition": "TREATMENT OF POSTSURGICAL PAIN PROVIDING ANALGESIA TO A PATIENT FOR UP TO 72 HOURS, FOR EXAMPLE, AFTER FOOT AND ANKLE, SMALL-TO-MEDIUM OPEN ABDOMINAL, AND LOWER EXTREMITY TOTAL JOINT ARTHROPLASTY SURGICAL PROCEDURES VIA INSTILLATION"
  },
  {
    "Code": "U-3418",
    "Definition": "A METHOD OF LOADING MEDICATION INTO A SYRINGE AND DELIVERING THE MEDICATION TO A TREATMENT SITE"
  },
  {
    "Code": "U-3419",
    "Definition": "DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER"
  },
  {
    "Code": "U-3420",
    "Definition": "A METHOD OF TREATING TESTOSTERONE DEFICIENCY IN MEN"
  },
  {
    "Code": "U-3421",
    "Definition": "TREATMENT OF COMPLICATED URINARY TRACT INFECTIONS (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY THE FOLLOWING SUSCEPTIBLE MICROORGANISMS: ESCHERICHIA COLI,KLEBSIELLA PNEUMONIA,ENTEROBACTER CLOACAE SPECIES COMPLEX WITH MEROPENEM & VABORBACTAM AS SPECIFIED"
  },
  {
    "Code": "U-3422",
    "Definition": "TREATMENT OF PEDIATRIC PATIENTS AGE 1 YEAR AND OLDER WITH CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD) AFTER FAILURE OF ONE OR MORE LINES OF SYSTEMIC THERAPY"
  },
  {
    "Code": "U-3423",
    "Definition": "METHOD OF TREATING GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM GRADE 2 OR GRADE 3 MYALGIA WHILE BEING ADMINISTERED RIPRETINIB DAILY"
  },
  {
    "Code": "U-3424",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 1-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND IVACAFTOR"
  },
  {
    "Code": "U-3425",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A MUTATION THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOUND OF CLAIM 1 OR COMPOSITION OF CLAIM 29 OF US11426407"
  },
  {
    "Code": "U-3426",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 1-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE DOSAGE UNIT COMPRISING LUMACAFTOR AS RECITED IN CLAIM 1 OF US PATENT 8716338 AND IVACAFTOR"
  },
  {
    "Code": "U-3427",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 1-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR FORM I AND IVACAFTOR"
  },
  {
    "Code": "U-3428",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 1-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE DOSAGE UNIT COMPRISING LUMACAFTOR AND IVACAFTOR AS RECITED IN CLAIM 1 OF US PATENT 9192606"
  },
  {
    "Code": "U-3429",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 1-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING LUMACAFTOR AND A SOLID COMPOSITION COMPRISING AMORPHOUS AND LESS THAN ABOUT 30% CRYSTALLINE IVACAFTOR"
  },
  {
    "Code": "U-3430",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN A PATIENT AGE 1-5 YEARS WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING A PHARMACEUTICAL COMPOSITION ACCORDING TO CLAIM 2 OF U.S. PATENT NO. 10,597,384, FURTHER COMPRISING IVACAFTOR"
  },
  {
    "Code": "U-3431",
    "Definition": "TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS WHO AWAKEN AT LEAST 2 TIMES PER NIGHT TO VOID BY INDUCING AN ANTIDIURETIC EFFECT BY INTRANASALLY ADMINISTERING A PLUME OF DROPLETS COMPRISING A DOSE OF ABOUT 0.05-5 MCG DESMOPRESSIN"
  },
  {
    "Code": "U-3432",
    "Definition": "TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS (EDS) IN PATIENTS 7 YEARS OF AGE AND OLDER WITH NARCOLEPSY WITH A MIXTURE OF SODIUM, POTASSIUM, MAGNESIUM, AND CALCIUM SALTS OF GHB ADMINISTERED BETWEEN 2 AND 4 HOURS AFTER EATING"
  },
  {
    "Code": "U-3433",
    "Definition": "INDICATED FOR THE TREATMENT OF SPASTICITY RESULTING FROM MULTIPLE SCLEROSIS"
  },
  {
    "Code": "U-3434",
    "Definition": "TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS IN ADULTS WHO ARE CANDIDATES FOR SYSTEMIC THERAPY OR PHOTOTHERAPY"
  },
  {
    "Code": "U-3435",
    "Definition": "METHOD OF TREATING IDA IN ADULT PATIENTS WITH NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE & WEIGHING AT LEAST 46.7 KG BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST 0.7 G OF ELEMENTAL IRON IN 15 MINUTES"
  },
  {
    "Code": "U-3436",
    "Definition": "METHOD OF TREATING IDA IN ADULT PATIENTS WITH NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE & WEIGHING AT LEAST 46.7 KG BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST 0.7 G OF ELEMENTAL IRON IN LESS THAN 15 MINUTES"
  },
  {
    "Code": "U-3437",
    "Definition": "METHOD TO TREAT IDA IN ADULTS & PEDIATRIC PATIENTS 1 YEAR & OLDER WITH INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON & HEAVY UTERINE BLEEDING OR GI DISORDER BY ADMINISTERING IV FERRIC CARBOXYMALTOSE TO GIVE AT LEAST 0.7 G OF IRON IN 15 MINUTES"
  },
  {
    "Code": "U-3438",
    "Definition": "METHOD TO TREAT IDA IN ADULTS & PEDIATRIC PATIENTS 1 YR & OLDER WITH INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON & WEIGHING AT LEAST 46.7 KG BY ADMINISTERING IV FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST 0.7 G OF ELEMENTAL IRON IN < 15 MINUTES"
  },
  {
    "Code": "U-3439",
    "Definition": "METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA OR VIA NERVE BLOCK, FOR EXAMPLE, NTERSCALENE BRACHIAL PLEXUS FOR REGIONAL ANALGESIA"
  },
  {
    "Code": "U-3440",
    "Definition": "A METHOD OF ADMINISTERING APREPITANT FOR PREVENTION OF POST-OPERATIVE NAUSEA AND VOMITING"
  },
  {
    "Code": "U-3441",
    "Definition": "A METHOD OF TREATING CYSTINURIA BY ORALLY ADMINISTERING TIOPRONIN WITH FOOD TO PREVENT CYSTINE STONE FORMATION IN ADULTS AND PEDIATRIC PATIENTS WITH SEVERE HOMOZYGOUS CYSTINURIA"
  },
  {
    "Code": "U-3442",
    "Definition": "TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOR IN PATIENTS PREVIOUSLY ADMINISTERED AT LEAST THREE TYROSINE KINASE INHIBITORS, WHERE ONE OF THE KINASE INHIBITORS IS IMATINIB"
  },
  {
    "Code": "U-3443",
    "Definition": "A METHOD OF REDUCING OTOTOXICITY IN A HUMAN PEDIATRIC PATIENT ABOUT 5 YEARS OF AGE OR UNDER WITH LOCALIZED MEDULLOBLASTOMA COMPRISING ADMINISTERING SODIUM THIOSULFATE ABOUT SIX HOURS AFTER ADMINISTRATION OF CISPLATIN"
  },
  {
    "Code": "U-3444",
    "Definition": "TREATMENT OF DEPRESSIVE SYMPTOMS IN ADULTS WITH MDD WITH ACUTE SUICIDAL IDEATION OR BEHAVIOR BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE AS A PHARMACEUTICAL COMPOSITION TWICE PER WEEK IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT"
  },
  {
    "Code": "U-3445",
    "Definition": "TREATMENT OF TREATMENT-RESISTANT DEPRESSION IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE TWICE PER WEEK AS A PHARMACEUTICAL COMPOSITION IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT"
  },
  {
    "Code": "U-3446",
    "Definition": "TREATMENT OF TREATMENT-RESISTANT DEPRESSION IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE AS A PHARMACEUTICAL COMPOSITION IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT"
  },
  {
    "Code": "U-3447",
    "Definition": "A METHOD OF TREATING CORONARY ARTERY DISEASE"
  },
  {
    "Code": "U-3448",
    "Definition": "A METHOD OF TREATING HYPERTENSION"
  },
  {
    "Code": "U-3449",
    "Definition": "USE IN COMBINATION WITH LENALIDOMIDE PLUS DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED ONE TO THREE LINES OF THERAPY"
  },
  {
    "Code": "U-3450",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH A REARRANGED DURING TRANSFECTION (RET) GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST"
  },
  {
    "Code": "U-3451",
    "Definition": "TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC MEDULLARY THYROID CANCER (MTC) WITH A RET MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY"
  },
  {
    "Code": "U-3452",
    "Definition": "TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC THYROID CANCER WITH A RET GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY"
  },
  {
    "Code": "U-3453",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH A RET GENE FUSION THAT HAVE PROGRESSED ON OR FOLLOWING PRIOR SYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS"
  },
  {
    "Code": "U-3454",
    "Definition": "METHOD OF TREATING OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION IN PATIENTS"
  },
  {
    "Code": "U-3455",
    "Definition": "TREATMENT OF OCULAR INFLAMMATION AND PAIN FOLLOWING OPHTHALMIC SURGERY"
  },
  {
    "Code": "U-3456",
    "Definition": "METHOD OF TREATING INTRAHEPATIC CHOLANGIOCARCINOMA"
  },
  {
    "Code": "U-3457",
    "Definition": "METHOD OF INDUCING OCULAR ANESTHESIA"
  },
  {
    "Code": "U-3458",
    "Definition": "A METHOD OF TREATING SEIZURES"
  },
  {
    "Code": "U-3459",
    "Definition": "TREATING SICKLE CELL DISEASE BY ADMINISTERING VOXELOTOR AND ANOTHER ACTIVE AGENT"
  },
  {
    "Code": "U-3460",
    "Definition": "TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS"
  },
  {
    "Code": "U-3461",
    "Definition": "INDICATED TO RAISE BLOOD PRESSURE IN ADULT PATIENTS WITH SEVERE, ACUTE HYPOTENSION"
  },
  {
    "Code": "U-3462",
    "Definition": "USE OF A LIQUID FORMULATION COMPRISING FUROSEMIDE TO TREAT CONGESTION DUE TO FLUID OVERLOAD (EDEMA) IN ADULTS WITH NYHA CLASS II\/III CHRONIC HEART FAILURE"
  },
  {
    "Code": "U-3463",
    "Definition": "USE OF TRINTELLIX FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) IN ADULTS"
  },
  {
    "Code": "U-3464",
    "Definition": "TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FGFR2 FUSION OR OTHER REARRANGEMENT BY ADMINISTERING ONCE DAILY A TABLET CONTAINING ABOUT 0.5 MG TO ABOUT 10 MG OF PEMIGATINIB"
  },
  {
    "Code": "U-3465",
    "Definition": "TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FGFR2 FUSION OR OTHER REARRANGEMENT BY ADMINISTERING PEMIGATINIB QD FOR 14 DAYS THEN NOT ADMINISTERING PEMIGATINIB FOR 7 DAYS IN A 21-DAY CYCLE"
  },
  {
    "Code": "U-3466",
    "Definition": "TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FGFR2 FUSION OR OTHER REARRANGEMENT BY ADMINISTERING PEMIGATINIB IN A DAILY DOSE OF ABOUT 5 MG TO ABOUT 20 MG"
  },
  {
    "Code": "U-3467",
    "Definition": "PREVENTION AND TREATMENT OF POST-OPERATIVE NAUSEA AND VOMITING"
  },
  {
    "Code": "U-3468",
    "Definition": "TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS"
  },
  {
    "Code": "U-3469",
    "Definition": "AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS"
  },
  {
    "Code": "U-3470",
    "Definition": "METHOD OF TREATING COMPLICATED URINARY TRACT INFECTIONS (CUTI), INCLUDING PYELONEPHRITIS, COMPRISING ADMINISTERING CEFIDEROCOL SULFATE TOSYLATE"
  },
  {
    "Code": "U-3471",
    "Definition": "METHOD OF TREATING HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA (HABP\/VABP) COMPRISING ADMINISTERING CEFIDEROCOL SULFATE TOSYLATE"
  },
  {
    "Code": "U-3472",
    "Definition": "METHOD TO TREAT IDA IN ADULTS WITH INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON & HEAVY UTERINE BLEEDING OR GI DISORDER WEIGHING AT LEAST 40 KG BY ADMINISTERING IV FERRIC CARBOXYMALTOSE TO GIVE AT LEAST 0.6 G OF IRON IN 15 MINUTES OR LESS"
  },
  {
    "Code": "U-3473",
    "Definition": "METHOD TO TREAT IRON DEFICIENCY ANEMIA IN ADULTS WITH INTOLERANCE OR UNSATISFACTORY RESPONSE TO ORAL IRON & WEIGHING AT LEAST 40 KG BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST 0.6 G OF ELEMENTAL IRON IN 15 MINUTES OR LESS"
  },
  {
    "Code": "U-3474",
    "Definition": "METHOD TO TREAT IRON DEFICIENCY ANEMIA IN ADULTS WITH NON-DIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE & WEIGHING AT LEAST 40 KG BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST 0.6 G OF ELEMENTAL IRON IN 15 MINUTES OR LESS"
  },
  {
    "Code": "U-3475",
    "Definition": "REDUCTION OF THE FREQUENCY OF ABDOMINAL PAIN AND DIARRHEA, IN AN INFLAMMATORY BOWEL DISEASE WITH DIARRHEA (IBS-D) PATIENT, WITH ELUXADOLINE TWICE DAILY WITH FOOD"
  },
  {
    "Code": "U-3476",
    "Definition": "TREATMENT OF ADULTS WITH MODERATE HEPATIC IMPAIRMENT AND RELAPSED OR REFRACTORY ADVANCED RENAL CELL CARCINOMA FOLLOWING TWO OR MORE PRIOR SYSTEMIC ANTI-CANCER THERAPIES WITH 1MG TIVOZANIB HCL ORALLY FOR 21 DAYS FOLLOWED BY NO DRUG FOR 7 DAYS"
  },
  {
    "Code": "U-3477",
    "Definition": "ACCELERATE THE TRANSIT OF A BARIUM MEAL THROUGH THE SMALL BOWEL, THEREBY DECREASING THE TIME AND EXTENT OF RADIATION ASSOCIATED WITH FLUOROSCOPY AND X-RAY EXAMINATION OF THE INTESTINAL TRACT"
  },
  {
    "Code": "U-3478",
    "Definition": "STIMULATE GALLBLADDER CONTRACTION, AS MAY BE ASSESSED BY VARIOUS METHODS OF DIAGNOSTIC IMAGING, OR TO OBTAIN BY DUODENAL ASPIRATION A SAMPLE OF CONCENTRATED BILE FOR ANALYSIS"
  },
  {
    "Code": "U-3479",
    "Definition": "STIMULATE PANCREATIC SECRETION IN COMBINATION WITH SECRETIN PRIOR TO OBTAINING A DUODENAL ASPIRATE FOR ANALYSIS"
  },
  {
    "Code": "U-3480",
    "Definition": "STIMULATE GALLBLADDER CONTRACTION. AS MAY BE ASSESSED BY VARIOUS METHODS OF DIAGNOSTIC IMAGING, OR TO OBTAIN BY DUODENAL ASPIRATION A SAMPLE OF CONCENTRATED BILE FOR ANALYSIS"
  },
  {
    "Code": "U-3481",
    "Definition": "DIAGNOSIS OF GALL BLADDER DISORDERS OR OTHER DIAGNOSTIC IMAGING BY STIMULATING GALLBLADDER CONTRACTION, AS MAY BE ASSESSED BY VARIOUS METHODS OF DIAGNOSTIC IMAGING, OR TO OBTAIN BY DUODENAL ASPIRATION A SAMPLE OF CONCENTRATED BILE FOR ANALYSIS"
  },
  {
    "Code": "U-3482",
    "Definition": "DIAGNOSIS OF PANCREATIC DISORDERS BY STIMULATING PANCREATIC SECRETION IN COMBINATION WITH SECRETIN PRIOR TO OBTAINING A DUODENAL ASPIRATE FOR ANALYSIS"
  },
  {
    "Code": "U-3483",
    "Definition": "DIAGNOSTIC IMAGING BY ACCELERATING THE TRAN IT OFA BARIUM MEAL THROUGH THE SMALL BOWEL, THEREBY DECREASING THE TIME AND EXTENT OF RADIATION ASSOCIATED WITH FLUOROSCOPY AND X-RAY EXAMINATION OF THE INTESTINAL TRACT"
  },
  {
    "Code": "U-3484",
    "Definition": "TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG) REQUIRING HOSPITALIZATION AND FOR WHOM CONCOMITANT USE OF CHLOROQUINE, OR AN ANALOG OR SALT THEREOF, IS NOT RECOMMENDED"
  },
  {
    "Code": "U-3485",
    "Definition": "TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (AT LEAST 28 DAYS OF AGE AND 3 KG) AND FOR WHOM CONCOMITANT USE OF CHLOROQUINE, OR AN ANALOG OR SALT THEREOF, IS NOT RECOMMENDED"
  },
  {
    "Code": "U-3486",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LYMPHOMA"
  },
  {
    "Code": "U-3487",
    "Definition": "TREATMENT OF ADULTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WITH OBJECTIVE SIGNS OF INFLAMMATION WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS"
  },
  {
    "Code": "U-3488",
    "Definition": "TREATMENT OF SPASTICITY RESULTING FROM MULTIPLE SCLEROSIS, PARTICULARLY FOR THE RELIEF OF FLEXOR SPASMS AND CONCOMITANT PAIN, CLONUS, AND MUSCULAR RIGIDITY"
  },
  {
    "Code": "U-3489",
    "Definition": "TREATMENT OF SPASTICITY RESULTING FROM SPINAL CORD INJURIES AND OTHER SPINAL CORD DISEASES"
  },
  {
    "Code": "U-3490",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), AS DETERMINED BY AN FDA APPROVED TEST, WHO HAVE RECEIVED AT LEAST ONE PRIOR SYSTEMIC THERAPY"
  },
  {
    "Code": "U-3491",
    "Definition": "METHOD OF TREATING LYMPHOMA"
  },
  {
    "Code": "U-3492",
    "Definition": "METHOD OF TREATING SARCOMA"
  },
  {
    "Code": "U-3493",
    "Definition": "THE TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS) IN PATIENTS 10 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-3494",
    "Definition": "ONCE DAILY TOPICAL TREATMENT OF PERSISTENT FACIAL ERYTHEMA ASSOCIATED WITH ROSACEA IN FEMALE ADULTS"
  },
  {
    "Code": "U-3495",
    "Definition": "A METHOD OF TREATING ACUTE MYELOID LEUKEMIA (AML) IN PATIENTS WITH AN ISOCITRATE DEHYDROGENASE-1 (IDH1) MUTATION"
  },
  {
    "Code": "U-3496",
    "Definition": "A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHERE THE CANCER IS ACUTE MYELOID LEUKEMIA (AML)"
  },
  {
    "Code": "U-3497",
    "Definition": "A METHOD OF TREATING A CANCER WHERE THE CANCER IS ACUTE MYELOID LEUKEMIA (AML)"
  },
  {
    "Code": "U-3498",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A MUTATION THAT IS RESPONSIVE BASED ON IN VITRO DATA BY ADMINISTERING DAILY ELX (200 MG OR 100 MG); TEZ; AND IVA"
  },
  {
    "Code": "U-3499",
    "Definition": "TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS (ABSSSI) IN ADULT AND PEDIATRIC PATIENTS USING A TWO-DOSE REGIMEN OF DALBAVANCIN"
  },
  {
    "Code": "U-3500",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH SEVERE ALOPECIA AREATA"
  },
  {
    "Code": "U-3501",
    "Definition": "PALBOCICLIB FOR HR-POS. HER2-NEG. ADVANCED OR METASTATIC BREAST CANCER IN COMBO WITH AN AROMATASE INHIBITOR IN PTS AS INITIAL ENDOCRINE-BASED THERAPY OR WITH FULVESTRANT WITH DISEASE PROGRESSION AFTER ENDOCRINE THERAPY"
  },
  {
    "Code": "U-3502",
    "Definition": "TREATMENT OF A UREA CYCLE DISORDER INVOLVING DEFICIENCIES OF CARBAMYLPHOSPHATE SYNTHETASE, ORNITHINE TRANSCARBAMYLASE, OR ARGININOSUCCINIC ACID SYNTHETASE"
  },
  {
    "Code": "U-3503",
    "Definition": "ADJUNCTIVE THERAPY TO ANTIDEPRESSANTS FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER"
  },
  {
    "Code": "U-3504",
    "Definition": "A METHOD TO DECREASE THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A PLATINUM\/ETOPOSIDE-CONTAINING REGIMEN THAT INCLUDES AN IMMUNE CHECKPOINT INHIBITOR FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER"
  },
  {
    "Code": "U-3505",
    "Definition": "FOR TOPICAL TREATMENT OF MODERATE AD IN NON-IMMUNOCOMPROMISED PATIENTS, WITH BASELINE BSA OF 3-20% AND ITCH NRS SCORE OF 4, WHOSE DISEASE IS NOT ADEQUATELY CONTROLLED WITH TOPICAL PRESCRIPTION THERAPIES OR WHEN THOSE THERAPIES ARE NOT ADVISABLE"
  },
  {
    "Code": "U-3506",
    "Definition": "TREATMENT OF INDOLENT SYSTEMIC MASTOCYTOSIS (ISM)"
  },
  {
    "Code": "U-3507",
    "Definition": "IN COMBINATION WITH OTHER ANTIRETROVIRAL(S), FOR THE TREATMENT OF HIV-1 INFECTION IN HEAVILY-TREATMENT EXPERIENCED ADULTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION"
  },
  {
    "Code": "U-3508",
    "Definition": "REDUCTION IN THE INCIDENCE OF RECURRENT VULVOVAGINAL CANDIDIASIS (RVVC) IN ADULT AND POST-MENARCHAL PEDIATRIC FEMALES"
  },
  {
    "Code": "U-3509",
    "Definition": "AS-NEEDED TREATMENT OR PREVENTION OF BRONCHOCONSTRICTION AND REDUCTION OF THE RISK OF EXACERBATIONS IN PATIENTS WITH ASTHMA 18 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-3510",
    "Definition": "COMBINATION TREATMENT OF COLORECTAL CANCER INCLUDING RAS WILD-TYPE HER2 (ERBB2)-POSITIVE OR -OVEREXPRESSING UNRESECTABLE OR METASTATIC COLORECTAL CANCER"
  },
  {
    "Code": "U-3511",
    "Definition": "TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULT FEMALE SUBJECTS AND SYMPTOMS THEREOF"
  },
  {
    "Code": "U-3512",
    "Definition": "TREATMENT OF IRRITABLE BOWEL SYNDROME WITH DIARRHEA (IBS-D) IN ADULT FEMALE SUBJECTS"
  },
  {
    "Code": "U-3513",
    "Definition": "TREATMENT OF SCHIZOPHRENIA IN ADULTS"
  },
  {
    "Code": "U-3514",
    "Definition": "INCREASING BLOOD PRESSURE IN A PATIENT HAVING DISTRIBUTIVE SHOCK"
  },
  {
    "Code": "U-3515",
    "Definition": "A METHOD FOR ADMINISTERING A THERAPEUTIC DOSE OF AN OPIOID ANTAGONIST COMPRISING AN EMERGENCY SYRINGE DEVICE"
  },
  {
    "Code": "U-3516",
    "Definition": "A METHOD FOR ADMINISTERING A THERAPEUTIC DOSE OF AN OPIOID ANTAGONIST COMPRISING AN EMERGENCY SYRINGE DEVICE INCLUDING A NEEDLE GUARD"
  },
  {
    "Code": "U-3517",
    "Definition": "A METHOD FOR ADMINISTERING A THERAPEUTIC DOSE OF AN OPIOID ANTAGONIST COMPRISING AN EMERGENCY SYRINGE DEVICE INCLUDING A WINDOW CONFIGURED TO ALLOW THE USER TO VIEW THE OPIOID ANTAGONIST IN THE SYRINGE"
  },
  {
    "Code": "U-3518",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL) AFTER AT LEAST TWO LINES OF SYSTEMIC THERAPY, INCLUDING A BTK INHIBITOR"
  },
  {
    "Code": "U-3519",
    "Definition": "TREATMENT WITH LENVIMA BY ADMINISTERING LENVIMA AS A SUSPENSION"
  },
  {
    "Code": "U-3520",
    "Definition": "TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS BY ADMINISTERING A COMPOSITION COMPRISING SOLRIAMFETOL HYDROCHLORIDE AND 2-CHLOROPROPANE, WHEREIN THE COMPOSITION COMPRISES LESS THAN ABOUT 5 PPM 2CHLOROPROPANE"
  },
  {
    "Code": "U-3521",
    "Definition": "TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS BY ADMINISTERING SOLRIAMFETOL TO A SUBJECT HAVING MILD, MODERATE, OR SEVERE RENAL IMPAIRMENT"
  },
  {
    "Code": "U-3522",
    "Definition": "METHOD OF TREATING EMESIS"
  },
  {
    "Code": "U-3523",
    "Definition": "TREATMENT OF AN ER-POSITIVE BREAST CANCER"
  },
  {
    "Code": "U-3524",
    "Definition": "TREATMENT OF AN ER-POSITIVE BREAST CANCER FOLLOWING AT LEAST ONE LINE OF ENDOCRINE THERAPY"
  },
  {
    "Code": "U-3525",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A MUTATION THAT IS RESPONSIVE BASED ON IN VITRO DATA BY ADMINISTERING THE COMPOSITION RECITED IN US 11564916 CLAIM 1"
  },
  {
    "Code": "U-3526",
    "Definition": "TREATMENT OF CF IN A PATIENT AGE 1 TO <6 YEARS AND WEIGHING 7 KG OR MORE WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE COMPOSITION RECITED IN CLAIM 1 OF US 11564916"
  },
  {
    "Code": "U-3527",
    "Definition": "TREATMENT OF CF IN A PATIENT AGE 6 YEARS AND OLDER WHO IS HOMOZYGOUS FOR F508DEL OR HAS AT LEAST ONE CFTR GENE MUTATION RESPONSIVE TO TEZ\/IVA BASED ON IN VITRO DATA AND\/OR CLINICAL EVIDENCE USING THE COMPOSITION RECITED IN US 11564916 CLAIM 1"
  },
  {
    "Code": "U-3528",
    "Definition": "TREATMENT OF CF IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND\/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 11564916"
  },
  {
    "Code": "U-3529",
    "Definition": "TREATMENT OF CF IN A PATIENT AGE 6 YEARS AND OLDER WHO IS HOMOZYGOUS FOR THE F508DEL MUTATION IN THE CFTR GENE USING THE COMPOSITION RECITED IN CLAIM 1 OF US 11564916"
  },
  {
    "Code": "U-3530",
    "Definition": "TREATMENT OF CF IN A PATIENT AGE 6 YEARS AND OLDER WHO HAS ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND\/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 11564916"
  },
  {
    "Code": "U-3531",
    "Definition": "TREATMENT OF A TYPE 2 DIABETES PATIENT WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE METFORMIN THERAPY USING A COMPOSITION COMPRISING AN EXTENDED RELEASE CORE COMPRISING METFORMIN AND AN OUTER COATING COMPRISING EMPAGLIFLOZIN AND LINAGLIPTIN"
  },
  {
    "Code": "U-3532",
    "Definition": "METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH TYPE 2 DIABETES MELLITUS BY ONCE DAILY ADMINISTRATION OF EMPAGLIFLOZIN"
  },
  {
    "Code": "U-3533",
    "Definition": "METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE BY ONCE DAILY ADMINISTRATION OF 10 MG OR 25 MG OF EMPAGLIFLOZIN"
  },
  {
    "Code": "U-3534",
    "Definition": "PREVENTIVE TREATMENT OF MIGRAINE IN ADULTS"
  },
  {
    "Code": "U-3535",
    "Definition": "A METHOD OF TREATING ANEMIA"
  },
  {
    "Code": "U-3536",
    "Definition": "TREATMENT OF DEPRESSION IN ADULTS WITH MOD AND ACUTE SUICIDAL IDEATION OR BEHAVIOR IN CONJUNCTION WITH AN ORAL ANTIDEPRESSANT BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE IN A MAINTENANCE PHASE WEEKLY OR LX EVERY 2 WEEKS AFTER INDUCTION PHASE"
  },
  {
    "Code": "U-3537",
    "Definition": "TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM GRADE 2 OR GRADE 3 ARTHRALGIA WHILE BEING ADMINISTERED RIPRETINIB DAILY"
  },
  {
    "Code": "U-3538",
    "Definition": "METHOD OF TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER"
  },
  {
    "Code": "U-3539",
    "Definition": "TREATING ACQUIRED, GENERALIZED HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD) IN A PREMENOPAUSAL FEMALE PATIENT WITH CONTROLLED HYPERTENSION BY INJECTING BREMELANOTIDE MORE THAN ONCE WITH AT LEAST 24 HOURS BETWEEN DOSES AND NO MORE THAN 8 DOSES PER MONTH"
  },
  {
    "Code": "U-3540",
    "Definition": "TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY INTRAVITREAL ADMINISTRATION OF PEGCETACOPLAN"
  },
  {
    "Code": "U-3541",
    "Definition": "TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERING COMPLEMENT INHIBITOR PEGCETACOPLAN"
  },
  {
    "Code": "U-3542",
    "Definition": "TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY INTRAVITREAL ADMINISTRATION OF PEGCETACOPLAN AND ALSO ADMINISTERING AN ANTI-VEGF AGENT"
  },
  {
    "Code": "U-3543",
    "Definition": "TREATMENT TO INCREASE BONE DENSITY IN MEN WITH OSTEOPOROSIS AT HIGH RISK FOR FRACTURE"
  },
  {
    "Code": "U-3544",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON IN VITRO DATA BY ADMINISTERING ELEXACAFTOR, IVACAFTOR, AND A SOLID DISPERSION OF TEZACAFTOR AND A POLYMER"
  },
  {
    "Code": "U-3545",
    "Definition": "TREATMENT OF CF IN A PATIENT AGE 6 YEARS AND OLDER WHO IS HOMOZYGOUS FOR F508DEL OR HAS AT LEAST ONE CFTR GENE MUTATION RESPONSIVE TO TEZ\/IVA BASED ON IN VITRO DATA AND\/OR CLINICAL EVIDENCE USING THE COMPOSITION RECITED IN US 11578062 CLAIM 6 OR 13"
  },
  {
    "Code": "U-3546",
    "Definition": "IN COMBINATION WITH ENDOCRINE THERAPY (TAMOXIFEN OR AN AROMATASE INHIBITOR) FOR THE ADJUVANT TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE, NODE POSITIVE, EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE"
  },
  {
    "Code": "U-3547",
    "Definition": "INTRAVENOUS SOTALOL DOSING REGIMEN FOR ACHIEVING STEADY STATE EXPOSURE IN A FACILITY THAT CAN PROVIDE ELECTROCARDIOGRAPHIC MONITORING"
  },
  {
    "Code": "U-3548",
    "Definition": "TREATMENT OF AML BY ORALLY ADMINISTERING VENETOCLAX WITH AZACITIDINE OR DECITABINE OR LOW-DOSE CYTARABINE TO ADULTS 75 YEARS OR OLDER OR HAVING CERTAIN COMORBIDITIES PER A DOSE RAMP-UP INCLUDING AN INITIAL 100 MG OR A FINAL 400 MG PER DAY DOSE"
  },
  {
    "Code": "U-3549",
    "Definition": "INTRAVENOUS SOTALOL DOSING REGIMEN FOR USE IN A FACILITY THAT CAN PROVIDE ELECTROCARDIOGRAPHIC MONITORING"
  },
  {
    "Code": "U-3550",
    "Definition": "FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER, IN THE ABSENCE OF LASER OR PHOTOTHERAPY, WHEREIN THE VITILIGO AFFECTS AT LEAST ONE OF THE LOWER EXTREMITIES, TRUNK, AND FEET OF THE PATIENT"
  },
  {
    "Code": "U-3551",
    "Definition": "FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER, IN THE ABSENCE OF PHOTOTHERAPY, WHEREIN THE VITILIGO AFFECTS AT LEAST ONE OF THE LOWER EXTREMITIES, TRUNK, AND FEET OF THE PATIENT"
  },
  {
    "Code": "U-3552",
    "Definition": "TREATMENT OF FRIEDREICH'S ATAXIA IN ADULTS AND ADOLESCENTS AGED 16 YEARS AND OLDER"
  },
  {
    "Code": "U-3553",
    "Definition": "A METHOD OF TREATING MILD TO MODERATE ACUTE PAIN IN ADULTS BY ADMINISTERING 975-1000 MG OF ACETAMINOPHEN AND 292.5-300 MG OF IBUPROFEN IN A SINGLE ADMINISTRATION"
  },
  {
    "Code": "U-3554",
    "Definition": "AS A SINGLE AGENT FOR THE TREATMENT OF ADULT PATIENTS WITH HISTIOCYTIC NEOPLASMS"
  },
  {
    "Code": "U-3555",
    "Definition": "ADMINISTRATION OF ZAVEGEPANT FOR ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA"
  },
  {
    "Code": "U-3556",
    "Definition": "TREATMENT OF RETT SYNDROME OR A SYMPTOM THEREOF"
  },
  {
    "Code": "U-3557",
    "Definition": "TREATMENT OF PARKINSON'S DISEASE, POST-ENCEPHALITIC PARKINSONISM, AND SYMPTOMATIC PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION OR MANGANESE INTOXICATION"
  },
  {
    "Code": "U-3558",
    "Definition": "AN ADJUNCTIVE TREATMENT OF ADULT PATIENTS WITH TAVNEOS (AVACOPAN) WITH SEVERE ACTIVE ANCA-ASSOCIATED VASCULITIS (GPA AND MPA) IN COMBINATION WITH STANDARD THERAPY INCLUDING GLUCOCORTICOIDS"
  },
  {
    "Code": "U-3559",
    "Definition": "A METHOD OF TARGETING RELEASE OF A NON-STEROIDAL ANTI-INFLAMMATORY DRUG (NSAID) TO THE SMALL INTESTINE OF THE SUBJECT WHEN ADMINISTERED ORALLY"
  },
  {
    "Code": "U-3560",
    "Definition": "FOR THE TREATMENT OF VERNAL KERATOCONJUNCTIVITIS IN CHILDREN AND ADULTS"
  },
  {
    "Code": "U-3561",
    "Definition": "TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF PILOCARPINE HCI FORMULATION ONCE DAILY"
  },
  {
    "Code": "U-3562",
    "Definition": "TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF PILOCARPINE HCI FORMULATION TWICE DAILY"
  },
  {
    "Code": "U-3563",
    "Definition": "DEXTROMETHORPHAN AND BUPROPION IN COMBINATION TO INCREASE DEXTROMETHORPHAN PLASMA LEVELS"
  },
  {
    "Code": "U-3564",
    "Definition": "MEKINIST IS INDICATED, IN COMBINATION WITH DABRAFENIB, FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH LOW-GRADE GLIOMA (LGG) WITH A BRAF V600E MUTATION WHO REQUIRE SYSTEMIC THERAPY"
  },
  {
    "Code": "U-3565",
    "Definition": "TAFINLAR IS INDICATED, IN COMBINATION WITH TRAMETINIB, FOR THE TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH LOW-GRADE GLIOMA (LGG) WITH A BRAF V600E MUTATION WHO REQUIRE SYSTEMIC THERAPY"
  },
  {
    "Code": "U-3566",
    "Definition": "TREATMENT OF CANDIDEMIA AND INVASIVE CANDIDIASIS WITH REZAFUNGIN BY INTRAVENOUS ADMINISTRATION"
  },
  {
    "Code": "U-3567",
    "Definition": "TO INCREASE MEAN ARTERIAL BLOOD PRESSURE IN ADULT PATIENTS WITH HYPOTENSION ASSOCIATED WITH SEPTIC SHOCK"
  },
  {
    "Code": "U-3568",
    "Definition": "TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FGFR2 FUSION OR OTHER REARRANGEMENT BY ADMINISTERING PEMIGATINIB WHILE AVOIDING THE CONCOMITANT USE OF STRONG AND MODERATE CYP3A INHIBITORS"
  },
  {
    "Code": "U-3569",
    "Definition": "TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CHOLANGIOCARCINOMA WITH A FGFR2 FUSION OR OTHER REARRANGEMENT BY ADMINISTERING PEMIGATINIB WHILE AVOIDING THE CONCOMITANT USE OF STRONG AND MODERATE CYP3A INDUCERS"
  },
  {
    "Code": "U-3570",
    "Definition": "TREATMENT OF RELAPSED OR REFRACTORY MYELOID\/LYMPHOID NEOPLASMS WITH FGFR1 REARRANGEMENT BY ADMINISTERING PEMIGATINIB WHILE AVOIDING THE CONCOMITANT USE OF STRONG AND MODERATE CYP3A INDUCERS"
  },
  {
    "Code": "U-3571",
    "Definition": "TREATMENT OF RELAPSED OR REFRACTORY MYELOID\/LYMPHOID NEOPLASMS WITH FGFR1 REARRANGEMENT BY ADMINISTERING PEMIGATINIB WHILE AVOIDING THE CONCOMITANT USE OF STRONG AND MODERATE CYP3A INHIBITORS"
  },
  {
    "Code": "U-3572",
    "Definition": "RAISE FOLATE LEVELS IN WOMEN WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION FOR THE PURPOSE OF REDUCING THE RISK OF A NEURAL TUBE DEFECT IN A PREGNANCY"
  },
  {
    "Code": "U-3573",
    "Definition": "TREATMENT OF MODERATE ACNE VULGARIS IN WOMEN AT LEAST 14 YEARS OF AGE IF THE PATIENT DESIRES AN ORAL CONTRACEPTIVE FOR BIRTH CONTROL"
  },
  {
    "Code": "U-3574",
    "Definition": "TREATMENT OF MOOD CHANGES AND\/OR ANXIETY AS SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER (PMDD) IN WOMEN WHO CHOOSE TO USE AN ORAL CONTRACEPTIVE AS THEIR METHOD OF CONTRACEPTION"
  },
  {
    "Code": "U-3575",
    "Definition": "TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN ADULTS WHO HAVE A MUTATION IN THE SUPEROXIDE DISMUTASE 1 (SOD1) GENE"
  },
  {
    "Code": "U-3576",
    "Definition": "TREATMENT OF NARCOLEPSY-RELATED CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS USING A ONCE-DAILY PHARMACEUTICAL FORMULATION COMPRISING AN OXYBATE"
  },
  {
    "Code": "U-3577",
    "Definition": "TREATMENT OF NARCOLEPSY-RELATED CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS USING A SINGLE DAILY, BEDTIME DOSE OF A GAMMA-HYDROXYBUTYRATE FORMULATION"
  },
  {
    "Code": "U-3578",
    "Definition": "TREATMENT OF NARCOLEPSY, CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS USING A ONCE-NIGHTLY GAMMA-HYDROXYBUTYRATE FORMULATION"
  },
  {
    "Code": "U-3579",
    "Definition": "TREATMENT OF NARCOLEPSY AND ASSOCIATED DISORDERS AND SYMPTOMS USING A COMPOSITION COMPRISING GAMMA-HYDROXYBUTYRATE ONCE DAILY"
  },
  {
    "Code": "U-3580",
    "Definition": "TREATMENT OF NARCOLEPSY USING A DOSE PROPORTIONAL, ORAL PHARMACEUTICAL COMPOSITION COMPRISING GAMMA-HYDROXYBUTYRATE ONCE DAILY"
  },
  {
    "Code": "U-3581",
    "Definition": "TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS IN ADULTS WITH NARCOLEPSY"
  },
  {
    "Code": "U-3582",
    "Definition": "LIQREV IS INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (WHO GROUP 1) IN ADULTS TO IMPROVE EXERCISE ABILITY AND DELAY CLINICAL WORSENING"
  },
  {
    "Code": "U-3583",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON IN VITRO DATA WITH AN EFFECTIVE AMOUNT OF ELX, TEZ, AND IVA"
  },
  {
    "Code": "U-3584",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON IN VITRO DATA BY ADMINISTERING ELEXACAFTOR, IVACAFTOR, AND A SOLID DISPERSION OF TEZACAFTOR AND A POLYMER"
  },
  {
    "Code": "U-3585",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A MUTATION THAT IS RESPONSIVE BASED ON IN VITRO DATA COMPRISING ADMINISTERING THE COMPOSITION RECITED IN US 11564916 CLAIM 1"
  },
  {
    "Code": "U-3586",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A MUTATION THAT IS RESPONSIVE BASED ON IN VITRO DATA BY ADMINISTERING DAILY ELX (100 MG OR 80 MG); TEZ; AND IVA"
  },
  {
    "Code": "U-3587",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON IN VITRO DATA WITH AN EFFECTIVE AMOUNT OF ELX, TEZ, AND IVA"
  },
  {
    "Code": "U-3588",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR"
  },
  {
    "Code": "U-3589",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR"
  },
  {
    "Code": "U-3590",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH AN EFFECTIVE AMOUNT OF ELX, TEZ, AND IVA"
  },
  {
    "Code": "U-3591",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE AT LEAST ONE F508DEL MUTATION OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA USING A SOLID COMPOSITION COMPRISING ELX, TEZ, AMORPHOUS IVA, AND < ~30% CRYSTALLINE IVA"
  },
  {
    "Code": "U-3592",
    "Definition": "TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELX, TEZ, AND IVA"
  },
  {
    "Code": "U-3593",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE A R117H MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR"
  },
  {
    "Code": "U-3594",
    "Definition": "TREATMENT OF IRON DEFICIENCY ANEMIA (DIA) IN ADULTS PATIENTS WHO HAVE INTOLERANCE TO ORAL IRON OR HAVE HAD UNSATISFACTORY RESPONSE TO ORAL IRON, WHO HAVE NON-HEMODIALYSIS DEPENDENT CHRONIC KIDNEY DISEASE, BY ADMINISTERING FERRIC DERISOMALTOSE"
  },
  {
    "Code": "U-3595",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A MUTATION THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOUND OF CLAIM 1 OR COMPOSITION OF CLAIM 29 OF US 11426407"
  },
  {
    "Code": "U-3596",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL COMPOSITION COMPRISING ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR"
  },
  {
    "Code": "U-3597",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A MUTATION THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOSITION ACCORDING TO ANY ONE OF CLAIMS 1-3 AND 7-9 OF US11179367"
  },
  {
    "Code": "U-3598",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE AT LEAST ONE F508DEL MUTATION OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA COMPRISING ADMINISTERING A COMPOSITION ACCORDING TO CLAIM 1 OF US 11147770"
  },
  {
    "Code": "U-3599",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE AT LEAST ONE F508DEL MUTATION OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA COMPRISING ADMINISTERING A COMPOSITION ACCORDING TO CLAIM 1 OF US 10272046"
  },
  {
    "Code": "U-3600",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US 10081621"
  },
  {
    "Code": "U-3601",
    "Definition": "TREATMENT OF A DISORDER TREATABLE WITH GAMMA-HYDROXYBUTYRATE USING A SINGLE, DAILY DOSE OF A GAMMA-HYDROXYBUTYRATE FORMULATION"
  },
  {
    "Code": "U-3602",
    "Definition": "TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS WITH A DOSING REGIMEN THAT INCLUDES ORAL ADMINISTRATION OF 75 MG ONCE DAILY FOR AT LEAST 3 DAYS FOLLOWED BY 150 MG ONCE DAILY"
  },
  {
    "Code": "U-3603",
    "Definition": "TREATMENT OF CF IN A PATIENT AGE 1 MONTH TO <4 MONTHS WHO HAS AT LEAST ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND\/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 11564916"
  },
  {
    "Code": "U-3604",
    "Definition": "TREATMENT OF CF IN A PATIENT AGE 1 MONTH TO <4 MONTHS WHO HAS AT LEAST ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND\/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 11147770"
  },
  {
    "Code": "U-3605",
    "Definition": "TREATMENT OF CF IN A PATIENT AGE 1 MONTH TO <4 MONTHS WHO HAS AT LEAST ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND\/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 10272046"
  },
  {
    "Code": "U-3606",
    "Definition": "TREATMENT OF CF IN A PATIENT AGE 1 MONTH TO <4 MONTHS WHO HAS AT LEAST ONE CFTR MUTATION RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND\/OR IN VITRO ASSAY DATA USING A SOLID COMPOSITION COMPRISING AMORPHOUS (LESS THAN ABOUT 30% CRYSTALLINE) IVACAFTOR"
  },
  {
    "Code": "U-3607",
    "Definition": "TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF USING IVACAFTOR IN A PATIENT AGE 1 MONTH TO <4 MONTHS WHO HAS AT LEAST ONE CFTR MUTATION RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND\/OR IN VITRO ASSAY DATA"
  },
  {
    "Code": "U-3608",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 1 MONTH TO <4 MONTHS WHO HAS A R117H MUTATION IN THE CFTR GENE"
  },
  {
    "Code": "U-3609",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS USING IVACAFTOR IN A PATIENT AGE 1 MONTH TO <4 MONTHS WHO HAS AT LEAST ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND\/OR IN VITRO ASSAY DATA"
  },
  {
    "Code": "U-3610",
    "Definition": "CO-ADMINISTRATION OF CENOBAMATE WITH PHENOBARBITAL AND\/OR PHENYTOIN FOR THE TREATMENT OF PARTIAL ONSET SEIZURES"
  },
  {
    "Code": "U-3611",
    "Definition": "TREATMENT OF PEDIATRIC PATIENTS WITH CENTRAL PRECOCIOUS PUBERTY"
  },
  {
    "Code": "U-3612",
    "Definition": "AS AN ADJUNCT TO DIET TO REDUCE LOW-DENSITY LIPOPROTEIN CHOLESTEROL IN ADULTS AND PEDIATRIC PATIENTS AGED 10 YEARS AND OLDER WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA"
  },
  {
    "Code": "U-3613",
    "Definition": "AS AN ADJUNCT TO OTHER LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) LOWERING THERAPIES, OR ALONE IF SUCH TREATMENTS ARE UNAVAILABLE, TO REDUCE LDL-C IN ADULTS AND PEDIATRIC PATIENTS AGED 10 YEARS AND OLDER WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA"
  },
  {
    "Code": "U-3614",
    "Definition": "POSITRON EMISSION TOMOGRAPHY (PET) OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) POSITIVE LESIONS IN MEN WITH PROSTATE CANCER WITH SUSPECTED METASTASIS WHO ARE CANDIDATES FOR INITIAL DEFINITIVE THERAPY"
  },
  {
    "Code": "U-3615",
    "Definition": "POSITRON EMISSION TOMOGRAPHY (PET) OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) POSITIVE LESIONS IN MEN WITH PROSTATE CANCER WITH SUSPECTED RECURRENCE BASED ON ELEVATED SERUM PROSTATE-SPECIFIC ANTIGEN (PSA) LEVEL"
  },
  {
    "Code": "U-3616",
    "Definition": "A METHOD OF ADMINISTERING AN OPIOID MAINTENANCE TREATMENT COMPRISING BUPRENORPHINE"
  },
  {
    "Code": "U-3617",
    "Definition": "A METHOD OF ADMINISTERING AN OPIOID MAINTENANCE TREATMENT COMPRISING BUPRENORPHINE. A METHOD OF TREATING OPIOID WITHDRAWAL USING AN OPIOID MAINTENANCE TREATMENT COMPRISING BUPRENORPHINE"
  },
  {
    "Code": "U-3618",
    "Definition": "A METHOD OF SUSTAINED DELIVERY OF BUPRENORPHINE TO A HUMAN OR NON-HUMAN ANIMAL BODY. A METHOD FOR TREATMENT FOR OPIOID MAINTENANCE THERAPY"
  },
  {
    "Code": "U-3619",
    "Definition": "A METHOD OF DELIVERY OF A BIOACTIVE AGENT BY SUBCUTANEOUS INJECTION. A METHOD OF TREATMENT OF A HUMAN FOR ADDICTION"
  },
  {
    "Code": "U-3620",
    "Definition": "A METHOD OF DELIVERY OF AN OPIOID BIOACTIVE AGENT. A METHOD OF TREATMENT OR PROPHYLAXIS OF A HUMAN OR NON-HUMAN ANIMAL FOR THE TREATMENT OF OPIOID ADDICTION AND\/OR THE SYMPTOMS OF OPIOID WITHDRAWAL"
  },
  {
    "Code": "U-3621",
    "Definition": "TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS DUE WITH MENOPAUSE"
  },
  {
    "Code": "U-3622",
    "Definition": "TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS DUE TO MENOPAUSE"
  },
  {
    "Code": "U-3623",
    "Definition": "MAINTENANCE TREATMENT OF ASTHMA IN PATIENTS AGED 5 YEARS AND OLDER. RECOMMENDED DOSAGES: BREO 100\/25 OR 200\/25 AGES 18 YEARS AND OLDER; BREO 100\/25 AGES 12-17 YEARS, AND BREO 50\/25, AGES 5-11 YEARS"
  },
  {
    "Code": "U-3624",
    "Definition": "TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS"
  },
  {
    "Code": "U-3626",
    "Definition": "TREATMENT OF SCHIZOPHRENIA BY ADMINISTRATION OF A SIX-MONTH PALIPERIDONE PALMITATE INJECTABLE SUSPENSION FILLED SYRINGE THAT HAS BEEN SHIPPED AND STORED IN A HORIZONAL POSITION"
  },
  {
    "Code": "U-3627",
    "Definition": "TREATMENT OF DRY EYE DISEASE (DED)"
  },
  {
    "Code": "U-3628",
    "Definition": "REDUCTION OF RISK OF CARDIOVASCULAR DEATH, HOSPITALIZATION FOR HEART FAILURE, AND URGENT HEART FAILURE IN ADULTS WITH HEART FAILURE OR TYPE 2 DIABETES MELLITUS, CHRONIC KIDNEY DISEASE, AND OTHER CARDIOVASCULAR RISK FACTORS"
  },
  {
    "Code": "U-3629",
    "Definition": "TREATMENT OF MILD-TO-MODERATE CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS WHO ARE AT HIGH RISK FOR PROGRESSION TO SEVERE COVID-19, INCLUDING HOSPITALIZATION OR DEATH"
  },
  {
    "Code": "U-3630",
    "Definition": "TREATING OPIOID OVERDOSE"
  },
  {
    "Code": "U-3631",
    "Definition": "TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS BRCA-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER IN COMBINATION WITH ABIRATERONE AND PREDNISONE OR PREDNISOLONE"
  },
  {
    "Code": "U-3632",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA"
  },
  {
    "Code": "U-3633",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA"
  },
  {
    "Code": "U-3634",
    "Definition": "METHOD OF TREATING IDA IN ADULT PATIENTS WEIGHING AT LEAST 46.7 KG WITH HEART FAILURE & NY HEART ASSOCIATION CLASS II\/III TO IMPROVE EXERCISE CAPACITY BY ADMINISTERING IV FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST 0.7 G OF ELEMENTAL IRON IN 15 MINUTES"
  },
  {
    "Code": "U-3635",
    "Definition": "METHOD TO TREAT IDA IN ADULTS WEIGHING AT LEAST 40 KG WITH HEART FAILURE & NY HEART ASSOCIATION CLASS II\/III TO IMPROVE EXERCISE CAPACITY BY ADMINISTERING IV FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 G OF ELEMENTAL IRON IN ABOUT  15 MIN"
  },
  {
    "Code": "U-3636",
    "Definition": "METHOD TO TREAT IDA IN ADULTS WEIGHING AT LEAST 40 KG WITH HEART FAILURE & NY HEART ASSOCIATION CLASS II\/III TO IMPROVE EXERCISE CAPACITY BY INTRAVENOUSLY ADMINISTERING FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 G OF ELEMENTAL IRON"
  },
  {
    "Code": "U-3637",
    "Definition": "METHOD TO TREAT IRON DEFICIENCY IN ADULTS WEIGHING AT LEAST 40 KG WITH HEART FAILURE & NY HEART ASSOCIATION CLASS II\/III TO IMPROVE EXERCISE CAPACITY BY ADMINISTERING IV FERRIC CARBOXYMALTOSE TO PROVIDE AT LEAST ABOUT 0.6 G OF ELEMENTAL IRON"
  },
  {
    "Code": "U-3638",
    "Definition": "A METHOD FOR TREATING AND\/OR REDUCING THE RISK OF ACUTE MYOCARDIAL INFARCTION"
  },
  {
    "Code": "U-3639",
    "Definition": "A METHOD FOR TREATING AND\/OR REDUCING THE RISK OF A CARDIOVASCULAR EVENT"
  },
  {
    "Code": "U-3640",
    "Definition": "A METHOD OF TREATING AND\/OR REDUCING THE RISK OF INFLAMMATION, ATHEROSCLEROTIC VASCULAR DISEASE, AND CHOLESTEROL CRYSTAL INDUCED INFLAMMATION WITHIN ATHEROSCLEROTIC PLAQUES"
  },
  {
    "Code": "U-3641",
    "Definition": "A METHOD OF TREATING AND\/OR REDUCING THE RISK OF A CARDIOVASCULAR EVENT; ACUTE CORONARY SYNDROME, OUT-OF-HOSPITAL CARDIAC ARREST, AND\/OR NONCARDIOEMBOLIC ISCHEMIC STROKE"
  },
  {
    "Code": "U-3642",
    "Definition": "A METHOD OF TREATING CARDIOVASCULAR DISEASE"
  },
  {
    "Code": "U-3643",
    "Definition": "METHOD OF TREATING AND\/OR REDUCING THE RISK OF A CARDIOVASCULAR EVENT"
  },
  {
    "Code": "U-3644",
    "Definition": "TREATMENT OF FUNCTIONAL CONSTIPATION IN PEDIATRIC PATIENTS 6 TO 17 YEARS OF AGE"
  },
  {
    "Code": "U-3645",
    "Definition": "ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY BUCCAL ADMINISTRATION"
  },
  {
    "Code": "U-3646",
    "Definition": "A METHOD OF TREATMENT OF OVARIAN CANCER OR FALLOPIAN TUBE CANCER"
  },
  {
    "Code": "U-3647",
    "Definition": "A METHOD OF TREATMENT OF RECURRENT OVARIAN CANCER OR FALLOPIAN TUBE CANCER ASSOCIATED WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BRCA-MUTATION"
  },
  {
    "Code": "U-3648",
    "Definition": "METHOD OF TREATING CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OR OLDER SUFFERING FROM ALAGILLE SYNDROME (ALGS)"
  },
  {
    "Code": "U-3649",
    "Definition": "METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 12 MONTHS OR OLDER SUFFERING FROM ALAGILLE SYNDROME (ALGS)"
  },
  {
    "Code": "U-3650",
    "Definition": "TREATMENT OF PATIENTS WITH POST-TRANSPLANT CYTOMEGALOVIRUS (CMV) INFECTION\/DISEASE REFRACTORY TO TREATMENT WITH GANCICLOVIR, VALGANCICLOVIR, CIDOFOVIR, OR FOSCARNET, WHERE THE PATIENT IS A STEM CELL, KIDNEY, OR LIVER TRANSPLANT RECIPIENT"
  },
  {
    "Code": "U-3651",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH HRR GENE-MUTATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) IN COMBINATION WITH ENZALUTAMIDE"
  },
  {
    "Code": "U-3652",
    "Definition": "AS AN ADJUNCT TO DIET AND STATIN THERAPY FOR THE TREATMENT OF ADULTS WITH PRIMARY HYPERLIPIDEMIA, INCLUDING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH), BY INHIBITING EXPRESSION OF THE PCSK9 GENE"
  },
  {
    "Code": "U-3653",
    "Definition": "MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS IN A PATIENT WITH MODERATE HEPATIC IMPAIRMENT"
  },
  {
    "Code": "U-3654",
    "Definition": "MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS USING 150 MG OR 200 MG ELAGOLIX WHILE CO-ADMINISTERING OMEPRAZOLE"
  },
  {
    "Code": "U-3655",
    "Definition": "MANAGEMENT OF HEAVY MENSTRUAL BLEEDING ASSOCIATED WITH UTERINE LEIOMYOMAS (FIBROIDS) USING 300 MG ELAGOLIX WHILE CO-ADMINISTERING OMEPRAZOLE"
  },
  {
    "Code": "U-3656",
    "Definition": "TREATMENT OF METASTATIC COLORECTAL CANCER ALONE OR WITH BEVACIZUMAB IN PATIENTS PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN-BASED CHEMOTHERAPY, AN ANTI-VEGF BIOLOGICAL THERAPY, AND IF RAS WILD-TYPE, AN ANTI-EGFR THERAPY"
  },
  {
    "Code": "U-3657",
    "Definition": "TREATMENT OF METASTATIC COLORECTAL CANCER ALONE OR WITH BEVACIZUMAB IN SEVERELY RENALLY IMPAIRED PATIENTS PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN THERAPY, AN ANTI-VEGF BIOLOGIC, AND IF RAS WILD-TYPE, ANTI-EGFR THERAPY"
  },
  {
    "Code": "U-3658",
    "Definition": "TREATMENT OF METASTATIC GASTRIC OR GJA IN SEVERELY RENALLY IMPAIRED PATIENTS TREATED WITH AT LEAST TWO LINES OF CHEMOTHERAPY THAT INCLUDED A FLUOROPYRIMIDINE, A PLATINUM, A TAXANE OR IRINOTECAN, AND IF APPROPRIATE, HER2\/NEU-TARGETED THERAPY"
  },
  {
    "Code": "U-3659",
    "Definition": "TREATMENT OF METASTATIC COLORECTAL CANCER WITH BEVACIZUMAB IN PATIENTS PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN- AND IRINOTECAN-BASED CHEMOTHERAPY, AN ANTI-VEGF BIOLOGICAL THERAPY, AND IF RAS WILD-TYPE, AN ANTI-EGFR THERAPY"
  },
  {
    "Code": "U-3660",
    "Definition": "TREATMENT OF PARTIAL-ONSET SEIZURES IN ADULTS AND IN PEDIATRIC PATIENTS WEIGHING AT LEAST 50 KG"
  },
  {
    "Code": "U-3661",
    "Definition": "COMBINATION WITH STANDARD CYTARABINE AND ANTHRACYCLINE INDUCTION AND CYTARABINE CONSOLIDATION, AND AS MAINTENANCE MONOTHERAPY FOLLOWING CONSOLIDATION CHEMOTHERAPY, FOR ADULT PATIENTS WITH NEWLY DIAGNOSED FLT3-ITD POSITIVE ACUTE MYELOID LEUKEMIA"
  },
  {
    "Code": "U-3662",
    "Definition": "DEXTROMETHORPHAN AND BUPROPRION IN COMBINATION TO TREAT MAJOR DEPRESSIVE DISORDER"
  },
  {
    "Code": "U-3663",
    "Definition": "TOPICAL TREATMENT OF MOLLUSCUM CONTAGIOSUM IN ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-3664",
    "Definition": "TOPICAL TREATMENT OF SKIN LESIONS CAUSED BY AN INFECTION WITH MOLLUSCUM CONTAGIOSUM IN ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-3665",
    "Definition": "TOPICAL DELIVERY OF A CANTHARIDIN FORMULATION TO ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER FOR TREATING MOLLUSCUM CONTAGIOSUM"
  },
  {
    "Code": "U-3666",
    "Definition": "USE IN ADULT AND PEDIATRIC PATIENTS WITH SUBOPTIMAL ECHOCARDIOGRAMS TO OPACIFY THE LEFT VENTRICULAR CHAMBER AND TO IMPROVE THE DELINEATION OF THE LEFT VENTRICULAR ENDOCARDIAL BORDER"
  },
  {
    "Code": "U-3667",
    "Definition": "USE IN ULTRASONOGRAPHY OF THE URINARY TRACT IN PEDIATRIC PATIENTS FOR THE EVALUATION OF SUSPECTED OR KNOWN VESICOURETERAL REFLUX"
  },
  {
    "Code": "U-3668",
    "Definition": "USE WITH ULTRASOUND OF THE LIVER IN ADULT AND PEDIATRIC PATIENTS TO CHARACTERIZE FOCAL LIVER LESIONS"
  },
  {
    "Code": "U-3669",
    "Definition": "USE OF VASCEPA TO REDUCE THE INCIDENCE OF STROKE IN AN ADULT PATIENT ON STATIN THERAPY AND WITH ELEVATED TRIGLYCERIDE LEVELS (>150 MG\/DL), WHEREIN THE PATIENT EXPERIENCES ATRIAL FIBRILLATION AND\/OR FLUTTER INSTEAD OF AN INCIDENCE OF STROKE"
  },
  {
    "Code": "U-3670",
    "Definition": "ADMINISTRATION OF AN EXTENDED RELEASE TABLET FOR THE TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY (NDO) IN PEDIATRIC PATIENTS AGED 3 YEARS AND OLDER AND WEIGHING 35 KG OR MORE"
  },
  {
    "Code": "U-3671",
    "Definition": "USE OF INTRANASAL NALOXONE FOR THE TREATMENT OF OPIOID OVERDOSE"
  },
  {
    "Code": "U-3672",
    "Definition": "MANAGEMENT OF MODERATE TO SEVERE PAIN ASSOCIATED WITH ENDOMETRIOSIS USING 150 MG ELAGOLIX FOR UP TO 24 MONTHS"
  },
  {
    "Code": "U-3673",
    "Definition": "TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY ADMINISTERTING AVACINCAPTAD PEGOL TO THE EYE"
  },
  {
    "Code": "U-3674",
    "Definition": "TREATMENT OF DEMODEX BLEPHARITIS VIA TOPICAL ADMINISTRATION TO AN OCULAR SURFACE"
  },
  {
    "Code": "U-3675",
    "Definition": "A PERCUTANEOUS HEPATIC PERFUSION PROCEDURE FOR TREATING A PATIENT WITH UVEAL MELANOMA WITH UNRESECTABLE HEPATIC METASTASES"
  },
  {
    "Code": "U-3676",
    "Definition": "REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA (MYOSITIS) OSSIFICANS PROGRESSIVA"
  },
  {
    "Code": "U-3677",
    "Definition": "ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN A PATIENT WITH SEVERE HEPATIC IMPAIRMENT"
  },
  {
    "Code": "U-3678",
    "Definition": "A METHOD FOR REDUCING THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A PLATINUM\/ETOPOSIDE-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER"
  },
  {
    "Code": "U-3679",
    "Definition": "A METHOD FOR REDUCING THE INCIDENCE OF CHEMOTHERAPY-INDUCED MYELOSUPPRESSION IN ADULT PATIENTS WHEN ADMINISTERED PRIOR TO A TOPOTECAN-CONTAINING REGIMEN FOR EXTENSIVE-STAGE SMALL CELL LUNG CANCER"
  },
  {
    "Code": "U-3680",
    "Definition": "A METHOD FOR TREATING A SUBJECT WITH UVEAL MELANOMA WITH UNRESECTABLE HEPATIC METASTASES"
  },
  {
    "Code": "U-3681",
    "Definition": "TREATMENT OF ACUTE CYANIDE POISONING THAT IS JUDGED TO BE SERIOUS OR LIFE-THREATENING"
  },
  {
    "Code": "U-3682",
    "Definition": "SODIUM THIOSULFATE INJECTION IS INDICATED FOR SEQUENTIAL USE WITH SODIUM NITRITE FOR THE TREATMENT OF ACUTE CYANIDE POISONING THAT IS JUDGED TO BE SERIOUS OR LIFE-THREATENING"
  },
  {
    "Code": "U-3683",
    "Definition": "A METHOD OF TREATING A PATIENT WITH UVEAL MELANOMA WITH UNRESECTABLE HEPATIC METASTASES"
  },
  {
    "Code": "U-3684",
    "Definition": "A METHOD OF TREATING AN ADULT PATIENT WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA HAVING A SUSCEPTIBLE IDH1 MUTATION"
  },
  {
    "Code": "U-3685",
    "Definition": "METHOD OF ADMINISTERING AN EFFECTIVE DOSE OF TROPICAMIDE AND PHENYLEPHRINE HYDROCHLORIDE TO AN EYE"
  },
  {
    "Code": "U-3686",
    "Definition": "TREATMENT OF EXACERBATIONS OF MULTIPLE SCLEROSIS IN ADULTS WITH CORTICOTROPIN BY PROMOTING NEW VESSEL FORMATION WHEREIN VCAM-1 EXPRESSION AND ANGIOPOETIN-2 EXPRESSION IS INCREASED AFTER THE ADMINISTERING"
  },
  {
    "Code": "U-3687",
    "Definition": "TREATMENT OF INFANTILE SPASMS WITH CORTICOTROPIN BY PROMOTING NEW VESSEL FORMATION WHEREIN VCAM-1 EXPRESSION AND ANGIOPOETIN-2 EXPRESSION IS INCREASED AFTER THE ADMINISTERING"
  },
  {
    "Code": "U-3688",
    "Definition": "TREATMENT OF OPHTHALMIC DISEASES WITH CORTICOTROPIN BY PROMOTING NEW VESSEL FORMATION WHEREIN VCAM-1 EXPRESSION AND ANGIOPOETIN-2 EXPRESSION IS INCREASED AFTER THE ADMINISTERING"
  },
  {
    "Code": "U-3689",
    "Definition": "DIAGNOSIS OF GALL BLADDER DISORDERS BY STIMULATING GALLBLADDER CONTRACTION, AS MAY BE ASSESSED BY VARIOUS METHODS OF DIAGNOSTIC IMAGING, OR TO OBTAIN BY DUODENAL ASPIRATION A SAMPLE OF CONCENTRATED BILE FOR ANALYSIS"
  },
  {
    "Code": "U-3690",
    "Definition": "A METHOD FOR PREVENTING OF POST-OPERATIVE NAUSEA AND VOMITING"
  },
  {
    "Code": "U-3691",
    "Definition": "TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION"
  },
  {
    "Code": "U-3692",
    "Definition": "A METHOD OF TREATING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA OR ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE BY DECREASING THE LEVEL OF LDL-C USING 180 MG BEMPEDOIC ACID AND 10 MG EZETIMIBE"
  },
  {
    "Code": "U-3693",
    "Definition": "TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS IN A BREAST-FEEDING PATIENT WHILE REDUCING INFANT EXPOSURE TO SOLRIAMFETOL"
  },
  {
    "Code": "U-3694",
    "Definition": "METHOD OF REDUCING OR AMELIORATING SEIZURES IN A PATIENT BY ADMINISTERING A LIQUID FORMULATION OF FENFLURAMINE WITH STIRIPENTOL THEREBY MODULATING DOWN THE FORMATION OF NORFENFLURAMINE AND RESULTING IN HIGHER LEVELS OF FENFLURAMINE"
  },
  {
    "Code": "U-3695",
    "Definition": "MAINTENANCE TREATMENT OF DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE OR SOMATIC BRCA-MUTED RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY"
  },
  {
    "Code": "U-3696",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE AT LEAST ONE F508DEL MUTATION OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA COMPRISING ADMINISTERING A COMPOSITION ACCORDING TO CLAIM 1 OF US 11752106"
  },
  {
    "Code": "U-3697",
    "Definition": "TREATMENT OF CF IN A PATIENT AGE 1 MONTH TO <6 YEARS WHO HAS AT LEAST ONE MUTATION IN THE CFTR GENE THAT IS RESPONSIVE TO IVACAFTOR BASED ON CLINICAL AND\/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 11752106"
  },
  {
    "Code": "U-3698",
    "Definition": "ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA BY SUBLINGUAL OR BUCCAL ADMINISTRATION"
  },
  {
    "Code": "U-3699",
    "Definition": "TREATMENT OF SUBJECTS WITH MAJOR DEPRESSION WITH SEXUAL DYSFUNCTION CAUSED BY EITHER MAJOR DEPRESSION OR PRIOR TREATMENTS, OR TREATMENT OF SUBJECTS WITH MAJOR DEPRESSION WITHOUT THE RISK OF SEXUAL DYSFUNCTION ADVERSE REACTIONS"
  },
  {
    "Code": "U-3700",
    "Definition": "TREATMENT OF ADULTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA WITH AN ORAL SOLUTION OF METHOTREXATE"
  },
  {
    "Code": "U-3701",
    "Definition": "TREATMENT OF ADULTS WITH MYCOSIS FUNGOIDES WITH AN ORAL SOLUTION OF METHOTREXATE"
  },
  {
    "Code": "U-3702",
    "Definition": "TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS WITH AN ORAL SOLUTION OF METHOTREXATE"
  },
  {
    "Code": "U-3703",
    "Definition": "TREATMENT OF ADULTS WITH RHEUMATOID ARTHRITIS WITH AN ORAL SOLUTION OF METHOTREXATE"
  },
  {
    "Code": "U-3704",
    "Definition": "TREATMENT OF ADULTS WITH SEVERE PSORIASIS WITH AN ORAL SOLUTION OF METHOTREXATE"
  },
  {
    "Code": "U-3705",
    "Definition": "TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY WHO HAVE AN APNEA\/HYPOPNEA INDEX 15 WITH A ONCE-NIGHTLY FORMULATION OF GAMMA-HYDROXYBUTYRATE"
  },
  {
    "Code": "U-3706",
    "Definition": "TREATMENT OF BLOATING ASSOCIATED WITH DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS-D) IN ADULT FEMALE SUBJECTS"
  },
  {
    "Code": "U-3707",
    "Definition": "A METHOD OF TREATING PATIENTS 1 YEAR OF AGE AND OLDER WITH CHRONIC PHASE PH+ CML, NEWLY-DIAGNOSED OR RESISTANT OR INTOLERANT TO PRIOR THERAPY"
  },
  {
    "Code": "U-3708",
    "Definition": "A METHOD OF TREATING PATIENTS WITH ACCELERATED, OR BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY"
  },
  {
    "Code": "U-3709",
    "Definition": "METHOD OF TREATING PRIMARY HYPEROXALURIA TYPE 1 (PH1)"
  },
  {
    "Code": "U-3710",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA BY ORALLY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY IN COMBINATION WITH INTRAVENOUS ADMINISTRATION OF OBINUTUZUMAB"
  },
  {
    "Code": "U-3711",
    "Definition": "A METHOD TO IMPROVE KIDNEY FUNCTION IN ADULTS WITH HEPATORENAL SYNDROME WITH RAPID REDUCTION IN KIDNEY FUNCTION"
  },
  {
    "Code": "U-3712",
    "Definition": "TOPICAL TREATMENT OF PLAQUE PSORIASIS, INCLUDING INTERTRIGINOUS AREAS, IN PATIENTS 6 YEARS OF AGE OR OLDER"
  },
  {
    "Code": "U-3713",
    "Definition": "TOPICAL TREATMENT OF ACNE VULGARIS IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-3714",
    "Definition": "TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS HAVING PRE-EXISTING SEVERE HEPATIC IMPAIRMENT AND SUFFERING FROM AN ADVERSE EVENT WHILE BEING ADMINISTERED RIPRETINIB DAILY"
  },
  {
    "Code": "U-3715",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) RECEIVING A MODERATE CYP3A INDUCER"
  },
  {
    "Code": "U-3716",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA (WM) RECEIVING A MODERATE CYP3A INDUCER"
  },
  {
    "Code": "U-3717",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LYMPHOMA (SLL) RECEIVING A MODERATE CYP3A INDUCER"
  },
  {
    "Code": "U-3718",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) RECEIVING A MODERATE CYP3A INDUCER, WHO HAVE RECEIVED AT LEAST ONE ANTICD20-BASED REGIMEN"
  },
  {
    "Code": "U-3719",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) RECEIVING A MODERATE CYP3A INDUCER, WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY"
  },
  {
    "Code": "U-3720",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RECEIVING A MODERATE CYP3A INDUCER"
  },
  {
    "Code": "U-3721",
    "Definition": "TREATMENT OF SECONDARY HYPERPARATHYROIDISM WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D IN CHRONIC KIDNEY DISEASE PATIENTS RECEIVING CHOLESTYRAMINE"
  },
  {
    "Code": "U-3722",
    "Definition": "TREATMENT OF SECONDARY HYPERPARATHYROIDISM WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D IN CHRONIC KIDNEY DISEASE PATIENTS RECEIVING PHENOBARBITAL OR OTHER ANTICONVULSANTS"
  },
  {
    "Code": "U-3723",
    "Definition": "TREATMENT OF SECONDARY HYPERPARATHYROIDISM WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D IN CHRONIC KIDNEY DISEASE PATIENTS RECEIVING CYP3A INHIBITORS"
  },
  {
    "Code": "U-3724",
    "Definition": "TO PRODUCE POST-SURGICAL ANALGESIA"
  },
  {
    "Code": "U-3725",
    "Definition": "ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY SUBLINGUAL OR BUCCAL ADMINISTRATION IN PATIENTS WITH SEVERE HEPATIC IMPAIRMENT"
  },
  {
    "Code": "U-3726",
    "Definition": "THE TREATMENT OF POMPE PATIENTS"
  },
  {
    "Code": "U-3727",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LYMPHOMA (SLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY"
  },
  {
    "Code": "U-3728",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY"
  },
  {
    "Code": "U-3729",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY"
  },
  {
    "Code": "U-3730",
    "Definition": "A METHOD FOR TREATING ULCERATIVE COLITIS BY ADMINISTERING ESTRASIMOD ARGININE IN AN AMOUNT EQUIVALENT TO ABOUT 2.0 MG OF ESTRASIMOD"
  },
  {
    "Code": "U-3731",
    "Definition": "A METHOD FOR TREATING ULCERATIVE COLITIS BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF THE FORM OF ESTRASIMOD ARGININE AS CLAIMED"
  },
  {
    "Code": "U-3732",
    "Definition": "A METHOD FOR TREATING ULCERATIVE COLITIS BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF ESTRASIMOD ARGININE"
  },
  {
    "Code": "U-3733",
    "Definition": "METHOD OF TREATING SEIZURES IN A PATIENT BY ADMINISTERING A LIQUID FORMULATION OF FENFLURAMINE OR ITS SALTS PLUS STIRIPENTOL THEREBY REDUCING NORFENFLURAMINE FORMATION WHILE INCREASING THE FENFLURAMINE LEVEL. PATIENTS CAN HAVE E.G. DRAVET OR LGS"
  },
  {
    "Code": "U-3734",
    "Definition": "METHOD OF TREATING SCHIZOPHRENIA IN A PATIENT WHO HAS PREVIOUSLY EXPERIENCED SIGNIFICANT WEIGHT GAIN INDUCED BY OLANZAPINE ALONE BY ADMINISTERING A COMPOSITION COMPRISING OLANZAPINE AND SAMIDORPHAN"
  },
  {
    "Code": "U-3735",
    "Definition": "TREATMENT OF GENERALIZED MYASTHENIA GRAVIS (GMG) IN AN ADULT PATIENT WHO IS ANTI-ACETYLCHOLINE RECEPTOR (ACHR) ANTIBODY POSITIVE BY SUBCUTANEOUS ADMINISTRATION OF C5 COMPLEMENT INHIBITOR ZILUCOPLAN"
  },
  {
    "Code": "U-3736",
    "Definition": "REDUCTION OF SERUM PHOSPHORUS IN ADULTS"
  },
  {
    "Code": "U-3737",
    "Definition": "MEKTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH ENCORAFENIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST"
  },
  {
    "Code": "U-3738",
    "Definition": "BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST"
  },
  {
    "Code": "U-3739",
    "Definition": "TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY AVOIDING THE ADMINISTRATION OF TASIMELTEON WITH FOOD"
  },
  {
    "Code": "U-3740",
    "Definition": "TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC) IN ADULTS"
  },
  {
    "Code": "U-3741",
    "Definition": "TREATMENT OF PRESBYOPIA"
  },
  {
    "Code": "U-3742",
    "Definition": "A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION WHEREIN THE CANCER IS RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES"
  },
  {
    "Code": "U-3743",
    "Definition": "A METHOD OF TREATING RELAPSED OR REFRACTORY MYELODYSPLASTIC SYNDROMES CHARACTERIZED BY THE PRESENCE OF A MUTANT ALLELE OF IDH1 BY ADMINISTERING A ONCE DAILY 500 MG ORAL DOSE TO A SUBJECT THAT HAS NOT INGESTED A HIGH-FAT MEAL"
  },
  {
    "Code": "U-3744",
    "Definition": "METHOD OF TREATING MILD TO MODERATE PAIN IN ADULTS"
  },
  {
    "Code": "U-3745",
    "Definition": "METHOD OF TREATING MODERATE TO SEVERE PAIN IN ADULTS AS AN ADJUNCT TO OPIOID ANALGESICS"
  },
  {
    "Code": "U-3746",
    "Definition": "METHODS OF MAKING AQUEOUS COMPOSITION AND TREATING PAIN, INFLAMMATION, FEVER, PATENT DUCTUS ATERIOSIS WITH AQUEOUS COMPOSITION"
  },
  {
    "Code": "U-3747",
    "Definition": "TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY"
  },
  {
    "Code": "U-3748",
    "Definition": "TOPICAL TREATMENT OF PLAQUE PSORIASIS, INCLUDING INTERTRIGINOUS AREAS, IN PATIENTS 6 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-3749",
    "Definition": "METHOD OF TREATING PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE BY ADMINISTERING TREPROSTINIL OR A SALT THEREOF BY INHALATION USING A DEVICE"
  },
  {
    "Code": "U-3750",
    "Definition": "TREATMENT OF GASTROINTESTINAL STROMAL TUMOR WITH A WILD TYPE KIT MUTATION IN PATIENTS PREVIOUSLY ADMINISTERED THREE OR MORE KINASE INHIBITORS, WHERE ONE OF THE KINASE INHIBITORS IS IMATINIB"
  },
  {
    "Code": "U-3751",
    "Definition": "TREATMENT OF CATAPLEXY OR EXCESSIVE DAYTIME SLEEPINESS IN PATIENTS WITH NARCOLEPSY WITH A ONCE-NIGHTLY GAMMA-HYDROXYBUTYRATE FORMULATION"
  },
  {
    "Code": "U-3752",
    "Definition": "METHOD OF TREATING DIABETIC HYPOGLYCEMIA"
  },
  {
    "Code": "U-3753",
    "Definition": "TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER WHO HAVE BEEN PREVIOUSLY TREATED WITH FLUOROPYRIMIDINE-, OXALIPLATIN-, AND IRINOTECAN-BASED CHEMOTHERAPY, ANTI-VEGF THERAPY, AND, IF RAS WILD-TYPE AND MEDICALLY APPROPRIATE, ANTI-EGFR THERAPY"
  },
  {
    "Code": "U-3754",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH PROGRESSING DESMOID TUMORS"
  },
  {
    "Code": "U-3755",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)"
  },
  {
    "Code": "U-3756",
    "Definition": "ACUTE TREATMENT OF AGITATION ASSOCIATED WITH BIPOLAR I OR II DISORDER BY SUBLINGUAL OR BUCCAL ADMINISTRATION"
  },
  {
    "Code": "U-3757",
    "Definition": "TREATMENT OF HYPOTHYROIDISM BY ORAL ADMINISTRATION OF L-THYROXINE TO A PATIENT ON AN EMPTY STOMACH 15 MINUTES BEFORE BREAKFAST"
  },
  {
    "Code": "U-3758",
    "Definition": "TREATMENT OF PITUITARY THYROTROPIN SUPPRESSION BY ORAL ADMINISTRATION OF L-THYROXINE TO A PATIENT ON AN EMPTY STOMACH 15 MINUTES BEFORE BREAKFAST"
  },
  {
    "Code": "U-3759",
    "Definition": "METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE IN PATIENTS WITH HEART FAILURE AND TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN"
  },
  {
    "Code": "U-3760",
    "Definition": "METHOD FOR REDUCING THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION IN PATIENTS WITH HEART FAILURE BY ADMINISTRATION OF EMPAGLIFLOZIN"
  },
  {
    "Code": "U-3761",
    "Definition": "ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (CLL\/SLL) WHO HAVE RECEIVED AT LEAST TWO PRIOR LINES OF THERAPY, INCLUDING A BTK INHIBITOR AND A BCL-2 INHIBITOR"
  },
  {
    "Code": "U-3762",
    "Definition": "TREATMENT WITH FULVESTRANT OF HR-POS. HER2-NEG. LOCALLY ADVANCED OR METASTATIC BREAST CANCER WITH PIK3CA\/AKT1\/PTEN-ALTERATION(S) FOLLOWING PROGRESSION ON ENDOCRINE THERAPY IN THE METASTATIC SETTING OR RECURRENCE ON OR WITHIN 12 MONTHS OF ADJUVANT THERAPY"
  },
  {
    "Code": "U-3763",
    "Definition": "TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC) WITH BIOCHEMICAL RECURRENCE (BCR) AT HIGH RISK FOR METASTASIS"
  },
  {
    "Code": "U-3764",
    "Definition": "TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS BY ADMINISTERING SOLRIAMFETOL TO A SUBJECT HAVING OBSTRUCTIVE SLEEP APNEA (OSA) AND NO, MILD, MODERATE, OR SEVERE RENAL IMPAIRMENT"
  },
  {
    "Code": "U-3765",
    "Definition": "TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS BY ADMINISTERING SOLRIAMFETOL TO A SUBJECT HAVING MODERATE OR SEVERE RENAL IMPAIRMENT"
  },
  {
    "Code": "U-3766",
    "Definition": "REDUCE THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE AND URGENT HEART FAILURE VISITS IN ADULTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION AND WITHOUT TYPE II DIABETES"
  },
  {
    "Code": "U-3767",
    "Definition": "USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN ADMINISTERED AT ELEVATED GASTRIC PH"
  },
  {
    "Code": "U-3768",
    "Definition": "USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN ADMINISTERED AT ELEVATED GASTRIC PH"
  },
  {
    "Code": "U-3769",
    "Definition": "USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN ADMINISTERED AT ELEVATED GASTRIC PH"
  },
  {
    "Code": "U-3770",
    "Definition": "USE OF DASATINIB FOR TREATMENT OF ADULTS WITH CHRONIC, ACCELERATED, OR MYELOID OR LYMPHOID BLAST PHASE PH+ CML WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY INCLUDING IMATINIB, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT"
  },
  {
    "Code": "U-3771",
    "Definition": "USE OF DASATINIB FOR TREATMENT OF ADULTS WITH PH+ ALL WITH RESISTANCE OR INTOLERANCE TO PRIOR THERAPY, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT"
  },
  {
    "Code": "U-3772",
    "Definition": "USE OF DASATINIB FOR TREATMENT OF NEWLY DIAGNOSED ADULTS WITH PH+ CML IN CHRONIC PHASE, WHEN COADMINISTERED WITH A GASTRIC ACID REDUCING AGENT"
  },
  {
    "Code": "U-3773",
    "Definition": "TOPICAL TREATMENT OF SEBORRHEIC DERMATITIS IN PATIENTS 9 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-3774",
    "Definition": "A CATHETER LOCK SOLUTION TO REDUCE CATHETER-RELATED BLOODSTREAM INFECTIONS IN ADULT PATIENTS RECEIVING HEMODIALYSIS THROUGH A CENTRAL VENOUS CATHETER"
  },
  {
    "Code": "U-3775",
    "Definition": "TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS BY ADMINISTERING SOLRIAMFETOL TO A SUBJECT HAVING NO, MILD, MODERATE, OR SEVERE RENAL IMPAIRMENT"
  },
  {
    "Code": "U-3776",
    "Definition": "TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR IS >=30 ML\/MIN\/1.73 M2 AND <60 ML\/MIN\/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL"
  },
  {
    "Code": "U-3777",
    "Definition": "TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION AND ORALLY ADMINISTERING EMPAGLIFLOZIN IN A DAILY AMOUNT OF 10 MG OR 25 MG IF THE EGFR>=45 ML\/MIN\/1.73 M2 AND <60 ML\/MIN\/1.73 M2, WHEREIN THE TREATMENT IMPROVES GLYCEMIC CONTROL"
  },
  {
    "Code": "U-3778",
    "Definition": "TREATMENT OF MAJOR DEPRESSIVE DISORDER BY ADMINISTERING DEXTROMETHORPHAN AND BUPROPION TO A SUBJECT HAVING MODERATE HEPATIC IMPAIRMENT"
  },
  {
    "Code": "U-3779",
    "Definition": "METHOD OF TREATING NEONATAL SEIZURES"
  },
  {
    "Code": "U-3780",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA FOLLOWING A PROGRAMMED DEATH RECEPTOR-1 OR PROGRAMMED DEATH-LIGAND INHIBITOR AND A VASCULAR ENDOTHELIAL GROWTH FACTOR TYROSINE KINASE INHIBITOR"
  },
  {
    "Code": "U-3781",
    "Definition": "REDUCTION IN LOSS OF KIDNEY FUNCTION IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) WHO ARE AT RISK OF DISEASE PROGRESSION"
  },
  {
    "Code": "U-3782",
    "Definition": "METHOD FOR ADMINISTERING MITAPIVAT OR A SALT OF MITAPIVAT TO MITIGATE DRUG INTERACTIONS IN PATIENTS WITH HEMOLYTIC ANEMIA THAT ARE TAKING MODERATE CYP3A INDUCERS"
  },
  {
    "Code": "U-3783",
    "Definition": "COMBINATION TREATMENT WITH TUCATINIB AND TRASTUZUMAB OF ADULTS WITH RAS WILD-TYPE HER2-POSITIVE UNRESECTABLE OR METASTATIC COLORECTAL CANCER THAT HAS PROGRESSED FOLLOWING PREVIOUS TREATMENT AS CLAIMED"
  },
  {
    "Code": "U-3784",
    "Definition": "USE OF ORAL OCTREOTIDE IN COMBINATION WITH A H2-RECEPTOR ANTAGONIST OR ANTACID FOR LONG-TERM MAINTENANCE TREATMENT IN ACROMEGALY PATIENTS WHO HAVE RESPONDED TO AND TOLERATED TREATMENT WITH OCTREOTIDE OR LANREOTIDE"
  },
  {
    "Code": "U-3785",
    "Definition": "METHOD OF PREVENTING PREGNANCY BY INSERTING A VAGINAL SYSTEM CONTAINING 103 MG OF SEGESTERONE ACETATE AND 17.4 MG OF ETHINYL ESTRADIOL FOR UP TO 1THIRTEEN 21\/7-DAY (IN\/OUT) CYCLES"
  },
  {
    "Code": "U-3786",
    "Definition": "ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN A PATIENT WITH SEVERE RENAL IMPAIRMENT"
  },
  {
    "Code": "U-3787",
    "Definition": "A METHOD FOR PREVENTING POST-OPERATIVE NAUSEA AND VOMITING"
  },
  {
    "Code": "U-3788",
    "Definition": "METHOD OF ADMINISTERING A NITRIC OXIDE RELEASING ACTIVE PHARMACEUTICAL INGREDIENT TO TREAT AND\/OR PREVENT VIRAL INFECTION"
  },
  {
    "Code": "U-3789",
    "Definition": "METHOD OF TREATING AND\/OR PREVENTING VIRAL INFECTION USING A NITRIC OXIDE RELEASING ACTIVE INGREDIENT"
  },
  {
    "Code": "U-3790",
    "Definition": "METHOD OF TREATING AND\/OR PREVENTING MOLLUSCUM CONTAGIOSUM WITH A NITRIC OXIDE RELEASING TOPICAL COMPOSITION"
  },
  {
    "Code": "U-3791",
    "Definition": "METHOD OF TREATING, PREVENTING, OR REDUCING LESIONS CAUSED BY MOLLUSCUM CONTAGIOSUM"
  },
  {
    "Code": "U-3792",
    "Definition": "METHOD OF TREATING AND\/OR PREVENTING VIRAL INFECTION WITH A TOPICAL NITRIC OXIDE RELEASING COMPONENT"
  },
  {
    "Code": "U-3793",
    "Definition": "METHOD OF ADMINISTERING A NITRIC OXIDE RELEASING API IN A COMBINATION TOPICAL COMPOSITION"
  },
  {
    "Code": "U-3794",
    "Definition": "METHOD OF TREATING AND\/OR PREVENTING VIRAL INFECTION WITH A TOPICAL COMPOSITION INCLUDING A NITRIC OXIDE RELEASING API"
  },
  {
    "Code": "U-3795",
    "Definition": "METHOD OF TREATING AND\/OR PREVENTING MOLLUSCUM CONTAGIOSUM WITH A TOPICAL COMPOSITION INCLUDING A NITRIC OXIDE RELEASING API"
  },
  {
    "Code": "U-3796",
    "Definition": "METHOD OF PREVENTING AND\/OR REDUCING APPEARANCE AND\/OR SIZE OF MALIGNANT LESION WITH A TOPICAL COMPOSITION INCLUDING A NITRIC OXIDE RELEASING API"
  },
  {
    "Code": "U-3797",
    "Definition": "METHOD OF TOPICALLY REDUCING LESIONS WITH TWO SEPARATELY STORED COMPONENTS"
  },
  {
    "Code": "U-3798",
    "Definition": "METHOD OF TOPICALLY REDUCING LESIONS WITH TWO SEPARATELY STORED COMPONENTS WHERE ONE COMPONENT INCLUDES A NITRIC OXIDE RELEASING COMPOUND"
  },
  {
    "Code": "U-3799",
    "Definition": "METHOD OF TOPICALLY REDUCING LESIONS WITH TWO SEPARATELY STORED COMPONENTS WHERE ONE COMPONENT INCLUDES WATER"
  },
  {
    "Code": "U-3800",
    "Definition": "METHOD OF APPLYING RELEASED NITRIC OXIDE TO SKIN FROM COMBINATION INCLUDING ANHYDROUS ALCOHOL GEL"
  },
  {
    "Code": "U-3801",
    "Definition": "METHOD OF INCREASING RELEASE OF NITRIC OXIDE FROM ANHYDROUS ALCOHOL GEL"
  },
  {
    "Code": "U-3802",
    "Definition": "METHOD OF TREATING SKIN AILMENT WITH NITRIC OXIDE RELEASING MACROMOLECULES AND HYDROPHILIC GEL"
  },
  {
    "Code": "U-3803",
    "Definition": "METHOD OF APPLICATION OF TOPICAL PHARMACEUTICAL COMPOSITION TO TREAT DERMATOLOGICAL CONDITION"
  },
  {
    "Code": "U-3804",
    "Definition": "TREATMENT OF PHARMACOLOGICALLY-INDUCED MYDRIASIS"
  },
  {
    "Code": "U-3805",
    "Definition": "TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 GENETIC ALTERATIONS WHOSE DISEASE HAS PROGRESSED ON OR AFTER AT LEAST ONE LINE OF PRIOR SYSTEMIC THERAPY"
  },
  {
    "Code": "U-3806",
    "Definition": "TREATMENT OF ADULTS WITH METASTATIC UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 GENETIC ALTERATIONS WHOSE DISEASE HAS PROGRESSED ON OR AFTER AT LEAST ONE LINE OF PRIOR SYSTEMIC THERAPY"
  },
  {
    "Code": "U-3807",
    "Definition": "TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC, SURGICALLY UNRESECTABLE UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 GENETIC ALTERATIONS WHOSE DISEASE HAS PROGRESSED ON OR AFTER AT LEAST ONE LINE OF PRIOR SYSTEMIC THERAPY"
  },
  {
    "Code": "U-3808",
    "Definition": "TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 GENETIC ALTERATIONS WHOSE DISEASE HAS PROGRESSED ON OR AFTER AT LEAST ONE LINE OF PRIOR SYSTEMIC THERAPY, WITH DOSING BASED ON SERUM PHOSPHATE LEVELS"
  },
  {
    "Code": "U-3809",
    "Definition": "IN COMBINATION WITH FULVESTRANT FOR TREATMENT OF ADULTS WITH HR-POSITIVE, HER-2-NEGATIVE, PIK3CA-MUTATED, ADVANCED OR METASTATIC BREAST CANCER"
  },
  {
    "Code": "U-3810",
    "Definition": "REDUCTION IN LOSS OF KIDNEY FUNCTION AND REDUCTION OF PROTEINURIA IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) WHO ARE AT RISK OF DISEASE PROGRESSION, BY RELEASE OF BUDESONIDE FROM THE FORMULATION"
  },
  {
    "Code": "U-3811",
    "Definition": "USE OF BIRCH TRITERPENES FOR THE TREATMENT OF WOUNDS ASSOCIATED WITH DYSTROPHIC AND JUNCTIONAL EPIDERMOLYSIS BULLOSA"
  },
  {
    "Code": "U-3812",
    "Definition": "TREATMENT OF DEPRESSION IN MDD WITH ACUTE SUICIDAL IDEATION\/BEHAVIOR WITH NASALLY ADMINISTERED ESKETAMINE WITH OAD IN A PATIENT WHO HAS MISSED A DOSE IN THE MAINTENANCE PHASE AND HAD WORSENING DEPRESSION SYMPTOMS BY RETURN TO HIGHER DOSING SCHEDULE"
  },
  {
    "Code": "U-3813",
    "Definition": "TREATMENT OF TRD WITH NASALLY ADMINISTERED ESKETAMINE IN CONJUNCTION WITH AN OAD IN A PATIENT WHO HAS MISSED A DOSE DURING THE MAINTENANCE PHASE AND HAD WORSENING OF DEPRESSION SYMPTOM BY RETURNING TO HIGHER DOSING SCHEDULE"
  },
  {
    "Code": "U-3814",
    "Definition": "USE OF SUSTAINED OR EXTENDED RELEASE ORAL 25-HYDROXYVITAMIN D3 IN TREATING SECONDARY HYPERPARATHROIDISM IN ADULT PATIENTS HAVING CHRONIC KIDNEY DISEASE STAGE 3 OR 4"
  },
  {
    "Code": "U-3815",
    "Definition": "TREATING SECONDARY HYPERPARATHYROIDISM IN STAGE 3 OR 4 CKD WITH SUSTAINED RELEASE 25-HYDROXYVITAMIN D TO REDUCE THE PATIENT'S SERUM PARATHYROID HORMONE LEVEL WHILE AVOIDING PTH OVERSUPPRESSION"
  },
  {
    "Code": "U-3816",
    "Definition": "TREATMENT OF HELICOBACTER PYLORI INFECTION USING THE ADMINISTERED DOSAGE FORMS IN ADULTS WITH DIFFERENT BODY MASS INDEX DETERMINATIONS"
  },
  {
    "Code": "U-3817",
    "Definition": "USE AS AN ANTICOAGULANT IN PATIENTS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI)"
  },
  {
    "Code": "U-3818",
    "Definition": "TREATMENT OF COMPLICATED INTRA-ABDOMINAL INFECTIONS, COMPLICATED URINARY TRACT INFECTIONS, AND HOSPITAL-ACQUIRED BACTERIAL PNEUMONIA AND VENTILATOR-ASSOCIATED BACTERIAL PNEUMONIA IN ADULT AND PEDIATRIC PATIENTS (AT LEAST 31 WEEKS GESTATIONAL AGE)"
  },
  {
    "Code": "U-3819",
    "Definition": "A METHOD OF PREVENTING PREGNANCY BY PROVIDING AN INTRAUTERINE SYSTEM (IUS), HOLDING AN INSERTER HANDLE WITH ONE HAND, INSERTING THE IUS INTO THE UTERUS, AND MOVING A SLIDER IN THE HANDLE TO RELEASE THE IUS WITHIN THE UTERUS"
  },
  {
    "Code": "U-3820",
    "Definition": "TREATMENT OF EOSINOPHILIC ESOPHAGITIS"
  },
  {
    "Code": "U-3821",
    "Definition": "DURING LEVOKETOCONAZOLE DOSAGE TITRATION FOR THE TREATMENT OF CUSHING'S SYNDROME IN PATIENTS WHO CONCOMITANTLY USE AN OCT2 SUBSTRATE, MONITORING THE SUBJECT FOR A DOSE LIMITING EVENT AND ADJUSTING THE DOSAGE OF THE OCT2 SUBSTRATE AS NEEDED"
  },
  {
    "Code": "U-3822",
    "Definition": "AS ADJUNCTIVE TREATMENT TO LEVODOPA\/CARBIDOPA IN PATIENTS WITH PARKINSON'S DISEASE EXPERIENCING 'OFF' EPISODES"
  },
  {
    "Code": "U-3823",
    "Definition": "TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WHOSE TUMORS HAVE EPIDERMAL GROWTH FACTOR RECEPTOR EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS IN COMBINATION WITH PEMETREXED AND PLATINUM-BASED CHEMOTHERAPY"
  },
  {
    "Code": "U-3824",
    "Definition": "TREATMENT OF METASTATIC PANCREATIC ADENOCARCINOMA IN COMBINATION WITH OXALIPLATIN, FLUOROURACIL, AND LEUCOVORIN"
  },
  {
    "Code": "U-3825",
    "Definition": "REDUCE THE RISK OF CARDIOVASCULAR DEATH AND WORSENING HEART FAILURE IN ADULTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION, WITHOUT TYPE II DIABETES, AND HAVING AN HBA1C OF < 5.7%"
  },
  {
    "Code": "U-3826",
    "Definition": "TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY INTRAVITREAL ADMINISTRATION OF 15 MG PEGCETACOPLAN EVERY OTHER MONTH"
  },
  {
    "Code": "U-3827",
    "Definition": "TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY INTRAVITREAL ADMINISTRATION OF 15 MG PEGCETACOPLAN MONTHLY"
  },
  {
    "Code": "U-3828",
    "Definition": "TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY INTRAVITREAL ADMINISTRATION OF 15 MG PEGCETACOPLAN MONTHLY OR EVERY OTHER MONTH"
  },
  {
    "Code": "U-3829",
    "Definition": "TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (WEIGHING AT LEAST 40 KG) REQUIRING HOSPITALIZATION"
  },
  {
    "Code": "U-3830",
    "Definition": "TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (WEIGHING AT LEAST 40 KG)"
  },
  {
    "Code": "U-3831",
    "Definition": "TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (BIRTH TO < 18 YEARS OF AGE WEIGHING > 1.5 KG) REQUIRING HOSPITALIZATION"
  },
  {
    "Code": "U-3832",
    "Definition": "TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (BIRTH TO < 18 YEARS OF AGE WEIGHING > 1.5 KG)"
  },
  {
    "Code": "U-3833",
    "Definition": "TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (WEIGHING AT LEAST 40 KG) REQUIRING HOSPITALIZATION AND FOR WHOM CONCOMITANT USE OF CHLOROQUINE, OR AN ANALOG OR SALT THEREOF, IS NOT RECOMMENDED"
  },
  {
    "Code": "U-3834",
    "Definition": "TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (WEIGHING AT LEAST 40 KG) AND FOR WHOM CONCOMITANT USE OF CHLOROQUINE, OR AN ANALOG OR SALT THEREOF, IS NOT RECOMMENDED"
  },
  {
    "Code": "U-3835",
    "Definition": "TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (BIRTH TO < 18 YEARS OF AGE WEIGHING > 1.5 KG) REQUIRING HOSPITALIZATION AND FOR WHOM CONCOMITANT USE OF CHLOROQUINE, OR AN ANALOG OR SALT THEREOF, IS NOT RECOMMENDED"
  },
  {
    "Code": "U-3836",
    "Definition": "TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (BIRTH TO < 18 YEARS OF AGE WEIGHING > 1.5 KG) AND FOR WHOM CONCOMITANT USE OF CHLOROQUINE, OR AN ANALOG OR SALT THEREOF, IS NOT RECOMMENDED"
  },
  {
    "Code": "U-3837",
    "Definition": "TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN ADULTS AND PEDIATRIC PATIENTS (WEIGHING AT LEAST 40 KG) REQUIRING HOSPITALIZATION AND FOR WHOM CONCOMITANT USE OF CHLOROQUINE, OR AN ANALOG OR SALT THEREOF, IF NOT RECOMMENDED"
  },
  {
    "Code": "U-3838",
    "Definition": "TREATMENT OF CORONAVIRUS DISEASE 2019 (COVID-19) IN NON-HOSPITALIZED ADULTS AND PEDIATRIC PATIENTS (WEIGHING AT LEAST 40 KG) AND FOR WHOM CONCOMITANT USE OF CHLOROQUINE, OR AN ANALOG OR SALT THEREOF, IF NOT RECOMMENDED"
  },
  {
    "Code": "U-3839",
    "Definition": "A METHOD OF TREATING PAIN BY ADMINISTERING BUPIVACAINE VIA LOCAL INFILTRATION IN PEDIATRIC PATIENTS AGED 6 TO LESS THAN 12 YEARS OLD UNDERGOING CARDIAC SURGERY"
  },
  {
    "Code": "U-3840",
    "Definition": "A METHOD OF TREATING PAIN BY ADMINISTERING BUPIVACAINE VIA LOCAL INFILTRATION IN PEDIATRIC PATIENTS AGED 6 TO LESS THAN 17 YEARS OLD UNDERGOING SPINE SURGERY"
  },
  {
    "Code": "U-3841",
    "Definition": "A METHOD OF ADMINISTERING BUPIVACAINE TO PRODUCE REGIONAL ANALGESIA VIA SCIATIC NERVE BLOCK IN THE POPLITEAL FOSSA IN ADULTS"
  },
  {
    "Code": "U-3842",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH 17P DELETION"
  },
  {
    "Code": "U-3843",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LYMPHOMA (SLL)"
  },
  {
    "Code": "U-3844",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH SMALL LYMPHOCYTIC LYMPHOMA (SLL) WITH 17P DELETION"
  },
  {
    "Code": "U-3845",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH WALDENSTROMS MACROGLOBULINEMIA (WM)"
  },
  {
    "Code": "U-3846",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA"
  },
  {
    "Code": "U-3847",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION"
  },
  {
    "Code": "U-3848",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA (SLL) WITH 17P DELETION"
  },
  {
    "Code": "U-3849",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY SMALL LYMPHOCYTIC LYMPHOMA (SLL)"
  },
  {
    "Code": "U-3850",
    "Definition": "TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTATIS (PFIC)"
  },
  {
    "Code": "U-3851",
    "Definition": "USE OF EXBLIFEP (CEFEPIME AND ENMETAZOBACTAM) FOR TREATING COMPLICATED URINARY TRACT INFECTIONS (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY DESIGNATED SUSCEPTIBLE MICROORGANISMS"
  },
  {
    "Code": "U-3852",
    "Definition": "USE OF SPECIFIED POLYMORPHS OF EXBLIFEP (CEFEPIME AND ENMETAZOBACTAM) FOR TREATING COMPLICATED URINARY TRACT INFECTIONS (CUTI) INCLUDING PYELONEPHRITIS CAUSED BY DESIGNATED SUSCEPTIBLE MICROORGANISMS"
  },
  {
    "Code": "U-3853",
    "Definition": "METHOD FOR LOWERING CHOLESTEROL LEVEL IN A HUMAN"
  },
  {
    "Code": "U-3854",
    "Definition": "LINAGLIPTIN (5 MG DAILY DOSE) AND METFORMIN (WITH OR WITHOUT INSULIN) FOR TREATING TYPE 2 DIABETES PATIENTS WITH RENAL IMPAIRMENT AND INSUFFICIENT GLYCEMIC CONTROL DESPITE PREVIOUS TREATMENT WITH METFORMIN ALONE OR IN COMBINATION WITH INSULIN"
  },
  {
    "Code": "U-3855",
    "Definition": "FOR CHRONIC WEIGHT MANAGEMENT IN ADULTS WITH AN INITIAL BODY MASS INDEX (BMI) OF: 30 KG\/M2 OR GREATER (OBESITY), OR 27 KG\/M2 OR GREATER (OVERWEIGHT) IN THE PRESENCE OF AT LEAST ONE WEIGHT-RELATED COMORBID CONDITION"
  },
  {
    "Code": "U-3856",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY"
  },
  {
    "Code": "U-3857",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH WALDENSTROM'S MACROGLOBULINEMIA (WM)"
  },
  {
    "Code": "U-3858",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA (MZL) WHO HAVE RECEIVED AT LEAST ONE PRIOR ANTI-CD20-BASED REGIMEN"
  },
  {
    "Code": "U-3859",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)"
  },
  {
    "Code": "U-3860",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL), IN COMBINATION WITH OBINUTUZUMAB, AFTER TWO OR MORE LINES OF SYSTEMIC THERAPY"
  },
  {
    "Code": "U-3861",
    "Definition": "TREATMENT OF ADULTS WITH NONCIRRHOTIC NONALCOHOLIC STEATOHEPATITIS (NASH) WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS)"
  },
  {
    "Code": "U-3862",
    "Definition": "METHOD OF TREATING FRIEDRICH'S ATAXIA BY ACTIVATING THE NRF2 PATHWAY"
  },
  {
    "Code": "U-3863",
    "Definition": "METHOD OF TREATING FRIEDRICH'S ATAXIA BY ACTIVATING THE NRF2 PATHWAY WHICH REDUCES OXIDATIVE STRESS"
  },
  {
    "Code": "U-3864",
    "Definition": "METHOD FOR REDUCING A RISK OF AT LEAST ONE CARDIOVASCULAR EVENT"
  },
  {
    "Code": "U-3865",
    "Definition": "TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER BY ADMINISTERING TASIMELTEON"
  },
  {
    "Code": "U-3866",
    "Definition": "TREATMENT OF HELICOBACTER PYLORI INFECTION IN ADULTS USING SPECIFIED DOSAGE FORM"
  },
  {
    "Code": "U-3867",
    "Definition": "METHOD FOR REDUCING A COMPOSITE ENDPOINT RISK OF MYOCARDIAL INFARCTION (MI), STROKE, CORONARY REVASCULARIZATION, UNSTABLE ANGINA REQUIRING HOSPITALIZATION, CARDIAC ARREST, AND CARDIOVASCULAR DEATH"
  },
  {
    "Code": "U-3868",
    "Definition": "METHOD FOR REDUCING ACUTE MYOCARDIAL INFARCTION RISK"
  },
  {
    "Code": "U-3869",
    "Definition": "ADJUNCTIVE TREATMENT TO LEVODOPA\/CARBIDOPA IN PATIENTS WITH PARKINSONS DISEASE EXPERIENCING OFF EPISODES"
  },
  {
    "Code": "U-3870",
    "Definition": "ADJUNCTIVE TREATMENT TO LEVODOPA\/CARBIDOPA IN PATIENTS WITH PARKINSONS DISEASE EXPERIENCING OFF EPISODES BY INCREASING L-DOPA AMOUNTS THAT REACH THE BRAIN"
  },
  {
    "Code": "U-3871",
    "Definition": "ADJUNCTIVE TREATMENT TO LEVODOPA\/CARBIDOPA IN PATIENTS WITH PARKINSONS DISEASE EXPERIENCING OFF EPISODES BY INHIBITING COMT IN THE PERIPHERY"
  },
  {
    "Code": "U-3872",
    "Definition": "ADJUNCTIVE TREATMENT TO LEVODOPA\/CARBIDOPA IN PATIENTS WITH PARKINSONS DISEASE EXPERIENCING OFF EPISODES BY REDUCING O-METHYLATION OF L-DOPA"
  },
  {
    "Code": "U-3873",
    "Definition": "A METHOD OF LOWERING LOW-DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) IN A HUMAN PATIENT IN NEED THEREOF COMPRISING ADMINISTRATION OF BEMPEDOIC ACID ALONE OR IN COMBINATION WITH OTHER LIPID LOWERING THERAPIES"
  },
  {
    "Code": "U-3874",
    "Definition": "IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS FOR THE TREATMENT OF HIV-1 INFECTION IN ANTIRETROVIRAL TREATMENT-NAIVE PATIENTS 2 YEARS OF AGE AND OLDER, WEIGHING AT LEAST 14KG, WITH HIV-1 RNA LESS THAN OR EQUAL TO 100,000 AT THE START OF THERAPY"
  },
  {
    "Code": "U-3875",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (FL) RECEIVING A MODERATE CYP3A INDUCER, IN COMBINATION WITH OBINUTUZUMAB, AFTER TWO OR MORE LINES OF SYSTEMIC THERAPY"
  },
  {
    "Code": "U-3876",
    "Definition": "TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS"
  },
  {
    "Code": "U-3877",
    "Definition": "TREATMENT OF HYPERTENSION IN COMBINATION WITH OTHER ANTIHYPERTENSIVE DRUGS, INCLUDING AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR, TO LOWER BLOOD PRESSURE IN ADULT PATIENTS WHO ARE NOT ADEQUATELY CONTROLLED ON OTHER DRUGS"
  },
  {
    "Code": "U-3878",
    "Definition": "TREATMENT OF HYPERTENSION IN COMBINATION WITH OTHER ANTIHYPERTENSIVE DRUGS, TO LOWER BLOOD PRESSURE IN ADULT PATIENTS WHO ARE NOT ADEQUATELY CONTROLLED ON OTHER DRUGS"
  },
  {
    "Code": "U-3879",
    "Definition": "TREATMENT OF HYPERTENSION IN COMBINATION WITH OTHER ANTIHYPERTENSIVE DRUGS, INCLUDING AN ANGIOTENSIN RECEPTOR BLOCKER, TO LOWER BLOOD PRESSURE IN ADULT PATIENTS WHO ARE NOT ADEQUATELY CONTROLLED ON OTHER DRUGS"
  },
  {
    "Code": "U-3880",
    "Definition": "TREATMENT OF CHRONIC HEPATITIS B VIRUS INFECTION IN ADULTS AND PEDIATRIC PATIENTS 6 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 25 KG"
  },
  {
    "Code": "U-3881",
    "Definition": "USE OF THE COMBINATION OF MACITENTAN AND TADALAFIL FOR THE CHRONIC TREATMENT OF ADULTS WITH PULMONARY ARTERIAL HYPERTENSION"
  },
  {
    "Code": "U-3882",
    "Definition": "METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION COMPRISING ADMINISTERING A COMBINATION OF MACITENTAN AND TADALAFIL"
  },
  {
    "Code": "U-3883",
    "Definition": "A METHOD OF LOWERING LDL-C OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA USING 180 MG BEMPEDOIC ACID AND 10 MG EZETIMIBE"
  },
  {
    "Code": "U-3884",
    "Definition": "A METHOD OF LOWERING LDL-C OR REDUCING THE RISK OF CARDIOVASCULAR DISEASE IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA USING A FIXED-DOSE COMBINATION OF 180 MG BEMPEDOIC ACID AND 10 MG EZETIMIBE"
  },
  {
    "Code": "U-3885",
    "Definition": "A METHOD FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY (DMD) USING GIVINOSTAT"
  },
  {
    "Code": "U-3886",
    "Definition": "METHOD OF TREATING BIPOLAR DISORDER BY ADMINISTERING A BILAYER TABLET COMPRISING OLANZAPINE AND SAMIDORPHAN"
  },
  {
    "Code": "U-3887",
    "Definition": "METHOD OF TREATING SCHIZOPHRENIA BY ADMINISTERING A BILAYER TABLET COMPRISING OLANZAPINE AND SAMIDORPHAN"
  },
  {
    "Code": "U-3888",
    "Definition": "TREATMENT OF PATIENTS WITH METASTATIC CASTRATION SENSITIVE PROSTATE CANCER"
  },
  {
    "Code": "U-3889",
    "Definition": "TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS RECEIVING OR WHO MAY RECEIVE A BETA-BLOCKER TREATMENT"
  },
  {
    "Code": "U-3890",
    "Definition": "A METHOD COMPRISING ADMINISTERING PEGULICIANINE TO A HUMAN AND OBTAINING AN IMAGE OF A TUMOR BED AFTER TUMOR RESECTION TO DISTINGUISH IN SITU CANCER CELLS FROM HEALTHY CELLS"
  },
  {
    "Code": "U-3891",
    "Definition": "TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS BEING TREATED WITH A BETA-BLOCKER OR IN ADULTS REINITIATING TREATMENT"
  },
  {
    "Code": "U-3892",
    "Definition": "TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS BY ADMINISTERING SOLRIAMFETOL TO A SUBJECT HAVING A HISTORY OF BIPOLAR DISORDERS AND MODERATE OR SEVERE RENAL IMPAIRMENT"
  },
  {
    "Code": "U-3893",
    "Definition": "TREATMENT OF SICKLE CELL DISEASE BY ADMINISTERING VOXELOTOR, AS RECITED IN CLAIM 10"
  },
  {
    "Code": "U-3894",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGE 6 AND OLDER WHO ARE HOMOZYGOUS FOR THE F508DEL MUTATION OR HAVE AT LEAST ONE CFTR GENE MUTATION THAT IS RESPONSIVE TO TEZACAFTOR\/IVACAFTOR WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US 11951212"
  },
  {
    "Code": "U-3895",
    "Definition": "TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF 200 MG OF IPTACOPAN TWICE DAILY"
  },
  {
    "Code": "U-3896",
    "Definition": "TREATMENT OF HEART FAILURE WITH ORAL PELLETS"
  },
  {
    "Code": "U-3897",
    "Definition": "TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS BEING TREATED CONCURRENTLY WITH ITRACONAZOLE"
  },
  {
    "Code": "U-3898",
    "Definition": "USE OF A PHARMACEUTICAL COMPOSITION OF ABOUT 0.5M SODIUM THIOSULFATE, ABOUT 0.004M BORIC ACID, AND A PH OF BETWEEN ABOUT 6.5 AND 8.9 FOR REDUCING OTOTOXICITY IN A PEDIATRIC PATIENT RECEIVING CISPLATIN FOR THE TREATMENT OF LOCALIZED CANCER"
  },
  {
    "Code": "U-3899",
    "Definition": "ADULT AND PEDIATRIC PATIENTS WEIGHING AT LEAST 10 KG AS A SOURCE OF ZINC, COPPER, MANGANESE, AND SELENIUM FOR PARENTERAL NUTRITION WHEN ORAL OR ENTERAL NUTRITION IS NOT POSSIBLE, INSUFFICIENT, OR CONTRAINDICATED"
  },
  {
    "Code": "U-3900",
    "Definition": "NEONATAL AND PEDIATRIC PATIENTS WEIGHING LESS THAN 10 KG AS A SOURCE OF ZINC, COPPER, MANGANESE, AND SELENIUM FOR PARENTERAL NUTRITION WHEN ORAL OR ENTERAL NUTRITION IS NOT POSSIBLE, INSUFFICIENT, OR CONTRAINDICATED"
  },
  {
    "Code": "U-3901",
    "Definition": "TREATMENT OF METASTATIC CASTRATION SENSITIVE PROSTATE CANCER"
  },
  {
    "Code": "U-3902",
    "Definition": "TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 GENETIC ALTERATIONS WHOSE DISEASE HAS PROGRESSED ON OR AFTER PRIOR PD-1 OR PD-L1 INHIBITOR THERAPY"
  },
  {
    "Code": "U-3903",
    "Definition": "A METHOD FOR TREATING A PEDIATRIC PATIENT WHO IS EXPERIENCING IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION RESULTING IN OXYGEN DESATURATION, WHEREIN THE PATIENT IS NOT DEPENDENT ON RIGHT-TO-LEFT SHUNTING OF BLOOD"
  },
  {
    "Code": "U-3904",
    "Definition": "ACUTE EXACERBATIONS OF MULTIPLE SCLEROSIS"
  },
  {
    "Code": "U-3905",
    "Definition": "ALLERGIC CONJUNCTIVITIS"
  },
  {
    "Code": "U-3906",
    "Definition": "ANTERIOR SEGMENT INFLAMMATION"
  },
  {
    "Code": "U-3907",
    "Definition": "AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: ACUTE GOUTY ARTHRITIS"
  },
  {
    "Code": "U-3908",
    "Definition": "AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: ANKYLOSING SPONDYLITIS"
  },
  {
    "Code": "U-3909",
    "Definition": "AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: JUVENILE RHEUMATOID ARTHRITIS"
  },
  {
    "Code": "U-3910",
    "Definition": "AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: PSORIATIC ARTHRITIS"
  },
  {
    "Code": "U-3911",
    "Definition": "AS ADJUNCTIVE THERAPY FOR SHORT-TERM ADMINISTRATION (TO TIDE THE PATIENT OVER AN ACUTE EPISODE OR EXACERBATION) IN: RHEUMATOID ARTHRITIS"
  },
  {
    "Code": "U-3912",
    "Definition": "ATOPIC DERMATITIS"
  },
  {
    "Code": "U-3913",
    "Definition": "CHORIORETINITIS"
  },
  {
    "Code": "U-3914",
    "Definition": "DIFFUSE POSTERIOR UVEITIS AND CHOROIDITIS"
  },
  {
    "Code": "U-3915",
    "Definition": "DURING AN EXACERBATION OR AS MAINTENANCE THERAPY IN SELECTED CASES OF: SYSTEMIC DERMATOMYOSITIS (POLYMYOSITIS)"
  },
  {
    "Code": "U-3916",
    "Definition": "DURING AN EXACERBATION OR AS MAINTENANCE THERAPY IN SELECTED CASES OF: SYSTEMIC LUPUS ERYTHEMATOSUS"
  },
  {
    "Code": "U-3917",
    "Definition": "IRIDOCYCLITIS"
  },
  {
    "Code": "U-3918",
    "Definition": "IRITIS"
  },
  {
    "Code": "U-3919",
    "Definition": "KERATITIS"
  },
  {
    "Code": "U-3920",
    "Definition": "OPTIC NEURITIS"
  },
  {
    "Code": "U-3921",
    "Definition": "SERUM SICKNESS"
  },
  {
    "Code": "U-3922",
    "Definition": "SEVERE ACUTE AND CHRONIC ALLERGIC AND INFLAMMATORY PROCESSES INVOLVING THE EYE AND ITS ADNEXA"
  },
  {
    "Code": "U-3923",
    "Definition": "SEVERE ERYTHEMA MULTIFORME (STEVENS-JOHNSON SYNDROME)"
  },
  {
    "Code": "U-3924",
    "Definition": "SEVERE PSORIASIS"
  },
  {
    "Code": "U-3925",
    "Definition": "SYMPTOMATIC SARCOIDOSIS"
  },
  {
    "Code": "U-3926",
    "Definition": "TO INDUCE A DIURESIS OR A REMISSION OF PROTEINURIA IN THE NEPHROTIC SYNDROME WITHOUT UREMIA OF THE IDIOPATHIC TYPE OR THAT DUE TO LUPUS ERYTHEMATOSUS"
  },
  {
    "Code": "U-3927",
    "Definition": "USE TO INCREASE LINEAR GROWTH IN PEDIATRIC PATIENTS WITH ACHONDROPLASIA WITH OPEN EPIPHYSES"
  },
  {
    "Code": "U-3928",
    "Definition": "FOR THE TREATMENT OF INTERMEDIATE OR HIGH-RISK MYELOFIBROSIS IN SUBJECTS HAVING A BASELINE PLATELET COUNT OF LESS THAN 50 BILLION\/L"
  },
  {
    "Code": "U-3929",
    "Definition": "MAINTENANCE TREATMENT WITH 15 MG\/KG OF BODY WEIGHT BEVACIZUMAB EVERY THREE WEEKS OF ADVANCED EPITHELIAL OVARIAN CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY AND ASSOCIATED WITH HRD-POSITIVE STATUS"
  },
  {
    "Code": "U-3930",
    "Definition": "MAINTENANCE TREATMENT WITH 15 MG\/KG OF BODY WEIGHT BEVACIZUMAB EVERY THREE WEEKS OF FALLOPIAN TUBE CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY AND ASSOCIATED WITH HRD-POSITIVE STATUS"
  },
  {
    "Code": "U-3931",
    "Definition": "MAINTENANCE TREATMENT WITH 15 MG\/KG OF BODY WEIGHT BEVACIZUMAB EVERY THREE WEEKS OF PRIMARY PERITONEAL CANCER IN COMPLETE OR PARTIAL RESPONSE TO FIRST-LINE PLATINUM-BASED CHEMOTHERAPY AND ASSOCIATED WITH HRD-POSITIVE STATUS"
  },
  {
    "Code": "U-3932",
    "Definition": "TREATMENT OF PATIENTS 12 YEARS AND OLDER WITH WARTS, HYPOGAMMAGLOBULINEMIA, INFECTIONS, AND MYELOKATHEXIS (WHIM) SYNDROME"
  },
  {
    "Code": "U-3933",
    "Definition": "TREATMENT OF EXTRAVASCULAR HEMOLYSIS (EVH) IN ADULTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) AS ADD-ON THERAPY TO RAVULIZUMAB OR ECULIZUMAB"
  },
  {
    "Code": "U-3934",
    "Definition": "TREATMENT OF NARCOLEPSY-RELATED CATAPLEXY OR EDS IN A HUMAN PATIENT WITH A ONCE-NIGHTLY GHB FORMULATION BY INITIATING TREATMENT WITH A DOSE EQUIVALENT TO 4.5 G OF SODIUM OXYBATE AND UPTITRATING IN INCREMENTS EQUIVALENT TO 1.5 G OF SODIUM OXYBATE"
  },
  {
    "Code": "U-3935",
    "Definition": "ACUTE TREATMENT OF AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER BY SUBLINGUAL OR BUCCAL ADMINISTRATION"
  },
  {
    "Code": "U-3936",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH SEVERE APLASTIC ANEMIA WHO HAVE HAD AN INSUFFICIENT RESPONSE TO IMMUNOSUPPRESSIVE THERAPY"
  },
  {
    "Code": "U-3937",
    "Definition": "TREATMENT OF THROMBOCYTOPENIA IN ADULT PATIENTS WITH CHRONIC HEPATITIS C TO ALLOW THE INITIATION AND MAINTENANCE OF INTERFERON-BASED THERAPY"
  },
  {
    "Code": "U-3938",
    "Definition": "TREATMENT OF THROMBOCYTOPENIA IN ADULT AND PEDIATRIC PATIENTS 6 YEARS AND OLDER WITH PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP)"
  },
  {
    "Code": "U-3939",
    "Definition": "INTRAMUSCULAR ADMINISTRATION OF RISPERIDONE IN EXTENDED RELEASE INJECTABLE SUSPENSION FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS"
  },
  {
    "Code": "U-3940",
    "Definition": "TREATMENT OF BIPOLAR DISORDER OR BIPOLAR DEPRESSION, INCLUDING ASSOCIATED DEPRESSIVE EPISODES"
  },
  {
    "Code": "U-3941",
    "Definition": "ADMINISTRATION OF RISPERIDONE IN EXTENDED RELEASE INJECTABLE SUSPENSION FOR TREATMENT OF SCHIZOPHRENIA IN ADULTS"
  },
  {
    "Code": "U-3942",
    "Definition": "TREATMENT OF SCHIZOPHRENIA IN ADULTS BY INTRAMUSCULAR ADMINISTRATION OF EXTENDED RELEASE INJECTABLE COMPOSITION"
  },
  {
    "Code": "U-3943",
    "Definition": "TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTRATION OF EXTENDED RELEASE INJECTABLE COMPOSITION"
  },
  {
    "Code": "U-3944",
    "Definition": "METHOD FOR DELIVERING AN EFFECTIVE AMOUNT OF CLONIDINE FOR A 24-HOUR PERIOD USING A SINGLE ORAL CLONIDINE COMPOSITION ACCORDING TO CLAIM 1 PRIOR TO BED TIME"
  },
  {
    "Code": "U-3945",
    "Definition": "TREATMENT OF PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS"
  },
  {
    "Code": "U-3946",
    "Definition": "TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH ACTIVE PSORIATIC ARTHRITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS"
  },
  {
    "Code": "U-3947",
    "Definition": "TOPICAL TREATMENT OF ROSACEA"
  },
  {
    "Code": "U-3948",
    "Definition": "USE OF A PHARMACEUTICAL COMPOSITION HAVING ABOUT 0.5M AQUEOUS ANHYDROUS SODIUM THIOSULFATE AND A CONCENTRATION OF BORATE IONS OF LESS THAN 0.05% FOR REDUCING OTOTOXICITY IN A PEDIATRIC PATIENT RECEIVING CISPLATIN FOR TREATMENT OF LOCALIZED CANCER"
  },
  {
    "Code": "U-3949",
    "Definition": "ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH A RET GENE FUSION THAT HAS PROGRESSED ON OR FOLLOWING PRIOR SYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS"
  },
  {
    "Code": "U-3950",
    "Definition": "TREATMENT OF ADULT OR PEDIATRIC PATIENTS 2 YEARS OF AGE OR OLDER WITH ADVANCED OR METASTATIC MEDULLARY THYROID CANCER (MTC) WITH A RET MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY"
  },
  {
    "Code": "U-3951",
    "Definition": "TREATMENT OF ADULT OR PEDIATRIC PATIENTS 2 YEARS OF AGE OR OLDER WITH ADVANCED OR METASTATIC THYROID CANCER WITH A RET GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY"
  },
  {
    "Code": "U-3952",
    "Definition": "USE OF A PHARMACEUTICAL COMPOSITION HAVING A CONCENTRATION OF ABOUT 0.5M AQUEOUS ANHYDROUS SODIUM THIOSULFATE AND ABOUT 0.004M BORIC ACID FOR REDUCING OTOTOXICITY IN A PEDIATRIC PATIENT RECEIVING CISPLATIN FOR TREATMENT OF LOCALIZED CANCER"
  },
  {
    "Code": "U-3953",
    "Definition": "TREATMENT, IN COMBINATION WITH CETUXIMAB, OF ADULT PATIENTS WITH KRAS G12C-MUTED LOCALLY ADVANCED OR METASTATIC COLORECTAL CANCER, PER FDA APPROVED TEST, WHERE PRIOR TREATMENT WITH FLUOROPYRIMIDINE-, OXALIPLATIN-, AND IRINOTECAN-BASED CHEMOTHERAPY"
  },
  {
    "Code": "U-3954",
    "Definition": "ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN ADULTS AND IN PEDIATRIC PATIENTS WEIGHING AT LEAST 50 KG"
  },
  {
    "Code": "U-3955",
    "Definition": "TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINATION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WHO HAVE HAD AN INADEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN PATIENTS UNABLE TO TOLERATE UDCA"
  },
  {
    "Code": "U-3956",
    "Definition": "TREATMENT OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) WITH TRANSFUSION-DEPENDENT ANEMIA"
  },
  {
    "Code": "U-3957",
    "Definition": "TREATMENT OF GASTROINTESTINAL STROMAL TUMOR COMPRISING ADMINISTERING ONCE DAILY, ONE OR MORE TABLETS COMPRISING RIPRETINIB"
  },
  {
    "Code": "U-3958",
    "Definition": "TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOR IN PATIENTS PREVIOUSLY ADMINISTERED 4 LINES OF PRIOR THERAPY, WHERE THE FIRST LINE OF PRIOR THERAPY IS IMATINIB"
  },
  {
    "Code": "U-3959",
    "Definition": "TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN A PATIENT SUFFERING FROM GRADE 2 ARTHRALGIA WHILE BEING ADMINISTERED RIPRETINIB DAILY"
  },
  {
    "Code": "U-3960",
    "Definition": "TREATMENT OF ADVANCED GASTROINTESTINAL STROMAL TUMOR IN PATIENTS PREVIOUSLY ADMINISTERED IMATINIB"
  },
  {
    "Code": "U-3961",
    "Definition": "TREATMENT OF ADULT AND PEDIATRIC PATIENTS >12 YEARS WITH SOLID TUMORS AND NTRK GENE FUSION THAT ARE LOCALLY ADVANCED OR METASTATIC OR LIKELY SURGICALLY UNRESECTABLE, AND HAVE PROGRESSED FOLLOWING TREATMENT OR HAVE NO SATISFACTORY ALTERNATIVE THERAPY"
  },
  {
    "Code": "U-3962",
    "Definition": "FOR THE MAINTENANCE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULT PATIENTS"
  },
  {
    "Code": "U-3963",
    "Definition": "TREATMENT OF CLINICALLY IMPORTANT HYPOTENSION OCCURRING IN THE SETTING OF ANESTHESIA"
  },
  {
    "Code": "U-3964",
    "Definition": "METHODS OF ADMINISTERING TESTOSTERONE UNDECANOATE FOR RESTORING TESTOSTERONE CONCENTRATION IN A HYPOGONADAL MALE SUBJECT"
  },
  {
    "Code": "U-3965",
    "Definition": "METHODS OF CONTINUING OR DISCONTINUING A DOSAGE REGIMEN OF A TESTOSTERONE UNDECANOATE PHARMACEUTICAL COMPOSITION TO A HYPOGONADAL MALE SUBJECT"
  },
  {
    "Code": "U-3966",
    "Definition": "REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIA OSSIFICANS (MYOSITIS) PROGRESSIVA"
  },
  {
    "Code": "U-3967",
    "Definition": "TREATING AN ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTION (ABSSSI) IN AN OVERWEIGHT OR OBESE PATIENT BY INTRAVENOUSLY (IV) ADMINISTERING 300MG OF DELAFLOXACIN OR A PHARMACEUTICALLY ACCEPTABLE SALT, TWICE A DAY"
  },
  {
    "Code": "U-3968",
    "Definition": "DOSING REGIMEN FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS BY ADMINISTERING AN INITIAL DOSE OF PALIPERIDONE PALMITATE FOLLOWED BY MONTHLY DOSE(S)"
  },
  {
    "Code": "U-3969",
    "Definition": "DOSING REGIMEN FOR THE TREATMENT OF SCHIZOAFFECTIVE DISORDER IN ADULTS AS MONOTHERAPY AND AS AN ADJUNCT TO MOOD STABILIZERS OR ANTIDEPRESSANTS BY ADMINISTERING AN INITIAL DOSE OF PALIPERIDONE PALMITATE FOLLOWED BY MONTHLY DOSE(S)"
  },
  {
    "Code": "U-3970",
    "Definition": "TOPICAL TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS"
  },
  {
    "Code": "U-3971",
    "Definition": "TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN PATIENTS SUFFERING FROM PALMAR-PLANTAR ERYTHRODYSESTHESIA SYNDROME"
  },
  {
    "Code": "U-3972",
    "Definition": "TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC UROTHELIAL CARCINOMA WITH SUSCEPTIBLE FGFR3 GENETIC ALTERATIONS (Y373C IDENTIFIED) WHOSE DISEASE HAS PROGRESSED ON OR AFTER AT LEAST ONE LINE OF PRIOR SYSTEMIC THERAPY"
  },
  {
    "Code": "U-3973",
    "Definition": "TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OF AGE AND OLDER WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)"
  },
  {
    "Code": "U-3974",
    "Definition": "TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 3 MONTHS OF AGE AND OLDER WITH ALAGILLE SYNDROME (ALGS)"
  },
  {
    "Code": "U-3975",
    "Definition": "IN COMBINATION WITH FULVESTRANT AS INITIAL ENDOCRINE-BASED THERAPY OR FOLLOWING DISEASE PROGRESSION ON ENDOCRINE THERAPY, FOR THE TREATMENT OF ADULT PATIENTS WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER"
  },
  {
    "Code": "U-3976",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH ALOPECIA AREATA"
  },
  {
    "Code": "U-3977",
    "Definition": "A METHOD OF TREATING A GLIOMA CHARACTERIZED BY AN IDHI MUTATION FOLLOWING SURGERY, WHEREIN THE GLIOMA IS GRADE 2 ASTROCYTOMA OR OLIGODENDROGLIOMA"
  },
  {
    "Code": "U-3978",
    "Definition": "A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 OR IDH2 MUTATION OR COMBINATION THEREOF FOLLOWING SURGERY, WHEREIN THE CANCER IS GRADE 2 ASTROCYTOMA OR OLIGODENDROGLIOMA"
  },
  {
    "Code": "U-3979",
    "Definition": "NASAL ADMINISTRATION OF EPINEPHRINE FOR THE TREATMENT OF ALLERGIC REACTIONS (TYPE I), INCLUDING ANAPHYLAXIS"
  },
  {
    "Code": "U-3980",
    "Definition": "TREATMENT OF PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN)"
  },
  {
    "Code": "U-3981",
    "Definition": "TREATMENT OF THE FOLLOWING INFECTIONS: COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND STAPHYLOCOCCUS AUREUS BLOOD STREAM INFECTIONS"
  },
  {
    "Code": "U-3982",
    "Definition": "TREATMENT OF HYPOPARATHYROIDISM IN ADULTS"
  },
  {
    "Code": "U-3983",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 1 YEAR TO 5 YEARS WHO ARE HOMOZYGOUS FOR THE F508DEL CFTR GENE MUTATION COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF IVA AND FORM I LUM AS RECITED IN, E.G., CLAIM 1 OF US 12065432"
  },
  {
    "Code": "U-3984",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR THE F508DEL CFTR GENE MUTATION COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF IVA AND FORM I LUM AS RECITED IN, E.G., CLAIM 1 OF US 12065432"
  },
  {
    "Code": "U-3985",
    "Definition": "FIRST-LINE TREATMENT OF ADULTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EGFR EXON 19 DELETIONS OR EXON 21 L858R SUBSTITUTION MUTATIONS, IN COMBINATION WITH AMIVANTAMAB"
  },
  {
    "Code": "U-3986",
    "Definition": "A METHOD OF TREATING AGITATION ASSOCIATED WITH SCHIZOPHRENIA OR BIPOLAR I OR II DISORDER"
  },
  {
    "Code": "U-3987",
    "Definition": "TOPICAL TREATMENT OF ACNE"
  },
  {
    "Code": "U-3988",
    "Definition": "USE FOR THE TREATMENT OF FOCAL SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME"
  },
  {
    "Code": "U-3989",
    "Definition": "USE FOR THE TREATMENT OF FOCAL SEIZURES ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX"
  },
  {
    "Code": "U-3990",
    "Definition": "TREATMENT OF HYPERTENSION IN PATIENTS WHO ARE IN NEED OF A LIQUID COMPOSITION OF TERAZOSIN"
  },
  {
    "Code": "U-3991",
    "Definition": "TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA (BPH) IN PATIENTS WHO ARE IN NEED OF A LIQUID COMPOSITION OF TERAZOSIN"
  },
  {
    "Code": "U-3992",
    "Definition": "ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN A PATIENT UNDERGOING TREATMENT WITH A WEAK OR MODERATE CYP3A4 INDUCER"
  },
  {
    "Code": "U-3993",
    "Definition": "TREATMENT OF PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) IN ADULTS AT RISK FOR DISEASE PROGRESSION"
  },
  {
    "Code": "U-3994",
    "Definition": "METHOD OF TREATING SEVERE ALOPECIA AREATA IN ADULTS AND ADOLESCENTS 12 YEARS AND OLDER BY ADMINISTERING RITLECTINIB"
  },
  {
    "Code": "U-3995",
    "Definition": "TO RESTORE BLOOD PRESSURE IN ADULT PATIENTS WITH ACUTE HYPOTENSIVE STATES"
  },
  {
    "Code": "U-3996",
    "Definition": "FIRST-LINE TREATMENT OF ADULTS PATIENTS WITH ADVANCED RENAL CELL CARCINOMA BY ADMINISTERING LENVIMA IN COMBINATION WITH PEMBROLIZUMAB"
  },
  {
    "Code": "U-3997",
    "Definition": "TREATMENT OF PATIENTS WITH PMMR\/NOT MSI-H ADVANCED ENDOMETRIAL CARCINOMA, HAVE DISEASE PROGRESSION FOLLOWING PRIOR SYSTEMIC THERAPY, AND ARE NOT CANDIDATES FOR CURATIVE SURGERY OR RADIATION, BY ADMINISTERING LENVIMA IN COMBINATION WITH PEMBROLIZUMAB"
  },
  {
    "Code": "U-3998",
    "Definition": "ADJUVANT TREATMENT OF ADULTS WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE STAGE II AND III EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE"
  },
  {
    "Code": "U-3999",
    "Definition": "IN COMBINATION WITH AN AROMATASE INHIBITOR FOR THE ADJUVANT TREATMENT OF ADULTS WITH HORMONE RECEPTOR (HR)-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE STAGE II AND III EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE"
  },
  {
    "Code": "U-4000",
    "Definition": "TREATMENT OF DEPRESSIVE EPISODES OR MAJOR DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR II DISORDER"
  },
  {
    "Code": "U-4001",
    "Definition": "TREATMENT OF ADVANCED PROSTATIC CANCER"
  },
  {
    "Code": "U-4002",
    "Definition": "POSITRON EMISSION TOMOGRAPHY (PET) OF PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-POSITIVE LESIONS IN MEN WITH PROSTATE CANCER"
  },
  {
    "Code": "U-4003",
    "Definition": "TREATMENT OF NOCTURIA DUE TO NOCTURNAL POLYURIA IN ADULTS WHO AWAKEN AT LEAST 2 TIMES PER NIGHT TO VOID BY INTRANASALLY ADMINISTERING A PLUME OF DROPLETS COMPRISING A DOSE OF 0.75 MCG OR 1.5 MCG DESMOPRESSIN"
  },
  {
    "Code": "U-4004",
    "Definition": "TREATMENT OF PARKINSONISM THAT MAY FOLLOW CARBON MONOXIDE INTOXICATION"
  },
  {
    "Code": "U-4005",
    "Definition": "TREATMENT OF PARKINSONISM THAT MAY FOLLOW MANGANESE INTOXICATION"
  },
  {
    "Code": "U-4006",
    "Definition": "TREATMENT OF A DISORDER TREATABLE WITH GHB USING A SINGLE DOSE OF A GHB FORMULATION IN AN AMOUNT EQUIVALENT TO 3 G TO 12 G OF SODIUM OXYBATE WHERE THE FORMULATION CONTAINS AN IMMEDIATE RELEASE PORTION AND A MODIFIED RELEASE PORTION"
  },
  {
    "Code": "U-4007",
    "Definition": "METHOD OF TREATING ACROMEGALY PATIENTS WHO HAVE HAD INADEQUATE RESPONSE TO OR CANNOT BE TREATED WITH SURGICAL RESECTION, PITUITARY IRRADIATION, AND BROMOCRIPTINE MESYLATE AT MAXIMALLY TOLERATED DOSES"
  },
  {
    "Code": "U-4008",
    "Definition": "METHOD OF TREATING PROFUSE WATERY DIARRHEA ASSOCIATED WITH VASOACTIVE INTESTINAL PEPTIDE TUMORS (VIPOMAS)-SECRETING TUMORS"
  },
  {
    "Code": "U-4009",
    "Definition": "METHOD OF TREATING SEVERE DIARRHEA AND FLUSHING EPISODES ASSOCIATED WITH METASTATIC CARCINOID TUMORS"
  },
  {
    "Code": "U-4010",
    "Definition": "TREATMENT OF PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE (STAGE III) NSCLC WHOSE DISEASE HAS NOT PROGRESSED DURING OR FOLLOWING PLATINUM-BASED CHEMORADIATION THERAPY AND WHOSE TUMORS HAVE EGFR EXON 19 DELETIONS OR EXON 21 L858R MUTATIONS"
  },
  {
    "Code": "U-4011",
    "Definition": "METHOD OF POSITRON EMISSION TOMOGRAPHY (PET) FOR CARDIAC IMAGING"
  },
  {
    "Code": "U-4012",
    "Definition": "PRETREATMENT AGAINST THE LETHAL EFFECTS OF SOMAN NERVE AGENT POISONING"
  },
  {
    "Code": "U-4013",
    "Definition": "A METHOD OF ADJUNCTIVE TREATING, PREVENTING AND\/OR AMELIORATING SEIZURES IN A PERSON WITH DRAVET SYNDROME COMPRISING ADMINISTERING FENFLURAMINE OR A SALT THEREOF IN A DOSE OF 0.2 MG\/KG\/DAY TO 0.5\/MG\/KG\/DAY AND DOSES OF STIRIPENTOL AND CLOBAZAM"
  },
  {
    "Code": "U-4014",
    "Definition": "TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CHRONIC GVHD) AFTER FAILURE OF AT LEAST TWO PRIOR LINES OF SYSTEMIC THERAPY IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH A GRADE 3 INFECTION ADVERSE REACTION"
  },
  {
    "Code": "U-4015",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1 AND 10"
  },
  {
    "Code": "U-4016",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 1, 10, AND 11"
  },
  {
    "Code": "U-4017",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 12 AND 21"
  },
  {
    "Code": "U-4018",
    "Definition": "ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETIS BY ORALLY ADMINISTERING A DOSAGE FORM COMPRISING BROMOCRIPTINE AND ONE OR MORE EXCIPIENTS AS RECITED IN CLAIMS 12, 21, AND 22"
  },
  {
    "Code": "U-4019",
    "Definition": "TREATMENT OF BIPOLAR DEPRESSION BY INHIBITING THE 5-HT2A RECEPTOR, INHIBITING THE SEROTONIN TRANSPORTER, AND\/OR MODULATING DOPAMINE D2 RECEPTOR FUNCTION, OR TREATMENT OF BIPOLAR DISORDER"
  },
  {
    "Code": "U-4020",
    "Definition": "TREATMENT OF SCHIZOPHRENIA BY INHIBITING THE 5-HT2A RECEPTOR, INHIBITING THE SEROTONIN TRANSPORTER, AND\/OR MODULATING DOPAMINE D2 RECEPTOR FUNCTION, OR TREATMENT OF SCHIZOPHRENIA"
  },
  {
    "Code": "U-4021",
    "Definition": "USE OF ARIMOCLOMOL, IN COMBINATION WITH MIGLUSTAT, FOR TREATMENT OF NEUROLOGICAL MANIFESTATIONS OF NIEMANN-PICK DISEASE TYPE C (NPC)"
  },
  {
    "Code": "U-4022",
    "Definition": "TREATMENT OF A DISORDER IN A HUMAN PATIENT WITH A ONCE-NIGHTLY GHB FORMULATION BY INITIATING TREATMENT WITH A DOSE EQUIVALENT TO 4.5 G OF SODIUM OXYBATE AND UPTITRATING IN INCREMENTS EQUIVALENT TO 1.5 G OF SODIUM OXYBATE"
  },
  {
    "Code": "U-4023",
    "Definition": "TREATMENT OF TYPE 2 DIABETES MELLITUS BY ADMINISTRATION OF EMPAGLIFLOZIN, LINAGLIPTIN AND METFORMIN"
  },
  {
    "Code": "U-4024",
    "Definition": "COMBINATION WITH PALBOCICLIB AND FULVESTRANT FOR TREATMENT OF ADULTS WITH ENDOCRINE-RESISTANT PIK3CA-MUTATED HR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER FOLLOWING RECURRENCE ON OR AFTER COMPLETING ADJUVANT ENDOCRINE THERAPY"
  },
  {
    "Code": "U-4025",
    "Definition": "A METHOD FOR THE TREATMENT OF POST-OPERATIVE INFLAMMATION FOLLOWING OCULAR SURGERY"
  },
  {
    "Code": "U-4026",
    "Definition": "USE IN TREATING UNCOMPLICATED URINARY TRACT INFECTIONS CAUSED BY ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, OR PROTEUS MIRABILIS"
  },
  {
    "Code": "U-4027",
    "Definition": "TREATMENT OF GASTRIC ADENOCARCINOMA"
  },
  {
    "Code": "U-4028",
    "Definition": "TREATMENT OF HEAD AND NECK CANCER"
  },
  {
    "Code": "U-4029",
    "Definition": "ACUTE TREATMENT OF AGITATION IN PATIENTS WITH SEVERE HEPATIC IMPAIRMENT"
  },
  {
    "Code": "U-4030",
    "Definition": "TREATMENT OF MOTOR FLUCTUATIONS IN ADULTS WITH ADVANCED PARKINSON'S DISEASE"
  },
  {
    "Code": "U-4031",
    "Definition": "REDUCTION OF HETEROTOPIC OSSIFICATION IN PATIENTS WITH FIBRODYSPLASIS (MYOSITIS) OSSIFICANS PROGRESSIVA"
  },
  {
    "Code": "U-4032",
    "Definition": "TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)"
  },
  {
    "Code": "U-4033",
    "Definition": "METHOD OF PROVIDING LOCAL OR REGIONAL ANALGESIA, FOR EXAMPLE, VIA INFILTRATION TO PROVIDE POSTSURGICAL LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK TO PROVIDE POSTSURGICAL REGIONAL ANALGESIA"
  },
  {
    "Code": "U-4034",
    "Definition": "TREATMENT OF SEIZURES ASSOCIATED WITH CYCLIN-DEPENDENT KINASE-LIKE-5 (CDLK5) DEFICIENCY DISORDER (CDD) IN PATIENTS 2 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-4035",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH ADVANCED PROSTATE CANCER, MODIFIED BY DOSE-SEPARATING ADMINISTRATIONS OF RELUGOLIX AND A P-GP INHIBITOR, WHEN CO-ADMINISTRATION OF RELUGOLIX AND THE P-GP INHIBITOR IS UNAVOIDABLE"
  },
  {
    "Code": "U-4036",
    "Definition": "TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH SOMATOSTATIN RECEPTOR-POSITIVE GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS (GEP-NETS), INCLUDING FOREGUT, MIDGUT, AND HINDGUT NEUROENDOCRINE TUMORS"
  },
  {
    "Code": "U-4037",
    "Definition": "METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION TO PROVIDE LOCAL ANALGESIA OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK TO PROVIDE REGIONAL ANALGESIA"
  },
  {
    "Code": "U-4038",
    "Definition": "ADJUNCTIVE TREATMENT TO LEVODOPA\/CARBIDOPA IN PATIENTS WITH PARKINSONS DISEASE EXPERIENCING OFF EPISODES BY ADMINISTERING WITHOUT FOOD"
  },
  {
    "Code": "U-4039",
    "Definition": "ADULT AND PEDIATRIC PATIENTS AS A SOURCE OF SELENIUM FOR PARENTERAL NUTRITION WHEN ORAL OR ENTERAL NUTRITION IS NOT POSSIBLE, INSUFFICIENT, OR CONTRAINDICATED"
  },
  {
    "Code": "U-4040",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC MALIGNANT PERIVASCULAR EPITHELIOID CELL TUMOR (PECOMA) WITH A DOSE ADMINISTERED ON DAYS 1 AND 8 OF A 21-DAY CYCLE"
  },
  {
    "Code": "U-4041",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC MALIGNANT PERIVASCULAR EPITHELIOID CELL TUMOR (PECOMA) WITH A DOSE OF 45 MG\/M2 OR 56 MG\/M2 ADMINISTERED ON DAYS 1 AND 8 OF A 21-DAY CYCLE"
  },
  {
    "Code": "U-4042",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC MALIGNANT PERIVASCULAR EPITHELIOID CELL TUMOR (PECOMA) WITH A DOSE OF 45 MG\/M2 ADMINISTERED ON DAYS 1 AND 8 OF A 21-DAY CYCLE"
  },
  {
    "Code": "U-4043",
    "Definition": "EMROSI IS INDICATED TO TREAT INFLAMMATORY LESIONS (PAPULES AND PUSTULES) OF ROSACEA IN ADULTS"
  },
  {
    "Code": "U-4044",
    "Definition": "TREATMENT OF IDIOPATHIC HYPERSOMNIA WITH A MIXTURE OF SODIUM, POTASSIUM, MAGNESIUM, AND CALCIUM SALTS OF GHB"
  },
  {
    "Code": "U-4045",
    "Definition": "TREATMENT OF RELAPSED OR REFRACTORY ACUTE LEUKEMIA WITH A LYSINE METHYLTRANSFERASE 2A GENE (KMT2A) TRANSLOCATION IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER"
  },
  {
    "Code": "U-4046",
    "Definition": "TREATMENT OF THE CARDIOMYOPATHY OF WILD-TYPE OR VARIANT TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM)"
  },
  {
    "Code": "U-4047",
    "Definition": "A METHOD FOR TREATING ULCERATIVE COLITIS BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF ESTRASIMOD ARGININE AS CLAIMED"
  },
  {
    "Code": "U-4048",
    "Definition": "TOPICAL TREATMENT OF ATOPIC DERMATITIS IN ADULTS AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-4049",
    "Definition": "ADJUNCTIVE TREATMENT OF CLASSIC CONGENITAL ADRENAL HYPERPLASIA (CAH)"
  },
  {
    "Code": "U-4050",
    "Definition": "USE IN REDUCING TRIGLYCERIDES IN ADULTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS)"
  },
  {
    "Code": "U-4051",
    "Definition": "BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH CETUXIMAB AND MFOLFOX6, FOR THE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST"
  },
  {
    "Code": "U-4052",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA COMPRISING ADMINISTERING A COMPOSITION ACCORDING TO CLAIM 1 OF US 11752106"
  },
  {
    "Code": "U-4053",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA WITH AN EFFECTIVE AMOUNT OF ELX, TEZ, AND IVA"
  },
  {
    "Code": "U-4054",
    "Definition": "TREATMENT OF CF IN PATIENTS 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA BY ADMINISTERING ELX, IVA, AND A SOLID DISPERSION ACCORDING TO US 11578062 CLAIM 1"
  },
  {
    "Code": "U-4055",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA COMPRISING ADMINISTERING THE COMPOSITION RECITED IN US 11564916 CLAIM 1"
  },
  {
    "Code": "U-4056",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA WITH AN EFFECTIVE AMOUNT OF ELX, TEZ, AND IVA"
  },
  {
    "Code": "U-4057",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA BY ADMINISTERING DAILY ELX (100 MG OR 80 MG); TEZ; AND IVA"
  },
  {
    "Code": "U-4058",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA WITH A COMPOUND OF CLAIM 1 OR COMPOSITION OF CLAIM 29 OF US 11426407"
  },
  {
    "Code": "U-4059",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US11179367"
  },
  {
    "Code": "U-4060",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA COMPRISING ADMINISTERING A COMPOSITION ACCORDING TO CLAIM 1 OF US 11147770"
  },
  {
    "Code": "U-4061",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR"
  },
  {
    "Code": "U-4062",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA COMPRISING ADMINISTERING A COMPOSITION ACCORDING TO CLAIM 1 OF US 10272046"
  },
  {
    "Code": "U-4063",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA BY ADMINISTERING THE COMPOSITION RECITED IN US 11564916 CLAIM 1"
  },
  {
    "Code": "U-4064",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA WITH AN EFFECTIVE AMOUNT OF ELX, TEZ, AND IVA"
  },
  {
    "Code": "U-4065",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US 10081621"
  },
  {
    "Code": "U-4066",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR"
  },
  {
    "Code": "U-4067",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA BY ADMINISTERING DAILY ELX (200 MG); TEZ; AND IVA"
  },
  {
    "Code": "U-4068",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS HAVING IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA USING A SOLID COMPOSITION OF ELX, TEZ, AMORPHOUS IVA, AND < ~30% CRYSTALLINE IVA"
  },
  {
    "Code": "U-4069",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA BY ADMINISTERING DAILY ELX (100 MG); TEZ; AND IVA"
  },
  {
    "Code": "U-4070",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA WITH A COMPOUND OF CLAIM 1 OR COMPOSITION OF CLAIM 29 OF US11426407"
  },
  {
    "Code": "U-4071",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US11179367"
  },
  {
    "Code": "U-4072",
    "Definition": "TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA WITH ELX, TEZ, AND IVA"
  },
  {
    "Code": "U-4073",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR"
  },
  {
    "Code": "U-4074",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA WITH AN EFFECTIVE AMOUNT OF ELX, TEZ, AND IVA"
  },
  {
    "Code": "U-4075",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US 10081621"
  },
  {
    "Code": "U-4076",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION GENE OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR"
  },
  {
    "Code": "U-4077",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR"
  },
  {
    "Code": "U-4078",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 6 YEARS AND OLDER HAVING IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA USING A SOLID COMPOSITION OF ELX, TEZ, AMORPHOUS IVA, AND < ~30% CRYSTALLINE IVA"
  },
  {
    "Code": "U-4079",
    "Definition": "TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA WITH ELX, TEZ, AND IVA"
  },
  {
    "Code": "U-4080",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR ANOTHER RESPONSIVE MUTATION IN THE CFTR GENE WITH A SOLID PHARMACEUTICAL COMPOSITION COMPRISING VNZ, TEZ, AMORPHOUS D-IVA, AND <30% CRYSTALLINE D-IVA"
  },
  {
    "Code": "U-4081",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH AN EFFECTIVE AMOUNT OF A PHARMACEUTICAL COMPOSITION COMPRISING VANZACAFTOR, TEZACAFTOR, AND DEUTIVACAFTOR"
  },
  {
    "Code": "U-4082",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR ANOTHER RESPONSIVE MUTATION IN THE CFTR GENE WITH VANZACAFTOR, TEZACAFTOR, AND DEUTIVACAFTOR"
  },
  {
    "Code": "U-4083",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR ANOTHER RESPONSIVE MUTATION IN THE CFTR GENE WITH VANZACAFTOR CALCIUM SALT HYDRATE FORM D, TEZACAFTOR, AND DEUTIVACAFTOR"
  },
  {
    "Code": "U-4084",
    "Definition": "TREATMENT OF A MODERATE TO MILD CLINICAL PHENOTYPE OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR ANOTHER RESPONSIVE MUTATION IN THE CFTR GENE WITH A PHARMACEUTICAL COMPOSITION COMPRISING VNZ, TEZ, AND D-IVA"
  },
  {
    "Code": "U-4085",
    "Definition": "REDUCTION IN LOSS OF KIDNEY FUNCTION IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) WHO ARE AT RISK OF DISEASE PROGRESSION, BY RELEASE OF BUDESONIDE FROM THE FORMULATION"
  },
  {
    "Code": "U-4086",
    "Definition": "REDUCTION OF PROTEINURIA IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) WHO ARE AT RISK OF DISEASE PROGRESSION, BY RELEASE OF BUDESONIDE FROM THE FORMULATION"
  },
  {
    "Code": "U-4087",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR ANOTHER RESPONSIVE MUTATION IN THE CFTR GENE WITH VNZ, D-IVA, AND A COMPOSITION ACCORDING TO CLAIM 1 OF US10081621"
  },
  {
    "Code": "U-4088",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR ANOTHER RESPONSIVE MUTATION IN THE CFTR GENE WITH 21.4 MG OF VNZ CALCIUM SALT HYDRATE FORM D, 100 MG OF TEZ, AND 250 MG OF D-IVA DAILY"
  },
  {
    "Code": "U-4089",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR ANOTHER RESPONSIVE MUTATION IN THE CFTR GENE WITH VNZ AND A COMPOSITION ACCORDING TO CLAIM 1 OF US11951212"
  },
  {
    "Code": "U-4090",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR ANOTHER RESPONSIVE MUTATION IN THE CFTR GENE WITH AN EFFECTIVE AMOUNT OF VANZACAFTOR, TEZACAFTOR, AND DEUTIVACAFTOR"
  },
  {
    "Code": "U-4091",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AN R117H MUTATION IN THE CFTR GENE WITH VANZACAFTOR, TEZACAFTOR, AND DEUTIVACAFTOR"
  },
  {
    "Code": "U-4092",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR ANOTHER RESPONSIVE MUTATION IN THE CFTR GENE WITH VNZ AND A COMPOSITION ACCORDING TO CLAIM 1 OF US10206877"
  },
  {
    "Code": "U-4093",
    "Definition": "TREATMENT OF CF IN PATIENTS 6 YEARS AND OLDER WITH AT LEAST ONE F508DEL OR G551D AND AN A455E, 2789+5G->A, OR 3849+10KBC->T CFTR MUTATION, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF US 10058546 FURTHER COMPRISING VNZ"
  },
  {
    "Code": "U-4094",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR ANOTHER RESPONSIVE MUTATION IN THE CFTR GENE WITH A COMPOSITION COMPRISING VNZ, TEZ, AND D-IVA WITH AT LEAST 90% ISOTOPIC ENRICHMENT FOR EACH DEUTERIUM ATOM"
  },
  {
    "Code": "U-4095",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR ANOTHER RESPONSIVE MUTATION IN THE CFTR GENE WITH A COMPOSITION ACCORDING TO CLAIM 1 OF US11564916, VNZ, AND TEZ"
  },
  {
    "Code": "U-4096",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR ANOTHER RESPONSIVE MUTATION IN THE CFTR GENE WITH VANZACAFTOR, DEUTIVACAFTOR, AND A SOLID DISPERSION ACCORDING TO CLAIM 1 OF US 11,578,062"
  },
  {
    "Code": "U-4097",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF CLAIM 1 OF US 9,012,496 FURTHER COMPRISING VNZ"
  },
  {
    "Code": "U-4098",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION OR ANOTHER RESPONSIVE MUTATION IN THE CFTR GENE WITH AN EFFECTIVE AMOUNT OF VNZ, TEZ, AND A COMPOSITION ACCORDING TO CLAIM 3 OF US 9,512,079"
  },
  {
    "Code": "U-4099",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE NOT PREVIOUSLY RECEIVED AN ALK-INHIBITOR"
  },
  {
    "Code": "U-4100",
    "Definition": "A METHOD OF TREATING MODERATE TO SEVERE OPIOID USE DISORDER BY ADMINISTERING BUPRENORPHINE ONCE WEEKLY"
  },
  {
    "Code": "U-4101",
    "Definition": "TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER TO WHOM RIFAMPIN IS ADMINISTERED WITH THE CO-ADMINISTRATION OF A DAILY DOSE OF 240 MG ENZALUTAMIDE"
  },
  {
    "Code": "U-4102",
    "Definition": "TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER WITH BIOCHEMICAL RECURRENCE AT HIGH RISK FOR METASTASIS TO WHOM RIFAMPIN IS ADMINISTERED WITH THE CO-ADMINISTRATION OF A DAILY DOSE OF 240 MG ENZALUTAMIDE"
  },
  {
    "Code": "U-4103",
    "Definition": "TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER TO WHOM RIFAMPIN IS ADMINISTERED WITH THE CO-ADMINISTRATION OF A DAILY DOSE OF 240 MG ENZALUTAMIDE"
  },
  {
    "Code": "U-4104",
    "Definition": "TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER TO WHOM RIFAMPIN IS ADMINISTERED WITH THE CO-ADMINISTRATION OF A DAILY DOSE OF 240 MG ENZALUTAMIDE"
  },
  {
    "Code": "U-4105",
    "Definition": "USE OF VASCEPA TO LOWER TRIGLYCERIDES AND LDL-C IN AN ADULT PATIENT ON STATIN THERAPY WITH CARDIOVASCULAR-RELATED DISEASE AND ELEVATED TRIGLYCERIDE (TG) LEVELS (ABOUT 200 MG\/DL TO ABOUT 500 MG\/DL)"
  },
  {
    "Code": "U-4106",
    "Definition": "TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS BY ADMINISTERING SOLRIAMFETOL TO A SUBJECT HAVING NO OR MILD RENAL IMPAIRMENT"
  },
  {
    "Code": "U-4107",
    "Definition": "IN COMBINATION WITH PANITUMUMAB FOR THE TREATMENT OF ADULT PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER (MCRC), AS DETERMINED BY AN FDA-APPROVED TEST, WHO HAVE RECEIVED PRIOR CHEMOTHERAPY"
  },
  {
    "Code": "U-4108",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA WHO ARE INELIGIBLE FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB"
  },
  {
    "Code": "U-4109",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA WHO ARE INELIGIBLE FOR AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION BY ADMINISTERING 100 MG OF ACALABRUTINIB TWICE DAILY IN COMBINATION WITH BENDAMUSTINE AND RITUXIMAB"
  },
  {
    "Code": "U-4110",
    "Definition": "TREATMENT OF SCHIZOPHRENIA IN A PATIENT PREVIOUSLY BEEN TREATED WITH ONCE-A-MONTH (PP1M) OR ONCE-EVERY-THREE-MONTHS (PP3M) PALIPERIDONE PALMITATE BY SWITCHING TO ONCE-EVERY-SIX-MONTH PALIPERIDONE PALMITATE USING A DOSING WINDOW OF A DOSING REGIMEN"
  },
  {
    "Code": "U-4111",
    "Definition": "TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS BY ADMINISTERING A LIQUID EDARAVONE COMPOSITION RELATIVE TO THE TIMING AND TYPE OF FOOD CONSUMPTION"
  },
  {
    "Code": "U-4112",
    "Definition": "TREATMENT OF TREATMENT-RESISTANT DEPRESSION IN ADULTS"
  },
  {
    "Code": "U-4113",
    "Definition": "TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG 2X WEEKLY FOR 4 WEEKS DURING THE INDUCTION PHASE"
  },
  {
    "Code": "U-4114",
    "Definition": "TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG 2X WEEKLY FOR 4 WEEKS DURING THE INDUCTION PHASE FOLLOWED BY A MAINTENANCE PHASE OF 56MG OR 84MG WEEKLY OR 1X EVERY TWO WEEKS"
  },
  {
    "Code": "U-4115",
    "Definition": "TREATMENT OF TREATMENT RESISTANT DEPRESSION BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE IN A MAINTENANCE PHASE WEEKLY OR 1X EVERY TWO WEEKS TO ADULTS WHO HAVE BEEN ADMINISTERED ESKETAMINE IN A INDUCTION PHASE FOR ABOUT 4 WEEKS"
  },
  {
    "Code": "U-4116",
    "Definition": "TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE 2X WEEKLY FOR 4 WEEKS DURING THE INDUCTION PHASE"
  },
  {
    "Code": "U-4117",
    "Definition": "TREATMENT OF TREATMENT-RESISTANT DEPRESSION IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE 2X WEEKLY FOR 4 WEEKS DURING THE INDUCTION PHASE FOLLOWED BY A MAINTENANCE PHASE OF 56MG OR 84MG WEEKLY OR 1X EVERY TWO WEEKS"
  },
  {
    "Code": "U-4118",
    "Definition": "TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE AS A PHARMACEUTICAL COMPOSITION"
  },
  {
    "Code": "U-4119",
    "Definition": "TREATMENT OF TREATMENT RESISTANT DEPRESSION IN ADULTS BY NASALLY ADMINISTERING 56MG OR 84MG OF ESKETAMINE TWICE PER WEEK AS A PHARMACEUTICAL COMPOSITION"
  },
  {
    "Code": "U-4120",
    "Definition": "TREATMENT OF TREATMENT-RESISTANT DEPRESSION WITH NASALLY ADMINISTERED ESKETAMINE IN A PATIENT WHO HAS MISSED A DOSE DURING THE MAINTENANCE PHASE AND HAD WORSENING OF DEPRESSION SYMPTOMS BY RETURNING TO A HIGHER DOSING SCHEDULE"
  },
  {
    "Code": "U-4121",
    "Definition": "ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN A PATIENT UNDERGOING TREATMENT WITH A MODERATE CYP3A4 INHIBITOR"
  },
  {
    "Code": "U-4122",
    "Definition": "ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN A PATIENT UNDERGOING TREATMENT WITH A WEAK CYP3A4 INHIBITOR"
  },
  {
    "Code": "U-4123",
    "Definition": "TREATMENT OF SOLID TUMORS THAT HAVE A NTRK GENE FUSION THROUGH COADMINISTRATION OF LAROTRECTINIB WITH POSACONAZOLE, BY DISCONTINUING POSACONAZOLE AND WAITING 3 TO 5 OF ITS HALF-LIVES, BEFORE ADMINISTERING A FULL LAROTRECTINIB DOSE"
  },
  {
    "Code": "U-4124",
    "Definition": "TREATMENT OF SOLID TUMORS CHARACTERIZED BY A GENE FUSION THROUGH COADMINISTRATION OF LAROTRECTINIB WITH POSACONAZOLE, BY DISCONTINUING POSACONAZOLE AND WAITING 3 TO 5 OF ITS HALF-LIVES, BEFORE ADMINISTERING A FULL LAROTRECTINIB DOSE"
  },
  {
    "Code": "U-4125",
    "Definition": "TREATMENT OF MODERATE TO SEVERE ACUTE PAIN IN ADULTS USING SUZETRIGINE"
  },
  {
    "Code": "U-4126",
    "Definition": "TREATMENT OF CF IN A PATIENT AGE 6 MONTHS TO <6 YEARS WHO HAS IN THE CFTR GENE AT LEAST ONE RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 12214083"
  },
  {
    "Code": "U-4127",
    "Definition": "TREATMENT OF CF IN A PATIENT AGE 1 MONTH TO <4 MONTHS WHO HAS IN THE CFTR GENE AT LEAST ONE RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 12214083"
  },
  {
    "Code": "U-4128",
    "Definition": "TREATMENT OF CF IN A PATIENT AGE 4 MONTHS TO <6 YEARS WHO HAS IN THE CFTR GENE AT LEAST ONE RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 12214083"
  },
  {
    "Code": "U-4129",
    "Definition": "METHOD OF LOWERING INTRAOCULAR PRESSURE IN PATIENTS WITH OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION"
  },
  {
    "Code": "U-4130",
    "Definition": "TREATMENT OF ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC PLEXIFORM NEUROFIBROMAS (PN) NOT AMENABLE TO COMPLETE RESECTION"
  },
  {
    "Code": "U-4131",
    "Definition": "TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC, WELL-DIFFERENTIATED EXTRA-PANCREATIC NEUROENDOCRINE TUMORS"
  },
  {
    "Code": "U-4132",
    "Definition": "A METHOD OF TREATING AND\/OR REDUCING THE RISK OF A CARDIOVASCULAR EVENT IN A PATIENT"
  },
  {
    "Code": "U-4133",
    "Definition": "REDUCING TMAX OF ORALLY ADMINISTERED MELOXICAM"
  },
  {
    "Code": "U-4134",
    "Definition": "RAPID DELIVERY OF MELOXICAM TO THE BLOOD OF A HUMAN BEING"
  },
  {
    "Code": "U-4135",
    "Definition": "IMPROVING ORAL BIOAVAILABILITY OF MELOXICAM"
  },
  {
    "Code": "U-4136",
    "Definition": "ACUTE TREATMENT OF MIGRAINE ASSOCIATED WITH ALLODYNIA"
  },
  {
    "Code": "U-4137",
    "Definition": "TREATING POST-TRANSPLANT CMV INFECTION\/DISEASE REFRACTORY TO GANCICLOVIR, VALGANCICLOVIR, CIDOFOVIR OR FOSCARNET BY ADMINISTERING 1200 MG MARIBAVIR TWICE DAILY, WHERE THE PATIENT IS CONCOMITANTLY EXPOSED TO OR RECEIVING PHENYTOIN OR PHENOBARBITAL"
  },
  {
    "Code": "U-4138",
    "Definition": "TREATMENT OF EDEMA IN PATIENTS WHO ARE IN NEED OF AN ORAL LIQUID SUSPENSION OF HYDROCHLOROTHIAZIDE"
  },
  {
    "Code": "U-4139",
    "Definition": "TREATMENT OF HYPERTENSION IN PATIENTS WHO ARE IN NEED OF AN ORAL LIQUID SUSPENSION OF HYDROCHLOROTHIAZIDE"
  },
  {
    "Code": "U-4140",
    "Definition": "REDUCING THE RISK OF SUSTAINED EGFR DECLINE, END-STAGE KIDNEY DISEASE, CV DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN ADULTS WITH CKD AT RISK OF PROGRESSION AND WITHOUT TYPE II DIABETES AFTER AT LEAST 4 MONTHS OF TREATMENT"
  },
  {
    "Code": "U-4141",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA COMPRISING ADMINISTERING A COMPOSITION ACCORDING TO CLAIM 1 OF US 12,214,083"
  },
  {
    "Code": "U-4142",
    "Definition": "ADMINISTERING TREOSULFAN AS A PREPARATIVE REGIMEN FOR ALLOGENEIC STEM CELL TRANSPLANTATION"
  },
  {
    "Code": "U-4143",
    "Definition": "GASTROINTESTINAL FLAVORED SOLUTION INDICATED FOR CLEANSING THE COLON IN PREPARATION FOR COLONOSCOPY"
  },
  {
    "Code": "U-4144",
    "Definition": "ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (CCL\/SLL) WHO HAVE RECEIVED AT LEAST TWO PRIOR LINES OF THERAPY, INCLUDING A BTK INHIBITOR AND A BCL-2 INHIBITOR"
  },
  {
    "Code": "U-4145",
    "Definition": "TREATMENT OF TENOSYNOVIAL GIANT CELL TUMOR"
  },
  {
    "Code": "U-4146",
    "Definition": "FIRST-LINE TREATMENT OF PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (HCC) USING DOSAGE MODIFICATIONS FOR ADVERSE REACTIONS"
  },
  {
    "Code": "U-4147",
    "Definition": "TREATMENT OF COMPLICATED INTRA-ABDOMINAL BACTERIAL INFECTIONS IN ADULT PATIENTS"
  },
  {
    "Code": "U-4148",
    "Definition": "METHOD OF ADMINISTERING BUPIVACAINE TO PRODUCE POSTSURGICAL REGIONAL ANALGESIA VIA AN ADDUCTOR CANAL BLOCK IN ADULTS"
  },
  {
    "Code": "U-4149",
    "Definition": "METHOD OF INCREASING THE AMOUNT OF TIME BEFORE POSTSURGICAL OPIOID MEDICATION IS ADMINISTERED TO A PATIENT BY ADMINISTERING BUPIVACAINE TO PRODUCE POSTSURGICAL REGIONAL ANALGESIA"
  },
  {
    "Code": "U-4150",
    "Definition": "METHOD OF REDUCING POSTSURGICAL OPIOID CONSUMPTION BY ADMINISTERING BUPIVACAINE TO PRODUCE POSTSURGICAL REGIONAL ANALGESIA"
  },
  {
    "Code": "U-4151",
    "Definition": "FOR THE TOPICAL TREATMENT OF NONSEGMENTAL VITILIGO IN ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER, WHEREIN THE DEPIGMENTED AREA IS  0.5% BSA ON THE FACE,  3% BSA ON NON-FACIAL AREAS, AND NOT >10% BSA ON TOTAL BODY AREA"
  },
  {
    "Code": "U-4152",
    "Definition": "METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION FOR LOCAL ANALGESIA; OR VIA INTERSCALENE BRACHIAL PLEXUS NERVE BLOCK, SCIATIC NERVE BLOCK IN THE POPLITEAL FOSSA, OR ADDUCTOR CANAL BLOCK FOR REGIONAL ANALGESIA"
  },
  {
    "Code": "U-4153",
    "Definition": "TREATING RAS WILD-TYPE HER2-POSITIVE UNRESECTABLE OR METASTATIC COLORECTAL CANCER THAT HAS PROGRESSED FOLLOWING PRIOR TREATMENT"
  },
  {
    "Code": "U-4154",
    "Definition": "TREATMENT AND REDUCTION OF RISK BY ADMINISTRATION OF EMPAGLIFLOZIN TO ADULTS WITH TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION"
  },
  {
    "Code": "U-4155",
    "Definition": "INTRAUTERINE DEVICE PROMOTING CONTRACEPTION UTILIZING COPPER WITHOUT BLOCKING OPENINGS OF TWO FALLOPIAN TUBES"
  },
  {
    "Code": "U-4156",
    "Definition": "TREATMENT OF PREVIOUSLY TREATED, UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC, WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS"
  },
  {
    "Code": "U-4157",
    "Definition": "THE TREATMENT OF DIABETIC MACULAR EDEMA (DME) IN PATIENTS WHO HAVE BEEN PREVIOUSLY TREATED WITH A COURSE OF CORTICOSTEROIDS AND DID HAVE A CLINICALLY SIGNIFICANT RISE IN INTRAOCULAR PRESSURE"
  },
  {
    "Code": "U-4158",
    "Definition": "A METHOD OF USING LOSARTAN FOR THE REDUCTION OF THE RISK OF STROKE IN PATIENTS WITH HYPERTENSION AND LEFT VENTRICULAR HYPERTROPHY"
  },
  {
    "Code": "U-4159",
    "Definition": "A METHOD OF USING LOSARTAN FOR THE TREATMENT OF HYPERTENSION"
  },
  {
    "Code": "U-4160",
    "Definition": "A METHOD OF USING LOSARTAN FOR THE TREATMENT OF DIABETIC NEPHROPATHY WITH AN ELEVATED SERUM CREATININE AND PROTEINURIA IN PATIENTS WITH TYPE 2 DIABETES AND A HISTORY OF HYPERTENSION"
  },
  {
    "Code": "U-4161",
    "Definition": "TREATMENT OF COMPLEMENT 3 GLOMERULOPATHY (C3G)"
  },
  {
    "Code": "U-4162",
    "Definition": "TREATMENT OF HIV INFECTION IN ADULTS AND PEDIATRIC PATIENTS WEIGHING AT LEAST 25KG USING A COMPOSITION CONTAINING A PHARMACOKINETIC ENHANCER THAT INHIBITS CYTOCHROME P450 MONOOXYGENASE"
  },
  {
    "Code": "U-4163",
    "Definition": "TREATMENT OF AMEBIASIS IN ADULTS AND PEDIATRIC PATIENTS"
  },
  {
    "Code": "U-4164",
    "Definition": "TREATMENT OF ANAEROBIC BACTERIAL INFECTIONS IN ADULTS"
  },
  {
    "Code": "U-4165",
    "Definition": "ROUTINE PROPHYLAXIS TO PREVENT OR REDUCE THE FREQUENCY OF BLEEDING EPISODES IN ADULT AND PEDIATRIC PATIENTS AGED 12 YEARS AND OLDER WITH HEMOPHILIA A OR B WITH OR WITHOUT FACTOR VIII OR IX INHIBITORS"
  },
  {
    "Code": "U-4166",
    "Definition": "TREATMENT OF FEMALE ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WEIGHING AT LEAST 40 KG WITH UNCOMPLICATED URINARY TRACT INFECTIONS (UUTI) CAUSED BY ESCHERICHIA COLI, KLEBSIELLA PNEUMONIAE, ENTEROCOCCUS FAECALIS"
  },
  {
    "Code": "U-4167",
    "Definition": "REDUCING HYPERPHAGIC AGGRESSIVE BEHAVIORS IN PRADER-WILLI SYNDROME PATIENTS"
  },
  {
    "Code": "U-4168",
    "Definition": "A METHOD FOR REDUCING A RISK OF AT LEAST ONE CARDIOVASCULAR EVENT"
  },
  {
    "Code": "U-4169",
    "Definition": "FOR TREATMENT OF ADULT PATIENTS WITH PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) WHO HAVE BEEN TREATED WITH ANDROGEN RECEPTOR PATHWAY INHIBITOR (ARPI) THERAPY"
  },
  {
    "Code": "U-4170",
    "Definition": "USE OF LEVACETYLLEUCINE FOR TREATMENT OF NEUROLOGICAL MANIFESTATIONS OF NIEMANN-PICK DISEASE TYPE-C (NPC)"
  },
  {
    "Code": "U-4171",
    "Definition": "USE OF EMPAGLIFLOZIN TO REDUCE THE RISK OF CARDIOVASCULAR DEATH IN ADULTS WITH CHRONIC KIDNEY DISEASE AT RISK OF PROGRESSION"
  },
  {
    "Code": "U-4172",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH LOW-GRADE UPPER TRACT UROTHELIAL CANCER"
  },
  {
    "Code": "U-4173",
    "Definition": "NASAL ADMINISTRATION OF DIAZEPAM FOR THE ACUTE TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY THAT ARE DISTINCT FROM A PATIENT'S USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 2 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-4174",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY SUBCUTANEOUS ADMINISTRATION OF A UNIT DOSE OF 1080 MG OF PEGCETACOPLAN IN A COMPOSITION OF CLAIM 1"
  },
  {
    "Code": "U-4175",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) BY TWICE-WEEKLY SUBCUTANEOUS ADMINISTRATION OF A UNIT DOSE OF 1080 MG OF PEGCETACOPLAN IN A COMPOSITION OF CLAIM 1"
  },
  {
    "Code": "U-4176",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA WITH A CLEAR CELL COMPONENT FOLLOWING A PROGRAMMED DEATH RECEPTOR-I OR PROGRAMMED DEATH-LIGAND 1 INHIBITOR AND A VASCULAR ENDOTHELIAL GROWTH FACTOR TYROSINE KINASE INHIBITOR"
  },
  {
    "Code": "U-4177",
    "Definition": "CUSHING'S SYNDROME, INCLUDING CUSHING'S DISEASE"
  },
  {
    "Code": "U-4178",
    "Definition": "TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) AND REDUCTION IN THE RISK OF RECURRENT VTE IN PEDIATRIC PATIENTS WITH BODY WEIGHT GREATER THAN OR EQUAL TO 35 KG"
  },
  {
    "Code": "U-4179",
    "Definition": "TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) AND REDUCTION IN THE RISK OF RECURRENT VTE IN PEDIATRIC PATIENTS WITH BODY WEIGHT FROM 4 TO LESS THAN 35 KG"
  },
  {
    "Code": "U-4180",
    "Definition": "TREATMENT OF VENOUS THROMBOEMBOLISM (VTE) AND REDUCTION IN THE RISK OF RECURRENT VTE IN PEDIATRIC PATIENTS WITH BODY WEIGHT FROM 2.6 TO LESS THAN 4 KG"
  },
  {
    "Code": "U-4181",
    "Definition": "TREATMENT OF COMPLEMENT 3 GLOMERULOPATHY (C3G) BY ADMINISTRATION OF 200 MG OF IPTACOPAN TWICE DAILY"
  },
  {
    "Code": "U-4182",
    "Definition": "EMERGENCY TREATMENT OF A KNOWN OR SUSPECTED OPIOID OVERDOSE\/SYMPTOM THEREOF IN A HUMAN CAUSED BY NATURAL OR SYNTHETIC OPIOIDS, SUCH AS REMIFENTANIL-INDUCED RESPIRATORY DEPRESSION, WITH 2.7MG NALMEFENE, ADMINISTERED AS 3MG NALMEFENE HYDROCHLORIDE"
  },
  {
    "Code": "U-4183",
    "Definition": "TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN A PATIENT SUFFERING FROM GRADE 3 ARTHRALGIA WHILE BEING ADMINISTERED RIPRETINIB DAILY"
  },
  {
    "Code": "U-4184",
    "Definition": "METHOD OF TREATING PAIN, FOR EXAMPLE, VIA INFILTRATION TO PROVIDE LOCAL ANALGESIA OR VIA A NERVE BLOCK TO PROVIDE REGIONAL ANALGESIA"
  },
  {
    "Code": "U-4185",
    "Definition": "METHOD TO PROVIDE PHOSPHORUS REPLACEMENT BY ADMINISTERING WITHOUT PRIOR DILUTION AN ISOTONIC, STERILE, AND READY-TO-USE SOLUTION COMPRISING ABOUT 15 MMOL PHOSPHORUS AND ABOUT 22 MEQ POTASSIUM FROM A FLEXIBLE CONTAINER"
  },
  {
    "Code": "U-4186",
    "Definition": "TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OF AGE AND OLDER WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC) WHO WEIGH 25 KILOGRAMS AND ABOVE"
  },
  {
    "Code": "U-4187",
    "Definition": "TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 3 MONTHS OF AGE AND OLDER WITH ALAGILLE SYNDROME (ALGS) WHO WEIGH 25 KILOGRAMS AND ABOVE"
  },
  {
    "Code": "U-4188",
    "Definition": "ACUTE TREATMENT OF CLUSTER HEADACHES"
  },
  {
    "Code": "U-4189",
    "Definition": "METHOD OF DECREASING EXCESSIVE DAYTIME SLEEPINESS BY ORALLY ADMINISTERING A DOSE PROPORTIONAL, PHARMACEUTICAL COMPOSITION COMPRISING IMMEDIATE RELEASE AND MODIFIED RELEASE GAMMA-HYDROXYBUTYRATE PORTIONS ONCE DAILY AT BEDTIME"
  },
  {
    "Code": "U-4190",
    "Definition": "FOR PRE-EXPOSURE PROPHYLAXIS TO REDUCE THE RISK OF SEXUALLY ACQUIRED HIV-1 IN ADULTS AND ADOLESCENTS WEIGHING AT LEAST 35 KG WHO ARE AT RISK FOR HIV-1 ACQUISITION"
  },
  {
    "Code": "U-4191",
    "Definition": "TREATMENT OF GASTROINTESTINAL STROMAL TUMORS IN A PATIENT SUFFERING FROM GRADE 3 PALMAR-PLANTAR ERYTHRODYSESTHESIA WHILE BEING ADMINISTERED RIPETRINIB DAILY"
  },
  {
    "Code": "U-4192",
    "Definition": "TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE"
  },
  {
    "Code": "U-4193",
    "Definition": "TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING IN 4 DOSES, AT LEAST 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE"
  },
  {
    "Code": "U-4194",
    "Definition": "METHODS OF RESTORING TESTOSTERONE CONCENTRATION FOR CONDITIONS ASSOCIATED WITH DEFICIENCY OR ABSENCE OF ENDOGENOUS TESTOSTERONE IN A MALE SUBJECT"
  },
  {
    "Code": "U-4195",
    "Definition": "TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC PHEOCHROMOCYTOMA OR PARAGANGLIOMA (PPGL)"
  },
  {
    "Code": "U-4196",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH KRAS-MUTATED RECURRENT LOW-GRADE SEROUS OVARIAN CANCER (LGSOC) WHO HAVE RECEIVED PRIOR SYSTEMIC THERAPY, IN COMBINATION WITH DEFACTINIB"
  },
  {
    "Code": "U-4197",
    "Definition": "TREATMENT OF OIC IN ADULTS WITH ADVANCED ILLNESS OR PAIN CAUSED BY ACTIVE CANCER WHO REQUIRE OPIOID DOSAGE ESCALATION FOR PALLIATIVE CARE"
  },
  {
    "Code": "U-4198",
    "Definition": "TREATMENT OF OPIOID-INDUCED CONSTIPATION (OIC) IN ADULTS WITH CHRONIC NON-CANCER PAIN, INCLUDING PATIENTS WITH CHRONIC PAIN RELATED TO PRIOR CANCER OR ITS TREATMENT WHO DO NOT REQUIRE FREQUENT (E.G., WEEKLY) OPIOID DOSAGE ESCALATION"
  },
  {
    "Code": "U-4199",
    "Definition": "DEFINITION USE CODE METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION OR PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL DISEASE BY ADMINISTERING TREPROSTINIL OR A SALT THEREOF BY USING AN INHALATION DEVICE"
  },
  {
    "Code": "U-4200",
    "Definition": "METHOD OF TREATING PULMONARY ARTERIAL HYPERTENSION OR PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL DISEASE BY ADMINISTERING TREPROSTINIL OR A SALT THEREOF BY USING AN INHALATION DEVICE"
  },
  {
    "Code": "U-4201",
    "Definition": "DOSAGE MODIFICATION FOLLOWING GRADE 3 TOXICITY OR INTOLERABLE SIDE EFFECT BY DISCONTINUING APALUTAMIDE UNTIL IMPROVEMENT TO ORIGINAL GRADE OR GRADE I IN TREATMENT OF MCRPC PATIENTS THAT INCREASES OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL"
  },
  {
    "Code": "U-4202",
    "Definition": "IMPROVEMENT OF OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL IN METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS BY TREATMENT WITH 240 MG ORAL APALUTAMIDE IN COMBINATION WITH ANDROGEN DEPRIVATION THERAPY"
  },
  {
    "Code": "U-4203",
    "Definition": "TOPICAL TREATMENT OF PLAQUE PSORIASIS OF THE SCALP AND BODY IN PATIENTS 12 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-4204",
    "Definition": "TREATMENT OF PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) IN ADULTS AT RISK OF RAPID DISEASE PROGRESSION, BY RELEASE OF BUDESONIDE FROM THE FORMULATION"
  },
  {
    "Code": "U-4205",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH KRAS-MUTATED RECURRENT LOW-GRADE SEROUS OVARIAN CANCER (LGSOC) WHO HAVE RECEIVED PRIOR SYSTEMIC THERAPY, IN COMBINATION WITH AVUTOMETINIB"
  },
  {
    "Code": "U-4206",
    "Definition": "TREATMENT OF ADULT AND PEDIATRIC PATIENTS 3 YEARS AND OLDER WITH ACUTE HEPATITIS C VIRUS (HCV) GENOTYPE 1, 2, 3, 4, 5 OR 6 INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS"
  },
  {
    "Code": "U-4207",
    "Definition": "TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)"
  },
  {
    "Code": "U-4208",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH NON-METASTATIC CASTRATION RESISTANT PROSTATE CANCER (NMCRPC)"
  },
  {
    "Code": "U-4209",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC)"
  },
  {
    "Code": "U-4210",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC) IN COMBINATION WITH DOCETAXEL"
  },
  {
    "Code": "U-4211",
    "Definition": "TREATING HYPERPHAGIA AND REDUCING HYPERPHAGIC AGGRESSIVE BEHAVIORS IN PRADER-WILLI SYNDROME PATIENTS"
  },
  {
    "Code": "U-4212",
    "Definition": "TREATING METASTATIC SCLC AFTER PLATINUM CHEMOTHERAPY WITH LURBINECTEDIN MONOTHERAPY BY REDUCING THE DOSE FOR GRADE 3 HEPATOTOXICITY FROM 3.2 TO 2.6 MG\/M2 AND 2.6 TO 2.0 MG\/M2 LURBINECTEDIN WITHIN 35 DAYS OF THE HIGHER DOSE IF HEPATOTOXICITY GRADE 1"
  },
  {
    "Code": "U-4213",
    "Definition": "ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN A PATIENT UNDERGOING TREATMENT WITH A BCRP AND\/OR P-GP ONLY INHIBITOR"
  },
  {
    "Code": "U-4214",
    "Definition": "A METHOD OF SWITCHING A PATIENT FROM DAILY ORAL RISPERIDONE THERAPY TO A LONG-ACTING INJECTABLE RISPERIDONE FORMULATION"
  },
  {
    "Code": "U-4215",
    "Definition": "TREATMENT OF PRIMARY OR SECONDARY ADRENOCORTICAL INSUFFICIENCY WITH AN ORAL LIQUID FORMULATION OF HYDROCORTISONE"
  },
  {
    "Code": "U-4216",
    "Definition": "TREATMENT OF ADRENAL INSUFFICIENCY WITH AN ORAL LIQUID FORMULATION OF HYDROCORTISONE"
  },
  {
    "Code": "U-4217",
    "Definition": "PET TO ESTIMATE AMYLOID BETA NEURITIC PLAQUE DENSITY IN ADULTS WITH COGNITIVE IMPAIRMENT: -EVALUATION OF ALZHEIMERS DISEASE AND OTHER CAUSES OF COGNITIVE DECLINE -SELECTION OF PATIENTS WHO ARE INDICATED FOR AMYLOID BETA-DIRECTED THERAPY"
  },
  {
    "Code": "U-4218",
    "Definition": "TREATMENT OF CF IN PATIENTS 6 YEARS AND OLDER WITH AT LEAST ONE F508DEL OR G551D AND AN R117H, A455E, 2789+5G->A, OR 3849+10KBC->T CFTR MUTATION, COMPRISING CONCURRENT COADMINISTRATION OF THE COMPOSITIONS OF US10058546 CLAIM 1 FURTHER COMPRISING VNZ"
  },
  {
    "Code": "U-4219",
    "Definition": "TREATMENT OF OVERACTIVE BLADDER (OAB) WITH SYMPTOMS OF URGE URINARY INCONTINENCE, URGENCY, AND URINARY FREQUENCY IN ADULT MALES ON PHARMACOLOGICAL THERAPY FOR BENIGN PROSTATIC HYPERPLASIA (BPH)"
  },
  {
    "Code": "U-4220",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 2 TO <6 YEARS OLD WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA BY ADMINISTERING DAILY ELX\/TEZ\/IVA (100 MG\/50 MG\/75 MG) + IVA (75 MG)"
  },
  {
    "Code": "U-4221",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA BY ADMINISTERING DAILY ELX\/TEZ\/IVA (200 MG\/100 MG\/150 MG) + IVA (150 MG)"
  },
  {
    "Code": "U-4222",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 6 TO <12 YEARS OLD WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA BY ADMINISTERING DAILY ELX\/TEZ\/IVA (100 MG\/50 MG\/75 MG) + IVA (75 MG)"
  },
  {
    "Code": "U-4223",
    "Definition": "TREATMENT OF ACUTE ATTACKS OF HEREDITARY ANGIOEDEMA (HAE) IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-4224",
    "Definition": "TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML\/MINUTE\/1.73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN"
  },
  {
    "Code": "U-4225",
    "Definition": "TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML\/MINUTE\/ 1.73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN"
  },
  {
    "Code": "U-4226",
    "Definition": "TREATMENT OF TYPE 2 DIABETES IN A PATIENT HAVING ESTIMATED GLOMERULAR FILTRATION RATE LEVELS DOWN TO 30 ML\/MINUTE\/1 .73 M2, ALBUMINURIA AND PREVIOUS MACROVASCULAR DISEASE BY ADMINISTERING LINAGLIPTIN IN COMBINATION WITH METFORMIN"
  },
  {
    "Code": "U-4227",
    "Definition": "METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS"
  },
  {
    "Code": "U-4228",
    "Definition": "METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS"
  },
  {
    "Code": "U-4229",
    "Definition": "METHOD OF IMPROVING GLYCEMIC CONTROL BY SUBCUTANEOUSLY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS"
  },
  {
    "Code": "U-4230",
    "Definition": "METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS"
  },
  {
    "Code": "U-4231",
    "Definition": "METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A FIRST ONCE-WEEKLY DOSE OF 2.5 MG TIRZEPATIDE FOR 4 WEEKS, INCREASING THE ONCE-WEEKLY DOSE BY INCREMENTS OF 2.5 MG TO A ONCE-WEEKLY MAINTENANCE DOSE OF 5, 10, OR 15 MG FOR 4 WEEKS"
  },
  {
    "Code": "U-4232",
    "Definition": "TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 2 WEEKS"
  },
  {
    "Code": "U-4233",
    "Definition": "VOSTALLY IS INDICATED FOR THE TREATMENT OF HYPERTENSION, TO LOWER BLOOD PRESSURE"
  },
  {
    "Code": "U-4234",
    "Definition": "PREVENTIVE TREATMENT OF MIGRAINE IN ADULTS UNDERGOING CONCURRENT TREATMENT WITH A STRONG CYP3A4 INHIBITOR"
  },
  {
    "Code": "U-4235",
    "Definition": "A METHOD OF REDUCING THE HEART RATE OF A SUBJECT SUFFERING FROM SUPRAVENTRICULAR TACHYCARDIA, WHEREIN LANDIOLOL IS ADMINISTERED PARENTERALLY AT A CONSTANT DOSE OF MORE THAN 20 MCG\/KG\/MIN FOR 2-20 HOURS, WHEREIN THE DOSE IS NOT HIGHER THAN 40 MCG\/KG\/MIN"
  },
  {
    "Code": "U-4236",
    "Definition": "DURING LEVOKETOCONAZOLE DOSAGE TITRATION FOR THE TREATMENT OF CUSHING'S SYNDROME IN PATIENTS WHO CONCOMITANTLY USE A MATE1 SUBSTRATE, MONITORING THE SUBJECT FOR A DOSE LIMITING EVENT AND ADJUSTING THE DOSAGE OF THE MATE1 SUBSTRATE AS NEEDED"
  },
  {
    "Code": "U-4237",
    "Definition": "METHOD OF INHIBITING JANUS KINASE 2 OR JANUS KINASE 3 TO TREAT MODERATE TO SEVERE CHRONIC HAND ECZEMA (CHE) IN ADULTS WHO HAVE HAD AN INADEQUATE RESPONSE TO, OR FOR WHOM TOPICAL CORTICOSTEROIDS ARE NOT ADVISABLE"
  },
  {
    "Code": "U-4238",
    "Definition": "TREATMENT OF ADULT AND PEDIATRIC PATIENTS AGED 12 YEARS AND OLDER WITH C3 GLOMERULOPATHY (C3G) OR PRIMARY IMMUNE-COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (IC-MPGN) BY ADMINISTRATION OF A UNIT DOSE OF PEGCETACOPLAN IN A COMPOSITION OF CLAIM 1"
  },
  {
    "Code": "U-4239",
    "Definition": "TREATMENT OF PEDIATRIC PATIENTS AGED 12 YEARS AND OLDER WEIGHING 35 KG TO LESS THAN 50 KG WITH C3G OR PRIMARY IC-MPGN BY TWICE WEEKLY SUBCUTANEOUS ADMINISTRATION OF A UNIT DOSE OF 810 MG OF PEGCETACOPLAN IN A COMPOSITION OF CLAIM 1"
  },
  {
    "Code": "U-4240",
    "Definition": "TREATMENT OF ADULT AND PEDIATRIC PATIENTS AGED 12 YEARS AND OLDER WEIGHING 50 KG OR HIGHER WITH C3G OR PRIMARY IC-MPGN BY TWICE WEEKLY SUBCUTANEOUS ADMINISTRATION OF A UNIT DOSE OF 1080 MG OFPEGCETACOPLAN IN A COMPOSITION OF CLAIM 1"
  },
  {
    "Code": "U-4241",
    "Definition": "TREATMENT OF ADULT AND PEDIATRIC PATIENTS AGED 12 YEARS AND OLDER WEIGHING 50 KG OR HIGHER WITH C3 GLOMERULOPATHY OR PRIMARY IMMUNECOMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS BY ADMINISTRATION OF 1080 MG OF PEGCETACOPLAN TWICE WEEKLY"
  },
  {
    "Code": "U-4242",
    "Definition": "TREATMENT OF ADULT AND PEDIATRIC PATIENTS AGED 12 YEARS AND OLDER WITH C3 GLOMERULOPATHY (C3G) OR PRIMARY IMMUNE-COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (IC-MPGN) BY ADMINISTRATION OF PEGCETACOPLAN"
  },
  {
    "Code": "U-4243",
    "Definition": "TREATMENT OF ADULT AND PEDIATRIC PATIENTS AGED 12 YEARS AND OLDER WITH C3G OR PRIMARY IC-MPGN BY ADMINISTRATION OF PEGCETACOPLAN SO AS TO REDUCE THE SENSITIVITY OF CELLS TO COMPLEMENT-MEDIATED DAMAGE"
  },
  {
    "Code": "U-4244",
    "Definition": "TREATMENT OF ADULT AND PEDIATRIC PATIENTS AGED 12 YEARS AND OLDER WITH C3 GLOMERULOPATHY (C3G) OR PRIMARY IMMUNE-COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS (IC-MPGN) BY ADMINISTRATION OF COMPLEMENT INHIBITOR PEGCETACOPLAN"
  },
  {
    "Code": "U-4245",
    "Definition": "USE OF ZONGERTINIB FOR TREATING NON-SMALL CELL LUNG CANCER (NSCLC)"
  },
  {
    "Code": "U-4246",
    "Definition": "FOR USE IN THE TREATMENT OF PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)"
  },
  {
    "Code": "U-4247",
    "Definition": "FOR USE IN THE TREATMENT OF PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA"
  },
  {
    "Code": "U-4248",
    "Definition": "FOR USE IN THE TREATMENT OF PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA AND\/OR LOCALLY ADVANCED OR METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)"
  },
  {
    "Code": "U-4249",
    "Definition": "AS AN ADJUNCT TO DIET AND EXERCISE FOR THE TREATMENT OF ADULTS WITH HYPERCHOLESTEROLEMIA, INCLUDING HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH), BY INHIBITING EXPRESSION OF THE PCSK9 GENE"
  },
  {
    "Code": "U-4250",
    "Definition": "METHOD OF TREATING HYPERPHENYLALANINEMIA (HPA) IN ADULT AND PEDIATRIC PATIENTS WITH SEPIAPTERIN-RESPONSIVE PHENYLKETONURIA (PKU) BY ADMINISTERING SEPIAPTERIN WITH FOOD"
  },
  {
    "Code": "U-4251",
    "Definition": "TREATMENT OF HYPERPHENYLALANINEMIA (HPA) IN ADULT AND PEDIATRIC PATIENTS WITH SEPIAPTERIN-RESPONSIVE PHENYLKETONURIA (PKU) BY ADMINISTERING SEPIAPTERIN"
  },
  {
    "Code": "U-4252",
    "Definition": "TREATING METASTATIC SCLC AFTER PLATINUM CHEMOTHERAPY WITH LURBINECTEDIN MONOTHERAPY BY REDUCING THE DOSE FOR GRADE 4 THROMBOCYTOPENIA OR GRADE 3 WITH BLEEDING FROM 3.2 TO 2.6 MG\/M2 AND 2.6 TO 2.0 MG\/M2 LURBINECTEDIN WITHIN 35 DAYS OF THE HIGHER DOSE"
  },
  {
    "Code": "U-4253",
    "Definition": "ATMEKSI IS INDICATED AS AN ADJUNCT TO REST, PHYSICAL THERAPY, AND OTHER MEASURES FOR THE RELIEF AND DISCOMFORT ASSOCIATED WITH ACUTE, PAINFUL MUSCULOSKELETAL CONDITIONS"
  },
  {
    "Code": "U-4254",
    "Definition": "METHOD OF TREATING ADULT AND PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH DIFFUSE MIDLINE GLIOMA HARBORING AN H3 K27M MUTATION WITH PROGRESSIVE DISEASE FOLLOWING PRIOR THERAPY"
  },
  {
    "Code": "U-4255",
    "Definition": "A METHOD FOR TREATING ULCERATIVE COLITIS BY ADMINISTERING ESTRASIMOD L-ARGININE IN AN AMOUNT EQUIVALENT TO ABOUT 2.0 MG OF ESTRASIMOD"
  },
  {
    "Code": "U-4256",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH RECURRENT LOW-GRADE INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER"
  },
  {
    "Code": "U-4257",
    "Definition": "TREATMENT OF NON-CYSTIC FIBROSIS BRONCHIECTASIS IN PATIENTS 12 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-4258",
    "Definition": "A METHOD OF TREATING PRIMARY HYPERLIPIDEMIA USING BEMPEDOIC ACID"
  },
  {
    "Code": "U-4259",
    "Definition": "TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CHRONIC GVHD) AFTER FAILURE OF AT LEAST TWO PRIOR LINES OF SYSTEMIC THERAPY IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER THROUGH INHIBITING RHO-ASSOCIATED, COILED-COIL CONTAINING PROTEIN KINASE"
  },
  {
    "Code": "U-4260",
    "Definition": "TREATMENT OF CHRONIC GRAFT-VERSUS-HOST DISEASE (CHRONIC GVHD) AFTER FAILURE OF AT LEAST TWO PRIOR LINES OF SYSTEMIC THERAPY IN ADULT AND PEDIATRIC PATIENTS 12 YEARS AND OLDER"
  },
  {
    "Code": "U-4261",
    "Definition": "TREATMENT OF DEPRESSIVE EPISODES ASSOCIATED WITH BIPOLAR DISORDER"
  },
  {
    "Code": "U-4262",
    "Definition": "A METHOD FOR THE TREATMENT OF ADULT PATIENTS WITH STABLE WILSON'S DISEASE WHO ARE DE-COPPERED AND TOLERANT TO PENICILLAMINE"
  },
  {
    "Code": "U-4263",
    "Definition": "TREATMENT OF SEVERE FROSTBITE IN ADULTS TO REDUCE THE RISK OF DIGIT AMPUTATIONS"
  },
  {
    "Code": "U-4264",
    "Definition": "TREATMENT OF ORAL ULCERS ASSOCIATED WITH BEHCET'S DISEASE BY ADMINISTERING APREMILAST WITH FOOD"
  },
  {
    "Code": "U-4265",
    "Definition": "TREATMENT OF PSORIATIC ARTHRITIS BY ADMINISTERING APREMILAST WITH FOOD"
  },
  {
    "Code": "U-4266",
    "Definition": "TREATMENT OF PLAQUE PSORIASIS BY ADMINISTERING APREMILAST WITH FOOD"
  },
  {
    "Code": "U-4267",
    "Definition": "METHOD FOR TREATING ADULT PATIENTS WITH PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT, BY ACHIEVING A PLATELET COUNT OF AT LEAST 50,000\/UL"
  },
  {
    "Code": "U-4268",
    "Definition": "METHOD OF INHIBITING BRUTON'S TYROSINE KINASE ACTIVITY IN ADULT PATIENTS WITH PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT"
  },
  {
    "Code": "U-4269",
    "Definition": "METHOD OF TREATING PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) IN ADULT PATIENTS WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT"
  },
  {
    "Code": "U-4270",
    "Definition": "METHOD OF TREATMENT OF ADULT PATIENTS WITH PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) WHO HAVE HAD AN INSUFFICIENT RESPONSE TO A PREVIOUS TREATMENT"
  },
  {
    "Code": "U-4271",
    "Definition": "ADJUNCTIVE THERAPY FOR PARTIAL-ONSET, PRIMARY GENERALIZED TONIC-CLONIC (PGTC), OR LENNOX-GASTAUT SEIZURES IN PATIENTS 2 YEARS AND OLDER"
  },
  {
    "Code": "U-4272",
    "Definition": "MAINTENANCE TREATMENT OF BIPOLAR I DISORDER TO DELAY MOOD EPISODES"
  },
  {
    "Code": "U-4273",
    "Definition": "CONVERSION TO MONOTHERAPY FOR PARTIAL-ONSET SEIZURES IN PATIENTS 16 YEARS AND OLDER"
  },
  {
    "Code": "U-4274",
    "Definition": "TREATMENT OF PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC, INOPERABLE PLEXIFORM NEUROFIBROMAS (PN)"
  },
  {
    "Code": "U-4275",
    "Definition": "TREATING HYPERPHAGIA AND REDUCING FOOD-RELATED BEHAVIORS IN PRADER-WILLI SYNDROME PATIENTS"
  },
  {
    "Code": "U-4276",
    "Definition": "TREATMENT OF FUNGAL OTIC INFECTION (FUNGAL OTITIS EXTERNA, OTOMYCOSIS) DUE TO ASPERGILLUS SPECIES AND CANDIDA SPECIES"
  },
  {
    "Code": "U-4277",
    "Definition": "METHOD FOR TREATING BARTH SYNDROME IN ADULT AND PEDIATRIC PATIENTS WEIGHING AT LEAST 30KG"
  },
  {
    "Code": "U-4278",
    "Definition": "TREATMENT OF ADULTS WITH ER-POSITIVE, HER2-NEGATIVE ESR1-MUTATED ADVANCED OR METASTATIC BREAST CANCER WITH DISEASE PROGRESSION FOLLOWING AT LEAST ONE LINE OF ENDOCRINE THERAPY"
  },
  {
    "Code": "U-4279",
    "Definition": "INTRANASAL BUMETANIDE FOR THE TREATMENT OF EDEMA"
  },
  {
    "Code": "U-4280",
    "Definition": "TREATMENT OF CHRONIC AUTOIMMUNE URTICARIA"
  },
  {
    "Code": "U-4281",
    "Definition": "TREATMENT OF CHRONIC SPONTANEOUS URTICARIA"
  },
  {
    "Code": "U-4282",
    "Definition": "TREATMENT OF ADULTS WITH ACROMEGALY WHO HAVE HEPATIC IMPAIRMENT AND AN INADEQUATE RESPONSE TO SURGERY AND\/OR FOR WHOM SURGERY IS NOT AN OPTION"
  },
  {
    "Code": "U-4283",
    "Definition": "TREATMENT OF ADULTS WITH ACROMEGALY WHO HAD AN INADEQUATE RESPONSE TO SURGERY AND\/OR FOR WHOM SURGERY IS NOT AN OPTION"
  },
  {
    "Code": "U-4284",
    "Definition": "TREATMENT OF NEUROLOGICAL MANIFESTATIONS OF NIEMANN-PICK DISEASE TYPE-C (NPC) FOR A DURATION OF GREATER THAN 3 MONTHS"
  },
  {
    "Code": "U-4285",
    "Definition": "TREATMENT OF NEUROLOGICAL MANIFESTATIONS OF NIEMANN-PICK DISEASE TYPE-C (NPC) FOR A DURATION OF AT LEAST ABOUT 3 MONTHS"
  },
  {
    "Code": "U-4286",
    "Definition": "A METHOD OF TREATING A CANCER CHARACTERIZED BY AN IDH1 MUTATION FOLLOWING SURGERY, WHEREIN THE CANCER IS GRADE 2 ASTROCYTOMA OR OLIGODENDROGLIOMA"
  },
  {
    "Code": "U-4287",
    "Definition": "DELAYING LOSS OF EGFR OR DELAYING PROGRESSION TO END-STAGE RENAL DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN TO PATIENTS WITH STAGE 2, 3, 4 OR 5 CHRONIC KIDNEY DISEASE"
  },
  {
    "Code": "U-4288",
    "Definition": "TREATMENT OF SEVERE PHOSPHATIDYLINOSITOL-3-KINASE CATALYTIC SUBUNIT ALPHA (PIK3CA)-RELATED OVERGROWTH SPECTRUM (PROS) HAVING AN OVERGROWTH OF MULTIPLE TISSUES, THAT REQUIRES SYSTEMIC THERAPY"
  },
  {
    "Code": "U-4289",
    "Definition": "TREATING POST-TRANSPLANT CMV INFECTION\/DISEASE REFRACTORY TO GANCICLOVIR, VALGANCICLOVIR, CIDOFOVIR OR FOSCARNET BY ADMINISTERING 1200 MG MARIBAVIR TWICE DAILY, WHERE PATIENT IS EXPOSED TO\/RECEIVING AN IMMUNOSUPPRESSANT AND PHENYTOIN OR PHENOBARBITAL"
  },
  {
    "Code": "U-4290",
    "Definition": "TREATMENT OF ORAL ULCERS ASSOCIATED WITH BEHCET'S DISEASE"
  },
  {
    "Code": "U-4291",
    "Definition": "TREATMENT OF PSORIATIC ARTHRITIS"
  },
  {
    "Code": "U-4292",
    "Definition": "TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS IN ADULTS IN COMBINATION WITH NINTEDANIB MONOETHANESULFONATE"
  },
  {
    "Code": "U-4293",
    "Definition": "TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH MODERATE RENAL IMPAIRMENT (30 ML\/MIN\/1.73 M2<=EGFR<60 ML\/MIN\/1.73 M2) BY ADMINISTRATION OF EMPAGLIFLOZIN"
  },
  {
    "Code": "U-4294",
    "Definition": "TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML\/MIN\/1.73 M2"
  },
  {
    "Code": "U-4295",
    "Definition": "TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION IN A PATIENT AND ADMINISTERING EMPAGLIFLOZIN IF THE EGFR IS >=30 ML\/MIN\/1.73 M2 AND <60 ML\/MIN\/1.73 M2"
  },
  {
    "Code": "U-4296",
    "Definition": "TREATING TYPE 2 DIABETES MELLITUS BY ASSESSING RENAL FUNCTION, ADMINISTERING 10 EMPAGLIFLOZIN IF THE EGFR IS >=30 ML\/MIN\/1.73 M2, AND ADMINISTERING 25 MG EMPAGLIFLOZIN IF REQUIRED FOR ADDITIONAL GLYCEMIC CONTROL AND THE EGER IS >=30 ML\/MIN\/1.73 M2"
  },
  {
    "Code": "U-4297",
    "Definition": "TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS IN ADULTS IN COMBINATION WITH NINTEDANIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF"
  },
  {
    "Code": "U-4298",
    "Definition": "TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS IN ADULTS"
  },
  {
    "Code": "U-4299",
    "Definition": "MAINTENANCE TREATMENT OF ADULT PATIENTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER (ES-SCLC) WHOSE DISEASE HAS NOT PROGRESSED AFTER FIRST-LINE INDUCTION THERAPY"
  },
  {
    "Code": "U-4300",
    "Definition": "TREATMENT OF PAROXYSMAL NOCTURAL HEMOGLOBINURIA (PNH) BY ADMINISTRATION OF 200 MG OF IPTACOPAN TWICE DAILY"
  },
  {
    "Code": "U-4301",
    "Definition": "TOPICAL TREATMENT OF MILD TO MODERATE ATOPIC DERMATITIS IN PEDIATRIC PATIENTS 2 TO 5 YEARS OF AGE"
  },
  {
    "Code": "U-4302",
    "Definition": "TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS OR RECEIVED AT LEAST ONE APPROVED SYSTEMIC THERAPY IF TNF BLOCKERS ARE CLINICALLY INADVISABLE"
  },
  {
    "Code": "U-4303",
    "Definition": "TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE WHO HAVE HAD AN INADEQUATE RESPONSE OR INTOLERANCE TO ONE OR MORE TNF BLOCKERS OR RECEIVED AT LEAST ONE APPROVED SYSTEMIC THERAPY IF TNF BLOCKERS ARE CLINICALLY INADVISABLE"
  },
  {
    "Code": "U-4304",
    "Definition": "TREATING TYPE 2 DIABETES MELLITUS IN A PATIENT WITH STAGE 3 CHRONIC KIDNEY DISEASE BY ADMINISTRATION OF EMPAGLIFLOZIN"
  },
  {
    "Code": "U-4305",
    "Definition": "TREATING METASTATIC SCLC AFTER PLATINUM CHEMOTHERAPY WITH LURBINECTEDIN MONOTHERAPY BY REDUCING THE DOSE FOR GRADE 4 OR ANY GRADE FEBRILE NEUTROPENIA FROM 3.2 TO 2.6 MG\/M2 AND 2.6 TO 2.0 MG\/M2 LURBINECTEDIN WITHIN 35 DAYS OF THE HIGHER DOSE"
  },
  {
    "Code": "U-4306",
    "Definition": "METHOD OF TREATING MILD TO MODERATE PAIN (SURGICAL) IN ADULTS"
  },
  {
    "Code": "U-4307",
    "Definition": "METHOD OF TREATING MODERATE TO SEVERE PAIN (SURGICAL) IN ADULTS AS AN ADJUNCT TO OPIOID ANALGESICS"
  },
  {
    "Code": "U-4308",
    "Definition": "IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE"
  },
  {
    "Code": "U-4309",
    "Definition": "IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE"
  },
  {
    "Code": "U-4310",
    "Definition": "TREATING OBESITY BY ADMINISTERING IN 4 DOSES, AT LEAST 2 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE"
  },
  {
    "Code": "U-4311",
    "Definition": "TREATING OBESITY BY ADMINISTERING IN 4 DOSES, ABOUT 4 WEEKS APART, A GIP:GLP-1 PEPTIDE HAVING A GIP:GLP-1 RECEPTOR AGONIST POTENCY RATIO IN A RANGE DETERMINED BY A CASEIN CAMP ASSAY, WHERE DOSES ARE 25%, 50% AND 75% OF 4TH DOSE"
  },
  {
    "Code": "U-4312",
    "Definition": "TREATMENT OF NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER WITH BIOCHEMICAL RECURRENCE AT HIGH RISK FOR METASTASIS BY ADMINISTERING TWO TABLETS EACH COMPRISING A SPRAY-DRIED DISPERSION OF 80 MG AMORPHOUS ENZALUTAMIDE AND 400 MG HPMCAS AS CLAIMED"
  },
  {
    "Code": "U-4313",
    "Definition": "TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER BY ADMINISTERING TWO TABLETS EACH COMPRISING A SPRAY-DRIED DISPERSION OF 80 MG AMORPHOUS ENZALUTAMIDE AND 400 MG HPMCAS AS CLAIMED"
  },
  {
    "Code": "U-4314",
    "Definition": "TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER BY ADMINISTERING TWO TABLETS EACH COMPRISING A SPRAY-DRIED DISPERSION OF 80 MG AMORPHOUS ENZALUTAMIDE AND 400 MG HPMCAS AS CLAIMED"
  },
  {
    "Code": "U-4315",
    "Definition": "A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, NA2HPO4, AND ABOUT 6.2-9.5 MG\/ML OF NACL"
  },
  {
    "Code": "U-4316",
    "Definition": "IMPROVING GLYCEMIC CONTROL IN ADULTS WITH T2DM BY ADMINISTERING, AT A PH OF 6.5-7.5, AN EFFECTIVE DOSE OF ABOUT 5-30 MG\/ML OF TIRZEPATIDE, ABOUT 0.67-2.68 MG\/ML OF NA2HPO4, ABOUT 6.2-9.5 MG\/ML OF NACL, AND OPTIONALLY ABOUT 3.0-7.0 MG\/ML PHENOL"
  },
  {
    "Code": "U-4317",
    "Definition": "A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH T2DM BY ADMINISTERING A 5 MG\/ML, 10 MG\/ML, 15 MG\/ML, 20 MG\/ML, 25 MG\/ML, OR 30 MG\/ML DOSE OF TIRZEPATIDE, NA2HPO4, AND ABOUT 8.2 MG\/ML OF NACL"
  },
  {
    "Code": "U-4318",
    "Definition": "A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH T2DM BY ADMINISTERING A COMPOSITION COMPRISING AN EFFECTIVE DOSE OF ABOUT 5-30 MG\/ML OF TIRZEPATIDE, ABOUT 1.34 MG\/ML OF NA2HPO4, ABOUT 8.2 MG\/ML OF NACL, WHEREIN THE COMPOSITION IS PH 6.5-7.5"
  },
  {
    "Code": "U-4319",
    "Definition": "A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH T2DM BY ADMINISTERING A 5 MG\/ML, 10 MG\/ML, 15 MG\/ML, 20 MG\/ML, 25 MG\/ML, OR 30 MG\/ML DOSE OF TIRZEPATIDE, ABOUT 1.34 MG\/ML OF NA2HPO4, AND ABOUT 6.2-9.5 MG\/ML OF NACL"
  },
  {
    "Code": "U-4320",
    "Definition": "A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG\/ML OF TIRZEPATIDE, ABOUT 0.67-2.68 MG\/ML OF NA2HPO4, ABOUT 6.2-9.5 MG\/ML OF NACL, AND OPTIONALLY ABOUT 3.0-7.0 MG\/ML PHENOL"
  },
  {
    "Code": "U-4321",
    "Definition": "A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG\/ML OF TIRZEPATIDE, ABOUT 1-3 MG\/ML OF NA2HPO4, AND ABOUT 6.2-9.5 MG\/ML OF NACL"
  },
  {
    "Code": "U-4322",
    "Definition": "A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG\/ML OF TIRZEPATIDE, NA2HPO4, ABOUT 7.0-9.0 MG\/ML OF NACL"
  },
  {
    "Code": "U-4323",
    "Definition": "A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG\/ML OF TIRZEPATIDE, NA2HPO4, AND ABOUT 6.2-9.5 MG\/ML OF NACL"
  },
  {
    "Code": "U-4324",
    "Definition": "A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG\/ML OF TIRZEPATIDE, NA2HPO4, AND ABOUT 8.2 MG\/ML OF NACL"
  },
  {
    "Code": "U-4325",
    "Definition": "A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 0.67-2.68 MG\/ML OF NA2HPO4, AND ABOUT 6.2-9.5 MG\/ML OF NACL"
  },
  {
    "Code": "U-4326",
    "Definition": "A METHOD FOR IMPROVING GLYCEMIC CONTROL IN ADULTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 1.34 MG\/ML OF NA2HPO4, AND ABOUT 6.2-9.5 MG\/ML OF NACL"
  },
  {
    "Code": "U-4327",
    "Definition": "TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA WITH A SUSCEPTIBLE NUCLEOPHOSMIN 1 (NPM1) MUTATION IN ADULT AND PEDIATRIC PATIENTS 1 YEAR AND OLDER"
  },
  {
    "Code": "U-4328",
    "Definition": "TREATING POST-TRANSPLANT CMV INFECTION\/DISEASE REFRACTORY TO GANCICLOVIR, VALGANCICLOVIR, CIDOFOVIR OR FOSCARNET BY ADMINISTERING 800 OR 1200 MG MARIBAVIR 2X DAILY WHERE PATIENT IS CONCOMITANTLY EXPOSED TO\/RECEIVING ANTICONVULSANT, IMMUNOSUPPRESSANT"
  },
  {
    "Code": "U-4329",
    "Definition": "TREATMENT OF PATIENTS WITH POST-TRANSPLANT CYTOMEGALOVIRUS (CMV) INFECTION\/DISEASE THAT IS REFRACTORY TO TREATMENT WITH GANCICLOVIR, VALGANCICLOVIR, CIDOFOVIR, OR FOSCARNET, BY ADMINISTERING 400 MG OF MARIBAVIR ORALLY TWICE DAILY"
  },
  {
    "Code": "U-4330",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA BY ADMINISTERING THE COMPOSITION RECITED IN US 12458635 CLAIM 1"
  },
  {
    "Code": "U-4331",
    "Definition": "TREATMENT OF RENALLY IMPAIRED PATIENTS WITH COMPLICATED URINARY TRACT INFECTIONS INCLUDING ACUTE PYELONEPHRITIS CAUSED BY SUSCEPTIBLE ISOLATES OF ESCHERICHIA COLI AND KLEBSIELLA PNEUMONIAE"
  },
  {
    "Code": "U-4332",
    "Definition": "TREATMENT OF PATIENTS WITH COMPLICATED URINARY TRACT INFECTIONS INCLUDING ACUTE PYELONEPHRITIS CAUSED BY SUSCEPTIBLE ISOLATES OF ESCHERICHIA COLI AND KLEBSIELLA PNEUMONIAE"
  },
  {
    "Code": "U-4333",
    "Definition": "TREATMENT OF CF IN PATIENTS AGED 2 TO < 6 YEARS OLD WHO HAVE IN THE CFTR GENE AT LEAST ONE F508DEL MUTATION OR A RESPONSIVE MUTATION BASED ON CLINICAL AND\/OR IN VITRO DATA COMPRISING ADMINISTERING THE COMPOSITION RECITED IN US 12458635 CLAIM 1"
  },
  {
    "Code": "U-4334",
    "Definition": "INCREASING SURVIVAL IN MCRPC PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL BY ADMINISTERING CABAZITAXEL IN COMBINATION WITH PREDNISONE OR PREDNISOLONE AFTER A PREMEDICATION REGIMEN THAT INCLUDES AN ANTIHISTAMINE"
  },
  {
    "Code": "U-4335",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 1 YEAR TO 5 YEARS WHO ARE HOMOZYGOUS FOR THE F508DEL CFTR GENE MUTATION COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF IVA AS RECITED IN, E.G., CLAIM 1 OF US 12458635, AND FORM I LUM"
  },
  {
    "Code": "U-4336",
    "Definition": "TREATMENT OF CF IN A PATIENT AGE 6 YEARS AND OLDER WHO IS HOMOZYGOUS FOR F508DEL OR HAS AT LEAST ONE CFTR GENE MUTATION RESPONSIVE TO TEZ\/IVA BASED ON IN VITRO DATA AND\/OR CLINICAL EVIDENCE USING THE COMPOSITION RECITED IN US 12458635 CLAIM 1"
  },
  {
    "Code": "U-4337",
    "Definition": "TREATMENT OF CF IN A PATIENT AGE 1 MONTH TO LESS THAN 6 YEARS OLD WHO HAS IN THE CFTR GENE AT LEAST ONE MUTATION RESPONSIVE TO IVA BASED ON CLINICAL AND\/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 12458635"
  },
  {
    "Code": "U-4338",
    "Definition": "TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO ARE HOMOZYGOUS FOR THE F508DEL CFTR GENE MUTATION COMPRISING ADMINISTERING AN EFFECTIVE AMOUNT OF IVA AS RECITED IN, E.G., CLAIM 1 OF US 12458635, AND FORM I LUM"
  },
  {
    "Code": "U-4339",
    "Definition": "TREATMENT OF CF IN A PATIENT AGE 6 YEARS AND OLDER WHO HAS IN THE CFTR GENE AT LEAST ONE MUTATION RESPONSIVE TO IVA BASED ON CLINICAL AND\/OR IN VITRO ASSAY DATA USING THE COMPOSITION RECITED IN CLAIM 1 OF US 12458635"
  },
  {
    "Code": "U-4340",
    "Definition": "TREATMENT OF MAJOR DEPRESSIVE DISORDER, ADJUNCTIVE TO ANTIDEPRESSANT THERAPY, OR ADJUNCTIVE TO ANTIDEPRESSANT THERAPY BY INHIBITING THE 5-HT2A RECEPTOR AND\/OR SEROTONIN TRANSPORTER, AND\/OR MODULATING DOPAMINE D2 RECEPTOR FUNCTION"
  },
  {
    "Code": "U-4341",
    "Definition": "TREATMENT OF MAJOR DEPRESSIVE DISORDER MEDIATED BY THE 5-HT2A RECEPTOR, SEROTONIN TRANSPORTER, AND\/OR DOPAMINE D1\/D2 SIGNALING PATHWAYS, ADJUNCTIVE TO ANTIDEPRESSANT TREATMENT"
  },
  {
    "Code": "U-4342",
    "Definition": "TREATMENT OF MAJOR DEPRESSIVE DISORDER ADJUNCTIVE TO ANTIDEPRESSANT THERAPY, INCLUDING TREATMENT RESISTANT MAJOR DEPRESSIVE DISORDER"
  },
  {
    "Code": "U-4343",
    "Definition": "MODULATION OF 5-HYDROXYTRYPTAMINE 2 RECEPTOR ACTIVITY IN MAJOR DEPRESSIVE DISORDER ADJUNCTIVE TO ANTIDEPRESSANT THERAPY"
  },
  {
    "Code": "U-4344",
    "Definition": "TREATMENT OF MAJOR DEPRESSIVE DISORDER ADJUNCTIVE TO ANTIDEPRESSANT TREATMENT"
  },
  {
    "Code": "U-4345",
    "Definition": "METHOD OF TREATING OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) IN PEDIATRIC PATIENTS 7 YEARS OF AGE AND OLDER"
  },
  {
    "Code": "U-4346",
    "Definition": "REDUCE THE RISK OF CARDIOVASCULAR DEATH AND HOSPITALIZATION FOR HEART FAILURE AND URGENT HEART FAILURE VISITS IN ADULTS WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION AND STRUCTURAL HEART DISEASE AND WITHOUT TYPE II DIABETES"
  },
  {
    "Code": "U-4347",
    "Definition": "METHOD OF TREATING ACUTE MYELOID LEUKEMIA"
  },
  {
    "Code": "U-4348",
    "Definition": "METHOD OF TREATING HEMATOLOGIC MALIGNANCY"
  },
  {
    "Code": "U-4349",
    "Definition": "METHOD OF TREATING ACUTE MYELOID LEUKEMIA WITH ZIFTOMENIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF"
  },
  {
    "Code": "U-4350",
    "Definition": "METHOD OF INHIBITING MENIN INTERACTION"
  },
  {
    "Code": "U-4351",
    "Definition": "METHOD OF TREATING LEUKEMIA"
  },
  {
    "Code": "U-4352",
    "Definition": "METHOD OF INHIBITING PROLIFERATION AND\/OR INDUCING APOPTOSIS IN A LEUKEMIA CELL WITH A NUCLEOPHOSMIN 1 (NPM1) MUTATION"
  },
  {
    "Code": "U-4353",
    "Definition": "METHOD OF TREATING LEUKEMIA WITH A NUCLEOPHOSMIN 1 (NPM1) MUTATION"
  },
  {
    "Code": "U-4354",
    "Definition": "METHOD OF TREATING MENIN-MEDIATED DISEASE"
  },
  {
    "Code": "U-4355",
    "Definition": "PREVENTIVE TREATMENT OF MIGRAINE IN ADULTS WITH SEVERE RENAL IMPAIRMENT OR END-STAGE RENAL DISEASE"
  },
  {
    "Code": "U-4356",
    "Definition": "IMPROVING THE PHARMACOKINETICS OF MELOXICAM IN A HUMAN BEING SUFFERING FROM MIGRAINE"
  },
  {
    "Code": "U-4357",
    "Definition": "TREATMENT OF ADULT AND PEDIATRIC PATIENTS 1 YEAR OF AGE AND OLDER WITH NEUROFIBROMATOSIS TYPE 1 (NF1) WHO HAVE SYMPTOMATIC, INOPERABLE PLEXIFORM NEUROFIBROMAS (PN)"
  },
  {
    "Code": "U-4358",
    "Definition": "TREATMENT OF THYMIDINE KINASE 2 DEFICIENCY (TK2D) IN ADULTS AND PEDIATRIC PATIENTS WITH AN AGE OF SYMPTOM ONSET ON OR BEFORE 12 YEARS"
  },
  {
    "Code": "U-4359",
    "Definition": "TREATMENT OF SEVERE PHOSPHATIDYLINOSITOL-3-KINASE CATALYTIC SUBUNIT ALPHA (PIK3CA)-RELATED OVERGROWTH SPECTRUM (PROS) HAVING AN OVERGROWTH OF MULTIPLE TISSUES, THAT REQUIRES SYSTEMIC THERAPY AND IS NOT RESPONSIVE TO RAPAMYCIN"
  },
  {
    "Code": "U-4360",
    "Definition": "USE TO REDUCE TRIGLYCERIDES IN ADULTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS)"
  },
  {
    "Code": "U-4361",
    "Definition": "TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WEIGHING AT LEAST 45 KG WHO HAVE LIMITED OR NO ALTERNATIVE OPTIONS WITH UNCOMPLICATED UROGENITAL GONORRHEA CAUSED BY SUSCEPTIBLE STRAINS OF NEISSERIA GONORRHOEAE"
  },
  {
    "Code": "U-4362",
    "Definition": "TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA OR SMALL LYMPHOCYTIC LYMPHOMA (CLL\/SLL) WHO HAVE PREVIOUSLY BEEN TREATED WITH A COVALENT BTK INHIBITOR"
  },
  {
    "Code": "U-4363",
    "Definition": "TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER BY ADMINISTERING A TABLET COMPRISING A SOLID DISPERSION COMPRISING AMORPHOUS ENZALUTAMIDE AND HPMCAS"
  },
  {
    "Code": "U-4364",
    "Definition": "TREATMENT OF PATIENTS WITH METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER BY ADMINISTERING A TABLET COMPRISING A SOLID DISPERSION COMPRISING AMORPHOUS ENZALUTAMIDE AND HPMCAS"
  },
  {
    "Code": "U-4365",
    "Definition": "TREATMENT OF PATIENTS WITH NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER WITH BIOCHEMICAL RECURRENCE AT HIGH RISK FOR METASTASIS BY ADMINISTERING A TABLET COMPRISING A SOLID DISPERSION COMPRISING AMORPHOUS ENZALUTAMIDE AND HPMCAS"
  },
  {
    "Code": "U-4366",
    "Definition": "TREATING HYPOGONADOTROPIC HYPOGONADISM BY ADMINISTERING TO A MALE WITH ALLERGIC OR SEASONAL RHINITIS 5.5MG TESTOSTERONE IN 0.122G TESTOSTERONE GEL IN EACH NOSTRIL 3 TIMES DAILY VIA A METERED DOSE PUMP ACTUATABLE 60 TIMES AND CONTAINING 11 G GEL"
  },
  {
    "Code": "U-4367",
    "Definition": "TREATING PRIMARY HYPOGONADISM BY ADMINISTERING TO A MALE WITH ALLERGIC OR SEASONAL RHINITIS 5.5MG TESTOSTERONE IN 0.122G TESTOSTERONE GEL IN EACH NOSTRIL 3 TIMES DAILY VIA A METERED DOSE PUMP ACTUATABLE 60 TIMES AND CONTAINING 11 G GEL"
  },
  {
    "Code": "U-4368",
    "Definition": "A METHOD FOR TREATING METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC), WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA2-MUTATION"
  },
  {
    "Code": "U-4369",
    "Definition": "TREATMENT OF UNCOMPLICATED UROGENITAL GONORRHEA DUE TO NEISSERIA GONORRHOEAE"
  },
  {
    "Code": "U-4370",
    "Definition": "TREATMENT OF A CARDIAC ARRHYTHMIA"
  },
  {
    "Code": "U-4371",
    "Definition": "TREATMENT OF ADULTS WITH SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) TO IMPROVE FUNCTIONAL CAPACITY AND SYMPTOMS"
  },
  {
    "Code": "U-4372",
    "Definition": "TREATMENT OF PROGRESSIVE PULMONARY FIBROSIS IN ADULTS IN COMBINATION WITH NINTEDANIB MONOETHANESULFONATE"
  },
  {
    "Code": "U-4373",
    "Definition": "TREATMENT OF PROGRESSIVE PULMONARY FIBROSIS IN ADULTS IN COMBINATION WITH NINTEDANIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF"
  },
  {
    "Code": "U-4374",
    "Definition": "MOUNJARO IS INDICATED AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS"
  },
  {
    "Code": "U-4375",
    "Definition": "A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG\/ML OF TIRZEPATIDE, ABOUT 0.67  2.68 MG\/ML OF NA2HPO4, ABOUT 6.2 -9.5 MG\/ML OF NAC1, AND OPTIONALLY ABOUT 3.0  7.0 MG\/ML PHENOL"
  },
  {
    "Code": "U-4376",
    "Definition": "A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, NA2HPO4, AND ABOUT 6.2  9.5 MG\/ML OF NACL"
  },
  {
    "Code": "U-4377",
    "Definition": "A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG\/ML OF TIRZEPATIDE, NA2HPO4, AND ABOUT 6.2 -9.5 MG\/ML OF NACL"
  },
  {
    "Code": "U-4378",
    "Definition": "A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG\/ML OF TIRZEPATIDE, ABOUT 1  3 MG\/ML OF NA2HPO4, AND ABOUT 6.2  9.5 MG\/ML OF NACL"
  },
  {
    "Code": "U-4379",
    "Definition": "A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 0.67  2.68 MG\/ML OF NA2HPO4, AND ABOUT 6.2  9.5 MG\/ML OF NACL"
  },
  {
    "Code": "U-4380",
    "Definition": "A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF TIRZEPATIDE, ABOUT 1.34 MG\/ML OF NA2HPO4, AND ABOUT 6.2  9.5 MG\/ML OF NACL"
  },
  {
    "Code": "U-4381",
    "Definition": "A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A 5 MG\/ML, 10 MG\/ML, 15 MG\/ML, 20 MG\/ML, 25 MG\/ML, OR 30 MG\/ML DOSE OF TIRZEPATIDE, ABOUT 1.34 MG\/ML OF NA2HPO4, AND ABOUT 6.2 -9.5 MG\/ML OF NACL"
  },
  {
    "Code": "U-4382",
    "Definition": "A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG\/ML OF TIRZEPATIDE, NA2HPO4, ABOUT 7.0  9.0 MG\/ML OF NACL"
  },
  {
    "Code": "U-4383",
    "Definition": "A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING AN EFFECTIVE DOSE OF ABOUT 5-30 MG\/ML OF TIRZEPATIDE, NA2HPO4, AND ABOUT 8.2 MG\/ML OF NACL"
  },
  {
    "Code": "U-4384",
    "Definition": "A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A 5 MG\/ML, 10 MG\/ML, 15 MG\/ML, 20 MG\/ML, 25 MG\/ML, OR 30 MG\/ML DOSE OF TIRZEPATIDE, NA2HPO4, AND ABOUT 8.2 MG\/ML OF NACL"
  },
  {
    "Code": "U-4385",
    "Definition": "IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING, AT A PH OF 6.5-7.5, AN EFFECTIVE DOSE OF ABOUT 5-30 MG\/ML OF TIRZEPATIDE, ABOUT 0.67-2.68 MG\/ML OF NA2HPO4, ABOUT 6.2-9.5 MG\/ML OF NAC1, AND OPTIONALLY ABOUT 3.0-7.0 MG\/ML PHENOL"
  },
  {
    "Code": "U-4386",
    "Definition": "A METHOD FOR IMPROVING GLYCEMIC CONTROL IN PATIENTS WITH T2DM BY ADMINISTERING A COMPOSITION COMPRISING AN EFFECTIVE DOSE OF ABOUT 5-30 MG\/ML OF TIRZEPATIDE, ABOUT 1.34 MG\/ML OF NA2HPO4, ABOUT 8.2 MG\/ML OF NAC1, WHEREIN THE COMPOSITION IS PH 6.5-7.5"
  },
  {
    "Code": "U-4387",
    "Definition": "METHOD OF WEIGHT REDUCTION"
  },
  {
    "Code": "U-4388",
    "Definition": "METHOD OF WEIGHT REDUCTION VIA ORAL ADMINISTRATION"
  },
  {
    "Code": "U-4389",
    "Definition": "METHOD OF WEIGHT REDUCTION AND MAINTENANCE OF WEIGHT REDUCTION VIA ORAL ADMINISTRATION"
  },
  {
    "Code": "U-4390",
    "Definition": "METHOD FOR USING A PYRUVATE KINASE ACTIVATOR TO MITIGATE DRUG INTERACTIONS IN ADULTS WITH HEMOLYTIC ANEMIA THAT ARE TAKING MODERATE CYP3A INDUCERS"
  },
  {
    "Code": "U-4391",
    "Definition": "METHOD OF USING A PYRUVATE KINASE ACTIVATOR FOR TREATING ANEMIA IN ADULTS WITH ALPHA OR BETA THALASSEMIA"
  },
  {
    "Code": "U-4392",
    "Definition": "METHOD OF USING A PYRUVATE KINASE ACTIVATOR FOR THE TREATMENT OF ANEMIA IN ADULTS WITH ALPHA OR BETA THALASSEMIA"
  },
  {
    "Code": "U-4393",
    "Definition": "METHOD OF USING A PYRUVATE KINASE ACTIVATOR FOR INCREASING RED BLOOD CELL LONGEVITY IN ADULTS WITH ALPHA OR BETA THALASSEMIA"
  },
  {
    "Code": "U-4394",
    "Definition": "TREATMENT OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION BY INTRAVITREAL ADMINISTRATION OF 15 MG PEGCETACOPLAN"
  },
  {
    "Code": "U-4395",
    "Definition": "TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS IN ADULTS BY ADMINISTERING 2 YEARLY TREATMENT COURSES WHEREIN PATIENTS WHO ARE SEROPOSITIVE TO VZV ARE VACCINATED WITH ZOSTER VACCINE RECOMBINANT, ADJUVANTED BETWEEN THE 1ST AND 2ND TREATMENT COURSE"
  },
  {
    "Code": "U-4396",
    "Definition": "PREVENTION OF VOMITING INDUCED BY MOTION IN ADULTS BY ADMINISTERING TRADIPITANT"
  },
  {
    "Code": "U-4397",
    "Definition": "TREATMENT OF OPIOID OVERDOSE"
  },
  {
    "Code": "U-4398",
    "Definition": "TREATMENT OF ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS CAUSED BY STREPTOCOCCUS DYSGALACTIAE WITH A SINGLE DOSE OF 1200MG ORITAVANCIN OR ITS SINGLE DOSE EQUIVALENT"
  },
  {
    "Code": "U-4399",
    "Definition": "TREATMENT OF RELAPSING FORMS OF MS IN ADULTS BY ADMINISTERING 2 YEARLY TREATMENT COURSES WHEREIN PATIENTS WHO ARE SEROPOSITIVE TO VZV ARE VACCINATED WITH ZOSTER VACCINE RECOMBINANT, ADJUVANTED WITHIN ABOUT 4 WEEKS PRIOR TO THE 1ST TREATMENT COURSE"
  },
  {
    "Code": "U-4400",
    "Definition": "TREATMENT OF TYPE 2 DIABETES BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS"
  },
  {
    "Code": "U-4401",
    "Definition": "METHOD OF IMPROVING GLYCEMIC CONTROL BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS"
  },
  {
    "Code": "U-4402",
    "Definition": "TREATMENT OF MODERATE TO SEVERE VASOMOTOR SYMPTOMS DUE TO MENOPAUSE BY ADMINISTERING 60 MG (ONE CAPSULE) OF LYNKUET ORALLY ONCE DAILY AT BEDTIME CONCOMITANTLY WITH A MODERATE CYP3A4 INHIBITOR"
  },
  {
    "Code": "U-4403",
    "Definition": "USE OF EMPAGLIFLOZIN AS AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PEDIATRIC PATIENTS AGED 10 YEARS TO 17 YEARS WITH TYPE 2 DIABETES MELLITUS"
  },
  {
    "Code": "U-4404",
    "Definition": "IN COMBINATION WITH AN AROMATASE INHIBITOR (LETROZOLE OR ANASTROZOLE) AS INITIAL ENDOCRINE-BASED THERAPY FOR TREATMENT OF ADULTS WITH HR-POSITIVE, HER2-NEGATIVE ADVANCED OR METASTATIC BREAST CANCER"
  },
  {
    "Code": "U-4405",
    "Definition": "IN COMBINATION WITH AN AROMATASE INHIBITOR (LETROZOLE OR ANASTROZOLE) FOR THE ADJUVANT TREATMENT OF ADULTS WITH HR-POSITIVE, HER2-NEGATIVE STAGE II AND III EARLY BREAST CANCER AT HIGH RISK OF RECURRENCE"
  },
  {
    "Code": "U-4406",
    "Definition": "METHOD OF POSITRON EMISSION TOMOGRAPHY (PET) FOR CARDIAC DISEASES"
  },
  {
    "Code": "U-4407",
    "Definition": "TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS (MS), TO INCLUDE CLINICALLY ISOLATED SYNDROME, RELAPSING-REMITTING DISEASE, AND ACTIVE SECONDARY PROGRESSIVE DISEASE, IN ADULTS RECEIVING A BETA-BLOCKER TREATMENT"
  },
  {
    "Code": "U-4408",
    "Definition": "TREATMENT OF FEMALE ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WEIGHING AT LEAST 40 KG WITH UNCOMPLICATED URINARY TRACT INFECTIONS (UUTI) CAUSED BY E. COLI, K. PNEUMONIAE, CITROBACTER FREUNDII COMPLEX, S. SAPROPHYTICUS, E. FAECALIS"
  },
  {
    "Code": "U-4409",
    "Definition": "METHOD OF IMPROVING WEIGHT MANAGEMENT BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS"
  },
  {
    "Code": "U-4410",
    "Definition": "METHOD OF TREATING OBESITY BY ADMINISTERING A ONCE WEEKLY ESCALATION DOSE OF 2.5 MG, 7.5 MG, OR 12.5 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS AND A ONCE-WEEKLY MAINTENANCE DOSE OF 5 MG, 10 MG, OR 15 MG OF TIRZEPATIDE FOR AT LEAST 4 WEEKS"
  },
  {
    "Code": "U-4411",
    "Definition": "A FIRST-LINE METHOD OF TREATING ADVANCED RENAL CELL CARCINOMA IN AN INDIVIDUAL BY ADMINISTERING AXITINIB AT A STARTING DOSE OF 5 MG TWICE DAILY IN COMBINATION WITH PEMBROLIZUMAB, WHERE THE AXITINIB DOSE IS INCREASED AS CLAIMED"
  },
  {
    "Code": "U-4412",
    "Definition": "A FIRST-LINE METHOD OF TREATING ADVANCED RENAL CELL CARCINOMA IN AN INDIVIDUAL BY ADMINISTERING AXITINIB AT A STARTING DOSE OF 5 MG TWICE DAILY IN COMBINATION WITH PEMBROLIZUMAB, WHERE THE AXITINIB DOSE IS REDUCED AS CLAIMED"
  }
]
